PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Barnes, PJ; Hansel, TT				Barnes, PJ; Hansel, TT			Prospects for new drugs for chronic obstructive pulmonary disease	LANCET			English	Review							NECROSIS-FACTOR-ALPHA; SELECTIVE PHOSPHODIESTERASE-4 INHIBITOR; NEUTROPHIL ELASTASE INHIBITOR; LEUKOTRIENE B-4 RECEPTOR; TRANS-RETINOIC ACID; IN-VIVO EFFICACY; ALVEOLAR MACROPHAGES; INCREASED EXPRESSION; DOUBLE-BLIND; PPAR-GAMMA	No currently available treatments have been shown to slow the progression of chronic obstructive pulmonary disease (COPD) or suppress the inflammation in small airways and lung parenchyma. However, several new treatments are in clinical development; some target the inflammatory process and others are directed against structural cells. A group of specific therapies are directed against the influx of inflammatory cells into the airways and lung parenchyma that occurs in COPD; these include agents directed against adhesion molecules and chemokines, as well as therapies to oppose tumour necrosis factor a and increase interleukin 10. Broad-range anti-inflammatory drugs are now in phase III development for COPD; they include inhibitors of phosphodiesterase 4. Other drugs that inhibit cell signalling include inhibitors of p38 mitogen-activated protein kinase, nuclear factor kappaB, and phosphoinositide-3-kinase gamma. More specific approaches are to give antioxidants, inhibitors of inducible nitric oxide synthase, and antagonists of leukotriene B, receptor. Inhibitors of epidermal-growth-factor-receptor kinase and calcium-activated chloride channels have the potential to prevent overproduction of mucus. Therapy to inhibit fibrosis is being developed against transforming growth factor beta1 and protease-activated receptor 2. There is also a search for inhibitors of serine proteinases and matrix metalloproteinases to prevent lung destruction and the development of emphysema, as well as drugs such as retinoids that might even reverse this process. Effective delivery of drugs to the sites of disease in the peripheral lung is an important consideration, and there is a need for validated biomarkers and monitoring techniques in early clinical studies with new therapies for COPD.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England	Imperial College London	Barnes, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England.	p.j.barnes@imperial.ac.uk		Barnes, Peter/0000-0002-5122-4018				Alsaeedi A, 2002, AM J MED, V113, P59, DOI 10.1016/S0002-9343(02)01143-9; Altose MD, 2000, NEW ENGL J MED, V343, P1902; Barnes PJ, 1999, THORAX, V54, P245, DOI 10.1136/thx.54.3.245; Barnes PJ, 2004, LANCET, V363, P731, DOI 10.1016/S0140-6736(04)15650-X; Barnes PJ, 2002, NOVART FDN SYMP, V248, P237; Barnes PJ, 2003, ANNU REV MED, V54, P113, DOI 10.1146/annurev.med.54.101601.152209; Barnes PJ, 2003, AM J RESP CRIT CARE, V167, P813, DOI 10.1164/rccm.200210-1142PP; Barnes PJ, 2001, EUR RESPIR J, V18, p67S, DOI 10.1183/09031936.01.00229901; Barnes PJ, 2002, NAT REV DRUG DISCOV, V1, P437, DOI 10.1038/nrd820; Barnes PJ, 2003, EUR RESPIR J, V22, P672, DOI 10.1183/09031936.03.00040703; Beeh KM, 2003, CHEST, V123, P1240, DOI 10.1378/chest.123.4.1240; Belloni PN, 2000, CHEST, V117, p235S, DOI 10.1378/chest.117.5_suppl_1.235S; Belvisi MG, 2003, INFLAMM RES, V52, P95, DOI 10.1007/s000110300020; Bundschuh DS, 2001, J PHARMACOL EXP THER, V297, P280; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Calverley PMA, 2003, LANCET, V362, P1053, DOI 10.1016/S0140-6736(03)14416-9; Caramori G, 2003, THORAX, V58, P348, DOI 10.1136/thorax.58.4.348; Castro AC, 2003, BIOORG MED CHEM LETT, V13, P2419, DOI 10.1016/S0960-894X(03)00408-6; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Compton CH, 2001, LANCET, V358, P265, DOI 10.1016/S0140-6736(01)05481-2; Crooks SW, 2000, EUR RESPIR J, V15, P274, DOI 10.1034/j.1399-3003.2000.15b09.x; Culpitt SV, 2003, THORAX, V58, P942, DOI 10.1136/thorax.58.11.942; Culpitt SV, 2003, AM J RESP CRIT CARE, V167, P24, DOI 10.1164/rccm.200204-298OC; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200; Dani JA, 2003, MOL PSYCHIATR, V8, P255, DOI 10.1038/sj.mp.4001284; Davenpeck KL, 2000, J ALLERGY CLIN IMMUN, V105, P769, DOI 10.1067/mai.2000.105121; Dawkins PA, 2001, THORAX, V56, P972, DOI 10.1136/thorax.56.12.972; de Boer WI, 1998, AM J RESP CRIT CARE, V158, P1951, DOI 10.1164/ajrccm.158.6.9803053; de Boer WI, 2000, J PATHOL, V190, P619, DOI 10.1002/(SICI)1096-9896(200004)190:5<619::AID-PATH555>3.0.CO;2-6; deGodoy I, 1996, AM J RESP CRIT CARE, V153, P633, DOI 10.1164/ajrccm.153.2.8564110; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; Di Stefano A, 2002, EUR RESPIR J, V20, P556, DOI 10.1183/09031936.02.00272002; Dowson LJ, 2001, AM J RESP CRIT CARE, V164, P1805, DOI 10.1164/ajrccm.164.10.2106036; Fedorak RN, 2000, GASTROENTEROLOGY, V119, P1473, DOI 10.1053/gast.2000.20229; Frungieri MB, 2002, P NATL ACAD SCI USA, V99, P15072, DOI 10.1073/pnas.232422999; Fujie K, 1999, INFLAMM RES, V48, P160, DOI 10.1007/s000110050440; Gamble E, 2003, AM J RESP CRIT CARE, V168, P976, DOI 10.1164/rccm.200212-1490OC; GOLD, GLOB STRAT DIAGN MAN; Gompertz S, 2002, CHEST, V122, P289, DOI 10.1378/chest.122.1.289; Hansel TT, 2003, FASEB J, V17, P1298, DOI 10.1096/fj.02-0633fje; Hansel TT, 2002, DRUGS TODAY, V38, P585, DOI 10.1358/dot.2002.38.9.696535; Hansel TT, 2001, NEW DRUGS ASTHMA ALL; HANSEL TT, 2004, ATLAS CHRONIC OBSTRU; Harris SG, 2002, ADV EXP MED BIOL, V507, P421; Hay Douglas W. P., 2001, Current Opinion in Pharmacology, V1, P242, DOI 10.1016/S1471-4892(01)00043-1; Hill AT, 1999, AM J RESP CRIT CARE, V160, P893, DOI 10.1164/ajrccm.160.3.9901091; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701, DOI 10.1164/ajrccm.162.2.9908132; Inoue A, 2003, LANCET, V361, P137, DOI 10.1016/S0140-6736(03)12190-3; Ishikawa T, 2003, CLIN EXP ALLERGY, V33, P808, DOI 10.1046/j.1365-2222.2003.01681.x; Ito K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/pnas.132556899; Ito K, 2001, FASEB J, V15, pA473; Jarvis B, 1999, DRUGS, V57, P945, DOI 10.2165/00003495-199957060-00014; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kantak KM, 2003, DRUGS, V63, P341, DOI 10.2165/00003495-200363040-00001; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693, DOI 10.1164/ajrccm.163.7.2009041; Kranenburg AR, 2002, AM J RESP CELL MOL, V27, P517, DOI 10.1165/rcmb.4474; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Kuss H, 2003, J PHARMACOL EXP THER, V307, P373, DOI 10.1124/jpet.103.053942; Lamontagne S, 2001, BRAIN RES, V920, P84, DOI 10.1016/S0006-8993(01)03023-2; Leung-Toung R, 2002, CURR MED CHEM, V9, P979, DOI 10.2174/0929867024606704; Lucey EC, 2003, RESPIRATION, V70, P200, DOI 10.1159/000070068; Luisetti M, 1996, CHEST, V110, pS278, DOI 10.1378/chest.110.6_Supplement.278S; Luisetti M, 1996, EUR RESPIR J, V9, P1482, DOI 10.1183/09031936.96.09071482; MacNee W, 2000, CHEST, V117, p303S, DOI 10.1378/chest.117.5_suppl_1.303S-a; Mak JCW, 2000, N-S ARCH PHARMACOL, V362, P520, DOI 10.1007/s002100000321; Mao JT, 2002, AM J RESP CRIT CARE, V165, P718, DOI 10.1164/ajrccm.165.5.2106123; Markham A, 2000, DRUGS, V59, P1341, DOI 10.2165/00003495-200059060-00010; Massaro GD, 1997, NAT MED, V3, P675, DOI 10.1038/nm0697-675; Meja KK, 2000, BRIT J PHARMACOL, V131, P1143, DOI 10.1038/sj.bjp.0703684; Miotto D, 2002, THORAX, V57, P146, DOI 10.1136/thorax.57.2.146; Montuschi P, 2003, THORAX, V58, P585, DOI 10.1136/thorax.58.7.585; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175, DOI 10.1164/ajrccm.162.3.2001063; Nadel Jay A., 2001, Current Opinion in Pharmacology, V1, P254, DOI 10.1016/S1471-4892(01)00045-5; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Noguera A, 1998, AM J RESP CRIT CARE, V158, P1664, DOI 10.1164/ajrccm.158.5.9712092; Otto WR, 2002, J PATHOL, V197, P527, DOI 10.1002/path.1160; Paredi P, 2000, AM J RESP CRIT CARE, V162, P369, DOI 10.1164/ajrccm.162.2.9909025; Patel HJ, 2003, J IMMUNOL, V170, P2663, DOI 10.4049/jimmunol.170.5.2663; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Poole PJ, 2001, BMJ-BRIT MED J, V322, P1271, DOI 10.1136/bmj.322.7297.1271; Rabinowitz MH, 2001, J MED CHEM, V44, P4252, DOI 10.1021/jm0102654; Reid Peter, 2002, Curr Opin Investig Drugs, V3, P1165; Robichaud A, 2002, J CLIN INVEST, V110, P1045, DOI 10.1172/JCI200215506; Rogers DF, 2002, CURR OPIN PHARMACOL, V2, P249, DOI 10.1016/S1471-4892(02)00146-7; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Russell REK, 2002, AM J RESP CELL MOL, V26, P602, DOI 10.1165/ajrcmb.26.5.4685; Rutgers SR, 2000, THORAX, V55, P12, DOI 10.1136/thorax.55.1.12; Saetta M, 2002, AM J RESP CRIT CARE, V165, P1404, DOI 10.1164/rccm.2107139; Saetta M, 2001, AM J RESP CRIT CARE, V163, P1304, DOI 10.1164/ajrccm.163.6.2009116; Sandford AJ, 2002, THORAX, V57, P736, DOI 10.1136/thorax.57.8.736; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Shapiro SD, 1999, AM J RESP CELL MOL, V20, P1100, DOI 10.1165/ajrcmb.20.6.f151; Shapiro SD, 2000, CHEST, V117, p223S, DOI 10.1378/chest.117.5_suppl_1.223S; Silbaugh SA, 2000, N-S ARCH PHARMACOL, V361, P397, DOI 10.1007/s002109900211; Stecenko AA, 2003, GENE THER, V10, P95, DOI 10.1038/sj.gt.3301947; Stockley RA, 1999, AM J RESP CRIT CARE, V160, pS49, DOI 10.1164/ajrccm.160.supplement_1.13; Sturton G, 2002, CHEST, V121, p192S, DOI 10.1378/chest.121.5_suppl.192S; Szafranski W, 2003, EUR RESPIR J, V21, P74, DOI 10.1183/09031936.03.00031402; Takanashi S, 1999, EUR RESPIR J, V14, P309, DOI 10.1034/j.1399-3003.1999.14b12.x; Takizawa H, 2001, AM J RESP CRIT CARE, V163, P1476, DOI 10.1164/ajrccm.163.6.9908135; Tashkin DP, 2001, LANCET, V357, P1571, DOI 10.1016/S0140-6736(00)04724-3; Traves SL, 2002, THORAX, V57, P590, DOI 10.1136/thorax.57.7.590; Underwood DC, 2000, AM J PHYSIOL-LUNG C, V279, pL895, DOI 10.1152/ajplung.2000.279.5.L895; Vernooy JH, 2002, AM J RESP CRIT CARE, V166, P1218, DOI 10.1164/rccm.2202023; Vestbo J, 2002, NOVART FDN SYMP, V248, P3; Vincken W, 2002, EUR RESPIR J, V19, P209, DOI 10.1183/09031936.02.00238702; Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058; Ward S, 2003, CHEM BIOL, V10, P207, DOI 10.1016/S1074-5521(03)00048-6; Yakymovych I, 2002, BIOCHEMISTRY-US, V41, P11000, DOI 10.1021/bi025936u; Yamamoto C, 1997, CHEST, V112, P505, DOI 10.1378/chest.112.2.505; Yang XD, 1999, J LEUKOCYTE BIOL, V66, P401, DOI 10.1002/jlb.66.3.401; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Zhou YH, 2002, NOVART FDN SYMP, V248, P150	119	141	169	0	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	2004	364	9438					985	996		10.1016/S0140-6736(04)17025-6	http://dx.doi.org/10.1016/S0140-6736(04)17025-6			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364192				2022-12-28	WOS:000223831000031
J	Yusuf, S; Hawken, S; Ounpuu, S; Dans, T; Avezum, A; Lanas, F; McQueen, M; Budaj, A; Pais, P; Varigos, J; Liu, LS				Yusuf, S; Hawken, S; Ounpuu, S; Dans, T; Avezum, A; Lanas, F; McQueen, M; Budaj, A; Pais, P; Varigos, J; Liu, LS		INTERHEART Study Investigators	Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study	LANCET			English	Article							CORONARY-HEART-DISEASE; APOLIPOPROTEIN-A-I; CHEMISTRY STANDARDIZATION PROJECT; INTERNATIONAL REFERENCE MATERIAL; CARDIOVASCULAR-DISEASE; ATTRIBUTABLE RISK; BLOOD-PRESSURE; GLOBAL BURDEN; POPULATION; MORTALITY	Background Although more than 80% of the global burden of cardiovascular disease occurs in low-income and middle-income countries, knowledge of the importance of risk factors is largely derived from developed countries. Therefore, the effect of such factors on risk of coronary heart disease in most regions of the world is unknown. Methods We established a standardised case-control study of acute myocardial infarction in 52 countries, representing every inhabited continent. 15152 cases and 14820 controls were enrolled. The relation of smoking, history of hypertension or diabetes, waist/hip ratio, dietary patterns, physical activity, consumption of alcohol, blood apolipoproteins (Apo), and psychosocial factors to myocardial infarction are reported here. Odds ratios and their 99% CIs for the association of risk factors to myocardial infarction and their population attributable risks (PAR) were calculated. Findings Smoking (odds ratio 2.87 for current vs never, PAR 35.7% for current and former vs never), raised ApoB/ApoA1 ratio (3.25 for top vs lowest quintile, PAR 49.2% for top four quintiles vs lowest quintile), history of hypertension (1.91, PAR 17.9%), diabetes (2.37, PAR 9.9%), abdominal obesity (1.12 for top vs lowest tertile and 1.62 for middle vs lowest tertile, PAR 20.1% for top two tertiles vs lowest tertile), psychosocial factors (2.67, PAR 32.5%), daily consumption of fruits and vegetables (0 . 70, PAR 13.7% for lack of daily consumption), regular alcohol consumption (0 . 91, PAR 6.7%), and regular physical activity (0 . 86, PAR 12.2%), were all significantly related to acute myocardial infarction (p<0 . 0001 for all risk factors and p=0 . 03 for alcohol). These associations were noted in men and women, old and young, and in all regions of the world. Collectively, these nine risk factors accounted for 90% of the PAR in men and 94% in women. Interpretation Abnormal lipids, smoking, hypertension, diabetes, abdominal obesity, psychosocial factors, consumption of fruits, vegetables, and alcohol, and regular physical activity account for most of the risk of myocardial infarction worldwide in both sexes and at all ages; in all regions. his finding suggests that approaches to prevention can be based on similar principles worldwide and have the potential to prevent most premature cases of myocardial infarction.	Hamilton Gen Hosp, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada	McMaster University; Population Health Research Institute	Yusuf, S (corresponding author), Hamilton Gen Hosp, Populat Hlth Res Inst, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	yusufs@mcmaster.ca	Lanas, Fernando/AAE-8842-2022; Avezum, Alvaro/AAP-7687-2020; Avezum, Alvaro AA/K-6137-2016	Avezum, Alvaro AA/0000-0002-3073-6890; Lanas, Fernando/0000-0003-3595-9759; Yusuf, Salim/0000-0003-4776-5601				[Anonymous], 1996, GLOBAL BURDEN DIS CO; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; BENICHOU J, 1990, BIOMETRICS, V46, P991, DOI 10.2307/2532443; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; Canto JG, 2003, JAMA-J AM MED ASSOC, V290, P947, DOI 10.1001/jama.290.7.947; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Collins R, 2003, LANCET, V361, P2005; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Engel LS, 2003, J NATL CANCER I, V95, P1404, DOI 10.1093/jnci/djg047; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MARCOVINA SM, 1993, CLIN CHEM, V39, P773; MARCOVINA SM, 1994, CLIN CHEM, V40, P586; Ounpuu S, 2001, AM HEART J, V141, P711, DOI 10.1067/mhj.2001.114974; Pais P, 1996, LANCET, V348, P358, DOI 10.1016/S0140-6736(96)02507-X; PARISH S, 1995, BMJ-BRIT MED J, V311, P471, DOI 10.1136/bmj.311.7003.471; Rosengren A, 2004, LANCET, V364, P953, DOI 10.1016/S0140-6736(04)17019-0; Rosengren A, 2001, EUR HEART J, V22, P136, DOI 10.1053/euhj.2000.2179; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; Stampfer MJ, 2000, NEW ENGL J MED, V343, P16, DOI 10.1056/NEJM200007063430103; Turnbull F, 2003, LANCET, V362, P1527; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Walldius G, 2001, LANCET, V358, P2026, DOI 10.1016/S0140-6736(01)07098-2; WALTER SD, 1975, BIOMETRIKA, V62, P371, DOI 10.1093/biomet/62.2.371; Wilhelmsen L, 1997, EUR HEART J, V18, P572; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487; Yusuf S, 2001, CIRCULATION, V104, P2855, DOI 10.1161/hc4701.099488	28	7278	7617	34	835	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	2004	364	9438					937	952		10.1016/S0140-6736(04)17018-9	http://dx.doi.org/10.1016/S0140-6736(04)17018-9			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364185	Green Published			2022-12-28	WOS:000223831000024
J	Fortin, NJ; Wright, SP; Eichenbaum, H				Fortin, NJ; Wright, SP; Eichenbaum, H			Recollection-like memory retrieval in rats is dependent on the hippocampus	NATURE			English	Article							HUMAN RECOGNITION MEMORY; OBJECT-RECOGNITION; EPISODIC MEMORY; FAMILIARITY; DAMAGE; LESIONS; MONKEYS; INFORMATION; COMPONENTS; INSIGHTS	Recognition memory may be supported by two independent types of retrieval, conscious recollection of a specific experience and a sense of familiarity gained from previous exposure to particular stimuli(1,2). In humans, signal detection techniques have been used to distinguish recollection and familiarity, respectively, in asymmetrical and curvilinear components of their receiver operating characteristic (ROC) curves, standard curves that represent item recognition across different levels of confidence or bias. To determine whether animals also employ multiple processes in recognition memory and to explore the anatomical basis of this distinction, we adapted these techniques to examine odour recognition memory in rats. Their ROC curve had asymmetrical and curvilinear components, indicating the existence of both recollection and familiarity in rats. Furthermore, following selective damage to the hippocampus the ROC curve became entirely symmetrical and remained curvilinear, supporting the view that the hippocampus specifically mediates the capacity for recollection.	Boston Univ, Ctr Memory & Brain, Boston, MA 02215 USA	Boston University	Eichenbaum, H (corresponding author), Boston Univ, Ctr Memory & Brain, 2 Cummington St, Boston, MA 02215 USA.	hbe@bu.edu		Fortin, Norbert/0000-0002-6793-6984	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009973] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG009973-070005, P01 AG009973] Funding Source: Medline; NIMH NIH HHS [R01 MH052090-05, R01 MH052090] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Beason-Held LL, 1999, HIPPOCAMPUS, V9, P562, DOI 10.1002/(SICI)1098-1063(1999)9:5<562::AID-HIPO10>3.0.CO;2-X; Brown MW, 2001, NAT REV NEUROSCI, V2, P51, DOI 10.1038/35049064; Bunsey M, 1996, NATURE, V379, P255, DOI 10.1038/379255a0; Clark RE, 1998, SCIENCE, V280, P77, DOI 10.1126/science.280.5360.77; Davachi L, 2002, J NEUROPHYSIOL, V88, P982, DOI 10.1152/jn.2002.88.2.982; Day M, 2003, NATURE, V424, P205, DOI 10.1038/nature01769; Dudchenko PA, 2000, J NEUROSCI, V20, P2964; Eacott MJ, 2004, J NEUROSCI, V24, P1948, DOI 10.1523/JNEUROSCI.2975-03.2004; EICHENBAUM H, 1994, BEHAV BRAIN SCI, V17, P449, DOI 10.1017/S0140525X00035391; Fortin NJ, 2002, NAT NEUROSCI, V5, P458, DOI 10.1038/nn834; HOCKLEY WE, 1992, J EXP PSYCHOL LEARN, V18, P1321, DOI 10.1037/0278-7393.18.6.1321; Kesner RP, 1990, NEUROBIOLOGY COMP CO, P179; Macmillan N. A., 1991, DETECTION THEORY USE; Manns JR, 2003, NEURON, V37, P171, DOI 10.1016/S0896-6273(02)01147-9; Mumby DG, 2002, LEARN MEMORY, V9, P49, DOI 10.1101/lm.41302; Mumby DG, 2001, BEHAV BRAIN RES, V127, P159, DOI 10.1016/S0166-4328(01)00367-9; Murray EA, 1998, J NEUROSCI, V18, P6568; Nemanic S, 2004, J NEUROSCI, V24, P2013, DOI 10.1523/JNEUROSCI.3763-03.2004; Ranganath C, 2003, NEUROPSYCHOLOGIA, V41, P378, DOI 10.1016/S0028-3932(02)00169-0; Sherman SJ, 2003, BEHAV NEUROSCI, V117, P526, DOI 10.1037/0735-7044.117.3.526; Stark CEL, 2000, J NEUROSCI, V20, P7776; Steckler T, 1998, PROG NEUROBIOL, V54, P313, DOI 10.1016/S0301-0082(97)00061-0; Tulving E, 2002, ANNU REV PSYCHOL, V53, P1, DOI 10.1146/annurev.psych.53.100901.135114; Wood ER, 2000, NEURON, V27, P623, DOI 10.1016/S0896-6273(00)00071-4; Yonelinas AP, 2002, J MEM LANG, V46, P441, DOI 10.1006/jmla.2002.2864; Yonelinas AP, 1998, NEUROPSYCHOLOGY, V12, P323, DOI 10.1037/0894-4105.12.3.323; Yonelinas AP, 2002, PSYCHON B REV, V9, P575, DOI 10.3758/BF03196315; Yonelinas AP, 2002, NAT NEUROSCI, V5, P1236, DOI 10.1038/nn961; Yonelinas AP, 2001, PHILOS T R SOC B, V356, P1363, DOI 10.1098/rstb.2001.0939; Zola SM, 2000, J NEUROSCI, V20, P451, DOI 10.1523/JNEUROSCI.20-01-00451.2000	30	329	336	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2004	431	7005					188	191		10.1038/nature02853	http://dx.doi.org/10.1038/nature02853			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356631	Green Accepted			2022-12-28	WOS:000223746000045
J	Shao, ZP; Haile, SM				Shao, ZP; Haile, SM			A high-performance cathode for the next generation of solid-oxide fuel cells	NATURE			English	Article							OXYGEN PERMEATION; MEMBRANES; ELECTROLYTE; STABILITY	Fuel cells directly and efficiently convert chemical energy to electrical energy(1). Of the various fuel cell types, solid-oxide fuel cells (SOFCs) combine the benefits of environmentally benign power generation with fuel flexibility. However, the necessity for high operating temperatures (800-1,000 degreesC) has resulted in high costs and materials compatibility challenges(2). As a consequence, significant effort has been devoted to the development of intermediate-temperature (500-700 degreesC) SOFCs. A key obstacle to reduced-temperature operation of SOFCs is the poor activity of traditional cathode materials for electrochemical reduction of oxygen in this temperature regime(2). Here we present Ba0.5Sr0.5Co0.8Fe0.2O3-delta(BSCF) as a new cathode material for reduced-temperature SOFC operation. BSCF, incorporated into a thin-film doped ceria fuel cell, exhibits high power densities (1,010 mW cm(-2) and 402 mW cm(-2) at 600 degreesC and 500 degreesC, respectively) when operated with humidified hydrogen as the fuel and air as the cathode gas. We further demonstrate that BSCF is ideally suited to 'single-chamber' fuel-cell operation, where anode and cathode reactions take place within the same physical chamber(3). The high power output of BSCF cathodes results from the high rate of oxygen diffusion through the material. By enabling operation at reduced temperatures, BSCF cathodes may result in widespread practical implementation of SOFCs.	CALTECH, Pasadena, CA 91125 USA	California Institute of Technology	Haile, SM (corresponding author), CALTECH, Pasadena, CA 91125 USA.	smhaile@caltech.edu	Haile, Sossina M/I-3448-2015; shao, zongping/B-5250-2013; Shao, Zongping/AAY-8177-2020	shao, zongping/0000-0002-4538-4218				Brandon NP, 2003, ANNU REV MATER RES, V33, P183, DOI 10.1146/annurev.matsci.33.022802.094122; Fleig J, 2003, ANNU REV MATER RES, V33, P361, DOI 10.1146/annurev.matsci.33.022802.093258; Fukunaga H, 2000, SOLID STATE IONICS, V132, P279, DOI 10.1016/S0167-2738(00)00642-1; Hibino T, 2000, SCIENCE, V288, P2031, DOI 10.1126/science.288.5473.2031; Huang KQ, 2001, J ELECTROCHEM SOC, V148, pA788, DOI 10.1149/1.1378289; Ishihara T, 2002, J ELECTROCHEM SOC, V149, pA823, DOI 10.1149/1.1480015; Kim S, 1998, SOLID STATE IONICS, V106, P189, DOI 10.1016/S0167-2738(97)00492-X; Ralph JM, 2003, J ELECTROCHEM SOC, V150, pA1518, DOI 10.1149/1.1617300; Shao ZP, 2001, J MEMBRANE SCI, V183, P181, DOI 10.1016/S0376-7388(00)00591-3; Shao ZP, 2000, J MEMBRANE SCI, V172, P177, DOI 10.1016/S0376-7388(00)00337-9; Steele BCH, 2000, SOLID STATE IONICS, V129, P95, DOI 10.1016/S0167-2738(99)00319-7; Steele BCH, 2001, NATURE, V414, P345, DOI 10.1038/35104620; Tsai T, 1997, SOLID STATE IONICS, V93, P207, DOI 10.1016/S0167-2738(96)00524-3; van Veen AC, 2003, CHEM COMMUN, P32, DOI 10.1039/b207848a; Xia CR, 2001, J AM CERAM SOC, V84, P1903; Xia CR, 2002, ADV MATER, V14, P521, DOI 10.1002/1521-4095(20020404)14:7<521::AID-ADMA521>3.3.CO;2-3; Xu SJ, 1999, CHEM ENG SCI, V54, P3839, DOI 10.1016/S0009-2509(99)00015-9	17	2578	2651	71	2094	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2004	431	7005					170	173		10.1038/nature02863	http://dx.doi.org/10.1038/nature02863			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356627	Green Accepted			2022-12-28	WOS:000223746000040
J	Read, J				Read, J			ABC of sexual health - Sexual problem's associated with infertility, pregnancy, and ageing	BMJ-BRITISH MEDICAL JOURNAL			English	Review												enderby@janeandray.ndo.co.uk						ADLER N, 1991, INFERTILITY PERSPECT; Baikie E., 2002, SEX RELATSH THER, V17, P289, DOI DOI 10.1080/14681990220149095; BANCROFT J, 1989, HUMAN SEXUALITY ITS, P282; BRECHER EM, 1984, LOVE SEX AGEING CONS; GUANOTRUJILLO B, 1987, HLTH CARE WOM INT, V5, P339; KAPLAN HS, 1993, NEW INJECTION TREATM, P142; MILLS JL, 1981, LANCET, V2, P136, DOI 10.1016/S0140-6736(81)90311-1; PESCE V, 2002, SEX RELATION THER, V17, P282; READ J, 1995, COUNSELLING FERTILIT, P104; REAMY K J, 1985, Journal of Psychosomatic Obstetrics and Gynecology, V4, P263, DOI 10.3109/01674828509016728; Savage W, 1984, Midwife Health Visit Community Nurse, V20, P398	11	34	34	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 4	2004	329	7465					559	561		10.1136/bmj.329.7465.559	http://dx.doi.org/10.1136/bmj.329.7465.559			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853DE	15345632	Green Published			2022-12-28	WOS:000223805800027
J	Baumiller, TK; Gahn, FJ				Baumiller, TK; Gahn, FJ			Testing predator-driven evolution with paleozoic crinoid arm regeneration	SCIENCE			English	Article							FLOROMETRA-SERRATISSIMA ECHINODERMATA; ADAPTATIONS; AUTOTOMY; TIME	Regenerating arms of crinoids represent direct evidence of nonlethal attacks by predators and provide an opportunity for exploring the importance of predation through geologic time. Analysis of 11 Paleozoic crinoid Lagerstatten revealed a significant increase in arm regeneration during the Siluro-Devonian. During this interval, referred to as the Middle Pateozoic Marine Revolution, the diversity of shell-crushing predators increased, and antipredatory morphologies among invertebrate prey, such as crinoids, became more common. Crinoid arm-regeneration data suggest an increase in nonlethal attacks at this time and represent a causal link between those patterns, which implies an important role for predator-driven evolution.	Univ Michigan, Museum Paleontol, Ann Arbor, MI 48105 USA; Smithsonian Inst, Natl Museum Nat Hist, Dept Paleobiol, Washington, DC 20013 USA	University of Michigan System; University of Michigan; Smithsonian Institution; Smithsonian National Museum of Natural History	Baumiller, TK (corresponding author), Univ Michigan, Museum Paleontol, Ann Arbor, MI 48105 USA.	tomaszb@umich.edu; gahn.forest@nmnh.si.edu	Baumiller, Tomasz K/C-3596-2012	Baumiller, Tomasz K/0000-0002-4506-9330				ALLMON WD, 1990, PALAEONTOLOGY, V33, P595; Baumiller T.K., 2003, P243; Baumiller TK, 2001, ECHINODERMS 2000, P3; BAUMILLER TK, 1994, ECHINODERMS THROUGH TIME, P193; Brett CE, 2003, T GEOBIOL, V20, P401; EFRON B, 1981, BIOMETRIKA, V68, P589, DOI 10.1093/biomet/68.3.589; FISHELSON L, 1974, MAR BIOL, V26, P183, DOI 10.1007/BF00388888; FOOTE M, 1995, PALEOBIOLOGY, V21, P273, DOI 10.1017/S0094837300013300; HOLLAND ND, 1981, ZOOMORPHOLOGY, V98, P169, DOI 10.1007/BF00310434; MEYER DL, 1985, PALEOBIOLOGY, V11, P154, DOI 10.1017/S0094837300011477; MEYER DL, 1984, MAR BIOL, V78, P179, DOI 10.1007/BF00394698; MEYER DL, 1993, J PALEONTOL, V67, P250, DOI 10.1017/S0022336000032170; MLADENOV PV, 1983, CAN J ZOOL, V61, P2873, DOI 10.1139/z83-375; NEUMANN C, 1998, FOSSILIEN, P175; OJI T, 1994, PALEOBIOLOGY, V20, P27, DOI 10.1017/S0094837300011118; Oji T, 1996, PALEOBIOLOGY, V22, P339, DOI 10.1017/S0094837300016328; Schneider J.A., 1988, P531; SCOTESE CR, 1990, GEO SOC MEM, V12, P1, DOI 10.1144/GSL.MEM.1990.012.01.01; SIGNOR PW, 1984, PALEOBIOLOGY, V10, P229, DOI 10.1017/S0094837300008174; SIMMS MJ, 1993, PALAEONTOLOGY, V36, P91; VERMEIJ G J, 1977, Paleobiology, V3, P245; Vermeij G.J., 1987, EVOLUTION ESCALATION; VERMEIJ GJ, 1994, ANNU REV ECOL SYST, V25, P219, DOI 10.1146/annurev.es.25.110194.001251; VERMEIJ GJ, 1981, SCIENCE, V214, P1024, DOI 10.1126/science.214.4524.1024; VERMEIJ GJ, 1985, AM NAT, V125, P470, DOI 10.1086/284354; WATERS JA, 1991, PALEOBIOLOGY, V17, P400, DOI 10.1017/S0094837300010733	26	72	80	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1453	1455		10.1126/science.1101009	http://dx.doi.org/10.1126/science.1101009			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353799				2022-12-28	WOS:000223761900045
J	Denicourt, C; Dowdy, SF				Denicourt, C; Dowdy, SF			Targeting apoptotic pathways in cancer cells	SCIENCE			English	Editorial Material							PROTEINS		Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Denicourt, C (corresponding author), Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA.	sdowdy@ucsd.edu		Denicourt, Catherine/0000-0001-8721-0163				Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; LEVIN VA, 1980, J MED CHEM, V23, P682, DOI 10.1021/jm00180a022; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Patch JA, 2002, CURR OPIN CHEM BIOL, V6, P872, DOI 10.1016/S1367-5931(02)00385-X; Pope RM, 2002, NAT REV IMMUNOL, V2, P527, DOI 10.1038/nri846; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191	11	82	95	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1411	1413		10.1126/science.1102974	http://dx.doi.org/10.1126/science.1102974			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353788				2022-12-28	WOS:000223761900031
J	Crooker, SA; Rickel, DG; Balatsky, AV; Smith, DL				Crooker, SA; Rickel, DG; Balatsky, AV; Smith, DL			Spectroscopy of spontaneous spin noise as a probe of spin dynamics and magnetic resonance	NATURE			English	Article							ATOMIC SPIN; DIODE-LASER; FLUCTUATIONS	Not all noise in experimental measurements is unwelcome. Certain fundamental noise sources contain valuable information about the system itself - a notable example being the inherent voltage fluctuations ( Johnson noise) that exist across any resistor, which allow the temperature to be determined(1,2). In magnetic systems, fundamental noise can exist in the form of random spin fluctuations(3,4). For example, statistical fluctuations of N paramagnetic spins should generate measurable noise of order rootN spins, even in zero magnetic field(5,6). Here we exploit this effect to perform perturbation-free magnetic resonance. We use off-resonant Faraday rotation to passively(7,8) detect the magnetization noise in an equilibrium ensemble of paramagnetic alkali atoms; the random fluctuations generate spontaneous spin coherences that precess and decay with the same characteristic energy and timescales as the macroscopic magnetization of an intentionally polarized or driven ensemble. Correlation spectra of the measured spin noise reveal g-factors, nuclear spin, isotope abundance ratios, hyperfine splittings, nuclear moments and spin coherence lifetimes - without having to excite, optically pump or otherwise drive the system away from thermal equilibrium. These noise signatures scale inversely with interaction volume, suggesting a possible route towards non-perturbative, sourceless magnetic resonance of small systems.	Los Alamos Natl Lab, Natl High Magnet Field Lab, Los Alamos, NM 87545 USA; Los Alamos Natl Lab, Div Theory, Los Alamos, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory	Crooker, SA (corresponding author), Los Alamos Natl Lab, Natl High Magnet Field Lab, POB 1663, Los Alamos, NM 87545 USA.	crooker@lanl.gov						ALEKSANDROV EB, 1981, ZH EKSP TEOR FIZ+, V81, P132; AWSCHALOM DD, 1992, SCIENCE, V258, P414, DOI 10.1126/science.258.5081.414; BLOCH F, 1946, PHYS REV, V70, P460, DOI 10.1103/PhysRev.70.460; Cleland AN, 2002, J APPL PHYS, V92, P2758, DOI 10.1063/1.1499745; Corney A., 1977, ATOMIC LASER SPECTRO, VFirst; HAPPER W, 1967, PHYS REV LETT, V18, P577, DOI 10.1103/PhysRevLett.18.577; HAPPER W, 1972, REV MOD PHYS, V44, P169, DOI 10.1103/RevModPhys.44.169; Imamoglu A, 1999, PHYS REV LETT, V83, P4204, DOI 10.1103/PhysRevLett.83.4204; ITANO WM, 1993, PHYS REV A, V47, P3554, DOI 10.1103/PhysRevA.47.3554; Ito T, 2003, J PHYS SOC JPN, V72, P962, DOI 10.1143/JPSJ.72.962; Joglekar YN, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.086803; Johnson JB, 1927, NATURE, V119, P50, DOI 10.1038/119050c0; Jury JC, 2002, IEEE T MAGN, V38, P3545, DOI 10.1109/TMAG.2002.802706; KASTLER A, 1967, SCIENCE, V158, P214, DOI 10.1126/science.158.3798.214; KUBO R, 1966, REP PROG PHYS, V29, P255, DOI 10.1088/0034-4885/29/1/306; Kuzmich A, 1999, PHYS REV A, V60, P2346, DOI 10.1103/PhysRevA.60.2346; Kuzmich A, 2000, PHYS REV LETT, V85, P1594, DOI 10.1103/PhysRevLett.85.1594; Mamin HJ, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.207604; MANASSEN Y, 1989, PHYS REV LETT, V62, P2531, DOI 10.1103/PhysRevLett.62.2531; Mitsui T, 2000, PHYS REV LETT, V84, P5292, DOI 10.1103/PhysRevLett.84.5292; Nussinov Z, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.085402; SLEATOR T, 1985, PHYS REV LETT, V55, P1742, DOI 10.1103/PhysRevLett.55.1742; Smith N, 2001, APPL PHYS LETT, V78, P1448, DOI 10.1063/1.1352694; Sorensen JL, 1998, PHYS REV LETT, V80, P3487, DOI 10.1103/PhysRevLett.80.3487; Weaver RL, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.134301; WEISSMAN MB, 1993, REV MOD PHYS, V65, P829, DOI 10.1103/RevModPhys.65.829; White DR, 1996, METROLOGIA, V33, P325, DOI 10.1088/0026-1394/33/4/6; Wolf SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/science.1065389; YABUZAKI T, 1991, PHYS REV LETT, V67, P2453, DOI 10.1103/PhysRevLett.67.2453; [No title captured]	30	187	190	1	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2004	431	7004					49	52		10.1038/nature02804	http://dx.doi.org/10.1038/nature02804			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343328	Green Submitted			2022-12-28	WOS:000223641500037
J	Kachalia, A; Studdert, DM				Kachalia, A; Studdert, DM			Professional liability issues in graduate medical education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MALPRACTICE; PHYSICIANS; LITIGATION; RESIDENTS; STEPS; CARE; LAW	Resident physicians, attending physicians, and graduate medical education (GME) institutions share a collective responsibility to deliver safe and appropriate care to patients. The law does not offer concessions in quality of care to accommodate GME. Resident physicians are generally held to the same standard of care as attending physicians in their respective specialties. This principle encourages resident physicians to seek supervision and attending physicians to provide the same. Attending physicians face malpractice exposure not only for the care they provide but also for the care they direct. In addition, they may be held vicariously liable for the negligence of resident physicians working with them, or directly liable for inadequate supervision. What constitutes adequate supervision is unsettled in the law. As the standards in this area evolve, it is reasonable to expect that the profession's and the public's heightened attention to patient safety will continue to move the courts toward higher standards of supervision. GME institutions and programs bear legal responsibility for both the care they deliver and the negligence of their employees. They also face liability for failing to administer safe systems of care. Work hour restrictions and a growing understanding of the role of organizational factors in contributing to and preventing medical injury may increase the legal expectations imposed on GME programs.	Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Studdert, DM (corresponding author), Harvard Univ, Sch Publ Hlth, 677 Huntington Ave, Boston, MA 02115 USA.	studdert@hsph.harvard.edu	Studdert, David/AAF-3116-2021	Studdert, David/0000-0003-0585-5537	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K02HS011285] Funding Source: NIH RePORTER; AHRQ HHS [KO2HS11285] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Accreditation Council for Graduate Medical Education, ACGME I REQ; ASCH DA, 1988, NEW ENGL J MED, V318, P771, DOI 10.1056/NEJM198803243181209; BERENSON RA, MED MALPRACTICE LIAB; Berger JE, 2000, PEDIATRICS, V106, P605; Blendon RJ, 2002, NEW ENGL J MED, V347, P1933, DOI 10.1056/NEJMsa022151; BRUBAKER B, 2004, WASHINGTON POST 0112, pE1; Charles S C, 1987, J Med Assoc Ga, V76, P171; CHARLES SC, 1985, AM J PSYCHIAT, V142, P437; Charles SC, 2001, WESTERN J MED, V174, P55, DOI 10.1136/ewjm.174.1.55; Friedrich MJ, 2001, JAMA-J AM MED ASSOC, V286, P1563, DOI 10.1001/jama.286.13.1563; Helms L B, 1995, J Contemp Health Law Policy, V11, P317; Mello MM, 2003, NEW ENGL J MED, V348, P2281, DOI 10.1056/NEJMp030064; Merenstein D, 2004, JAMA-J AM MED ASSOC, V291, P15, DOI 10.1001/jama.291.1.15; Miller FH, 2003, JAMA-J AM MED ASSOC, V289, P913, DOI 10.1001/jama.289.7.913; Peters PG, 2002, IOWA LAW REV, V87, P909; PRAGER IO, 1999, AM MED NEWS     0322, P1; PRAGER IO, 1999, AM MED NEWS     0322, P57; Roberts RG, 2003, POSTGRAD MED, V114, P9, DOI 10.3810/pgm.2003.12.1554; Schoenbaum SC, 2004, ANN INTERN MED, V140, P51, DOI 10.7326/0003-4819-140-1-200401060-00011; Studdert DM, 2004, NEW ENGL J MED, V350, P283, DOI 10.1056/NEJMhpr035470; TORRY S, 1991, WASH POST       0107, pF5; Ward JL, 2001, J LEGAL MED, V22, P283, DOI 10.1080/019476401750365237; Whetsell Jennifer F, 2003, Ann Health Law, V12, P23; YUNGTUM JR, 1995, CREIGHTON LAW REV, V29, P379; NATL PRACTITIONER DA	25	50	51	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2004	292	9					1051	1056		10.1001/jama.292.9.1051	http://dx.doi.org/10.1001/jama.292.9.1051			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VH	15339896				2022-12-28	WOS:000223568700018
J	Burnell, RH; O'Keefe, M				Burnell, RH; O'Keefe, M			Asking parents unaskable questions	LANCET			English	Editorial Material							ETHICS; SUDDEN; DEATH		Univ Adelaide, Womens & Childrens Hosp, Dept Paediat, Adelaide, SA 5006, Australia	University of Adelaide; Womens & Childrens Hospital Australia	O'Keefe, M (corresponding author), Univ Adelaide, Womens & Childrens Hosp, Dept Paediat, Adelaide, SA 5006, Australia.	maree.okeefe@adelaide.edu.au		O'Keefe, Maree/0000-0002-0371-5322				Dent A, 1996, ARCH DIS CHILD, V74, P522, DOI 10.1136/adc.74.6.522; Dyregrov K, 2004, SOC SCI MED, V58, P391, DOI 10.1016/S0277-9536(03)00205-3; Edwards SJL, 2004, J MED ETHICS, V30, P88, DOI 10.1136/jme.2002.000166; Evans M, 2002, J MED ETHICS, V28, P41, DOI 10.1136/jme.28.1.41; PARKES CM, 1995, DEATH STUD, V19, P171, DOI 10.1080/07481189508252723; ROSENBLATT PC, 1995, DEATH STUD, V19, P139, DOI 10.1080/07481189508252721; VANCE JC, 1995, PEDIATRICS, V96, P933	7	18	18	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	2004	364	9436					737	738		10.1016/S0140-6736(04)16950-X	http://dx.doi.org/10.1016/S0140-6736(04)16950-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337385				2022-12-28	WOS:000223569600006
J	Kiso, M; Mitamura, K; Sakai-Tagawa, Y; Shiraishi, K; Kawakami, C; Kimura, K; Hayden, FG; Sugaya, N; Kawaoka, Y				Kiso, M; Mitamura, K; Sakai-Tagawa, Y; Shiraishi, K; Kawakami, C; Kimura, K; Hayden, FG; Sugaya, N; Kawaoka, Y			Resistant influenza A viruses in children treated with oseltarnivir: descriptive study	LANCET			English	Article							INHIBITOR SUSCEPTIBILITY NETWORK; NEURAMINIDASE INHIBITORS; SIALIC-ACID; IN-VITRO; ACTIVE-SITE; OSELTAMIVIR; SELECTION; CELLS; 4-GUANIDINO-NEU5AC2EN; SENSITIVITY	Background Oseltamivir is an effective inhibitor of influenza virus neuraminidase. Although viruses resistant to oseltamivir emerge less frequently than those resistant to amantadine or rimantadine, information on oseltamivir-resistant viruses arising during clinical use of the drug in children is limited. Our aim was to investigate oseltamivir resistance in a group of children treated for influenza. Methods We analysed influenza A viruses (H3N2) collected from 50 children before and during treatment with oseltamivir. We sequenced the genes for neuraminidase and haemagglutinin and studied the mutant neuraminidases for their sensitivity to oseltamivir carboxylate. Findings We found neuraminidase mutations in viruses from nine patients (18%), six of whom had mutations at position 292 (Arg292Lys) and two at position 119 (Glu119Val), which are known to confer resistance to neuraminidase inhibitors. We also identified another mutation (Asn294Ser) in one patient. Sensitivity testing to oseltamivir carboxylate revealed that the neuraminidases of viruses that have an Arg292Lys, Glu119Val, or Asn294Ser mutation were about 10(4)-10(5)-fold, 500-fold, or 300-fold more resistant than their pretreatment neuraminidases, respectively. Oseltamivir-resistant viruses were first detected at day 4 of treatment and on each successive day of the study. More than 10(3) infectious units per mL of virus were detected in some of the patients who did not shed drug-resistant viruses, even after 5 days of treatment. Interpretation Oseltamivir-resistant mutants in children being treated for influenza with oseltamivir arise more frequently than previously reported. Furthermore, children can be a source of viral transmission, even after 5 days of treatment with oseltamivir.	Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Virol,Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama, Japan; Kawasaki Municipal Hosp, Dept Paediat, Kawasaki, Kanagawa, Japan; Yokohama City Inst Hlth, Yokohama, Kanagawa, Japan; Isehara Kyodo Hosp, Dept Paediat, Isehara, Kanagawa, Japan; Univ Virginia, Sch Med, Charlottesville, VA 22908 USA; Keiyu Hosp, Dept Paediat, Yokohama, Kanagawa, Japan; Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA	University of Tokyo; Japan Science & Technology Agency (JST); University of Virginia; University of Wisconsin System; University of Wisconsin Madison	Kawaoka, Y (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Virol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	kawaoka@ims.u-tokyo.ac.jp						Barnett JM, 1999, VIROLOGY, V265, P286, DOI 10.1006/viro.1999.0058; BURMEISTER WP, 1992, EMBO J, V11, P49, DOI 10.1002/j.1460-2075.1992.tb05026.x; Carr J, 2002, ANTIVIR RES, V54, P79, DOI 10.1016/S0166-3542(01)00215-7; Gubareva LV, 2004, VIRUS RES, V103, P199, DOI 10.1016/j.virusres.2004.02.034; Gubareva LV, 1998, J INFECT DIS, V178, P1257, DOI 10.1086/314440; Gubareva LV, 1997, J VIROL, V71, P3385, DOI 10.1128/JVI.71.5.3385-3390.1997; Gubareva LV, 1996, J VIROL, V70, P1818, DOI 10.1128/JVI.70.3.1818-1827.1996; Gubareva LV, 2001, J INFECT DIS, V183, P523, DOI 10.1086/318537; Gubareva LV, 2000, LANCET, V355, P827, DOI 10.1016/S0140-6736(99)11433-8; Hayden FG, 2001, PHILOS T R SOC B, V356, P1877, DOI 10.1098/rstb.2001.1007; Herlocher ML, 2003, J INFECT DIS, V188, P1355, DOI 10.1086/379049; Herlocher ML, 2002, ANTIVIR RES, V54, P99, DOI 10.1016/S0166-3542(01)00214-5; Jackson HC, 2000, CLIN DRUG INVEST, V20, P447, DOI 10.2165/00044011-200020060-00007; Kim CU, 1997, J AM CHEM SOC, V119, P681, DOI 10.1021/ja963036t; Matrosovich M, 2003, J VIROL, V77, P8418, DOI 10.1128/JVI.77.15.8418-8425.2003; McKimm-Breschkin JL, 2000, ANTIVIR RES, V47, P1, DOI 10.1016/S0166-3542(00)00103-0; OXFORD JS, 1970, NATURE, V226, P82, DOI 10.1038/226082a0; Ozaki H, 2004, J VIROL, V78, P1851, DOI 10.1128/JVI.78.4.1851-1857.2004; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; Shiraishi K, 2003, J INFECT DIS, V188, P57, DOI 10.1086/375799; Tai CY, 1998, ANTIMICROB AGENTS CH, V42, P3234, DOI 10.1128/AAC.42.12.3234; Tisdale M, 2000, REV MED VIROL, V10, P45, DOI 10.1002/(SICI)1099-1654(200001/02)10:1&lt;45::AID-RMV265&gt;3.0.CO;2-R; TOBITA K, 1975, MED MICROBIOL IMMUN, V162, P9, DOI 10.1007/BF02123572; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; VARGHESE JN, 1992, PROTEINS, V14, P327, DOI 10.1002/prot.340140302; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; Wetherall NT, 2003, J CLIN MICROBIOL, V41, P742, DOI 10.1128/JCM.41.2.742-750.2003; Whitley RJ, 2001, PEDIATR INFECT DIS J, V20, P127, DOI 10.1097/00006454-200102000-00002; Zambon M, 2001, ANTIVIR RES, V49, P147, DOI 10.1016/S0166-3542(01)00124-3	30	595	671	3	39	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	2004	364	9436					759	765		10.1016/S0140-6736(04)16934-1	http://dx.doi.org/10.1016/S0140-6736(04)16934-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337401				2022-12-28	WOS:000223569600026
J	Benvenuti, F; Hugues, S; Walmsley, M; Ruf, S; Fetler, L; Popoff, M; Tybulewicz, VLJ; Amigorena, S				Benvenuti, F; Hugues, S; Walmsley, M; Ruf, S; Fetler, L; Popoff, M; Tybulewicz, VLJ; Amigorena, S			Requirement of Rac1 and Rac2 expression by mature dendritic cells for T cell priming	SCIENCE			English	Article							IMMUNOLOGICAL SYNAPSE; CUTTING EDGE; CYTOSKELETON; RHO; GTPASE	Upon maturation, dendritic cells (DCs) acquire the unique ability to activate naive T cells. We used time-lapse video microscopy and two-photon imaging of intact lymph nodes to show that after establishing initial contact between their dendrites and naive T lymphocytes, mature DCs migrate toward the contacted lymphocytes. Subsequently, the DCs; tightly entrap the T cells within a complex net of membrane extensions. The Rho family guanosine triphosphatases Rac1 and Rac2 but not Rho itself control the formation of dendrites in mature DCs, their polarized short-range migration toward T cells, and T cell priming.	Inst Curie, INSERM, U365, F-75005 Paris, France; Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England; Inst Curie, CNRS, UMR 168, F-75005 Paris, France; Inst Pasteur, Unite Toxines Microbiennes, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; MRC National Institute for Medical Research; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Amigorena, S (corresponding author), Inst Curie, INSERM, U365, 26 Rue Ulm, F-75005 Paris, France.	sebastian.amigorena@curie.fr	Benvenuti, Federica/O-1100-2013; Fetler, luc/M-9034-2018	hugues, stephanie/0000-0002-1031-5909; Amigorena, Sebastian/0000-0001-8583-8416; Tybulewicz, Victor/0000-0003-2439-0798; Benvenuti, Federica/0000-0002-1908-8052				Al-Alwan MM, 2003, J IMMUNOL, V171, P4479, DOI 10.4049/jimmunol.171.9.4479; Al-Alwan MM, 2001, J IMMUNOL, V166, P1452, DOI 10.4049/jimmunol.166.3.1452; Benvenuti F, 2004, J IMMUNOL, V172, P292, DOI 10.4049/jimmunol.172.1.292; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Granucci F, 2003, BLOOD, V102, P2940, DOI 10.1182/blood-2002-12-3651; Kobayashi M, 2001, J IMMUNOL, V167, P3585, DOI 10.4049/jimmunol.167.7.3585; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lantz O, 2000, NAT IMMUNOL, V1, P54, DOI 10.1038/76917; Lanzavecchia A, 2001, CURR OPIN IMMUNOL, V13, P291, DOI 10.1016/S0952-7915(00)00218-1; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Miller MJ, 2004, P NATL ACAD SCI USA, V101, P998, DOI 10.1073/pnas.0306407101; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Wells CM, 2004, J CELL SCI, V117, P1259, DOI 10.1242/jcs.00997	16	188	197	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	2004	305	5687					1150	1153		10.1126/science.1099159	http://dx.doi.org/10.1126/science.1099159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326354				2022-12-28	WOS:000223557400047
J	Hotez, PJ; Brooker, S; Bethony, JM; Bottazzi, ME; Loukas, A; Xiao, SH				Hotez, PJ; Brooker, S; Bethony, JM; Bottazzi, ME; Loukas, A; Xiao, SH			Hookworm infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CUTANEOUS LARVA MIGRANS; NECATOR-AMERICANUS; IRON STATUS; ANCYLOSTOMA-DUODENALE; INTESTINAL NEMATODES; HELMINTH INFECTIONS; ANEMIA; CHILDREN; EPIDEMIOLOGY; DISEASE		George Washington Univ, Dept Microbiol & Trop Med, Washington, DC 20037 USA; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England; Queensland Inst Med Res, Div Infect Dis & Immunol, Brisbane, Qld 4006, Australia; Chinese Ctr Dis Control & Prevent, Inst Parasit Dis, Shanghai, Peoples R China	George Washington University; University of London; London School of Hygiene & Tropical Medicine; QIMR Berghofer Medical Research Institute; Chinese Center for Disease Control & Prevention; National Institute of Parasitic Diseases, Chinese Center for Disease Control & Prevention	Hotez, PJ (corresponding author), George Washington Univ, Dept Microbiol & Trop Med, Ross Hall 736,2300 Eye St NW, Washington, DC 20037 USA.	mtmpjh@gwumc.edu	Loukas, Alex/B-7355-2014	Loukas, Alex/0000-0002-0896-8441; Hotez, Peter/0000-0001-8770-1042; Bottazzi, Maria Elena/0000-0002-8429-0476	FOGARTY INTERNATIONAL CENTER [K01TW000009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032726, R29AI032726] Funding Source: NIH RePORTER; FIC NIH HHS [1K01 TW00009] Funding Source: Medline; NIAID NIH HHS [AI-32726] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albanese G, 2003, DERMATOL CLIN, V21, P283, DOI 10.1016/S0733-8635(02)00085-2; Albonico M, 1998, INT J EPIDEMIOL, V27, P530, DOI 10.1093/ije/27.3.530; Albonico M, 2003, ACTA TROP, V86, P233, DOI 10.1016/S0001-706X(03)00043-3; Albonico M, 2003, B WORLD HEALTH ORGAN, V81, P343; ALBONICO M, 1995, T ROY SOC TROP MED H, V89, P538, DOI 10.1016/0035-9203(95)90101-9; Anyaeze CM, 2003, TROP DOCT, V33, P174, DOI 10.1177/004947550303300321; Asaolu SO, 2003, ACTA TROP, V86, P283, DOI 10.1016/S0001-706X(03)00060-3; Belperio PS, 2004, AM J MED, V116, P27, DOI 10.1016/j.amjmed.2003.12.010; Bethony J, 2002, CLIN INFECT DIS, V35, P1336, DOI 10.1086/344268; Blackwell V, 2001, BRIT J DERMATOL, V145, P434, DOI 10.1046/j.1365-2133.2001.04406.x; Bleakley H, 2003, J EUR ECON ASSOC, V1, P376, DOI 10.1162/154247603322391017; Brooker S, 1999, T ROY SOC TROP MED H, V93, P240, DOI 10.1016/S0035-9203(99)90007-X; BROOKER S, IN PRESS ADV PARASIT; Bundy D. A. P., 1995, Enteric infection 2: intestinal helminths., P5; BUNDY DAP, 1995, T ROY SOC TROP MED H, V89, P521, DOI 10.1016/0035-9203(95)90093-4; BUNDY DAP, 1990, T ROY SOC TROP MED H, V84, P115, DOI 10.1016/0035-9203(90)90399-Y; Caumes E, 2002, BRIT J DERMATOL, V146, P314, DOI 10.1046/j.0007-0963.2001.04531.x; Chan MS, 1997, INT J EPIDEMIOL, V26, P1392, DOI 10.1093/ije/26.6.1392; CHANDLER AC, 1929, HOOKWORM DIS ITS DIS, P277; Crompton DWT, 2000, PARASITOLOGY, V121, pS39, DOI 10.1017/S0031182000006454; de Silva NR, 2003, ACTA TROP, V86, P197, DOI 10.1016/S0001-706X(03)00035-4; de Silva NR, 2003, TRENDS PARASITOL, V19, P547, DOI 10.1016/j.pt.2003.10.002; Del Valle A, 2003, MOL BIOCHEM PARASIT, V129, P167, DOI 10.1016/S0166-6851(03)00121-X; Despommier D, 2000, PARASITIC DIS; DOCK G, 1910, HOOKWORM DIS, P115; Fincham JE, 2003, ACTA TROP, V86, P315, DOI 10.1016/S0001-706X(03)00063-9; Geisbert TW, 2003, LANCET, V362, P1953, DOI 10.1016/S0140-6736(03)15012-X; *GEN SEQ CTR, PAR NEM SEQ PROJ; GILLES HM, 1964, Q J MED, V33, P1; Guyatt H, 2000, PARASITOL TODAY, V16, P153, DOI 10.1016/S0169-4758(99)01634-8; Guyatt HL, 2000, LANCET, V356, P2101, DOI 10.1016/S0140-6736(05)74313-0; Guyatt HL, 2001, AM J TROP MED HYG, V64, P36, DOI 10.4269/ajtmh.2001.64.36; Guyatt HL, 2001, B WORLD HEALTH ORGAN, V79, P695; Hawdon JM, 1996, J PARASITOL, V82, P642, DOI 10.2307/3283794; Hawdon JM, 1996, CURR OPIN GENET DEV, V6, P618, DOI 10.1016/S0959-437X(96)80092-X; Horton J, 2003, TRENDS PARASITOL, V19, P405, DOI 10.1016/S1471-4922(03)00171-5; HOTEZ PJ, 1995, SCI AM, V272, P68, DOI 10.1038/scientificamerican0695-68; Hotez PJ, 2003, INT J PARASITOL, V33, P1245, DOI 10.1016/S0020-7519(03)00158-9; HOTEZ PJ, 2002, CHINA QUART, V172, P1029; Loukas A, 2001, CLIN MICROBIOL REV, V14, P689, DOI 10.1128/CMR.14.4.689-703.2001; Lozoff B, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e51; LWAMBO NJS, 1992, EPIDEMIOL INFECT, V108, P469, DOI 10.1017/S0950268800049980; Mabaso MLH, 2003, TROP MED INT HEALTH, V8, P722, DOI 10.1046/j.1365-3156.2003.01086.x; MAXWELL C, 1987, AM J TROP MED HYG, V37, P126, DOI 10.4269/ajtmh.1987.37.126; MIGUEL E, 2004, WORMS IDENTIFYING IM; Nacher M, 2001, AM J TROP MED HYG, V65, P136, DOI 10.4269/ajtmh.2001.65.136; Nacher M, 2002, J PARASITOL, V88, P55, DOI 10.1645/0022-3395(2002)088[0055:IHIAAW]2.0.CO;2; NUTMAN TB, 1987, J INFECT DIS, V155, P309, DOI 10.1093/infdis/155.2.309; Olatunde B O, 1994, Afr J Med Med Sci, V23, P221; Olsen A, 1998, T ROY SOC TROP MED H, V92, P643, DOI 10.1016/S0035-9203(98)90795-7; Parkinson J, 2003, TRENDS PARASITOL, V19, P283, DOI 10.1016/S1471-4922(03)00132-6; Prociv P, 1996, ACTA TROP, V62, P23, DOI 10.1016/S0001-706X(96)00016-2; Quinnell RJ, 2001, T ROY SOC TROP MED H, V95, P139, DOI 10.1016/S0035-9203(01)90138-5; Sakti H, 1999, TROP MED INT HEALTH, V4, P322, DOI 10.1046/j.1365-3156.1999.00410.x; Sampathkumar V, 1997, Indian J Matern Child Health, V8, P73; Shulman CE, 1996, T ROY SOC TROP MED H, V90, P535, DOI 10.1016/S0035-9203(96)90312-0; Smillie WG, 1926, J EDUC PSYCHOL, V17, P314, DOI 10.1037/h0072931; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; STEPHENSON LS, 1989, AM J TROP MED HYG, V41, P78, DOI 10.4269/ajtmh.1989.41.78; Stoltzfus RJ, 1997, NUTR REV, V55, P223, DOI 10.1111/j.1753-4887.1997.tb01609.x; Stoltzfus RJ, 1998, AM J CLIN NUTR, V68, P179, DOI 10.1093/ajcn/68.1.179; Stoltzfus RJ, 1997, AM J CLIN NUTR, V65, P153, DOI 10.1093/ajcn/65.1.153; Stoltzfus RJ, 2000, J NUTR, V130, P1724, DOI 10.1093/jn/130.7.1724; WilliamsBlangero S, 1997, HUM BIOL, V69, P201; Williamson AL, 2003, TRENDS PARASITOL, V19, P417, DOI 10.1016/S1471-4922(03)00189-2; WOLPERT S, 2001, GANDHIS PASSION LIFE, P214; *WORLD BANK, 2003, SCH DEW GLANC; World Health Organization, 2002, WHO TRADITIONAL MED, P1; YU SH, 1995, ACTA TROP, V59, P265, DOI 10.1016/0001-706X(95)00089-W	69	422	441	1	58	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2004	351	8					799	807		10.1056/NEJMra032492	http://dx.doi.org/10.1056/NEJMra032492			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847CY	15317893	Green Accepted			2022-12-28	WOS:000223367900012
J	Lin, HC				Lin, HC			Small intestinal bacterial overgrowth - A framework for understanding irritable bowel syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LACTULOSE BREATH TEST; FUNCTIONAL ABDOMINAL-PAIN; NERVOUS-SYSTEM; METHANE PRODUCTION; IMMUNE-SYSTEM; IBS SUBJECTS; MAST-CELLS; TRANSLOCATION; SYMPTOMS; DISTENSION	Context Irritable bowel syndrome (IBS), which affects 11% to 14% of the population, is a puzzling condition with multiple models of pathophysiology including altered motility, visceral hypersensitivity, abnormal brain-gut interaction, autonomic dysfunction, and immune activation. Although no conceptual framework accounts for all the symptoms and observations in IBS, a unifying explanation may exist since 92% of these patients share the symptom of bloating regardless of their predominant complaint. Evidence Acquisition Ovid MEDLINE was searched through May 2004 for relevant English-language articles beginning with those related to bloating, gas, and IBS. Bibliographies of pertinent articles and books were also scanned for additional suitable citations. Evidence Synthesis The possibility that small intestinal bacterial overgrowth (SIBO) may explain bloating in IBS is supported by greater total hydrogen excretion after lactulose ingestion, a correlation between the pattern of bowel movement and the type of excreted gas, a prevalence of abnormal lactulose breath test in 84% of IBS patients, and a 75% improvement of IBS symptoms after eradication of SIBO. Altered gastrointestinal motility and sensation, changed activity of the central nervous system, and increased sympathetic drive and immune activation may be understood as consequences of the host response to SIBO. Conclusions The gastrointestinal and immune effects of SIBO provide a possible unifying framework for understanding frequent observations in IBS, including postprandial bloating and distension, altered motility, visceral hypersensitivity, abnormal brain-gut interaction, autonomic dysfunction, and immune activation.	Univ So Calif, Keck Sch Med, Dept Med, Div Gastrointestinal & Liver Dis, Los Angeles, CA 90033 USA	University of Southern California	Lin, HC (corresponding author), Univ So Calif, Keck Sch Med, Dept Med, Div Gastrointestinal & Liver Dis, 2011 Zonal Ave,HMR 101, Los Angeles, CA 90033 USA.	henry.c.lin@usc.edu						Aaron LA, 2001, ANN INTERN MED, V134, P868, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00011; ABRAHAMSSON H, 1987, SCAND J GASTROENTERO, V22, P21, DOI 10.3109/00365528709090996; AGGARWAL A, 1994, GASTROENTEROLOGY, V106, P945, DOI 10.1016/0016-5085(94)90753-6; Anisman H, 2003, ANN MED, V35, P2, DOI 10.1080/07853890310004075; [Anonymous], 1992, GASTROENTEROL INT; Banks WA, 2002, NEUROIMMUNOMODULAT, V10, P319, DOI 10.1159/000071472; Berg BM, 2004, BRAIN BEHAV IMMUN, V18, P149, DOI 10.1016/S0889-1591(03)00113-2; BERG RD, 1988, ARCH SURG-CHICAGO, V123, P1359; BERG RD, 1979, INFECT IMMUN, V23, P403, DOI 10.1128/IAI.23.2.403-411.1979; BESEDOVSKY H, 1983, SCIENCE, V221, P564, DOI 10.1126/science.6867729; BULBRING E, 1958, J PHYSIOL-LONDON, V140, P381; CARLSON S L, 1987, Brain Behavior and Immunity, V1, P52, DOI 10.1016/0889-1591(87)90006-7; Castex N, 1998, AM J PHYSIOL-GASTR L, V274, pG210, DOI 10.1152/ajpgi.1998.274.1.G210; Castiglione F, 2003, ALIMENT PHARM THERAP, V18, P1107, DOI 10.1046/j.1365-2036.2003.01800.x; CELIK AF, 1995, ALIMENT PHARM THER, V9, P63; Chadwick VS, 2002, GASTROENTEROLOGY, V122, P1778, DOI 10.1053/gast.2002.33579; CHAMI TN, 1991, AM J GASTROENTEROL, V86, P599; Choi YK, 2003, AM J GASTROENTEROL, V98, P1348, DOI [10.1016/S0002-9270(03)00251-X, 10.1111/j.1572-0241.2003.07476.x]; CODE C F, 1975, Journal of Physiology (Cambridge), V246, P289; Coelho AM, 2000, AM J PHYSIOL-GASTR L, V279, pG781, DOI 10.1152/ajpgi.2000.279.4.G781; Collins SM, 2002, GASTROENTEROLOGY, V122, P2078, DOI 10.1053/gast.2002.34097; Collins SM, 2001, GUT, V49, P743, DOI 10.1136/gut.49.6.743; COLLINS SM, 1999, CAN J GASTROENTEROL, V13, P47; DEITCH EA, 1991, CRIT CARE MED, V19, P785, DOI 10.1097/00003246-199106000-00010; DRASAR BS, 1969, GASTROENTEROLOGY, V56, P71; Drossman DA, 2003, GASTROENTEROLOGY, V125, P19, DOI 10.1016/S0016-5085(03)00669-3; DROSSMAN DA, 1993, DIGEST DIS SCI, V38, P1569, DOI 10.1007/BF01303162; Drossman DA, 2002, GASTROENTEROLOGY, V123, P2108, DOI 10.1053/gast.2002.37095; Dunlop SP, 2003, GASTROENTEROLOGY, V125, P1651, DOI 10.1053/j.gastro.2003.09.028; Dunlop SP, 2003, AM J GASTROENTEROL, V98, P1578, DOI 10.1016/S0002-9270(03)000375-7; FIEDOREK SC, 1990, J PEDIATR GASTR NUTR, V10, P473, DOI 10.1097/00005176-199005000-00010; Goldstein R, 2000, ISRAEL MED ASSOC J, V2, P583; Gonsalkorale WM, 2003, GUT, V52, P91, DOI 10.1136/gut.52.1.91; GORBACH SL, 1971, GASTROENTEROLOGY, V60, P1110; Goyal RK, 1996, NEW ENGL J MED, V334, P1106, DOI 10.1056/NEJM199604253341707; Gwee KA, 2003, GUT, V52, P523, DOI 10.1136/gut.52.4.523; Gwee KA, 1996, LANCET, V347, P150, DOI 10.1016/S0140-6736(96)90341-4; Hasko G, 2001, NEUROCHEM RES, V26, P1039, DOI 10.1023/A:1012305122327; HUSEBYE E, 1995, GASTROENTEROLOGY, V109, P1078, DOI 10.1016/0016-5085(95)90565-0; Husebye E, 2001, AM J PHYSIOL-GASTR L, V280, pG368, DOI 10.1152/ajpgi.2001.280.3.G368; Kim HJ, 2003, ALIMENT PHARM THER, V17, P895, DOI 10.1046/j.1365-2036.2003.01543.x; King TS, 1998, LANCET, V352, P1187, DOI 10.1016/S0140-6736(98)02146-1; Koide A, 2000, AM J GASTROENTEROL, V95, P1735; KRUIS W, 1984, GASTROENTEROLOGY, V87, P1; LASSER RB, 1975, NEW ENGL J MED, V293, P524, DOI 10.1056/NEJM197509112931103; Lea R, 2003, GASTROENTEROLOGY, V124, pA398, DOI 10.1016/S0016-5085(03)82012-7; LEVITT MD, 1983, GASTROENTEROLOGY, V85, P769; LEVITT MD, 1969, NEW ENGL J MED, V281, P122, DOI 10.1056/NEJM196907172810303; Lewis MJV, 2001, GUT, V48, P216, DOI 10.1136/gut.48.2.216; LIN HC, 2002, NEUROGASTROENT MOTIL, V14, P437; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; Marshall JK, 2004, GASTROENTEROLOGY, V126, pA520; MAXTON DG, 1991, GUT, V32, P662, DOI 10.1136/gut.32.6.662; Nayak A K, 1997, Indian J Gastroenterol, V16, P137; Neal KR, 1997, BRIT MED J, V314, P779, DOI 10.1136/bmj.314.7083.779; Nieuwenhuijs VB, 1998, ANN SURG, V228, P188, DOI 10.1097/00000658-199808000-00007; Nucera G, 2004, GASTROENTEROLOGY, V126, pA511; Orr WC, 2000, AM J GASTROENTEROL, V95, P2865, DOI 10.1016/S0002-9270(00)01110-2; PETITPIERRE M, 1985, ANN ALLERGY, V54, P538; Pimentel M, 2004, DIGEST DIS SCI, V49, P84, DOI 10.1023/B:DDAS.0000011607.24171.c0; Pimentel M, 2003, AM J GASTROENTEROL, V98, P412, DOI 10.1016/S0002-9270(02)05902-6; Pimentel M, 2003, DIGEST DIS SCI, V48, P86, DOI 10.1023/A:1021738515885; Pimentel M, 2002, DIGEST DIS SCI, V47, P2639, DOI 10.1023/A:1021039032413; Pimentel M, 2000, AM J GASTROENTEROL, V95, P3503, DOI 10.1111/j.1572-0241.2000.03368.x; Riordan SM, 1997, SCAND J GASTROENTERO, V32, P556, DOI 10.3109/00365529709025099; RITCHIE J, 1973, GUT, V14, P125, DOI 10.1136/gut.14.2.125; RIVIER C, 1993, ANN NY ACAD SCI, V697, P97, DOI 10.1111/j.1749-6632.1993.tb49926.x; RUMESSEN JJ, 1985, SCAND J GASTROENTERO, V20, P1267, DOI 10.3109/00365528509089288; Sen S, 2002, EUR J GASTROEN HEPAT, V14, P753, DOI 10.1097/00042737-200207000-00007; Serra J, 2001, GUT, V48, P14, DOI 10.1136/gut.48.1.14; Silverman DHS, 1997, GASTROENTEROLOGY, V112, P64, DOI 10.1016/S0016-5085(97)70220-8; Simren M, 2003, GASTROENTEROLOGY, V124, pA163, DOI 10.1016/S0016-5085(03)80815-6; Sperber AD, 1999, AM J GASTROENTEROL, V94, P3541, DOI 10.1111/j.1572-0241.1999.01643.x; Spiller RC, 2000, GUT, V47, P804, DOI 10.1136/gut.47.6.804; STROCCHI A, 1994, GUT, V35, P1098, DOI 10.1136/gut.35.8.1098; Thompson WG, 1999, GUT, V45, P43; THOMPSON WG, 1986, CAN MED ASSOC J, V134, P111; Tornblom H, 2002, GASTROENTEROLOGY, V123, P1972, DOI 10.1053/gast.2002.37059; TOSKES PP, 1998, SLEISENGER FORDTRANS, P1523; TRIADAFILOPOULOS G, 1991, DIGEST DIS SCI, V36, P59, DOI 10.1007/BF01300088; VALDOVINOS MA, 1993, SCAND J GASTROENTERO, V28, P963, DOI 10.3109/00365529309098292; van der Veek P, 2004, GASTROENTEROLOGY, V126, pA52; Van Felius ID, 2003, NEUROGASTROENT MOTIL, V15, P267, DOI 10.1046/j.1365-2982.2003.00410.x; VANTRAPPEN G, 1977, J CLIN INVEST, V59, P1158, DOI 10.1172/JCI108740; VEALE D, 1991, BRIT J RHEUMATOL, V30, P220; Wein AJ, 2002, UROLOGY, V59, P68, DOI 10.1016/S0090-4295(01)01640-5; Wessely S, 1999, LANCET, V354, P936, DOI 10.1016/S0140-6736(98)08320-2; WESTON AP, 1993, DIGEST DIS SCI, V38, P1590, DOI 10.1007/BF01303164; WHORWELL PJ, 1999, IRRITABLE BOWEL SYND, P71; Wilson KH, 1999, TXB GASTROENTEROLOGY, P624; Wirthlin DJ, 1996, J SURG RES, V60, P307, DOI 10.1006/jsre.1996.0048; Woodcock NP, 2001, J CLIN PATHOL, V54, P619, DOI 10.1136/jcp.54.8.619	92	287	315	1	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2004	292	7					852	858		10.1001/jama.292.7.852	http://dx.doi.org/10.1001/jama.292.7.852			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847FO	15316000	Bronze			2022-12-28	WOS:000223378300026
J	Lane, R				Lane, R			On reflection - The perils of myopia	LANCET			English	Article									Lancet, London NW1 7BY, England		Lane, R (corresponding author), Lancet, London NW1 7BY, England.								0	0	0	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	2004	364	9434					575	575		10.1016/S0140-6736(04)16834-7	http://dx.doi.org/10.1016/S0140-6736(04)16834-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	845WD	15329944				2022-12-28	WOS:000223275100014
J	Priori, SG; Napolitano, C; Schwartz, PJ; Grillo, M; Bloise, R; Ronchetti, E; Moncalvo, C; Tulipani, C; Veia, A; Bottelli, G; Nastoli, J				Priori, SG; Napolitano, C; Schwartz, PJ; Grillo, M; Bloise, R; Ronchetti, E; Moncalvo, C; Tulipani, C; Veia, A; Bottelli, G; Nastoli, J			Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ARRHYTHMIAS	Context Data on the efficacy of beta-blockers in the 3 most common genetic long QT syndrome (LQTS) loci are limited. Objective To describe and assess outcome in a large systematically genotyped population of beta-blocker-treated LQTS patients. Design, Setting, and Patients Consecutive LQTS-genotyped patients (n=335) in Italy treated with beta-blockers for an average of 5 years. Main Outcome Measures Cardiac events (syncope, ventricular tachycardia/torsades de pointes, cardiac arrest, and sudden cardiac death) while patients received beta-blocker therapy according to genotype. Results Cardiac events among patients receiving beta-blocker therapy occurred in 19 of 187 (10%) LQT1 patients, 27 of 120 (23%) LQT2 patients, and 9 of 28 (32%) LQT3 patients (P<.001). The risk of cardiac events was higher among LQT2 (adjusted relative risk, 2.81; 95% confidence interval [CI], 1.50-5.27; P=.001) and LQT3 (adjusted relative risk, 4.00; 95% CI, 2.45-8.03; P<.001) patients than among LQT1 patients, suggesting inadequate protection from beta-blocker therapy. Other important predictors of risk were a QT interval corrected for heart rate that was more than 500 ms in patients receiving therapy (adjusted relative risk, 2.01; 95% CI, 1.16-3.51; P=.01) and occurrence of a first cardiac event before the age of 7 years (adjusted RR, 4.34; 95% CI, 2.35-8.03; P<.001). Conclusion Among patients with genetic LQTS treated with &beta;-blockers, there is a high rate of cardiac events, particularly among patients with LQT2 and LQT3 genotypes.	Univ Pavia, Maugeri Fdn, IRCCS, I-27100 Pavia, Italy; Policlin San Matteo, IRCCS, Dept Cardiol, I-27100 Pavia, Italy	Istituti Clinici Scientifici Maugeri IRCCS; University of Pavia; IRCCS Fondazione San Matteo; University of Pavia	Priori, SG (corresponding author), Univ Pavia, Maugeri Fdn, IRCCS, Via Ferrata 8, I-27100 Pavia, Italy.	spriori@fsm.it	bloise, raffaella/AAC-2922-2020; Napolitano, Carlo/K-4760-2016; Priori, Silvia G G/A-6116-2014; napolitano, carlo/ABI-4608-2020; Priori, Silvia G/ABH-6894-2020; Schwartz, Peter J/J-4267-2016	bloise, raffaella/0000-0003-3485-9596; Napolitano, Carlo/0000-0002-7643-4628; Priori, Silvia G G/0000-0001-6877-0288; napolitano, carlo/0000-0002-7643-4628; Priori, Silvia G/0000-0001-6877-0288; Schwartz, Peter J/0000-0003-0367-1048; ronchetti, elena/0000-0002-9185-7848; Nastoli, janni/0000-0002-5888-5951	Telethon [GP0227Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Groh WJ, 1996, AM J CARDIOL, V78, P703, DOI 10.1016/S0002-9149(96)00403-3; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Moss AJ, 2000, CIRCULATION, V101, P616, DOI 10.1161/01.CIR.101.6.616; Priori SG, 2001, EUR HEART J, V22, P1374, DOI 10.1053/euhj.2001.2824; Priori SG, 2003, NEW ENGL J MED, V348, P1866, DOI 10.1056/NEJMoa022147; ROMANO C, 1963, Clin Pediatr (Bologna), V45, P656; Schwartz PJ, 2001, CIRCULATION, V103, P89; Schwartz PJ, 2004, CIRCULATION, V109, P1826, DOI 10.1161/01.CIR.0000125523.14403.1E; SCHWARTZ PJ, 2000, CARDIAC ELECTROPHYSI, P597; WARD O C, 1964, J Ir Med Assoc, V54, P103	10	417	432	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2004	292	11					1341	1344		10.1001/jama.292.11.1341	http://dx.doi.org/10.1001/jama.292.11.1341			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853YL	15367556	Bronze			2022-12-28	WOS:000223866800026
J	Abzhanov, A; Protas, M; Grant, BR; Grant, PR; Tabin, CJ				Abzhanov, A; Protas, M; Grant, BR; Grant, PR; Tabin, CJ			Bmp4 and morphological variation of beaks in Darwin's finches	SCIENCE			English	Article								Darwin's finches are a classic example of species diversification by natural selection. Their impressive variation in beak morphology is associated with the exploitation of a variety of ecological niches, but its developmental basis is unknown. We performed a comparative analysis of expression patterns of various growth factors in species comprising the genus Geospiza. We found that expression of Bmp4 in the mesenchyme of the upper beaks strongly correlated with deep and broad beak morphology. When misexpressed in chicken embryos, Bmp4 caused morphological transformations paralleling the beak morphology of the large ground finch G. magnirostris.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA	Harvard University; Harvard Medical School; Princeton University	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056246] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK56246] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOWMAN ROBERT I., 1961, UNIV CALIFORNIA PUBL ZOOL, V58, P1; Darwin C, 1988, VOYAGE BEAGLE; Freeman S., 2003, EVOLUTIONARY ANAL; Futuyma D. J., 1998, EVOLUTIONARY BIOL; Grant P.R., 1999, RECOGNITION STATES L, V2; GRANT PR, 1981, PROC R SOC SER B-BIO, V212, P403, DOI 10.1098/rspb.1981.0046; Kanzler B, 2000, DEVELOPMENT, V127, P1095; Lack D., 1947, DARWINS FINCHES; Petren K, 1999, P ROY SOC B-BIOL SCI, V266, P321, DOI 10.1098/rspb.1999.0641; PRICE TD, 1985, AM NAT, V125, P169, DOI 10.1086/284336; Schluter D., 2000, ECOLOGY ADAPTIVE RAD; Schneider RA, 2003, SCIENCE, V299, P565, DOI 10.1126/science.1077827; Schneider RA, 2001, DEVELOPMENT, V128, P2755	13	540	561	8	343	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	2004	305	5689					1462	1465		10.1126/science.1098095	http://dx.doi.org/10.1126/science.1098095			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353802				2022-12-28	WOS:000223761900048
J	Escrig, S; Capmas, F; Dupre, B; Allegre, CJ				Escrig, S; Capmas, F; Dupre, B; Allegre, CJ			Osmium isotopic constraints on the nature of the DUPAL anomaly from Indian mid-ocean-ridge basalts	NATURE			English	Article							ISLAND BASALTS; UPPER-MANTLE; ABYSSAL PERIDOTITES; GRANULITE XENOLITHS; CONTINENTAL-CRUST; TRIPLE JUNCTION; SYSTEMATICS; GEOCHEMISTRY; LITHOSPHERE; PERSPECTIVE	The isotopic compositions of mid-ocean-ridge basalts (MORB) from the Indian Ocean have led to the identification of a large-scale isotopic anomaly relative to Pacific and Atlantic ocean MORB1. Constraining the origin of this so-called DUPAL anomaly(2) may lead to a better understanding of the genesis of upper-mantle heterogeneity. Previous isotopic studies(3-10) have proposed recycling of ancient subcontinental lithospheric mantle or sediments with oceanic crust to be responsible for the DUPAL signature. Here we report Os, Pb, Sr and Nd isotopic compositions of Indian MORB from the Central Indian ridge, the Rodriguez triple junction and the South West Indian ridge. All measured samples have higher Os-187/Os-188 ratios than the depleted upper-mantle value(11,12) and Pb, Sr and Nd isotopic compositions that imply the involvement of at least two distinct enriched components in the Indian upper-mantle. Using isotopic and geodynamical arguments, we reject both subcontinental lithospheric mantle and recycled sediments with oceanic crust as the cause of the DUPAL anomaly. Instead, we argue that delamination of lower continental crust may explain the DUPAL isotopic signature of Indian MORB.	Univ Paris 07, CNRS,UMR 7579, Inst Phys Globe Paris, Lab Geochim & Cosmochim, F-75252 Paris 05, France; Univ Toulouse 3, CNRS, UMR 5563, Lab Mecan & Transfert Geol, F-31400 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut de Recherche pour le Developpement (IRD)	Escrig, S (corresponding author), Univ Paris 07, CNRS,UMR 7579, Inst Phys Globe Paris, Lab Geochim & Cosmochim, 4 Pl Jussieu, F-75252 Paris 05, France.	escrig@eps.harvard.edu		Escrig, Stephane/0000-0002-7525-4000				Chesley J, 2004, EARTH PLANET SC LETT, V219, P49, DOI 10.1016/S0012-821X(03)00698-8; COHEN RS, 1984, EARTH PLANET SC LETT, V68, P209, DOI 10.1016/0012-821X(84)90153-5; DOSSO L, 1988, EARTH PLANET SC LETT, V88, P47, DOI 10.1016/0012-821X(88)90045-3; DUPRE B, 1983, NATURE, V303, P142, DOI 10.1038/303142a0; HAMELIN B, 1985, NATURE, V315, P196, DOI 10.1038/315196a0; HAMELIN B, 1985, EARTH PLANET SC LETT, V76, P288; Hanan BB, 1996, SCIENCE, V272, P991, DOI 10.1126/science.272.5264.991; HART SR, 1984, NATURE, V309, P753, DOI 10.1038/309753a0; HAURI EH, 1993, EARTH PLANET SC LETT, V114, P353, DOI 10.1016/0012-821X(93)90036-9; Hirschmann MM, 1996, CONTRIB MINERAL PETR, V124, P185, DOI 10.1007/s004100050184; HUANG YM, 1995, GEOCHIM COSMOCHIM AC, V59, P4905, DOI 10.1016/0016-7037(95)00335-5; Jull M, 2001, J GEOPHYS RES-SOL EA, V106, P6423, DOI 10.1029/2000JB900357; Kamenetsky VS, 2001, GEOLOGY, V29, P243, DOI 10.1130/0091-7613(2001)029<0243:ROGCLI>2.0.CO;2; Levasseur S, 1998, SCIENCE, V282, P272, DOI 10.1126/science.282.5387.272; MAHONEY J, 1992, J GEOPHYS RES-SOL EA, V97, P19771, DOI 10.1029/92JB01424; MAHONEY JJ, 1989, J GEOPHYS RES-SOLID, V94, P4033, DOI 10.1029/JB094iB04p04033; Mahoney JJ, 1996, GEOLOGY, V24, P615, DOI 10.1130/0091-7613(1996)024<0615:BELFAN>2.3.CO;2; MARTIN CE, 1991, GEOCHIM COSMOCHIM AC, V55, P1421, DOI 10.1016/0016-7037(91)90318-Y; MICHARD A, 1986, EARTH PLANET SC LETT, V78, P104, DOI 10.1016/0012-821X(86)90176-7; PEGRAM WJ, 1992, EARTH PLANET SC LETT, V111, P59, DOI 10.1016/0012-821X(92)90169-V; PRICE RC, 1986, EARTH PLANET SC LETT, V78, P379, DOI 10.1016/0012-821X(86)90005-1; Rehkamper M, 1999, GEOCHIM COSMOCHIM AC, V63, P3915, DOI 10.1016/S0016-7037(99)00219-7; Rehkamper M, 1997, EARTH PLANET SC LETT, V147, P93, DOI 10.1016/S0012-821X(97)00009-5; REISBERG L, 1993, EARTH PLANET SC LETT, V120, P149, DOI 10.1016/0012-821X(93)90236-3; ROGERS NW, 1982, NATURE, V299, P409, DOI 10.1038/299409a0; ROYBARMAN M, 1994, GEOCHIM COSMOCHIM AC, V58, P5043, DOI 10.1016/0016-7037(94)90230-5; ROYBARMAN M, 1995, EARTH PLANET SC LETT, V129, P145, DOI 10.1016/0012-821X(94)00238-T; Rudnick R.L., 1992, CONTINENTAL LOWER CR, P269; RUDNICK RL, 1995, REV GEOPHYS, V33, P267, DOI 10.1029/95RG01302; Saal AE, 1998, NATURE, V393, P58, DOI 10.1038/29966; Schaefer BF, 2002, NATURE, V420, P304, DOI 10.1038/nature01172; Schiano P, 1997, EARTH PLANET SC LETT, V150, P363, DOI 10.1016/S0012-821X(97)00098-8; SNOW JE, 1995, EARTH PLANET SC LETT, V133, P411, DOI 10.1016/0012-821X(95)00099-X	33	141	153	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2004	431	7004					59	63		10.1038/nature02904	http://dx.doi.org/10.1038/nature02904			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343331				2022-12-28	WOS:000223641500040
J	Zandt, G; Gilbert, H; Owens, TJ; Ducea, M; Saleeby, J; Jones, CH				Zandt, G; Gilbert, H; Owens, TJ; Ducea, M; Saleeby, J; Jones, CH			Active foundering of a continental arc root beneath the southern Sierra Nevada in California	NATURE			English	Article							RAYLEIGH-TAYLOR INSTABILITY; UPPER-MANTLE BENEATH; POTASSIC VOLCANISM; THERMAL EVOLUTION; DELAMINATION; CRUST; LITHOSPHERE; RANGE; BASIN; TECTONICS	Seismic data provide images of crust - mantle interactions during ongoing removal of the dense batholithic root beneath the southern Sierra Nevada mountains in California. The removal appears to have initiated between 10 and 3 Myr ago with a Rayleigh Taylor-type instability, but with a pronounced asymmetric flow into a mantle downwelling (drip) beneath the adjacent Great Valley. A nearly horizontal shear zone accommodated the detachment of the ultramafic root from its granitoid batholith. With continuing flow into the mantle drip, viscous drag at the base of the remaining similar to35-km-thick crust has thickened the crust by similar to7 km in a narrow welt beneath the western flank of the range. Adjacent to the welt and at the top of the drip, a V-shaped cone of crust is being dragged down tens of kilometres into the core of the mantle drip, causing the disappearance of the Moho in the seismic images. Viscous coupling between the crust and mantle is therefore apparently driving present-day surface subsidence.	Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA; Univ S Carolina, Dept Geol Sci, Columbia, SC 29208 USA; CALTECH, Dept Geol & Planetary Sci, Pasadena, CA 91125 USA; Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA	University of Arizona; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; California Institute of Technology; University of Colorado System; University of Colorado Boulder	Zandt, G (corresponding author), Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA.	zandt@geo.arizona.edu	Jones, Craig H/K-2224-2017; Ducea, Mihai N./AAA-4145-2021; Ducea, Mihai/C-2872-2011	Jones, Craig H/0000-0002-1698-0408; Ducea, Mihai N./0000-0002-5322-0782; Gilbert, Hersh/0000-0002-7446-3898				Atwater T, 1998, INT GEOL REV, V40, P375, DOI 10.1080/00206819809465216; BINDSCHADLER DL, 1990, J GEOPHYS RES-SOLID, V95, P21329, DOI 10.1029/JB095iB13p21329; Bostock MG, 2002, NATURE, V417, P536, DOI 10.1038/417536a; Boyd OS, 2004, SCIENCE, V305, P660, DOI 10.1126/science.1099181; Davis G.H., 2011, STRUCTURAL GEOLOGY R; Dickinson WR, 2002, INT GEOL REV, V44, P1, DOI 10.2747/0020-6814.44.1.1; Ducea M, 1998, INT GEOL REV, V40, P78, DOI 10.1080/00206819809465199; Ducea M.N., 2001, GSA TODAY, V11, P4, DOI [DOI 10.1130/1052-5173(2001)011%3C0004:TCATGB%3E2.0.CO;2, DOI 10.1130/1052-5173(2001)011<0004:TCATGB>2.0.C0;2]; Ducea MN, 1996, J GEOPHYS RES-SOL EA, V101, P8229, DOI 10.1029/95JB03452; Ducea MN, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000643; Ducea MN, 1998, CONTRIB MINERAL PETR, V133, P169, DOI 10.1007/s004100050445; Dueker KG, 1997, J GEOPHYS RES-SOL EA, V102, P8313, DOI 10.1029/96JB03857; DUMITRU TA, 1990, J GEOPHYS RES-SOLID, V95, P4925, DOI 10.1029/JB095iB04p04925; Farmer GL, 2002, GEOL SOC AM BULL, V114, P754; Fliedner MM, 2000, J GEOPHYS RES-SOL EA, V105, P10899, DOI 10.1029/2000JB900029; Furlong KP, 1999, GEOLOGY, V27, P127, DOI 10.1130/0091-7613(1999)027<0127:ECTAAT>2.3.CO;2; FURLONG KP, 2003, INT BOOK SERIES, V7, P92; Gilbert HJ, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001194; Hartog R, 2000, J GEOPHYS RES-SOL EA, V105, P7909, DOI 10.1029/1999JB900422; House MA, 1997, EARTH PLANET SC LETT, V151, P167, DOI 10.1016/S0012-821X(97)81846-8; Houseman GA, 1997, GEOPHYS J INT, V128, P125, DOI 10.1111/j.1365-246X.1997.tb04075.x; Houseman GA, 2000, J GEOPHYS RES-SOL EA, V105, P16237, DOI 10.1029/2000JB900118; Jones CH, 1998, J GEOPHYS RES-SOL EA, V103, P10065, DOI 10.1029/97JB03540; JONES CH, 1994, J GEOPHYS RES-SOL EA, V99, P4567, DOI 10.1029/93JB01232; JONES CH, IN PRESS GEOL SOC AM; Jull M, 2001, J GEOPHYS RES-SOL EA, V106, P6423, DOI 10.1029/2000JB900357; KAY RW, 1991, GEOL RUNDSCH, V80, P259, DOI 10.1007/BF01829365; KAY RW, 1993, TECTONOPHYSICS, V219, P177, DOI 10.1016/0040-1951(93)90295-U; Kind R, 2002, SCIENCE, V298, P1219, DOI 10.1126/science.1078115; LANGE RA, 1993, GEOLOGY, V21, P949, DOI 10.1130/0091-7613(1993)021<0949:PVNMBC>2.3.CO;2; Liu M, 1998, GEOLOGY, V26, P299, DOI 10.1130/0091-7613(1998)026<0299:SNUADL>2.3.CO;2; Manley CR, 2000, GEOLOGY, V28, P811, DOI 10.1130/0091-7613(2000)28<811:TOVITS>2.0.CO;2; Molnar P, 2004, GEOPHYS J INT, V156, P555, DOI 10.1111/j.1365-246X.2004.02138.x; Neil EA, 1999, GEOPHYS J INT, V138, P89, DOI 10.1046/j.1365-246x.1999.00841.x; Park SK, 1996, J GEOPHYS RES-SOL EA, V101, P16241, DOI 10.1029/96JB01211; Pysklywec RN, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000252; Ruppert S, 1998, TECTONOPHYSICS, V286, P237, DOI 10.1016/S0040-1951(97)00268-0; Saleeby J, 2003, TECTONICS, V22, DOI 10.1029/2002TC001374; Saleeby J, 2003, GEOL SOC AM BULL, V115, P655, DOI 10.1130/0016-7606(2003)115<0655:SOTLSF>2.0.CO;2; Saleeby J, 2004, GEOLOGY, V32, P245, DOI 10.1130/G19958.1; SALTUS RW, 1991, TECTONICS, V10, P325, DOI 10.1029/90TC02681; Schott B, 1999, GEOPHYS RES LETT, V26, P513, DOI 10.1029/1998GL900257; Schott B, 1998, TECTONOPHYSICS, V296, P225, DOI 10.1016/S0040-1951(98)00154-1; Wernicke B, 1996, SCIENCE, V271, P190, DOI 10.1126/science.271.5246.190; Wernicke B., 1992, CORDILLERAN OROGEN C, P553, DOI DOI 10.1130/DNAG-GNA-G3.553; ZANDT G, 1993, SCIENCE, V261, P460, DOI 10.1126/science.261.5120.460; Zandt G, 2003, INT GEOL REV, V45, P213, DOI 10.2747/0020-6814.45.3.213; Zhu LP, 2000, J GEOPHYS RES-SOL EA, V105, P2969, DOI 10.1029/1999JB900322; ZIMMERMAN ME, 2003, EOS S, V84	49	341	350	0	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2004	431	7004					41	46		10.1038/nature02847	http://dx.doi.org/10.1038/nature02847			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343326				2022-12-28	WOS:000223641500035
J	Strandberg, TE; Pyorala, K; Cook, TJ; Wilhelmsen, L; Faergeman, O; Thorgeirsson, G; Pedersen, TR; Kjekshus, J				Strandberg, TE; Pyorala, K; Cook, TJ; Wilhelmsen, L; Faergeman, O; Thorgeirsson, G; Pedersen, TR; Kjekshus, J		4S Grp	Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)	LANCET			English	Article							CARDIAC OUTCOMES; CORONARY EVENTS; HEART-DISEASE; CHOLESTEROL; PREVENTION; PRAVASTATIN; STATINS; AVERAGE; ATORVASTATIN; FLUVASTATIN	Background The effects of cholesterol-lowering treatment with statins on mortality and risk of cancer beyond the usual 5-6-year trial periods are unknown. We extended post-trial follow-up of participants in the Scandinavian Simvastatin Survival Study (4S) to investigate cause-specific mortality and incidence of cancer 5 years after closure of 14 the trial. Methods 4S was a randomised double-blind trial of simivastatin or placebo in patients with coronary heart disease, serum total cholesterol 5.5-8.0 mmol/L, and serum triglycerides 2.5 mmol/L or lower. The double-blind period lasted for a median of 5.4 years (range for survivors 4.9-6.3) and ended in 1994. After the trial, most patients in both groups received open-label lipid-lowering treatment. National registers were used to assess mortality and causes of death and cancer incidence in the original treatment groups for a median total follow-up time of 10.4 years (range for survivors 9.9-11.3). Analysis was by intention to treat. Findings 414 patients originally allocated simvastatin and 468 assigned placebo died during the 10.4-year follow-up (relative risk 0.85 [95% CI 0.74-0.97], p=0.02), a difference largely attributable to lower coronary mortality in the simvastatin group (238 vs 300 deaths; 0.76 [0.64-0.90], p=0.0018). 85 cancer deaths arose in the simvastatin group versus 100 in the placebo group (0.81 [0.60-1.08], p=0.14), and 227 incident cancers were reported in the simvastin group versus 248 in the placebo group (0.88 [0.73-1.05], p=0.15). Incidence of any specific type of cancer did not A rise in the simvastatin group. Interpretation Simvastatin treatment for 5 years in a placebo-controlled trial, followed by open-label statin therapy, was associated with survival benefit over 10 years of follow-up compared with open-label statin therapy for the past 5 years only. No difference was noted in mortality from and incidence of cancer between the original simvastatin group and placebo group.	Univ Helsinki, Dept Med, Helsinki 00029, Finland; Kuopio Univ Hosp, Dept Med, SF-70210 Kuopio, Finland; Merck Res Labs, Rahway, NJ USA; Univ Gothenburg, Cardiovasc Inst, Gothenburg, Sweden; Arhus Univ Hosp, Aarhus, Denmark; Landspitalinn Univ Hosp, Reykjavik, Iceland; Ullevaal Univ Hosp, Ctr Prevent Med, Oslo, Norway; Univ Oslo, Rikshosp Univ Hosp, Dept Cardiol, Oslo, Norway	University of Helsinki; Kuopio University Hospital; University of Eastern Finland; Merck & Company; University of Gothenburg; Aarhus University; Landspitali National University Hospital; University of Oslo; University of Oslo; National Hospital Norway	Strandberg, TE (corresponding author), Univ Helsinki, Dept Med, PL340, Helsinki 00029, Finland.	timo.strandberg@hus.fi						Bjerre LM, 2001, AM J MED, V110, P716, DOI 10.1016/S0002-9343(01)00705-7; Bonetti PO, 2003, EUR HEART J, V24, P225, DOI 10.1016/S0195-668X(02)00419-0; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; ENGELAND A, 1995, APMIS S, V45, P1; Guallar E, 2001, AM J MED, V110, P738, DOI 10.1016/S0002-9343(01)00758-6; Holdaas H, 2003, LANCET, V361, P2024, DOI 10.1016/S0140-6736(03)13638-0; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423; Newman TB, 1996, JAMA-J AM MED ASSOC, V275, P55, DOI 10.1001/jama.275.1.55; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 2000, AM J CARDIOL, V86, P257, DOI 10.1016/S0002-9149(00)00910-3; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Serruys PWJC, 2002, JAMA-J AM MED ASSOC, V287, P3215, DOI 10.1001/jama.287.24.3215; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; Tonkin A, 1998, NEW ENGL J MED, V339, P1349	20	257	266	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	2004	364	9436					771	777		10.1016/S0140-6736(04)16936-5	http://dx.doi.org/10.1016/S0140-6736(04)16936-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337403				2022-12-28	WOS:000223569600028
J	Wu, ZC; Chen, ZH; Du, X; Logan, JM; Sippel, J; Nikolou, M; Kamaras, K; Reynolds, JR; Tanner, DB; Hebard, AF; Rinzler, AG				Wu, ZC; Chen, ZH; Du, X; Logan, JM; Sippel, J; Nikolou, M; Kamaras, K; Reynolds, JR; Tanner, DB; Hebard, AF; Rinzler, AG			Transparent, conductive carbon nanotube films	SCIENCE			English	Article							THIN-FILMS; ABSORPTION-SPECTROSCOPY; ELECTRONIC-STRUCTURE; TRANSISTORS	We describe a simple process for the fabrication of ultrathin, transparent, optically homogeneous, electrically conducting films of pure single-waited carbon nanotubes and the transfer of those films to various substrates. For equivalent sheet resistance, the films exhibit optical transmittance comparable to that of commercial indium tin oxide in the visible spectrum, but far superior transmittance in the technologically relevant 2- to 5-micrometer infrared spectral band. These characteristics indicate broad applicability of the films for electrical coupling in photonic devices. in an example application, the films are used to construct an electric field-activated optical modulator, which constitutes an optical analog to the nanotube-based field effect transistor.	Univ Florida, Dept Phys, Gainesville, FL 32611 USA; Univ Florida, Dept Chem, Gainesville, FL 32611 USA; MTA SzFKI, H-1525 Budapest, Hungary	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Rinzler, AG (corresponding author), Univ Florida, Dept Phys, Gainesville, FL 32611 USA.	rinzler@phys.ufl.edu	Iannone, Raffaele/L-3758-2014; Macchiaroli, Roberto/AAS-2112-2021; Chen, Zhihong/D-2019-2012; Kamaras, Katalin/A-3916-2009; Fera, Marcello/I-1284-2019; Han, Jinhua/F-9464-2010; Wu, Zhuangchun/C-9252-2011; wu, zhuangchun/E-8046-2012	Iannone, Raffaele/0000-0002-7937-7745; Macchiaroli, Roberto/0000-0001-6260-676X; Kamaras, Katalin/0000-0002-0390-3331; Fera, Marcello/0000-0002-3418-355X; wu, zhuangchun/0000-0003-3362-0882; Tanner, David/0000-0003-1940-4710; Chen, Zhihong/0000-0001-5934-739X; Logan, Jonathan/0000-0003-2554-9457				Chandrasekhar P, 2003, SYNTHETIC MET, V135, P23, DOI 10.1016/S0379-6779(02)00682-3; Ginley D., 2001, MAT RES SOC S P, V668, pH2; Gordon RG, 2000, MRS BULL, V25, P52, DOI 10.1557/mrs2000.151; Heinze S, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.106801; Hennrich F, 2003, PHYS CHEM CHEM PHYS, V5, P178, DOI 10.1039/b208270e; Hennrich F, 2002, PHYS CHEM CHEM PHYS, V4, P2273, DOI 10.1039/b201570f; Itkis ME, 2002, NANO LETT, V2, P155, DOI 10.1021/nl0156639; Javey A, 2003, NATURE, V424, P654, DOI 10.1038/nature01797; Kavan L, 2001, J PHYS CHEM B, V105, P10764, DOI 10.1021/jp011709a; Kazaoui S, 1999, PHYS REV B, V60, P13339, DOI 10.1103/PhysRevB.60.13339; Kazaoui S, 2001, APPL PHYS LETT, V78, P3433, DOI 10.1063/1.1372208; Kruger M, 2001, APPL PHYS LETT, V78, P1291, DOI 10.1063/1.1350427; Lee K, 2004, NANO LETT, V4, P911, DOI 10.1021/nl0496522; MANN D, 2003, NATURE, V424, P654; Rosenblatt S, 2002, NANO LETT, V2, P869, DOI 10.1021/nl025639a; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Windisch CF, 2002, THIN SOLID FILMS, V420, P89, DOI 10.1016/S0040-6090(02)00740-X	17	2557	2730	36	1281	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2004	305	5688					1273	1276		10.1126/science.1101243	http://dx.doi.org/10.1126/science.1101243			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850PJ	15333836				2022-12-28	WOS:000223624600036
J	Griffin, AS; West, SA; Buckling, A				Griffin, AS; West, SA; Buckling, A			Cooperation and competition in pathogenic bacteria	NATURE			English	Article							CYSTIC-FIBROSIS PATIENTS; PSEUDOMONAS-AERUGINOSA; VISCOUS POPULATIONS; EVOLUTION; VIRULENCE; ALTRUISM; CONFLICT; RELATEDNESS; PARASITES; INFECTION	Explaining altruistic cooperation is one of the greatest challenges for evolutionary biology(1-3). One solution to this problem is if costly cooperative behaviours are directed towards relatives(4,5). This idea of kin selection has been hugely influential and applied widely from microorganisms to vertebrates(2-10). However, a problem arises if there is local competition for resources, because this leads to competition between relatives, reducing selection for cooperation(3,11-14). Here we use an experimental evolution approach to test the effect of the scale of competition, and how it interacts with relatedness. The cooperative trait that we examine is the production of siderophores, iron-scavenging agents, in the pathogenic bacterium Pseudomonas aeruginosa(15-17). As expected, our results show that higher levels of cooperative siderophore production evolve in the higher relatedness treatments. However, our results also show that more local competition selects for lower levels of siderophore production and that there is a significant interaction between relatedness and the scale of competition, with relatedness having less effect when the scale of competition is more local. More generally, the scale of competition is likely to be of particular importance for the evolution of cooperation in microorganisms, and also the virulence of pathogenic microorganisms, because cooperative traits such as siderophore production have an important role in determining virulence(6,9,17-19).	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	University of Edinburgh; University of Bath	Griffin, AS (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, Kings Bldg,W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	a.griffin@ed.ac.uk	Griffin, Ashleigh/C-6244-2014; West, Stuart A/M-3608-2014	Griffin, Ashleigh/0000-0001-7674-9825; West, Stuart A/0000-0003-2152-3153; Buckling, Angus/0000-0003-1170-4604				Brown SP, 1999, P ROY SOC B-BIOL SCI, V266, P1899, DOI 10.1098/rspb.1999.0864; Brown SP, 2002, TRENDS MICROBIOL, V10, P401, DOI 10.1016/S0966-842X(02)02413-7; Crespi BJ, 2001, TRENDS ECOL EVOL, V16, P178, DOI 10.1016/S0169-5347(01)02115-2; De Vos D, 2001, ARCH MICROBIOL, V175, P384, DOI 10.1007/s002030100278; Frank, 1998, FDN SOCIAL EVOLUTION; Frank SA, 1996, Q REV BIOL, V71, P37, DOI 10.1086/419267; Gandon S, 2001, NATURE, V414, P751, DOI 10.1038/414751a; Grafen A, 1984, BEHAV ECOLOGY EVOLUT, V2, P62; Griffin AS, 2003, SCIENCE, V302, P634, DOI 10.1126/science.1089402; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.micro.48.1.743; HAMILTON WD, 1963, AM NAT, V97, P354, DOI 10.1086/497114; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HAMILTON WD, 1996, NARROW ROADS GENE LA, V1; HOOGKAMPKORSTANJE JAA, 1995, J CLIN MICROBIOL, V33, P572, DOI 10.1128/JCM.33.3.572-575.1995; KELLER L, 2002, ENCY EVOLUTION, P595; Meyer JM, 1996, INFECT IMMUN, V64, P518, DOI 10.1128/IAI.64.2.518-523.1996; Pepper JW, 2000, J THEOR BIOL, V206, P355, DOI 10.1006/jtbi.2000.2132; QUELLER DC, 1994, EVOL ECOL, V8, P70, DOI 10.1007/BF01237667; Queller DC, 1998, BIOSCIENCE, V48, P165, DOI 10.2307/1313262; Rainey PB, 2003, NATURE, V425, P72, DOI 10.1038/nature01906; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; Strassmann JE, 2000, NATURE, V408, P965, DOI 10.1038/35050087; Szathmary E, 1995, MAJOR TRANSITIONS EV; TAYLOR PD, 1992, EVOL ECOL, V6, P352, DOI 10.1007/BF02270971; Velicer GJ, 2003, TRENDS MICROBIOL, V11, P330, DOI 10.1016/S0966-842X(03)00152-5; Velicer GJ, 2003, NATURE, V425, P75, DOI 10.1038/nature01908; West SA, 2001, NATURE, V409, P510, DOI 10.1038/35054057; West SA, 2003, P ROY SOC B-BIOL SCI, V270, P37, DOI 10.1098/rspb.2002.2209; West SA, 2002, SCIENCE, V296, P72, DOI 10.1126/science.1065507; WILSON DS, 1992, EVOL ECOL, V6, P331, DOI 10.1007/BF02270969	30	675	689	8	336	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2004	430	7003					1024	1027		10.1038/nature02744	http://dx.doi.org/10.1038/nature02744			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329720	Green Published			2022-12-28	WOS:000223514900042
J	Halestrap, AP				Halestrap, AP			Dual role for the ADP/ATP translocator?	NATURE			English	Editorial Material							PERMEABILITY TRANSITION PORE; ADENINE-NUCLEOTIDE TRANSLOCASE; CYCLOPHILIN-D; CELL-DEATH; CHANNEL; CARRIER		Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Halestrap, AP (corresponding author), Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England.	a.halestrap@bristol.ac.uk	Halestrap, Andrew P/G-7275-2011	Halestrap, Andrew/0000-0001-5374-2778	British Heart Foundation [RG/03/002/15663] Funding Source: Medline	British Heart Foundation(British Heart Foundation)		Brustovetsky N, 2002, BIOCHEMISTRY-US, V41, P11804, DOI 10.1021/bi0200110; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P281, DOI 10.1016/0005-2736(90)90177-P; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; PEYROULA EP, 2003, NATURE, V426, P39; STUBBS M, 1978, BIOCHEM J, V172, P333, DOI 10.1042/bj1720333; Waldmeier PC, 2003, CURR MED CHEM, V10, P1485, DOI 10.2174/0929867033457160	11	74	76	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2004	430	7003								10.1038/nature02816	http://dx.doi.org/10.1038/nature02816			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15332302	Bronze			2022-12-28	WOS:000223514900032
J	Nagao, K; Adachi, Y; Yanagida, M				Nagao, K; Adachi, Y; Yanagida, M			Separase-mediated cleavage of cohesin at interphase is required for DNA repair	NATURE			English	Article							SISTER-CHROMATID SEPARATION; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; S-PHASE; SACCHAROMYCES-CEREVISIAE; DAMAGE CHECKPOINT; CUT2 PROTEOLYSIS; EXCISION-REPAIR; BUDDING YEAST; ANAPHASE	Sister chromatids are held together by cohesins(1). At anaphase, separase is activated by degradation of its inhibitory partner, securin(2,3). Separase then cleaves cohesins(4-6), thus allowing sister chromatid separation. Fission yeast securin (Cut2) has destruction boxes and a separase (Cut1) interaction site in the amino and carboxyl terminus, respectively(7,8). Here we show that securin is essential for separase stability and also for proper repair of DNA damaged by ultraviolet, X-ray and g-ray irradiation. The cut2(EA2) mutant is defective in the repair of ultraviolet damage lesions, although the DNA damage checkpoint is activated normally. In double mutant analysis of ultraviolet sensitivity, checkpoint kinase chk1 (ref. 9) and excision repair rad13 (ref. 10) mutants were additive with cut2(EA2), whereas recombination repair rhp51 (ref. 11) and cohesin subunit rad21 (ref. 12) mutants were not. Cohesin was hyper-modified on ultraviolet irradiation in a Rad3 kinase-dependent way(13). Experiments using either mutant cohesin that cannot be cleaved by separase or a protease-dead separase provide evidence that this DNA repair function of securin-separase acts through the cleavage of cohesin. We propose that the securin-separase complex might aid DNA repair by removing local cohesin in interphase cells.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Sakyo Ku, Kyoto 6068501, Japan; Okinawa Inst Sci & Technol, Initial Res Project, Okinawa 9042234, Japan	Kyoto University; Kyoto University; Okinawa Institute of Science & Technology Graduate University	Yanagida, M (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Yoshida Honmachi, Kyoto 6068501, Japan.	yanagida@kozo.lif.kyoto-u.ac.jp		Nagao, Koji/0000-0003-1418-6988				Aono N, 2002, NATURE, V417, P197, DOI 10.1038/417197a; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Esashi F, 1999, MOL CELL, V4, P167, DOI 10.1016/S1097-2765(00)80364-0; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; Jager H, 2001, GENE DEV, V15, P2572, DOI 10.1101/gad.207301; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Kumada K, 1998, CURR BIOL, V8, P633, DOI 10.1016/S0960-9822(98)70250-7; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; MURIS DFR, 1993, NUCLEIC ACIDS RES, V21, P4586, DOI 10.1093/nar/21.19.4586; Nakamura T, 2002, GENES CELLS, V7, P1113, DOI 10.1046/j.1365-2443.2002.00586.x; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yonemasu R, 1997, NUCLEIC ACIDS RES, V25, P1553, DOI 10.1093/nar/25.8.1553	29	109	111	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2004	430	7003					1044	1048		10.1038/nature02803	http://dx.doi.org/10.1038/nature02803			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329725				2022-12-28	WOS:000223514900047
J	Weidinger, M; Moller, P; Fynbo, JPU				Weidinger, M; Moller, P; Fynbo, JPU			The Lyman-alpha glow of gas falling into the dark matter halo of a z=3 galaxy	NATURE			English	Article							QUASARS; EMISSION; INFALL	Quasars are the visible signatures of gas falling into the deep potential well of super-massive black holes in the centres of distant galaxies. It has been suggested(1) that quasars are formed when two massive galaxies collide and merge, leading to the prediction that quasars should be found in the centres of regions of largest overdensity in the early Universe. In dark matter (DM)-dominated models of the early Universe, massive DM halos are predicted to attract the surrounding gas, which falls towards their centres. The neutral gas is not detectable in emission by itself, but gas falling into the ionizing cone of such a quasar will glow in the Lyman-alpha line of hydrogen, effectively imaging the DM halo(2). Here we present a Lyalpha image of a DM halo at redshift z = 3, along with a two-dimensional spectrum of the gaseous halo. Our observations are best understood in the context of the standard model for DM haloes(3); we infer a mass of (2-7) x 10(12) solar masses ( M.) for the halo.	European So Observ, D-85748 Garching, Germany; Aarhus Univ, Inst Phys & Astron, DK-8000 Aarhus C, Denmark; Univ Copenhagen, Astron Observ, DK-2100 Copenhagen O, Denmark	European Southern Observatory; Aarhus University; University of Copenhagen	Weidinger, M (corresponding author), European So Observ, Karl Schwarzschild Str 2, D-85748 Garching, Germany.	mweiding@eso.org	Fynbo, Johan P. U./L-8496-2014	Fynbo, Johan P. U./0000-0002-8149-8298				Barkana R, 2004, MON NOT R ASTRON SOC, V347, P59, DOI 10.1111/j.1365-2966.2004.07177.x; Barkana R, 2003, NATURE, V421, P341, DOI 10.1038/nature01330; Blundell KM, 2003, ASTROPHYS J, V591, pL103, DOI 10.1086/377295; Bunker A, 2003, ASTROPHYS SPACE SCI, V284, P357, DOI 10.1023/A:1024038312479; CARLBERG RG, 1990, ASTROPHYS J, V350, P505, DOI 10.1086/168406; Elvis M, 2000, ASTROPHYS J, V545, P63, DOI 10.1086/317778; Fynbo JU, 2000, ASTRON ASTROPHYS, V353, P457; Gould A, 1996, ASTROPHYS J, V468, P462, DOI 10.1086/177707; Haiman Z, 2001, ASTROPHYS J, V556, P87, DOI 10.1086/321567; HECKMAN TM, 1991, ASTROPHYS J, V381, P373, DOI 10.1086/170660; LAWRENCE A, 1991, MON NOT R ASTRON SOC, V252, P586, DOI 10.1093/mnras/252.4.586; Moller P., 2000, MESSENGER, V99, P31; MOLLER P, 2000, ESO MESSENGER, V99, P33; Navarro JF, 1997, ASTROPHYS J, V490, P493, DOI 10.1086/304888	14	60	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2004	430	7003					999	1001		10.1038/nature02793	http://dx.doi.org/10.1038/nature02793			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329713	Green Submitted			2022-12-28	WOS:000223514900035
J	Farley-Hills, E; Sivasankar, R; Martin, M				Farley-Hills, E; Sivasankar, R; Martin, M			Drug points: Fatal liver failure associated with pioglitazone	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Ysbyty Gwynedd Hosp, Bangor LL57 2PW, Gwynedd, Wales		Farley-Hills, E (corresponding author), Ysbyty Gwynedd Hosp, Bangor LL57 2PW, Gwynedd, Wales.	edward.farley-hills@nww-tr.wales.nhs.uk						Chase AP, 2002, AM J GASTROENTEROL, V97, P502; Isley William L, 2003, Expert Opin Drug Saf, V2, P581, DOI 10.1517/14740338.2.6.581; Scheen Andre J., 2001, Drug Safety, V24, P873, DOI 10.2165/00002018-200124120-00002; Tolman Keith G, 2003, Clin Liver Dis, V7, P369, DOI 10.1016/S1089-3261(03)00020-5	4	21	22	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 21	2004	329	7463					429	429		10.1136/bmj.329.7463.429	http://dx.doi.org/10.1136/bmj.329.7463.429			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849EA	15321899	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000223520300017
J	Hattori, N; Mizuno, Y				Hattori, N; Mizuno, Y			Pathogenetic mechanisms of parkin in Parkinson's disease	LANCET			English	Review							RECESSIVE JUVENILE PARKINSONISM; UBIQUITIN-PROTEIN LIGASE; ALPHA-SYNUCLEIN; GENE-PRODUCT; MUTATIONS; ONSET; DEGRADATION; PROTEASOMES; ASSOCIATION; DELETIONS	Context The cause and pathogenesis of Parkinson's disease remain unknown; mitochondrial dysfunction, oxidative damage, environmental factors, and genetic predisposition might all be involved. Identification of the causative genes for familial Parkinson's diseases allow study of the pathogenesis of the disease at the molecular level. Starting point Katja Hedrich and colleagues studied 75 Serbian patients with early-onset Parkinson's disease for DJ-1 mutations (Neurology 2004; 62: 389-94). One patient was a compound heterozygote and another had a heterozygous exon deletion. DJ-1 mutations seem to be rare in this European population. By contrast, parkin mutations have been found in about 50% of familial cases and in 10-20% of cases without a positive family history. Where next The fact that parkin is a ubiquitin ligase gives special meaning to the molecular mechanism of neurodegeneration in general. In Parkinson's disease, Lewy bodies are immunoreactive for ubiquitin. Accumulation of abnormal proteins has also been seen in other neurodegenerative disorders. Disturbance of protein degradation by the ubiquitin-proteasome system might have a critical role in neurodegeneration. Although alpha-synuclein mutations are infrequent, alpha-synuclein accumulates in Lewy bodies, and alpha-synuclein fibrils impair the 26S proteasome function. UCH-L1 is also an abundant deubiquitylating enzyme, and its mutation is linked to PARK5. Furthermore, DJ-1 might interact with SUMO-1 (small ubiquitin-like modifier), which can counteract ubiquitin and stabilise proteins against degradation by the 26S proteasome. Uncovering the mechanisms of protein degradation should add importantly to understanding the neurodegenerative process in these neurodegenerative diseases.	Juntendo Univ, Sch Med, Dept Neurol, Tokyo 1138421, Japan	Juntendo University	Hattori, N (corresponding author), Juntendo Univ, Sch Med, Dept Neurol, Tokyo 1138421, Japan.	nhattori@med.juntendo.ac.jp	Hattori, Nobutaka/ACR-0069-2022					Choi P, 2003, MOL BRAIN RES, V117, P179, DOI 10.1016/S0169-328X(03)00318-8; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Corti O, 2003, HUM MOL GENET, V12, P1427, DOI 10.1093/hmg/ddg159; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; Farrer M, 2001, ANN NEUROL, V50, P293, DOI 10.1002/ana.1132; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; Hattori N, 1998, ANN NEUROL, V44, P935, DOI 10.1002/ana.410440612; Hedrich K, 2004, NEUROLOGY, V62, P389, DOI 10.1212/01.WNL.0000113022.51739.88; Hilker R, 2001, ANN NEUROL, V49, P367, DOI 10.1002/ana.74; Huynh DP, 2003, HUM MOL GENET, V12, P2587, DOI 10.1093/hmg/ddg269; Huynh DP, 2000, ANN NEUROL, V48, P737, DOI 10.1002/1531-8249(200011)48:5<737::AID-ANA7>3.3.CO;2-4; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Itier JM, 2003, HUM MOL GENET, V12, P2277, DOI 10.1093/hmg/ddg239; Khan NL, 2003, BRAIN, V126, P1279, DOI 10.1093/brain/awg142; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klein C, 2000, ANN NEUROL, V48, P65, DOI 10.1002/1531-8249(200007)48:1<65::AID-ANA10>3.0.CO;2-L; Lohmann E, 2003, ANN NEUROL, V54, P176, DOI 10.1002/ana.10613; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Mori H, 1998, NEUROLOGY, V51, P890, DOI 10.1212/WNL.51.3.890; Oliveira SA, 2003, ANN NEUROL, V53, P624, DOI 10.1002/ana.10524; Periquet M, 2003, BRAIN, V126, P1271, DOI 10.1093/brain/awg136; Ren Y, 2003, J NEUROSCI, V23, P3316; Sakata E, 2003, EMBO REP, V4, P301, DOI 10.1038/sj.embor.embor764; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; van de Warrenburg BPC, 2001, NEUROLOGY, V56, P555, DOI 10.1212/WNL.56.4.555; West AB, 2002, HUM MOL GENET, V11, P2787, DOI 10.1093/hmg/11.22.2787; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhao JH, 2003, J CELL SCI, V116, P4011, DOI 10.1242/jcs.00700	33	98	102	2	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	2004	364	9435					722	724		10.1016/S0140-6736(04)16901-8	http://dx.doi.org/10.1016/S0140-6736(04)16901-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325839				2022-12-28	WOS:000223428900036
J	Hilton, M				Hilton, M			Tonsillectomy technique - tradition versus technology	LANCET			English	Editorial Material							POST-TONSILLECTOMY; HEMORRHAGE; HEMOSTASIS		Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England	University of Exeter	Hilton, M (corresponding author), Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England.	Malcolm.Hilton@rdehc-tr.swest.nhs.uk						HAASE FR, 1962, ARCHIV OTOLARYNGOL, V75, P125; HANDLER SD, 1986, LARYNGOSCOPE, V96, P1243; Krishna P, 2001, LARYNGOSCOPE, V111, P1358, DOI 10.1097/00005537-200108000-00008; KRISTENSEN S, 1984, CLIN OTOLARYNGOL, V9, P347, DOI 10.1111/j.1365-2273.1984.tb01519.x; PINDER D, 2001, COCHRANE DB SYST REV, P2211; RAMSDEN R, 2004, COMMUNICATION    MAR; SIODLAK MZ, 1985, ANN ROY COLL SURG, V67, P167; WATSON MG, 1993, J LARYNGOL OTOL, V107, P711, DOI 10.1017/S0022215100124211; Wei JL, 2000, OTOLARYNG HEAD NECK, V123, P229, DOI 10.1067/mhn.2000.107454; Windfuhr JP, 2003, ANN OTO RHINOL LARYN, V112, P63, DOI 10.1177/000348940311200113	10	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	2004	364	9435					642	643		10.1016/S0140-6736(04)16908-0	http://dx.doi.org/10.1016/S0140-6736(04)16908-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325811				2022-12-28	WOS:000223428900005
J	Dormans, JP; Garg, S				Dormans, JP; Garg, S			Rotationplasty for Ewing's sarcoma of the distal femur	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia	Dormans, JP (corresponding author), Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2004	351	8					E7	E7		10.1056/ENEJMicm030590	http://dx.doi.org/10.1056/ENEJMicm030590			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847CY	15317906				2022-12-28	WOS:000223367900014
J	Holman, MJ; Kavelaars, JJ; Grav, T; Gladman, BJ; Fraser, WC; Milisavljevic, D; Nicholson, PD; Burns, JA; Carruba, V; Petit, JM; Rousselot, P; Mousis, O; Marsden, BG; Jacobson, RA				Holman, MJ; Kavelaars, JJ; Grav, T; Gladman, BJ; Fraser, WC; Milisavljevic, D; Nicholson, PD; Burns, JA; Carruba, V; Petit, JM; Rousselot, P; Mousis, O; Marsden, BG; Jacobson, RA			Discovery of five irregular moons of Neptune	NATURE			English	Article							ASSISTED CAPTURE; GAS-DRAG; SATELLITES; URANUS; INCLINATION; OBJECTS; JUPITER; SEARCH	Each giant planet of the Solar System has two main types of moons. 'Regular' moons are typically larger satellites with prograde, nearly circular orbits in the equatorial plane of their host planets at distances of several to tens of planetary radii. The 'irregular' satellites (which are typically smaller) have larger orbits with significant eccentricities and inclinations. Despite these common features, Neptune's irregular satellite system, hitherto thought to consist of Triton and Nereid, has appeared unusual. Triton is as large as Pluto and is postulated to have been captured from heliocentric orbit; it traces a circular but retrograde orbit at 14 planetary radii from Neptune. Nereid, which exhibits one of the largest satellite eccentricities, is believed to have been scattered from a regular satellite orbit to its present orbit during Triton's capture(1,2). Here we report the discovery of five irregular moons of Neptune, two with prograde and three with retrograde orbits. These exceedingly faint (apparent red magnitude m(R) = 5 24.2-25.4) moons, with diameters of 30 to 50 km, were presumably captured by Neptune.	Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Natl Res Council Canada, Victoria, BC V9E ZE7, Canada; Univ Oslo, Inst Theoret Astrophys, N-0315 Oslo, Norway; Univ British Columbia, Dept Phys & Astron, Vancouver, BC V6T 1Z1, Canada; McMaster Univ, Dept Phys & Astron, Hamilton, ON L8S 4M1, Canada; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; Obervatoire Besancon, F-25010 Besancon, France; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; National Research Council Canada; University of Oslo; University of British Columbia; McMaster University; Cornell University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Holman, MJ (corresponding author), Harvard Smithsonian Ctr Astrophys, 60 Garden St, Cambridge, MA 02138 USA.	mholman@cfa.harvard.edu	Mousis, Olivier/X-2712-2019; Carruba, Valerio/P-2419-2019; Carruba, Valerio/H-5529-2012	Carruba, Valerio/0000-0003-2786-0740; Carruba, Valerio/0000-0003-2786-0740				Alard C, 2000, ASTRON ASTROPHYS SUP, V144, P363, DOI 10.1051/aas:2000214; Allen RL, 2001, ASTROPHYS J, V549, pL241, DOI 10.1086/319165; Astakhov SA, 2003, NATURE, V423, P264, DOI 10.1038/nature01622; Brown MJI, 1998, PUBL ASTRON SOC AUST, V15, P325, DOI 10.1071/AS98325; Carruba V, 2002, ICARUS, V158, P434, DOI 10.1006/icar.2002.6896; COLOMBO G, 1971, ICARUS, V15, P186, DOI 10.1016/0019-1035(71)90073-X; Cuk M, 2004, ICARUS, V167, P369, DOI 10.1016/j.icarus.2003.09.026; Gladman B, 2000, ICARUS, V147, P320, DOI 10.1006/icar.2000.6463; Gladman B, 2001, NATURE, V412, P163, DOI 10.1038/35084032; Gladman B, 1998, ASTRON J, V116, P2042, DOI 10.1086/300573; Gladman BJ, 1998, NATURE, V392, P897, DOI 10.1038/31890; GOLDREICH P, 1989, SCIENCE, V245, P500, DOI 10.1126/science.245.4917.500; Grav T, 2003, ICARUS, V166, P33, DOI 10.1016/j.icarus.2003.07.005; GRAV T, 2004, ASTROPH0405605; HENON M, 1970, ASTRON ASTROPHYS, V9, P24; HEPPENHEIMER TA, 1977, ICARUS, V30, P385, DOI 10.1016/0019-1035(77)90173-7; HOGG DW, 1994, ICARUS, V107, P304, DOI 10.1006/icar.1994.1025; Kavelaars JJ, 2004, ICARUS, V169, P474, DOI 10.1016/j.icarus.2004.01.009; KESSLER DJ, 1981, ICARUS, V48, P39, DOI 10.1016/0019-1035(81)90151-2; KOZAI Y, 1962, ASTRON J, V67, P591, DOI 10.1086/108790; LANDOLT AU, 1992, ASTRON J, V104, P340, DOI 10.1086/116242; MCKINNON WB, 1984, NATURE, V311, P355, DOI 10.1038/311355a0; Nesvorny D, 2003, ASTRON J, V126, P398, DOI 10.1086/375461; Petit JM, 2004, MON NOT R ASTRON SOC, V347, P471, DOI 10.1111/j.1365-2966.2004.07217.x; POLLACK JB, 1979, ICARUS, V37, P587, DOI 10.1016/0019-1035(79)90016-2; Rettig TW, 2001, ICARUS, V154, P313, DOI 10.1006/icar.2001.6715; Sheppard SS, 2003, NATURE, V423, P261, DOI 10.1038/nature01584; SHEPPARD SS, 2003, 8193 IAU	30	46	47	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2004	430	7002					865	867		10.1038/nature02832	http://dx.doi.org/10.1038/nature02832			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318214				2022-12-28	WOS:000223369800034
J	Zucchero, TM; Cooper, ME; Maher, BS; Daack-Hirsch, S; Nepomuceno, B; Ribeiro, L; Caprau, D; Christensen, K; Suzuki, Y; Machida, J; Natsume, N; Yoshiura, KI; Vieira, AR; Orioli, IM; Castilla, EE; Moreno, L; Arcos-Burgos, M; Lidral, AC; Field, LL; Liu, YE; Ray, A; Goldstein, TH; Schultz, RE; Shi, M; Johnson, MK; Kondo, S; Schutte, BC; Marazita, ML; Murray, JC				Zucchero, TM; Cooper, ME; Maher, BS; Daack-Hirsch, S; Nepomuceno, B; Ribeiro, L; Caprau, D; Christensen, K; Suzuki, Y; Machida, J; Natsume, N; Yoshiura, KI; Vieira, AR; Orioli, IM; Castilla, EE; Moreno, L; Arcos-Burgos, M; Lidral, AC; Field, LL; Liu, YE; Ray, A; Goldstein, TH; Schultz, RE; Shi, M; Johnson, MK; Kondo, S; Schutte, BC; Marazita, ML; Murray, JC			Interferon regulatory factor 6 (IRF6) gene variants and the risk of isolated cleft lip or palate	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AUTOSOMAL MAJOR LOCUS; FAMILY-BASED TESTS; LINKAGE ANALYSIS; UNIFIED APPROACH; CLINICAL-TRIALS; ASSOCIATION; MSX1; METAANALYSIS; FREQUENCIES; REGIONS	BACKGROUND: Cleft lip or palate (or the two in combination) is a common birth defect that results from a mixture of genetic and environmental factors. We searched for a specific genetic factor contributing to this complex trait by examining large numbers of affected patients and families and evaluating a specific candidate gene. METHODS: We identified the gene that encodes interferon regulatory factor 6 (IRF6) as a candidate gene on the basis of its involvement in an autosomal dominant form of cleft lip and palate, Van der Woude's syndrome. A single-nucleotide polymorphism in this gene results in either a valine or an isoleucine at amino acid position 274 (V274I). We carried out transmission-disequilibrium testing for V274I in 8003 individual subjects in 1968 families derived from 10 populations with ancestry in Asia, Europe, and South America, haplotype and linkage analyses, and case-control analyses, and determined the risk of cleft lip or palate that is associated with genetic variation in IRF6. RESULTS: Strong evidence of overtransmission of the valine (V) allele was found in the entire population data set (P<10(sup -9)); moreover, the results for some individual populations from South America and Asia were highly significant. Variation at IRF6 was responsible for 12 percent of the genetic contribution to cleft lip or palate and tripled the risk of recurrence in families that had already had one affected child. CONCLUSIONS: DNA-sequence variants associated with IRF6 are major contributors to cleft lip, with or without cleft palate. The contribution of variants in single genes to cleft lip or palate is an important consideration in genetic counseling.	Univ Iowa, Coll Dent, Iowa City, IA 52242 USA; Univ Pittsburgh, Sch Dent Med, Pittsburgh, PA USA; HOPE Fdn, Bacolod City, Philippines; Univ Sao Paulo, Hosp Rehabil Craniofacial Anomalies, Sao Paulo, Brazil; Univ So Denmark, Inst Publ Hlth, Odense, Denmark; Aichi Gakuin Univ, Sch Dent, Nagoya, Aichi 464, Japan; Nagasaki Univ, Sch Med, Nagasaki 852, Japan; Univ Fed Rio de Janeiro, Estudio Collaborat Latino Amer Malformac Congenit, Rio De Janeiro, Brazil; Oswaldo Cruz Fdn, ECLAMC, Rio De Janeiro, Brazil; Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina; Univ Antioquia, Inst Biol, Medellin, Colombia; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Zhabei Genet Inst, Shanghai, Peoples R China	University of Iowa; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Universidade de Sao Paulo; University of Southern Denmark; Aichi Gakuin University; Nagasaki University; Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Universidad de Antioquia; University of British Columbia	Murray, JC (corresponding author), Univ Iowa, Coll Dent, S Grand Ave,2182 ML, Iowa City, IA 52242 USA.	jeff-murray@uiowa.edu	Christensen, Kaare/C-2360-2009; Cooper, Mark/AAC-5326-2020; Bicudo, Lucilene/ABA-5679-2020; Maher, Brion S/F-9185-2010; Arcos-Burgos, Mauricio/H-1326-2017	Christensen, Kaare/0000-0002-5429-5292; Daack-Hirsch, Sandra/0000-0003-1192-7154; Arcos-Burgos, Mauricio/0000-0002-8529-0574	NIDCR NIH HHS [R01 DE014667-07, R01 DE014667-05, K02 DE015291-03, R01 DE014667-04, K02 DE015291-05, R01 DE014667-06, K02 DE015291-01, R01 DE014667, DE14667, DE11948, R01 DE014667-02, K02 DE015291-02, R01 DE014667-03, P60 DE13076, R01 DE014667-08, DE08559, R01 DE016148, DE09886, R01 DE014667-01, K02 DE015291-04, DE13513, K02 DE015291] Funding Source: Medline; NIEHS NIH HHS [ES10876] Funding Source: Medline; NIGMS NIH HHS [GM08629] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE016148, R37DE008559] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013513, R01DE008559, K02DE015291, R01DE014667, P60DE013076, R01DE009886, R01DE011948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010876] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008629] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BURDICK AB, 1985, J CRAN GENET DEV BIO, V5, P181; Cann HM, 2002, SCIENCE, V296, P261; Christensen K, 2004, BRIT MED J, V328, P1405, DOI 10.1136/bmj.38106.559120.7C; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; ELSTON RC, 1971, HUM HERED, V21, P523, DOI 10.1159/000152448; Field L. Leigh, 1994, European Journal of Human Genetics, V2, P159; Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625; Horvath S, 2004, GENET EPIDEMIOL, V26, P61, DOI 10.1002/gepi.10295; Houdayer C, 2001, AM J MED GENET, V104, P86, DOI 10.1002/1096-8628(20011115)104:1<86::AID-AJMG10053>3.0.CO;2-E; Jezewski PA, 2003, J MED GENET, V40, P399, DOI 10.1136/jmg.40.6.399; Kondo S, 2002, NAT GENET, V32, P285, DOI 10.1038/ng985; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D; Marazita ML, 2004, AM J HUM GENET, V75, P161, DOI 10.1086/422475; Marazita ML, 2002, AM J HUM GENET, V71, P349, DOI 10.1086/341944; Marazita ML, 2002, CLEFT PALATE-CRAN J, V39, P149, DOI 10.1597/1545-1569(2002)039<0149:NCLWOW>2.0.CO;2; MARAZITA ML, 1992, AM J HUM GENET, V51, P648; Moreno LM, 2004, AM J MED GENET A, V125A, P135, DOI 10.1002/ajmg.a.20425; Mossey P., 2002, CLEFT LIP PALATE, P127; Murray JC, 1997, CLEFT PALATE-CRAN J, V34, P7, DOI 10.1597/1545-1569(1997)034<0007:CAESOC>2.3.CO;2; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; Rabinowitz D, 2000, HUM HERED, V50, P211, DOI 10.1159/000022918; RAY AK, 1993, AM J HUM GENET, V52, P1006; Romitti PA, 1999, TERATOLOGY, V59, P39, DOI 10.1002/(SICI)1096-9926(199901)59:1<39::AID-TERA9>3.0.CO;2-7; Schaid DJ, 1999, AM J EPIDEMIOL, V149, P706; Schliekelman P, 2002, AM J HUM GENET, V71, P1369, DOI 10.1086/344779; Schultz RE, 2004, AM J MED GENET A, V125A, P17, DOI 10.1002/ajmg.a.20424; Scott L, 2000, GENET EPIDEMIOL, V19, P381, DOI 10.1002/1098-2272(200012)19:4<381::AID-GEPI9>3.0.CO;2-B; Shi M, 2003, BIRTH DEFECTS RES A, V67, P545, DOI 10.1002/bdra.10076; Sobel E, 1996, AM J HUM GENET, V58, P1323; Terwilliger J., 1994, HDB HUMAN GENETIC LI; van den Boogaard MJH, 2000, NAT GENET, V25, P125; van den Boogaard MJH, 2000, NAT GENET, V24, P342, DOI 10.1038/74155; Vieira AR, 2003, J DENT RES, V82, P289, DOI 10.1177/154405910308200409; Weinberg CR, 1999, AM J HUM GENET, V64, P1186, DOI 10.1086/302337	38	436	468	0	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2004	351	8					769	780		10.1056/NEJMoa032909	http://dx.doi.org/10.1056/NEJMoa032909			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847CY	15317890	Green Accepted			2022-12-28	WOS:000223367900009
J	Vinkers, DJ; Gussekloo, J; Stek, ML; Westendorp, RGJ; van der Mast, RC				Vinkers, DJ; Gussekloo, J; Stek, ML; Westendorp, RGJ; van der Mast, RC			Temporal relation between depression and cognitive impairment in old age: prospective population based study	BRITISH MEDICAL JOURNAL			English	Article							ALZHEIMERS-DISEASE; LEIDEN 85-PLUS; SCALE GDS-15; RISK-FACTOR; COMMUNITY; DEMENTIA; SYMPTOMS; DECLINE	Objective To examine the temporal relation between depression and cognitive impairment in old age. Design Prospective, population based study, with four years of follow up. Setting City of Leiden, the Netherlands. Participants 500 people aged 85 years at recruitment. Main outcome measures Annual assessments of depressive symptoms (15 item geriatric depression scale), global cognitive function (mini-mental state examination), attention (Stroop test), processing speed (letter digit coding test), and immediate and delayed recall (12 word learning test). Results At 85 years old, participants' depressive symptoms and cognitive impairment were highly significantly correlated (P<0.001). During follow up, an accelerated annual increase of depressive symptoms was associated with impaired attention (0.08 points (95% confidence interval 0.01 to 0.16)), immediate recall (0.17 points (0.09 to 0.25)), and delayed recall (0.10 points (0.02 to 0.18)) at baseline. In contrast, depressive symptoms at baseline were not related to an accelerated cognitive decline during follow tip (P>0.05). Conclusion Care givers should be aware of the development of depressive symptoms when cognitive impairment is present. However, the presence of depression only does not increase the risk of cognitive decline.	Leiden Univ, Med Ctr, Dept Gen Internal Med, Sect Gerontol & Geriatr, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Psychiat, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Vinkers, DJ (corresponding author), Leiden Univ, Med Ctr, Dept Gen Internal Med, Sect Gerontol & Geriatr, POB 9600, NL-2300 RC Leiden, Netherlands.	d.j.vinkers@lumc.nl	Gussekloo, Jacobijn/ABE-3879-2021	Gussekloo, Jacobijn/0000-0001-7186-8278				Bootsma-van der Wiel A, 2002, J CLIN EPIDEMIOL, V55, P1119, DOI 10.1016/S0895-4356(02)00505-X; Brodaty H, 2003, PSYCHOL MED, V33, P1263, DOI 10.1017/S0033291703008195; Cervilla JA, 2000, PSYCHOL MED, V30, P1017, DOI 10.1017/S0033291799002779; Chen PJ, 1999, ARCH GEN PSYCHIAT, V56, P261, DOI 10.1001/archpsyc.56.3.261; de Craen AJM, 2003, INT J GERIATR PSYCH, V18, P63, DOI 10.1002/gps.773; Devanand DP, 1996, ARCH GEN PSYCHIAT, V53, P175; Dufouil C, 1996, AM J EPIDEMIOL, V144, P634; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Geerlings SW, 2002, PSYCHOL MED, V32, P609, DOI 10.1017/S0033291702005585; Green RC, 2003, ARCH NEUROL-CHICAGO, V60, P753, DOI 10.1001/archneur.60.5.753; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310; Henderson AS, 1997, PSYCHOL MED, V27, P119, DOI 10.1017/S0033291796004199; Houx PJ, 2002, J NEUROL NEUROSUR PS, V73, P385, DOI 10.1136/jnnp.73.4.385; Jonker C, 2000, INT J GERIATR PSYCH, V15, P983, DOI 10.1002/1099-1166(200011)15:11<983::AID-GPS238>3.0.CO;2-5; Jorm AF, 2001, AUST NZ J PSYCHIAT, V35, P776, DOI 10.1046/j.1440-1614.2001.00967.x; Macdonald AJD, 1997, BRIT MED J, V315, P413, DOI 10.1136/bmj.315.7105.413; MIGLIORELLI R, 1995, AM J PSYCHIAT, V152, P37; Paterniti S, 2002, BRIT J PSYCHIAT, V181, P406, DOI 10.1192/bjp.181.5.406; Schweitzer I, 2002, INT J GERIATR PSYCH, V17, P997, DOI 10.1002/gps.525; Vinkers DJ, 2004, INT J GERIATR PSYCH, V19, P80, DOI 10.1002/gps.1043; Wilson RS, 2004, J NEUROL NEUROSUR PS, V75, P126; WILSON RS, 1984, J NEUROL NEUROSUR PS, V75, P126; Yaffe K, 1999, ARCH GEN PSYCHIAT, V56, P425, DOI 10.1001/archpsyc.56.5.425; YESAVAGE JA, 1982, J PSYCHIATR RES, V1, P37; Zubenko GS, 2003, AM J PSYCHIAT, V160, P857, DOI 10.1176/appi.ajp.160.5.857	25	153	161	1	13	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 16	2004	329	7471					881	883		10.1136/bmj.38216.604664.DE	http://dx.doi.org/10.1136/bmj.38216.604664.DE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	863MU	15345599	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000224566800014
J	Chen, MS; Goodman, DW				Chen, MS; Goodman, DW			The structure of catalytically active gold on titania	SCIENCE			English	Article							LOW-TEMPERATURE OXIDATION; CO OXIDATION; CARBON-MONOXIDE; SUPPORTED GOLD; CATALYSTS; ADSORPTION; TIO2; AU; NANOPARTICLES; TIO2(110)	The high catalytic activity of gold clusters on oxides has been attributed to structural effects (including particle thickness and shape and metal oxidation state), as well as to support effects. We have created well-ordered gold monolayers and bilayers that completely wet (cover) the oxide support, thus eliminating particle shape and direct support effects. High-resolution electron energy loss spectroscopy and carbon monoxide adsorption confirm that the gold atoms are bonded to titanium atoms. Kinetic measurements for the catalytic oxidation of carbon monoxide show that the gold bilayer structure is significantly more active (by more than an order of magnitude) than the monolayer.	Texas A&M Univ, Dept Chem, College Stn, TX 77842 USA	Texas A&M University System; Texas A&M University College Station	Goodman, DW (corresponding author), Texas A&M Univ, Dept Chem, College Stn, TX 77842 USA.	goodman@mail.chem.tamu.edu	Chen, Mingshu/G-4590-2010	Chen, Mingshu/0000-0002-4923-9632				Bell AT, 2003, SCIENCE, V299, P1688, DOI 10.1126/science.1083671; Boccuzzi F, 2001, J CATAL, V202, P256, DOI 10.1006/jcat.2001.3290; Bond GC, 1999, CATAL REV, V41, P319, DOI 10.1081/CR-100101171; Bondzie VA, 1999, CATAL LETT, V63, P143, DOI 10.1023/A:1019012903936; Chen M., UNPUB; Chen MS, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.155404; Choudhary TV, 2002, J CATAL, V207, P247, DOI 10.1006/jcat.2002.3525; Chusuei CC, 2001, TOP CATAL, V14, P71; Cosandey F, 2001, SURF REV LETT, V8, P73, DOI 10.1016/S0218-625X(01)00088-4; Goodman DW, 2003, J CATAL, V216, P213, DOI 10.1016/S0021-9517(02)00112-4; Guo Q, 1999, SURF SCI, V437, P49, DOI 10.1016/S0039-6028(99)00678-0; Guzman J, 2004, J AM CHEM SOC, V126, P2672, DOI 10.1021/ja039426e; HARUTA M, 1993, J CATAL, V144, P175, DOI 10.1006/jcat.1993.1322; Haruta M, 2002, CATTECH, V6, P102, DOI 10.1023/A:1020181423055; HARUTA M, 1989, J CATAL, V115, P301, DOI 10.1016/0021-9517(89)90034-1; HOLMES PD, 1990, J VAC SCI TECHNOL, V8, P2585; Liu ZP, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.266102; Lopez N, 2004, J CATAL, V223, P232, DOI 10.1016/j.jcat.2004.01.001; LUPINI AR, UNPUB; Meier DC, 2004, J AM CHEM SOC, V126, P1892, DOI 10.1021/ja030359y; Molina LM, 2004, J CHEM PHYS, V120, P7673, DOI 10.1063/1.1687337; OUTKA DA, 1987, SURF SCI, V179, P351, DOI 10.1016/0039-6028(87)90062-8; Pietron JJ, 2002, NANO LETT, V2, P545, DOI 10.1021/nl025536s; Rodriguez JA, 2002, J AM CHEM SOC, V124, P5242, DOI 10.1021/ja020115y; Ruggiero C, 1997, SURF SCI, V377, P583, DOI 10.1016/S0039-6028(96)01451-3; Schubert MM, 2001, J CATAL, V197, P113, DOI 10.1006/jcat.2000.3069; Valden M, 1998, SCIENCE, V281, P1647, DOI 10.1126/science.281.5383.1647; Vijay A, 2003, J CHEM PHYS, V118, P6536, DOI 10.1063/1.1557919; Wahlstrom E, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.026101	29	1437	1465	18	961	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	2004	306	5694					252	255		10.1126/science.1102420	http://dx.doi.org/10.1126/science.1102420			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861MC	15331772				2022-12-28	WOS:000224419700032
J	de Lemos, JA; Blazing, MA; Wiviott, SD; Lewis, EF; Fox, KAA; White, HD; Rouleau, JL; Pedersen, TR; Gardner, LH; Mukherjee, R; Ramsey, KE; Palmisano, J; Bilheimer, DW; Pfeffer, MA; Califf, RM; Braunwald, E				de Lemos, JA; Blazing, MA; Wiviott, SD; Lewis, EF; Fox, KAA; White, HD; Rouleau, JL; Pedersen, TR; Gardner, LH; Mukherjee, R; Ramsey, KE; Palmisano, J; Bilheimer, DW; Pfeffer, MA; Califf, RM; Braunwald, E		A Z Investigators	Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes - Phase Z of the A to Z trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIPID-LOWERING THERAPY; MYOCARDIAL-INFARCTION; EFFICACY; TIROFIBAN; OUTCOMES; HEPARIN; EVENTS; SAFETY	Context Limited data are available evaluating how the timing and intensity of statin therapy following an acute coronary syndrome (ACS) event affect clinical outcome. Objective To compare early initiation of an intensive statin regimen with delayed initiation of a less intensive regimen in patients with ACS. Design, Setting, and Participants International, randomized, double-blind trial of patients with ACS receiving 40 mg/d of simvastatin for 1 month followed by 80 mg/d thereafter (n=2265) compared with ACS patients receiving placebo for 4 months followed by 20 mg/d of simvastatin (n=2232), who were enrolled in phase Z of the A to Z trial between December 29, 1999, and January 6, 2003. Main Outcome Measure The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, readmission for ACS, and stroke. Follow-up was for at least 6 months and up to 24 months. Results Among the patients in the placebo plus simvastatin group, the median low-density lipoprotein (LDL) cholesterol level achieved while taking placebo was 122 mg/dL (3.16 mmol/L) at 1 month and was 77 mg/dL (1.99 mmol/L) at 8 months while taking 20 mg/d of simvastatin. Among the patients in the simvastatin only group, the median LDL cholesterol level achieved at 1 month while taking 40 mg/d of simvastatin was 68 mg/dL (1.76 mmol/L) and was 63 mg/dL (1.63 mmol/L) at 8 months while taking 80 mg/d of simvastatin. A total of 343 patients (16.7%) in the placebo plus simvastatin group experienced the primary end point compared with 309 (14.4%) in the simvastatin only group (40 mg/80 mg) (hazard ratio [HR], 0.89; 95% confidence interval [CI] 0.76-1.04; P=.14). Cardiovascular death occurred in 109 (5.4%) and 83 (4.1%) patients in the 2 groups (HR, 0.75; 95% CI, 0.57-1.00; P=.05) but no differences were observed in other individual components of the primary end point. No difference was evident during the first 4 months between the groups for the primary end point (HR, 1.01; 95% CI, 0.83-1.25; P=.89), but from 4 months through the end of the study the primary end point was significantly reduced in the simvastatin only group (HR, 0.75; 95% CI, 0.60-0.95; P=.02). Myopathy (creatine kinase >10 times the upper limit of normal associated with muscle symptoms) occurred in 9 patients (0.4%) receiving simvastatin 80 mg/d, in no patients receiving lower doses of simvastatin, and in 1 patient receiving placebo (P=.02). Conclusions The trial did not achieve the prespecified end point. However, among patients with ACS, the early initiation of an aggressive simvastatin regimen resulted in a favorable trend toward reduction of major cardiovascular events.	Univ Texas, SW Med Ctr, Div Cardiol, Donald W Reynolds Cardiovasc Clin Res Ctr, Dallas, TX 75390 USA; Duke Clin Res Inst, Durham, NC USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Univ Edinburgh, Dept Cardiol Res, Edinburgh, Midlothian, Scotland; Green Lane Hosp, Dept Cardiol, Auckland 3, New Zealand; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Ullevaal Univ Hosp, Ctr Prevent Med, Oslo, Norway; Merck & Co Inc, Whitehouse Stn, NJ USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Duke University; Harvard University; Brigham & Women's Hospital; University of Edinburgh; Universite de Montreal; University of Oslo; Merck & Company	de Lemos, JA (corresponding author), Univ Texas, SW Med Ctr, Div Cardiol, Donald W Reynolds Cardiovasc Clin Res Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	james.delemos@utsouthwestern.edu	de Lemos, James/ABD-6669-2021; Wiviott, Stephen/HIK-2534-2022; Fox, keith A A/I-3742-2013	Fox, Keith/0000-0002-0140-2752				Aronow HD, 2001, LANCET, V357, P1063, DOI 10.1016/S0140-6736(00)04257-4; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Blazing MA, 2004, JAMA-J AM MED ASSOC, V292, P55, DOI 10.1001/jama.292.1.55; Blazing MA, 2001, AM HEART J, V142, P211, DOI 10.1067/mhj.2001.116959; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Davidson MH, 2000, NUTR METAB CARDIOVAS, V10, P253; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Kokko J, 2000, CECIL TXB MED, P522; Newby LK, 2002, JAMA-J AM MED ASSOC, V287, P3087, DOI 10.1001/jama.287.23.3087; Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071; PEDERSEN TR, 1994, LANCET, V344, P1383; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Spencer FA, 2004, ANN INTERN MED, V140, P857, DOI 10.7326/0003-4819-140-11-200406010-00006; Stenestrand U, 2001, JAMA-J AM MED ASSOC, V285, P430, DOI 10.1001/jama.285.4.430; Tonkin A, 1998, NEW ENGL J MED, V339, P1349	17	1002	1051	1	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2004	292	11					1307	1316		10.1001/jama.292.11.1307	http://dx.doi.org/10.1001/jama.292.11.1307			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853YL	15337732	Bronze			2022-12-28	WOS:000223866800022
J	Singh, JA				Singh, JA			Standards of care in the antiretroviral rollout world	LANCET			English	Editorial Material							PERINATAL TRANSMISSION; TRIALS		CAPRISA, Durban, South Africa; Univ KwaZulu Natal, Howard Coll, Sch Law, ZA-4041 Durban, South Africa; Univ Toronto, Joint Ctr Bioeth, Toronto, ON, Canada	University of Kwazulu Natal; University of Toronto	Singh, JA (corresponding author), CAPRISA, Durban, South Africa.	singhj9@ukzn.ac.za	Singh, Jerome Amir/ABG-1573-2021					Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; Council for International Organizations of Medical Sciences WHO, 2002, INT ETH GUID BIOM RE; hhs, 1979, BELM REP ETH PRINC G; Institute of Medicine, 2004, SCAL TREATM GLOB AID; Karim SSA, 1998, AM J PUBLIC HEALTH, V88, P564, DOI 10.2105/AJPH.88.4.564; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; *OHCHR UNAIDS, HIV AIDS HUM RIGHTS; *TREATM ACT CAMP A, 2004, 1 TREATM ACT CAMP AI; *WHO, TREAT 3 MILL 2005 MA; *WHO, 2003, SCAL ANT THER RES SE; *WHO, 2004, 3 5 PROGR REP; World Medical Association, DECL HELS ETH PRINC	12	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	2004	364	9438					920	922		10.1016/S0140-6736(04)17040-2	http://dx.doi.org/10.1016/S0140-6736(04)17040-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364176				2022-12-28	WOS:000223831000009
J	Knepper, MA; Agre, P				Knepper, MA; Agre, P			The atomic architecture of a gas channel	SCIENCE			English	Editorial Material							AMMONIUM TRANSPORT; PROTEIN; KIDNEY		NIH, Kidney & Electrolyte Metab Lab, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; Johns Hopkins University; Johns Hopkins University	Knepper, MA (corresponding author), NIH, Kidney & Electrolyte Metab Lab, Bldg 10, Bethesda, MD 20892 USA.	kneperm@nhlbi.nih.gov; pagre@jhmi.edu	Knepper, Mark/AAF-8412-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL001285] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 HL999999, Z01 HL001285-21] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Cartron JP, 1999, BEST PRACT RES CL HA, V12, P655, DOI 10.1053/beha.1999.0047; Khademi S, 2004, SCIENCE, V305, P1587, DOI 10.1126/science.1101952; KNEPPER MA, 1989, PHYSIOL REV, V69, P179, DOI 10.1152/physrev.1989.69.1.179; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; NAHKHOUL NL, 2004, PFLUGERS ARCH, V447, P807; Soupene E, 2004, P NATL ACAD SCI USA, V101, P7787, DOI 10.1073/pnas.0401809101; WALTER A, 1986, J MEMBRANE BIOL, V90, P207, DOI 10.1007/BF01870127; Weiner ID, 2003, GASTROENTEROLOGY, V124, P1432, DOI 10.1016/S0016-5085(03)00277-4	8	25	25	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	2004	305	5690					1573	1574		10.1126/science.1103191	http://dx.doi.org/10.1126/science.1103191			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361612				2022-12-28	WOS:000223891200028
J	Lipton, JM; Westra, S; Haverty, CE; Roberts, D; Harris, NL; Insoft, RM; Friedmann, A; Billett, A; Lehmann, L				Lipton, JM; Westra, S; Haverty, CE; Roberts, D; Harris, NL; Insoft, RM; Friedmann, A; Billett, A; Lehmann, L			Newborn twins with thrombocytopenia, coagulation defects, and hepatosplenomegaly - Familial hemophagocytic lymphohistiocytosis, caused by a mutation in the perforin gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							REVEALS		Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA; Schneider Childrens Hosp, Div Pediat Hematol Oncol & Stem Cell Transplantat, New Hyde Pk, NY USA; Massachusetts Gen Hosp, Serv Gynecol Obstet, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Lipton, JM (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA.		Haverty, Carrie/AAV-5306-2020	Haverty, Carrie/0000-0003-1446-4220				Arico M, 2002, BRIT J HAEMATOL, V119, P180, DOI 10.1046/j.1365-2141.2002.03773.x; Arico M, 2001, BRIT J HAEMATOL, V114, P761, DOI 10.1046/j.1365-2141.2001.02936.x; Arico M, 2001, BLOOD, V97, P1131, DOI 10.1182/blood.V97.4.1131; Certain S, 2000, BLOOD, V95, P979; Clementi R, 2002, BLOOD, V100, P2266, DOI 10.1182/blood-2002-04-1030; Dufourcq-Lagelouse R, 1999, AM J HUM GENET, V64, P172, DOI 10.1086/302194; Duval M, 1999, J PEDIATR-US, V134, P236, DOI 10.1016/S0022-3476(99)70423-3; Ericson KG, 2001, AM J HUM GENET, V68, P590, DOI 10.1086/318796; Feldmann J, 2002, BRIT J HAEMATOL, V117, P965, DOI 10.1046/j.1365-2141.2002.03534.x; Filipovich AH, 2002, IMMUNOL ALLERGY CLIN, V22, P281, DOI 10.1016/S0889-8561(01)00009-1; GEORGE D, 1995, SEMIN THROMB HEMOST, V21, P276, DOI 10.1055/s-2007-1000649; Henter JI, 1998, HEMATOL ONCOL CLIN N, V12, P417, DOI 10.1016/S0889-8588(05)70520-7; Henter JI, 2002, MED PEDIATR ONCOL, V38, P305, DOI 10.1002/mpo.1340; HENTER JI, 1991, SEMIN ONCOL, V18, P29; JANKA GE, 1983, EUR J PEDIATR, V140, P221, DOI 10.1007/BF00443367; Khabbaze Y, 2001, J PEDIAT HEMATOL ONC, V23, P469, DOI 10.1097/00043426-200110000-00016; Kim CJ, 2001, AM J OBSTET GYNECOL, V185, P496, DOI 10.1067/mob.2001.116689; Kogawa K, 2002, BLOOD, V99, P61, DOI 10.1182/blood.V99.1.61; Lee SM, 2004, J MED GENET, V41, P137, DOI 10.1136/jmg.2003.011528; Levendoglu-Tugal O, 2002, J PEDIAT HEMATOL ONC, V24, P405, DOI 10.1097/00043426-200206000-00017; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Ohadi M, 1999, AM J HUM GENET, V64, P165, DOI 10.1086/302187; Ravelli A, 1996, J PEDIATR-US, V128, P275, DOI 10.1016/S0022-3476(96)70408-0; Ryan AK, 1997, J MED GENET, V34, P798, DOI 10.1136/jmg.34.10.798; Sainio S, 2000, OBSTET GYNECOL, V95, P441, DOI 10.1016/S0029-7844(99)00543-8; Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957; Trambas CM, 2003, NAT IMMUNOL, V4, P399, DOI 10.1038/ni0503-399; Ueda I, 2003, BRIT J HAEMATOL, V121, P503, DOI 10.1046/j.1365-2141.2003.04298.x; Uellner R, 1997, EMBO J, V16, P7287, DOI 10.1093/emboj/16.24.7287	29	28	29	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2004	351	11					1120	1130		10.1056/NEJMcpc049019	http://dx.doi.org/10.1056/NEJMcpc049019			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CX	15356310				2022-12-28	WOS:000223733900013
J	Meng, QJ; Liu, JY; Varricchio, DJ; Huang, T; Gao, CL				Meng, QJ; Liu, JY; Varricchio, DJ; Huang, T; Gao, CL			Parental care in an ornithischian dinosaur	NATURE			English	Article							BIRDS		Dalian Nat Hist Museum, Dalian, Peoples R China; Montana State Univ, Dept Earth Sci, Bozeman, MT 59717 USA; Paleo World Res Fdn, Asian Operat B122 2, Taipei 106, Taiwan	Montana State University System; Montana State University Bozeman	Meng, QJ (corresponding author), Dalian Nat Hist Museum, 40 Xicun St, Dalian, Peoples R China.	djv@montana.edu		Huang, Timothy/0000-0001-5381-2596				[Anonymous], 1985, NATL GEOGRAPHIC SOC; Bakker RT, 2004, LIFE O PAST, P301; Carpenter K., 1999, EGGS NESTS BABY DINO; Erickson GM, 2000, ZOOL J LINN SOC-LOND, V130, P551, DOI 10.1006/zjls.2000.0243; Geist NR, 1996, SCIENCE, V272, P712, DOI 10.1126/science.272.5262.712; Gill F. B., 1990, ORNITHOLOGY; Groenewald GH, 2001, PALAIOS, V16, P148, DOI 10.2307/3515526; Horner JR, 2000, ANNU REV EARTH PL SC, V28, P19, DOI 10.1146/annurev.earth.28.1.19; Kavanau JL., 1987, LOVEBIRDS COCKATIELS; MAGNUSSON WE, 1989, REPROD CROCODILES AL, P118; Tullberg BS, 2002, PHILOS T R SOC B, V357, P251, DOI 10.1098/rstb.2001.0932; WESOLOWSKI T, 1994, AM NAT, V143, P39, DOI 10.1086/285595; Zhou ZH, 2003, NATURE, V421, P807, DOI 10.1038/nature01420	13	70	76	2	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	2004	431	7005					145	146		10.1038/431145a	http://dx.doi.org/10.1038/431145a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356619	Green Published			2022-12-28	WOS:000223746000032
J	Kipling, D; Davis, T; Ostler, EL; Faragher, RGA				Kipling, D; Davis, T; Ostler, EL; Faragher, RGA			What can progeroid syndrome tell us about human aging?	SCIENCE			English	Review							HUTCHINSON-GILFORD-PROGERIA; WERNER-SYNDROME; LIFE-SPAN; IN-VITRO; SYNDROME FIBROBLASTS; MOLECULAR-BASIS; CELL-DIVISION; SENESCENCE; TELOMERASE; GENETICS	Human genetic diseases that resemble accelerated aging provide useful models for gerontologists. They combine known single-gene mutations with deficits in selected tissues that are reminiscent of changes seen during normal aging. Here, we describe recent progress toward linking molecular and cellular changes with the phenotype seen in two of these disorders. One in particular, Werner syndrome, provides evidence to support the hypothesis that the senescence of somatic cells may be a causal agent of normal aging.	Univ Brighton, Sch Pharm & Biomol Sci, Brighton BN2 4GJ, E Sussex, England; Cardiff Univ, Sch Med, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales	University of Brighton; Cardiff University	Faragher, RGA (corresponding author), Univ Brighton, Sch Pharm & Biomol Sci, Cockcroft Bldg, Brighton BN2 4GJ, E Sussex, England.	rgaf@brighton.ac.uk		Ostler, Elizabeth/0000-0001-6092-8423; Faragher, Richard/0000-0001-8366-9014				Baird DM, 2004, HUM MOL GENET, V13, P1515, DOI 10.1093/hmg/ddh159; Bird J, 2003, EXP GERONTOL, V38, P1319, DOI 10.1016/j.exger.2003.09.011; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Bond J, 2004, EXP CELL RES, V292, P151, DOI 10.1016/j.yexcr.2003.09.021; Bridger JM, 2004, EXP GERONTOL, V39, P717, DOI 10.1016/j.exger.2004.02.002; Carter CS, 2002, J GERONTOL A-BIOL, V57, pB177, DOI 10.1093/gerona/57.5.B177; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Chang S, 2004, NAT GENET, V36, P877, DOI 10.1038/ng1389; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; DAVIS I, 1983, STUDIES BIOL, V151; Davis T, 2003, J CELL SCI, V116, P1349, DOI 10.1242/jcs.00331; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; Espejel S, 2002, EXP CELL RES, V276, P242, DOI 10.1006/excr.2002.5533; Evans RJ, 2003, CANCER RES, V63, P4854; Faragher RGA, 2003, BIOL AGING MODULAT, V3, P1; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; FUKUCHI K, 1990, HUM GENET, V84, P249; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Funk WD, 2000, EXP CELL RES, V258, P270, DOI 10.1006/excr.2000.4945; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; GOTO M, 1985, ADV EXP MED BIOL, V190, P263; Halvorsen TL, 2000, J ENDOCRINOL, V166, P103, DOI 10.1677/joe.0.1660103; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Herndon LA, 2002, NATURE, V419, P808, DOI 10.1038/nature01135; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Huffman KE, 2000, J BIOL CHEM, V275, P19719, DOI 10.1074/jbc.M002843200; James SE, 2000, MECH AGEING DEV, V121, P139; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; KILL IR, 1994, J CELL SCI, V107, P571; Kipling D, 1997, J CLIN PATHOL-MOL PA, V50, P234; Kirkwood TBL, 1996, BIOESSAYS, V18, P1009, DOI 10.1002/bies.950181211; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kyng KJ, 2003, P NATL ACAD SCI USA, V100, P12259, DOI 10.1073/pnas.2130723100; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; LeckaCzernik B, 1996, EXP GERONTOL, V31, P159, DOI 10.1016/0531-5565(95)02014-4; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MARTIN GM, 1985, ADV EXP MED BIOL, V190, P161; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Miller RA, 2004, AGING CELL, V3, P47, DOI 10.1111/j.1474-9728.2004.00081.x; Miller RA, 2000, BIOCHEM SOC T, V28, P241, DOI 10.1042/bst0280241; Minamino T, 2004, J MOL CELL CARDIOL, V36, P175, DOI 10.1016/j.yjmcc.2003.11.010; Mounkes LC, 2003, NATURE, V423, P298, DOI 10.1038/nature01631; Ostler EL, 2002, EXP GERONTOL, V37, P285, DOI 10.1016/S0531-5565(01)00194-2; Partridge L, 2002, CURR BIOL, V12, pR544, DOI 10.1016/S0960-9822(02)01048-5; Pichierri P, 2004, BIOESSAYS, V26, P306, DOI 10.1002/bies.10411; POPPER K, 2002, ROUTLEDGE CLASSICS S; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Rodriguez-Lopez AM, 2002, AGING CELL, V1, P30, DOI 10.1046/j.1474-9728.2002.00002.x; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; SALK D, 1981, HUM GENET, V58, P310, DOI 10.1007/BF00294930; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Shay JW, 2001, SCIENCE, V291, P839, DOI 10.1126/science.1058546; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Shen JC, 2001, MECH AGEING DEV, V122, P921, DOI 10.1016/S0047-6374(01)00248-2; Strehler B. L, 1962, TIME CELLS AGING; TOLLEFSBOL TO, 1984, AGE, V7, P75, DOI 10.1007/BF02432205; Von Zglinicki T, 2003, EXP GERONTOL, V38, P1259, DOI 10.1016/j.exger.2003.09.015; Wallis CV, 2004, EXP GERONTOL, V39, P461, DOI 10.1016/j.exger.2003.12.015; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	66	130	137	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1426	1431		10.1126/science.1102587	http://dx.doi.org/10.1126/science.1102587			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353794				2022-12-28	WOS:000223761900037
J	Salic, A; Waters, JC; Mitchison, TJ				Salic, A; Waters, JC; Mitchison, TJ			Vertebrate shugoshin links sister centromere cohesion and kinetochore microtubule stability in mitosis	CELL			English	Article							MEIOSIS-I; CHROMOSOME CONGRESSION; CHROMATID COHESION; AURORA-B; CENP-E; SPINDLE; ANAPHASE; PROTEIN; ATTACHMENT; CLEAVAGE	Drosophila MEI-S332 and fungal Sgo1 genes are essential for sister centromere cohesion in meiosis I. We demonstrate that the related vertebrate Sgo localizes to kinetochores and is required to prevent premature sister centromere separation in mitosis, thus providing an explanation for the differential cohesion observed between the arms and the centromeres of mitotic sister chromatids. Sgo is degraded by the anaphase-promoting complex, allowing the separation of sister centromeres in anaphase. Intriguingly, we show that Sgo interacts strongly with microtubules in vitro and that it regulates kinetochore microtubule stability in vivo, consistent with a direct microtubule interaction. Sgo is thus critical for mitotic progression and chromosome segregation and provides an unexpected link between sister centromere cohesion and microtubule interactions at kinetochores.	Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Salic, A (corresponding author), Harvard Univ, Sch Med, Dept Syst Biol, 240 Longwood Ave, Boston, MA 02115 USA.	adrian_salic@hms.harvard.edu	Salic, Adrian/GXG-1611-2022					Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; DeLuca JG, 2002, J CELL BIOL, V159, P549, DOI 10.1083/jcb.200208159; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Katis VL, 2004, CURR BIOL, V14, P560, DOI 10.1016/j.cub.2004.03.001; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; Kitajima TS, 2004, NATURE, V427, P510, DOI 10.1038/nature02312; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Marston AL, 2004, SCIENCE, V303, P1367, DOI 10.1126/science.1094220; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; McCleland ML, 2003, GENE DEV, V17, P101, DOI 10.1101/gad.1040903; McEwen BF, 1998, CHROMOSOMA, V107, P366, DOI 10.1007/s004120050320; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; Moore DP, 1998, J CELL BIOL, V140, P1003, DOI 10.1083/jcb.140.5.1003; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Rabitsch KP, 2004, CURR BIOL, V14, P287, DOI 10.1016/j.cub.2004.01.051; RATTNER JB, 1993, CELL MOTIL CYTOSKEL, V26, P214, DOI 10.1002/cm.970260305; Rieder CL, 1999, J CELL SCI, V112, P2607; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Scanlan M J, 2001, Cancer Immun, V1, P4; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Vagnarelli P, 2004, EMBO REP, V5, P167, DOI 10.1038/sj.embor.7400077; Waters JC, 1999, CURR BIOL, V9, P649, DOI 10.1016/S0960-9822(99)80287-5; Waters JC, 1996, J CELL SCI, V109, P2823; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; ZHAI Y, 1995, J CELL BIOL, V131, P721, DOI 10.1083/jcb.131.3.721	37	250	255	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2004	118	5					567	578		10.1016/j.cell.2004.08.016	http://dx.doi.org/10.1016/j.cell.2004.08.016			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	852BN	15339662	Bronze			2022-12-28	WOS:000223730300008
J	Stroud, RM; Nittler, LR; Alexander, CMO				Stroud, RM; Nittler, LR; Alexander, CMO			Polymorphism in presolar Al2O3 grains from asymptotic giant branch stars	SCIENCE			English	Article							TRANSMISSION ELECTRON-MICROSCOPY; DUST FEATURES; AMORPHIZATION; GRAPHITE; EMISSION; SPECTRA; ORIGIN; GAS	We report microstructural and isotopic analyses of two presolar Al2O3 grains. Aluminum oxide is important cosmically, because its presence has been detected in the infrared spectra of the circumstellar envelopes of O-rich asymptotic giant branch stars and because it is predicted to be the first solid to condense in these stellar environments. The two grain structures, one corundum and the other amorphous, confirm that asymptotic giant branch stars produce both phases. The variation in structure and Ti content demonstrates that Al2O3 can condense in the absence of TiO2 seed clusters but that Ti may be important in determining the crystal structure.	USN, Res Lab, Washington, DC 20375 USA; Carnegie Inst Sci, Dept Terr Magnetism, Washington, DC 20015 USA	United States Department of Defense; United States Navy; Naval Research Laboratory; Carnegie Institution for Science	Stroud, RM (corresponding author), USN, Res Lab, Code 6360, Washington, DC 20375 USA.	stroud@nrl.navy.mil	Stroud, Rhonda M/S-4584-2018; Alexander, Conel M. O'D./N-7533-2013; Stroud, Rhonda M./C-5503-2008; Stroud, Rhonda/GQZ-0151-2022	Stroud, Rhonda M/0000-0001-5242-8015; Alexander, Conel M. O'D./0000-0002-8558-1427; Stroud, Rhonda M./0000-0001-5242-8015; Stroud, Rhonda/0000-0001-5242-8015				Bernatowicz TJ, 1996, ASTROPHYS J, V472, P760, DOI 10.1086/178105; Boothroyd AI, 1999, ASTROPHYS J, V510, P232, DOI 10.1086/306546; Choi BG, 1998, SCIENCE, V282, P1284, DOI 10.1126/science.282.5392.1284; Clayton DD, 2004, ANNU REV ASTRON ASTR, V42, P39, DOI 10.1146/annurev.astro.42.053102.134022; Croat TK, 2003, GEOCHIM COSMOCHIM AC, V67, P4705, DOI 10.1016/S0016-7037(03)00463-0; Daulton TL, 2002, SCIENCE, V296, P1852, DOI 10.1126/science.1071136; Daulton TL, 1996, GEOCHIM COSMOCHIM AC, V60, P4853, DOI 10.1016/S0016-7037(96)00223-2; Draine BT, 2003, ANNU REV ASTRON ASTR, V41, P241, DOI 10.1146/annurev.astro.41.011802.094840; Dwek E, 1996, ASTROPHYS J, V457, P244, DOI 10.1086/176725; Gail HP, 1998, FARADAY DISCUSS, V109, P303, DOI 10.1039/a709290c; Gail HP, 2003, LECT NOTES PHYS, V609, P55; Glaccum W, 1995, ASTR SOC P, V73, P395; Heaney PJ, 2001, AM MINERAL, V86, P1094; Jager C, 2003, ASTRON ASTROPHYS, V401, P57, DOI 10.1051/0004-6361:20030002; Jeong KS, 1999, IAU SYMP, P233; Jones AP, 1996, ASTROPHYS J, V469, P740, DOI 10.1086/177823; Lee MR, 2003, MINERAL MAG, V67, P581, DOI 10.1180/0026461036730119; Levin I, 1998, J AM CERAM SOC, V81, P1995; LITTLEMARENIN IR, 1986, 88342 NASA, P137; Lodders K, 1999, IAU SYMP, P279; Lodders K, 1997, AIP CONF PROC, P391, DOI 10.1063/1.53317; Nittler LR, 1997, ASTROPHYS J, V483, P475, DOI 10.1086/304234; Nittler LR, 2003, EARTH PLANET SC LETT, V209, P259, DOI 10.1016/S0012-821X(02)01153-6; NITTLER LR, 2001, METEORIT PLANET SCI, V36, pA149; Posch T, 1999, ASTRON ASTROPHYS, V352, P609; SALPETER EE, 1977, ANNU REV ASTRON ASTR, V15, P267, DOI 10.1146/annurev.aa.15.090177.001411; Sloan GC, 2003, ASTROPHYS J, V594, P483, DOI 10.1086/376857; Sogawa H, 1999, ASTROPHYS J, V516, pL33, DOI 10.1086/311992; Speck AK, 2000, ASTRON ASTROPHYS SUP, V146, P437, DOI 10.1051/aas:2000274; Stround RM, 2002, METEORIT PLANET SCI, V37, pA137; TIELENS AGGM, 1994, ASTROPHYS J, V431, P321, DOI 10.1086/174488; TIELENS AGGM, 1990, FROM MIRAS TO PLANETARY NEBULAE : WHICH PATH FOR STELLAR EVOLUTION ?, P186; Wang SX, 1997, J APPL PHYS, V81, P587, DOI 10.1063/1.364219; Zinkle SJ, 1996, NUCL INSTRUM METH B, V116, P92, DOI 10.1016/0168-583X(96)00016-X; Zinner E, 1998, ANNU REV EARTH PL SC, V26, P147, DOI 10.1146/annurev.earth.26.1.147	35	79	79	2	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1455	1457		10.1126/science.1101099	http://dx.doi.org/10.1126/science.1101099			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353800				2022-12-28	WOS:000223761900046
J	Levine, F; Mercola, M				Levine, F; Mercola, M			No pancreatic endocrine stem cells?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BETA-CELLS		Burnham Inst, San Diego, CA USA; Univ Calif San Diego, San Diego, CA 92103 USA	University of California System; University of California San Diego	Levine, F (corresponding author), Burnham Inst, San Diego, CA USA.		Levine, Fred/L-2693-2013	Levine, Fred/0000-0002-7336-2526				BONNERWEIR S, 1993, DIABETES, V42, P1715, DOI 10.2337/diabetes.42.12.1715; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Guo CY, 2002, GENESIS, V32, P8, DOI 10.1002/gene.10021; Halvorsen TL, 2000, J ENDOCRINOL, V166, P103, DOI 10.1677/joe.0.1660103; HAYEK A, 1995, DIABETES, V44, P1458, DOI 10.2337/diabetes.44.12.1458	5	9	13	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2004	351	10					1024	1026		10.1056/NEJMcibr041779	http://dx.doi.org/10.1056/NEJMcibr041779			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	850UB	15342812				2022-12-28	WOS:000223637400015
J	Inoue, K; Saito, J; Miyazaki, M; Ejiri, S; Munakata, M				Inoue, K; Saito, J; Miyazaki, M; Ejiri, S; Munakata, M			A Kendo player with haemoptysis	LANCET			English	Editorial Material									Fukushima Med Univ, Sch Med, Dept Pulm Med, Fukushima 9601295, Japan; Fukushima Med Univ, Sch Med, Dept Radiol, Fukushima 9601295, Japan; Fukushima Med Univ, Sch Med, Dept Orthoped, Fukushima 9601295, Japan	Fukushima Medical University; Fukushima Medical University; Fukushima Medical University	Inoue, K (corresponding author), Fukushima Med Univ, Sch Med, Dept Pulm Med, Hikarigaoka 1, Fukushima 9601295, Japan.	kinoue@fmu.ac.jp						Bliss S, 2002, NEW ENGL J MED, V347, P1876, DOI 10.1056/NEJMcps021566; Ellis MH, 2000, CHEST, V117, P43, DOI 10.1378/chest.117.1.43; Rock G, 1997, CLIN J SPORT MED, V7, P94, DOI 10.1097/00042752-199704000-00004	3	0	0	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	2004	364	9436					814	814		10.1016/S0140-6736(04)16944-4	http://dx.doi.org/10.1016/S0140-6736(04)16944-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337411				2022-12-28	WOS:000223569600036
J	Pawlak, DB; Kushner, JA; Ludwig, DS				Pawlak, DB; Kushner, JA; Ludwig, DS			Effects of dietary glycaemic index on adiposity, glucose homoeostasis, and plasma lipids in animals	LANCET			English	Article							INSULIN-RESISTANCE; OBESITY; RISK; ADIPONECTIN; LOAD; FAT; SECRETION; PROFILE; FIBER; RATS	Background Clinical studies suggest a role for dietary glycaemic index (GI) in bodyweight regulation and diabetes risk. However, partly because manipulation of GI can produce changes in potentially confounding dietary factors such as fibre content, palatability, and energy density, its relevance to human health remains controversial. This study examined the independent effects of GI in animals. Methods Partially pancreatectomised male Sprague-Dawley rats were given diets with identical nutrients, except for the type of starch: high-GI (n=11) or low-GI (n=10). The animals were fed in a controlled way to maintain the same mean bodyweight in the two groups for 18 weeks. Further experiments examined the effects of GI in rats in a crossover design and C57BL/6J mice in a parallel design. Findings Despite having similar mean bodyweight (547.9 [SE 13.4] vs 549.2 [15.2] g), rats given high-GI food had more body fat (97.8 [13.6] vs 57.3 [7.2] g; p=0.0152) and less lean body mass (450.1 [9.6] vs 491.9 [11.7] g; p=0.0120) than those given low-GI food. The high-GI group also had greater increases over time in the areas under the curve for blood glucose and plasma insulin after oral glucose, lower plasma adiponectin concentrations, higher plasma triglyceride concentrations, and severe disruption of islet-cell architecture. Mice on the high-GI diet had almost twice the body fat of those on the low-GI diet after 9 weeks. Interpretation These findings provide a mechanistic basis for interpretation of studies of GI in human beings. Relevance to practice The term GI describes how a food, meal, or diet affects blood sugar during the postprandial. period. GI as an independent factor can cause obesity and increase risks of diabetes and heart disease in animals. Use of low-GI diets in prevention and treatment of human disease merits thorough examination.	Childrens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Ludwig, DS (corresponding author), Childrens Hosp, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.	david.ludwig@childrens.harvard.edu	Kushner, Jake A/AAF-5049-2022; Kushner, Jake A/AFJ-8198-2022	Kushner, Jake A/0000-0002-3646-1744; Kushner, Jake A/0000-0002-3646-1744; Ludwig, David/0000-0003-3307-8544	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059240] Funding Source: NIH RePORTER; NICHD NIH HHS [T32HD07277] Funding Source: Medline; NIDDK NIH HHS [1R01DK059240] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bouche C, 2002, DIABETES CARE, V25, P822, DOI 10.2337/diacare.25.5.822; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; CUMMINGS JH, 1995, AM J CLIN NUTR, V61, p938S, DOI 10.1093/ajcn/61.4.938S; Cusin Isabelle, 1992, International Journal of Obesity, V16, pS1; Finegood DT, 2001, DIABETES, V50, P1021, DOI 10.2337/diabetes.50.5.1021; FROST G, 1994, DIABETIC MED, V11, P397, DOI 10.1111/j.1464-5491.1994.tb00292.x; JENKINS DJA, 1987, AM J CLIN NUTR, V46, P968, DOI 10.1093/ajcn/46.6.968; Kabir M, 1998, J NUTR, V128, P35, DOI 10.1093/jn/128.1.35; Kim JK, 2000, J CLIN INVEST, V105, P1791, DOI 10.1172/JCI8305; KLOPPEL G, SURV SYNTH PATHOL RE, V4, P110; Koyama M, 1998, AM J PATHOL, V153, P537, DOI 10.1016/S0002-9440(10)65596-4; Kushner JA, 2002, J CLIN INVEST, V109, P1193, DOI 10.1172/JCI200214439; LAJVARDI A, 1993, J NUTR, V123, P2059; LEAHY JL, 1988, J CLIN INVEST, V81, P1407, DOI 10.1172/JCI113470; LererMetzger M, 1996, BRIT J NUTR, V75, P723, DOI 10.1079/BJN19960176; Liu SM, 2000, AM J CLIN NUTR, V71, P1455; Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414; Ludwig DS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e26; Morita T, 1999, J NUTR, V129, P2081, DOI 10.1093/jn/129.11.2081; OSCAI LB, 1982, AM J PHYSIOL, V242, pR212, DOI 10.1152/ajpregu.1982.242.3.R212; PIROZZO S, 2002, COCHRANE LIB; RASTOGI GK, 1973, DIABETES, V22, P804, DOI 10.2337/diab.22.11.804; ROTHWELL NJ, 1979, BRIT J NUTR, V41, P625, DOI 10.1079/BJN19790078; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; Salmeron J, 1997, DIABETES CARE, V20, P545, DOI 10.2337/diacare.20.4.545; Senn S, 2002, CROSS OVER TRIALS CL; Song SH, 2003, ENDOCRINOLOGY, V144, P3399, DOI 10.1210/en.2003-0056; Spieth LE, 2000, ARCH PEDIAT ADOL MED, V154, P947, DOI 10.1001/archpedi.154.9.947; Spranger J, 2003, LANCET, V361, P226, DOI 10.1016/S0140-6736(03)12255-6; TISAVIPAT A, 1974, J APPL PHYSIOL, V37, P699, DOI 10.1152/jappl.1974.37.5.699; West DB, 1998, AM J CLIN NUTR, V67, p505S, DOI 10.1093/ajcn/67.3.505S; Willett W C, 2002, Obes Rev, V3, P59, DOI 10.1046/j.1467-789X.2002.00060.x; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Zietz B, 2003, FEBS LETT, V545, P103, DOI 10.1016/S0014-5793(03)00568-4	34	234	240	2	39	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	2004	364	9436					778	785		10.1016/S0140-6736(04)16937-7	http://dx.doi.org/10.1016/S0140-6736(04)16937-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337404				2022-12-28	WOS:000223569600029
J	Cooper, ER; Andrews, CD; Wheatley, PS; Webb, PB; Wormald, P; Morris, RE				Cooper, ER; Andrews, CD; Wheatley, PS; Webb, PB; Wormald, P; Morris, RE			Ionic liquids and eutectic mixtures as solvent and template in synthesis of zeolite analogues	NATURE			English	Article							ALUMINOPHOSPHATE; SILICA; WATER	The challenges associated with synthesizing porous materials(1) mean that new classes of zeolites (zeotypes)-such as aluminosilicate zeolites(2,3) and zeolite analogues(4)-together with new methods of preparing known zeotypes(5), continue to be of great importance. Normally these materials are prepared hydrothermally with water as the solvent in a sealed autoclave under autogenous pressure(6). The reaction mixture usually includes an organic template or 'structure-directing agent' that guides the synthesis pathway towards particular structures. Here we report the preparation of aluminophosphate zeolite analogues by using ionic liquids(7) and eutectic mixtures(8). An imidazolium-based ionic liquid acts as both solvent and template, leading to four zeotype frameworks under different experimental conditions. The structural characteristics of the materials can be traced back to the solvent chemistry used. Because of the vanishingly low vapour pressure of ionic liquids, synthesis takes place at ambient pressure, eliminating safety concerns associated with high hydrothermal pressures. The ionic liquid can also be recycled for further use. A choline chloride/urea eutectic mixture(8) is also used in the preparation of a new zeotype framework.	Univ St Andrews, Sch Chem, St Andrews KY16 9ST, Fife, Scotland	University of St Andrews	Cooper, ER (corresponding author), Univ St Andrews, Sch Chem, Purdie Bldg, St Andrews KY16 9ST, Fife, Scotland.	rem1@st-and.ac.uk	Morris, Russell/G-4285-2010	Morris, Russell/0000-0001-7809-0315; Webb, Paul/0000-0003-2532-344X				Abbott AP, 2003, CHEM COMMUN, P70, DOI 10.1039/b210714g; Adams CJ, 2001, AUST J CHEM, V54, P679, DOI 10.1071/CH01191; Camblor MA, 1999, TOP CATAL, V9, P59, DOI 10.1023/A:1019154304344; Cammarata L, 2001, PHYS CHEM CHEM PHYS, V3, P5192, DOI 10.1039/b106900d; Corma A, 2002, NATURE, V418, P514, DOI 10.1038/nature00924; Cundy CS, 2003, CHEM REV, V103, P663, DOI 10.1021/cr020060i; Dai S, 2000, CHEM COMMUN, P243, DOI 10.1039/a907147d; Davis ME, 2002, NATURE, V417, P813, DOI 10.1038/nature00785; Del Popolo MG, 2004, J PHYS CHEM B, V108, P1744, DOI 10.1021/jp0364699; ESTERMANN M, 1991, NATURE, V352, P320, DOI 10.1038/352320a0; Feng PY, 1997, NATURE, V388, P735, DOI 10.1038/41937; Feng PY, 1998, MICROPOR MESOPOR MAT, V23, P221, DOI 10.1016/S1387-1811(98)00119-X; Freyhardt CC, 1996, NATURE, V381, P295, DOI 10.1038/381295a0; Friedrichs OD, 1999, NATURE, V400, P644, DOI 10.1038/23210; Hanke CG, 2003, J PHYS CHEM B, V107, P10873, DOI 10.1021/jp034221d; HUO QH, 1992, J CHEM SOC CHEM COMM, P875, DOI 10.1039/c39920000875; KIRCHNER RM, 1994, ZEOLITES, V14, P523, DOI 10.1016/0144-2449(94)90185-6; Lee H, 2003, NATURE, V425, P385, DOI 10.1038/nature01980; LOBO RF, 1995, J INCLUS PHENOM MOL, V21, P47; Medina ME, 2004, J MATER CHEM, V14, P845, DOI 10.1039/b311618b; Oliver S, 1997, J MATER CHEM, V7, P807, DOI 10.1039/a606828f; RICHARDSON JW, 1988, ACTA CRYSTALLOGR B, V44, P367, DOI 10.1107/S0108768188003076; ROBSON H, 2001, VERIFIED SYNTHESIS Z, P45; Rogers RD, 2003, SCIENCE, V302, P792, DOI 10.1126/science.1090313; Taulelle F, 1999, J AM CHEM SOC, V121, P12148, DOI 10.1021/ja991295n; Wasserscheid P., 2003, IONIC LIQUIDS SYNTHE, P9; Yu J, 1998, CHEM MATER, V10, P1208, DOI 10.1021/cm980019p; Yu JH, 2003, ACCOUNTS CHEM RES, V36, P481, DOI 10.1021/ar0201557; ZONES SI, 1989, ZEOLITES, V9, P458, DOI 10.1016/0144-2449(89)90039-0	29	1045	1106	16	785	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2004	430	7003					1012	1016		10.1038/nature02860	http://dx.doi.org/10.1038/nature02860			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329717				2022-12-28	WOS:000223514900039
J	Scherer, FM				Scherer, FM			The pharmaceutical industry - Prices and progress	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DRUG DEVELOPMENT; INNOVATION; TRENDS		Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA	Harvard University	Scherer, FM (corresponding author), Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA.							[Anonymous], 1965, LOGIC COLLECTIVE ACT; [Anonymous], 2000, PROTECTING THEIR INT; [Anonymous], 1997, PHARM PRICE REGULATI; Bond R.S., 1977, SALES PROMOTION PROD; *C BUDG OFF, 1996, MED REB PRESCR DRUGS, P28; Centers for Medicare and Medicaid Services, NAT HLTH EXP PROJ; DANZON PATRICIA M., 1997, PHARM PRICE REGULATI, P15; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; DiMasi JA, 2000, DRUG INF J, V34, P1169, DOI 10.1177/009286150003400425; *FED TRAD COMMN, 2002, GETT NOT WRIT EFF FI, P1; GIACOTTO C, 2003, EXPLAINING PHARM R D; GRANVILLE B, 2002, EC ESSENTIAL MED; HARRIS G, 2003, NY TIMES        0627, pC1; Harris G., 2003, NY TIMES        0910, pC2; Kaitin KI, 2000, DRUG INF J, V34, P673, DOI 10.1177/009286150003400303; KUMAR P, 2003, IMS HLTH BUSINES MAY; LICHTENBERG FR, IN PRESS MEASURING C; Lu ZJ, 1998, REV ECON STAT, V80, P108, DOI 10.1162/003465398557212; MASSON A, 1985, GENERIC SUBSTITUTION, P65; *MED PAYM ADV COMM, 2003, REP C VAR INN MED, P149; Morton FS, 1997, RAND J ECON, V28, P269, DOI 10.2307/2555805; *OFF TECHN ASS, 1993, PHARM R D COSTS RISK, P73; *PHARM RES MAN AM, 2003, PHARM IND PROF 2003, P76; *PHARM RES MAN AM, 2003, PHARM IND PROF 2003, P79; *PHARM RES MAN AM, 2003, PHARM IND PROF 2003, P62; Reichert JM, 2000, TRENDS BIOTECHNOL, V18, P364, DOI 10.1016/S0167-7799(00)01473-6; Schelling F.W.J., 1995, IND POLICY PHARM IND, P36; Scherer FM, 2001, HEALTH AFFAIR, V20, P216, DOI 10.1377/hlthaff.20.5.216; Scherer FM, 2000, RES POLICY, V29, P559, DOI 10.1016/S0048-7333(99)00089-X; SCHERER FM, 1993, J ECON PERSPECT, V7, P97, DOI 10.1257/jep.7.3.97; SCHERER FM, 1990, IND MARK STRUCT, P582; SCHERER FM, 2002, EC ESSENTIAL MED, P38; *US BUR CENS, 2002, STAT ABSTR US 2002; Wagner JL, 2004, ANNU REV PUBL HEALTH, V25, P475, DOI 10.1146/annurev.publhealth.25.101802.123042; MEDICARE MEDICAID ST; MEDICARE MEDICAID S	36	83	87	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2004	351	9					927	932		10.1056/NEJMhpr040117	http://dx.doi.org/10.1056/NEJMhpr040117			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849BM	15329432				2022-12-28	WOS:000223512500017
J	Tariq, SM; George, J				Tariq, SM; George, J			Inhaled foreign body	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Sultan Qaboos Univ Hosp, Muscat, Oman	Sultan Qaboos University	Tariq, SM (corresponding author), Sultan Qaboos Univ Hosp, Muscat, Oman.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2004	351	9					E8	E8		10.1056/ENEJMicm030604	http://dx.doi.org/10.1056/ENEJMicm030604			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849BM	15329439				2022-12-28	WOS:000223512500014
J	Garg, A				Garg, A			Statins for all patients with type 2 diabetes: not so soon	LANCET			English	Editorial Material							CORONARY HEART-DISEASE; VASCULAR-DISEASE; CHOLESTEROL; PREVALENCE; MANAGEMENT; RISK		Univ Texas, SW Med Ctr Dallas, Ctr Human Nutr, Div Nutr & Metab Dis, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Garg, A (corresponding author), Univ Texas, SW Med Ctr Dallas, Ctr Human Nutr, Div Nutr & Metab Dis, Dallas, TX 75390 USA.	abhimanyu.garg@utsouthwestern.edu						Chi ZS, 2001, DIABETOLOGIA, V44, pS82, DOI 10.1007/PL00002944; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2003, LANCET, V361, P2005; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI 10.1001/jama.288.23.2998; GARG A, 1990, DIABETES CARE, V13, P153, DOI 10.2337/diacare.13.2.153; GARG A, 1988, NEW ENGL J MED, V318, P81, DOI 10.1056/NEJM198801143180204; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Lee ET, 2001, DIABETOLOGIA, V44, pS3, DOI 10.1007/PL00002936; Liu J, 2004, JAMA-J AM MED ASSOC, V291, P2591, DOI 10.1001/jama.291.21.2591; NELSON RG, 1990, CIRCULATION, V81, P987, DOI 10.1161/01.CIR.81.3.987; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Snow V, 2004, ANN INTERN MED, V140, P644, DOI 10.7326/0003-4819-140-8-200404200-00012; Stevens RJ, 2001, CLIN SCI, V101, P671, DOI 10.1042/CS20000335	13	20	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	2004	364	9435					641	642		10.1016/S0140-6736(04)16907-9	http://dx.doi.org/10.1016/S0140-6736(04)16907-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325810				2022-12-28	WOS:000223428900004
J	Harfe, BD; Scherz, PJ; Nissim, S; Tian, F; McMahon, AP; Tabin, CJ				Harfe, BD; Scherz, PJ; Nissim, S; Tian, F; McMahon, AP; Tabin, CJ			Evidence for an expansion-based temporal Shh gradient in specifying vertebrate digit identities	CELL			English	Article							DEVELOPING CHICK LIMB; SONIC-HEDGEHOG; RETINOIC ACID; POLARIZING ACTIVITY; SIGNALING ACTIVITY; LOCAL APPLICATION; REPORTER STRAIN; FEEDBACK LOOP; LONG-RANGE; EXPRESSION	The zone of polarizing activity (ZPA) in the posterior limb bud produces Sonic Hedgehog (Shh) protein, which plays a critical role in establishing distinct fates along the anterior-posterior axis. This activity has been modeled as a concentration-dependent response to a diffusible morphogen. Using recombinase base mapping in the mouse, we determine the ultimate fate of the Shh-producing cells. Strikingly, the descendants of the Shh-producing cells encompass all cells in the two most posterior digits and also contribute to the middle digit. Our analysis suggests that, while specification of the anterior digits depends upon differential concentrations of Shh, the length of time of exposure to Shh is critical in the specification of the differences between the most posterior digits. Genetic studies of the effects of limiting accessibility of Shh within the limb support this, model, in which the effect of the Shh morphogen is dictated by a temporal as well as a spatial gradient.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; Harvard Univ, Biolabs, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; State University System of Florida; University of Florida; Harvard University	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, NRB Room 360,77 Ave Louis Pasteur, Boston, MA 02115 USA.	tabin@genetics.med.harvard.edu	McMahon, Andrew P/ABE-7520-2020	Nissim, Sahar/0000-0002-2303-6415	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD032443, R37HD032443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033642, R37NS033642] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR08642] Funding Source: Medline; NICHD NIH HHS [HD32443] Funding Source: Medline; NINDS NIH HHS [NS33642] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Burke R, 1999, CELL, V99, P803, DOI 10.1016/S0092-8674(00)81677-3; Caspary T, 2002, CURR BIOL, V12, P1628, DOI 10.1016/S0960-9822(02)01147-8; Chiang C, 2001, DEV BIOL, V236, P421, DOI 10.1006/dbio.2001.0346; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; Drossopoulou G, 2000, DEVELOPMENT, V127, P1337; Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; Goff DJ, 1997, DEVELOPMENT, V124, P627; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Guo QX, 2003, DEV BIOL, V264, P166, DOI 10.1016/j.ydbio.2003.08.012; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HELMS J, 1994, DEVELOPMENT, V120, P3267; Karp SJ, 2000, DEVELOPMENT, V127, P543; Kraus P, 2001, MECH DEVELOP, V100, P45, DOI 10.1016/S0925-4773(00)00492-5; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Le YZ, 1999, ANAL BIOCHEM, V270, P334, DOI 10.1006/abio.1999.4110; Leone DP, 2003, MOL CELL NEUROSCI, V22, P430, DOI 10.1016/S1044-7431(03)00029-0; Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092-8674(01)00369-5; Litingtung Y, 2002, NATURE, V418, P979, DOI 10.1038/nature01033; LOPEZMARTINEZ A, 1995, CURR BIOL, V5, P791, DOI 10.1016/S0960-9822(95)00156-4; Ma Y, 2002, CELL, V111, P63, DOI 10.1016/S0092-8674(02)00977-7; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marigo V, 1996, DEVELOPMENT, V122, P1225; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Murtaugh LC, 1999, GENE DEV, V13, P225, DOI 10.1101/gad.13.2.225; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; Park HL, 2000, DEVELOPMENT, V127, P1593; Pathi S, 2001, MECH DEVELOP, V106, P107, DOI 10.1016/S0925-4773(01)00427-0; Pearse RV, 2001, DEV BIOL, V239, P15, DOI 10.1006/dbio.2001.0430; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Sanz-Ezquerro JJ, 2000, DEVELOPMENT, V127, P4811; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; Saunders J.W., 1967, MAJOR PROBLEMS DEV B, P289; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; TIAN H, 2004, IN PRESS DEVELOPEMEN; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; Vargesson N, 1997, DEVELOPMENT, V124, P1909; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wilkinson DG, 1992, WHOLE MOUNT IN SITU, P75; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; Yang Y, 1997, DEVELOPMENT, V124, P4393	46	730	742	3	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2004	118	4					517	528		10.1016/j.cell.2004.07.024	http://dx.doi.org/10.1016/j.cell.2004.07.024			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	850YS	15315763	Bronze			2022-12-28	WOS:000223650900013
J	Kozar, K; Ciemerych, MA; Rebel, VI; Shigematsu, H; Zagozdon, A; Sicinska, E; Geng, Y; Yu, QY; Bhattacharya, S; Bronson, RT; Akashi, K; Sicinski, P				Kozar, K; Ciemerych, MA; Rebel, VI; Shigematsu, H; Zagozdon, A; Sicinska, E; Geng, Y; Yu, QY; Bhattacharya, S; Bronson, RT; Akashi, K; Sicinski, P			Mouse development and cell proliferation in the absence of D-cyclins	CELL			English	Article							HEMATOPOIETIC STEM-CELLS; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; CDK INHIBITORS; MICE; PROGRESSION; PROGENITOR; P27(KIP1); BMI-1; PHOSPHORYLATION	D-type cyclins (cyclins D1, D2, and D3 are regarded as essential links between cell environment and the core cell cycle machinery. We tested the requirement for D-cyclins in mouse development and in proliferation by generating mice lacking all D-cyclins. We found that these cyclin D1(-/-)D2(-/-)D3(-/-) mice develop until mid/late gestation and die due to heart abnormalities combined with a severe anemia. Our analyses revealed that the D-cyclin; are critically required for the expansion of hematopoietic stem cells. In contrast, cyclin D-deficient fibroblasts proliferate nearly normally but show increased requirement for mitogenic stimulation in cell cycle re-entry. We found that the proliferation of cyclin D1(-/-)D2(-/-)D3(-/-) cells is resistant to the inhibition by p16(INK4a), but it critically depends on CDK2. Lastly, we found that cells lacking D-cyclins display reduced susceptibility to the oncogenic transformation. Our results reveal the presence of alternative mechanisms that allow cell cycle progression in a cyclin D-indeperdent fashion.	Harvard Univ, Sch Med, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Oxford, Dept Cardiovasc Med, Oxford OX3 7BN, England; Tufts Univ, Sch Vet Med, North Grafton, MA 01536 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Oxford; Tufts University	Sicinski, P (corresponding author), Harvard Univ, Sch Med, Dept Canc Biol, Boston, MA 02115 USA.	peter_sicinski@dfci.harvard.edu	Bhattacharya, Shoumo/F-4127-2010	Bhattacharya, Shoumo/0000-0002-5571-0478; Ciemerych, Maria A./0000-0003-0387-4179; Rebel, Vivienne/0000-0002-3862-3903; Kozar-Kaminska, Katarzyna/0000-0002-2397-2975	NCI NIH HHS [CA85296, CA108420] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085296, R01CA108420] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Colucci F, 2000, J IMMUNOL, V164, P5140, DOI 10.4049/jimmunol.164.10.5140; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Huard JMT, 1999, DEVELOPMENT, V126, P1927; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MORRISON SJ, 1995, P NATL ACAD SCI USA, V92, P10302, DOI 10.1073/pnas.92.22.10302; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Park M, 1999, DEVELOPMENT, V126, P4849; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Solvason N, 2000, INT IMMUNOL, V12, P631, DOI 10.1093/intimm/12.5.631; SPANGRUDE GJ, 1990, J IMMUNOL, V145, P3661; Sucov HM, 1998, ANNU REV PHYSIOL, V60, P287, DOI 10.1146/annurev.physiol.60.1.287; Traver D, 2001, BLOOD, V98, P627, DOI 10.1182/blood.V98.3.627; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	38	514	534	1	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2004	118	4					477	491		10.1016/j.cell.2004.07.025	http://dx.doi.org/10.1016/j.cell.2004.07.025			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	850YS	15315760	Bronze			2022-12-28	WOS:000223650900010
J	Sacchini, V; Borgen, PI				Sacchini, V; Borgen, PI			Can radiation therapy for breast cancer be avoided?	LANCET			English	Editorial Material							CONSERVING SURGERY; RADIOTHERAPY; IMPACT		Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Sacchini, V (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10021 USA.	sacchinv@mskcc.org						Early Breast Canc Trialists Collaborat, 2000, LANCET, V355, P1757, DOI 10.1016/S0140-6736(00)02263-7; Hughes KS, 2004, NEW ENGL J MED, V351, P971, DOI 10.1056/NEJMoa040587; Mor V, 2000, SURGERY, V128, P847, DOI 10.1067/msy.2000.109530; Veronesi Umberto, 2003, Breast J, V9, P106, DOI 10.1046/j.1524-4741.2003.09208.x; Vinh-Hung V, 2004, JNCI-J NATL CANCER I, V96, P115, DOI 10.1093/jnci/djh013; Vinh-Hung V, 2003, RADIOTHER ONCOL, V67, P147, DOI 10.1016/S0167-8140(03)00002-1; Vinh-Hung V, 2002, RADIOTHER ONCOL, V64, P281, DOI 10.1016/S0167-8140(02)00105-6	7	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	2004	364	9438					916	917		10.1016/S0140-6736(04)17037-2	http://dx.doi.org/10.1016/S0140-6736(04)17037-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364173				2022-12-28	WOS:000223831000006
J	Gauderman, WJ; Avol, E; Gilliland, F; Vora, H; Thomas, D; Berhane, K; McConnell, R; Kuenzli, N; Lurmann, F; Rappaport, E; Margolis, H; Bates, D; Peters, J				Gauderman, WJ; Avol, E; Gilliland, F; Vora, H; Thomas, D; Berhane, K; McConnell, R; Kuenzli, N; Lurmann, F; Rappaport, E; Margolis, H; Bates, D; Peters, J			The effect of air pollution on lung development from 10 to 18 years of age	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOUTHERN CALIFORNIA COMMUNITIES; OBSTRUCTIVE RESPIRATORY-DISEASE; PULMONARY-FUNCTION; FUNCTION GROWTH; CHRONIC EXPOSURE; UCLA POPULATION; PREADOLESCENT CHILDREN; PARTICULATE MATTER; DIFFERING LEVELS; FOLLOW-UP	Background: Whether exposure to air pollution adversely affects the growth of lung function during the period of rapid lung development that occurs between the ages of 10 and 18 years is unknown. Methods: In this prospective study, we recruited 1759 children (average age, 10 years) from schools in 12 southern California communities and measured lung function annually for eight years. The rate of attrition was approximately 10 percent per year. The communities represented a wide range of ambient exposures to ozone, acid vapor, nitrogen dioxide, and particulate matter. Linear regression was used to examine the relationship of air pollution to the forced expiratory volume in one second (FEV1) and other spirometric measures. Results: Over the eight-year period, deficits in the growth of FEV1 were associated with exposure to nitrogen dioxide (P=0.005), acid vapor (P=0.004), particulate matter with an aerodynamic diameter of less than 2.5 microm (PM2.5) (P=0.04), and elemental carbon (P=0.007), even after adjustment for several potential confounders and effect modifiers. Associations were also observed for other spirometric measures. Exposure to pollutants was associated with clinically and statistically significant deficits in the FEV1 attained at the age of 18 years. For example, the estimated proportion of 18-year-old subjects with a low FEV1 (defined as a ratio of observed to expected FEV1 of less than 80 percent) was 4.9 times as great at the highest level of exposure to PM2.5 as at the lowest level of exposure (7.9 percent vs. 1.6 percent, P=0.002). Conclusions: The results of this study indicate that current levels of air pollution have chronic, adverse effects on lung development in children from the age of 10 to 18 years, leading to clinically significant deficits in attained FEV1 as children reach adulthood.	Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA; Sonoma Technol, Petaluma, CA USA; State Calif, Air Resouces Board, Sacramento, CA USA; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	University of Southern California; University of British Columbia	Gauderman, WJ (corresponding author), Univ So Calif, Dept Prevent Med, 1540 Alcazar St,Suite 220, Los Angeles, CA 90089 USA.	jimg@usc.edu	Kuenzli, Nino/F-7195-2014; Fahimifar, Sepideh/M-5303-2019	Kuenzli, Nino/0000-0001-8360-080X; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011627, P30ES007048] Funding Source: NIH RePORTER; NIEHS NIH HHS [5P30ES07048, 1P01ES11627] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASHLEY F, 1975, ANN INTERN MED, V82, P739, DOI 10.7326/0003-4819-82-6-739; Avol E.L., 1998, RES REP HLTH EFF I, V82, P1; Avol EL, 2001, AM J RESP CRIT CARE, V164, P2067, DOI 10.1164/ajrccm.164.11.2102005; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477, DOI 10.1164/ajrccm.153.2.8564086; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3, DOI 10.1164/ajrccm.153.1.8542133; Churg A, 2003, ENVIRON HEALTH PERSP, V111, P714, DOI 10.1289/ehp.6042; DETELS R, 1991, AM J PUBLIC HEALTH, V81, P350, DOI 10.2105/AJPH.81.3.350; DETELS R, 1987, CHEST, V92, P594, DOI 10.1378/chest.92.4.594; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587, DOI 10.1164/ajrccm/139.3.587; *ENV PROT AG, 2003, 454K03001 ENV PROT A; FRIEDMAN GD, 1976, NEW ENGL J MED, V294, P1071, DOI 10.1056/NEJM197605132942001; Frischer T, 1999, AM J RESP CRIT CARE, V160, P390, DOI 10.1164/ajrccm.160.2.9809075; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Gauderman WJ, 2002, AM J RESP CRIT CARE, V166, P76, DOI 10.1164/rccm.2111021; Hole DJ, 1996, BRIT MED J, V313, P711; Horak F, 2002, EUR RESPIR J, V19, P838, DOI 10.1183/09031936.02.00512001; Jedrychowski W, 1999, ENVIRON HEALTH PERSP, V107, P669, DOI 10.2307/3434460; KANNEL WB, 1983, AM HEART J, V105, P311, DOI 10.1016/0002-8703(83)90532-X; Knuiman MW, 1999, ANN EPIDEMIOL, V9, P297, DOI 10.1016/S1047-2797(98)00066-0; Mckean MC, 2001, EUR RESPIR J, V18, P23, DOI 10.1183/09031936.01.00073101; NIOSH, 1999, 5040 NIOSH; Ochs M, 2004, AM J RESP CRIT CARE, V169, P120, DOI 10.1164/rccm.200308-1107OC; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760, DOI 10.1164/ajrccm.159.3.9804143; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768, DOI 10.1164/ajrccm.159.3.9804144; Raizenne M, 1996, ENVIRON HEALTH PERSP, V104, P506, DOI 10.2307/3432991; Sarnat JA, 2001, ENVIRON HEALTH PERSP, V109, P1053, DOI 10.2307/3454961; SAS Institute, 2002, SAS STAT US GUID VER, VSixth; Schroeder EB, 2003, AM J EPIDEMIOL, V158, P1171, DOI 10.1093/aje/kwg276; Schunemann HJ, 2000, CHEST, V118, P656, DOI 10.1378/chest.118.3.656; SCHWARTZ J, 1989, ENVIRON RES, V50, P309, DOI 10.1016/S0013-9351(89)80012-X; Sherwin RP, 2000, VIRCHOWS ARCH, V437, P422, DOI 10.1007/s004280000262; TAGER IB, 1985, AM REV RESPIR DIS, V131, P752; Tager IB, 1999, AM J RESP CRIT CARE, V160, P387; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; TASHKIN DP, 1994, AM J RESP CRIT CARE, V149, P1209, DOI 10.1164/ajrccm.149.5.8173761; Tolocka MP, 2001, AEROSOL SCI TECH, V34, P88; WANG XB, 1993, AM REV RESPIR DIS, V148, P1502, DOI 10.1164/ajrccm/148.6_Pt_1.1502; WANG XB, 1994, AM J RESP CRIT CARE, V149, P1420, DOI 10.1164/ajrccm.149.6.8004293; WARE JH, 1986, AM REV RESPIR DIS, V133, P834	39	896	923	4	179	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2004	351	11					1057	1067		10.1056/NEJMoa040610	http://dx.doi.org/10.1056/NEJMoa040610			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CX	15356303	Bronze			2022-12-28	WOS:000223733900005
J	Hsu, GW; Ober, M; Carell, T; Beese, LS				Hsu, GW; Ober, M; Carell, T; Beese, LS			Error-prone replication of oxidatively damaged DNA by a high-fidelity DNA polymerase	NATURE			English	Article							STEADY-STATE; INSERTION; MUTATIONS; KINETICS; CRYSTAL; EXO(-); SITE; 8-OXO-7,8-DIHYDROGUANINE; RESOLUTION; FRAGMENT	Aerobic respiration generates reactive oxygen species that can damage guanine residues and lead to the production of 8-oxoguanine (8oxoG), the major mutagenic oxidative lesion in the genome(1). Oxidative damage is implicated in ageing(2) and cancer, and its prevalence presents a constant challenge to DNA polymerases that ensure accurate transmission of genomic information. When these polymerases encounter 8oxoG, they frequently catalyse misincorporation of adenine in preference to accurate incorporation of cytosine(3). This results in the propagation of G to T transversions, which are commonly observed somatic mutations associated with human cancers(4,5). Here, we present sequential snapshots of a high-fidelity DNA polymerase during both accurate and mutagenic replication of 8oxoG. Comparison of these crystal structures reveals that 8oxoG induces an inversion of the mismatch recognition mechanisms that normally proofread DNA, such that the 8oxoG.adenine mismatch mimics a cognate base pair whereas the 8oxoG.cytosine base pair behaves as a mismatch. These studies reveal a fundamental mechanism of error-prone replication and show how 8oxoG, and DNA lesions in general, can form mismatches that evade polymerase error-detection mechanisms, potentially leading to the stable incorporation of lethal mutations.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Munich, Dept Chem & Biochem, D-81377 Munich, Germany	Duke University; University of Munich	Beese, LS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	lsb@biochem.duke.edu	beese, lorena/G-4993-2010; Carell, Thomas/G-4799-2012	Carell, Thomas/0000-0001-7898-2831				BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CULP SJ, 1989, CHEM RES TOXICOL, V2, P416, DOI 10.1021/tx00012a010; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Freisinger E, 2004, EMBO J, V23, P1494, DOI 10.1038/sj.emboj.7600158; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Johnson SJ, 2004, CELL, V116, P803, DOI 10.1016/S0092-8674(04)00252-1; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; Krahn JM, 2003, STRUCTURE, V11, P121, DOI 10.1016/S0969-2126(02)00930-9; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; Lowe LG, 1996, BIOCHEMISTRY-US, V35, P9840, DOI 10.1021/bi960485x; Miller H, 1997, BIOCHEMISTRY-US, V36, P15336, DOI 10.1021/bi971927n; Nair DT, 2004, NATURE, V430, P377, DOI 10.1038/nature02692; OTWINOWSKI Z, 1997, ENZYMOLOGY MACROMO A; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047	27	252	258	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2004	431	7005					217	221		10.1038/nature02908	http://dx.doi.org/10.1038/nature02908			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15322558				2022-12-28	WOS:000223746000051
J	Samar, S				Samar, S			Global health - Despite the odds - Providing reproductive health care to Afghan women	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	4	4	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2004	351	11					1047	1049		10.1056/NEJMp048170	http://dx.doi.org/10.1056/NEJMp048170			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CX	15356299				2022-12-28	WOS:000223733900001
J	Psaty, BM; Furberg, CD				Psaty, BM; Furberg, CD			Contemplating ACTION - long-acting nifedipine in stable angina	LANCET			English	Editorial Material							PRACTICE GUIDELINES COMMITTEE; ASSOCIATION TASK-FORCE; AMERICAN-COLLEGE; MYOCARDIAL-INFARCTION; ACC/AHA GUIDELINES; HEALTH OUTCOMES; MANAGEMENT; UPDATE; RISK		Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98101 USA; Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University	Psaty, BM (corresponding author), Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA.	psaty@u.washington.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043201, R01HL074745, R01HL068639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009556] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; EPSTEIN M, 1995, ARCH INTERN MED, V155, P2150, DOI 10.1001/archinte.155.20.2150; Fox KM, 2003, LANCET, V362, P782; Furberg CD, 1996, CIRCULATION, V93, P1475; Gibbons RJ, 2003, CIRCULATION, V107, P149, DOI 10.1161/01.CIR.0000047041.66447.29; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; Psaty BM, 2004, JAMA-J AM MED ASSOC, V292, P43, DOI 10.1001/jama.292.1.43-c; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Ruzicka Marcel, 1995, P2815; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; Williams SV, 2001, ANN INTERN MED, V135, P530, DOI 10.7326/0003-4819-135-7-200110020-00014; Yusuf S, 2000, NEW ENGL J MED, V342, P145	16	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2004	364	9437					817	818		10.1016/S0140-6736(04)16992-4	http://dx.doi.org/10.1016/S0140-6736(04)16992-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351169				2022-12-28	WOS:000223685200003
J	von Schoen-Angerer, T				von Schoen-Angerer, T			Understanding health care in the south Caucasus: examples from Armenia	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-ETHICS; GEORGIA; REFORM		Med Sans Frontieres, Yerevan 375012, Armenia		von Schoen-Angerer, T (corresponding author), Med Sans Frontieres, Kollnischen Pk 1, D-10179 Berlin, Germany.	tavschoen@yahoo.com		von Schoen-Angerer, Tido/0000-0003-3601-7480				ANAKHASSIAN K, 2001, ASSESSMENT SITUATION; Badurashvili I, 2001, PUBLIC HEALTH, V115, P394, DOI 10.1038/sj.ph.1900808; BALABANOVA D, IN PRESS HLTH SERVIC; Beaglehole R., 2003, WORLD HLTH REPORT 20; CASSILETH BR, 1995, JAMA-J AM MED ASSOC, V273, P1569, DOI 10.1001/jama.273.20.1569; Claeys P, 2001, SEX TRANSM DIS, V28, P372, DOI 10.1097/00007435-200107000-00003; Collins T, 2003, J COMMUN HEALTH, V28, P99, DOI 10.1023/A:1022643329631; Grabbe L, 2000, FAM MED, V32, P201; *HOP HELP NGO UNFP, 2001, REP SOM ASP COMM SEX; Hovhannisyan S, 2001, HLTH CARE SYSTEMS TR, P31; Hutin YJF, 2003, BMJ-BRIT MED J, V327, P1075, DOI 10.1136/bmj.327.7423.1075; KHACHIKYAN K, 2001, TREATMENT PREVENTION; Lewis M, 2002, FUNDING HLTH CARE OP, P184; Mawer C, 2001, LANCET, V358, P445, DOI 10.1016/S0140-6736(01)05621-5; McKee M, 2001, BRIT MED J, V323, P1051, DOI 10.1136/bmj.323.7320.1051; Pavin M, 2003, TROP MED INT HEALTH, V8, P182, DOI 10.1046/j.1365-3156.2003.00992.x; PELLEGRINO ED, 1995, JAMA-J AM MED ASSOC, V273, P1622, DOI 10.1001/jama.273.20.1622; Platt L, 2000, INT J STD AIDS, V11, P563, DOI 10.1258/0956462001916524; Poloshij B, 2001, ACTA PSYCHIAT SCAND, V104, P56, DOI 10.1034/j.1600-0447.2001.1040s2056.x; Quliyeva DP, 1999, CROAT MED J, V40, P210; Skarbinski J, 2002, JAMA-J AM MED ASSOC, V287, P1043, DOI 10.1001/jama.287.8.1043; SLOGETT A, 2002, EVALUATION REPORT RE; STAINES V, 1999, HLTH SECTOR STRATEGY, P46; THEOCHAROPOULOS Y, 2003, ACCESS HLTH CARE TCH; Toon PD, 1998, BRIT MED J, V317, P741, DOI 10.1136/bmj.317.7160.741; VANBAELEN L, 2004, KNOWLEDGE ATTITUDES; Whitehead M, 2001, LANCET, V358, P833, DOI 10.1016/S0140-6736(01)05975-X; *WORLD BANK, POV RED STRAT PRSPS	28	10	10	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 4	2004	329	7465					562	565		10.1136/bmj.329.7465.562	http://dx.doi.org/10.1136/bmj.329.7465.562			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853DE	15345633	Green Published			2022-12-28	WOS:000223805800028
J	Pagano, M; Jackson, PK				Pagano, M; Jackson, PK			Wagging the dogma: Tissue-specific cell cycle control in the mouse embryo	CELL			English	Editorial Material							DEPENDENT KINASES; PROGRESSION; PHOSPHATASE; ABSENCE; COMPLEX; GROWTH; PHASE	The family of cyclin-dependent kinases (Cdks) lies at the core of the machinery that drives the cell division cycle. Studies in cultured mammalian cells have provided insight into the cellular functions of many Cdks. Recent Cdk and cyclin knockouts in the mouse show that the functions of G1 cell cycle regulatory genes are often essential only in specific cell types, pointing to our limited understanding of tissue-specific expression, redundancy, and compensating mechanisms in the Cdk network.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Canc Inst, New York, NY 10016 USA; Stanford Univ, Sch Med, Dept Pathol, Palo Alto, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol, Palo Alto, CA 94305 USA; Stanford Univ, Sch Med, Dept Immunol, Palo Alto, CA 94305 USA	New York University; New York University; Stanford University; Stanford University; Stanford University	Pagano, M (corresponding author), NYU, Sch Med, Dept Pathol, 550 1St Ave, New York, NY 10016 USA.	michele.pagano@med.nyu.edu; pjackson@stanford.edu		pagano, michele/0000-0003-3210-2442; Jackson, Peter/0000-0002-1742-2539				Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; Frei C, 2004, DEV CELL, V6, P241, DOI 10.1016/S1534-5807(03)00409-X; Gladden AB, 2003, CANCER CELL, V4, P160, DOI 10.1016/S1535-6108(03)00217-4; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Kohn MJ, 2004, MOL CELL BIOL, V24, P7197, DOI 10.1128/MCB.24.16.7197-7205.2004; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Lincoln AJ, 2002, NAT GENET, V30, P446, DOI 10.1038/ng856; Lorenz S, 2003, PLANT MOL BIOL, V53, P227, DOI 10.1023/B:PLAN.0000009295.07016.87; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Park M, 1999, DEVELOPMENT, V126, P4849; Wirth KG, 2004, GENE DEV, V18, P88, DOI 10.1101/gad.285404; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209	18	66	68	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	2004	118	5					535	538		10.1016/j.cell.2004.08.013	http://dx.doi.org/10.1016/j.cell.2004.08.013			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	852BN	15339658	Bronze			2022-12-28	WOS:000223730300004
J	Roth, GS; Mattison, JA; Ottinger, MA; Chachich, ME; Lane, MA; Ingram, DK				Roth, GS; Mattison, JA; Ottinger, MA; Chachich, ME; Lane, MA; Ingram, DK			Aging in rhesus monkeys: Relevance to human health interventions	SCIENCE			English	Editorial Material							NONHUMAN PRIMATE MODELS; AGE-RELATED DECLINE; CALORIC RESTRICTION; DIETARY RESTRICTION; CYTOKINE PRODUCTION; METABOLIC SYNDROME; BRAIN; LONGEVITY; MENOPAUSE; RATS	Progress in gerontologicat research has been promoted through the use of numerous animal models, which have helped identify possible mechanisms of aging and age-related chronic diseases and evaluate possible interventions with potential relevance to human aging and disease. Further development of nonhuman primate models, particularly rhesus monkeys, could accelerate this progress, because their closer genetic relationship to humans produces a highly similar aging phenotype. Because the relatively tong lives of primates increase the administrative and economic demands on research involving them, new emphasis has emerged on increasing the efficient use of these valuable resources through cooperative, interdisciplinary research.	NIA, Lab Expt Gerontol, Intramural Res Program, Gerontol Res Ctr,NIH, Baltimore, MD 21224 USA; Univ Maryland, Dept Anim & Avian Sci, College Pk, MD 20742 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Maryland; University of Maryland College Park	Ingram, DK (corresponding author), NIA, Lab Expt Gerontol, Intramural Res Program, Gerontol Res Ctr,NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	ingramd@grc.nia.nih.gov			NATIONAL INSTITUTE ON AGING [Z01AG000304] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASKERVILLE A, 1992, J COMP PATHOL, V107, P49, DOI 10.1016/0021-9975(92)90095-C; Bellino FL, 2003, BIOL REPROD, V68, P10, DOI 10.1095/biolreprod.102.005215; Black A, 2001, BONE, V28, P295, DOI 10.1016/S8756-3282(00)00452-X; Bodkin NL, 2003, HORM METAB RES, V35, P617, DOI 10.1055/s-2003-43510; Bodkin NL, 2003, J GERONTOL A-BIOL, V58, P212; BODKIN NL, 1995, J GERONTOL A-BIOL, V50, pB142, DOI 10.1093/gerona/50A.3.B142; Brewer M, 2001, COMPARATIVE MED, V51, P424; Calhoun ME, 2004, J COMP NEUROL, V475, P238, DOI 10.1002/cne.20181; CHAKRABORTY M, 1995, CANCER RES, V55, P1525; CLARKSON TB, 1994, JAMA-J AM MED ASSOC, V271, P317; Colman RJ, 1999, METHODS AGING RES, P249; Duan HL, 2003, CEREB CORTEX, V13, P950, DOI 10.1093/cercor/13.9.950; Dunbar CE, 2001, J INTERN MED, V249, P329, DOI 10.1046/j.1365-2796.2001.00805.x; Dunnett SB, 2001, TRENDS PHARMACOL SCI, V22, P211, DOI 10.1016/S0165-6147(00)01707-7; FANTON JW, 1991, RADIAT RES, V126, P141, DOI 10.2307/3577812; Gilardi KVK, 1997, BIOL REPROD, V57, P335, DOI 10.1095/biolreprod57.2.335; Grondin R, 2002, BRAIN, V125, P2191, DOI 10.1093/brain/awf234; HEILBRONN L, 2004, 33 ANN M AM AG ASS S; Herndon JG, 1998, NEUROBIOL AGING, V19, P267, DOI 10.1016/S0197-4580(98)00054-2; HUBBARD GB, 1985, VET PATHOL, V22, P88, DOI 10.1177/030098588502200116; KALER LW, 1986, ENDOCRINOLOGY, V119, P566, DOI 10.1210/endo-119-2-566; KAUFMAN PL, 1982, EXP EYE RES, V34, P287, DOI 10.1016/0014-4835(82)90061-6; Keuker JIH, 2003, NEUROBIOL AGING, V24, P157, DOI 10.1016/S0197-4580(02)00062-3; Kim JJ, 2001, CLIN CANCER RES, V7, p882S; Kim MJ, 1997, J NUTR, V127, P2293, DOI 10.1093/jn/127.12.2293; Kordower JH, 2003, ANN NEUROL, V53, pS120, DOI 10.1002/ana.10485; Kramer PA, 2002, J ORTHOP RES, V20, P399, DOI 10.1016/S0736-0266(01)00122-X; Lane MA, 1997, J CLIN ENDOCR METAB, V82, P2093, DOI 10.1210/jc.82.7.2093; Lane MA, 1996, P NATL ACAD SCI USA, V93, P4159, DOI 10.1073/pnas.93.9.4159; Mascarucci P, 2001, AGING-CLIN EXP RES, V13, P85, DOI 10.1007/BF03351530; Matochik JA, 2000, NEUROBIOL AGING, V21, P591, DOI 10.1016/S0197-4580(00)00134-2; Mattison JA, 2003, EXP GERONTOL, V38, P35, DOI 10.1016/S0531-5565(02)00146-8; MATTISON JA, IN PRESS NEUROBIOL A; Morris ED, 1999, J CEREBR BLOOD F MET, V19, P218, DOI 10.1097/00004647-199902000-00013; Moscrip TD, 2000, J GERONTOL A-BIOL, V55, pB373, DOI 10.1093/gerona/55.8.B373; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Peters A, 2002, PROG BRAIN RES, V136, P455; Price DL, 1991, BRAIN PATHOL, V1, P287, DOI 10.1111/j.1750-3639.1991.tb00672.x; Ramsey JJ, 2000, EXP GERONTOL, V35, P1131, DOI 10.1016/S0531-5565(00)00166-2; Rapp PR, 2003, J NEUROSCI, V23, P5708; Rink L, 1998, MECH AGEING DEV, V102, P199, DOI 10.1016/S0047-6374(97)00153-X; Roth GS, 1997, J GERONTOL A-BIOL, V52, pB98, DOI 10.1093/gerona/52A.2.B98; ROTH GS, 1995, NAT MED, V1, P414, DOI 10.1038/nm0595-414; Roth GS, 2002, SCIENCE, V297, P811, DOI 10.1126/science.1071851; Roth GS, 2001, J CLIN ENDOCR METAB, V86, P3292, DOI 10.1210/jc.86.7.3292; SCHWARTZ SM, 1992, AM J PHYS ANTHROPOL, V89, P109, DOI 10.1002/ajpa.1330890110; Sell DR, 1996, P NATL ACAD SCI USA, V93, P485, DOI 10.1073/pnas.93.1.485; SEPEHR S, 2003, ACTA NEUROPATHOL, V105, P145; Small SA, 2004, P NATL ACAD SCI USA, V101, P7181, DOI 10.1073/pnas.0400285101; Smith DE, 1999, P NATL ACAD SCI USA, V96, P10893, DOI 10.1073/pnas.96.19.10893; Smucny DA, 2004, J MED PRIMATOL, V33, P48, DOI 10.1111/j.1600-0684.2003.00052.x; Steinbaum SR, 2004, PROG CARDIOVASC DIS, V46, P321, DOI 10.1016/j.pcad.2003.08.005; Torre P, 2000, HEARING RES, V142, P131, DOI 10.1016/S0378-5955(00)00025-3; Uno H, 1996, NEUROBIOL AGING, V17, P275, DOI 10.1016/0197-4580(95)02063-2; Valverde CR, 2000, COMPARATIVE MED, V50, P540; Voytko ML, 2001, SYNAPSE, V39, P95, DOI 10.1002/1098-2396(20010101)39:1<95::AID-SYN12>3.0.CO;2-2; Voytko ML, 1999, NEUROBIOL AGING, V20, P617, DOI 10.1016/S0197-4580(99)00097-4; Weindruch R., 1988, RETARDATION AGING DI; Winegar DA, 2001, J LIPID RES, V42, P1543; Wise PM, 2002, RECENT PROG HORM RES, V57, P235, DOI 10.1210/rp.57.1.235; Zhang ZM, 2000, J GERONTOL A-BIOL, V55, pB473, DOI 10.1093/gerona/55.10.B473	61	243	250	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1423	1426		10.1126/science.1102541	http://dx.doi.org/10.1126/science.1102541			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353793				2022-12-28	WOS:000223761900036
J	Desiraju, GR				Desiraju, GR			Midsummer madness	NATURE			English	Editorial Material									Univ Hyderabad, Sch Chem, Hyderabad 500046, Andhra Pradesh, India	University of Hyderabad	Desiraju, GR (corresponding author), Univ Hyderabad, Sch Chem, Hyderabad 500046, Andhra Pradesh, India.		Desiraju, Gautam R./AAQ-6388-2021; Desiraju, Gautam R/B-1565-2009					Desiraju G.R., 1999, WEAK HYDROGEN BOND S; DESIRAJU GR, 1995, ANGEW CHEM INT EDIT, V34, P2311, DOI 10.1002/anie.199523111; DESIRAJU GR, 1989, CRYSTAL ENG; 2004, CHEM EUR J, V10, P3783	4	6	6	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2004	431	7004					25	25		10.1038/431025a	http://dx.doi.org/10.1038/431025a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343313	Bronze			2022-12-28	WOS:000223641500022
J	Escher, M; Perneger, TV; Chevrolet, JC				Escher, M; Perneger, TV; Chevrolet, JC			National questionnaire survey on what influences doctors' decisions about admission to intensive care	BRITISH MEDICAL JOURNAL			English	Article							ILL PATIENTS; UNIT; TRIAGE; PHYSICIANS; RESUSCITATION; CANCER; ALLOCATION; RESOURCES; JUDGMENT; SUPPORT	Objectives To determine what influences doctors' decisions about admission of patients to intensive care. Design National questionnaire survey using eight clinical vignettes involving hypothetical patients. Setting Switzerland. Participants 402 Swiss doctors specialising in intensive care. Main outcome measures Rating of factors influencing decisions on admission and response to eight hypothetical clinical scenarios. Results Of 381 doctors agreeing to participate, 232 (61%) returned questionnaires. Most rated as important or very important the prognosis of the underlying disease (82%) and of the acute illness (81%) and the patients' wishes (71%). Few considered the important socioeconomic circumstances of the patient (20%), religious beliefs (3%) and emotional state (6%). In the vignettes, underlying disease (cancer versus non-cancerous disease) was not associated with admission to intensive care, but four other factors were: patients' wishes (odds ratio 3.0, 95% confidence interval 2.0 to 4.6), upbeat personality (2.9, 1.9 to 4.4), younger age (1.5, 1.1 to 2.2), and a greater number of beds available in intensive care (1.8, 1.2 to 2.5). Conclusions Doctors' decisions to admit patients to intensive care are influenced by patients' wishes and ethically problematic non-medical factors such as a patient's personality or availability of beds. Patients with cancer are not discriminated against.	Univ Hosp Geneva, Div Clin Pharmacol & Toxicol, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Qual Care Unit, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Med Intens Care Div, CH-1211 Geneva 14, Switzerland	University of Geneva; University of Geneva; University of Geneva	Escher, M (corresponding author), Univ Hosp Geneva, Div Clin Pharmacol & Toxicol, CH-1211 Geneva 14, Switzerland.	monica.escher@hcuge.ch						Azoulay E, 2000, CRIT CARE MED, V28, P3044, DOI 10.1097/00003246-200008000-00061; Azoulay E, 2001, CRIT CARE MED, V29, P2132, DOI 10.1097/00003246-200111000-00014; Claessens MT, 2000, J AM GERIATR SOC, V48, pS146, DOI 10.1111/j.1532-5415.2000.tb03124.x; Coppola KM, 2001, ARCH INTERN MED, V161, P431, DOI 10.1001/archinte.161.3.431; Egol A, 1999, CRIT CARE MED, V27, P633; EISENBERG JM, 1979, ANN INTERN MED, V90, P957, DOI 10.7326/0003-4819-90-6-957; ELY JW, 1992, J AM GERIATR SOC, V40, P471, DOI 10.1111/j.1532-5415.1992.tb02013.x; Furnham A, 2000, J SOC BEHAV PERS, V15, P185; Ghusn HF, 1997, J AM GERIATR SOC, V45, P1118, DOI 10.1111/j.1532-5415.1997.tb05977.x; Hanson LC, 1996, ARCH INTERN MED, V156, P785, DOI 10.1001/archinte.156.7.785; JACOBS P, 1990, CRIT CARE MED, V18, P1282, DOI 10.1097/00003246-199011000-00020; Joynt GM, 2001, INTENS CARE MED, V27, P1459, DOI 10.1007/s001340101041; KOHLENBERGER C, 1994, JAMA-J AM MED ASSOC, V271, P1200; Lanken PN, 1997, AM J RESP CRIT CARE, V156, P1282; LAWRENCE VA, 1987, ARCH INTERN MED, V147, P1637, DOI 10.1001/archinte.147.9.1637; NUCKTON TJ, 1995, ARCH INTERN MED, V155, P1087, DOI 10.1001/archinte.155.10.1087; Redelmeier DA, 2001, CAN MED ASSOC J, V164, P358; Sprung CL, 1997, INTENS CARE MED, V23, P1011, DOI 10.1007/s001340050449; SUHL J, 1994, ARCH INTERN MED, V154, P90, DOI 10.1001/archinte.154.1.90; Tanvetyanon T, 2003, CRIT CARE MED, V31, P60, DOI 10.1097/00003246-200301000-00009; Tarnow-Mordi WO, 2000, LANCET, V356, P185, DOI 10.1016/S0140-6736(00)02478-8; Vincent JL, 1998, INTENS CARE MED, V24, P1251, DOI 10.1007/s001340050758; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525	23	80	84	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 21	2004	329	7463					425	428		10.1136/bmj.329.7463.425	http://dx.doi.org/10.1136/bmj.329.7463.425			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849EA	15321898	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000223520300015
J	Gasser, S; Kuhn, M; Speich, R				Gasser, S; Kuhn, M; Speich, R			Drug points: Severe necrotising leucocytoclastic vasculitis in a patient taking bosentan	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION		Univ Hosp, Dept Internal Med, Div Pulm Dis, CH-8031 Zurich, Switzerland; Cantonal Hosp, Dept Internal Med, Div Pulm Dis, CH-7000 Chur 7, Switzerland	University of Zurich; University Zurich Hospital	Gasser, S (corresponding author), Univ Hosp, Dept Internal Med, Div Pulm Dis, CH-8031 Zurich, Switzerland.	sgasser@uhbs.ch						Channick RN, 2001, LANCET, V358, P1119, DOI 10.1016/S0140-6736(01)06250-X; Rubin LJ, 2002, NEW ENGL J MED, V346, P896, DOI 10.1056/NEJMoa012212	2	6	6	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 21	2004	329	7463					430	430		10.1136/bmj.329.7463.430	http://dx.doi.org/10.1136/bmj.329.7463.430			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849EA	15321900	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000223520300018
J	Piura, B				Piura, B			Women undergoing termination of pregnancy should be screened for gestational trophoblastic neoplasia	LANCET			English	Editorial Material							EPIDEMIOLOGY		Ben Gurion Univ Negev, Dept Obstet & Gynaecol, Unit Gynaecol Oncol, Soroka Med Ctr, IL-84101 Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, IL-84101 Beer Sheva, Israel	Ben Gurion University; Soroka Medical Center; Ben Gurion University	Piura, B (corresponding author), Ben Gurion Univ Negev, Dept Obstet & Gynaecol, Unit Gynaecol Oncol, Soroka Med Ctr, IL-84101 Beer Sheva, Israel.	piura@bgumail.bgu.ac.il						Elam-Evans Laurie D, 2003, MMWR Surveill Summ, V52, P1; Henshaw SK, 1999, INT FAM PLAN PERSPEC, V25, pS30, DOI 10.2307/2991869; JOHNSTON WR, 2003, HIST ABORTION STAT I; JOHNSTON WR, 2003, HIST ABORTION STAT U; Royal College of Obstricians and Gynaecologist, 2004, 38 ROYAL COLL OBST G; Seckl MJ, 2000, LANCET, V356, P36, DOI 10.1016/S0140-6736(00)02432-6; SEMER DA, 1995, SEMIN ONCOL, V22, P109; Steigrad SJ, 2003, BEST PRACT RES CL OB, V17, P837, DOI 10.1016/S1521-6934(03)00049-X; Thomas J, 2003, INT J GYNECOL OBSTET, V83, P327, DOI 10.1016/S0020-7292(03)00305-9	9	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	2004	364	9435					645	646		10.1016/S0140-6736(04)16910-9	http://dx.doi.org/10.1016/S0140-6736(04)16910-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325813				2022-12-28	WOS:000223428900007
J	Vaudaux, P; Schrenzel, J				Vaudaux, P; Schrenzel, J			Nosocomial bacteraemia caused by Staphylococcus aureus	LANCET			English	Editorial Material							INFECTIONS; MUPIROCIN; VANCOMYCIN; CARRIAGE; STRAINS		Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva 14, Switzerland	University of Geneva	Vaudaux, P (corresponding author), Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva 14, Switzerland.	pierre.vaudaux@hcuge.ch	Schrenzel, Jacques/AAC-5685-2021; Schrenzel, Jacques/P-8525-2017	Schrenzel, Jacques/0000-0001-5464-7764; Schrenzel, Jacques/0000-0001-5464-7764				Fridkin SK, 2003, CLIN INFECT DIS, V36, P429, DOI 10.1086/346207; Gillet Y, 2002, LANCET, V359, P753, DOI 10.1016/S0140-6736(02)07877-7; Harbarth S, 2000, CLIN INFECT DIS, V31, P1380, DOI 10.1086/317484; Kalmeijer MD, 2002, CLIN INFECT DIS, V35, P353, DOI 10.1086/341025; Laupland KB, 2004, CRIT CARE MED, V32, P992, DOI 10.1097/01.CCM.0000119424.31648.1E; Muto CA, 2003, INFECT CONT HOSP EP, V24, P362, DOI 10.1086/502213; Naimi TS, 2003, JAMA-J AM MED ASSOC, V290, P2976, DOI 10.1001/jama.290.22.2976; Perl TM, 2002, NEW ENGL J MED, V346, P1871, DOI 10.1056/NEJMoa003069; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; Pittet D, 1996, INFECT CONT HOSP EP, V17, P496; von Eiff C, 2001, NEW ENGL J MED, V344, P11, DOI 10.1056/NEJM200101043440102; Wertheim HFL, 2004, ANN INTERN MED, V140, P419, DOI 10.7326/0003-4819-140-6-200403160-00007; Whitener CJ, 2004, CLIN INFECT DIS, V38, P1049, DOI 10.1086/382357	13	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	2004	364	9435					644	645		10.1016/S0140-6736(04)16909-2	http://dx.doi.org/10.1016/S0140-6736(04)16909-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325812				2022-12-28	WOS:000223428900006
J	Pedersen, TH; Nielsen, OB; Lamb, GD; Stephenson, DG				Pedersen, TH; Nielsen, OB; Lamb, GD; Stephenson, DG			Intracellular acidosis enhances the excitability of working muscle	SCIENCE			English	Article							FROG SKELETAL-MUSCLE; CHLORIDE CONDUCTANCE; LACTIC-ACID; FIBERS; RAT; POTASSIUM; CHANNELS; FATIGUE; TWITCH; PH	Intracellular acidification of skeletal muscles is commonly thought to contribute to muscle fatigue. However, intracellular acidosis also acts to preserve muscle excitability when muscles become depolarized, which occurs with working muscles. Here, we show that this process may be mediated by decreased chloride permeability, which enables action potentials to still be propagated along the internal network of tubules in a muscle fiber (the T system) despite muscle depolarization. These results implicate chloride ion channels in muscle function and emphasize that intracellular acidosis of muscle has protective effects during muscle fatigue.	La Trobe Univ, Dept Zool, Melbourne, Vic 3086, Australia; Univ Aarhus, Dept Physiol, DK-8000 Aarhus, Denmark	La Trobe University; Aarhus University	Stephenson, DG (corresponding author), La Trobe Univ, Dept Zool, Melbourne, Vic 3086, Australia.	G.Stephenson@zoo.latrobe.edu.au		Holm Pedersen, Thomas/0000-0002-1060-4989; Nielsen, Ole Baekgaard/0000-0003-3535-7862				Balog EM, 2001, J APPL PHYSIOL, V90, P228, DOI 10.1152/jappl.2001.90.1.228; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; Coonan JR, 1998, J PHYSIOL-LONDON, V509, P551, DOI 10.1111/j.1469-7793.1998.551bn.x; DULHUNTY AF, 1979, J MEMBRANE BIOL, V45, P293, DOI 10.1007/BF01869290; FITTS RH, 1994, PHYSIOL REV, V74, P49, DOI 10.1152/physrev.1994.74.1.49; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; HODGKIN AL, 1959, J PHYSIOL-LONDON, V148, P127, DOI 10.1113/jphysiol.1959.sp006278; HUTTER OF, 1967, J PHYSIOL-LONDON, V189, P403, DOI 10.1113/jphysiol.1967.sp008176; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; LAMB GD, 1994, J PHYSIOL-LONDON, V478, P331, DOI 10.1113/jphysiol.1994.sp020253; Launikonis BS, 2004, J GEN PHYSIOL, V123, P231, DOI 10.1085/jgp.200308946; Nielsen OB, 2001, J PHYSIOL-LONDON, V536, P161, DOI 10.1111/j.1469-7793.2001.t01-1-00161.x; Ortenblad N, 2003, J PHYSIOL-LONDON, V548, P139, DOI 10.1113/jphysiol.2002.036657; PALADE PT, 1977, J GEN PHYSIOL, V69, P325, DOI 10.1085/jgp.69.3.325; Posterino GS, 2000, J PHYSIOL-LONDON, V527, P131, DOI 10.1111/j.1469-7793.2000.t01-2-00131.x; Posterino GS, 2001, PFLUG ARCH EUR J PHY, V442, P197, DOI 10.1007/s004240100528; Ruff RL, 1996, ACTA PHYSIOL SCAND, V156, P159, DOI 10.1046/j.1365-201X.1996.189000.x; Sejersted OM, 2000, PHYSIOL REV, V80, P1411, DOI 10.1152/physrev.2000.80.4.1411; Sjogaard G, 1990, Acta Physiol Scand Suppl, V593, P1; Stephenson DG, 1998, ACTA PHYSIOL SCAND, V162, P229, DOI 10.1046/j.1365-201X.1998.0304f.x; Westerblad H, 2002, NEWS PHYSIOL SCI, V17, P17	21	225	232	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	2004	305	5687					1144	1147		10.1126/science.1101141	http://dx.doi.org/10.1126/science.1101141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326352				2022-12-28	WOS:000223557400045
J	Roper, C; Pearce, R; Nair, S; Sharp, B; Nosten, F; Anderson, T				Roper, C; Pearce, R; Nair, S; Sharp, B; Nosten, F; Anderson, T			Intercontinental spread of pyrimethamine-resistant malaria	SCIENCE			English	Article							ANTIMALARIAL-DRUG-RESISTANCE; PLASMODIUM-FALCIPARUM; MUTATIONS		Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; SW Fdn Biomed Res, San Antonio, TX 78284 USA; MRC, Durban, South Africa; Shoklo Malaria Res Unit, Mae Sot, Tak, Thailand	University of London; London School of Hygiene & Tropical Medicine; Texas Biomedical Research Institute; Mahidol University	Roper, C (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	cally.roper@lshtm.ac.uk	Nosten, Francois/AAC-5509-2019; Roper, Cally/K-2989-2013	Nosten, Francois/0000-0002-7951-0745; Roper, Cally/0000-0002-6545-309X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI048071] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cortese JF, 2002, J INFECT DIS, V186, P999, DOI 10.1086/342946; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; Nair S, 2003, MOL BIOL EVOL, V20, P1526, DOI 10.1093/molbev/msg162; Plowe CV, 1997, J INFECT DIS, V176, P1590, DOI 10.1086/514159; Roper C, 2003, LANCET, V361, P1174, DOI 10.1016/S0140-6736(03)12951-0; Ryan ET, 2000, NEW ENGL J MED, V342, P1716, DOI 10.1056/NEJM200006083422306; White N, 1999, PHILOS T R SOC B, V354, P739, DOI 10.1098/rstb.1999.0426; WHITE NJ, 1992, J ANTIMICROB CHEMOTH, V30, P571, DOI 10.1093/jac/30.5.571; Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813	9	374	378	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2004	305	5687					1124	1124		10.1126/science.1098876	http://dx.doi.org/10.1126/science.1098876			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326348				2022-12-28	WOS:000223557400037
J	Edwards, M; Richardson, AJ				Edwards, M; Richardson, AJ			Impact of climate change on marine pelagic phenology and trophic mismatch	NATURE			English	Article							NORTH-SEA; PHYTOPLANKTON BLOOMS; CONSEQUENCES; TEMPERATURE; COPEPODS; GROWTH	Phenology, the study of annually recurring life cycle events such as the timing of migrations and flowering, can provide particularly sensitive indicators of climate change(1). Changes in phenology may be important to ecosystem function because the level of response to climate change may vary across functional groups and multiple trophic levels. The decoupling of phenological relationships will have important ramifications for trophic interactions, altering food-web structures and leading to eventual ecosystem-level changes. Temperate marine environments may be particularly vulnerable to these changes because the recruitment success of higher trophic levels is highly dependent on synchronization with pulsed planktonic production(2,3). Using long-term data of 66 plankton taxa during the period from 1958 to 2002, we investigated whether climate warming signals(4) are emergent across all trophic levels and functional groups within an ecological community. Here we show that not only is the marine pelagic community responding to climate changes, but also that the level of response differs throughout the community and the seasonal cycle, leading to a mismatch between trophic levels and functional groups.	The Lab, Sir Alister Hardy Fdn Ocean Sci, Plymouth PL1 2PB, Devon, England		Edwards, M (corresponding author), The Lab, Sir Alister Hardy Fdn Ocean Sci, Citadel Hill, Plymouth PL1 2PB, Devon, England.	maed@sahfos.ac.uk	Richardson, Anthony J/B-3649-2010	Richardson, Anthony J/0000-0002-9289-7366; Edwards, Martin/0000-0002-5716-4714				Beaugrand G, 2003, PROG OCEANOGR, V58, P235, DOI 10.1016/j.pocean.2003.08.006; Beaugrand G, 2002, SCIENCE, V296, P1692, DOI 10.1126/science.1071329; Beaugrand G, 2003, NATURE, V426, P661, DOI 10.1038/nature02164; Colebrook J. M., 1965, Bulletin of Marine Ecology, V6, P123; COLEBROOK JM, 1979, MAR BIOL, V51, P23, DOI 10.1007/BF00389027; Cushing D. H., 1990, ADV MAR BIOL, P250, DOI DOI 10.1016/S0065-2881(08)60202-3); Eilertsen HC, 2000, S AFR J MARINE SCI, V22, P323, DOI 10.2989/025776100784125717; EILERTSEN HC, 1995, MAR ECOL PROG SER, V116, P303, DOI 10.3354/meps116303; Greve W, 1996, ICES J MAR SCI, V53, P951, DOI 10.1006/jmsc.1996.0117; Greve W., 2004, PHENOLOGY INTEGRATIV, P385; Harrington R, 1999, TRENDS ECOL EVOL, V14, P146, DOI 10.1016/S0169-5347(99)01604-3; Hirst AG, 2003, LIMNOL OCEANOGR, V48, P1988, DOI 10.4319/lo.2003.48.5.1988; Hjort J., 1914, RAPP P V REUN CONS I, V20, P1; Hughes L, 2000, TRENDS ECOL EVOL, V15, P56, DOI 10.1016/S0169-5347(99)01764-4; Lindley JA, 1998, INVERTEBR REPROD DEV, V33, P209, DOI 10.1080/07924259.1998.9652633; McCarty JP, 2001, CONSERV BIOL, V15, P320, DOI 10.1046/j.1523-1739.2001.015002320.x; McQuoid MR, 1996, J PHYCOL, V32, P889, DOI 10.1111/j.0022-3646.1996.00889.x; Parmesan C, 2003, NATURE, V421, P37, DOI 10.1038/nature01286; Pyper BJ, 1998, CAN J FISH AQUAT SCI, V55, P2127; Root TL, 2003, NATURE, V421, P57, DOI 10.1038/nature01333; Schiermeier Q, 2004, NATURE, V428, P4, DOI 10.1038/428004a; Siegismund F, 2001, CLIMATE RES, V18, P39, DOI 10.3354/cr018039; Sverdrup H.U., 1953, J CONSEILCONSEIL PER, V18, P287, DOI [10.1093/icesjms/18.3.287, DOI 10.1093/ICESJMS/18.3.287]; TOWNSEND DW, 1992, NATURE, V360, P59, DOI 10.1038/360059a0; van Haren H, 1998, J MAR RES, V56, P655, DOI 10.1357/002224098765213621; VANBEUSEKOM JEE, 1994, 6471 DAN ENV PROT AG; Walther GR, 2002, NATURE, V416, P389, DOI 10.1038/416389a; WARNER AJ, 1994, PROG OCEANOGR, V34, P237, DOI 10.1016/0079-6611(94)90011-6; WEAR RG, 1974, J MAR BIOL ASSOC UK, V54, P745, DOI 10.1017/S0025315400022918	29	1491	1536	16	949	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					881	884		10.1038/nature02808	http://dx.doi.org/10.1038/nature02808			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318219				2022-12-28	WOS:000223369800039
J	Steinbrook, R				Steinbrook, R			Antiretroviral medications - From Thailand to Africa	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	2	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2004	351	8					739	739		10.1056/NEJMp048201	http://dx.doi.org/10.1056/NEJMp048201			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847CY	15317884				2022-12-28	WOS:000223367900003
J	Pui, CH; Relling, MV				Pui, CH; Relling, MV			Can the genotoxicity of chemotherapy be predicted?	LANCET			English	Editorial Material							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHILDHOOD-CANCER; CHILDREN; SURVIVORS		St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Pui, CH (corresponding author), St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.	Ching-hon.pui@stjude.org	Pui, Ching-Hon/N-8076-2018	Pui, Ching-Hon/0000-0003-0303-5658	NATIONAL CANCER INSTITUTE [P01CA071907, R29CA051001, R37CA036401, P30CA021765, R01CA078224, R01CA051001, R01CA036401, U01CA060419, R01CA060419] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061393] Funding Source: NIH RePORTER; NCI NIH HHS [CA 71907, CA 71970, CA 78224, CA 36401, CA 21765, CA 60419, CA 51001] Funding Source: Medline; NIGMS NIH HHS [GM 61393, GM 61374] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhatia S, 2002, NAT REV CANCER, V2, P124, DOI 10.1038/nrc722; CROM WR, 1987, CLIN PHARMACOKINET, V12, P168, DOI 10.2165/00003088-198712030-00002; Evans WE, 2004, NATURE, V429, P464, DOI 10.1038/nature02626; Fuscoe JC, 1998, MUTAT RES-GEN TOX EN, V419, P107, DOI 10.1016/S1383-5718(98)00129-6; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Neglia JP, 2001, J NATL CANCER I, V93, P618, DOI 10.1093/jnci/93.8.618; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Pui CH, 2000, BRIT J HAEMATOL, V109, P13, DOI 10.1046/j.1365-2141.2000.01843.x; Rice SC, 2004, CANCER RES, V64, P4464, DOI 10.1158/0008-5472.CAN-03-3940; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	10	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 11	2004	364	9438					917	918		10.1016/S0140-6736(04)17038-4	http://dx.doi.org/10.1016/S0140-6736(04)17038-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364174				2022-12-28	WOS:000223831000007
J	Isaacs, SL; Schroeder, SA				Isaacs, SL; Schroeder, SA			Class - The ignored determinant of the nation's health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SOCIAL-CLASS; SOCIOECONOMIC-FACTORS; MORTALITY RISK; INCOME; INEQUALITIES; DISPARITIES; DIFFERENTIALS; RACE; MEN		Ctr Hlth & Social Policy, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Isaacs, SL (corresponding author), Ctr Hlth & Social Policy, 847 25th Ave, San Francisco, CA 94121 USA.		Schiaffino, Melody K/E-9629-2011					Adler NE, 2002, HEALTH AFFAIR, V21, P60, DOI 10.1377/hlthaff.21.2.60; ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ANGELL M, 2000, IS INEQUALITY BAD OU, P42; Black D, 1982, INEQUALITIES HLTH BL; BLANE D, 1995, AM J PUBLIC HEALTH, V85, P903, DOI 10.2105/AJPH.85.7.903; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; DANIELS N, 2000, IS INEQUALITY BAD OU; Deaton A, 2002, HEALTH AFFAIR, V21, P13, DOI 10.1377/hlthaff.21.2.13; EXWORTHY M, 2003, TACKLING HLTH INEQUA; FEIN O, 1995, J GEN INTERN MED, V10, P577, DOI 10.1007/BF02640369; GURALNIK JM, 1993, NEW ENGL J MED, V329, P110, DOI 10.1056/NEJM199307083290208; *I MED, 2003, FUT PUBL HLTH 21 CEN, P20; Institute of Medicine Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, 2003, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; JARVIS MJ, 1999, SOCIAL DETERMINANTS, P244; *JOINT CTR DAT, 1997, AFR AM HLTH; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; Kawachi I., 2003, NEIGHBORHOODS HLTH; KRIEGER N, 1994, INT J HEALTH SERV, V24, P25, DOI 10.2190/2JG7-YMD5-WCP2-XXNT; KRUGMAN P, 2002, NY TIMES MAGAZI 1020, P63; Lantz PM, 1998, JAMA-J AM MED ASSOC, V279, P1703, DOI 10.1001/jama.279.21.1703; Lochner K, 2001, AM J PUBLIC HEALTH, V91, P385, DOI 10.2105/AJPH.91.3.385; MARMOR M, 2000, IS INEQUALITY BAD OU, P53; Marmot M, 2001, NEW ENGL J MED, V345, P134, DOI 10.1056/NEJM200107123450210; MARMOT MG, 1984, LANCET, V1, P1003; McDonough P, 1997, AM J PUBLIC HEALTH, V87, P1476, DOI 10.2105/AJPH.87.9.1476; MCEWEN BS, 1999, SOCIOECONOMIC STATUS; McGinnis JM, 2002, HEALTH AFFAIR, V21, P78, DOI 10.1377/hlthaff.21.2.78; *NAT CTR HLTH STAT, 2003, DHHS PUBL, P89; *NAT CTR HLTH STAT, 1998, DHHS PUBL, P3; *NAT CTR HLTH STAT, 2002, DHHS PUBL, P198; NAVARRO V, 1990, LANCET, V336, P1238, DOI 10.1016/0140-6736(90)92846-A; Pratt M, 1999, MED SCI SPORT EXER, V31, pS526, DOI 10.1097/00005768-199911001-00007; Roux AVD, 2001, NEW ENGL J MED, V345, P99, DOI 10.1056/NEJM200107123450205; Schroeder SA, 1996, NEW ENGL J MED, V334, P1130, DOI 10.1056/NEJM199604253341713; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P486, DOI 10.2105/AJPH.86.4.486; Smith GD, 1998, LANCET, V351, P934, DOI 10.1016/S0140-6736(05)60603-4; Smith GD, 1994, EUROPEAN J PUBLIC HL, V4, P131, DOI DOI 10.1093/EURPUB/4.2.131; *STAT OFF, 1998, IND INQ IN HLTH REP; Steinbrook R, 2004, NEW ENGL J MED, V350, P1486, DOI 10.1056/NEJMp048060; THOMAS S, 2001, HLTH ISSUES BLACK CO, P543; Wilkinson RG, 2001, INCOME SOCIOECONOMIC, P29; WILLIAMS DR, 1995, ANNU REV SOCIOL, V21, P349, DOI 10.1146/annurev.so.21.080195.002025; WILLIAMS DR, 2001, INCOME SOCIOECONOMIC, P74; WILLIAMS DR, 2001, INCOME SOCIOECONOMIC, P70; WILLIAMS DR, 2001, INCOME SOCIOECONOMIC, P69; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; Winslow R., 2003, WALL STREET J, pA1; Wong MD, 2002, NEW ENGL J MED, V347, P1585, DOI 10.1056/NEJMsa012979	48	278	281	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2004	351	11					1137	1142		10.1056/NEJMsb040329	http://dx.doi.org/10.1056/NEJMsb040329			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	852CX	15356313				2022-12-28	WOS:000223733900016
J	Pirotta, M; Gunn, J; Chondros, P; Grover, S; O'Malley, P; Hurley, S; Garland, S				Pirotta, M; Gunn, J; Chondros, P; Grover, S; O'Malley, P; Hurley, S; Garland, S			Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							ALTERNATIVE MEDICINE; VAGINITIS; THRUSH	Objective To test whether oral or vaginal lactobacillus can prevent vulvovaginitis after antibiotic treatment. Design Randomised, placebo controlled, double blind, factorial 2x2 trial. Setting Fifty general practices and 16 pharmacies in Melbourne, Australia. Participants Non-pregnant women aged 18-50 years who required a short course of oral antibiotics for a non-gynaecological infection: 278 were enrolled in the study, and results were available for 235. Interventions Lactobacillus preparations taken orally or vaginally, or both, from enrolment until four days after completion of their antibiotic course. Main outcome measures Participants' reports of symptoms of post-antibiotic vulvovaginitis, with microbiological evidence of candidiasis provided by a self obtained vaginal swab. Results Overall, 55/235 (23% (95% confidence interval 18% to 29%)) women developed post-antibiotic vulvovaginitis. Compared with placebo, the odds ratio for developing post-antibiotic vulvovaginitis with oral lactobacillus was 1.06 (95% confidence interval 0.58 to 1.94) and with vaginal lactobacillus 1.38 (0.75 to 2.54). Compliance with antibiotics and interventions was high. The trial was terminated after the second interim analysis because of lack of effect of the interventions. Given the data at this time, the chances of detecting a significant reduction in vulvovaginitis with oral or vaginal lactobacillus treatment were less than 0.032 and 0.0006 respectively if the trial proceeded to full enrolment. Conclusions The use of oral or vaginal forms of lactobacillus to prevent post-antibiotic vulvovaginitis is not supported by these results. Further research on this subject is unlikely to be fruitful, unless new understandings about the pathogenesis of post-antibiotic vulvovaginitis indicate a possible role for lactobacillus.	Dept Gen Practice, Carlton, Vic 3053, Australia; Royal Hosp Women, Carlton, Vic, Australia; Univ Melbourne, Sch Populat Hlth, Carlton, Vic 3053, Australia	University of Melbourne	Pirotta, M (corresponding author), Dept Gen Practice, 200 Berkeley St, Carlton, Vic 3053, Australia.	m.pirotta@unimelb.edu.au	Pirotta, Marie V/A-7653-2010; Chondros, Patty/AAT-6426-2020	Gunn, Jane/0000-0001-8836-7525; Chondros, Patty/0000-0003-0393-8734				Bernal S, 1996, DIAGN MICR INFEC DIS, V24, P201, DOI 10.1016/0732-8893(96)00063-6; Bluestein D, 1991, Fam Pract Res J, V11, P319; Chapple A, 2000, J REPROD INFANT PSYC, V18, P309, DOI 10.1080/713683045; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Fidel Paul L Jr, 2002, Int Rev Immunol, V21, P515, DOI 10.1080/08830180215015; HILTON E, 1992, ANN INTERN MED, V116, P353, DOI 10.7326/0003-4819-116-5-353; Hospenthal DR, 2002, J CLIN MICROBIOL, V40, P4768, DOI 10.1128/JCM.40.12.4768-4770.2002; Jennison C, 2000, GROUP SEQUENTIAL MET; KLEBANOFF SJ, 1991, J INFECT DIS, V164, P94, DOI 10.1093/infdis/164.1.94; MacLennan AH, 2002, PREV MED, V35, P166, DOI 10.1006/pmed.2002.1057; MCGROARTY JA, 1993, FEMS IMMUNOL MED MIC, V6, P251, DOI 10.1111/j.1574-695X.1993.tb00337.x; Mombelli B, 2000, INT J ANTIMICROB AG, V16, P531, DOI 10.1016/S0924-8579(00)00322-8; Nelson DB, 2003, J CLIN EPIDEMIOL, V56, P862, DOI 10.1016/S0895-4356(03)00073-8; Nyirjesy P, 1997, OBSTET GYNECOL, V90, P50, DOI 10.1016/S0029-7844(97)00242-1; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pirotta Marie, 2004, BMC Fam Pract, V5, P5, DOI 10.1186/1471-2296-5-5; Pirotta MV, 2003, MED J AUSTRALIA, V179, P43, DOI 10.5694/j.1326-5377.2003.tb05418.x; PIZZORNO LU, 2002, NATURAL MED INSTRUCT; POCOCK SJ, 1992, BMJ-BRIT MED J, V305, P235, DOI 10.1136/bmj.305.6847.235; REDONDOLOPEZ V, 1990, REV INFECT DIS, V12, P856; Sobel JD, 1998, AM J OBSTET GYNECOL, V178, P203, DOI 10.1016/S0002-9378(98)80001-X; Sobel JD, 1996, J CLIN MICROBIOL, V34, P2497, DOI 10.1128/JCM.34.10.2497-2499.1996	22	63	72	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 4	2004	329	7465					548	551		10.1136/bmj.38210.494977.DE	http://dx.doi.org/10.1136/bmj.38210.494977.DE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853DE	15333452	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000223805800023
J	Ehrlich, M; Boll, W; van Oijen, A; Hariharan, R; Chandran, K; Nibert, ML; Kirchhausen, T				Ehrlich, M; Boll, W; van Oijen, A; Hariharan, R; Chandran, K; Nibert, ML; Kirchhausen, T			Endocytosis by random initiation and stabilization of clathrin-coated pits	CELL			English	Article							MEDIATED ENDOCYTOSIS; VESICLE FORMATION; PLASMA-MEMBRANE; AP COMPLEXES; DYNAMIN; FIBROBLASTS; RECEPTOR; CELL; DIFFUSION; SIGNALS	Clathrin-coated vesicles carry traffic from the plasma membrane to endosomes. We report here the real-time visualization of cargo sorting and endocytosis by clathrin-coated pits in living cells. We have detected the formation of coats by monitoring incorporation of fluorescently tagged clathrin or its adaptor AP-2; we have also followed clathrin-mediated uptake of transferrin and of single LDL or reovirus particles. The intensity of a cargo-loaded clathrin cluster grows steadily during its lifetime, and the time required to complete assembly is proportional to the size of the cargo particle. These results are consistent with a nucleation-growth mechanism and an approximately constant growth rate. There are no strongly preferred nucleation sites. A proportion of the nucleation events are weak and short lived. Cargo incorporation occurs primarily or exclusively in a newly formed coated pit. Our data lead to a model in which coated pits initiate randomly but collapse unless stabilized, perhaps by cargo capture.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Indian Inst Sci, Dept Comp Sci, Bangalore 560012, Karnataka, India; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Indian Institute of Science (IISC) - Bangalore; Harvard University; Harvard Medical School	Kirchhausen, T (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 200 Longwood Ave, Boston, MA 02115 USA.	kirchhausen@crystal.harvard.edu	van Oijen, Antoine/I-3167-2014; Chandran, Kartik/I-2232-2012	van Oijen, Antoine/0000-0002-1794-5161; Ehrlich, Marcelo/0000-0002-2352-1808	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036548] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36548] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Clairmont KB, 1997, CELL MOL LIFE SCI, V53, P611, DOI 10.1007/s000180050080; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; De Tulleo L, 1998, EMBO J, V17, P4585, DOI 10.1093/emboj/17.16.4585; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Forrest JC, 2003, J BIOL CHEM, V278, P48434, DOI 10.1074/jbc.M305649200; Fujiwara T, 2002, J CELL BIOL, V157, P1071, DOI 10.1083/jcb.200202050; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GOLDSTEIN B, 1981, P NATL ACAD SCI USA, V7, P5695; HANSEN SH, 1992, EXP CELL RES, V199, P19, DOI 10.1016/0014-4827(92)90457-J; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merrifield CJ, 2004, EUR J CELL BIOL, V83, P13, DOI 10.1078/0171-9335-00356; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Musacchio A, 1999, MOL CELL, V3, P761, DOI 10.1016/S1097-2765(01)80008-3; Newmyer SL, 2003, DEV CELL, V4, P929, DOI 10.1016/S1534-5807(03)00157-6; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; PAUL RW, 1989, VIROLOGY, V172, P382, DOI 10.1016/0042-6822(89)90146-3; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Rappoport JZ, 2003, J CELL SCI, V116, P847, DOI 10.1242/jcs.00289; Rappoport JZ, 2003, J BIOL CHEM, V278, P47357, DOI 10.1074/jbc.C300390200; REYNOLDS GD, 1985, AM J PATHOL, V121, P200; RIPLEY BD, 1976, J APPL PROBAB, V13, P255, DOI 10.2307/3212829; SAKO Y, 1994, J CELL BIOL, V125, P1251, DOI 10.1083/jcb.125.6.1251	30	658	671	4	59	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2004	118	5					591	605		10.1016/j.cell.2004.08.017	http://dx.doi.org/10.1016/j.cell.2004.08.017			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	852BN	15339664	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000223730300010
J	Ahima, RS				Ahima, RS			Body fat, leptin, and hypothalamic amenorrhea	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NEUROENDOCRINE		Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA	University of Pennsylvania	Ahima, RS (corresponding author), Univ Penn, Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.		Ahima, Rexford/W-1394-2019					Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Chan JL, 2003, J CLIN INVEST, V111, P1409, DOI 10.1172/JCI200317490; FRISCH RE, 1990, BAILLIERE CLIN OB GY, V4, P419, DOI 10.1016/S0950-3552(05)80302-5; Oral EA, 2002, J CLIN ENDOCR METAB, V87, P3110, DOI 10.1210/jc.87.7.3110	4	36	40	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2004	351	10					959	962		10.1056/NEJMp048214	http://dx.doi.org/10.1056/NEJMp048214			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	850UB	15342803				2022-12-28	WOS:000223637400005
J	Reed, MB; Domenech, P; Manca, C; Su, H; Barczak, AK; Kreiswirth, BN; Kaplan, G; Barry, CE				Reed, MB; Domenech, P; Manca, C; Su, H; Barczak, AK; Kreiswirth, BN; Kaplan, G; Barry, CE			A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response	NATURE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; GENE; SUPPRESSION; COMPLEX; LEPRAE; BIOSYNTHESIS; VIRULENT; FAMILY; MICE	Fifty million new infections with Mycobacterium tuberculosis occur annually, claiming 2 - 3 million lives from tuberculosis worldwide(1). Despite the apparent lack of significant genetic heterogeneity between strains of M. tuberculosis(2,3), there is mounting evidence that considerable heterogeneity exists in molecules important in disease pathogenesis. These differences may manifest in the ability of some isolates to modify the host cellular immune response, thereby contributing to the observed diversity of clinical outcomes(4-7). Here we describe the identification and functional relevance of a highly biologically active lipid species - a polyketide synthase-derived phenolic glycolipid (PGL) produced by a subset of M. tuberculosis isolates belonging to the W-Beijing family(8) that show 'hyperlethality' in murine disease models. Disruption of PGL synthesis results in loss of this hypervirulent phenotype without significantly affecting bacterial load during disease. Loss of PGL was found to correlate with an increase in the release of the pro-inflammatory cytokines tumour-necrosis factor-alpha and interleukins 6 and 12 in vitro. Furthermore, the overproduction of PGL by M. tuberculosis or the addition of purified PGL to monocyte-derived macrophages was found to inhibit the release of these pro-inflammatory mediators in a dose-dependent manner.	NIAID, TB Res Sect, NIH, Rockville, MD 20852 USA; Publ Hlth Res Inst, Lab Mycobacterial Immun & Pathogenesis, Newark, NJ 07103 USA; Publ Hlth Res Inst, TB Ctr, Newark, NJ 07103 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Barry, CE (corresponding author), NIAID, TB Res Sect, NIH, 12441 Parklawn Dr, Rockville, MD 20852 USA.	clifton_barry@nih.gov	Barry, Clifton E/ABE-7992-2020; Barry, III, Clifton/H-3839-2012	Barry, Clifton E/0000-0002-2927-270X; Barry, III, Clifton/0000-0002-2927-270X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054338, Z01AI000783] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline; NIAID NIH HHS [R01 AI054338, R01 AI054338-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bifani PJ, 2002, TRENDS MICROBIOL, V10, P45, DOI 10.1016/S0966-842X(01)02277-6; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Constant P, 2002, J BIOL CHEM, V277, P38148, DOI 10.1074/jbc.M206538200; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002; FOURNIE JJ, 1989, INFECT IMMUN, V57, P3653, DOI 10.1128/IAI.57.11.3653-3659.1989; Gaora PO, 1997, MED PRIN PRACT, V6, P91; GARBE TR, 1994, MICROBIOL-SGM, V140, P133, DOI 10.1099/13500872-140-1-133; Glynn JR, 2002, EMERG INFECT DIS, V8, P843; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Hashimoto K, 2002, INFECT IMMUN, V70, P5167, DOI 10.1128/IAI.70.9.5167-5176.2002; HUNTER SW, 1981, J BACTERIOL, V147, P728, DOI 10.1128/JB.147.3.728-735.1981; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; Manca C, 1999, J IMMUNOL, V162, P6740; Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998; MANCA C, IN PRESS INFECT IMMU; Marmiesse M, 2004, MICROBIOL-SGM, V150, P483, DOI 10.1099/mic.0.26662-0; MEHRA V, 1984, NATURE, V308, P194, DOI 10.1038/308194a0; Ng V, 2000, CELL, V103, P511, DOI 10.1016/S0092-8674(00)00142-2; North RJ, 1999, INFECT IMMUN, V67, P5483, DOI 10.1128/IAI.67.10.5483-5485.1999; Pelicic V, 1997, P NATL ACAD SCI USA, V94, P10955, DOI 10.1073/pnas.94.20.10955; SILVA CL, 1993, INT J LEPROSY, V61, P107; Sirakova TD, 2001, J BIOL CHEM, V276, P16833, DOI 10.1074/jbc.M011468200; Slayden R A, 2001, Methods Mol Med, V54, P229, DOI 10.1385/1-59259-147-7:229; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; Tiruviluamala P, 2002, ANNU REV PUBL HEALTH, V23, P403, DOI 10.1146/annurev.publhealth.23.100901.140519; VACHULA M, 1989, J IMMUNOL, V142, P1696; Valway SE, 1998, NEW ENGL J MED, V338, P633, DOI 10.1056/NEJM199803053381001; Vergne I, 1998, FRONT BIOSCI, V3, pd865	30	570	594	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2004	431	7004					84	87		10.1038/nature02837	http://dx.doi.org/10.1038/nature02837			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343336				2022-12-28	WOS:000223641500046
J	Tanimoto, H; Heisenberg, M; Gerber, B				Tanimoto, H; Heisenberg, M; Gerber, B			Event timing turns punishment to reward	NATURE			English	Editorial Material							SYNAPTIC MODIFICATION; DOPAMINE NEURONS; INHIBITION		Univ Wurzburg, Biozentrum, Lehrstuhl Genet & Neurobiol, D-97074 Wurzburg, Germany	University of Wurzburg	Tanimoto, H (corresponding author), Univ Wurzburg, Biozentrum, Lehrstuhl Genet & Neurobiol, D-97074 Wurzburg, Germany.	hiromut@biozentrum.uni-wuerzburg.de	Tanimoto, Hiromu/J-6810-2016	Gerber, Bertram/0000-0003-3003-0051				Abbott LF, 2000, NAT NEUROSCI, V3, P1178, DOI 10.1038/81453; Bi GQ, 2001, ANNU REV NEUROSCI, V24, P139, DOI 10.1146/annurev.neuro.24.1.139; Froemke RC, 2002, NATURE, V416, P433, DOI 10.1038/416433a; Hellstern F, 1998, LEARN MEMORY, V4, P429, DOI 10.1101/lm.4.5.429; RESCORLA RA, 1965, J COMP PHYSIOL PSYCH, V59, P406, DOI 10.1037/h0022060; Schwaerzel M, 2002, NEURON, V35, P951, DOI 10.1016/S0896-6273(02)00832-2; Schwaerzel M, 2003, J NEUROSCI, V23, P10495, DOI 10.1523/jneurosci.23-33-10495.2003; SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128; Tobler PN, 2003, J NEUROSCI, V23, P10402; Ungless MA, 2004, SCIENCE, V303, P2040, DOI 10.1126/science.1093360; Wagner A.R., 1981, P5	11	126	126	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2004	430	7003					983	983		10.1038/430983a	http://dx.doi.org/10.1038/430983a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329711	Bronze			2022-12-28	WOS:000223514900031
J	Pelling, AE; Sehati, S; Gralla, EB; Valentine, JS; Gimzewski, JK				Pelling, AE; Sehati, S; Gralla, EB; Valentine, JS; Gimzewski, JK			Local nanomechanical motion of the cell wall of Saccharomyces cerevisiae	SCIENCE			English	Article							SPONTANEOUS OSCILLATIONS; MECHANICAL-PROPERTIES; MICROBIAL-CELLS; FORCE; ELASTICITY; MOVEMENT; PULSE	We demonstrate that the cell wall of living Saccharomyces cerevisiae (baker's yeast) exhibits local temperature-dependent nanomechanical motion at characteristic frequencies. The periodic motions in the range of 0.8 to 1.6 kHz with amplitudes of similar to3 nm were measured using the cantilever of an atomic force microscope (AFM). Exposure of the cells to a metabolic inhibitor causes the periodic motion to cease. From the strong frequency dependence on temperature, we derive an activation energy of 58 kj/mol, which is consistent with the cell's metabolism involving molecular motors such as kinesin, dynein, and myosin. The magnitude of the forces observed (similar to10 nN) suggests concerted nanomechanical activity is operative in the cell.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Gimzewski, JK (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	gim@chem.ucla.edu	Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X; Pelling, Andrew/0000-0003-3732-7472; gimzewski, james/0000-0003-4333-6957	NIDDK NIH HHS [DK46828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		A-Hassan E, 1998, BIOPHYS J, V74, P1564, DOI 10.1016/S0006-3495(98)77868-3; Arnoldi M, 2000, PHYS REV E, V62, P1034, DOI 10.1103/PhysRevE.62.1034; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Bowen WR, 2001, J COLLOID INTERF SCI, V237, P54, DOI 10.1006/jcis.2001.7437; Charras GT, 2002, BIOPHYS J, V82, P2970, DOI 10.1016/S0006-3495(02)75638-5; Ding DQ, 1998, J CELL SCI, V111, P701; Domke J, 1999, EUR BIOPHYS J BIOPHY, V28, P179, DOI 10.1007/s002490050198; Doyle T, 1996, P NATL ACAD SCI USA, V93, P3886, DOI 10.1073/pnas.93.9.3886; Gad M, 1997, CELL BIOL INT, V21, P697, DOI 10.1006/cbir.1997.0214; HARRIS CM, 1988, SHOCK VIBRATION HDB; HOH JH, 1994, J CELL SCI, V107, P1105; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; JOHNSTON M, 1992, MOL BIOL YEAST SACCH; Julicher F, 2001, CR ACAD SCI IV-PHYS, V2, P849, DOI 10.1016/S1296-2147(01)01228-8; Julicher F, 1997, PHYS REV LETT, V78, P4510, DOI 10.1103/PhysRevLett.78.4510; KAMIMURA S, 1989, NATURE, V340, P476, DOI 10.1038/340476a0; KASAS S, 1995, BIOPHYS J, V68, P1678, DOI 10.1016/S0006-3495(95)80344-9; Kawaguchi K, 2000, BIOCHEM BIOPH RES CO, V272, P895, DOI 10.1006/bbrc.2000.2856; Kawaguchi K, 2001, CELL MOTIL CYTOSKEL, V49, P41, DOI 10.1002/cm.1019; Levy R, 2002, NANOTECHNOLOGY, V13, P33, DOI 10.1088/0957-4484/13/1/307; Maksym GN, 2000, J APPL PHYSIOL, V89, P1619, DOI 10.1152/jappl.2000.89.4.1619; Rotsch C, 1997, CELL BIOL INT, V21, P685, DOI 10.1006/cbir.1997.0213; Szabo B, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.041910; Touhami A, 2003, LANGMUIR, V19, P4539, DOI 10.1021/la034136x; Vilfan A, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.114101; Yasuda K, 1996, BIOPHYS J, V70, P1823, DOI 10.1016/S0006-3495(96)79747-3; Zhang PC, 2001, NATURE, V413, P428, DOI 10.1038/35096578	27	279	292	4	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	2004	305	5687					1147	1150		10.1126/science.1097640	http://dx.doi.org/10.1126/science.1097640			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326353				2022-12-28	WOS:000223557400046
J	Unniraman, S; Fugmann, SD; Schatz, DG				Unniraman, S; Fugmann, SD; Schatz, DG			UNGstoppable switching	SCIENCE			English	Editorial Material							URACIL-DNA GLYCOSYLASE; SOMATIC HYPERMUTATION; RECOMBINATION		Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University	Unniraman, S (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.	shyam.unniraman@yale.edu; sebastian.fugmann@yale.edu; david.schatz@yale.edu	Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176				Begum NA, 2004, SCIENCE, V305, P1160, DOI 10.1126/science.1098444; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Li ZQ, 2004, GENE DEV, V18, P1, DOI 10.1101/gad.1161904; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0	7	6	6	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2004	305	5687					1113	1114		10.1126/science.1102692	http://dx.doi.org/10.1126/science.1102692			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326342				2022-12-28	WOS:000223557400031
J	van Staaij, BK; van den Akker, EH; Rovers, MM; Hordijk, GJ; Hoes, AW; Schilder, AGM				van Staaij, BK; van den Akker, EH; Rovers, MM; Hordijk, GJ; Hoes, AW; Schilder, AGM			Effectiveness of adenotonsillectomy in children with mild symptoms of throat infections or adenotonsillar hypertrophy: open, randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; OBSTRUCTIVE SLEEP-APNEA; CLINICAL-TRIALS; TONSILLECTOMY; HEALTH; (ADENO)TONSILLECTOMY; IDENTIFICATION; ADENOIDECTOMY; PERSPECTIVE; INSTRUMENT	Objective To assess the effectiveness of adenotonsillectomy in children with mild symptoms of throat infections or adenotonsillar hypertrophy. Design Open, randomised controlled trial. Setting 21 general hospitals and three academic centres in the Netherlands. Participants 300 children aged 2-8 years requiring adenotonsillectomy. Intervention Adenotonsillectomy compared with watchful waiting. Main outcome measures Episodes of fever, throat infections, upper respiratory tract infections, and health related quality of life. Results During the median follow up period of 22 months, children in the adenotonsillectomy group had 2.97 episodes of fever per person year compared with 3.18 in the watchful waiting group (difference -0.21, 95% confidence interval -0.54 to 0.12), 0.56 throat infections per person year compared with 0.77 (-0.21, -0.36 to -0.06), and 5.47 upper respiratory tract infections per person year compared with 6.00 (-0.53, -0.97 to -0.08). No clinically relevant differences were found for health related quality of life. Adenotonsillectomy was more effective in children with a history of three to six throat infections than in those with none to two. 12 children had surgery related complications. Conclusion Adenotonsillectomy in children with mild symptoms of throat infections or adenotonsillar hypertrophy has no major clinical benefits over watchful waiting.	Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Otorhinolaryngol, NL-3508 AB Utrecht, Netherlands; Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 AB Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Otorhinolaryngol Head & Neck Surg, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Schilder, AGM (corresponding author), Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Otorhinolaryngol, POB 85090, NL-3508 AB Utrecht, Netherlands.	A.Schilder@wkz.azu.nl	Rovers, Maroeska/F-2969-2014	Rovers, Maroeska/0000-0002-3095-170X; Schilder, Anne/0000-0002-5496-4580				*AM AC OT HEAD NEC, CLIN IND OT HEAD NEC; *AM AC OT HEAD NEC, 2000, CLIN IND OT HEAD NEC; Blair RL, 1996, J LARYNGOL OTOL, V110, P1; Blais JC, 1996, RAPID COMMUN MASS SP, V10, P1; BROUILETTE R, 1984, J PEDIATR-US, V105, P10, DOI 10.1016/S0022-3476(84)80348-0; Capper R, 2001, CLIN OTOLARYNGOL, V26, P371, DOI 10.1046/j.1365-2273.2001.00485.x; Conlon BJ, 1997, INT J PEDIATR OTORHI, V41, P155, DOI 10.1016/S0165-5876(97)00073-6; de Serres LM, 2000, ARCH OTOLARYNGOL, V126, P1423, DOI 10.1001/archotol.126.12.1423; DONNELLY MJ, 1994, J LARYNGOL OTOL, V108, P131, DOI 10.1017/S0022215100126088; ESKERUD JR, 1992, FAM PRACT, V9, P263, DOI 10.1093/fampra/9.3.263; Faulconbridge RV, 2000, CLIN OTOLARYNGOL, V25, P110; Fekkes M, 2000, QUAL LIFE RES, V9, P961, DOI 10.1023/A:1008981603178; Flanary VA, 2003, LARYNGOSCOPE, V113, P1639, DOI 10.1097/00005537-200310000-00003; Mawson S R, 1968, J Laryngol Otol, V82, P963, DOI 10.1017/S0022215100069747; Mawson S R, 1967, J Laryngol Otol, V81, P777, DOI 10.1017/S0022215100067694; MCKEE WJE, 1963, BRIT J PREV SOC MED, V17, P133; MCKEE WJE, 1963, BRIT J PREV SOC MED, V17, P49; McLeod RS, 1999, WORLD J SURG, V23, P1210, DOI 10.1007/s002689900649; Nieminen P, 2000, ARCH OTOLARYNGOL, V126, P481, DOI 10.1001/archotol.126.4.481; Paradise J.L., 2003, PEDIATRICS, V110, P7; PARADISE JL, 1984, NEW ENGL J MED, V310, P674, DOI 10.1056/NEJM198403153101102; Raat H, 2002, J CLIN EPIDEMIOL, V55, P67, DOI 10.1016/S0895-4356(01)00411-5; SOMAN M, 1985, J FAM PRACTICE, V21, P117; Stewart MG, 2001, ARCH OTOLARYNGOL, V127, P29, DOI 10.1001/archotol.127.1.29; van den Akker EH, 2004, CLIN OTOLARYNGOL, V29, P161, DOI 10.1111/j.0307-7772.2004.00771.x; Van den Akker EH, 2003, ACTA OTO-LARYNGOL, V123, P297, DOI 10.1080/0036554021000028096; van den Akker EH, 2003, INT J PEDIATR OTORHI, V67, P603, DOI 10.1016/S0165-5876(03)00063-6; van der Graaf Y, 1998, EUR J RADIOL, V27, P108, DOI 10.1016/S0720-048X(97)00159-9; van Staaij BK, 2003, INT J PEDIATR OTORHI, V67, P1091, DOI 10.1016/S0165-5876(03)00198-8; Wolfensberger M, 2000, INT J PEDIATR OTORHI, V56, P199, DOI 10.1016/S0165-5876(00)00441-9	30	91	94	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 18	2004	329	7467					651	654		10.1136/bmj.38210.827917.7C	http://dx.doi.org/10.1136/bmj.38210.827917.7C			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	856JU	15361407	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000224042300017
J	Karlawish, JH; Bonnie, RJ; Appelbaum, PS; Lyketsos, C; James, B; Knopman, D; Patusky, C; Kane, RA; Karlan, PS				Karlawish, JH; Bonnie, RJ; Appelbaum, PS; Lyketsos, C; James, B; Knopman, D; Patusky, C; Kane, RA; Karlan, PS			Addressing the ethical, legal, and social issues raised by voting by persons with dementia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVALENCE	This article addresses an emerging policy problem in the United States: participation in the electoral process by citizens with dementia. At present, health care professionals, family caregivers, and long-term care staff lack adequate guidance to decide whether individuals with dementia should be precluded from or assisted in casting a ballot. Voting by persons with dementia raises a series of important questions about the autonomy of individuals with dementia, the integrity of the electoral process, and the prevention of fraud. Three subsidiary issues warrant special attention: development of a method to assess capacity to vote; identification of appropriate kinds of assistance to enable persons with cognitive impairment to vote; and formulation of uniform and workable policies for voting in long-term care settings. In some instances, extrapolation from existing policies and research permits reasonable recommendations to guide policy and practice. However, in other instances, additional research is necessary.	Univ Penn, Inst Aging, Dept Med, Ctr Bioeth, Philadelphia, PA 19104 USA; Univ Penn, Fels Inst Govt, Philadelphia, PA 19104 USA; Univ Virginia, Sch Law, Charlottesville, VA 22903 USA; Univ Virginia, Sch Med, Charlottesville, VA 22908 USA; Univ Virginia, Inst Law Psychiat & Publ Policy, Charlottesville, VA USA; Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA; Johns Hopkins Univ, Dept Psychiat, Div Geriatr Psychiat & Neuropsychiat, Baltimore, MD USA; Mayo Clin, Dept Neurol, Alzheimers Dis Res Ctr, Rochester, MN USA; Univ Minnesota, Sch Publ Hlth, Long Term Care Resources Ctr, Minneapolis, MN USA; Stanford Univ, Sch Law, Stanford, CA 94305 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Virginia; University of Virginia; University of Virginia; University of Massachusetts System; University of Massachusetts Worcester; Johns Hopkins University; Mayo Clinic; University of Minnesota System; University of Minnesota Twin Cities; Stanford University	Karlawish, JH (corresponding author), Univ Penn, Inst Aging, Dept Med, Ctr Bioeth, 3615 Chestnut St, Philadelphia, PA 19104 USA.	jasonkar@mail.med.upenn.edu		James, Bryan/0000-0003-1932-151X	NIA NIH HHS [U19 AG010483] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U19AG010483] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*ADM AG, OLD AM MONTH; ALVAREZ M, 2003, ABSENTEE VOTES COUNT; Appelbaum PS, 2000, MACARTHUR COMPETENCE; Buchanan Allen E., 1989, DECIDING OTHERS ETHI; *FED EL COMM, NAT REG FORM; *FED EL COMM, FED EL 2000 EL RES U; Goffman E., 1961, ASYLUMS; Grisso T, 1998, MACARTHUR COMPETENCE; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; HISCHMAN KB, 2004, J GERIATR PSYCHIA NE, V17, P55; ISSACHAROFF S, 2001, LAW DEMOCRACY LEGAL; Karlawish JHT, 2002, NEUROLOGY, V58, P1100, DOI 10.1212/WNL.58.7.1100; Karlawish JHT, 2001, NEUROLOGY, V56, P789, DOI 10.1212/WNL.56.6.789; Keyssar, 2009, RIGHT VOTE CONTESTED; Magaziner J, 2000, GERONTOLOGIST, V40, P663, DOI 10.1093/geront/40.6.663; OSULLIVAN JL, 2002, J HLTH CARE LAW POLI, V4, P325; Ott BR, 2003, NEUROLOGY, V60, P1546, DOI 10.1212/01.WNL.0000061481.46191.75; PRESLEY SA, 2000, WASHINGTON POST 0103, pA1; risso T, 2002, EVALUATING COMPETENC, P309; ROSENBLATT A, IN PRESS J AM GERIAT; SALES BD, 1982, DISABLED PERSONS LAW, V1, P99; SHERMAN J, 2004, LONDON TIMES    0611, P11; *TASK FORC NAT COM, 2001, TASK FORC REP ACC RE; TATE A, 2000, CHICAGO REPORTER NOV, V29, P10; *U PENNS ALZH DIS, DEV PRACT GUID VOT P; 2000, ALZHEIMER PAGE; 2001, FED REG, V66, P512; 2001, NEWSDAY         0812, pA22	28	45	46	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2004	292	11					1345	1350		10.1001/jama.292.11.1345	http://dx.doi.org/10.1001/jama.292.11.1345			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853YL	15367557	Green Submitted			2022-12-28	WOS:000223866800027
J	Rouault, TA				Rouault, TA			Pathogenic bacteria prefer heme	SCIENCE			English	Editorial Material							STAPHYLOCOCCUS-AUREUS; IRON; ACQUISITION		NICHHD, Sect Human Iron Metab, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Rouault, TA (corresponding author), NICHHD, Sect Human Iron Metab, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.	trou@helix.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001602] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001602] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Andrews SC, 2003, FEMS MICROBIOL REV, V27, P215, DOI 10.1016/S0168-6445(03)00055-X; Boyd PW, 2004, NATURE, V428, P549, DOI 10.1038/nature02437; Braun V, 2003, FRONT BIOSCI-LANDMRK, V8, pS1409, DOI 10.2741/1232; BRITTENHAM GM, 1994, IRON METABOLISM HLTH, P31; CORNELISSEN CN, 1994, MOL MICROBIOL, V14, P843, DOI 10.1111/j.1365-2958.1994.tb01320.x; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672; LEE BC, 1995, MOL MICROBIOL, V18, P383, DOI 10.1111/j.1365-2958.1995.mmi_18030383.x; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; Mills MM, 2004, NATURE, V429, P292, DOI 10.1038/nature02550; NISHINA Y, 1992, INFECT IMMUN, V60, P2128, DOI 10.1128/IAI.60.5.2128-2132.1992; Rohde KH, 2003, FRONT BIOSCI-LANDMRK, V8, pD1186, DOI 10.2741/1133; Schneeberg Norman G, 2002, Trans Stud Coll Physicians Phila, V24, P157; Skaar EP, 2004, SCIENCE, V305, P1626, DOI 10.1126/science.1099930; Skaar EP, 2004, J BIOL CHEM, V279, P436, DOI 10.1074/jbc.M307952200; Walczyk T, 2002, SCIENCE, V295, P2065, DOI 10.1126/science.1069389	16	57	60	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2004	305	5690					1577	1578		10.1126/science.1102975	http://dx.doi.org/10.1126/science.1102975			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361615				2022-12-28	WOS:000223891200031
J	Lindholt, JS				Lindholt, JS			Endovascular aneurysm repair	LANCET			English	Editorial Material							ABDOMINAL AORTIC-ANEURYSMS; TRIAL		Viborg Hosp, Dept Vasc Surg, Vasc Res Unit, DK-8800 Viborg, Denmark	Aarhus University	Lindholt, JS (corresponding author), Viborg Hosp, Dept Vasc Surg, Vasc Res Unit, DK-8800 Viborg, Denmark.	Jes.S.Lindholt@Syghusviborg.dk	Lindholt, Jes/J-2907-2014	Lindholt, Jes/0000-0001-9536-4488				Adriaensen MEAPM, 2002, RADIOLOGY, V224, P739, DOI 10.1148/radiol.2243011675; Harris Peter L, 2004, Vascular, V12, P33; Harris PL, 2000, J VASC SURG, V32, P739, DOI 10.1067/mva.2000.109990; LINDHOLT JS, 1998, THESIS FADLS FORLAG, P63; *NAT I CLIN EXC, 2001, TECHN APPR PROC SER, V5; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; Powell JT, 1998, LANCET, V352, P1649; Prinssen M, 2004, EUR J VASC ENDOVASC, V27, P121, DOI 10.1016/j.ejvs.2003.11.006; Prinssen M, 2002, J CARDIOVASC SURG, V43, P379	9	4	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	2004	364	9437					818	820		10.1016/S0140-6736(04)16993-6	http://dx.doi.org/10.1016/S0140-6736(04)16993-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351170				2022-12-28	WOS:000223685200004
J	Wu, P; Jiang, TX; Suksaweang, S; Widelitz, RB; Chuong, CM				Wu, P; Jiang, TX; Suksaweang, S; Widelitz, RB; Chuong, CM			Molecular shaping of the beak	SCIENCE			English	Article							FACE; EVOLUTION; OUTGROWTH	Beak shape is a classic example of evolutionary diversification. Beak development in chicken and duck was used to examine morphological variations among avian species. There is only one proliferative zone in the frontonasal mass of chickens, but two in ducks. These growth zones are associated with bone morphogenetic protein 4 (BMP4) activity. By "tinkering" with BMP4 in beak prominences, the shapes of the chicken beak can be modulated.	Univ So Calif, Dept Pathol, Keck Sch Med, Los Angeles, CA 90033 USA	University of Southern California	Chuong, CM (corresponding author), Univ So Calif, Dept Pathol, Keck Sch Med, 2011 Zonal Ave,HMR 315B, Los Angeles, CA 90033 USA.	chuong@pathfinder.usc.edu		Suksaweang, Sanong/0000-0002-0142-5911	NCI NIH HHS [CA83716, R01 CA083716] Funding Source: Medline; NIAMS NIH HHS [R01 AR042177-10, R01 AR047364-02, R01 AR047364-03, R01 AR047364, R01 AR047364-01A2, AR42177, R01 AR042177-07, R01 AR042177-09, AR47364, R01 AR042177-08S1, R01 AR042177, R01 AR042177-08, R01 AR042177-07S1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047364, R01AR042177] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abzhanov A, 2004, SCIENCE, V305, P1462, DOI 10.1126/science.1098095; Ashique AM, 2002, DEVELOPMENT, V129, P4647; Ashique AM, 2002, INT J DEV BIOL, V46, P243; FEDUCCIA A, 1999, ORIGIN EVOLUTION BIR, P93; FRANCISWEST PH, 1994, DEV DYNAM, V201, P168, DOI 10.1002/aja.1002010207; Grant PR, 2002, SCIENCE, V296, P707, DOI 10.1126/science.1070315; Helms JA, 2003, NATURE, V423, P326, DOI 10.1038/nature01656; Hu D, 2003, DEVELOPMENT, V130, P1749, DOI 10.1242/dev.00397; MacDonald ME, 2004, DEV DYNAM, V230, P335, DOI 10.1002/dvdy.20041; Richman JM, 2003, BIOESSAYS, V25, P554, DOI 10.1002/bies.10288; von Dassow G, 1999, J EXP ZOOL, V285, P307, DOI 10.1002/(SICI)1097-010X(19991215)285:4<307::AID-JEZ2>3.3.CO;2-M	11	194	209	2	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1465	1466		10.1126/science.1098109	http://dx.doi.org/10.1126/science.1098109			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353803	Green Accepted			2022-12-28	WOS:000223761900049
J	Annas, GJ; Elias, S				Annas, GJ; Elias, S			Politics, morals and embryos	NATURE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02118 USA; Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA	Boston University; Northwestern University; Feinberg School of Medicine	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, 715 Albany St, Boston, MA 02118 USA.			Annas, George/0000-0001-5836-7831				Annas GJ, 1996, NEW ENGL J MED, V334, P1329, DOI 10.1056/NEJM199605163342012; ANNAS GJ, IN PRESS AM BIOETHIC; [Anonymous], 2004, BIOTECHNOLOGY RES AG; *BRIT MED ASS, 2001, MED PROF HUM RIGHTS; Charo RA, 2004, J LAW MED ETHICS, V32, P307, DOI 10.1111/j.1748-720X.2004.tb00477.x; Fuller L., 1969, MORALITY LAW	6	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2004	431	7004					19	20		10.1038/431019a	http://dx.doi.org/10.1038/431019a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343308	Green Published			2022-12-28	WOS:000223641500018
J	Hughes, KS; Schnaper, LA; Berry, D; Cirrincione, C; McCormick, B; Shank, B; Wheeler, J; Champion, LA; Smith, TJ; Smith, BL; Shapiro, C; Muss, HB; Winer, E; Hudis, C; Wood, W; Sugarbaker, D; Henderson, I C; Norton, L				Hughes, KS; Schnaper, LA; Berry, D; Cirrincione, C; McCormick, B; Shank, B; Wheeler, J; Champion, LA; Smith, TJ; Smith, BL; Shapiro, C; Muss, HB; Winer, E; Hudis, C; Wood, W; Sugarbaker, D; Henderson, I C; Norton, L		Canc Leukemia Grp B; Radiation Therapy Oncology Grp; Eastern Cooperative Oncology Grp	Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; CONSERVATIVE SURGERY; RADIATION-THERAPY; CLINICAL-TRIALS; RANDOMIZED-TRIAL; TOTAL MASTECTOMY; CARCINOMA	BACKGROUND: In women 70 years of age or older who have early breast cancer, it is unclear whether lumpectomy plus tamoxifen is as effective as lumpectomy followed by tamoxifen plus radiation therapy. METHODS: Between July 1994 and February 1999, we randomly assigned 636 women who were 70 years of age or older and who had clinical stage I (T1N0M0 according to the tumor-node-metastasis classification), estrogen-receptor-positive breast carcinoma treated by lumpectomy to receive tamoxifen plus radiation therapy (317 women) or tamoxifen alone (319 women). Primary end points were the time to local or regional recurrence, the frequency of mastectomy for recurrence, breast-cancer-specific survival, the time to distant metastasis, and overall survival. RESULTS: The only significant difference between the two groups was in the rate of local or regional recurrence at five years (1 percent in the group given tamoxifen plus irradiation and 4 percent in the group given tamoxifen alone, P<0.001). There were no significant differences between the two groups with regard to the rates of mastectomy for local recurrence, distant metastases, or five-year rates of overall survival (87 percent in the group given tamoxifen plus irradiation and 86 percent in the tamoxifen group, P=0.94). Assessment by physicians and patients of cosmetic results and adverse events uniformly rated tamoxifen plus irradiation inferior to tamoxifen alone. CONCLUSIONS: Lumpectomy plus adjuvant therapy with tamoxifen alone is a realistic choice for the treatment of women 70 years of age or older who have early, estrogen-receptor-positive breast cancer.	Massachusetts Gen Hosp, Div Surg Oncol, Avon Comprehens Breast Evaluat Ctr, Breast Ovarian Canc Genet & Risk Assessment Progr, Boston, MA 02114 USA; Greater Baltimore Med Ctr, Baltimore, MD USA; Canc & Leukemia Grp B Stat Ctr, Durham, NC USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Mt Sinai Sch Med, New York, NY USA; Sutter Hlth, Alta Bates Comprehens Canc Ctr, Berkeley, CA USA; Morristown Mem Hosp, Morristown, NJ USA; Ohio State Univ, Columbus, OH 43210 USA; Univ Vermont, Burlington, VT USA; Dana Farber Partners Canc Ctr, Boston, MA USA; Emory Univ, Sch Med, Atlanta, GA USA; Univ Calif San Francisco, Mountain View, CA USA	Harvard University; Massachusetts General Hospital; Greater Baltimore Medical Center; Memorial Sloan Kettering Cancer Center; Icahn School of Medicine at Mount Sinai; Atlantic Health System; University System of Ohio; Ohio State University; University of Vermont; Harvard University; Dana-Farber Cancer Institute; Emory University; University of California System; University of California San Francisco	Hughes, KS (corresponding author), Massachusetts Gen Hosp, Div Surg Oncol, Avon Comprehens Breast Evaluat Ctr, Breast Ovarian Canc Genet & Risk Assessment Progr, 100 Blossom St,Cox 626, Boston, MA 02114 USA.	kshughes@partners.org	Hughes, Kevin/Q-3578-2018; Hudis, Clifford/AAW-9482-2021	Hughes, Kevin/0000-0003-4084-6484; Hudis, Clifford/0000-0001-7144-8791; Mc Cormick, Beryl/0000-0002-4550-0565; Norton, Larry/0000-0003-3701-9250; Smith, Thomas/0000-0003-3040-6434	NCI NIH HHS [CA02599, CA03927, CA08025, CA11789, CA12449, CA32291, CA33601, CA31983, CA35279, CA37135, CA21060, CA26806, CA41287, CA47545, CA04326, CA47555, CA47559, CA04457, CA31946, CA47577, CA60138, CA74811, CA77298, CA07968, CA77406, CA77440, CA77651, CA77658, CA12046] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA060138, U10CA011789, U10CA041287, U10CA037135, U10CA007968, U10CA047577, U10CA026806, U10CA047559, U10CA047545, U10CA077651, U10CA004326, U10CA031946, U10CA008025, U10CA035279, U10CA002599, U10CA031983, U10CA077298, U10CA004457, U10CA033601, U10CA012046, U10CA074811, U10CA047555, U10CA012449, U10CA077658, U10CA032291, U10CA003927, U10CA077406, U10CA021060] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON RN, 1999, NATAL VITAL STAT REP, V47; *BUR CENS, 1997, CURR POP REP P70, V61; Early Breast Canc Trialists Collaborat, 2000, LANCET, V355, P1757, DOI 10.1016/S0140-6736(00)02263-7; FISHER B, 1994, WORLD J SURG, V18, P63, DOI 10.1007/BF00348193; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102; GRAYDON JE, 1994, J ADV NURS, V19, P617, DOI 10.1111/j.1365-2648.1994.tb01131.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNUTH DE, 1997, ART COMPUTER PROGRAM, V2, P32; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LICHTER AS, 1992, J CLIN ONCOL, V10, P976, DOI 10.1200/JCO.1992.10.6.976; MCCREADY DR, 1992, CAN J SURG, V35, P641; MCCREADY DR, 1992, CAN J SURG, V35, P485; NEMOTO T, 1991, CANCER, V67, P2079, DOI 10.1002/1097-0142(19910415)67:8<2079::AID-CNCR2820670812>3.0.CO;2-S; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; ROSE MA, 1989, ARCH SURG-CHICAGO, V124, P153; STABLIEN DM, 1994, FINAL REPORT REANALY; Stewart HJ, 1996, BRIT J CANCER, V74, P297, DOI 10.1038/bjc.1996.356; WAZER DE, 1992, J CLIN ONCOL, V10, P356, DOI 10.1200/JCO.1992.10.3.356; Whelan TJ, 2000, CANCER-AM CANCER SOC, V88, P2260, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2260::AID-CNCR9>3.3.CO;2-D; WOLMARK N, 2000, P AN M AM SOC CLIN, V19, pA70	22	705	728	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2004	351	10					971	977		10.1056/NEJMoa040587	http://dx.doi.org/10.1056/NEJMoa040587			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	850UB	15342805	Green Submitted, Green Published			2022-12-28	WOS:000223637400007
J	Smith, GCS; Wood, AM; Pell, JP; White, IR; Crossley, JA; Dobbie, R				Smith, GCS; Wood, AM; Pell, JP; White, IR; Crossley, JA; Dobbie, R			Second-trimester maternal serum levels of alpha-fetoprotein and the subsequent risk of sudden infant death syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SCOTLAND; WEIGHT; BIRTH; FETAL	BACKGROUND: Unexplained stillbirth and the sudden infant death syndrome (SIDS) share some features. A raised maternal serum level of alpha-fetoprotein during the second trimester of pregnancy is a marker of placental dysfunction and a strong predictor of the risk of unexplained stillbirth. It is unknown whether alpha-fetoprotein levels also predict the risk of SIDS. METHODS: We linked a prenatal-screening database for women in western Scotland with databases of maternity, perinatal death, and birth and death certifications to assess the association between second-trimester levels of maternal serum alpha-fetoprotein and the subsequent risk of SIDS. RESULTS: Among 214,532 women with singleton births, there were 114 cases of SIDS (incidence, 2.7 per 10,000 births among women with alpha-fetoprotein levels in the lowest quintile and 7.5 per 10,000 births among those with levels in the highest quintile). When the lowest quintile was used as a referent, the unadjusted odds ratios for SIDS for the second through fifth quintiles were 1.7 (95 percent confidence interval, 0.8 to 3.5), 1.8 (95 percent confidence interval, 0.9 to 3.7), 2.5 (95 percent confidence interval, 1.3 to 4.8), and 2.8 (95 percent confidence interval, 1.4 to 5.4), respectively (P for trend = 0.001). The risk of SIDS varied inversely with the birth-weight percentile and the gestational age at delivery; after adjustment for these factors, the odds ratios for SIDS were 1.7 (95 percent confidence interval, 0.8 to 3.5), 1.7 (95 percent confidence interval, 0.8 to 3.5), 2.2 (95 percent confidence interval, 1.1 to 4.4), and 2.2 (95 percent confidence interval, 1.1 to 4.3), respectively (P for trend = 0.01). CONCLUSIONS: There is a direct association between second-trimester maternal serum alpha-fetoprotein levels and the risk of SIDS, which may be mediated in part through impaired fetal growth and preterm birth.	Univ Cambridge, Dept Obstet & Gynaecol, Cambridge, England; Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England; Greater Glasgow Hlth Board, Dept Publ Hlth, Glasgow, Lanark, Scotland; Yorkhill Natl Hlth Serv Trust, Inst Med Genet, Glasgow, Lanark, Scotland; Common Serv Agcy, Informat & Stat Div, Edinburgh, Midlothian, Scotland	University of Cambridge; MRC Biostatistics Unit; University of Cambridge; University of Glasgow	Smith, GCS (corresponding author), Univ Cambridge, Rosie Matern Hosp, Dept Obstet & Gynaecol, Robinson Way, Cambridge CB2 2QQ, England.	gcss2@cam.ac.uk	Smith, Gordon/A-8070-2008; Wood, Angela/GZA-5762-2022	Smith, Gordon/0000-0003-2124-0997; Wood, Angela/0000-0002-7937-304X; White, Ian/0000-0002-6718-7661; Pell, Jill/0000-0002-8898-7035				Alm B, 2001, ARCH DIS CHILD, V84, P24, DOI 10.1136/adc.84.1.24; Brooke H, 1997, BMJ-BRIT MED J, V314, P1516, DOI 10.1136/bmj.314.7093.1516; CAMPBELL S, 1993, ULTRASOUND OBST GYN, P1431; COLE SK, 1980, PERINATAL AUDIT SURV, P39; Crossley J A, 1994, J Med Screen, V1, P180; *CROWN OFF, 1998, DEATH PROC FISC; EVANS E, 1990, CLIN APPL ULTRASONIC; Fifer WP, 2002, SEMIN PERINATOL, V26, P89, DOI 10.1053/sper.2002.29854; HANSON M, 1994, ADV EXP MED BIOL, V360, P99; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; *INF STAT DIV NHS, 2001, SCOTT PER INF MORT R; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; MCLOONE P, 1994, BRIT MED J, V309, P1465, DOI 10.1136/bmj.309.6967.1465; Mizejewski GJ, 2001, EXP BIOL MED, V226, P377, DOI 10.1177/153537020122600503; Neveux LM, 1996, PRENATAL DIAG, V16, P1115, DOI 10.1002/(SICI)1097-0223(199612)16:12<1115::AID-PD3>3.0.CO;2-6; Sadler DW, 1998, J CLIN PATHOL, V51, P689, DOI 10.1136/jcp.51.9.689; Shinozuka N, 2000, AM J PHYSIOL-HEART C, V278, pH41, DOI 10.1152/ajpheart.2000.278.1.H41; Smith GCS, 2000, AM J EPIDEMIOL, V151, P614, DOI 10.1093/oxfordjournals.aje.a010249; Sullivan FM, 2002, PAEDIATR PERINAT EP, V16, P96; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R; WALLER DK, 1993, EPIDEMIOLOGY, V4, P471, DOI 10.1097/00001648-199309000-00014; Waller DK, 1996, OBSTET GYNECOL, V88, P816; WALSH S, 1995, MED HYPOTHESES, V45, P73, DOI 10.1016/0306-9877(95)90206-6	23	29	32	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2004	351	10					978	986		10.1056/NEJMoa040963	http://dx.doi.org/10.1056/NEJMoa040963			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	850UB	15342806				2022-12-28	WOS:000223637400008
J	Caldwell, PHY; Murphy, SB; Butow, PN; Craig, JC				Caldwell, PHY; Murphy, SB; Butow, PN; Craig, JC			Clinical trials in children	LANCET			English	Review							RANDOMIZED CONTROLLED-TRIALS; COOPERATIVE-ONCOLOGY-GROUP; PLACEBO-CONTROLLED TRIALS; INFORMED-CONSENT; PHYSICIAN PARTICIPATION; BREAST-CANCER; LYMPHOBLASTIC-LEUKEMIA; RECRUITING MINORITIES; CHILDHOOD-CANCER; PARENTS	The imperative to undertake randomised trials in children arises from extraordinary advances in basic biomedical sciences, needing a matching commitment to translational research if child health is to reap the benefits from this new knowledge. Unfortunately, many prescribed treatments for children have not been adequately tested in children, sometimes resulting in harmful treatments being given and beneficial treatments being withheld. Government, industry, funding agencies, and clinicians are responsible for research priorities being adult-focused because of the greater burden of disease in adults, coupled with financial and marketing considerations. This bias has meant that the equal rights of children to participate in trials has not always been recognised. This is changing, however, as the need for clinical trials in children has been increasingly recognised by the scientific community and broader public, leading to new legislation in some countries making trials of interventions mandatory in children as well as adults before drug approval is given. Trials in children are more challenging than those in adults. The pool of eligible children entering trials is often small because many conditions are uncommon in children, and the threshold for gaining consent is often higher and more complex because parents have to make decisions about trial participation on behalf of their child. Uncertain about what is best, despite supporting the notion of trials in principle, parents and paediatricians generally opt for the new intervention or for standard care rather than trial participation. In this review, we explore issues relating to trial participation for children and suggest some strategies for improving the conduct of clinical trials involving children.	Childrens Hosp Westmead, Ctr Kidney Res, Sydney, NSW 2145, Australia; Univ Sydney, Dept Paediat & Child Hlth, Sydney, NSW 2006, Australia; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Univ Sydney, Sch Psychol, Sydney, NSW 2006, Australia; Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney; University of Texas System; University of Texas Health San Antonio; University of Sydney; University of Sydney	Caldwell, PHY (corresponding author), Childrens Hosp Westmead, Ctr Kidney Res, Locked Bag 4001, Sydney, NSW 2145, Australia.	Patrinac@chw.edu.au	Craig, Jonathan/E-2813-2013; Caldwell, Patrina/C-4211-2013	Craig, Jonathan/0000-0002-2548-4035; Caldwell, Patrina/0000-0003-1124-6578				*AM AC PED, GUID ETH COND STUD E; Anderson B J, 1999, Paediatr Drugs, V1, P93, DOI 10.2165/00128072-199901020-00003; BENSON AB, 1991, J CLIN ONCOL, V9, P2067, DOI 10.1200/JCO.1991.9.11.2067; Bleyer WA, 1996, J NATL CANCER I, V88, P377, DOI 10.1093/jnci/88.6.377; BOTSTEIN P, 1995, FDA ENCOURAGING DRUG; BROOME ME, CHILDRENS ASSENT CLI; Caldwell PHY, 2003, J PEDIATR-US, V142, P554, DOI 10.1067/mpd.2003.192; Caldwell PHY, 2002, J PEDIATR-US, V141, P798, DOI 10.1067/mpd.2002.129173; Campbell H, 1998, ARCH DIS CHILD, V79, P192, DOI 10.1136/adc.79.2.192; CHANG RW, 1990, J BONE JOINT SURG AM, V72A, P1451, DOI 10.2106/00004623-199072100-00004; CHESSELLS JM, 1992, BLOOD REV, V6, P193, DOI 10.1016/0268-960X(92)90015-I; CHESSELLS JM, 1995, LANCET, V345, P143, DOI 10.1016/S0140-6736(95)90164-7; Childhood Asthma Management Program Res Grp, 1999, J ASTHMA, V36, P217; *CLIN PHARM THER, 1999, 100 ANN M AM SOC CLI; Cohen SN, 1999, PEDIATRICS, V104, P644; COLLET JP, 1991, THERAPIE, V46, P139; DAVIS S, 1985, CANCER-AM CANCER SOC, V56, P1710, DOI 10.1002/1097-0142(19851001)56:7<1710::AID-CNCR2820560741>3.0.CO;2-T; Dickert N, 1999, NEW ENGL J MED, V341, P198, DOI 10.1056/NEJM199907153410312; Dobson R., 2002, BMJ-BRIT MED J, V325, P796; ELLIS P, 1999, CANC FORUM, V23, P153; Ellis PM, 1999, AUST NZ J SURG, V69, P486, DOI 10.1046/j.1440-1622.1999.01608.x; Ellis PM, 1999, BREAST, V8, P182, DOI 10.1054/brst.1999.0036; *EUR, ETH RUL FP6; Fallowfield L, 1997, EUR J CANCER, V33, P2221, DOI 10.1016/S0959-8049(97)00253-0; Featherstone K, 1998, BRIT MED J, V317, P1177, DOI 10.1136/bmj.317.7167.1177; Halpern SD, 2002, J GEN INTERN MED, V17, P689, DOI 10.1046/j.1525-1497.2002.11024.x; Harth SC, 1995, SOC SCI MED, V41, P1647, DOI 10.1016/0277-9536(95)00058-F; Hayman RM, 2001, J PAEDIATR CHILD H, V37, P51, DOI 10.1046/j.1440-1754.2001.00612.x; ICH Steering Committee, 1996, ICH HARM TRIP GUID G; *INT C HARM, ICH TOP E11 CLIN INV; JANOFSKY J, 1981, J PEDIATR-US, V98, P842, DOI 10.1016/S0022-3476(81)80865-7; Jong GW, 2001, LANCET, V357, P398, DOI 10.1016/S0140-6736(05)71537-3; KAUFFMAN RE, 1995, PEDIATRICS, V95, P286; Kauffman RE, 1999, PEDIATRICS, V104, P603; Kaufman JL, 2002, NEW ENGL J MED, V346, P2093; Kopelman LM, 2000, J MED PHILOS, V25, P745; LAMPRILL J, 1999, TRIALS PAEDIAT MED C; Langley JM, 1998, CLIN INVEST MED, V21, P12; Levene M, 1996, LANCET, V347, P475, DOI 10.1016/S0140-6736(96)90054-9; McCaskill-Stevens W, 1999, J CLIN ONCOL, V17, P1029, DOI 10.1200/JCO.1999.17.3.1029; Meaux J B, 2001, Issues Compr Pediatr Nurs, V24, P241; *MED RES COUNC, GEN PRACT RES FRAM; Medical Research Council, 1991, ETH COND RES CHILDR; Miller FG, 2003, NEW ENGL J MED, V348, P1383, DOI 10.1056/NEJMsb030228; Miller FG, 2003, J PEDIATR-US, V142, P102, DOI 10.1067/mpd.2003.43; MORROW GR, 1994, CANCER, V74, P2676, DOI 10.1002/cncr.1994.2820740918; MURPHY SB, 1995, MED PEDIATR ONCOL, V24, P279, DOI 10.1002/mpo.2950240502; MURPHY SB, 2001, J PEDIAT HEMATOL ONC, V3, P546; NAHATA MC, 1997, LICENSING MED CHILDR; National Cancer Institute, CENTR I REV BOARD IN; National Institutes of Health, NIH POL GUID INCL CH; NORDENBERG N, 1999, FDA CONSUMER MAGAZIN, P33; Normand C, 2000, ARCH DIS CHILD, V82, P177; PEART N, 2000, CURR LEGAL ISSUES, V3, P421; PETO V, 1993, FAM PRACT, V10, P207, DOI 10.1093/fampra/10.2.207; *RACP, PAED POL ETH RES CHI; Ries L.A.G., 1999, CANC INCIDENCE SURVI; Roberts R, 2003, JAMA-J AM MED ASSOC, V290, P905, DOI 10.1001/jama.290.7.905; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; Ross JA, 1996, CANCER, V77, P201, DOI 10.1002/(SICI)1097-0142(19960101)77:1<201::AID-CNCR32>3.0.CO;2-7; Ross LF, 2003, J PEDIATR-US, V142, P108, DOI 10.1067/mpd.2003.84; Ross LF, 2001, JAMA-J AM MED ASSOC, V286, P3076; ROSS LF, 2003, AM J LAW MED; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; Schmidt B, 1999, J PEDIATR-US, V134, P151, DOI 10.1016/S0022-3476(99)70428-2; SEGELOV E, 1992, ANN ONCOL, V3, P103, DOI 10.1093/oxfordjournals.annonc.a058119; Shuster E, 1997, NEW ENGL J MED, V337, P1436, DOI 10.1056/NEJM199711133372006; SILVERMAN WA, 1956, PEDIATRICS, V18, P614; Simar MR, 2000, DRUG INF J, V34, P809, DOI 10.1177/009286150003400317; Siminoff LA, 2000, J CLIN ONCOL, V18, P1203, DOI 10.1200/JCO.2000.18.6.1203; Simone JV, 1998, J CLIN ONCOL, V16, P2904, DOI 10.1200/JCO.1998.16.9.2904; Smith Lynn, 2002, JONAS Healthc Law Ethics Regul, V4, P104, DOI 10.1097/00128488-200212000-00004; Smyth RL, 1999, LANCET, V354, pS21; Smyth RL, 2001, BRIT MED J, V322, P1377, DOI 10.1136/bmj.322.7299.1377; Snowdon C, 1997, SOC SCI MED, V45, P1337, DOI 10.1016/S0277-9536(97)00063-4; Steinbrook R, 2002, NEW ENGL J MED, V347, P1462, DOI 10.1056/NEJMhpr021646; STILLER CA, 1990, BRIT J CANCER, V62, P806, DOI 10.1038/bjc.1990.383; SWANSON GM, 1995, J NATL CANCER I, V87, P1747, DOI 10.1093/jnci/87.23.1747; Tait AR, 2003, ANESTHESIOLOGY, V99, P819, DOI 10.1097/00000542-200310000-00012; Tait AR, 2003, ANESTHESIOLOGY, V98, P603, DOI 10.1097/00000542-200303000-00005; TARNOWSKI KJ, 1990, PEDIATRICS, V85, P58; TAYLOR KM, 1992, SOC SCI MED, V35, P217, DOI 10.1016/0277-9536(92)90169-Q; TAYLOR KM, 1994, J CLIN ONCOL, V12, P1796, DOI 10.1200/JCO.1994.12.9.1796; TAYLOR KM, 1985, CANCER TREAT REP, V69, P1095; TAYLOR KM, 1987, J HEALTH SOC BEHAV, V28, P389, DOI 10.2307/2136792; TAYLOR KM, 1992, ANN OPHTHALMOL, V24, P337; TAYLOR KM, 1984, NEW ENGL J MED, V310, P1363, DOI 10.1056/NEJM198405243102106; TAYLOR KM, 1987, CANCER, V60, P1415, DOI 10.1002/1097-0142(19870915)60:6<1415::AID-CNCR2820600641>3.0.CO;2-2; Tercyak KP, 1998, DIABETES CARE, V21, P213, DOI 10.2337/diacare.21.2.213; THONG YH, 1991, PEDIATRICS, V87, P568; Turner S, 1998, BRIT MED J, V316, P343, DOI 10.1136/bmj.316.7128.343; van Stuijvenberg M, 1998, ARCH DIS CHILD, V79, P120, DOI 10.1136/adc.79.2.120; VIST GE, 2001, COCHRANE LIB; WALTERSPIEL JN, 1990, PEDIATRICS, V85, P119; WEISE KL, NATL PRACTICES REGAR; Welton AJ, 1999, BRIT MED J, V318, P1114, DOI 10.1136/bmj.318.7191.1114; Wendler D, 2002, J PEDIATR-US, V141, P166, DOI 10.1067/mpd.2002.124381; Wiley FM, 1999, CANCER PRACT, V7, P248, DOI 10.1046/j.1523-5394.1999.75010.x; Wilson JT, 1999, PEDIATRICS, V104, P585; World Medical Association, WORLD MED ASS DECL H; ZIMMERMAN R, 2001, WALL STREET J   0205; Zupancic JAF, 1997, PEDIATRICS, V99, pE61; 1991, J NATL CANC I, V83; 2003, FDA CONSUMER MAG JAN	104	315	317	1	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	2004	364	9436					803	811		10.1016/S0140-6736(04)16942-0	http://dx.doi.org/10.1016/S0140-6736(04)16942-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337409				2022-12-28	WOS:000223569600034
J	Sharp, D				Sharp, D			As we said ...	LANCET			English	Editorial Material							SELF-CITATION		The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							AKSNES DW, 2002, 7 NORD WORKSH BIBL R; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Craddock N, 1996, BRIT MED J, V313, P1659, DOI 10.1136/bmj.313.7072.1659; Gami AS, 2004, CAN MED ASSOC J, V170, P1925, DOI 10.1503/cmaj.1031879; GARFIELD E, 1963, AM DOC, V14, P195, DOI 10.1002/asi.5090140304; Garfield E., 1992, SCI PUBL POLICY, V19, P321, DOI [DOI 10.1093/SPP/19.5.321, 10.1093/spp/19.5.321]; HAMILTON DP, 1991, SCIENCE, V251, P25, DOI 10.1126/science.1986409; Jennings Charles, 1999, Neuro Endocrinol Lett, V20, P7; MCVEIGH ME, 2002, J CITATION REPORTS S; Morrison PJ, 1997, BRIT MED J, V314, P832, DOI 10.1136/bmj.314.7083.832b; *NAT U SING LIBR, SEARCH WOS EL SELF C; PENDLEBURY DA, 1991, SCIENCE, V251, P1410, DOI 10.1126/science.251.5000.1410-b; Seglen PO, 1997, BRIT MED J, V314, P498	13	1	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	2004	364	9436					744	744		10.1016/S0140-6736(04)16955-9	http://dx.doi.org/10.1016/S0140-6736(04)16955-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337390				2022-12-28	WOS:000223569600011
J	Montoya, JP; Holl, CM; Zehr, JP; Hansen, A; Villareal, TA; Capone, DG				Montoya, JP; Holl, CM; Zehr, JP; Hansen, A; Villareal, TA; Capone, DG			High rates of N-2 fixation by unicellular diazotrophs in the oligotrophic Pacific Ocean	NATURE			English	Article							NORTH-ATLANTIC OCEAN; CYANOBACTERIUM TRICHODESMIUM-THIEBAUTII; NITROGEN-FIXATION; MARINE CYANOBACTERIUM; EXTENSIVE BLOOM; SITU RATES; DENITRIFICATION; SPP.; GENE	The availability of nitrogen is important in regulating biological productivity in marine environments. Deepwater nitrate has long been considered the major source of new nitrogen supporting primary production in oligotrophic regions of the open ocean, but recent studies have showed that biological N-2 fixation has a critical role in supporting oceanic new production(1-7). Large colonial cyanobacteria in the genus Trichodesmium and the heterocystous endosymbiont Richelia have traditionally been considered the dominant marine N-2 fixers, but unicellular diazotrophic cyanobacteria and bacterioplankton have recently been found in the picoplankton and nanoplankton community of the North Pacific central gyre, and a variety of molecular and isotopic evidence suggests that these unicells could make a major contribution to the oceanic N budget(8). Here we report rates of N-2 fixation by these small, previously overlooked diazotrophs that, although spatially variable, can equal or exceed the rate of N-2 fixation reported for larger, more obvious organisms. Direct measurements of N-15(2) fixation by small diazotrophs in various parts of the Pacific Ocean, including the waters off Hawaii where the unicellular diazotrophs were first characterized, show that N-2 fixation by unicellular diazotrophs can support a significant fraction of total new production in oligotrophic waters.	Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; Univ Calif Santa Cruz, Dept Ocean Sci, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Inst Marine Sci, Santa Cruz, CA 95064 USA; Univ Hawaii, Sch Ocean & Earth Sci & Technol, Honolulu, HI 96822 USA; Univ Texas, Inst Marine Sci, Port Aransas, TX 78373 USA; Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ So Calif, Wrigley Inst Environm Studies, Los Angeles, CA 90089 USA	University System of Georgia; Georgia Institute of Technology; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; University of Hawaii System; University of Texas System; University of Southern California; University of Southern California	Montoya, JP (corresponding author), Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA.	j.montoya@biology.gatech.edu	Zehr, Jonathan P/B-3513-2014; Villareal, Tracy A/I-9462-2012; Montoya, Joseph/C-3115-2013	Zehr, Jonathan P/0000-0002-5691-5408; Villareal, Tracy A/0000-0002-5717-8163; Montoya, Joseph/0000-0001-7197-4660				Allen CB, 1996, DEEP-SEA RES PT I, V43, P917, DOI 10.1016/0967-0637(96)00022-2; Aufdenkampe AK, 2002, DEEP-SEA RES PT II, V49, P2619, DOI 10.1016/S0967-0645(02)00051-6; Capone DG, 1997, SCIENCE, V276, P1221, DOI 10.1126/science.276.5316.1221; Capone DG, 1998, MAR ECOL PROG SER, V172, P281, DOI 10.3354/meps172281; CAPONE DG, 1990, APPL ENVIRON MICROB, V56, P3532, DOI 10.1128/AEM.56.11.3532-3536.1990; Carpenter EJ, 2004, DEEP-SEA RES PT I, V51, P173, DOI 10.1016/j.dsr.2003.10.006; CARPENTER EJ, 1991, SCIENCE, V254, P1356, DOI 10.1126/science.254.5036.1356; CARPENTER EJ, 1977, LIMNOL OCEANOGR, V22, P60, DOI 10.4319/lo.1977.22.1.0060; Carpenter EJ, 1999, MAR ECOL PROG SER, V185, P273, DOI 10.3354/meps185273; Chen YB, 1996, J PHYCOL, V32, P916, DOI 10.1111/j.0022-3646.1996.00916.x; Deutsch C, 2001, GLOBAL BIOGEOCHEM CY, V15, P483, DOI 10.1029/2000GB001291; Dore JE, 2002, LIMNOL OCEANOGR, V47, P1595, DOI 10.4319/lo.2002.47.6.1595; Falcon LI, 2004, APPL ENVIRON MICROB, V70, P765, DOI 10.1128/AEM.70.2.765-770.2004; GOERING JJ, 1966, LIMNOL OCEANOGR, V11, P614, DOI 10.4319/lo.1966.11.4.0614; Gruber N, 1997, GLOBAL BIOGEOCHEM CY, V11, P235, DOI 10.1029/97GB00077; GUNDERSEN KR, 1976, PAC SCI, V30, P45; Karl D, 1997, NATURE, V388, P533, DOI 10.1038/41474; Lee K, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014198; Lipschultz F, 1996, BIOGEOCHEMISTRY, V35, P261, DOI 10.1007/BF02179830; Michaels AF, 1996, BIOGEOCHEMISTRY, V35, P181, DOI 10.1007/BF02179827; Montoya JP, 2002, LIMNOL OCEANOGR, V47, P1617, DOI 10.4319/lo.2002.47.6.1617; Montoya JP, 1996, APPL ENVIRON MICROB, V62, P986, DOI 10.1128/AEM.62.3.986-993.1996; Orcutt KM, 2001, DEEP-SEA RES PT II, V48, P1583, DOI 10.1016/S0967-0645(00)00157-0; Saino T, 1977, BIOL NITROGEN FIXATI; Tillett D, 2000, J PHYCOL, V36, P251, DOI 10.1046/j.1529-8817.2000.99079.x; Wessel P., 1998, EOS T AM GEOPHYS UN, V79, P579, DOI [10.1029/98EO00426, DOI 10.1029/98EO00426, DOI 10.1029/98E000426]; ZEHR JP, 1989, APPL ENVIRON MICROB, V55, P2522, DOI 10.1128/AEM.55.10.2522-2526.1989; Zehr JP, 2001, METHOD MICROBIOL, V30, P271, DOI 10.1016/S0580-9517(01)30049-1; Zehr JP, 2001, NATURE, V412, P635, DOI 10.1038/35088063	29	444	466	3	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2004	430	7003					1027	1031		10.1038/nature02824	http://dx.doi.org/10.1038/nature02824			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329721				2022-12-28	WOS:000223514900043
J	Sobel, JD; Wiesenfeld, HC; Martens, M; Danna, P; Hooton, TM; Rompalo, A; Sperling, M; Livengood, CI; Horowitz, B; Von Thron, J; Edwards, L; Panzer, H; Chu, T				Sobel, JD; Wiesenfeld, HC; Martens, M; Danna, P; Hooton, TM; Rompalo, A; Sperling, M; Livengood, CI; Horowitz, B; Von Thron, J; Edwards, L; Panzer, H; Chu, T			Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERMITTENT PROPHYLACTIC TREATMENT; VULVOVAGINAL CANDIDIASIS; KETOCONAZOLE THERAPY; WOMEN; CLOTRIMAZOLE; CANDIDOSIS; INFECTION; VAGINITIS; SINGLE	BACKGROUND: No safe and convenient regimen has proved to be effective for the management of recurrent vulvovaginal candidiasis. METHODS: After inducing clinical remission with open-label fluconazole given in three 150-mg doses at 72-hour intervals, we randomly assigned 387 women with recurrent vulvovaginal candidiasis to receive treatment with fluconazole (150 mg) or placebo weekly for six months, followed by six months of observation without therapy. The primary outcome measure was the proportion of women in clinical remission at the end of the first six-month period. Secondary efficacy measures were the clinical outcome at 12 months, vaginal mycologic status, and time to recurrence on the basis of Kaplan-Meier analysis. RESULTS: Weekly treatment with fluconazole was effective in preventing symptomatic vulvovaginal candidiasis. The proportions of women who remained disease-free at 6, 9, and 12 months in the fluconazole group were 90.8 percent, 73.2 percent, and 42.9 percent, as compared with 35.9 percent, 27.8 percent, and 21.9 percent, respectively, in the placebo group (P< 0.001). The median time to clinical recurrence in the fluconazole group was 10.2 months, as compared with 4.0 months in the placebo group (P<0.001). There was no evidence of fluconazole resistance in isolates of Candida albicans or of superinfection with C. glabrata. Fluconazole was discontinued in one patient because of headache. CONCLUSIONS: Long-term weekly treatment with fluconazole can reduce the rate of recurrence of symptomatic vulvovaginal candidiasis. However, a long-term cure remains difficult to achieve.	Wayne State Univ, Sch Med, Div Infect Dis, Detroit, MI USA; Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA; Hennepin Cty Med Ctr, Dept Obstet & Gynecol, Minneapolis, MN 55415 USA; Phys Associates Florida, Orlando, FL USA; Univ Washington, Div Allergy & Infect Dis, Seattle, WA 98195 USA; Johns Hopkins Univ, Div Infect Dis, Baltimore, MD USA; Edinger Med Grp & Res Ctr, Fountain Valley, CA USA; Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA; SHE Med Associates, Hartford, CT USA; Insignia Care Women, Tampa, FL USA; Mid Charlotte Dermatol & Res, Charlotte, NC USA; Pfizer Pharmaceut Inc, New York, NY USA	Wayne State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Hennepin County Medical Center; University of Washington; University of Washington Seattle; Johns Hopkins University; Duke University; Pfizer	Sobel, JD (corresponding author), Wayne State Univ, Harper Hosp, Div Infect Dis, 5 Hudson,Rm 5929,3990 John R St, Detroit, MI 48201 USA.	jsobel@med.wayne.edu						BALSDON MJ, 1988, GENITOURIN MED, V64, P124; CREATSAS GC, 1993, CLIN THER, V15, P662; DAVIDSON F, 1978, BRIT J VENER DIS, V54, P176; Fidel PL, 1996, CLIN MICROBIOL REV, V9, P335, DOI 10.1128/CMR.9.3.335; FONG IW, 1994, GENITOURIN MED, V70, P124; Foxman B, 1998, J WOMENS HEALTH, V7, P1167, DOI 10.1089/jwh.1998.7.1167; Foxman B, 2000, SEX TRANSM DIS, V27, P230, DOI 10.1097/00007435-200004000-00009; HOUANG ET, 1990, ANTIMICROB AGENTS CH, V34, P909, DOI 10.1128/AAC.34.5.909; LEWIS JH, 1984, GASTROENTEROLOGY, V86, P503; MERKUS JMWM, 1990, BRIT J CLIN PRACT, V44, P81; National Committee for Clinical Laboratory Standards, 1994, DEV IN VITR SUSC TES; REEF SE, 1995, CLIN INFECT DIS, V20, pS80, DOI 10.1093/clinids/20.Supplement_1.S80; ROTH AC, 1990, GENITOURIN MED, V66, P357; Schuman P, 1997, ANN INTERN MED, V126, P689, DOI 10.7326/0003-4819-126-9-199705010-00003; Sobel Jack D., 2002, Curr Infect Dis Rep, V4, P514, DOI 10.1007/s11908-002-0038-7; SOBEL JD, 1985, OBSTET GYNECOL, V65, P435; SOBEL JD, 1989, OBSTET GYNECOL, V73, P330; SOBEL JD, 1986, NEW ENGL J MED, V315, P1455, DOI 10.1056/NEJM198612043152305; SOBEL JD, 1985, AM J OBSTET GYNECOL, V152, P924, DOI 10.1016/S0002-9378(85)80003-X; Sobel JD, 2001, AM J OBSTET GYNECOL, V185, P363, DOI 10.1067/mob.2001.115116; Sobel JD, 1992, INT J GYNECOL OBS S1, V37, P17; SPINILLO A, 1992, J REPROD MED, V37, P343; SPINILLO A, 1993, OBSTET GYNECOL, V81, P721	23	261	294	1	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2004	351	9					876	883		10.1056/NEJMoa033114	http://dx.doi.org/10.1056/NEJMoa033114			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849BM	15329425	Bronze			2022-12-28	WOS:000223512500009
J	Tseng, CW; Brook, RH; Keeler, E; Steers, WN; Mangione, CM				Tseng, CW; Brook, RH; Keeler, E; Steers, WN; Mangione, CM			Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SENIORS	Context The majority of Medicare drug benefits in managed care (Medicare+Choice) have annual dollar limits or caps and many beneficiaries face temporary but potentially significant gaps in coverage after exceeding caps before the end of the year. in the new national Medicare drug benefit, beneficiaries with high medication expenditures will also face a period without drug coverage when their total drug costs exceed annual caps but are not high enough to qualify for catastrophic coverage. Objective To describe strategies adopted by beneficiaries exceeding annual drug benefit caps to lower prescription costs, the type of medications involved, and their financial burden. Design, Setting, and Participants A survey (completed in 2002) of Medicare+Choice beneficiaries aged 65 years and older with high medication costs and benefits capped on the plan's share of drug costs (65% response rate). The different caps offered in different counties were used as a natural experiment. Study participants (n=665) exceeded a $750 or $1200 yearly cap in 2001 and had coverage gaps of 75 to 180 days. Control participants (n=643) had $2000 caps, which they did not exceed. Study and control participants were matched by average total drug expenditures per month. Main Outcome Measures Proportion of beneficiaries reporting specific strategies to decrease medication costs, medications affected, and difficulty paying for prescriptions. Results In multivariate analyses adjusting for demographic and health characteristics, a higher proportion of patients exceeding caps reported using less prescribed medication than controls (18% vs 10%, respectively; P<.001), but similar proportions reported stopping medications completely (8% for both, P=.86) and of not starting prescribed medications (6% vs 5%, P=39). Patients exceeding caps more often called pharmacies to find the best price (46% vs 29%, P<.001), switched medications (15% vs 9%, P=.002), used samples (34% vs 27%, P=.006), and had difficulty paying for prescriptions (62% vs 37%, P<.001). Twelve of the 20 therapeutic classes most often affected by decreases in use of medication were for chronic health problems such as hypertension, hyperlipidemia, and emphysema or asthma. Conclusions Medicare beneficiaries often decreased use of essential medications and experienced difficulty paying for prescriptions during gaps in coverage. Health professionals need to explore how they can lessen the impact of caps on patients' health and financial burden.	Univ Hawaii, Dept Family Practice & Community Hlth, Honolulu, HI 96822 USA; Pacific Hlth Res Inst, Honolulu, HI USA; Univ Calif Los Angeles, Ctr Hlth Sci, Robert Wood Johnson Fdn, Clin Scholars Program, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; RAND Corp, Santa Monica, CA USA	University of Hawaii System; Pacific Health Research & Education Institute; Robert Wood Johnson Foundation (RWJF); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; RAND Corporation	Tseng, CW (corresponding author), 846 S Hotel St,Suite 303, Honolulu, HI 96813 USA.	cwtseng@hawaii.edu			NATIONAL INSTITUTE ON AGING [P30AG021684] Funding Source: NIH RePORTER; NIA NIH HHS [AG21684] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams AS, 2001, HEALTH AFFAIR, V20, P276, DOI 10.1377/hlthaff.20.1.276; *COMM FUND, 2003, MED PLUS CHOIC PLANS; Cox Emily R, 2002, J Manag Care Pharm, V8, P360; Cox ER, 2001, MED CARE, V39, P296, DOI 10.1097/00005650-200103000-00009; Craig BM, 2003, HEALTH AFFAIR, V22, P175, DOI 10.1377/hlthaff.22.3.175; *CTR STUD HLTH SYS, 2002, AFF PRESCR DRUGS NOT; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; Graubard BI, 1999, BIOMETRICS, V55, P652, DOI 10.1111/j.0006-341X.1999.00652.x; *KAIS FAM FDN, 2003, SID SID COMP PRESCR; *KAIS FAM FDN, 2004, DO PATT PRESCR DRUG; Kaiser Family Foundation the Commonwealth Fund and Tufts-New England Medical Center, 2002, SEN PRESCR DRUGS FIN; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Mojtabai R, 2003, HEALTH AFFAIR, V22, P220, DOI 10.1377/hlthaff.22.4.220; Poisal JA, 2001, HEALTH AFFAIR, V20, P74, DOI 10.1377/hlthaff.20.2.74; Steinman MA, 2001, J GEN INTERN MED, V16, P793, DOI 10.1046/j.1525-1497.2001.10412.x; Taira DA, 2003, AM J MANAG CARE, V9, P305; Tseng CW, 2003, JAMA-J AM MED ASSOC, V290, P222, DOI 10.1001/jama.290.2.222	18	114	115	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2004	292	8					952	960		10.1001/jama.292.8.952	http://dx.doi.org/10.1001/jama.292.8.952			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WR	15328327	Bronze, Green Submitted			2022-12-28	WOS:000223429200020
J	Tucker, TJ; Mazithulela, G				Tucker, TJ; Mazithulela, G			Development of an AIDS vaccine: perspective from the South African AIDS vaccine initiative	BMJ-BRITISH MEDICAL JOURNAL			English	Article							STRATEGIES	Most work on HIV vaccines is being done in the public sector rather than the pharmaceutical industry. Although international cooperation is producing candidate vaccines, greater investment is needed to speed up progress.	S African MRC, S African AIDS Vaccine Initiat, ZA-7505 Tygerberg, South Africa	South African Medical Research Council	Tucker, TJ (corresponding author), S African MRC, S African AIDS Vaccine Initiat, POB 19070, ZA-7505 Tygerberg, South Africa.	saavi@mrc.ac.za						BRONNENKANT L, 1994, AIDS RES HUM RETROV, V10, pS311; Burton DR, 2004, SCIENCE, V303, P316, DOI 10.1126/science.1094620; Dayan GH, 2004, VACCINE, V22, P475, DOI 10.1016/j.vaccine.2003.07.007; Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916; McNeil JG, 2004, SCIENCE, V303, P961, DOI 10.1126/science.1096161; Stebbing Justin, 2003, AIDS Rev, V5, P205; *UN, 2003, AIDS REP	7	6	6	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 21	2004	329	7463					454	456		10.1136/bmj.329.7463.454	http://dx.doi.org/10.1136/bmj.329.7463.454			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849EA	15321907	Green Published			2022-12-28	WOS:000223520300028
J	Greenwood, B				Greenwood, B			Between hope and a hard place	NATURE			English	Article							MALARIA; MORTALITY		London Sch Hyg & Trop Med, Malaria Ctr, London, England	University of London; London School of Hygiene & Tropical Medicine	Greenwood, B (corresponding author), London Sch Hyg & Trop Med, Malaria Ctr, London, England.							[Anonymous], 2003, AFR MAL REP 2003; Coleman PG, 2004, TROP MED INT HEALTH, V9, P433, DOI 10.1111/j.1365-3156.2004.01225.x; Korenromp EL, 2003, LANCET INFECT DIS, V3, P349, DOI 10.1016/S1473-3099(03)00657-1; Phillips-Howard PA, 2003, AM J TROP MED HYG, V68, P23, DOI 10.4269/ajtmh.2003.68.23; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a	5	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2004	430	7002					926	927		10.1038/430926a	http://dx.doi.org/10.1038/430926a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318230				2022-12-28	WOS:000223369800053
J	She, XW; Horvath, JE; Jiang, ZS; Liu, G; Furey, TS; Christ, L; Clark, R; Graves, T; Gulden, CL; Alkan, C; Bailey, JA; Sahinalp, C; Rocchi, M; Haussler, D; Wilson, RK; Miller, W; Schwartz, S; Eichler, EE				She, XW; Horvath, JE; Jiang, ZS; Liu, G; Furey, TS; Christ, L; Clark, R; Graves, T; Gulden, CL; Alkan, C; Bailey, JA; Sahinalp, C; Rocchi, M; Haussler, D; Wilson, RK; Miller, W; Schwartz, S; Eichler, EE			The structure and evolution of centromeric transition regions within the human genome	NATURE			English	Article							RECENT SEGMENTAL DUPLICATIONS; ALPHA-SATELLITE DNA; GENETIC DEFINITION; SEQUENCE; EXPANSION; PRIMATES; REPEAT; ORIGIN	An understanding of how centromeric transition regions are organized is a critical aspect of chromosome structure and function; however, the sequence context of these regions has been difficult to resolve on the basis of the draft genome sequence. We present a detailed analysis of the structure and assembly of all human pericentromeric regions (5 megabases). Most chromosome arms ( 35 out of 43) show a gradient of dwindling transcriptional diversity accompanied by an increasing number of interchromosomal duplications in proximity to the centromere. At least 30% of the centromeric transition region structure originates from euchromatic gene-containing segments of DNA that were duplicatively transposed towards pericentromeric regions at a rate of six-seven events per million years during primate evolution. This process has led to the formation of a minimum of 28 new transcripts by exon exaptation and exon shuffling, many of which are primarily expressed in the testis. The distribution of these duplicated segments is nonrandom among pericentromeric regions, suggesting that some regions have served as preferential acceptors of euchromatic DNA.	Case Western Reserve Univ, Sch Med, Ctr Computat Genom, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA 98195 USA; Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, UCSC Genome Bioinformat Grp, Santa Cruz, CA 95064 USA; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Simon Fraser Univ, Sch Comp Sci, Burnaby, BC V5A 1S6, Canada; Univ Bari, DAPEG, Sez Genet, I-70126 Bari, Italy; Penn State Univ, Ctr Comparat Genom & Bioinformat, University Pk, PA 16802 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; University of Washington; University of Washington Seattle; University of California System; University of California Santa Cruz; Washington University (WUSTL); Simon Fraser University; Universita degli Studi di Bari Aldo Moro; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Eichler, EE (corresponding author), Case Western Reserve Univ, Sch Med, Ctr Computat Genom, Dept Genet, Cleveland, OH 44106 USA.	eee@gs.washington.edu	Wilson, Richard K./AAF-4139-2019; Sahinalp, Suleyman Cenk/X-7843-2018; Alkan, Can/D-2982-2009	Wilson, Richard K./0000-0002-1992-1358; Sahinalp, Suleyman Cenk/0000-0002-5050-0682; Alkan, Can/0000-0002-5443-0706; Rocchi, Mariano/0000-0002-9451-5616; Furey, Terry/0000-0001-5546-9672	Telethon [E.0672] Funding Source: Medline	Telethon(Fondazione Telethon)		Alexandrov I, 2001, CHROMOSOMA, V110, P253, DOI 10.1007/s004120100146; Bailey JA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-r23; Bailey JA, 2003, AM J HUM GENET, V73, P823, DOI 10.1086/378594; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Bailey JA, 2002, AM J HUM GENET, V70, P83, DOI 10.1086/338458; Bailey JA, 2001, GENOME RES, V11, P1005, DOI 10.1101/gr.GR-1871R; BALDINI A, 1993, HUM GENET, V90, P577; Copenhaver GP, 1999, SCIENCE, V286, P2468, DOI 10.1126/science.286.5449.2468; Courseaux A, 2003, GENOME RES, V13, P369, DOI 10.1101/gr.490303; Crosier M, 2002, GENOME RES, V12, P67, DOI 10.1101/gr.213702; Eder V, 2003, MOL BIOL EVOL, V20, P1506, DOI 10.1093/molbev/msg165; Eichler EE, 2001, TRENDS GENET, V17, P661, DOI 10.1016/S0168-9525(01)02492-1; Eichler EE, 1998, GENOME RES, V8, P758, DOI 10.1101/gr.8.8.758; Golfier G, 2003, GENE, V312, P51, DOI 10.1016/S0378-1119(03)00673-5; Guy J, 2003, GENOME RES, V13, P159, DOI 10.1101/gr.644503; Hillier LW, 2003, NATURE, V424, P157, DOI 10.1038/nature01782; Horvath JE, 2001, HUM MOL GENET, V10, P2215, DOI 10.1093/hmg/10.20.2215; Horvath JE, 2003, MOL BIOL EVOL, V20, P1463, DOI 10.1093/molbev/msg158; Horvath JE, 2000, HUM MOL GENET, V9, P113, DOI 10.1093/hmg/9.1.113; Horvath JE, 2000, GENOME RES, V10, P839, DOI 10.1101/gr.10.6.839; *INT SYST HUM CYT, 1981, CYTOGENET CELL GENET, V31, P1; Istrail S, 2004, P NATL ACAD SCI USA, V101, P1916, DOI 10.1073/pnas.0307971100; Jackson M, 2003, CURR OPIN GENET DEV, V13, P629, DOI 10.1016/j.gde.2003.10.011; Jackson MS, 1999, HUM MOL GENET, V8, P205, DOI 10.1093/hmg/8.2.205; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee C, 1997, HUM GENET, V100, P291, DOI 10.1007/s004390050508; Leem SH, 2004, GENOME RES, V14, P239, DOI 10.1101/gr.1929904; Liu G, 2003, GENOME RES, V13, P358, DOI 10.1101/gr.923303; Locke DP, 2003, GENOME RES, V13, P347, DOI 10.1101/gr.1003303; LOCKE DP, IN PRESS CYTOGENET G; Nagaki K, 2004, NAT GENET, V36, P138, DOI 10.1038/ng1289; RUDD MK, IN PRES TRENDS GENET; SCHNEIDER M, 1979, MATURITAS, V1, P153, DOI 10.1016/0378-5122(79)90002-1; Schueler MG, 2001, SCIENCE, V294, P109, DOI 10.1126/science.1065042; Thomas JW, 2003, GENOME RES, V13, P55, DOI 10.1101/gr.791403; Tuzun E, 2004, GENOME RES, V14, P493, DOI 10.1101/gr.1907504; Ventura M, 2003, GENOME RES, V13, P2059, DOI 10.1101/gr.1155103; Ventura M, 2001, GENOME RES, V11, P595, DOI 10.1101/gr.152101; WILLARD HF, 1987, J MOL EVOL, V25, P207, DOI 10.1007/BF02100014; YUNIS JJ, 1982, SCIENCE, V215, P1525, DOI 10.1126/science.7063861	40	151	155	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					857	864		10.1038/nature02806	http://dx.doi.org/10.1038/nature02806			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318213				2022-12-28	WOS:000223369800033
J	Ursin, R; Jennewein, T; Aspelmeyer, M; Kaltenbaek, R; Lindenthal, M; Walther, P; Zeilinger, A				Ursin, R; Jennewein, T; Aspelmeyer, M; Kaltenbaek, R; Lindenthal, M; Walther, P; Zeilinger, A			Communications - Quantum teleportation across the Danube	NATURE			English	Editorial Material							OPERATIONS; QUBITS; STATE		Univ Vienna, Inst Expt Phys, A-1090 Vienna, Austria; Austrian Acad Sci, A-1090 Vienna, Austria	University of Vienna; Austrian Academy of Sciences	Ursin, R (corresponding author), Univ Vienna, Inst Expt Phys, Strudlhofgasse 4, A-1090 Vienna, Austria.	rupert.ursin@univie.ac.at	Walther, Philip/O-2993-2019; Aspelmeyer, Markus/C-4098-2017; Ursin, Rupert/E-9548-2012; Zeilinger, Anton/A-1170-2011; Kaltenbaek, Rainer/C-8141-2015; Walther, Philip/D-6346-2018	Walther, Philip/0000-0002-4964-817X; Aspelmeyer, Markus/0000-0003-4499-7335; Ursin, Rupert/0000-0002-9403-269X; Kaltenbaek, Rainer/0000-0002-9991-9919; Walther, Philip/0000-0002-4964-817X				BENNETT CH, 1993, PHYS REV LETT, V70, P1895, DOI 10.1103/PhysRevLett.70.1895; Bose S, 1998, PHYS REV A, V57, P822, DOI 10.1103/PhysRevA.57.822; Bouwmeester D, 1997, NATURE, V390, P575, DOI 10.1038/37539; Briegel HJ, 1998, PHYS REV LETT, V81, P5932, DOI 10.1103/PhysRevLett.81.5932; Kim YH, 2001, PHYS REV LETT, V86, P1370, DOI 10.1103/PhysRevLett.86.1370; Lutkenhaus N, 1999, PHYS REV A, V59, P3295, DOI 10.1103/PhysRevA.59.3295; POPESCU S, 1994, PHYS REV LETT, V72, P797, DOI 10.1103/PhysRevLett.72.797	11	231	236	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2004	430	7002					849	849		10.1038/430849a	http://dx.doi.org/10.1038/430849a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318210				2022-12-28	WOS:000223369800030
J	Oransky, I				Oransky, I			George Widmer Thorn - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com						THORN GW, PUBLICATION LIST	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	2004	364	9433					496	496		10.1016/S0140-6736(04)16794-9	http://dx.doi.org/10.1016/S0140-6736(04)16794-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844BS	15320337	Bronze			2022-12-28	WOS:000223132700016
J	Bath-Hextall, F; Bong, J; Perkins, W; Williams, H				Bath-Hextall, F; Bong, J; Perkins, W; Williams, H			Interventions for basal cell carcinoma of the skin: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							IMIQUIMOD 5-PERCENT CREAM; PHOTODYNAMIC THERAPY; METHYL AMINOLEVULINATE; CRYOSURGERY; RADIOTHERAPY; CRYOTHERAPY; SURGERY	Objectives To assess the effects of treatments for basal cell carcinoma. Methods Systematic review of randomised controlled trials. Main outcome measure Recurrence of basal cell carcinoma at three years or beyond, assessed clinically. Studies reviewed Randomised controlled trials of interventions for histologically confirmed basal cell carcinoma (published and unpublished material; no language restrictions). Results 25 studies were identified, covering seven therapeutic categories. Only one study of surgical excision versus radiotherapy contained primary outcome data, which showed significantly more persistent tumours and recurrences in the radiotherapy group compared with surgery (odds ratio 0.09, 95% confidence interval 0.01 to 0.67). One study compared cryotherapy with surgery, with inconclusive results at one year. In a comparison of radiotherapy with cryotherapy, significantly more recurrences occurred at one year in the cryotherapy group. Preliminary studies suggest a short term success rate of 87-88% for imiquimod cream in the treatment of superficial basal cell carcinoma, although this cream has not been compared with surgery. No consistent evidence was found for the other treatment modalities. Conclusions Little good quality research has been done on the treatments used for the most common cancer in humans. Most trials have included only people with basal cell carcinoma occurring at low risk sites. Only one trial measured recurrence at four years; recurrence rates at one year should be interpreted with caution. Surgery and radiotherapy seem to be the most effective treatments; surgery showed the lowest failure rates. Other treatments might have some use but need to be compared with surgery.	Queens Med Ctr, Ctr Evidence Based Dermatol, Nottingham NG7 2UH, England; Queens Med Ctr, Dept Dermatol, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Bath-Hextall, F (corresponding author), Queens Med Ctr, Ctr Evidence Based Dermatol, Nottingham NG7 2UH, England.	fiona.bath-hextall@nottingham.ac.uk	Bath-Hextall, Fiona/B-8722-2008	Bath-Hextall, Fiona/0000-0001-6583-029X; williams, hywel/0000-0002-5646-3093				Alpsoy Erkan, 1996, Journal of Dermatology (Tokyo), V23, P394; [Anonymous], 1987, J ROY COLL PHYS LOND, V21, P91; Avril MF, 1997, BRIT J CANCER, V76, P100, DOI 10.1038/bjc.1997.343; Basset-Seguin N, 2003, BRIT J DERMATOL, V149, P46; Bath FJ, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD003412, 10.1002/14651858.CD003412]; BENTNER K, 1999, J AM ACAD DERMATOL, V11, P1002; BREUNINGER H, 1991, J DERMATOL SURG ONC, V17, P574, DOI 10.1111/j.1524-4725.1991.tb03655.x; CARO I, 2003, 12 C EUR AC DERM VEN; Clarke M, 2000, COCHRANE REV HDB 4 1; CORNELL RC, 1990, J AM ACAD DERMATOL, V23, P694, DOI 10.1016/0190-9622(90)70276-N; EDWARDS L, 1990, ARCH DERMATOL, V126, P1029, DOI 10.1001/archderm.126.8.1029; Enejder AMK, 2000, ACTA DERM-VENEREOL, V80, P19; FOLEY P, 2003, AUSTRALAS J DERMATOL, V44, pA5; FRANCHIMONT C, 1982, BRIT J DERMATOL, V106, P305, DOI 10.1111/j.1365-2133.1982.tb01728.x; FRAUCHIMONT C, 1982, BRIT J DERMATOL, V100, P305; Geisse JK, 2002, J AM ACAD DERMATOL, V47, P390, DOI 10.1067/mjd.2002.126215; GILBODY JS, 1994, AUST J PUBLIC HEALTH, V18, P218; GOODWIN R, 2001, BRIT J DERMATOL, V145, P17; HALL VL, 1986, CLIN RADIOL, V37, P33, DOI 10.1016/S0009-9260(86)80161-1; LO JS, 1991, J AM ACAD DERMATOL, V24, P715, DOI 10.1016/0190-9622(91)70108-E; Mallon E, 1996, DERMATOL SURG, V22, P854, DOI 10.1111/j.1524-4725.1996.tb00588.x; Marks R, 2001, J AM ACAD DERMATOL, V44, P807, DOI 10.1067/mjd.2001.113689; Miller BH, 1997, J AM ACAD DERMATOL, V36, P72, DOI 10.1016/S0190-9622(97)70328-1; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; PEARL DK, 1986, INT J EPIDEMIOL, V15, P502, DOI 10.1093/ije/15.4.502; Petit JY, 2000, PLAST RECONSTR SURG, V105, P2544, DOI 10.1097/00006534-200006000-00039; PRESTON DS, 1992, NEW ENGL J MED, V327, P1649, DOI 10.1056/NEJM199212033272307; PUNJABI S, 2000, EUR ACAD DERMATOL S1, V14, P47; Rhodes LE, 2004, ARCH DERMATOL, V140, P17, DOI 10.1001/archderm.140.1.17; Rogozinski TT., 1997, PRZEGL DERMATOL, V84, P259; Romagosa R, 2000, DERMATOL SURG, V26, P338, DOI 10.1046/j.1524-4725.2000.99227.x; SCHREIBER MM, 1990, J AM ACAD DERMATOL, V23, P1114, DOI 10.1016/0190-9622(90)70343-G; Shumack S, 2002, ARCH DERMATOL, V138, P1165, DOI 10.1001/archderm.138.9.1165; Soler AM, 2000, PHOTOCHEM PHOTOBIOL, V71, P724, DOI 10.1562/0031-8655(2000)071<0724:PTOSBC>2.0.CO;2; Sterry W, 2002, BRIT J DERMATOL, V147, P1227, DOI 10.1046/j.1365-2133.2002.05069.x; Telfer NR, 1999, BRIT J DERMATOL, V141, P415; Thissen MRTM, 1999, ARCH DERMATOL, V135, P1177, DOI 10.1001/archderm.135.10.1177; Thissen MRTM, 2000, DERMATOL SURG, V26, P759, DOI 10.1046/j.1524-4725.2000.ds00064.x; TOPE WD, 2003, 9 WORLD C CANC SKIN; Wang I, 2001, BRIT J DERMATOL, V144, P832, DOI 10.1046/j.1365-2133.2001.04141.x; ZAYNOUN S, 1985, J AM ACAD DERMATOL, V12, P522, DOI 10.1016/S0190-9622(85)70073-4	41	92	94	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	2004	329	7468					705	708		10.1136/bmj.38219.515266.AE	http://dx.doi.org/10.1136/bmj.38219.515266.AE			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	858RV	15364703	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000224210300014
J	Krantz, I; Lowhagen, GB; Ahlberg, BM; Nilstun, T				Krantz, I; Lowhagen, GB; Ahlberg, BM; Nilstun, T			Ethics of screening for asymptomatic herpes virus type 2 infection	BRITISH MEDICAL JOURNAL			English	Article							HSV-2 SPECIFIC SEROLOGY; GENITAL HERPES; ANTENATAL PATIENTS; NEONATAL HERPES; PUBLIC-HEALTH; ANTIBODY		Umea Univ, Dept Publ Hlth & Clin Med, S-90187 Umea, Sweden; Lund Univ, Dept Med Eth, S-22100 Lund, Sweden; Skaraborg Inst Res & Dev, Skovde, Sweden; Sahlgrens Univ Hosp, Dept Dermatol & Venereol, S-41345 Gothenburg, Sweden	Umea University; Lund University; Sahlgrenska University Hospital	Krantz, I (corresponding author), Skaraborgsinst, Stn Gatan 12, SE-54130 Skovde, Sweden.	ingela.krantz@skaraborg-institute.se						Arvin Ann M, 2002, Herpes, V9, P48; Brown ZA, 2000, REV MED VIROL, V10, P141, DOI 10.1002/(SICI)1099-1654(200005/06)10:3&lt;141::AID-RMV280&gt;3.0.CO;2-2; Brugha R, 1997, INT J EPIDEMIOL, V26, P698, DOI 10.1093/ije/26.4.698; Copas AJ, 2002, SEX TRANSM INFECT, V78, P430, DOI 10.1136/sti.78.6.430; Corey L, 2000, JAMA-J AM MED ASSOC, V283, P791, DOI 10.1001/jama.283.6.791; FLEMING DT, 1997, NEW ENGL J MED, V337, P105; GILLON R, 1994, BRIT MED J, V309, P184, DOI 10.1136/bmj.309.6948.184; Green J, 2003, SEX TRANSM INFECT, V79, P42, DOI 10.1136/sti.79.1.42; Kinghorn GR, 1998, DERMATOL CLIN, V16, P663, DOI 10.1016/S0733-8635(05)70030-9; Malkin JE, 2002, SEX TRANSM INFECT, V78, P201, DOI 10.1136/sti.78.3.201; Mindel A, 2000, SEX TRANSM INFECT, V76, P287, DOI 10.1136/sti.76.4.287; Mindel Adrian, 2002, Herpes, V9, P35; Mullan HM, 2003, SEX TRANSM INFECT, V79, P129, DOI 10.1136/sti.79.2.129; Patrick David M, 2002, Herpes, V9, P32; Rouse DJ, 2000, AM J OBSTET GYNECOL, V183, P400, DOI 10.1067/mob.2000.105967; Smith A, 2000, INT J STD AIDS, V11, P15, DOI 10.1258/0956462001914841; Vyse AJ, 2000, SEX TRANSM INFECT, V76, P183, DOI 10.1136/sti.76.3.183; Wilkinson D, 2000, REV MED VIROL, V10, P145, DOI 10.1002/(SICI)1099-1654(200005/06)10:3&lt;145::AID-RMV281&gt;3.0.CO;2-O	18	14	15	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 11	2004	329	7466					618	621		10.1136/bmj.329.7466.618	http://dx.doi.org/10.1136/bmj.329.7466.618			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	854SK	15361449	Green Published			2022-12-28	WOS:000223923400023
J	Richardson, AJ; Schoeman, DS				Richardson, AJ; Schoeman, DS			Climate impact on plankton ecosystems in the Northeast Atlantic	SCIENCE			English	Article							MARINE-PHYTOPLANKTON; PATTERNS; BIODIVERSITY; TEMPERATURE; RECRUITMENT; OSCILLATION; INDICATOR; FISHERIES; TRENDS	It is now widely accepted that global warming is occurring, yet its effects on the world's largest ecosystem, the marine pelagic realm, are largely unknown. We show that sea surface warming in the Northeast Atlantic is accompanied by increasing phytoplankton abundance in cooler regions and decreasing phytoplankton abundance in warmer regions. This impact propagates up the food web (bottom-up control) through copepod herbivores to zooplankton carnivores because of tight trophic coupling. Future warming is therefore likely to alter the spatial distribution of primary and secondary pelagic production, affecting ecosystem services and placing additional stress on already-depleted fish and mammal populations.	Sir Alister Hardy Fdn Ocean Sci Lab, Plymouth PL1 2PB, Devon, England; Univ Port Elizabeth, Dept Zool, Port Elizabeth, South Africa	Nelson Mandela University	Richardson, AJ (corresponding author), Sir Alister Hardy Fdn Ocean Sci Lab, Citadel Hill, Plymouth PL1 2PB, Devon, England.	anr@sahfos.ac.uk	Richardson, Anthony J/B-3649-2010	Richardson, Anthony J/0000-0002-9289-7366; Schoeman, David/0000-0003-1258-0885				AEBISCHER NJ, 1990, NATURE, V347, P753, DOI 10.1038/347753a0; Beaugrand G, 2002, SCIENCE, V296, P1692, DOI 10.1126/science.1071329; Beaugrand G, 2003, NATURE, V426, P661, DOI 10.1038/nature02164; Bouman HA, 2003, MAR ECOL PROG SER, V258, P19, DOI 10.3354/meps258019; Carder KL, 1999, J GEOPHYS RES-OCEANS, V104, P5403, DOI 10.1029/1998JC900082; COLEBROOK J M, 1975, Bulletins of Marine Ecology, V8, P143; Cury P, 2000, ICES J MAR SCI, V57, P603, DOI 10.1006/jmsc.2000.0712; CUSHING DH, 1989, J PLANKTON RES, V11, P1, DOI 10.1093/plankt/11.1.1; Daskalov GM, 2002, MAR ECOL PROG SER, V225, P53, DOI 10.3354/meps225053; Falkowski PG, 1998, SCIENCE, V281, P200, DOI 10.1126/science.281.5374.200; Fromentin JM, 1996, MAR ECOL PROG SER, V134, P111, DOI 10.3354/meps134111; Houghton J. T., 2001, CLIMATE CHANGE 2001; Hughes L, 2000, TRENDS ECOL EVOL, V15, P56, DOI 10.1016/S0169-5347(99)01764-4; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; Irigoien X, 2004, NATURE, V429, P863, DOI 10.1038/nature02593; Li WKW, 2002, NATURE, V419, P154, DOI 10.1038/nature00994; Micheli F, 1999, SCIENCE, V285, P1396, DOI 10.1126/science.285.5432.1396; O'Brien CM, 2000, NATURE, V404, P142, DOI 10.1038/35004654; Parsons LS, 2001, PROG OCEANOGR, V49, P167, DOI 10.1016/S0079-6611(01)00021-0; Planque B, 1999, CAN J FISH AQUAT SCI, V56, P2069, DOI 10.1139/cjfas-56-11-2069; Pyper BJ, 1998, CAN J FISH AQUAT SCI, V55, P2127; Reid PC, 2003, PROG OCEANOGR, V58, P117, DOI 10.1016/j.pocean.2003.08.002; ROEMMICH D, 1995, SCIENCE, V267, P1324, DOI 10.1126/science.267.5202.1324; Sathyendranath S, 2001, INT J REMOTE SENS, V22, P249, DOI 10.1080/014311601449925; Shurin JB, 2002, ECOL LETT, V5, P785, DOI 10.1046/j.1461-0248.2002.00381.x; Worm B, 2003, ECOLOGY, V84, P162, DOI 10.1890/0012-9658(2003)084[0162:MAOCSI]2.0.CO;2	26	544	576	7	263	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2004	305	5690					1609	1612		10.1126/science.1100958	http://dx.doi.org/10.1126/science.1100958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361622				2022-12-28	WOS:000223891200040
J	Andersen, KK; Azuma, N; Barnola, JM; Bigler, M; Biscaye, P; Caillon, N; Chappellaz, J; Clausen, HB; DahlJensen, D; Fischer, H; Fluckiger, J; Fritzsche, D; Fujii, Y; Goto-Azuma, K; Gronvold, K; Gundestrup, NS; Hansson, M; Huber, C; Hvidberg, CS; Johnsen, SJ; Jonsell, U; Jouzel, J; Kipfstuhl, S; Landais, A; Leuenberger, M; Lorrain, R; Masson-Delmotte, V; Miller, H; Motoyama, H; Narita, H; Popp, T; Rasmussen, SO; Raynaud, D; Rothlisberger, R; Ruth, U; Samyn, D; Schwander, J; Shoji, H; Siggard-Andersen, ML; Steffensen, JP; Stocker, T; Sveinbjornsdottir, AE; Svensson, A; Takata, M; Tison, JL; Thorsteinsson, T; Watanabe, O; Wilhelms, F; White, JWC				Andersen, KK; Azuma, N; Barnola, JM; Bigler, M; Biscaye, P; Caillon, N; Chappellaz, J; Clausen, HB; DahlJensen, D; Fischer, H; Fluckiger, J; Fritzsche, D; Fujii, Y; Goto-Azuma, K; Gronvold, K; Gundestrup, NS; Hansson, M; Huber, C; Hvidberg, CS; Johnsen, SJ; Jonsell, U; Jouzel, J; Kipfstuhl, S; Landais, A; Leuenberger, M; Lorrain, R; Masson-Delmotte, V; Miller, H; Motoyama, H; Narita, H; Popp, T; Rasmussen, SO; Raynaud, D; Rothlisberger, R; Ruth, U; Samyn, D; Schwander, J; Shoji, H; Siggard-Andersen, ML; Steffensen, JP; Stocker, T; Sveinbjornsdottir, AE; Svensson, A; Takata, M; Tison, JL; Thorsteinsson, T; Watanabe, O; Wilhelms, F; White, JWC		N Greenland Ice Core Project	High-resolution record of Northern Hemisphere climate extending into the last interglacial period	NATURE			English	Article							GREENLAND ICE-SHEET; CORE PROJECT; DELTA O-18; SEA-LEVEL; TEMPERATURE-CHANGE; OXYGEN-ISOTOPE; GLACIAL CYCLE; BASAL MELT; GRIP; GISP2	Two deep ice cores from central Greenland, drilled in the 1990s, have played a key role in climate reconstructions of the Northern Hemisphere, but the oldest sections of the cores were disturbed in chronology owing to ice folding near the bedrock. Here we present an undisturbed climate record from a North Greenland ice core, which extends back to 123,000 years before the present, within the last interglacial period. The oxygen isotopes in the ice imply that climate was stable during the last interglacial period, with temperatures 5 degreesC warmer than today. We find unexpectedly large temperature differences between our new record from northern Greenland and the undisturbed sections of the cores from central Greenland, suggesting that the extent of ice in the Northern Hemisphere modulated the latitudinal temperature gradients in Greenland. This record shows a slow decline in temperatures that marked the initiation of the last glacial period. Our record reveals a hitherto unrecognized warm period initiated by an abrupt climate warming about 115,000 years ago, before glacial conditions were fully developed. This event does not appear to have an immediate Antarctic counterpart, suggesting that the climate see-saw between the hemispheres (which dominated the last glacial period) was not operating at this time.	Univ Copenhagen, Niels Bohr Inst Astron Phys & Geophys, DK-2100 Copenhagen OE, Denmark; Nagaoka Univ Technol, Nagaoka, Niigata 9402188, Japan; CNRS, Lab Glaciol & Geophys Environm, F-38402 St Martin Dheres, France; Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Ctr Etud Saclay, Inst Pierre Simon Laplace, Lab Sci Climat & Environm, UMR CEA CNRS, F-91191 Gif Sur Yvette, France; Alfred Wegener Inst Polar & Marine Res, D-27515 Bremerhaven, Germany; Natl Inst Polar Res, Itabashi Ku, Tokyo 1738515, Japan; Nord Volcanol Inst, IS-108 Reykjavik, Iceland; Stockholm Univ, Dept Phys Geog & Quaternary Geol, S-10691 Stockholm, Sweden; Free Univ Brussels, Fac Sci, Dept Sci Terre & Environm, B-1050 Brussels, Belgium; Res Inst Humanity & Nat, Kamigyo Ku, Kyoto 6020878, Japan; Univ Colorado, INSTAAR, Boulder, CO 80309 USA; Kitami Inst Technol, Kitami, Hokkaido 0908507, Japan; Natl Energy Author, IS-108 Reykjavik, Iceland	University of Copenhagen; Niels Bohr Institute; Nagaoka University of Technology; Centre National de la Recherche Scientifique (CNRS); University of Bern; Columbia University; UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research; Research Organization of Information & Systems (ROIS); National Institute of Polar Research (NIPR) - Japan; University of Iceland; Stockholm University; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Research Institute for Humanity & Nature (RIHN); University of Colorado System; University of Colorado Boulder; Kitami Institute of Technology	DahlJensen, D (corresponding author), Univ Copenhagen, Niels Bohr Inst Astron Phys & Geophys, Juliane Maries Vej 30, DK-2100 Copenhagen OE, Denmark.	ddj@gfy.ku.dk; sigfus@gfy.ku.dk	Rasmussen, Sune/B-5560-2008; Caillon, Nicolas/B-7127-2019; Svensson, Anders/A-2643-2010; Fischer, Hubertus/A-1211-2014; Jonsell, Ulf/F-3116-2015; Fluckiger, Jacqueline/G-3457-2011; White, James W.C./A-7845-2009; Leuenberger, Markus C/K-9655-2016; Raynaud, Dominique/H-9626-2016; Rasmussen, Sune Olander/AAA-3190-2021; Stocker, Thomas/B-1273-2013; raynaud, dominique/ABG-4718-2020; Hvidberg, Christine S./E-8934-2015; Chappellaz, Jérôme A./A-4872-2011; Andersen, Katrine/B-4082-2016; Masson-Delmotte, Valerie L/G-1995-2011; Dahl-Jensen, Dorthe/N-4401-2016; Dahl-Jensen, Dorthe/AAO-6951-2020; Tison, Jean-Louis/F-4065-2015	Rasmussen, Sune/0000-0002-4177-3611; Caillon, Nicolas/0000-0002-6318-6194; Svensson, Anders/0000-0002-4364-6085; Fischer, Hubertus/0000-0002-2787-4221; Jonsell, Ulf/0000-0001-6532-8590; White, James W.C./0000-0001-6041-4684; Leuenberger, Markus C/0000-0003-4299-6793; Rasmussen, Sune Olander/0000-0002-4177-3611; Hvidberg, Christine S./0000-0002-9665-1339; Andersen, Katrine/0000-0003-4178-2195; Masson-Delmotte, Valerie L/0000-0001-8296-381X; Dahl-Jensen, Dorthe/0000-0002-1474-1948; Dahl-Jensen, Dorthe/0000-0002-1474-1948; Huber, Christof/0000-0001-5767-045X; Tison, Jean-Louis/0000-0002-9758-3454; LANDAIS, Amaelle/0000-0002-5620-5465; Wilhelms, Frank/0000-0001-7688-3135; Steffensen, Jorgen Peder/0000-0002-5516-1093; Miller, Heinrich/0000-0003-1015-2828; Fritzsche, Diedrich/0000-0002-0018-8993				ALLEY RB, 1995, NATURE, V373, P393, DOI 10.1038/373393b0; ANKLIN M, 1993, NATURE, V364, P203, DOI 10.1038/364203a0; BENDER M, 1994, NATURE, V372, P663, DOI 10.1038/372663a0; BENNIKE O, 1994, BOREAS, V23, P479; Blunier T, 1998, NATURE, V394, P739, DOI 10.1038/29447; Brook EJ, 1996, SCIENCE, V273, P1087, DOI 10.1126/science.273.5278.1087; Caillon N, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017838; Caillon N, 2001, J GEOPHYS RES-ATMOS, V106, P31893, DOI 10.1029/2001JD900145; Chappellaz J, 1997, J GEOPHYS RES-OCEANS, V102, P26547, DOI 10.1029/97JC00164; CHAPPELLAZ J, 1993, NATURE, V366, P443, DOI 10.1038/366443a0; CHARLES CD, 1994, SCIENCE, V263, P508, DOI 10.1126/science.263.5146.508; CHARLES CD, 1995, SCIENCE, V269, P247, DOI 10.1126/science.269.5221.247; Clausen HB, 1997, J GEOPHYS RES-OCEANS, V102, P26707, DOI 10.1029/97JC00587; Cuffey KM, 2000, NATURE, V404, P591, DOI 10.1038/35007053; CUFFEY KM, 1995, SCIENCE, V270, P455, DOI 10.1126/science.270.5235.455; DahlJensen D, 2003, ANN GLACIOL-SER, V37, P207, DOI 10.3189/172756403781815492; DahlJensen D, 2002, ANN GLACIOL-SER, V35, P1, DOI 10.3189/172756402781817275; DahlJensen D, 1997, J GLACIOL, V43, P300, DOI 10.3189/S0022143000003245; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Dawes P., 1976, GEOLOGY GREENLAND, P248; Fahnestock M, 2001, SCIENCE, V294, P2338, DOI 10.1126/science.1065370; Fahnestock MA, 2001, J GEOPHYS RES-ATMOS, V106, P34035, DOI 10.1029/2001JD900194; Fluckiger J, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002122; Fuchs A, 1996, GEOPHYS RES LETT, V23, P1049, DOI 10.1029/96GL00588; Gregory JM, 2004, NATURE, V428, P616, DOI 10.1038/428616a; Grinsted A, 2002, ANN GLACIOL-SER, V35, P527, DOI 10.3189/172756402781817130; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; Huybrechts P, 2002, QUATERNARY SCI REV, V21, P203, DOI 10.1016/S0277-3791(01)00082-8; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; Johnsen SJ, 2001, J QUATERNARY SCI, V16, P299, DOI 10.1002/jqs.622; Johnsen SJ, 1997, J GEOPHYS RES-OCEANS, V102, P26397, DOI 10.1029/97JC00167; JOHNSEN SJ, 1995, TELLUS B, V47, P624, DOI 10.1034/j.1600-0889.47.issue5.9.x; Khodri M, 2001, NATURE, V410, P570, DOI 10.1038/35069044; Kukla G, 1997, QUATERNARY SCI REV, V16, P605, DOI 10.1016/S0277-3791(96)00114-X; Landais A., 2003, J GEOPHYS RES, P108, DOI [10.1029/2002JD0003147, DOI 10.1029/2002JD0003147]; LETREGUILLY A, 1991, J GLACIOL, V37, P149; LETREGUILLY A, 1991, GLOBAL PLANET CHANGE, V90, P385, DOI 10.1016/0921-8181(91)90004-G; Marshall SJ, 2000, EARTH PLANET SC LETT, V179, P73, DOI 10.1016/S0012-821X(00)00108-4; McManus JF, 2002, QUATERNARY RES, V58, P17, DOI 10.1006/qres.2002.2367; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; PETIT JR, IN PRESS LESSONS EXO; Reeh N, 2002, ANN GLACIOL-SER, V35, P136, DOI 10.3189/172756402781817365; Schwander J, 1997, J GEOPHYS RES-ATMOS, V102, P19483, DOI 10.1029/97JD01309; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; Shackleton NJ, 2000, PALEOCEANOGRAPHY, V15, P565, DOI 10.1029/2000PA000513; Stocker TF, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2003PA000920; SUWA M, 2003, GEOPH RES ABSTR, V5; TAYLOR KC, 1993, NATURE, V366, P549, DOI 10.1038/366549a0; Waelbroeck C, 2002, QUATERNARY SCI REV, V21, P295, DOI 10.1016/S0277-3791(01)00101-9; Watanabe O, 2003, NATURE, V422, P509, DOI 10.1038/nature01525	50	1993	2078	21	477	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2004	431	7005					147	151		10.1038/nature02805	http://dx.doi.org/10.1038/nature02805			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356621	Green Submitted			2022-12-28	WOS:000223746000034
J	Blacker, CVR; Greenwood, DT; Wesnes, KA; Wilson, R; Woodward, C; Howe, I; Ali, T				Blacker, CVR; Greenwood, DT; Wesnes, KA; Wilson, R; Woodward, C; Howe, I; Ali, T			Effect of galantamine hydrobromide in chronic fatigue syndrome - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PITUITARY-ADRENAL AXIS; GALANTHAMINE HYDROBROMIDE; STIMULATION; ACTIVATION; RESPONSES; CORTISOL; SLEEP	Context There is no established pharmacological treatment for the core symptoms of chronic fatigue syndrome (CFS). Galantamine hydrobromide, an acetyl cholesterone inhibitor, has pharmacological properties that might benefit patients with CFS. Objective To compare the efficacy and tolerability of galantamine hydrobromide in patients with CFS. Design, Setting, and Patients Randomized, double-blind trial conducted June 1997 through July 1999 at 35 outpatient centers in the United Kingdom (n=17), United States (n=14), the Netherlands (n=2), Sweden (n=1), and Belgium (n=1) involving 434 patients with a clinical diagnosis of CFS (modified US Centers for Disease Control and Prevention criteria). Interventions A total of 89 patients were randomly assigned to receive 2.5 mg of galantamine hydrobromide; 86 patients, 5.0 mg; 91 patients, 7.5 mg; and 86 patients, 10 mg (these patients received medicine in the tablet form 3 times per day); a total of 82 patients received matching placebo tablets 3 times per day. Main Outcome Measures The primary efficacy variable was the global change on the Clinician Global Impression Scale after 4, 8,12, and 16 weeks of treatment. Secondary outcomes were changes in core symptoms of CFS on the Chalder Fatigue Rating Scale, the Fibromyalgia Impact Questionnaire, and the Pittsburgh Sleep Quality Index; changes in quality of life on the Nottingham Health Profile; and assessment of plasma-free cortisol levels and cognitive performance on a computer-based battery of tests. Results After 16 weeks, there were no statistically significant differences between any of the galantamine or placebo groups in clinical condition on the Clinician Global Impression Scale, or for any of the secondary end points. Exploratory regression analysis failed to detect any consistent prognostic factor that might have influenced the primary or any secondary outcome measures. Conclusion This trial did not demonstrate any benefit of galantamine over placebo in the treatment of patients with CFS.	Univ Exeter, Dept Hlth & Social Sci, Exeter, Devon, England; Marix Drug Dev Ltd, Cardiff, S Glam, Wales; PPD Dev, Cambridge, England; Cognit Drug Res Ltd, Goring On Thames, England; Spica Consultants Ltd, E Grafton, England; Shire Pharmaceut Dev Ltd, Basingstoke, Hants, England; Bioenvis Ltd, Edinburgh, Midlothian, Scotland	University of Exeter; Shire Pharmaceuticals Limited	Blacker, CVR (corresponding author), Wonford House Hosp, Dept Hlth & Social Sci, Dryden Rd, Exeter EX2 5AF, Devon, England.	c.v.r.blacker@btinternet.com	Wesnes, Keith A/D-7148-2018	Wesnes, Keith/0000-0002-4498-8511				BECH P, 1993, ACTA PSYCHIAT SCAND, V87, P3, DOI 10.1111/j.1600-0447.1993.tb05583.x; BOULWARE DW, 1990, POSTGRAD MED, V87, P211; BURCKHARDT CS, 1991, J RHEUMATOL, V18, P728; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; CLEARE AJ, 1995, J AFFECT DISORDERS, V34, P283, DOI 10.1016/0165-0327(95)00026-J; COZANITIS DA, 1974, ANAESTHESIA, V29, P163, DOI 10.1111/j.1365-2044.1974.tb00615.x; CROFFORD LJ, 1994, ARTHRITIS RHEUM-US, V37, P1583, DOI 10.1002/art.1780371105; DAVIS BM, 1982, PSYCHONEUROENDOCRINO, V7, P347, DOI 10.1016/0306-4530(82)90038-5; de Deyn PP, 2004, INT J NEUROPSYCHOPH, V7, pS382; DEMITRACK MA, 1991, J CLIN ENDOCR METAB, V73, P1224, DOI 10.1210/jcem-73-6-1224; DINAN TG, 1996, J CHRONIC FATIGUE SY, V2, P69; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; GANN H, 1994, PSYCHIAT RES, V51, P253; Gopel W, 1971, Psychiatr Neurol Med Psychol (Leipz), V23, P712; MAJEED T, 1996, J CHRONIC FATIGUE SY, V2, P118; McKeith I, 2000, LANCET, V356, P2031, DOI 10.1016/S0140-6736(00)03399-7; MOLDOFSKY H, 1988, J RHEUMATOL, V15, P1701; RAINER M, 1989, PHARM INTERVENTIONS, P223; Scott LV, 1998, ACTA PSYCHIAT SCAND, V97, P450, DOI 10.1111/j.1600-0447.1998.tb10030.x; Scott LV, 1998, PSYCHOL MED, V28, P285, DOI 10.1017/S0033291797006260; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; SNORRASON E, 1991, LANCET, V337, P557, DOI 10.1016/0140-6736(91)91347-W; Snorrason E, 1996, J CHRONIC FATIGUE SY, V2, P35, DOI DOI 10.1300/J092v02n02_04; Warren G, 1999, ACTA NEUROL SCAND, V99, P112, DOI 10.1111/j.1600-0404.1999.tb00667.x; Wesnes K., 1998, J PSYCHOPHARMACOL SA, V12, pA46; Wesnes KA, 1997, PSYCHOPHARMACOL BULL, V33, P677; WESNES KA, 1991, ANN NY ACAD SCI, V640, P268; WESNES KA, 2003, ACNP 42 ANN M SAN JU, P171; WESNES KA, 2002, EVIDENCE BASED DEMEN, P639; Wesnes Keith, 1994, Psychopharmacology Bulletin, V30, P139; WESSELY S, 1998, CHRONIC FATIGUE ITS, P135; White KP, 1996, PAIN, V64, P211, DOI 10.1016/0304-3959(95)00213-8; Whitehead J, 1997, DESIGN ANAL SEQUENTI; Whiting P, 2001, JAMA-J AM MED ASSOC, V286, P1360, DOI 10.1001/jama.286.11.1360; WILCOCK GK, 1996, 4 INT C ALZH DIS REL	36	27	28	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2004	292	10					1195	1204		10.1001/jama.292.10.1195	http://dx.doi.org/10.1001/jama.292.10.1195			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851ZA	15353532				2022-12-28	WOS:000223723800019
J	Singer, PA				Singer, PA		BMJ Ethics Comm	Consent to the publication of patient information	BRITISH MEDICAL JOURNAL			English	Article									Univ Toronto, Joint Ctr Bioeth, Toronto, ON M5G 1L4, Canada	University of Toronto	Singer, PA (corresponding author), Univ Toronto, Joint Ctr Bioeth, 88 Coll St, Toronto, ON M5G 1L4, Canada.	peter.singer@utoronto.ca						ANDRADE C, 2002, BRIT MED J, V325, P1169; Bernstein M, 2003, CAN J SURG, V46, P144; COLLINS I, 2002, BRIT MED J, V325, P1358; *GEN MED COUNC, CONF PROT PROV INF P; Gottlieb S, 2001, BRIT MED J, V322, P259; *INT COMM MED J ED, 2004, UN REQ MAN SUBM BIOM; JOSEFSON D, 2001, BRIT MED J, V323, P472; KERR D, 2002, BRIT MED J, V325, P1011; PALIMAR P, 2002, BRIT MED J, V325, P1104; Shah S, 2000, JAMA-J AM MED ASSOC, V284, P1897, DOI 10.1001/jama.284.15.1897; Smith R, 1998, BMJ-BRIT MED J, V316, P949, DOI 10.1136/bmj.316.7136.949	11	24	25	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 4	2004	329	7465					566	568		10.1136/bmj.329.7465.566	http://dx.doi.org/10.1136/bmj.329.7465.566			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853DE	15345634	Green Published			2022-12-28	WOS:000223805800029
J	Travis, P; Bennett, S; Haines, A; Pang, T; Bhutta, Z; Hyder, AA; Pielemeier, NR; Mills, A; Evans, T				Travis, P; Bennett, S; Haines, A; Pang, T; Bhutta, Z; Hyder, AA; Pielemeier, NR; Mills, A; Evans, T			Overcoming health-systems constraints to achieve the Millennium Development Goals	LANCET			English	Article								Effective interventions exist for many priority health problems in low income countries; prices are falling, and funds are increasing. However, progress towards agreed health goals remains slow. There is increasing consensus that stronger health systems are key to achieving improved health outcomes. There is much less agreement on quite how to strengthen them. Part of the challenge is to get existing and emerging knowledge about more (and less) effective strategies into practice. The evidence base also remains remarkably weak, partly because health-systems research has an image problem. The forthcoming Ministerial Summit on Health Research seeks to help define a learning agenda for health systems, so that by 2015, substantial progress will have been made to reducing the system constraints to achieving the MDGs.	WHO, Dept Hlth Syst Policies & Operat, CH-1211 Geneva, Switzerland; WHO, Dept Res Policy & Cooperat, CH-1211 Geneva, Switzerland; WHO, Dept Evidence & Informat Policy Cluster, CH-1211 Geneva, Switzerland; ABT Associates Inc, Partners Hlth Reformplus Project, Bethesda, MD USA; London Sch Hyg & Trop Med, London WC1, England; Aga Khan Univ, Karachi, Pakistan; Johns Hopkins Univ, Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Alliance Hlth Policy & Syst Res, Geneva, Switzerland	World Health Organization; World Health Organization; World Health Organization; ABT Associates; University of London; London School of Hygiene & Tropical Medicine; Aga Khan University; Johns Hopkins University	Travis, P (corresponding author), WHO, Dept Hlth Syst Policies & Operat, CH-1211 Geneva, Switzerland.	travisp@who.int	Hyder, Adnan/AAT-9503-2021	Mills, Anne/0000-0001-9863-9950; Hyder, Adnan/0000-0002-7292-577X; Haines, Andy/0000-0002-8053-4605; bennett, sara/0000-0001-8094-8798				*ALM AT, 1978, DECL AL AT INT C PRI; [Anonymous], 2004, WORLD REP ROAD TRAFF; ATUN RA, IN PRESS EUR J PUBLI; ATUN RA, IN PRESS B WHO; Bhutta ZA, 2004, BMJ-BRIT MED J, V328, P816, DOI 10.1136/bmj.328.7443.816; BROEKMANS J, 2004, M MILL DEV GOALS REV; CHEN LC, 2004, HARNESSING POWER HUM; Claeson M, 2003, LANCET, V362, P323, DOI 10.1016/S0140-6736(03)13977-3; CLEMENS M, 2004, 40 CTR GLOB DEV; Dollar David, 1998, ASSESSING AID WHAT W; FREEDMAN L, 2004, MILLENNIUM PROJECT I; Gilson L., 1997, PRIVATE HLTH PROVIDE, P276; GONZALEZBLOCK M, 2004, WHO B; Hanson K, 2003, J INT DEV, V15, P1, DOI DOI 10.1002/JID.963; Janovsky Katja., 1996, HLTH POLICY SYSTEMS, P11; MEEK S, 6 WHO; Mogedal S., 2000, DIS ERADICATION FRIE; MUNISHI G, 2003, J INT DEV, V15, P115; Nunn P, 2002, B WORLD HEALTH ORGAN, V80, P471; SACHS J, 2004, ECONOMIST, P21; Soucat A, 2002, MARGINAL BUDGETING B; *TASKF HLTH SYST R, IN PRESS LANCET; WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804; WHO, 2004, HIGH LEV FOR HLTH MD; *WHO, 1996, TDRGEN961 WHO; *WHO, 2002, STRAT APPR IMPR REPR; *WHO, 2003, M 2 HOC COMM TB EP R; *WHO DEP CHILD AD, 2003, PROGR REP MAY 2002 A; *WORLD BANK, 2003, MILL DEV GOALS HLTH; World Health Organization, 2000, WORLD HLTH REP 2000; World Health Organization, 2004, WORLD HLTH REP 2004; World Health Organization, 2001, MACR HLTH INV HLTH E; 2004, LANCET, V363, P1745	33	531	545	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2004	364	9437					900	906		10.1016/S0140-6736(04)16987-0	http://dx.doi.org/10.1016/S0140-6736(04)16987-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351199				2022-12-28	WOS:000223685200038
J	Woodman, AM; Douglas, JF; Jefferson, JA				Woodman, AM; Douglas, JF; Jefferson, JA			Recurrent hyperkalaemia cured by amputation	LANCET			English	Editorial Material									Belfast City Hosp, Reg Nephrol Unit, Belfast BT9 7AB, Antrim, North Ireland	Belfast City Hospital	Woodman, AM (corresponding author), Belfast City Hosp, Reg Nephrol Unit, Belfast BT9 7AB, Antrim, North Ireland.	alastair.woodman@virgin.net	Jefferson, Jonathan/AAA-9679-2019					HARRINGTON JT, 1975, NEW ENGL J MED, V293, P1241, DOI 10.1056/NEJM197512112932407; SANSOM SC, 2001, TXB NEPHROLOGY, P276	2	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	2004	364	9437					908	908		10.1016/S0140-6736(04)16989-4	http://dx.doi.org/10.1016/S0140-6736(04)16989-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351201				2022-12-28	WOS:000223685200040
J	Rose, C; Wright, G				Rose, C; Wright, G			Inscribed matter as an energy efficient means of communication with an extraterrestrial civilization	NATURE			English	Article							INTERSTELLAR; SPACE	It is well known that electromagnetic radiation - radio waves can in principle be used to communicate over interstellar distances(1,2). By contrast, sending physical artefacts has seemed extravagantly wasteful of energy, and imagining human travel between the stars even more so(3,4). The key consideration in earlier work, however, was the perceived need for haste. If extraterrestrial civilizations existed within a few tens of light years, radio could be used for two-way communication on timescales comparable to human lifetimes ( or at least the longevities of human institutions). Here we show that if haste is unimportant, sending messages inscribed on some material can be strikingly more energy efficient than communicating by electromagnetic waves. Because messages require protection from cosmic radiation and small messages could be difficult to find among the material clutter near a recipient, `inscribed matter' is most effective for long archival messages ( as opposed to potentially short "we exist" announcements). The results suggest that our initial contact with extraterrestrial civilizations may be more likely to occur through physical artefacts - essentially messages in a bottle - than via electromagnetic communication.	Rutgers State Univ, Dept Elect & Comp Engn, WINLAB, Piscataway, NJ 08854 USA; Antiope Associates, Fair Haven, NJ 07704 USA	Rutgers State University New Brunswick	Rose, C (corresponding author), Rutgers State Univ, Dept Elect & Comp Engn, WINLAB, Piscataway, NJ 08854 USA.	crose@winlab.rutgers.edu	Rose, Christopher/M-5309-2018	Rose, Christopher/0000-0002-6123-7154				BRACEWELL R, 1960, NATURE, V187, P670; BUSSARD RW, 1965, FUNDAMENTALS NUCL FL, P16; COCCONI G, 1959, NATURE, V184, P844, DOI 10.1038/184844a0; COVER TM, 1991, ELEMENTS INFORMATION, P247; CRICK FHC, 1973, ICARUS, V19, P341, DOI 10.1016/0019-1035(73)90110-3; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; Landauer R, 1996, SCIENCE, V272, P1914, DOI 10.1126/science.272.5270.1914; Mileikowsky C, 2000, ICARUS, V145, P391, DOI 10.1006/icar.1999.6317; PAPAGIANNIS MD, 1978, Q J ROY ASTRON SOC, V19, P277; PIERCE JR, 1959, P IRE, V47, P1053, DOI 10.1109/JRPROC.1959.287133; Purcell E., 1963, INTERSTELLAR COMMUNI, P121; SCHWARTZ RN, 1961, NATURE, V190, P205, DOI 10.1038/190205a0; Skolnik Merrill, 2002, INTRO RADAR SYSTEMS, V3rd, P4; Stuhlinger E., 1964, ION PROPULSION SPACE; TOWNES CH, 1983, P NATL ACAD SCI USA, V80, P1147, DOI 10.1073/pnas.80.4.1147	15	51	51	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2004	431	7004					47	49		10.1038/nature02884	http://dx.doi.org/10.1038/nature02884			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343327				2022-12-28	WOS:000223641500036
J	Joensuu, H; Lehtimaki, T; Holli, K; Elomaa, L; Turpeenniemi-Hujanen, T; Kataja, V; Anttila, A; Lundin, M; Isola, J; Lundin, J				Joensuu, H; Lehtimaki, T; Holli, K; Elomaa, L; Turpeenniemi-Hujanen, T; Kataja, V; Anttila, A; Lundin, M; Isola, J; Lundin, J			Risk for distant recurrence of breast cancer detected by mammography screening or other methods	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERVAL CARCINOMAS; PROGNOSTIC-FACTORS; SURVIVAL; PROGRAM; DISEASE; COHORT; WOMEN; NATIONWIDE; FEATURES; TRIAL	Context Selection of systemic adjuvant therapies for women diagnosed as having breast cancer is based on risk estimations for cancer recurrence. In such estimations, tumors detected by mammography screening are considered to be associated with a similar risk of recurrence as tumors of similar size found by other methods. Objective To compare the risk of recurrence and survival among women with cancerous tumors detected by mammography screening compared with other methods (outside of screening). Design, Setting, and Patients Retrospective study comparing clinical, histopathological, and biological features of cancerous tumors detected by mammography screening compared with tumors detected outside of screening. Women diagnosed as having breast cancer in 1991 or 1992 were identified from the Finnish Cancer Registry (n=2842). The median follow-up time was 9.5 years. Cancer biological variables were analyzed from tumor tissue microarrays using immunohistochemistry or in situ hybridization and included ERBB2, TP53, and MK167 expression and ERBB2 amplification data. Main Outcome Measures Univariate and multivariate analyses of potential risk factors for distant recurrence of breast cancer and 10-year survival. Results Of the 1983 women with unilateral invasive breast cancer, data on tumor diameter were available for 1918 women. Women with cancerous tumors detected by mammography screening had better estimated 10-year distant disease-free survival than women with tumors found outside of screening (tumor size of less than or equal to 10 mm [n=386] 92% vs 85% [P=.04]; 11-20 mm [n=808] 88% vs 76% [P<.001]; 21-30 mm [n=409] 86% vs 63% [P=.008]; >30 mm [n=315] 68% vs 50% [P=.12], respectively). In a Cox multivariate model that included cancer biological factors, the relative hazard ratio for distant recurrence among women with tumors detected outside of screening (HR, 1.90; 95% confidence interval, 1.15-3.11) was significantly higher than among women with tumors detected by mammography screening (P=.01). Breast cancer diagnosis by mammography screening was an independent prognostic variable reducing the relative HR for distant recurrence. This effect was equal to or greater than the effect of 1-cm decrease in tumor diameter (HR, 1.20; 95% confidence interval, 1.10-1.31). Conclusions Cancerous tumors detected by mammography screening are associated with a better prognosis than tumors of similar size found outside of screening. The risk of distant metastases is overestimated for women diagnosed as having cancer by mammography screening unless the method of detection is taken into account in risk estimations.	Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00029 Helsinki, Finland; Tampere Univ Hosp, Dept Pallliat Med, Tampere, Finland; Tampere Univ Hosp, Dept Oncol, Tampere, Finland; Univ Turku, Cent Hosp, Dept Oncol, FIN-20520 Turku, Finland; Oulu Univ, Cent Hosp, Dept Radiotherapy & Oncol, SF-90220 Oulu, Finland; Kuopio Univ Hosp, Dept Oncol, Kuopio, Finland; Finnish Canc Registry, FIN-00170 Helsinki, Finland; Tampere Univ, Inst Med Technol, Tampere, Finland; Folkhalsan Res Ctr, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University Hospital; Tampere University; Tampere University Hospital; University of Turku; University of Oulu; Kuopio University Hospital; University of Eastern Finland; Finnish Cancer Registry; Tampere University; Folkhalsan Research Center	Joensuu, H (corresponding author), Univ Helsinki, Cent Hosp, Dept Oncol, Haartmaninkatu 4,POB 180, FIN-00029 Helsinki, Finland.	heikki.joensuu@hus.fi	Lundin, Johan/I-1843-2018; Lehtimäki, Terho/AAD-1094-2022; Lundin, Johan/AAC-8510-2020	Lundin, Johan/0000-0002-2681-4139; Lehtimäki, Terho/0000-0002-2555-4427; Lundin, Johan/0000-0002-2681-4139; Joensuu, Heikki/0000-0003-0281-2507; Kataja, Vesa/0000-0003-4846-4843				[Anonymous], 1981, HIST TYP BREAST TUM; BREKELMANS CT, 1995, EUR J CANCER, V31A, P1830, DOI 10.1016/0959-8049(95)00324-C; Burrell HC, 1996, RADIOLOGY, V199, P811, DOI 10.1148/radiology.199.3.8638010; Colacurci N, 2001, MATURITAS, V40, P159, DOI 10.1016/S0378-5122(01)00232-8; COX DR, 1972, J R STAT SOC B, V34, P187; Crosier M, 1999, CLIN CANCER RES, V5, P2682; DALAND E. M., 1927, Surgery, Gynecology and Obstetrics, V44, P264; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FRISELL J, 1992, BREAST CANCER RES TR, V24, P11, DOI 10.1007/BF01832353; Gilliland FD, 2000, J NATL CANCER I, V92, P743, DOI 10.1093/jnci/92.9.743; Goldhirsch A, 2001, J CLIN ONCOL, V19, P3817, DOI 10.1200/JCO.2001.19.18.3817; Groenendijk RPR, 2000, BRIT J CANCER, V82, P381; Hakama M, 1997, BRIT MED J, V314, P864; HOLFORD TR, 1991, J CLIN EPIDEMIOL, V44, P29, DOI 10.1016/0895-4356(91)90198-I; HOLMBERG LH, 1986, LANCET, V2, P27; IKEDA DM, 1992, AM J ROENTGENOL, V159, P287, DOI 10.2214/ajr.159.2.1632342; JOENSUU H, 1995, J CLIN ONCOL, V13, P62, DOI 10.1200/JCO.1995.13.1.62; Klemi PJ, 2003, BREAST, V12, P308, DOI 10.1016/S0960-9776(03)00096-1; KLEMI PJ, 1992, BRIT MED J, V304, P467, DOI 10.1136/bmj.304.6825.467; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lee AKC, 1997, CANCER-AM CANCER SOC, V79, P761, DOI 10.1002/(SICI)1097-0142(19970215)79:4<761::AID-CNCR13>3.3.CO;2-K; Lundin J, 2001, J CLIN ONCOL, V19, P28, DOI 10.1200/JCO.2001.19.1.28; Magee B, 1999, CLIN ONCOL-UK, V11, P40, DOI 10.1053/clon.1999.9007; MANTEL N, 1959, J NATL CANCER I, V22, P719; Moody-Ayers SY, 2000, ARCH INTERN MED, V160, P1109, DOI 10.1001/archinte.160.8.1109; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; Nielsen M, 1989, APMIS Suppl, V10, P1; PEETERS PHM, 1989, BRIT J CANCER, V59, P929, DOI 10.1038/bjc.1989.196; Porter PL, 1999, J NATL CANCER I, V91, P2020, DOI 10.1093/jnci/91.23.2020; Rampaul RS, 2001, EUR J SURG ONCOL, V27, P229, DOI 10.1053/ejso.2001.1114; Schroen AA, 1996, J SURG ONCOL, V63, P141, DOI 10.1002/(SICI)1096-9098(199611)63:3<141::AID-JSO2>3.0.CO;2-D; SENIE RT, 1994, CANCER-AM CANCER SOC, V73, P1666, DOI 10.1002/1097-0142(19940315)73:6<1666::AID-CNCR2820730619>3.0.CO;2-E; Tabar L, 2000, LANCET, V355, P429; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; Vitak B, 1998, EUR RADIOL, V8, P639, DOI 10.1007/s003300050452; VONROSEN A, 1985, BREAST CANCER RES TR, V6, P221, DOI 10.1007/BF01806772; WADE P, 1946, BRIT J RADIOL, V19, P272, DOI 10.1259/0007-1285-19-223-272; Welch HG, 1997, ANN INTERN MED, V127, P1023, DOI 10.7326/0003-4819-127-11-199712010-00014; Yassin M M, 2003, Asian J Surg, V26, P101, DOI 10.1016/S1015-9584(09)60229-3; Zahl PH, 2004, BMJ-BRIT MED J, V328, P921, DOI 10.1136/bmj.38044.666157.63	40	148	151	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2004	292	9					1064	1073		10.1001/jama.292.9.1064	http://dx.doi.org/10.1001/jama.292.9.1064			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VH	15339900				2022-12-28	WOS:000223568700022
J	Cuervo, AM; Stefanis, L; Fredenburg, R; Lansbury, PT; Sulzer, D				Cuervo, AM; Stefanis, L; Fredenburg, R; Lansbury, PT; Sulzer, D			Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy	SCIENCE			English	Article							RAT-LIVER LYSOSOMES; PARKINSONS-DISEASE; CYTOSOLIC PROTEINS; SELECTIVE UPTAKE; PROTEASOME; NEURONS; SYSTEM; AGGREGATION; MECHANISMS; PATHWAY	Aberrant alpha-synuclein degradation is implicated in Parkinson's disease pathogenesis because the protein accumulates in the Lewy inclusion bodies associated with the disease. Little is known, however, about the pathways by which wild-type alpha-synuclein is normally degraded. We found that wild-type alpha-synuclein was selectively translocated into lysosomes for degradation by the chaperone-mediated autophagy pathway. The pathogenic A53T and A30P alpha-synuctein mutants bound to the receptor for this pathway on the lysosomal membrane, but appeared to act as uptake blockers, inhibiting both their own degradation and that of other substrates. These findings may underlie the toxic gain-of-function by the mutants.	Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Acad Athens, Fdn Biomed Res, Neurobiol Lab, Athens 11527, Greece; Columbia Univ, Dept Neurol & Pathol, New York, NY 10032 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis,Dept Neurol, Cambridge, MA 02139 USA; Columbia Univ, Dept Neurosci, New York State Psychiat Inst, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Dept Neurosci, New York State Psychiat Inst, Dept Neurol, New York, NY 10032 USA	Yeshiva University; Albert Einstein College of Medicine; Academy of Athens; Columbia University; Harvard University; Brigham & Women's Hospital; Columbia University; New York State Psychiatry Institute; Columbia University; New York State Psychiatry Institute	Cuervo, AM (corresponding author), Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Anat & Struct Biol, Bronx, NY 10461 USA.	amcuervo@aecom.yu.edu	Stefanis, Leonidas/AAD-7192-2019	Cuervo, Ana Maria/0000-0002-0771-700X	NATIONAL INSTITUTE ON AGING [R01AG021904] Funding Source: NIH RePORTER; NIA NIH HHS [AG021904] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Ancolio K, 2000, NEUROSCI LETT, V285, P79, DOI 10.1016/S0304-3940(00)01049-1; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Cuervo AM, 1998, J MOL MED-JMM, V76, P6, DOI 10.1007/s109-1998-8099-y; CUERVO AM, 1994, J BIOL CHEM, V269, P26374; Cuervo AM, 1997, J BIOL CHEM, V272, P5606, DOI 10.1074/jbc.272.9.5606; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dice J. F., 2000, LYSOSOMAL PATHWAYS P; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; Fuertes G, 2003, BIOCHEM J, V375, P75, DOI 10.1042/BJ20030282; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Grantcharova V, 2001, CURR OPIN STRUC BIOL, V11, P70, DOI 10.1016/S0959-440X(00)00176-7; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Lee HJ, 2004, J NEUROSCI, V24, P1888, DOI 10.1523/JNEUROSCI.3809-03.2004; Massey A., UNPUB; McNaught KSP, 2001, NAT REV NEUROSCI, V2, P589, DOI 10.1038/35086067; Nussbaum RL, 1997, HUM MOL GENET, V6, P1687, DOI 10.1093/hmg/6.10.1687; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Rideout HJ, 2002, MOL CELL NEUROSCI, V21, P223, DOI 10.1006/mcne.2002.1173; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Salvador N, 2000, J BIOL CHEM, V275, P27447; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Wilson CA, 2004, J CELL BIOL, V165, P335, DOI 10.1083/jcb.200403061	28	1466	1510	1	162	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2004	305	5688					1292	1295		10.1126/science.1101738	http://dx.doi.org/10.1126/science.1101738			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850PJ	15333840				2022-12-28	WOS:000223624600042
J	Hanaguri, T; Lupien, C; Kohsaka, Y; Lee, DH; Azuma, M; Takano, M; Takagi, H; Davis, JC				Hanaguri, T; Lupien, C; Kohsaka, Y; Lee, DH; Azuma, M; Takano, M; Takagi, H; Davis, JC			A 'checkerboard' electronic crystal state in lightly hole-doped Ca2-xNaxCuO2Cl2	NATURE			English	Article							QUASI-PARTICLE STATES; PSEUDOGAP; MAGNETISM; PHASES; MODEL	The phase diagram of hole-doped copper oxides shows four different electronic phases existing at zero temperature. Familiar among these are the Mott insulator, high-transition-temperature superconductor and metallic phases. A fourth phase, of unknown identity, occurs at light doping along the zero-temperature bound of the 'pseudogap' regime(1). This regime is rich in peculiar electronic phenomena(1), prompting numerous proposals that it contains some form of hidden electronic order. Here we present low-temperature electronic structure imaging studies of a lightly hole-doped copper oxide: Ca2-xNaxCuO2Cl2. Tunnelling spectroscopy (at energies \E\ > 100 meV) reveals electron extraction probabilities greatly exceeding those for injection, as anticipated for a doped Mott insulator. However, for \E\ < 100 meV, the spectrum exhibits a V-shaped energy gap centred on E = 0. States within this gap undergo intense spatial modulations, with the spatial correlations of a four CuO2-unit-cell square 'checkerboard', independent of energy. Intricate atomic-scale electronic structure variations also exist within the checkerboard. These data are consistent with an unanticipated crystalline electronic state, possibly the hidden electronic order, existing in the zero-temperature pseudogap regime of Ca2-xNaxCuO2Cl2.	Cornell Univ, Dept Phys, LASSP, Ithaca, NY 14853 USA; RIKEN, Inst Phys & Chem Res, Magnet Mat Lab, Wako, Saitama 3510198, Japan; Japan Sci & Technol Agcy, Kawaguchi 3320012, Japan; Univ Tokyo, Dept Adv Mat Sci, Kashiwa, Chiba 2778651, Japan; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Kyoto Univ, Chem Res Inst, Uji, Kyoto 6010011, Japan	Cornell University; RIKEN; Japan Science & Technology Agency (JST); University of Tokyo; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Kyoto University	Takagi, H (corresponding author), Cornell Univ, Dept Phys, LASSP, Ithaca, NY 14853 USA.	hanaguri@riken.jp; jcdavis@ccmr.cornell.edu	Hanaguri, Tetsuo/I-6710-2012; TAKAGI, HIDENORI/Q-1041-2019; Azuma, Masaki/C-2945-2009; Kohsaka, Yuhki/A-4428-2009; Takagi, Hidenori/B-2935-2010; Lupien, Christian/C-2148-2008	Hanaguri, Tetsuo/0000-0003-2896-0081; TAKAGI, HIDENORI/0000-0001-5700-3761; Azuma, Masaki/0000-0002-8378-321X; Kohsaka, Yuhki/0000-0002-6459-2661; Lupien, Christian/0000-0003-1767-8603				ANDERSON PW, 2004, SUGGESTED 4 X 4 STRU; Bosch M, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.092501; Chakravarty S, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.094503; Chen HD, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.137004; CHEN HD, 2004, PAIR DENSITY WAVE PS; Cren T, 2001, EUROPHYS LETT, V54, P84, DOI 10.1209/epl/i2001-00232-4; FU H, 2004, CHARGE ORDERING OBSE; HIROI Z, 1994, NATURE, V371, P139, DOI 10.1038/371139a0; Hoffman JE, 2002, SCIENCE, V295, P466, DOI 10.1126/science.1066974; Howald C, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.100504; Kivelson SA, 1998, NATURE, V393, P550, DOI 10.1038/31177; Kohsaka Y, 2002, J AM CHEM SOC, V124, P12275, DOI 10.1021/ja026680i; KOHSAKA Y, 2004, IN PRESS PHYS REV LE; LEE PA, 2003, PSEUDOGAP COMPETING; MACHIDA K, 1989, PHYSICA C, V158, P192, DOI 10.1016/0921-4534(89)90316-X; McElroy K, 2003, NATURE, V422, P592, DOI 10.1038/nature01496; MCELROY K, 2004, DESTRUCTION ANTINODA; Podolsky D, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.094514; Ronning F, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.165101; Ronning F, 1998, SCIENCE, V282, P2067, DOI 10.1126/science.282.5396.2067; Sachdev S, 2000, SCIENCE, V288, P475, DOI 10.1126/science.288.5465.475; TESANOVIC Z, 2004, CHARGE MODULATION SP; Timusk T, 1999, REP PROG PHYS, V62, P61, DOI 10.1088/0034-4885/62/1/002; Varma CM, 1997, PHYS REV B, V55, P14554, DOI 10.1103/PhysRevB.55.14554; Vershinin M, 2004, SCIENCE, V303, P1995, DOI 10.1126/science.1093384; Vojta M, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.104505; Wei JYT, 1998, PHYS REV B, V57, P3650, DOI 10.1103/PhysRevB.57.3650; White SR, 2000, PHYS REV B, V61, P6320, DOI 10.1103/PhysRevB.61.6320; ZAANEN J, 1989, PHYS REV B, V40, P7391, DOI 10.1103/PhysRevB.40.7391	30	574	579	1	107	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2004	430	7003					1001	1005		10.1038/nature02861	http://dx.doi.org/10.1038/nature02861			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329714	Green Submitted			2022-12-28	WOS:000223514900036
J	Begum, NA; Kinoshita, K; Kakazu, N; Muramatsu, M; Nagaoka, H; Shinkura, R; Biniszkiewicz, D; Boyer, LA; Jaenisch, R; Honjo, T				Begum, NA; Kinoshita, K; Kakazu, N; Muramatsu, M; Nagaoka, H; Shinkura, R; Biniszkiewicz, D; Boyer, LA; Jaenisch, R; Honjo, T			Uracil DNA glycosylase activity is dispensable for immunloglobulin class switch	SCIENCE			English	Article							SINGLE-STRANDED-DNA; CYTIDINE DEAMINASE AID; SOMATIC HYPERMUTATION; CRYSTAL-STRUCTURE; HISTONE H2AX; RECOMBINATION; ENZYME; MICE; REPLICATION; MUTATIONS	Activation-induced cytidine deaminase (AID) is required for the DNA cleavage step in immunoglobulin class switch recombination (CSR). AID is proposed to deaminate cytosine to generate uracil (U) in either mRNA or DNA. In the second instance, DNA cleavage depends on uracil DNA glycosylase (UNG) for removal of U. Using phosphorylated histone gamma-H2AX focus formation as a marker of DNA cleavage, we found that the UNG inhibitor Ugi did not inhibit DNA cleavage in immunoglobulin heavy chain (IgH) locus during CSR, even though Ugi blocked UNG binding to DNA and strongly inhibited CSR. Strikingly, UNG mutants that had lost the capability of removing U rescued CSR in UNG(-/-) B cells. These results indicate that UNG is involved in the repair step of CSR yet by an unknown mechanism. The dispensability of U removal in the DNA cleavage step of CSR requires a reconsideration of the model of DNA deamination by AID.	Kyoto Univ, Grad Sch Med, Dept Med Chem & Mol Biol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Kyoto University; Kyoto Prefectural University of Medicine; Massachusetts Institute of Technology (MIT); Whitehead Institute	Honjo, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med Chem & Mol Biol, Sakyo Ku, Kyoto 6068501, Japan.	honjo@mfour.med.kyoto-u.ac.jp	Muramatsu, Masamichi/C-4339-2015; Honjo, Tasuku/N-4470-2016	Muramatsu, Masamichi/0000-0002-0153-3533; Begum, Nasim/0000-0001-7177-188X				Anant S, 2001, CURR OPIN LIPIDOL, V12, P159, DOI 10.1097/00041433-200104000-00009; Bosma GC, 2002, J EXP MED, V196, P1483, DOI 10.1084/jem.20001871; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; De Silva FS, 2003, J VIROL, V77, P159, DOI 10.1128/JVI.77.1.159-166.2003; Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481; Doi T, 2003, P NATL ACAD SCI USA, V100, P2634, DOI 10.1073/pnas.0437710100; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Honjo T, 2004, IMMUNITY, V20, P659, DOI 10.1016/j.immuni.2004.05.011; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Ito S, 2004, P NATL ACAD SCI USA, V101, P1975, DOI 10.1073/pnas.0307335101; Kinoshita K, 2001, P NATL ACAD SCI USA, V98, P12620, DOI 10.1073/pnas.221454398; Manis JP, 2002, IMMUNITY, V16, P607, DOI 10.1016/S1074-7613(02)00306-0; Martin A, 2003, J EXP MED, V198, P1171, DOI 10.1084/jem.20030880; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nagaoka H, 2002, J EXP MED, V195, P529, DOI 10.1084/jem.20012144; Nambu Y, 2003, SCIENCE, V302, P2137, DOI 10.1126/science.1092481; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Shinkura R, 2004, NAT IMMUNOL, V5, P707, DOI 10.1038/ni1086; Sohail A, 2003, NUCLEIC ACIDS RES, V31, P2990, DOI 10.1093/nar/gkg464	29	91	91	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	2004	305	5687					1160	1163		10.1126/science.1098444	http://dx.doi.org/10.1126/science.1098444			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326357				2022-12-28	WOS:000223557400050
J	Hughes, IA				Hughes, IA			Female development - All by default?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Cambridge, Dept Paediat, Cambridge, England	University of Cambridge	Hughes, IA (corresponding author), Univ Cambridge, Dept Paediat, Cambridge, England.							Dale TC, 1998, BIOCHEM J, V329, P209; JOST A, 1953, RECENT PROG HORM RES, V8, P379; MacLaughlin DT, 2004, NEW ENGL J MED, V350, P367, DOI 10.1056/NEJMra022784; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068	4	7	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2004	351	8					748	750		10.1056/NEJMp048185	http://dx.doi.org/10.1056/NEJMp048185			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847CY	15317887				2022-12-28	WOS:000223367900006
J	Mulligan, SJ; MacVicar, BA				Mulligan, SJ; MacVicar, BA			Calcium transients in astrocyte endfeet cause cerebrovascular constrictions	NATURE			English	Article							CEREBRAL-BLOOD-FLOW; ARACHIDONIC-ACID; BRAIN-SLICES; PHOTOLYSIS; MICROSCOPY; EXCITATION; 20-HETE; CORTEX	Cerebral blood flow (CBF) is coupled to neuronal activity and is imaged in vivo to map brain activation(1). CBF is also modified by afferent projection fibres that release vasoactive neurotransmitters(2,3) in the perivascular region, principally on the astrocyte endfeet(4,5) that outline cerebral blood vessels(6). However, the role of astrocytes in the regulation of cerebrovascular tone remains uncertain. Here we determine the impact of intracellular Ca2+ concentrations ([Ca2+](i)) in astrocytes on the diameter of small arterioles by using two-photon Ca2+ uncaging(7,8) to increase [Ca2+](i). Vascular constrictions occurred when Ca2+ waves evoked by uncaging propagated into the astrocyte endfeet and caused large increases in [Ca2+](i). The vasoactive neurotransmitter noradrenaline(2,3) increased [Ca2+](i) in the astrocyte endfeet, the peak of which preceded the onset of arteriole constriction. Depressing increases in astrocyte [Ca2+](i) with BAPTA inhibited the vascular constrictions in noradrenaline. We find that constrictions induced in the cerebrovasculature by increased [Ca2+](i) in astrocyte endfeet are generated through the phospholipase A(2)-arachidonic acid pathway and 20-hydroxyeicosatetraenoic acid production. Vasoconstriction by astrocytes is a previously unknown mechanism for the regulation of CBF.	Univ British Columbia, Dept Psychiat, Brain Res Inst, Vancouver, BC V6T 2B5, Canada	University of British Columbia	MacVicar, BA (corresponding author), Univ British Columbia, Dept Psychiat, Brain Res Inst, 2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada.	bmacvica@interchange.ubc.ca	MacVicar, Brian/AAI-7729-2020; MacVicar, Brian/P-1553-2015	MacVicar, Brian/0000-0003-4596-4623; MacVicar, Brian/0000-0003-4596-4623				Basarsky TA, 1998, J NEUROSCI, V18, P7189; Brown EB, 1999, BIOPHYS J, V76, P489, DOI 10.1016/S0006-3495(99)77217-6; Chaigneau E, 2003, P NATL ACAD SCI USA, V100, P13081, DOI 10.1073/pnas.2133652100; Chillon J., 2002, CEREBRAL BLOOD FLOW, P395; Cohen Z, 1997, J CEREBR BLOOD F MET, V17, P894, DOI 10.1097/00004647-199708000-00008; Dreier JP, 2001, J PHYSIOL-LONDON, V531, P515, DOI 10.1111/j.1469-7793.2001.0515i.x; DUFFY S, 1995, J NEUROSCI, V15, P5535; Duffy S, 1996, J NEUROSCI, V16, P71; Farooqui AA, 1997, J NEUROCHEM, V69, P889; Gebremedhin D, 2000, CIRC RES, V87, P60, DOI 10.1161/01.RES.87.1.60; GOADSBY PJ, 2002, CEREBRAL BLOOD FLOW, P172; KANG J, 2000, IMAGING NEURONS LAB; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; Miyata N, 2001, BRIT J PHARMACOL, V133, P325, DOI 10.1038/sj.bjp.0704101; Paspalas CD, 1996, GLIA, V17, P133, DOI 10.1002/(SICI)1098-1136(199606)17:2<133::AID-GLIA5>3.0.CO;2-3; RAICHLE ME, 1975, P NATL ACAD SCI USA, V72, P3726, DOI 10.1073/pnas.72.9.3726; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Simard M, 2003, J NEUROSCI, V23, P9254; Soeller C, 1999, MICROSC RES TECHNIQ, V47, P182; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; WALZ W, 1988, BRAIN RES, V443, P321, DOI 10.1016/0006-8993(88)91626-5; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; Zhuo L, 1997, DEV BIOL, V187, P36, DOI 10.1006/dbio.1997.8601; Zonta M, 2003, NAT NEUROSCI, V6, P43, DOI 10.1038/nn980	24	642	666	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2004	431	7005					195	199		10.1038/nature02827	http://dx.doi.org/10.1038/nature02827			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356633				2022-12-28	WOS:000223746000047
J	Cooper, BS; Stone, SP; Kibbler, CC; Cookson, BD; Roberts, JA; Medley, GF; Duckworth, G; Lai, R; Ebrahim, S				Cooper, BS; Stone, SP; Kibbler, CC; Cookson, BD; Roberts, JA; Medley, GF; Duckworth, G; Lai, R; Ebrahim, S			Isolation measures in the hospital management of methicillin resistant Staphylococcus aureus (XMSA): Systematic review of the literature	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INTENSIVE-CARE-UNIT; INFECTION-CONTROL MEASURES; EPIDEMIOLOGIC ANALYSIS; INTRANASAL MUPIROCIN; OUTBREAK; MRSA; CARRIAGE; MICROBIOLOGY; COLONIZATION; SURVEILLANCE	Objective To evaluate the evidence for the effectiveness of isolation measures in reducing the incidence of methicillin resistant Staphylococcus aureus (MRSA) colonisation and infection in hospital inpatients. Design Systematic review of published articles. Data sources Medline, Embase, CINAHL, Cochrane Library, System for Information on Grey Literature in Europe (SIGLE), and citation lists (1966-2000). Review methods Articles reporting MRSA related outcomes and describing an isolation policy were selected. No quality restrictions were imposed on studies using isolation wards or nurse. cohorting. Other studies were included if they were prospective or employed planned comparisons of retrospective data. Results 46 studies were accepted; 18 used isolation wards, nine used nurse cohorting, and 19 used other isolation policies. Most were interrupted time series, with few planned formal prospective studies. All but one reported multiple interventions. Consideration of potential confounders, measures to prevent bias, and appropriate statistical analysis were mostly lacking. No conclusions could be drawn in a third of studies. Most others provided evidence consistent with a reduction of MRSA acquisition. Six long interrupted time series provided the strongest evidence. Four of these provided evidence that intensive control measures including patient isolation were effective in controlling MRSA. In two others, isolation wards failed to prevent endemic MRSA. Conclusion Major methodological weaknesses and inadequate reporting in published research mean that many plausible alternative explanations for reductions in MRSA acquisition associated with interventions cannot be excluded. No well designed studies exist that allow the role of isolation measures alone to be assessed. None the less, there is evidence that concerted efforts that include isolation can reduce MRSA even in endemic settings. Current isolation measures recommended in national guidelines should continue to be applied until further research establishes otherwise.	UCL Royal Free & Univ Coll Med Sch, Acad Dept Geriatr Med, London NW3 2PF, England; Univ London, Royal Free & Univ Coll Med Sch, Univ Dept Med Microbiol, London NW3 2PF, England; Cent Publ Hlth Lab, Hlth Protect Agcy, Lab Healthcare Associated Infect, London NW9 5HT, England; Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Collaborat Ctr Econ Infect Dis, London WC1E 7HT, England; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Hlth Protect Agcy, Div Healthcare Associated Infect & Antimicrobial, London NW9 5EQ, England; UCL Royal Free & Univ Coll Med Sch, Univ Lib, London, England; Univ Bristol, Sch Med, Dept Social Med, Bristol BS8 2PR, Avon, England	University of London; University College London; UCL Medical School; University of London; University College London; Health Protection Agency; Public Health England; University of London; London School of Hygiene & Tropical Medicine; University of Warwick; Health Protection Agency; Public Health England; University of London; University College London; UCL Medical School; University of Bristol	Stone, SP (corresponding author), UCL Royal Free & Univ Coll Med Sch, Acad Dept Geriatr Med, Royal Free Campus, London NW3 2PF, England.	s.stone@rfc.ucl.ac.uk	Cooper, Ben/HGC-7082-2022; Medley, Graham/B-7289-2008	Medley, Graham/0000-0002-0030-7278; Cooper, Ben/0000-0002-9445-7217				ALVAREZ S, 1985, AM J INFECT CONTROL, V13, P115, DOI 10.1016/S0196-6553(85)80012-2; ARNOW PM, 1982, J TRAUMA, V22, P954, DOI 10.1097/00005373-198211000-00012; Ayliffe GAJ, 1998, J HOSP INFECT, V39, P253, DOI 10.1016/S0195-6701(98)90293-6; Back NA, 1996, INFECT CONT HOSP EP, V17, P227; Barakate MS, 1999, AUST NZ J SURG, V69, P712, DOI 10.1046/j.1440-1622.1999.01689.x; Barakate MS, 2000, J HOSP INFECT, V44, P19, DOI 10.1053/jhin.1999.0635; BELL SM, 1982, MED J AUSTRALIA, V1, P472, DOI 10.5694/j.1326-5377.1982.tb132420.x; BLUMBERG LH, 1994, EUR J CLIN MICROBIOL, V13, P82, DOI 10.1007/BF02026131; BOYCE JM, 1981, ANN INTERN MED, V95, P241, DOI 10.7326/0003-4819-95-2-241_3; BRADY LM, 1990, MED J AUSTRALIA, V152, P240, DOI 10.5694/j.1326-5377.1990.tb120917.x; Campbell JR, 1998, INFECT CONT HOSP EP, V19, P924; Centers for Disease Control and Prevention, 2002, MMWR-MORBID MORTAL W, V51, P565; COELLO R, 1994, EUR J CLIN MICROBIOL, V13, P74, DOI 10.1007/BF02026130; Cook T.C., 1979, QUASIEXPERIMENTATION; Cooper B S, 2003, Health Technol Assess, V7, P1; Cooper BS, 2004, P NATL ACAD SCI USA, V101, P10223, DOI 10.1073/pnas.0401324101; Cosseron-Zerbib M, 1998, J HOSP INFECT, V40, P225, DOI 10.1016/S0195-6701(98)90140-2; COX RA, 1995, J HOSP INFECT, V29, P87, DOI 10.1016/0195-6701(95)90191-4; Crowcroft NS, 2002, BRIT MED J, V325, P1390, DOI 10.1136/bmj.325.7377.1390; DUCKWORTH GJ, 1988, J HOSP INFECT, V11, P1, DOI 10.1016/0195-6701(88)90034-5; ELHAGRASY M, 1997, EMIRATES MED J, V15, P17; *EPOC REV GROUP, 2001, COCHR LIB DAT; Esveld M I, 1999, Ned Tijdschr Geneeskd, V143, P205; FAOAGALI JL, 1992, J HOSP INFECT, V20, P113, DOI 10.1016/0195-6701(92)90113-Z; Farrington M, 1998, QJM-MON J ASSOC PHYS, V91, P539, DOI 10.1093/qjmed/91.8.539; Garner Julia S., 1996, Infection Control and Hospital Epidemiology, V17, P53; Girou E, 1998, CLIN INFECT DIS, V27, P543, DOI 10.1086/514695; Girou E, 2000, INFECT CONT HOSP EP, V21, P583, DOI 10.1086/501807; Grimes DA, 2002, LANCET, V359, P341, DOI 10.1016/S0140-6736(02)07500-1; Harbarth S, 2000, J HOSP INFECT, V46, P43, DOI 10.1053/jhin.2000.0798; Hartstein AI, 1997, INFECT CONT HOSP EP, V18, P42; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; Jernigan JA, 1996, AM J EPIDEMIOL, V143, P496, DOI 10.1093/oxfordjournals.aje.a008770; JONES MR, 1987, NEW ZEAL MED J, V100, P369; Kac G, 2000, ARCH DERMATOL, V136, P735, DOI 10.1001/archderm.136.6.735; Landman D, 1999, CLIN INFECT DIS, V28, P1062, DOI 10.1086/514743; LAW MR, 1988, EPIDEMIOL INFECT, V101, P301, DOI 10.1017/S0950268800054224; LINNEMANN CC, 1982, AM J EPIDEMIOL, V115, P941, DOI 10.1093/oxfordjournals.aje.a113381; LUGEON C, 1995, INFECT CONT HOSP EP, V16, P260; Mayall B, 1996, J HOSP INFECT, V32, P257, DOI 10.1016/S0195-6701(96)90036-5; Ministry of Health, 2002, GUID CONTR METH RES; Morton V, 2003, BRIT MED J, V326, P1083, DOI 10.1136/bmj.326.7398.1083; MULLER W, 1993, EUR SOCIOL REV, V9, P1; MULLIGAN ME, 1993, AM J MED, V94, P313, DOI 10.1016/0002-9343(93)90063-U; MURRAYLEISURE KA, 1990, INFECT CONT HOSP EP, V11, P343; NNIS System, 2002, AM J INFECT CONTROL, V30, P458, DOI 10.1067/mic.2002.130032; ONESKO KM, 1987, INFECT CONT HOSP EP, V8, P284, DOI 10.1017/S019594170006625X; OTO MA, 1992, REV CHIL PEDIATR, V63, P134; Papia G, 1999, INFECT CONT HOSP EP, V20, P473, DOI 10.1086/501655; PEARMAN JW, 1985, MED J AUSTRALIA, V142, P103, DOI 10.5694/j.1326-5377.1985.tb133044.x; Perry CM, 2001, DRUGS, V61, P525, DOI 10.2165/00003495-200161040-00008; PFALLER MA, 1991, DIAGN MICR INFEC DIS, V14, P209, DOI 10.1016/0732-8893(91)90034-D; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; Public Health Laboratory Service, 2002, COMMUN DIS REP CDR W, V12; Rahman M, 2000, J HOSP INFECT, V44, P151; RIBNER BS, 1986, INFECT CONT HOSP EP, V7, P317, DOI 10.1017/S0195941700064341; Salgado CD, 2002, LANCET INFECT DIS, V2, P383; Schlunzen L, 1997, Ugeskr Laeger, V159, P431; Selkon J B, 1980, J Hosp Infect, V1, P41, DOI 10.1016/0195-6701(80)90030-4; SHANSON DC, 1985, J HOSP INFECT, V6, P285, DOI 10.1016/S0195-6701(85)80132-8; SHANSON DC, 1976, LANCET, V2, P1347; Souweine B, 2000, J HOSP INFECT, V45, P107, DOI 10.1053/jhin.2000.0734; SPICER WJ, 1984, J HOSP INFECT, V5, P45, DOI 10.1016/0195-6701(84)90029-X; Stone SP, 1997, AGE AGEING, V26, P165, DOI 10.1093/ageing/26.3.165; Stone SP, 1998, AGE AGEING, V27, P561, DOI 10.1093/ageing/27.5.561; TALON D, 1995, J HOSP INFECT, V30, P39, DOI 10.1016/0195-6701(95)90247-3; Tambic A, 1999, EUR J CLIN MICROBIOL, V18, P335, DOI 10.1007/PL00015015; Turnidge JD, 2000, MICROB DRUG RESIST, V6, P223; WARD TT, 1981, INFECT CONT HOSP EP, V2, P453, DOI 10.1017/S0195941700055715; *WIERKGR INF PREV, 1994, MAN POL METH RES STA; Yano M, 2000, SURG TODAY, V30, P16, DOI 10.1007/PL00010040; YOSHIDA J, 1995, J GASTROENTEROL, V30, P718, DOI 10.1007/BF02349637	72	239	245	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 4	2004	329	7465					533	538		10.1136/bmj.329.7465.533	http://dx.doi.org/10.1136/bmj.329.7465.533			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853DE	15345626	Bronze, Green Published, Green Submitted, Green Accepted			2022-12-28	WOS:000223805800016
J	Luoma, P; Melberg, A; Rinne, JO; Kaukonen, JA; Nupponen, NN; Chalmers, RM; Oldfors, A; Rautakorpi, I; Peltonen, L; Majamaa, K; Somer, H; Suomalainen, A				Luoma, P; Melberg, A; Rinne, JO; Kaukonen, JA; Nupponen, NN; Chalmers, RM; Oldfors, A; Rautakorpi, I; Peltonen, L; Majamaa, K; Somer, H; Suomalainen, A			Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study	LANCET			English	Article							PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; AUTOSOMAL-DOMINANT; MULTIPLE DELETIONS; MTDNA DELETIONS; POLG MUTATIONS; DISEASE; FEATURES; DISORDERS; ENCEPHALOMYOPATHY; HYPOGONADISM	Background Mutations in the gene encoding mitochondrial DNA polymerase gamma (POLG), the enzyme that synthesises mitochondrial DNA (mtDNA), have been associated with a mitochondrial disease-autosomal dominant or recessive progressive external ophthalmoplegia-and multiple deletions of mtDNA. Mitochondrial dysfunction is also suspected to participate in the pathogenesis of Parkinson's disease. However, no primary gene defects affecting mitochondrial proteins causing mendelian transmission of parkinsonism have been characterised. We aimed to analyse the gene sequence of POLG in patients with progressive external ophthalmoplegia and their healthy relatives. Methods In seven families of various ethnic origins we assessed patients with progressive external ophthalmoplegia and unaffected individuals by clinical, biochemical, morphological, and molecular genetic characterisation and positron emission tomography (PET). Findings We recorded mutations in POLG in members of all seven families. Clinical assessment showed significant cosegregation of parkinsonism with POLG mutations (p<0.0001), and PET findings were consistent with dopaminergic neuron loss. Post-mortem examination in two individuals showed loss of pigmented neurons and pigment phagocytosis in substantia nigra without Lewy bodies. Furthermore, most women with progressive external ophthalmoplegia had early menopause before age 35 years. The POLG gene defect resulted in secondary accumulation of mtDNA deletions in patients' tissues. Interpretation Dysfunction of mitochondrial POLG causes a severe progressive multisystem disorder including parkinsonism and premature menopause, which are not typical of mitochondrial disease. Cosegregation of parkinsonism and POLG mutations in our families suggests that when defective, this gene can underlie mendelian transmission of parkinsonism. Relevance to practice Awareness that mitochondrial POLG mutations can underlie parkinsonism is important for clinicians working in diagnosis of movement disorders, as well as for studies of the genetics of Parkinson's disease. Further, progressive external ophthalmoplegia with muscle weakness and neuropathy can mask symptoms of parkinsonism, and clinicians should pay special attention to detect and treat parkinsonism in those individuals.	Univ Helsinki, Biomedicum Helsinki, Programme Neurosci, FIN-00290 Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, Dept Neurol, FIN-00290 Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, Dept Oncol, FIN-00290 Helsinki, Finland; Univ Helsinki, Cent Hosp, Helsinki, Finland; Natl Publ Hlth Inst, Dept Mol Med, Helsinki, Finland; Univ Helsinki, Dept Med Genet, Helsinki, Finland; Univ Uppsala Hosp, Dept Neurosci & Neurol, Uppsala, Sweden; Univ Turku, Turku PET Ctr, Turku, Finland; Inst Neurol, Univ Dept Clin Neurol, London WC1N 3BG, England; Gothenburg Univ, Sahlgrens Hosp, Dept Pathol, S-41345 Gothenburg, Sweden; Cent Hosp Lapland, Dept Neurol, Rovaniemi, Finland; Univ Oulu, Bioctr, Oulu, Finland; Univ Oulu, Dept Neurol, Oulu, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare; University of Helsinki; Uppsala University; Uppsala University Hospital; University of Turku; University of London; University College London; Sahlgrenska University Hospital; University of Gothenburg; University of Oulu; University of Oulu	Suomalainen, A (corresponding author), Univ Helsinki, Biomedicum Helsinki, Programme Neurosci, Room C522B,Haartmaninkatu 8, FIN-00290 Helsinki, Finland.	anu.wartiovaara@helsinki.fi	Majamaa, Kari/A-1344-2012	Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195; Oldfors, Anders/0000-0002-5758-7397; Majamaa, Kari/0000-0002-9070-3791				Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a; Casali C, 2001, NEUROLOGY, V56, P802, DOI 10.1212/WNL.56.6.802; Chalmers RM, 1996, J NEUROL SCI, V143, P41, DOI 10.1016/S0022-510X(96)00032-9; CHECCARELLI N, 1994, J NEUROL SCI, V123, P74, DOI 10.1016/0022-510X(94)90206-2; de Rijk MC, 2000, NEUROLOGY, V54, pS21; Dekker MCJ, 2003, BRAIN, V126, P1722, DOI 10.1093/brain/awg172; Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279; Gu GY, 2002, J NEUROPATH EXP NEUR, V61, P634, DOI 10.1093/jnen/61.7.634; Guttman M, 2003, MOVEMENT DISORD, V18, P313, DOI 10.1002/mds.10333; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Kaukonen J, 1999, AM J HUM GENET, V65, P256, DOI 10.1086/302445; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278; LESTIENNE P, 1990, J NEUROCHEM, V55, P1810, DOI 10.1111/j.1471-4159.1990.tb04973.x; Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9; LUNDBERG PO, 1962, ACTA NEUROL SCAND, V38, P142; Melberg A, 1996, MUSCLE NERVE, V19, P1561, DOI 10.1002/(SICI)1097-4598(199612)19:12<1561::AID-MUS5>3.0.CO;2-8; Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79; Orth M, 2002, NEUROCHEM INT, V40, P533, DOI 10.1016/S0197-0186(01)00124-3; Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425; OZAWA T, 1990, BIOCHEM BIOPH RES CO, V172, P483, DOI 10.1016/0006-291X(90)90698-M; Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200; Rinne JO, 1999, SYNAPSE, V31, P119, DOI 10.1002/(SICI)1098-2396(199902)31:2<119::AID-SYN4>3.3.CO;2-F; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; Siciliano G, 2001, J NEUROL NEUROSUR PS, V71, P685, DOI 10.1136/jnnp.71.5.685; Speciale SG, 2002, NEUROTOXICOL TERATOL, V24, P607, DOI 10.1016/S0892-0362(02)00222-2; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; *STANF GEN TECHN C, DHPLC MELT PROGR; Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244; SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856; Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379; Suomalainen A, 2000, MOL BIOTECHNOL, V15, P123, DOI 10.1385/MB:15:2:123; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246; Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002; Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0; Zhang J, 2002, PARKINSONISM RELAT D, V8, P165, DOI 10.1016/S1353-8020(01)00041-4	40	422	439	0	25	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2004	364	9437					875	882		10.1016/S0140-6736(04)16983-3	http://dx.doi.org/10.1016/S0140-6736(04)16983-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351195				2022-12-28	WOS:000223685200034
J	Lambrechts, D; Carmeliet, P				Lambrechts, D; Carmeliet, P			Sculpting heart valves with NFATc and VEGF	CELL			English	Editorial Material							ENDOCARDIAL CUSHION FORMATION	Heart valves are of vital importance for our moment-to-moment existence, but how they form remains a mystery. In this issue of Cell, Chang et al. reveal a novel role for calcineurin, NFATs, and VEGF in valve formation (Chang et al., 2004). Dynamic changes in NFAT/VEGF expression in regional myocardial and endocardial fields and developmental windows orchestrate this complex process.	Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven	Lambrechts, D (corresponding author), Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium.		Verdrengh, Evelien/H-4571-2012; Lambrechts, Diether/AAJ-3167-2020; Carmeliet, Peter/AAQ-5140-2020	Lambrechts, Diether/0000-0002-3429-302X; Carmeliet, Peter/0000-0001-7961-1821				Chang CP, 2004, CELL, V118, P649, DOI 10.1016/j.cell.2004.08.010; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Dor Y, 2003, ANAT REC PART A, V271A, P202, DOI 10.1002/ar.a.10026; Dor Y, 2001, DEVELOPMENT, V128, P1531; Enciso JM, 2003, J CELL BIOL, V160, P605, DOI 10.1083/jcb.200209014; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Miquerol L, 2000, DEVELOPMENT, V127, P3941; Schroeder JA, 2003, J MOL MED-JMM, V81, P392, DOI 10.1007/s00109-003-0456-5; Schulz RA, 2004, DEV BIOL, V266, P1, DOI 10.1016/j.ydbio.2003.10.008; Stalmans I, 2003, NAT MED, V9, P173, DOI 10.1038/nm819	11	22	24	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	2004	118	5					532	534		10.1016/j.cell.2004.08.022	http://dx.doi.org/10.1016/j.cell.2004.08.022			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	852BN	15339657	Bronze			2022-12-28	WOS:000223730300003
J	Minetti, E; Montoli, A				Minetti, E; Montoli, A			Bilateral renal arteriovenous malformation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Osped Niguarda Ca Granda, I-20162 Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda	Minetti, E (corresponding author), Osped Niguarda Ca Granda, I-20162 Milan, Italy.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2004	351	10					E9	E9		10.1056/ENEJMicm030333	http://dx.doi.org/10.1056/ENEJMicm030333			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	850UB	15342819				2022-12-28	WOS:000223637400012
J	Barzansky, B; Etzel, SI				Barzansky, B; Etzel, SI			Educational programs in US medical schools, 2003-2004	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context US medical schools continue to change their organizational structures, staffing patterns, and educational programs. Objective To review the status of US medical school educational programs in the 2003-2004 academic year, compared with 1993-1994. Data Sources The Liaison Committee on Medical Education (LCME) Annual Medical School Questionnaire for 2003-2004 and the Association of American Medical Colleges Directory of American Medical Education for the years 1983-1984, 1993-1994, and 2003-2004. Data Synthesis The number of full-time faculty members in the 126 LCME-accredited medical schools increased from 90975 in 1993-1994 to 114549 in 20032004 (+26%), whereas the number of enrolled students remained essentially unchanged (66453 in 1993-1994 and 67166 in 2003-2004). In 2003-2004, 48% of medical school deans held another title at the medical center or university level, such as vice president for health affairs. There are 94 medical schools that have a comprehensive clinical examination using the standardized patient/objective structured clinical examination format; 59 schools require students to pass this examination for graduation. As of spring 2004, 58 schools will require students in the class of 2005 to pass the new US Medical Licensing Examination Step 2 Clinical Skills examination. Conclusions The role of the medical school dean has expanded over time and is associated with the creation of a discrete administrative structure for the educational program. The number of full-time medical school faculty continues to increase, whereas the number of enrolled students remains steady. Considerable variability exists among medical schools in their use of standardized clinical evaluations.	Amer Med Assoc, Div Undergrad Med Educ Policy & Stand, Chicago, IL 60610 USA; Amer Med Assoc, Div Grad Med Educ, Chicago, IL 60610 USA	American Medical Association; American Medical Association	Barzansky, B (corresponding author), Amer Med Assoc, Div Undergrad Med Educ Policy & Stand, 515 N State St, Chicago, IL 60610 USA.	barbara_barzansky@ama-assn.org						*AAMC, 1993, AAMC DIR AM MED ED; *AAMC, 1983, AAMC DIR AM MED ED; *AAMC, 2002, AAMC DAT; *AAMC, 2003, AAMC DIR AM MED ED; *AAMC DAT WAR, 2003, APPL MATR FIL; *ASS AM MED COLL, 2003, ALL SCH REPORT; BANASZAKHOLL J, 1994, ACAD MED, V69, P1, DOI 10.1097/00001888-199401000-00001; Barzansky B, 1999, JAMA-J AM MED ASSOC, V282, P840, DOI 10.1001/jama.282.9.840; Barzansky B, 2003, JAMA-J AM MED ASSOC, V290, P1190, DOI 10.1001/jama.290.9.1190; BURROW GN, 1993, ACAD MED, V68, P585, DOI 10.1097/00001888-199308000-00001; CROWLEY AE, 1984, JAMA-J AM MED ASSOC, V252, P1525; JONAS HS, 1994, JAMA-J AM MED ASSOC, V272, P694; KEVIN R, 1998, ACAD MED, V73, P640; Krakower JY, 2000, JAMA-J AM MED ASSOC, V284, P1127, DOI 10.1001/jama.284.9.1127; LIPPARD V, 1974, HALF CENTURY AM MED, P51; 2004, USMLE STEP 2 CLIN SK	16	60	61	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2004	292	9					1025	1031		10.1001/jama.292.9.1025	http://dx.doi.org/10.1001/jama.292.9.1025			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VH	15339892				2022-12-28	WOS:000223568700014
J	Giulini, A; Wang, J; Jackson, D				Giulini, A; Wang, J; Jackson, D			Control of phyllotaxy by the cytokinin-inducible response regulator homologue ABPHYL1	NATURE			English	Article							TRANSCRIPTION FACTOR; GENE ENCODES; SHOOT; EXPRESSION; PATTERN; MAIZE; PHOSPHORELAY; GROWTH; AMP1	Phyllotaxy describes the geometric pattern of leaves and flowers, and has intrigued botanists and mathematicians for centuries(1,2). How these patterns are initiated is poorly understood, and this is partly due to the paucity of mutants(3). Signalling by the plant hormone auxin appears to determine the site of leaf initiation; however, this observation does not explain how distinct patterns of phyllotaxy are initiated(4). abphyl1 (abph1) mutants of maize initiate leaves in a decussate pattern ( that is, paired at 1808), in contrast to the alternating or distichous phyllotaxy observed in wild-type maize and other grasses(5). Here we show that ABPH1 is homologous to two-component response regulators and is induced by the plant hormone cytokinin. ABPH1 is expressed in the embryonic shoot apical meristem, and its spatial expression pattern changes rapidly with cytokinin treatment. We propose that ABPH1 controls phyllotactic patterning by negatively regulating the cytokinin-induced expansion of the shoot meristem, thereby limiting the space available for primordium initiation at the apex.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Jackson, D (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	jacksond@cshl.edu						Asakura Y, 2003, PLANT MOL BIOL, V52, P331, DOI 10.1023/A:1023971315108; Brandstatter I, 1998, PLANT CELL, V10, P1009, DOI 10.1105/tpc.10.6.1009; CALLOS JD, 1994, PLANT J, V6, P1, DOI 10.1046/j.1365-313X.1994.6010001.x; CHAUDHURY AM, 1993, PLANT J, V4, P907, DOI 10.1046/j.1365-313X.1993.04060907.x; Che P, 2002, PLANT CELL, V14, P2771, DOI 10.1105/tpc.006668; D'Agostino IB, 2000, PLANT PHYSIOL, V124, P1706, DOI 10.1104/pp.124.4.1706; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; GREEN PB, 1994, J EXP BOT, V45, P1775, DOI 10.1093/jxb/45.Special_Issue.1775; GREYSON RI, 1978, CAN J BOT, V56, P1545, DOI 10.1139/b78-183; Helliwell CA, 2001, PLANT CELL, V13, P2115, DOI 10.1105/tpc.13.9.2115; Hutchison CE, 2002, PLANT CELL, V14, pS47, DOI 10.1105/tpc.010444; Hwang I, 2001, NATURE, V413, P383, DOI 10.1038/35096500; Jackson D, 1999, DEVELOPMENT, V126, P315; JACKSON D, 1994, DEVELOPMENT, V120, P405; Jean R. V., 1994, PHYLLOTAXIS SYSTEMIC; Klar AJS, 2002, NATURE, V417, P595, DOI 10.1038/417595a; Kuhlemeier C, 2001, TRENDS PLANT SCI, V6, P187, DOI 10.1016/S1360-1385(01)01894-5; Lohrmann J, 2001, MOL GENET GENOMICS, V265, P2, DOI 10.1007/s004380000400; Mok DWS, 2001, ANNU REV PLANT PHYS, V52, P89, DOI 10.1146/annurev.arplant.52.1.89; Reinhardt D, 2003, NATURE, V426, P255, DOI 10.1038/nature02081; ROBERTS J, 1994, J CURRICULUM SUPERVI, V9, P136; Sakai H, 2001, SCIENCE, V294, P1519, DOI 10.1126/science.1065201; Sakakibara H, 1998, PLANT J, V14, P337, DOI 10.1046/j.1365-313X.1998.00134.x; SCHWABE WW, 1984, POSITIONAL CONTROLS; Sheen J, 2002, SCIENCE, V296, P1650, DOI 10.1126/science.1071883; SKOOG F, 1957, Symp Soc Exp Biol, V11, P118; Taguchi-Shiobara F, 2001, GENE DEV, V15, P2755, DOI 10.1101/gad.208501; Taniguchi M, 1998, FEBS LETT, V429, P259, DOI 10.1016/S0014-5793(98)00611-5; To JPC, 2004, PLANT CELL, V16, P658, DOI 10.1105/tpc.018978; Werner T, 2001, P NATL ACAD SCI USA, V98, P10487, DOI 10.1073/pnas.171304098	30	212	234	4	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2004	430	7003					1031	1034		10.1038/nature02778	http://dx.doi.org/10.1038/nature02778			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329722				2022-12-28	WOS:000223514900044
J	Schnitzer, TJ; Burmester, GR; Mysler, E; Hochberg, MC; Doherty, M; Ehrsam, E; Gitton, X; Krammer, G; Mellein, B; Matchaba, P; Gimona, A; Hawkey, CJ				Schnitzer, TJ; Burmester, GR; Mysler, E; Hochberg, MC; Doherty, M; Ehrsam, E; Gitton, X; Krammer, G; Mellein, B; Matchaba, P; Gimona, A; Hawkey, CJ		TARGET Study Grp	Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; OF-RHEUMATOLOGY CRITERIA; LARGE OUTCOMES TRIALS; SELECTIVE INHIBITORS; HELICOBACTER-PYLORI; COX-2 INHIBITORS; OSTEOARTHRITIS; RISK; CLASSIFICATION; TOXICITY	Background Cyclo-oxygenase 2 (COX2)-selective inhibitors should reduce ulcer complications compared with nonselective non-steroidal anti-inflammatory drugs, but evidence is limited, and the possibility that these inhibitors increase cardiovascular events has been raised. The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) aimed to assess gastrointestinal and cardiovascular safety of the COX2 inhibitor lumiracoxib compared with two non-steroidal anti-inflammatory drugs, naproxen and ibuprofen. Methods 18 325 patients age 50 years or older with osteoarthritis were randomised to lumiracoxib 400 mg once daily (n=9156), naproxen 500 mg twice daily (4754), or ibuprofen 800 mg three times daily (4415) for 52 weeks, in two substudies of identical design (lumiracoxib vs ibuprofen or naproxen). Randomisation was stratified for low-dose aspirin use and age. The primary endpoint was the difference in time-to-event distribution of upper gastrointestinal ulcer complications (bleeding, perforation, or obstruction); analysis was by modified intention to treat. The principle measure of adverse cardiovascular events was the Antiplatelet Trialists' Collaboration endpoint (myocardial infarction, stroke, or cardiovascular death); this analysis was intention to treat. Findings 81 (0.44%) patients did not start treatment and 7120 (39%) did not complete the study. In patients not taking aspirin, the cumulative 1-year incidence of ulcer complications was 1.09% (95% Cl 0.82-1.36) with nonsteroidal anti-inflammatory drugs (64 events) versus 0.25% (95% CI 0.12-0.39) with lumiracoxib (14 events; hazard ratio 0.21 [95% CI 0.12-0.37], p<0.0001). Reductions in ulcer complications were also significant in the overall population (0.34 [0.22-0.52], p<0.0001) but not in those taking aspirin (0.79 [0.40-1.55], p=0.4876). In the overall population, 0.55% (50/9127) of those on non-steroidal anti-inflammatory drugs and 0.65% (59/9117) of those on lumiracoxib reached the cardiovascular endpoint (1.14 [0.78-1.66], p=0.5074). Interpretation Lumiracoxib showed a three to four-fold reduction in ulcer complications compared with nonsteroidal anti-inflammatory drugs without an increase in the rate of serious cardiovascular events, suggesting that lumiracoxib is an appropriate treatment for patients with osteoarthritis.	Univ Hosp, Wolfson Digest Dis Ctr, Trials Unit, Inst Clin Res, Nottingham NG7 2UH, England; Northwestern Univ, Off Clin Res & Training, Feinberg Sch Med, Chicago, IL 60611 USA; Humboldt Univ, Charite Univ Med Berlin, Dept Rheumat & Clin Immunol, Berlin, Germany; Org Med Invest, Dept Rheumatol, Buenos Aires, DF, Argentina; Univ Maryland, Sch Med, Div Clin Immunol & Rheumatol, Baltimore, MD 21201 USA; Univ Nottingham, City Hosp, Nottingham, England; Novartis Pharmaceut, Basel, Switzerland; Novartis Pharmaceut, E Hanover, NJ USA	Nottingham University Hospital NHS Trust; University of Nottingham; Northwestern University; Feinberg School of Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University System of Maryland; University of Maryland Baltimore; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; Novartis; Novartis	Hawkey, CJ (corresponding author), Univ Hosp, Wolfson Digest Dis Ctr, Trials Unit, Inst Clin Res, Nottingham NG7 2UH, England.	cj.hawkey@nottingham.ac.uk	Burmester, Gerd R./AAY-7514-2020	Doherty, Michael/0000-0002-5763-8326				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ALTMAN R, 1991, ARTHRITIS RHEUM, V34, P505, DOI 10.1002/art.1780340502; ALTMAN R, 1990, ARTHRITIS RHEUM, V33, P1601, DOI 10.1002/art.1780331101; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; Benevolenskaya L, 2003, ANN RHEUM DIS, V62, P270; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Bruns W, 2002, ADV STU P M, V33, P1; COX DR, 1972, J R STAT SOC B, V34, P187; Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140-6736(04)16894-3; FitzGerald G, 2003, NAT REV DRUG DISCOV, V2, P879, DOI 10.1038/nrd1225; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; FRIES JF, 1991, J RHEUMATOL, V18, P6; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; Gillen D, 2001, PHARMACOL TOXICOL, V89, P281, DOI 10.1034/j.1600-0773.2001.d01-161.x; Graham David Y., 2001, American Journal of Medicine, V110, p58S, DOI 10.1016/S0002-9343(00)00644-6; Grundy SM, 1999, J AM COLL CARDIOL, V34, P1348, DOI 10.1016/S0735-1097(99)00387-3; Hawkey C, 2003, ARTHRITIS RHEUM, V48, pS79; Hawkey CJ, 2004, ALIMENT PHARM THER, V20, P51, DOI 10.1111/j.1365-2036.2004.02026.x; Hawkey CJ, 2003, GUT, V52, P600, DOI 10.1136/gut.52.4.600; Hawkey CJ, 2002, GUT, V51, P336, DOI 10.1136/gut.51.3.336; Hawkey CJ, 2001, CLIN EXP RHEUMATOL, V19, pS23; HAWKEY CJ, IN PRESS J RHEUM; Hochberg MC, 2002, SEMIN ARTHRITIS RHEU, V32, P4, DOI 10.1053/sarh.2002.37215; Hochberg MC, 2001, CLIN EXP RHEUMATOL, V19, pS15; *IMS HLTH, IMS MIDAS QUANT MEAS; *IMS HLTH, IMS MIDAS PRESCR INS; Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742; Juni P, 2002, BRIT MED J, V324, P1287, DOI 10.1136/bmj.324.7349.1287; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; Kivitz AJ, 2004, ALIMENT PHARM THER, V19, P1189, DOI 10.1111/j.1365-2036.2004.01956.x; KUIPERS EJ, 1995, ALIMENT PHARM THER, V9, P331; Laine L, 2002, J PAIN SYMPTOM MANAG, V23, pS5, DOI 10.1016/S0885-3924(02)00368-8; Laine L, 2001, GASTROENTEROLOGY, V120, P594, DOI 10.1053/gast.2001.21907; Mangold JB, 2004, DRUG METAB DISPOS, V32, P566, DOI 10.1124/dmd.32.5.566; Marshall P.J., 2002, ANN RHEUM DIS S1, V61, P259; *MERCK, 2004, VIOXX REF TABL OR SU; *NOV PHARM, 2003, PRESCR INF VOLT DICH; Pham T, 2003, J RHEUMATOL, V30, P1648; *PHARM PFIZ, CEL PRESCR INF; Rordorf C, 2003, ALIMENT PHARM THER, V18, P533, DOI 10.1046/j.1365-2036.2003.01691.x; SCOTT G, 2002, ANN RHEUM DIS S1, V61, P242; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; TANNENBAUM H, 2004, ANN RHEUM DIS   0227; U.S. FOOD & DRUG ADMIN, STAT REV BRIEF DOC A; *US FDA, FDA SPONT REP HEP AD; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407	47	487	509	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	2004	364	9435					665	674		10.1016/S0140-6736(04)16893-1	http://dx.doi.org/10.1016/S0140-6736(04)16893-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325831				2022-12-28	WOS:000223428900028
J	Lazarus, SA; Bowen, K; Garg, ML				Lazarus, SA; Bowen, K; Garg, ML			Tomato juice and platelet aggregation in type 2 diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							IN-VITRO; EXTRACT		Univ Newcastle, Fac Hlth, Dept Nutr & Dietet, Newcastle, NSW 2308, Australia; Royal Newcastle Hosp, Diabet Educ Ctr, Newcastle, NSW 2300, Australia	University of Newcastle	Lazarus, SA (corresponding author), Univ Newcastle, Fac Hlth, Dept Nutr & Dietet, Newcastle, NSW 2308, Australia.	manohar.garg@newcastle.edu.au	Garg, Manohar L/A-5795-2009	Garg, Manohar/0000-0003-0514-0865				Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Dutta-Roy AK, 2001, PLATELETS, V12, P218, DOI 10.1080/09537100120058757; Lazarus SA, 2004, INT J FOOD SCI NUTR, V55, P249, DOI 10.1080/09637480410001734003; Vinik AI, 2001, DIABETES CARE, V24, P1476, DOI 10.2337/diacare.24.8.1476; Willcox JK, 2003, CRIT REV FOOD SCI, V43, P1, DOI 10.1080/10408690390826437; Yamamoto J, 2003, BRIT J NUTR, V90, P1031, DOI 10.1079/BJN2003994	6	30	32	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2004	292	7					805	806		10.1001/jama.292.7.805	http://dx.doi.org/10.1001/jama.292.7.805			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847FO	15315994				2022-12-28	WOS:000223378300020
J	Leggett, T				Leggett, T			Physics - Superfluidity in a crystal?	SCIENCE			English	Editorial Material							ANGULAR-MOMENTUM		Univ Illinois, Dept Phys, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Leggett, T (corresponding author), Univ Illinois, Dept Phys, 1110 W Green St, Urbana, IL 61801 USA.	aleggett@uiuc.edu						ANDREEV AF, 1969, ZH EKSP TEOR FIZ, V29, P1107; Andronikashvili E.L., 1946, J PHYS USSR, V10, P201; Chevy F, 2000, PHYS REV LETT, V85, P2223, DOI 10.1103/PhysRevLett.85.2223; HESS GB, 1967, PHYS REV LETT, V19, P216, DOI 10.1103/PhysRevLett.19.216; Kim E, 2004, SCIENCE, V305, P1941, DOI 10.1126/science.1101501; Leggett AJ, 2001, REV MOD PHYS, V73, P307, DOI 10.1103/RevModPhys.73.307; London F., 1954, SUPERFLUIDS, VII, P144; MEISEL MW, 1992, PHYSICA B, V178, P121, DOI 10.1016/0921-4526(92)90186-V	8	28	28	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	2004	305	5692					1921	1922		10.1126/science.1103584	http://dx.doi.org/10.1126/science.1103584			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	857RM	15345780				2022-12-28	WOS:000224136000034
J	Warner, E; Plewes, DB; Hill, KA; Causer, PA; Zubovits, JT; Jong, RA; Cutrara, MR; DeBoer, G; Yaffe, MJ; Messner, SJ; Meschino, WS; Piron, CA; Narod, SA				Warner, E; Plewes, DB; Hill, KA; Causer, PA; Zubovits, JT; Jong, RA; Cutrara, MR; DeBoer, G; Yaffe, MJ; Messner, SJ; Meschino, WS; Piron, CA; Narod, SA			Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-RISK; INTERPRETATION MODEL; INITIAL-EXPERIENCE; SCREENING WOMEN; NEEDLE-BIOPSY; CANCER; LESIONS; DIAGNOSIS; MRI; PERFORMANCE	Context Current recommendations for women who have a BRCA1 or BRCA2 mutation are to undergo breast surveillance from age 25 years onward with mammography annually and clinical breast examination (CBE) every 6 months; however, many tumors are detected at a relatively advanced stage. Magnetic resonance imaging (MRI) and ultrasound may improve the ability to detect breast cancer at an early stage. Objective To compare the sensitivity and specificity of 4 methods of breast cancer surveillance (mammography, ultrasound, MRI, and CBE) in women with hereditary susceptibility to breast cancer due to a BRCA1 or BRCA2 mutation. Design, Setting, and Participants A surveillance study of 236 Canadian women aged 25 to 65 years with BRCA1 or BRCA2 mutations who underwent 1 to 3 annual screening examinations, consisting of MRI, mammography, and ultrasound at a single tertiary care teaching hospital between November 3, 1997, and March 31, 2003. On the day of imaging and at 6-month intervals, CBE was performed. Main Outcome Measures Sensitivity and specificity of each of the 4 surveillance modalities, and sensitivity of all 4 screening modalities vs mammography and CBE. Results Each imaging modality was read independently by a radiologist and scored on a 5-point Breast Imaging Reporting and Data System scale. All lesions with a score of 4 or 5 (suspicious or highly suspicious for malignancy) were biopsied. There were 22 cancers detected (16 invasive and 6 ductal carcinoma in situ). Of these, 17 (77%) were detected by MRI vs 8 (36%) by mammography, 7 (33%) by ultrasound, and 2 (9.1%) by CBE. The sensitivity and specificity (based on biopsy rates) were 77% and 95.4% for MRI, 36% and 99.8% for mammography, 33% and 96% for ultrasound, and 9.1% and 99.3% for CBE, respectively. There was 1 interval cancer. All 4 screening modalities combined had a sensitivity of 95% vs 45% for mammography and CBE combined. Conclusions In BRCA1 and BRCA2 mutation carriers, MRI is more sensitive for detecting breast cancers than mammography, ultrasound, or CBE alone. Whether surveillance regimens that include MRI will reduce mortality from breast cancer in high-risk women requires further investigation.	Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med, Div Med Oncol, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med Biophys, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med Imaging, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Pathol, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Div Clin Trials & Epidemiol, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Prevent Oncol, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Family & Community Med, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Ctr Res Womens Hlth, Toronto, ON, Canada; Univ Toronto, Toronto, ON, Canada; N York Gen Hosp, Dept Genet, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University Toronto Affiliates; North York General Hospital	Warner, E (corresponding author), Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	ellen.warner@sw.ca	Narod, Steven A/AAA-6112-2022					American College of Radiology and (ACR) reporting system, 1993, BREAST IM REP DAT SY, P15; Armes JE, 2002, PATHOLOGY, V34, P309, DOI 10.1080/00313020220147113; *BREAST CANC SCREE, 2002, IARC HDB CANC PREV, V7; Brekelmans CTM, 2001, J CLIN ONCOL, V19, P924, DOI 10.1200/JCO.2001.19.4.924; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; CAUSER P, 2003, MED LAT ACC MRI GUID, V3; Chang J, 1999, LANCET, V353, P2070, DOI 10.1016/S0140-6736(05)77887-9; Chen JJ, 1999, CANCER RES, V59, p1752S; DALY MB, 2003, NCCN 2003 GEN AM HIG; Daniel BL, 2001, J MAGN RESON IMAGING, V13, P896, DOI 10.1002/jmri.1128; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Goffin J, 2001, J NATL CANCER I, V93, P1754, DOI 10.1093/jnci/93.22.1754; Gordon PB, 2002, RADIOL CLIN N AM, V40, P431, DOI 10.1016/S0033-8389(01)00014-8; Goss PE, 1998, J CLIN ONCOL, V16, P338, DOI 10.1200/JCO.1998.16.1.338; Greenman RL, 1998, MAGNET RESON MED, V39, P108, DOI 10.1002/mrm.1910390117; Kolb TM, 2002, RADIOLOGY, V225, P165, DOI 10.1148/radiol.2251011667; Konyer NB, 2002, RADIOLOGY, V222, P830, DOI 10.1148/radiol.2223001310; Kriege M, 2001, Fam Cancer, V1, P163, DOI 10.1023/A:1021135809870; Kuhl CK, 1999, RADIOLOGY, V211, P101, DOI 10.1148/radiology.211.1.r99ap38101; Kuhl CK, 2001, RADIOLOGY, V220, P31, DOI 10.1148/radiology.220.1.r01jl0731; Kuhl CK, 2000, RADIOLOGY, V215, P267, DOI 10.1148/radiology.215.1.r00ap01267; Kuhl CK, 2003, P AN M AM SOC CLIN, V22, P2; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; Leach MO, 2002, J EXP CLIN CANC RES, V21, P107; Liberman L, 2003, AM J ROENTGENOL, V181, P1283, DOI 10.2214/ajr.181.5.1811283; Liberman L, 2002, AM J ROENTGENOL, V179, P171, DOI 10.2214/ajr.179.1.1790171; Mendelson EB, 2001, SEMIN ROENTGENOL, V36, P217, DOI 10.1053/sroe.2001.25125; Morris EA, 2003, AM J ROENTGENOL, V181, P619, DOI 10.2214/ajr.181.3.1810619; Morris EA, 2001, SEMIN ROENTGENOL, V36, P238, DOI 10.1053/sroe.2001.25116; Narod S, 2003, J NATL CANCER I, V95, P1552, DOI 10.1093/jnci/djg078; Nunes LW, 1997, RADIOLOGY, V202, P833, DOI 10.1148/radiology.202.3.9051042; Nunes LW, 1999, RADIOGRAPHICS, V19, P79, DOI 10.1148/radiographics.19.1.g99ja0379; Nunes LW, 1997, AM J ROENTGENOL, V169, P409, DOI 10.2214/ajr.169.2.9242744; OREL SG, 1994, RADIOLOGY, V193, P97, DOI 10.1148/radiology.193.1.8090928; PIRON CA, 2001, HYBRID IMAGING GUIDA, P155; Podo F, 2002, J EXP CLIN CANC RES, V21, P115; Rosenberg RD, 1998, RADIOLOGY, V209, P511, DOI 10.1148/radiology.209.2.9807581; Scheuer L, 2002, J CLIN ONCOL, V20, P1260, DOI 10.1200/JCO.2002.20.5.1260; STAVROS AT, 1995, RADIOLOGY, V196, P123, DOI 10.1148/radiology.196.1.7784555; Stoutjesdijk MJ, 2001, JNCI-J NATL CANCER I, V93, P1095, DOI 10.1093/jnci/93.14.1095; Sun CC, 1996, LANCET, V348, P408, DOI 10.1016/S0140-6736(05)65027-1; Tilanus-Linthorst MMA, 2000, BREAST CANCER RES TR, V63, P53, DOI 10.1023/A:1006480106487; Warner E, 2001, J CLIN ONCOL, V19, P3524, DOI 10.1200/JCO.2001.19.15.3524; Warren R, 2001, EUR J RADIOL, V39, P50, DOI 10.1016/S0720-048X(00)00237-0; WEINREB JC, 1995, RADIOLOGY, V196, P593, DOI 10.1148/radiology.196.3.7644617	45	828	851	3	53	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2004	292	11					1317	1325		10.1001/jama.292.11.1317	http://dx.doi.org/10.1001/jama.292.11.1317			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853YL	15367553	Bronze			2022-12-28	WOS:000223866800023
J	Ezzati, M				Ezzati, M			How can cross-country research on health risks strengthen interventions? Lessons from INTERHEART	LANCET			English	Editorial Material							CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; SERUM-CHOLESTEROL; BLOOD-PRESSURE; REDUCTION; MORTALITY		Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Ezzati, M (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.	mezzati@hsph.harvard.edu			NATIONAL INSTITUTE ON AGING [P01AG017625] Funding Source: NIH RePORTER; NIA NIH HHS [P01-AG17625] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BULL FC, 2004, COMP QUANTIFICATION, P729; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; EVANS AS, 1976, YALE J BIOL MED, V49, P175; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Ezzati M, 2003, LANCET, V362, P271, DOI 10.1016/S0140-6736(03)13968-2; Jee SH, 1999, JAMA-J AM MED ASSOC, V282, P2149, DOI 10.1001/jama.282.22.2149; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Lawes CMM, 2003, J HYPERTENS, V21, P707, DOI 10.1097/01.hjh.0000052492.18130.07; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; LOCK K, 2004, COMP QUANTIFICATION, P597; Magnus P, 2001, ARCH INTERN MED, V161, P2657, DOI 10.1001/archinte.161.22.2657; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; Murray CJL, 2003, LANCET, V361, P717, DOI 10.1016/S0140-6736(03)12655-4; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; Preston SH, 1976, MORTALITY PATTERNS N; Rehm J, 2004, COMP QUANTIFICATION, P959; Stampfer MJ, 2000, NEW ENGL J MED, V343, P16, DOI 10.1056/NEJM200007063430103; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Yusuf S, 2002, LANCET, V360, P2, DOI 10.1016/S0140-6736(02)09358-3; Zhang X, 2003, INT J EPIDEMIOL, V32, P563, DOI 10.1093/ije/dyg106	20	15	15	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	2004	364	9438					912	914		10.1016/S0140-6736(04)17035-9	http://dx.doi.org/10.1016/S0140-6736(04)17035-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364171				2022-12-28	WOS:000223831000004
J	Smeeth, L; Cook, C; Fombonne, E; Heavey, L; Rodrigues, LC; Smith, PG; Hall, AJ				Smeeth, L; Cook, C; Fombonne, E; Heavey, L; Rodrigues, LC; Smith, PG; Hall, AJ			MMR vaccination and pervasive developmental disorders: a case-control study	LANCET			English	Article							MUMPS-RUBELLA VACCINATION; PRACTICE RESEARCH DATABASE; EPIDEMIOLOGIC EVIDENCE; CAUSAL ASSOCIATION; NO EVIDENCE; MEASLES; AUTISM; CHILDREN; POPULATION; IMMUNIZATION	Background Concern that measles-mumps-rubella (MMR) vaccination might cause autism has led to a fall in vaccine coverage. We investigated whether MMR vaccination is associated with an increased risk of autism or other pervasive developmental disorders. Methods We did a matched case-control study using the UK General Practice Research Database. Cases were people born in 1973 or later who had first recorded diagnosis of pervasive developmental disorder while registered with a contributing general practice between 1987 and 2001. Controls were matched on age, sex, and general practice. Findings 1294 cases and 4469 controls were included. 1010 cases (78.1%) had MMR vaccination recorded before diagnosis, compared with 3671 controls (82.1%) before the age at which their matched case was diagnosed. After adjustment for age at joining the database, the odds ratio for association between MMR and pervasive developmental disorder was 0 . 86 (95% CI 0 . 68-1.09). Findings were similar when restricted to children with a diagnosis of autism, to those vaccinated with MMR before the third birthday, or to the period before media coverage of the hypothesis linking MMR with autism. Interpretation Our findings suggest that MMR vaccination is not associated with an increased risk of pervasive developmental disorders.	Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1E 7HT, England; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; McGill Univ, Montreal Childrens Hosp, Dept Psychiat, Montreal, PQ H3A 2T5, Canada; Kings Coll London, Inst Psychiat, London WC2R 2LS, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; McGill University; University of London; King's College London	Smeeth, L (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, Keppel St, London WC1E 7HT, England.	autism@lshtm.ac.uk	Fombonne, Eric/M-4893-2018; smith, peter/ABH-9627-2020; RODRIGUES, LAURA CUNHA/AAO-4130-2021; Smeeth, Liam/X-5862-2018	Fombonne, Eric/0000-0002-8605-3538; smith, peter/0000-0003-0080-7560; Smeeth, Liam/0000-0002-9168-6022; Rodrigues, Laura Cunha/0000-0001-9008-660X	Medical Research Council [G108/492] Funding Source: Medline; MRC [G108/492] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BURTON D, 2000, OPENING STATEMENT CH; Chen W, 2004, PSYCHOL MED, V34, P543, DOI 10.1017/S0033291703001259; CLAYTON D, 1993, CONDITIONAL LOGISTIC, P290; Dales L, 2001, JAMA-J AM MED ASSOC, V285, P1183, DOI 10.1001/jama.285.9.1183; *DEP HLTH, 2002, DEPT HLTH STAT B; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DeStefano F, 2004, PEDIATRICS, V113, P259, DOI 10.1542/peds.113.2.259; DeStefano Frank, 2004, Expert Rev Vaccines, V3, P19, DOI 10.1586/14760584.3.1.19; DeWilde S, 2001, BRIT J GEN PRACT, V51, P226; *DIR PUBL HLTH, 2002, MEASL LOND INC CURR; Farrington CP, 2001, VACCINE, V19, P3632, DOI 10.1016/S0264-410X(01)00097-4; FINE PEM, 1992, AM J EPIDEMIOL, V136, P121, DOI 10.1093/oxfordjournals.aje.a116479; Fombonne E, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-5; Fombonne E, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e58; Furlano RI, 2001, J PEDIATR-US, V138, P366, DOI 10.1067/mpd.2001.111323; Geier DA, 2004, MED SCI MONITOR, V10, pPI33; GILLBERG C, 1998, AUTISM, V2, P423; Hollowell J, 1997, Popul Trends, P36; Jansen VAA, 2003, SCIENCE, V301, P804, DOI 10.1126/science.1086726; Jefferson T, 2003, VACCINE, V21, P3954, DOI 10.1016/S0264-410X(03)00271-8; Jick H, 2003, PHARMACOTHERAPY, V23, P1524, DOI 10.1592/phco.23.15.1524.31955; Jick H, 2003, EPIDEMIOLOGY, V14, P630, DOI 10.1097/01.EDE.0000082044.88833.c4; Kaye JA, 2001, BRIT MED J, V322, P460, DOI 10.1136/bmj.322.7284.460; Loff B, 1998, LANCET, V352, P1368, DOI 10.1016/S0140-6736(05)60771-4; Madsen KM, 2002, NEW ENGL J MED, V347, P1477, DOI 10.1056/NEJMoa021134; Makela A, 2002, PEDIATRICS, V110, P957, DOI 10.1542/peds.110.5.957; MANTEL N, 1959, J NATL CANCER I, V22, P719; Miller Elizabeth, 2003, Semin Pediatr Infect Dis, V14, P199, DOI 10.1016/S1045-1870(03)00034-7; NAZARETH I, 1993, BRIT MED J, V307, P32, DOI 10.1136/bmj.307.6895.32; *OFF NAT STAT, 1998, SER OFF NAT STAT MB6, V1; Patja A, 2000, PEDIATR INFECT DIS J, V19, P1127, DOI 10.1097/00006454-200012000-00002; Ramsay ME, 2002, BRIT J GEN PRACT, V52, P912; Rapin I, 1997, NEW ENGL J MED, V337, P97, DOI 10.1056/NEJM199707103370206; SALISBURY D, 1996, IMMUNISATION INFECT; Smeeth L, 2002, LANCET, V359, P2112, DOI 10.1016/S0140-6736(02)08918-3; Smeeth L, 2001, BMC PUBLIC HEALTH, V1, DOI 10.1186/1471-2458-1-2; Spitzer WO, 2003, NEW ENGL J MED, V348, P951; Taylor B, 2002, BRIT MED J, V324, P393, DOI 10.1136/bmj.324.7334.393; Taylor B, 1999, LANCET, V353, P2026, DOI 10.1016/S0140-6736(99)01239-8; Uhlmann V, 2002, J CLIN PATHOL-MOL PA, V55, P84, DOI 10.1136/mp.55.2.84; Van Staa TP, 1994, PHARMACOEPIDEM DR S, V3, P15, DOI DOI 10.1002/PDS.2630030106; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; Wakefield AJ, 2000, AM J GASTROENTEROL, V95, P2285; Wakefield Andrew J., 2000, Adverse Drug Reactions and Toxicological Reviews, V19, P265; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; Wilson K, 2003, ARCH PEDIAT ADOL MED, V157, P628, DOI 10.1001/archpedi.157.7.628; 2003, DRUG THER B, V41, P25	47	129	134	1	51	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	2004	364	9438					963	969		10.1016/S0140-6736(04)17020-7	http://dx.doi.org/10.1016/S0140-6736(04)17020-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364187				2022-12-28	WOS:000223831000026
J	Busse, FH				Busse, FH			Visualizing the dynamics of the onset of turbulence	SCIENCE			English	Editorial Material							PIPE-FLOW; SHEAR		Univ Bayreuth, Inst Phys, D-95440 Bayreuth, Germany	University of Bayreuth	Busse, FH (corresponding author), Univ Bayreuth, Inst Phys, POB 101251, D-95440 Bayreuth, Germany.	busse@uni-bayreuth.de						CLEVER RM, 1992, J FLUID MECH, V234, P511, DOI 10.1017/S0022112092000892; Draad AA, 1998, J FLUID MECH, V361, P297, DOI 10.1017/S0022112098008702; EGGELS JGM, 1994, J FLUID MECH, V268, P175, DOI 10.1017/S002211209400131X; Faisst H, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.224502; HAGEN G, 1839, POGG ANN, V46, P423, DOI DOI 10.1002/ANDP.18391220304; Hof B, 2004, SCIENCE, V305, P1594, DOI 10.1126/science.1100393; NAGATA M, 1990, J FLUID MECH, V217, P519, DOI 10.1017/S0022112090000829; Reynolds O., 1883, P R SOC LOND, V35, P84, DOI [10.1098/rspl.1883.0018, DOI 10.1098/RSPL.1883.0018]; Waleffe F, 1998, PHYS REV LETT, V81, P4140, DOI 10.1103/PhysRevLett.81.4140; Wedin H, 2004, J FLUID MECH, V508, P333, DOI 10.1017/S0022112004009346	10	14	17	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2004	305	5690					1574	1575		10.1126/science.1102824	http://dx.doi.org/10.1126/science.1102824			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361613				2022-12-28	WOS:000223891200029
J	Kunde, VG; Flasar, FM; Jennings, DE; Bezard, B; Strobel, DF; Conrath, BJ; Nixon, CA; Bjoraker, GL; Romani, PN; Achterberg, RK; Simon-Miller, AA; Irwin, P; Brasunas, JC; Pearl, JC; Smith, MD; Orton, GS; Gierasch, PJ; Spilker, LJ; Carlson, RC; Mamoutkine, AA; Calcutt, SB; Read, PL; Taylor, FW; Fouchet, T; Parrish, P; Barucci, A; Courtin, R; Coustenis, A; Gautier, D; Lellouch, E; Marten, A; Prange, R; Biraud, Y; Ferrari, C; Owen, TC; Abbas, MM; Samuelson, RE; Raulin, F; Ade, P; Cesarsky, CJ; Grossman, KU; Coradini, A				Kunde, VG; Flasar, FM; Jennings, DE; Bezard, B; Strobel, DF; Conrath, BJ; Nixon, CA; Bjoraker, GL; Romani, PN; Achterberg, RK; Simon-Miller, AA; Irwin, P; Brasunas, JC; Pearl, JC; Smith, MD; Orton, GS; Gierasch, PJ; Spilker, LJ; Carlson, RC; Mamoutkine, AA; Calcutt, SB; Read, PL; Taylor, FW; Fouchet, T; Parrish, P; Barucci, A; Courtin, R; Coustenis, A; Gautier, D; Lellouch, E; Marten, A; Prange, R; Biraud, Y; Ferrari, C; Owen, TC; Abbas, MM; Samuelson, RE; Raulin, F; Ade, P; Cesarsky, CJ; Grossman, KU; Coradini, A			Jupiter's atmospheric composition from the Cassini thermal infrared spectroscopy experiment	SCIENCE			English	Article							COMET SHOEMAKER-LEVY-9; JOVIAN SYSTEM; HCN; STRATOSPHERE; PRECIPITATION; EXCITATION; VOYAGER-1; EVOLUTION; IMPACTS; IO	The Composite Infrared Spectrometer observed Jupiter in the thermal infrared during the swing-by of the Cassini spacecraft. Results include the detection of two new stratospheric species, the methyl radical and diacetylene, gaseous species present in the north and south auroral infrared hot spots; determination of the variations with latitude of acetylene and ethane, the latter a tracer of atmospheric motion; observations of unexpected spatial distributions of carbon dioxide and hydrogen cyanide, both considered to be products of comet Shoemaker-Levy 9 impacts; characterization of the morphology of the auroral infrared hot spot acetylene emission; and a new evaluation of the energetics of the northern auroral infrared hot spot.	Univ Maryland, Dept Astron, College Pk, MD 20742 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Observ Paris, LESIA, CNRS, UMR8109, F-91925 Meudon, France; Johns Hopkins Univ, Dept Earth & Planetary Sci, Baltimore, MD 21218 USA; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; Space Sci & Applicat Inc, Lanham, MD 20706 USA; Univ Oxford, Clarendon Lab, Oxford OX1 3PU, England; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; CEA Saclay, Serv Astrophys, F-91191 Gif Sur Yvette, France; Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; NASA, George C Marshall Space Flight Ctr, Huntsville, AL 35812 USA; Univ Paris 07, LISA, CNRS, UMR 7583, F-94010 Creteil, France; Univ Paris 12, LISA, CNRS, UMR 7583, F-94010 Creteil, France; Cardiff Univ, Sch Phys & Astron, Cardiff CF24 3YB, S Glam, Wales; European So Observ, D-85748 Garching, Germany; Gesamthsch Wuppertal, Dept Phys, D-5600 Wuppertal 1, Germany; CNR, Inst Astrophys Spatiale, Area Recerca Tor Vergata, I-00133 Rome, Italy	University System of Maryland; University of Maryland College Park; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Sorbonne Universite; Universite Paris Cite; Johns Hopkins University; Cornell University; University of Oxford; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Hawaii System; National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Cite; Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Cite; Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Cardiff University; European Southern Observatory; University of Wuppertal; Consiglio Nazionale delle Ricerche (CNR)	Kunde, VG (corresponding author), Univ Maryland, Dept Astron, College Pk, MD 20742 USA.	Virgil.G.Kunde.1@gsfc.nasa.gov	Ferrari, Cécile/P-9735-2016; Orton, Glenn/AAD-9862-2020; Flasar, F Michael/C-8509-2012; Jennings, Donald/D-7978-2012; Smith, Michael/C-8875-2012; brasunas, john/I-2798-2013; Strobel, Darrell5/AAO-6643-2021; Nixon, Conor A/A-8531-2009; Fouchet, Thierry/C-6374-2017; Elbaz, David/AAB-4141-2020; Simon, Amy/C-8020-2012; Bjoraker, Gordon L/D-5032-2012; Romani, Paul N/D-2729-2012	Ferrari, Cécile/0000-0001-5962-7439; Strobel, Darrell5/0000-0002-0944-8675; Nixon, Conor A/0000-0001-9540-9121; Fouchet, Thierry/0000-0001-9040-8285; Elbaz, David/0000-0002-7631-647X; Simon, Amy/0000-0003-4641-6186; Taylor, Fred/0000-0002-0675-9769; Irwin, Patrick Gerard Joseph/0000-0002-6772-384X; Achterberg, Richard/0000-0002-7643-7626; Ade, Peter/0000-0002-5127-0401; Bezard, Bruno/0000-0002-5433-5661; Calcutt, Simon/0000-0002-0102-3170				ANICICH VG, 1986, ASTROPHYS J SUPPL S, V62, P553, DOI 10.1086/191151; Banaszkiewicz M, 2000, ICARUS, V147, P386, DOI 10.1006/icar.2000.6448; Bezard B, 1997, ICARUS, V125, P94, DOI 10.1006/icar.1996.5610; BUNCE EW, 2004, IN PRESS J GEOPHYS R; CALDWELL J, 1980, ICARUS, V44, P667, DOI 10.1016/0019-1035(80)90135-9; Clarke JT, 2002, NATURE, V415, P997, DOI 10.1038/415997a; CONNERNEY JEP, 1993, SCIENCE, V262, P1035, DOI 10.1126/science.262.5136.1035; Coustenis A, 1999, PLANET SPACE SCI, V47, P1305, DOI 10.1016/S0032-0633(99)00053-7; DROSSART P, 1993, J GEOPHYS RES-PLANET, V98, P18803, DOI 10.1029/93JE01801; Flasar FM, 2004, NATURE, V427, P132, DOI 10.1038/nature02142; GEHRELS N, 1983, J GEOPHYS RES-SPACE, V88, P5537, DOI 10.1029/JA088iA07p05537; Gladstone GR, 1996, ICARUS, V119, P1, DOI 10.1006/icar.1996.0001; Gladstone GR, 2002, NATURE, V415, P1000, DOI 10.1038/4151000a; Griffith CA, 2004, ICARUS, V170, P58, DOI 10.1016/j.icarus.2004.02.006; HANEL R, 1979, SCIENCE, V204, P972, DOI 10.1126/science.204.4396.972-a; HANEL R, 1979, SCIENCE, V206, P952, DOI 10.1126/science.206.4421.952; Hill TW, 2001, J GEOPHYS RES-SPACE, V106, P8101, DOI 10.1029/2000JA000302; Ingersoll AP, 1998, ICARUS, V135, P251, DOI 10.1006/icar.1998.5971; KIM SJ, 1985, ICARUS, V64, P233, DOI 10.1016/0019-1035(85)90088-0; Kunde V, 1996, P SOC PHOTO-OPT INS, V2803, P162, DOI 10.1117/12.253416; LELLOUCH E, 1995, NATURE, V373, P592, DOI 10.1038/373592a0; Lellouch E, 2002, ICARUS, V159, P112, DOI 10.1006/icar.2002.6929; MARTEN A, 1995, GEOPHYS RES LETT, V22, P1589, DOI 10.1029/95GL00949; Moreno R, 2003, PLANET SPACE SCI, V51, P591, DOI 10.1016/S0032-0633(03)00072-2; Moses J. I., 1996, COLLISION COMET SHOE; MOSES JI, IN PRESS JUPITER PLA; NOLL KS, 1996, COLLISION COMET SHOE; ORTON G, 2003, B AM ASTRON SOC, V35; ORTON GS, 1991, SCIENCE, V252, P537, DOI 10.1126/science.252.5005.537; Pallier L, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL018041; Pallier L, 2001, PLANET SPACE SCI, V49, P1159, DOI 10.1016/S0032-0633(01)00023-X; Porco CC, 2003, SCIENCE, V299, P1541, DOI 10.1126/science.1079462; Prange R, 1998, J GEOPHYS RES-PLANET, V103, P20195, DOI 10.1029/98JE01128; PRANGE R, 2003, AM GEOPH UN FALL M; REGO D, 1994, J GEOPHYS RES-PLANET, V99, P17075, DOI 10.1029/93JE03432; SCHOEBERL MR, 1992, J GEOPHYS RES-ATMOS, V97, P7859, DOI 10.1029/91JD02168; Strobel D.F., 1983, INT REV PHYS CHEM, V3, P145, DOI [10.1080/01442358309353342, DOI 10.1080/01442358309353342]; WAITE JH, 1983, J GEOPHYS RES-SPACE, V88, P6143, DOI 10.1029/JA088iA08p06143	38	53	53	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	2004	305	5690					1582	1586		10.1126/science.1100240	http://dx.doi.org/10.1126/science.1100240			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15319491				2022-12-28	WOS:000223891200034
J	Sininger, YS; Cone-Wesson, B				Sininger, YS; Cone-Wesson, B			Asymmetric cochlear processing mimics hemispheric specialization	SCIENCE			English	Article							EVOKED OTOACOUSTIC EMISSIONS; NEONATAL HEARING IMPAIRMENT; OLIVOCOCHLEAR SYSTEM; PERINATAL-PERIOD; IDENTIFICATION; MECHANISMS		Univ Calif Los Angeles, David Geffen Sch Med, Div Head & Neck Surg, Ctr Hlth Sci 62 132, Los Angeles, CA 90095 USA; Univ Arizona, Dept Speech Language & Hearing Sci, Tucson, AZ 85721 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Arizona	Sininger, YS (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Head & Neck Surg, Ctr Hlth Sci 62 132, Los Angeles, CA 90095 USA.	ysininger@mednet.ucla.edu						Aidan D, 1997, ACTA OTO-LARYNGOL, V117, P25, DOI 10.3109/00016489709117986; Dehaene-Lambertz G, 2000, J COGNITIVE NEUROSCI, V12, P449, DOI 10.1162/089892900562264; Gorga MP, 2000, EAR HEARING, V21, P400, DOI 10.1097/00003446-200010000-00007; KEMP DT, 1978, J ACOUST SOC AM, V64, P1386, DOI 10.1121/1.382104; KIMURA D, 1964, Q J EXP PSYCHOL, V16, P355, DOI 10.1080/17470216408416391; Moore JK, 1999, AUDIOL NEURO-OTOL, V4, P311, DOI 10.1159/000013855; Moore JK, 2002, ANN OTO RHINOL LARYN, V111, P7, DOI 10.1177/00034894021110S502; MORLET T, 1993, ACTA OTO-LARYNGOL, V113, P271, DOI 10.3109/00016489309135808; Norton SJ, 2000, EAR HEARING, V21, P425, DOI 10.1097/00003446-200010000-00008; Shera CA, 2004, EAR HEARING, V25, P86, DOI 10.1097/01.AUD.0000121200.90211.83; VEUILLET E, 1991, J NEUROPHYSIOL, V65, P724, DOI 10.1152/jn.1991.65.3.724; Zatorre RJ, 2002, TRENDS COGN SCI, V6, P37, DOI 10.1016/S1364-6613(00)01816-7	12	73	80	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2004	305	5690					1581	1581		10.1126/science.1100646	http://dx.doi.org/10.1126/science.1100646			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361617				2022-12-28	WOS:000223891200033
J	Wouters, EFM				Wouters, EFM			Management of severe COPD	LANCET			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; VOLUME-REDUCTION SURGERY; QUALITY-OF-LIFE; POSITIVE-PRESSURE VENTILATION; ATRIAL-NATRIURETIC-PEPTIDE; RESPIRATORY MUSCLE STRENGTH; RANDOMIZED CONTROLLED-TRIAL; STANDARD MEDICAL THERAPY; AIR-FLOW OBSTRUCTION; TERM OXYGEN-THERAPY	Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide, and the burden of the disorder will continue to increase over the next 20 years despite medical intervention. Apart from smoking cessation, no approach or agent affects the rate of decline in lung function and progression of the disease. Especially in the later phase, COPD is a multicomponent disorder, and various integrated intervention strategies are needed as part of the optimum management programme. This seminar describes largely non-pharmacological interventions aimed at improving health status and function of disabled patients. Exacerbations become progressively more troublesome as baseline lung function declines, commonly necessitating hospital admission and associated with the development of acute respiratory failure.	Univ Hosp Maastricht, Dept Resp Med, NL-6229 HX Maastricht, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC)	Wouters, EFM (corresponding author), Univ Hosp Maastricht, Dept Resp Med, NL-6229 HX Maastricht, Netherlands.	e.wouters@lung.azm.nl	Wouters, Emiel/ABD-6200-2021					Aaron SD, 2003, NEW ENGL J MED, V348, P2618, DOI 10.1056/NEJMoa023161; ADNOT S, 1990, AM REV RESPIR DIS, V141, P1178, DOI 10.1164/ajrccm/141.5_Pt_1.1178; Agusti AGN, 2002, AM J RESP CRIT CARE, V166, P485, DOI 10.1164/rccm.2108013; ANAND IS, 1992, CIRCULATION, V86, P12, DOI 10.1161/01.CIR.86.1.12; Anderson HR, 1997, EUR RESPIR J, V10, P1064, DOI 10.1183/09031936.97.10051064; [Anonymous], 1980, Ann Intern Med, V93, P391; ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; AVDEEV SN, 1998, ANESTEZIOL REANI MAY; Baarends EM, 1997, EUR RESPIR J, V10, P2807, DOI 10.1183/09031936.97.10122807; Bach PB, 2001, ANN INTERN MED, V134, P600, DOI 10.7326/0003-4819-134-7-200104030-00016; Barbe F, 1996, EUR RESPIR J, V9, P1240, DOI 10.1183/09031936.96.09061240; Barbera JA, 1997, EUR RESPIR J, V10, P1285, DOI 10.1183/09031936.97.10061285; BAUDOUIN SV, 1992, THORAX, V47, P550, DOI 10.1136/thx.47.7.550; Baudouin SV, 1997, THORAX, V52, P401, DOI 10.1136/thx.52.5.401; BAUER FK, 1965, AM J MED SCI, V250, P245, DOI 10.1097/00000441-196509000-00001; BAUM GL, 1959, AM HEART J, V4, P593; Belman MJ, 1996, AM J RESP CRIT CARE, V153, P967, DOI 10.1164/ajrccm.153.3.8630581; Bestall JC, 1999, THORAX, V54, P581, DOI 10.1136/thx.54.7.581; Bhowmik A, 2000, THORAX, V55, P114, DOI 10.1136/thorax.55.2.114; BONE R, 1994, CHEST, V105, P1411; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; Bratel T, 2000, RESP MED, V94, P1221, DOI 10.1053/rmed.2000.0953; Brochard L, 2000, THORAX, V55, P817, DOI 10.1136/thorax.55.10.817; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; Brug J, 2004, PATIENT EDUC COUNS, V52, P249, DOI 10.1016/S0738-3991(03)00099-5; Brusasco V, 2003, THORAX, V58, P399, DOI 10.1136/thorax.58.5.399; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; CAMPBELL RHA, 1975, CLIN SCI MOL MED, V49, P323, DOI 10.1042/cs0490323; CARLONE S, 1989, AM J MED SCI, V298, P243, DOI 10.1097/00000441-198910000-00006; Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802; CASABURI R, 1991, AM REV RESPIR DIS, V143, P9, DOI 10.1164/ajrccm/143.1.9; Celikel T, 1998, CHEST, V114, P1636, DOI 10.1378/chest.114.6.1636; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; Chailleux E, 2003, CHEST, V123, P1460, DOI 10.1378/chest.123.5.1460; CHRYSTYN H, 1988, BRIT MED J, V297, P1506, DOI 10.1136/bmj.297.6662.1506; Clark CJ, 2000, EUR RESPIR J, V15, P92, DOI 10.1034/j.1399-3003.2000.15a17.x; Clini E, 1999, AM J RESP CRIT CARE, V159, pA295; Collet JP, 1997, AM J RESP CRIT CARE, V156, P1719, DOI 10.1164/ajrccm.156.6.9612096; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592; COOPER CB, 1987, B EUR PHYSIOPATH RES, V23, P15; Cooper JD, 1997, ANN THORAC SURG, V63, P312; Creutzberg EC, 2003, NUTRITION, V19, P120, DOI 10.1016/S0899-9007(02)00841-9; Creutzberg EC, 2000, AM J RESP CRIT CARE, V161, P745, DOI 10.1164/ajrccm.161.3.9808075; Curtis JR, 2003, EUR RESPIR J, V21, p36S, DOI 10.1183/09031936.03.00078102; CURTIS JR, 1994, THORAX, V49, P162, DOI 10.1136/thx.49.2.162; Curtis JR, 2002, CHEST, V122, P356, DOI 10.1378/chest.122.1.356; Davies L, 1999, LANCET, V354, P456, DOI 10.1016/S0140-6736(98)11326-0; DAVIS AL, 1987, CHEST, V92, P204, DOI 10.1378/chest.92.2.204; de Leeuw PW, 2003, EUR RESPIR J, V22, p33S, DOI 10.1183/09031936.03.00000603a; DEANGELIS C, 1993, AM J NEPHROL, V13, P173, DOI 10.1159/000168613; DECRAMER M, 1992, AM REV RESPIR DIS, V146, P800, DOI 10.1164/ajrccm/146.3.800; DECRAMER M, 1994, AM J RESP CRIT CARE, V150, P11, DOI 10.1164/ajrccm.150.1.8025735; Decramer M, 1997, EUR RESPIR J, V10, P417, DOI 10.1183/09031936.97.10020417; deGodoy I, 1996, AM J RESP CRIT CARE, V153, P633, DOI 10.1164/ajrccm.153.2.8564110; DELEEUW PW, 1978, ACTA MED SCAND, P9; Dentener MA, 2001, THORAX, V56, P721, DOI 10.1136/thorax.56.9.721; DIFRANCIA M, 1994, AM J RESP CRIT CARE, V150, P1453, DOI 10.1164/ajrccm.150.5.7952575; Dikensoy O, 2002, INT J CLIN PRACT, V56, P85; Donner CF, 1997, EUR RESPIR J, V10, P744; Donohue JF, 2002, CHEST, V122, P47, DOI 10.1378/chest.122.1.47; Drazen JM, 2003, NEW ENGL J MED, V348, P2134, DOI 10.1056/NEJMe030058; Eaton T, 2002, EUR RESPIR J, V20, P306, DOI 10.1183/09031936.02.00301002; Eller J, 1998, CHEST, V113, P1542, DOI 10.1378/chest.113.6.1542; Engelen MPKJ, 1998, AM J CLIN NUTR, V68, P1298, DOI 10.1093/ajcn/68.6.1298; Engelen MPKJ, 2000, AM J CLIN NUTR, V71, P733, DOI 10.1093/ajcn/71.3.733; ENGELEN MPKJ, 1994, EUR RESPIR J, V7, P1793, DOI 10.1183/09031936.94.07101793; FARBER MO, 1977, J LAB CLIN MED, V90, P373; FARBER MO, 1975, J LAB CLIN MED, V85, P41; FARBER MO, 1982, ARCH INTERN MED, V142, P1326, DOI 10.1001/archinte.142.7.1326; FARBER MO, 1984, CHEST, V85, P49, DOI 10.1378/chest.85.1.49; Ferreira IM, 2000, CHEST, V117, P672, DOI 10.1378/chest.117.3.672; Fishman A, 2003, NEW ENGL J MED, V348, P2059; Fishman A, 2001, NEW ENGL J MED, V345, P1075; FISHMAN AP, 1994, AM J RESP CRIT CARE, V149, P825, DOI 10.1164/ajrccm.149.3.8118655; FISHMAN AP, 1951, CIRCULATION, V3, P703, DOI 10.1161/01.CIR.3.5.703; Flaherty KR, 2001, CHEST, V119, P1337, DOI 10.1378/chest.119.5.1337; FLENLEY DC, 1981, LANCET, V1, P681; Foglio K, 1999, EUR RESPIR J, V13, P125, DOI 10.1183/09031936.99.13112599; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Garcia-Aymerich J, 2001, AM J RESP CRIT CARE, V164, P1002, DOI 10.1164/ajrccm.164.6.2006012; Geddes D, 2000, NEW ENGL J MED, V343, P239, DOI 10.1056/NEJM200007273430402; Gelb AF, 1999, CHEST, V116, P1608, DOI 10.1378/chest.116.6.1608; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; GOLDSTEIN RS, 1994, LANCET, V344, P1394, DOI 10.1016/S0140-6736(94)90568-1; Gore JM, 2000, THORAX, V55, P1000, DOI 10.1136/thorax.55.12.1000; Gorecka D, 1997, THORAX, V52, P674, DOI 10.1136/thx.52.8.674; GORIS AHC, 1997, AM J RESP CRIT CARE, V155, pA498; GrayDonald K, 1996, AM J RESP CRIT CARE, V153, P961, DOI 10.1164/ajrccm.153.3.8630580; Griffiths TL, 2001, THORAX, V56, P779, DOI 10.1136/thorax.56.10.779; Griffiths TL, 2000, LANCET, V355, P362, DOI 10.1016/S0140-6736(99)07042-7; Groenewegen KH, 2003, RESP MED, V97, P770, DOI 10.1016/S0954-6111(03)00026-X; Hasford B, 1998, EUR RESPIR J, V11, P992, DOI 10.1183/09031936.98.11040992; HEGELE RG, 1995, AM J RESP CRIT CARE, V151, P1659; Hosenpud JD, 2001, J HEART LUNG TRANSPL, V20, P805, DOI 10.1016/S1053-2498(01)00323-0; Howes TQ, 1996, THORAX, V51, P516, DOI 10.1136/thx.51.5.516; ISADA CM, 1994, RESP INFECT SCI BASI, P621; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Jones PW, 2003, EUR RESPIR J, V21, p13S, DOI 10.1183/09031936.03.00077803; Jones PW, 1997, AM J RESP CRIT CARE, V155, P1283, DOI 10.1164/ajrccm.155.4.9105068; JUAN G, 1984, NEW ENGL J MED, V310, P874, DOI 10.1056/NEJM198404053101402; Kessler R, 1999, AM J RESP CRIT CARE, V159, P158, DOI 10.1164/ajrccm.159.1.9803117; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; LAABAN JP, 1993, CHEST, V103, P1362, DOI 10.1378/chest.103.5.1362; Landbo C, 1999, AM J RESP CRIT CARE, V160, P1856, DOI 10.1164/ajrccm.160.6.9902115; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Lightowler JV, 2003, BMJ-BRIT MED J, V326, P185, DOI 10.1136/bmj.326.7382.185; MACNEE W, 1994, AM J RESP CRIT CARE, V150, P833, DOI 10.1164/ajrccm.150.3.8087359; MACNEE W, 2002, CHRONIC OBSTRUCTIVE, P145; Madison JM, 1998, LANCET, V352, P467, DOI 10.1016/S0140-6736(97)11081-9; MAHLER DA, 1992, AM REV RESPIR DIS, V145, P467, DOI 10.1164/ajrccm/145.2_Pt_1.467; Mahler DA, 1999, CHEST, V115, P957, DOI 10.1378/chest.115.4.957; Maltais F, 1997, AM J RESP CRIT CARE, V155, P555, DOI 10.1164/ajrccm.155.2.9032194; Maltais F, 1996, AM J RESP CRIT CARE, V153, P288, DOI 10.1164/ajrccm.153.1.8542131; Maltais F, 2002, AM J RESP CRIT CARE, V165, P698, DOI 10.1164/ajrccm.165.5.2109093; MANNIX ET, 1990, CHEST, V97, P840, DOI 10.1378/chest.97.4.840; Mazolewski P, 1999, CHEST, V116, P693, DOI 10.1378/chest.116.3.693; MCKAY SE, 1993, THORAX, V48, P227, DOI 10.1136/thx.48.3.227; *METR LIF INS CO, 1983, B METROPOLITAN LIFE, V64, P1; Meyers BF, 2003, THORAX, V58, P634, DOI 10.1136/thorax.58.7.634; Miravitlles M, 1999, CHEST, V116, P40, DOI 10.1378/chest.116.1.40; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Mobbs KJ, 1999, RESP MED, V93, P540, DOI 10.1016/S0954-6111(99)90152-X; MOSER KM, 1973, NEW ENGL J MED, V288, P427, DOI 10.1056/NEJM197303012880901; Muir JF, 1999, AM J RESP CRIT CARE, V159, pA295; MULLOY E, 1993, AM REV RESPIR DIS, V148, P1030, DOI 10.1164/ajrccm/148.4_Pt_1.1030; MURCIANO D, 1989, NEW ENGL J MED, V320, P1521, DOI 10.1056/NEJM198906083202304; MURCIANO D, 1984, NEW ENGL J MED, V311, P349, DOI 10.1056/NEJM198408093110601; Murphy TF, 1999, J INFECT DIS, V180, P404, DOI 10.1086/314870; Nandi K, 2003, THORAX, V58, P670, DOI 10.1136/thorax.58.8.670; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; Nishimura K, 2002, CHEST, V121, P1434, DOI 10.1378/chest.121.5.1434; O'Donnell DE, 2001, AM J RESP CRIT CARE, V164, P770, DOI 10.1164/ajrccm.164.5.2012122; ODRISCOLL BR, 1992, RESP MED, V86, P317, DOI 10.1016/S0954-6111(06)80031-4; Oga T, 2003, AM J RESP CRIT CARE, V167, P544, DOI 10.1164/rccm.200206-583OC; Osman LM, 1997, THORAX, V52, P67; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; Palange P, 1998, THORAX, V53, P989, DOI 10.1136/thx.53.11.989; PALANGE P, 1995, CHEST, V107, P1206, DOI 10.1378/chest.107.5.1206; Palange P, 1998, CHEST, V114, P12, DOI 10.1378/chest.114.1.12; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; PEAKE MD, 1989, BRIT MED J, V298, P523, DOI 10.1136/bmj.298.6672.523-b; Plant PK, 2003, THORAX, V58, P537, DOI 10.1136/thorax.58.6.537; Plant PK, 2003, BRIT MED J, V326, P956, DOI 10.1136/bmj.326.7396.956; Plant PK, 2001, THORAX, V56, P708, DOI 10.1136/thorax.56.9.708; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; Pompeo E, 2000, ANN THORAC SURG, V70, P948, DOI 10.1016/S0003-4975(00)01646-5; Pouw EM, 2000, CLIN NUTR, V19, P95, DOI 10.1054/clnu.1999.0074; Ram FS, 2002, COCHRANE DB SYST REV, V2; Ramsey SD, 2003, NEW ENGL J MED, V348, P2092; Ramsey SD, 2001, ANN THORAC SURG, V71, P995, DOI 10.1016/S0003-4975(00)02283-9; REITZ BA, 1982, NEW ENGL J MED, V306, P557, DOI 10.1056/NEJM198203113061001; Rennard S, 2002, EUR RESPIR J, V20, P799, DOI 10.1183/09031936.02.03242002; Rennard SI, 2001, AM J RESP CRIT CARE, V163, P1087, DOI 10.1164/ajrccm.163.5.9903053; Rice KL, 2000, AM J RESP CRIT CARE, V162, P174, DOI 10.1164/ajrccm.162.1.9909066; RIES AL, 1991, J CLIN EPIDEMIOL, V44, P497, DOI 10.1016/0895-4356(91)90212-R; RIES AL, 1995, ANN INTERN MED, V122, P823, DOI 10.7326/0003-4819-122-11-199506010-00003; Roberts CM, 1996, THORAX, V51, P831, DOI 10.1136/thx.51.8.831; Robinson TD, 2000, AM J RESP CRIT CARE, V161, P1524, DOI 10.1164/ajrccm.161.5.9904119; Rodarte J, 1999, J THORAC CARDIOV SUR, V118, P518; Rodriguez-Roisin R, 2000, CHEST, V117, p398S, DOI 10.1378/chest.117.5_suppl_2.398S; Rutten-van Molken MPMH, 1999, RESP MED, V93, P779, DOI 10.1016/S0954-6111(99)90262-7; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; SCHALEKAMP MA, 1971, CLIN SCI, V41, P219, DOI 10.1042/cs0410219; Schols AMWJ, 1999, AM J RESP CRIT CARE, V160, P1220, DOI 10.1164/ajrccm.160.4.9811033; SCHOLS AMWJ, 1991, AM J CLIN NUTR, V53, P421, DOI 10.1093/ajcn/53.2.421; Schols AMWJ, 1998, AM J RESP CRIT CARE, V157, P1791, DOI 10.1164/ajrccm.157.6.9705017; Schols AMWJ, 1996, THORAX, V51, P819, DOI 10.1136/thx.51.8.819; SCHOLS AMWJ, 1995, AM J RESP CRIT CARE, V152, P1268, DOI 10.1164/ajrccm.152.4.7551381; SCHOLS AMWJ, 1993, AM REV RESPIR DIS, V147, P1151, DOI 10.1164/ajrccm/147.5.1151; Schols AMWJ, 2000, CLIN CHEST MED, V21, P753, DOI 10.1016/S0272-5231(05)70182-9; Schwebel C, 2000, EUR RESPIR J, V16, P1050, DOI 10.1034/j.1399-3003.2000.16f05.x; Sciurba FC, 1996, NEW ENGL J MED, V334, P1095, DOI 10.1056/NEJM199604253341704; Seemungal TAR, 2000, AM J RESP CRIT CARE, V161, P1608, DOI 10.1164/ajrccm.161.5.9908022; Seemungal TAR, 2000, EUR RESPIR J, V16, P677, DOI 10.1034/j.1399-3003.2000.16d19.x; Senderovitz T, 1999, RESP MED, V93, P715, DOI 10.1016/S0954-6111(99)90038-0; SENEFF MG, 1995, JAMA-J AM MED ASSOC, V274, P1852, DOI 10.1001/jama.274.23.1852; Sethi S, 2002, NEW ENGL J MED, V347, P465, DOI 10.1056/NEJMoa012561; Sethi S, 2000, CHEST, V117, p380S, DOI 10.1378/chest.117.5_suppl_2.380S; Sharkey RA, 1997, THORAX, V52, P411, DOI 10.1136/thx.52.5.411; Sharkey RA, 1999, CHEST, V115, P1588, DOI 10.1378/chest.115.6.1588; Shoup R, 1997, EUR RESPIR J, V10, P1576, DOI 10.1183/09031936.97.10071576; SIMBERKOFF MS, 1986, NEW ENGL J MED, V315, P1318, DOI 10.1056/NEJM198611203152104; Singer HK, 2001, CHEST, V120, P1246, DOI 10.1378/chest.120.4.1246; SMITH CB, 1980, J INFECT DIS, V141, P271, DOI 10.1093/infdis/141.3.271; STEWART AG, 1991, THORAX, V46, P829, DOI 10.1136/thx.46.11.829; Takabatake N, 1999, AM J RESP CRIT CARE, V159, P1215, DOI 10.1164/ajrccm.159.4.9806134; Tashkin DP, 1996, AM J MED, V100, pS62, DOI 10.1016/S0002-9343(96)80109-4; TAYLOR DR, 1985, AM REV RESPIR DIS, V131, P747; Thompson WH, 1996, AM J RESP CRIT CARE, V154, P407, DOI 10.1164/ajrccm.154.2.8756814; Toma TP, 2003, LANCET, V361, P931, DOI 10.1016/S0140-6736(03)12762-6; Troosters T, 2000, AM J MED, V109, P207, DOI 10.1016/S0002-9343(00)00472-1; ULRIK CS, 1995, THORAX, V50, P750, DOI 10.1136/thx.50.7.750; *USDA US DEP HHS, 2000, HOM GARD B, V232; Vermeeren MAP, 1997, EUR RESPIR J, V10, P2264, DOI 10.1183/09031936.97.10102264; Vincken W, 2002, EUR RESPIR J, V19, P209, DOI 10.1183/09031936.02.00238702; Vitacca M, 1996, EUR RESPIR J, V9, P1487, DOI 10.1183/09031936.96.09071487; WEGNER RE, 1994, EUR RESPIR J, V7, P725, DOI 10.1183/09031936.94.07040725; WILLIAMS JH, 1986, ANN INTERN MED, V104, P106, DOI 10.7326/0003-4819-104-1-106; WILSON DO, 1989, AM REV RESPIR DIS, V139, P1435, DOI 10.1164/ajrccm/139.6.1435; WINTER RJD, 1989, THORAX, V44, P58, DOI 10.1136/thx.44.1.58; Wordley J, 1997, OCCUP ENVIRON MED, V54, P108, DOI 10.1136/oem.54.2.108; Wouters EFM, 2003, RESP MED, V97, pS3, DOI 10.1016/S0954-6111(03)80020-3	205	57	58	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2004	364	9437					883	895		10.1016/S0140-6736(04)16984-5	http://dx.doi.org/10.1016/S0140-6736(04)16984-5			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351196				2022-12-28	WOS:000223685200035
J	Chen, IA; Roberts, RW; Szostak, JW				Chen, IA; Roberts, RW; Szostak, JW			The emergence of competition between model protocells	SCIENCE			English	Article							VESICLES; GROWTH	The transition from independent molecular entities to cellular structures with integrated behaviors was a crucial aspect of the origin of life. We show that simple physical principles can mediate a coordinated interaction between genome and compartment boundary, independent of any genomic functions beyond self-replication. RNA, encapsulated in fatty acid vesicles, exerts an osmotic pressure on the vesicle membrane that drives the uptake of additional membrane components, leading to membrane growth at the expense of relaxed vesicles, which shrink. Thus, more efficient RNA replication could cause faster cell growth, leading to the emergence of Darwinian evolution at the cellular level.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Massachusetts Gen Hosp, Howard Hughes Med Inst, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Program Biophys, Cambridge, MA 02138 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; California Institute of Technology	Szostak, JW (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.	szostak@molbio.mgh.harvard.edu		Chen, Irene/0000-0001-6040-7927	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008313, T32GM007753] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartel David P., 1999, Trends in Cell Biology, V9, pM9, DOI 10.1016/S0962-8924(99)01669-4; Chen IA, 2004, BIOPHYS J, V87, P988, DOI 10.1529/biophysj.104.039875; Chen IA, 2004, P NATL ACAD SCI USA, V101, P7965, DOI 10.1073/pnas.0308045101; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2857, DOI 10.1021/bi00333a007; GEBICKI JM, 1973, NATURE, V243, P232, DOI 10.1038/243232a0; Hanczyc MM, 2003, SCIENCE, V302, P618, DOI 10.1126/science.1089904; Jin AJ, 1999, EUR BIOPHYS J BIOPHY, V28, P187, DOI 10.1007/s002490050199; JONES JD, 1989, BIOCHEMISTRY-US, V28, P129, DOI 10.1021/bi00427a019; Landweber LF, 1998, BIOSCIENCE, V48, P94, DOI 10.2307/1313134; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; Monnard PA, 2002, ASTROBIOLOGY, V2, P139, DOI 10.1089/15311070260192237; Morowitz H.J., 1992, BEGINNINGS CELLULAR; MUI BLS, 1993, BIOPHYS J, V64, P443, DOI 10.1016/S0006-3495(93)81385-7; NEEDHAM D, 1990, BIOPHYS J, V58, P997, DOI 10.1016/S0006-3495(90)82444-9; Olbrich K, 2000, BIOPHYS J, V79, P321, DOI 10.1016/S0006-3495(00)76294-1; Shoemaker SD, 2002, IND ENG CHEM RES, V41, P324, DOI 10.1021/ie010049t; Szostak JW, 2001, NATURE, V409, P387, DOI 10.1038/35053176; WALDE P, 1994, J AM CHEM SOC, V116, P11649, DOI 10.1021/ja00105a004; Watson J. D., 1965, MOL BIOL GENE; Zhang FL, 1996, BIOCHEMISTRY-US, V35, P16055, DOI 10.1021/bi961685b	20	297	311	1	136	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1474	1476		10.1126/science.1100757	http://dx.doi.org/10.1126/science.1100757			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353806	Green Accepted			2022-12-28	WOS:000223761900052
J	Mazelin, L; Bernet, A; Bonod-Bidaud, C; Pays, L; Arnaud, S; Gespach, C; Bredesen, DE; Scoazec, JY; Mehlen, P				Mazelin, L; Bernet, A; Bonod-Bidaud, C; Pays, L; Arnaud, S; Gespach, C; Bredesen, DE; Scoazec, JY; Mehlen, P			Netrin-1 controls colorectal tumorigenesis by regulating apoptosis	NATURE			English	Article							CANCER DCC; RECEPTORS UNC5H; GENE; SUPPRESSOR; DEPENDENCE; MECHANISM; TUMORS; MICE	The expression of the protein DCC ( deleted in colorectal cancer) is lost or markedly reduced in numerous cancers and in the majority of colorectal cancers due to loss of heterozygosity in chromosome 18q, and has therefore been proposed to be a tumour suppressor(1). However, the rarity of mutations found in DCC, the lack of cancer predisposition of DCC mutant mice, and the presence of other tumour suppressor genes in 18q have raised doubts about the function of DCC as a tumour suppressor(2). Unlike classical tumour suppressors, DCC has been shown to induce apoptosis conditionally: by functioning as a dependence receptor, DCC induces apoptosis unless DCC is engaged by its ligand, netrin-1 (ref. 3). Here we show that inhibition of cell death by enforced expression of netrin-1 in mouse gastrointestinal tract leads to the spontaneous formation of hyperplastic and neoplastic lesions. Moreover, in the adenomatous polyposis coli mutant background associated with adenoma formation, enforced expression of netrin-1 engenders aggressive adenocarcinomatous malignancies. These data demonstrate that netrin-1 can promote intestinal tumour development, probably by regulating cell survival. Thus, a netrin-1 receptor or receptors function as conditional tumour suppressors.	Univ Lyon, CNRS,UMR 5534, Apoptosis Differentiat Lab, Eqiuipe Labellisee La Ligue Mol & Cellular Genet, F-69622 Villeurbanne, France; Hop St Antoine, INSERM, U482, F-75571 Paris, France; Buck Inst Age Res, Novato, CA 94945 USA; INSERM, U45, F-69437 Lyon, France; ANIPATH, F-69437 Lyon, France; Ctr Leon Berard, F-69373 Lyon, France	Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Buck Institute for Research on Aging; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Mehlen, P (corresponding author), Univ Lyon, CNRS,UMR 5534, Apoptosis Differentiat Lab, Eqiuipe Labellisee La Ligue Mol & Cellular Genet, F-69622 Villeurbanne, France.	mehlen@univ-lyon1.fr	Mazelin, Laetitia/AAD-9319-2020; Bernet, Agnes/GSN-2702-2022; bonod-bidaud, christelle/AAN-9236-2021	Mazelin, Laetitia/0000-0002-4001-2132; Pays, Laurent/0000-0003-0720-2273; BONOD, Christelle/0000-0002-7180-2727				Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Bredesen DE, 1998, CELL DEATH DIFFER, V5, P365, DOI 10.1038/sj.cdd.4400378; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Forcet C, 2002, NATURE, V417, P443, DOI 10.1038/nature748; Hsu Y H, 2001, Kaohsiung J Med Sci, V17, P351; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLINGELHUTZ AJ, 1993, ONCOGENE, V8, P95; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; Mehlen P, 2004, APOPTOSIS, V9, P37, DOI 10.1023/B:APPT.0000012120.66221.b2; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Meyerhardt JA, 1999, CELL GROWTH DIFFER, V10, P35; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; Simon TC, 1997, J BIOL CHEM, V272, P10652; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Thibert C, 2003, SCIENCE, V301, P843, DOI 10.1126/science.1085405; Thiebault K, 2003, P NATL ACAD SCI USA, V100, P4173, DOI 10.1073/pnas.0738063100	22	234	251	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2004	431	7004					80	84		10.1038/nature02788	http://dx.doi.org/10.1038/nature02788			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343335				2022-12-28	WOS:000223641500045
J	Tang, HX; Masmanidis, S; Kawakami, RK; Awschalom, DD; Roukes, ML				Tang, HX; Masmanidis, S; Kawakami, RK; Awschalom, DD; Roukes, ML			Negative intrinsic resistivity of an individual domain wall in epitaxial (Ga,Mn)As microdevices	NATURE			English	Article							WIRES; MAGNETORESISTANCE; FERROMAGNETS; SCATTERING; RESISTANCE; FILMS	Magnetic domains, and the boundaries that separate them ( domain walls, DWs), play a central role in the science of magnetism(1). Understanding and controlling domains is important for many technological applications in spintronics, and may lead to new devices(2). Although theoretical efforts have elucidated several mechanisms underlying the resistance of a single DW3-8, various experiments(9-15) report conflicting results, even for the overall sign of the DW resistance. The question of whether an individual DW gives rise to an increase or decrease of the resistance therefore remains open. Here we report an approach to DW studies in a class of ferromagnetic semiconductors ( as opposed to metals(16,17)) that offer promise for spintronics(18). These experiments involve microdevices patterned from monocrystalline (Ga, Mn) As epitaxial layers. The giant planar Hall effect that we previously observed(19) in this material enables direct, real-time observation of the propagation of an individual magnetic DW along multiprobe devices. We apply steady and pulsed magnetic fields, to trap and carefully position an individual DW within each separate device studied. This protocol reproducibly enables high-resolution magnetoresistance measurements across an individual wall. We consistently observe negative intrinsic DW resistance that scales with channel width. This appears to originate from sizeable quantum corrections to the magnetoresistance.	CALTECH, Pasadena, CA 91125 USA; Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA	California Institute of Technology; University of California System; University of California Santa Barbara	Roukes, ML (corresponding author), CALTECH, Pasadena, CA 91125 USA.	roukes@caltech.edu	Tang, Hong/D-1587-2009; Roukes, Michael L/E-9787-2010					Allwood DA, 2002, SCIENCE, V296, P2003, DOI 10.1126/science.1070595; BERGER L, 1978, J APPL PHYS, V49, P2156, DOI 10.1063/1.324716; CABRERA GG, 1974, PHYS STATUS SOLIDI B, V62, P217, DOI 10.1002/pssb.2220620122; Danneau R, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.157201; Ebels U, 2000, PHYS REV LETT, V84, P983, DOI 10.1103/PhysRevLett.84.983; Ferre J, 2002, TOP APPL PHYS, V83, P127; Hubert A., 1998, MAGNETIC DOMAINS ANA; Klein L, 2000, PHYS REV LETT, V84, P6090, DOI 10.1103/PhysRevLett.84.6090; Levy PM, 1997, PHYS REV LETT, V79, P5110, DOI 10.1103/PhysRevLett.79.5110; Ohno H, 1998, SCIENCE, V281, P951, DOI 10.1126/science.281.5379.951; Ono T, 1999, SCIENCE, V284, P468, DOI 10.1126/science.284.5413.468; Potashnik SJ, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.012408; Ruediger U, 1998, PHYS REV LETT, V80, P5639, DOI 10.1103/PhysRevLett.80.5639; TANG H, UNPUB PHYS REV LETT; Tang HX, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.107201; TANG HX, 2002, THESIS CALTECH; TANG HX, 2004, UNPUB PHYS REV B; Taniyama T, 1999, PHYS REV LETT, V82, P2780, DOI 10.1103/PhysRevLett.82.2780; Tatara G, 1997, PHYS REV LETT, V78, P3773, DOI 10.1103/PhysRevLett.78.3773; van Gorkom RP, 1999, PHYS REV LETT, V83, P4401, DOI 10.1103/PhysRevLett.83.4401; Viret M, 2000, PHYS REV LETT, V85, P3962, DOI 10.1103/PhysRevLett.85.3962; Viret M, 1996, PHYS REV B, V53, P8464, DOI 10.1103/PhysRevB.53.8464; Welp U, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.167206; Wolf SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/science.1065389; Xu YB, 2000, PHYS REV B, V61, P14901, DOI 10.1103/PhysRevB.61.R14901; Yamanouchi M, 2004, NATURE, V428, P539, DOI 10.1038/nature02441	26	64	64	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2004	431	7004					52	56		10.1038/nature02809	http://dx.doi.org/10.1038/nature02809			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343329				2022-12-28	WOS:000223641500038
J	Kreicbergs, U; Valdimarsdottir, U; Steineck, G; Henter, JI				Kreicbergs, U; Valdimarsdottir, U; Steineck, G; Henter, JI			A population-based nationwide study of parents' perceptions of a questionnaire on their child's death due to cancer	LANCET			English	Article								A proposed nationwide postal questionnaire to Swedish parents who had lost a child due to cancer between 1992 and 1997 was denied approval by the local ethics committee. However, a pilot study to assess the harm and benefit of the questionnaire was approved. 95% of parents found the pilot study valuable; thus, we were allowed to proceed with the main study, which consisted of 129 questions about the child's care and death and five about the parents' perceptions of the study. 423 (99%) parents found the investigation valuable, 285 (68%) were positively affected, and 123 (28%) were negatively affected (10 [2%] of whom, very much). Although the numerical data cannot be directly translated to ethical conclusions, they can provide guidance for future ethical decisions.	Karolinska Inst, Karolinska Hosp Z6 01, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Karolinska Inst, Karolinska Hosp Q6 05, Dept Woman & Child Hlth, Childhood Canc Res Unit, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Steineck, G (corresponding author), Karolinska Inst, Karolinska Hosp Z6 01, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden.	Gunnar.Steineck@onkpat.ki.se	Harding, Richard/G-9729-2012; Steineck, Gunnar/W-1515-2019	Steineck, Gunnar/0000-0002-0787-3969; Henter, Jan-Inge/0000-0002-0629-2126; Valdimarsdottir, Unnur/0000-0001-5382-946X				[Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373; Evans M, 2002, J MED ETHICS, V28, P41, DOI 10.1136/jme.28.1.41; KREUGER A, 1981, AM J PEDIAT HEMATOL, V3, P233; Radestad I, 1996, BRIT MED J, V312, P1505, DOI 10.1136/bmj.312.7045.1505; Scott DA, 2002, MED J AUSTRALIA, V177, P507, DOI 10.5694/j.1326-5377.2002.tb04921.x	5	80	80	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	2004	364	9436					787	789		10.1016/S0140-6736(04)16939-0	http://dx.doi.org/10.1016/S0140-6736(04)16939-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337406				2022-12-28	WOS:000223569600031
J	Baudouin, SV				Baudouin, SV			Exogenous surfactant replacement in ARDS - One day, someday, or never?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RESPIRATORY-DISTRESS-SYNDROME		Royal Victoria Infirm, Univ Dept Surg Sci, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Royal Victoria Infirm, Dept Anaesthesia, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Baudouin, SV (corresponding author), Royal Victoria Infirm, Univ Dept Surg Sci, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.							Anzueto A, 1996, NEW ENGL J MED, V334, P1417, DOI 10.1056/NEJM199605303342201; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Haitsma Jack J, 2004, Curr Opin Crit Care, V10, P18, DOI 10.1097/00075198-200402000-00004; Robertson B, 1998, BBA-MOL BASIS DIS, V1408, P346, DOI 10.1016/S0925-4439(98)00080-5; Wyncoll DLA, 1999, LANCET, V354, P497, DOI 10.1016/S0140-6736(98)08129-X	5	34	38	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2004	351	9					853	855		10.1056/NEJMp048172	http://dx.doi.org/10.1056/NEJMp048172			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849BM	15329420				2022-12-28	WOS:000223512500004
J	Piccirillo, JF				Piccirillo, JF			Acute bacterial sinusitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MAXILLARY SINUSITIS; COMMUNITY-ACQUIRED SINUSITIS; RANDOMIZED CONTROLLED TRIAL; APPROPRIATE ANTIBIOTIC USE; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ACUTE RHINOSINUSITIS; PHYSICAL-EXAMINATION; GENERAL-PRACTICE; PRIMARY-CARE		Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Clin Outcomes Res Off, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Clin Outcomes Res Off, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Piccirillo, JF (corresponding author), Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Clin Outcomes Res Off, Box 8115,660 S Euclid Ave, St Louis, MO 63110 USA.	piccirij@msnotes.wustl.edu						*AG HLTH CAR POL R, 1999, AHCPR PUBL; AXELSSON A, 1970, ACTA OTO-LARYNGOL, V69, P302, DOI 10.3109/00016487009123368; AXELSSON A, 1970, ACTA OTO-LARYNGOL, V70, P71, DOI 10.3109/00016487009181861; Balk EM, 2001, J GEN INTERN MED, V16, P701, DOI 10.1111/j.1525-1497.2001.00429.x; Benninger MS, 1997, OTOLARYNG HEAD NECK, V117, pS41, DOI 10.1016/S0194-5998(97)70006-8; BERG O, 1986, Rhinology (Utrecht), V24, P223; BERG O, 1988, ACTA OTO-LARYNGOL, V105, P343, DOI 10.3109/00016488809097017; BERG O, 1988, SCAND J INFECT DIS, V20, P511, DOI 10.3109/00365548809032499; Bhattacharyya T, 1997, ARCH OTOLARYNGOL, V123, P1189; BOLGER WE, 1991, LARYNGOSCOPE, V101, P56; Braun JJ, 1997, ALLERGY, V52, P650, DOI 10.1111/j.1398-9995.1997.tb01044.x; DINGLE JH, 1964, ILLNESS HOME STUDY 2, P347; DOHLMAN AW, 1994, CLIN EXP ALLERGY, V24, P1094, DOI 10.1111/j.1365-2222.1994.tb03313.x; Dolor RJ, 2001, JAMA-J AM MED ASSOC, V286, P3097, DOI 10.1001/jama.286.24.3097; Engels EA, 2000, J CLIN EPIDEMIOL, V53, P852, DOI 10.1016/S0895-4356(00)00209-2; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; Gananca M, 1973, Curr Med Res Opin, V1, P362, DOI 10.1185/03007997309111694; Gwaltney JM, 2004, CLIN INFECT DIS, V38, P227, DOI 10.1086/380641; GWALTNEY JM, 1992, J ALLERGY CLIN IMMUN, V90, P457, DOI 10.1016/0091-6749(92)90169-3; Gwaltney JM, 1996, CLIN INFECT DIS, V23, P1209, DOI 10.1093/clinids/23.6.1209; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; GWALTNEY JM, 1981, ANN OTO RHINOL LARYN, V90, P68, DOI 10.1177/00034894810903S216; GWALTNEY JM, 1967, J AMER MED ASSOC, V202, P494, DOI 10.1001/jama.202.6.494; HANSEN JG, 1995, BRIT MED J, V311, P233, DOI 10.1136/bmj.311.6999.233; HAVAS TE, 1988, ARCH OTOLARYNGOL, V114, P856; Henry DC, 2003, ANTIMICROB AGENTS CH, V47, P2770, DOI 10.1128/AAC.47.9.2770-2774.2003; Hickner JM, 2001, ANN INTERN MED, V134, P498, DOI 10.7326/0003-4819-134-6-200103200-00017; JOUSIMIESSOMER HR, 1988, J CLIN MICROBIOL, V26, P1919, DOI 10.1128/JCM.26.10.1919-1925.1988; Laine Karri, 1998, Rhinology (Utrecht), V36, P2; Lindbaek M, 1996, BMJ-BRIT MED J, V313, P325, DOI 10.1136/bmj.313.7053.325; MARCHANT CD, 1992, J PEDIATR-US, V120, P72, DOI 10.1016/S0022-3476(05)80601-8; MCNEILL R A, 1963, J Laryngol Otol, V77, P1009, DOI 10.1017/S0022215100061673; MELTZER EO, 1993, J ALLERGY CLIN IMMUN, V92, P812, DOI 10.1016/0091-6749(93)90058-N; Piccirillo JF, 2001, JAMA-J AM MED ASSOC, V286, P1849, DOI 10.1001/jama.286.15.1849; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P408, DOI 10.1016/S0091-6749(99)70464-1; Savolainen S, 1997, ACTA OTO-LARYNGOL, P148; Snow V, 2001, ANN INTERN MED, V134, P495, DOI 10.7326/0003-4819-134-6-200103200-00016; Stalman W, 1997, BRIT J GEN PRACT, V47, P794; vanBuchem FL, 1997, LANCET, V349, P683, DOI 10.1016/S0140-6736(96)07585-X; Varonen H, 2003, RHINOLOGY, V41, P37; VUORINEN P, 1962, J Laryngol Otol, V76, P359, DOI 10.1017/S0022215100059442; WIKLUND L, 1994, ACTA OTO-LARYNGOL, P57; WILLIAMS JW, 1993, JAMA-J AM MED ASSOC, V270, P1242, DOI 10.1001/jama.270.10.1242; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705; WILLIAMS JW, 1995, JAMA-J AM MED ASSOC, V273, P1015, DOI 10.1001/jama.273.13.1015; WILLIAMS JW, 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000243	46	43	48	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2004	351	9					902	910		10.1056/NEJMcp035553	http://dx.doi.org/10.1056/NEJMcp035553			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849BM	15329428				2022-12-28	WOS:000223512500012
J	Brown, P; Keynes, M; Ryan, R; Yung, M; Browne, J; Copley, L; Horrocks, J; Lewsey, J; Lowe, D; Luton, A; van der Meulen, I; Bingham, B; Black, N; Dixon, S; Shurlock, L; Flood, L; Haggard, M; Ludgate, S; Hopper, J; Oates, J; Ramsden, RT; Shotton, J; Tomkinson, A; Toner, J; Weiner, G; Woods, P; van der Meulen, J				Brown, P; Keynes, M; Ryan, R; Yung, M; Browne, J; Copley, L; Horrocks, J; Lewsey, J; Lowe, D; Luton, A; van der Meulen, I; Bingham, B; Black, N; Dixon, S; Shurlock, L; Flood, L; Haggard, M; Ludgate, S; Hopper, J; Oates, J; Ramsden, RT; Shotton, J; Tomkinson, A; Toner, J; Weiner, G; Woods, P; van der Meulen, J		Natl Prospective Tonsillectomy Aud	Tonsillectomy technique as a risk factor for postoperative haemorrhage	LANCET			English	Article							POST-TONSILLECTOMY; HEMOSTASIS; DIATHERMY	Background Tonsillectomy is one of the most frequent surgical procedures. "Hot" tonsillectomy techniques (eg, diathermy and coblation) have become well established, but there is little evidence to suggest that they are better than traditional "cold steel" dissection with only packs or ties for haemostasis. Methods We obtained data for the occurrence of complications after all tonsillectomies done since July, 2003, in England and Northern Ireland. We recorded postoperative haemorrhages and other complications, taking place within 28 days of surgery, that led to delayed discharge, return to theatre, or re-admission. By February, 2004, the audit had included 13 554 patients, of whom 11796 (87%) in 252 hospitals consented to electronic submission of their tonsillectomy data. Thus, 75% of the hospitals where tonsillectomies are done submitted data for 60% of all eligible patients. Findings Haemorrhage occurred in 389 patients (3.3%). 59 patients (0.5%) had a primary haemorrhage (during initial stay), 337 (2.9%) a secondary haemorrhage (after discharge), and seven had both. The overall haemorrhage rate was 3.1 times (95% CI 1.9-5.0) higher with bipolar diathermy tonsillectomy than with cold steel tonsillectomy without any use of diathermy (p<0.001). The corresponding relative risk for coblation tonsillectomy was 3.4 (1.9-6.2; p<0.001). When cold steel was used for dissection and diathermy only for haemostasis the relative risk was 2.2 (1.3-3.7; p=0.002). Interpretation The use of techniques such as diathermy and coblation increased postoperative haemorrhage. These methods should therefore be used with appropriate caution and only after proper training.	Royal Coll Surgeons England, Clin Effectiveness Unit, London Sch Hyg & Trop Med, London WC2A 3PE, England	Royal College of Surgeons of England; University of London; London School of Hygiene & Tropical Medicine	van der Meulen, J (corresponding author), Royal Coll Surgeons England, Clin Effectiveness Unit, London Sch Hyg & Trop Med, 35-43 Lincolns Inn Fields, London WC2A 3PE, England.	Jan.vanderMeulen@lshtm.ac.uk	Lewsey, James/F-7546-2010	van der Meulen, Jan/0000-0002-9451-2335				Belloso A, 2003, LARYNGOSCOPE, V113, P2010, DOI 10.1097/00005537-200311000-00029; Black N, 1997, BRIT MED J, V315, P381, DOI 10.1136/bmj.315.7105.381; CARMODY D, 1982, J LARYNGOL OTOL, V96, P635, DOI 10.1017/S0022215100092926; Krishna P, 2001, LARYNGOSCOPE, V111, P1358, DOI 10.1097/00005537-200108000-00008; Leinbach RF, 2003, OTOLARYNG HEAD NECK, V129, P360, DOI 10.1016/S0194-5998(03)00729-0; MURTY GE, 1990, J LARYNGOL OTOL, V104, P549, DOI 10.1017/S0022215100113131; PINDER D, 2002, COCHRANE LIB; WATSON MG, 1993, J LARYNGOL OTOL, V107, P711, DOI 10.1017/S0022215100124211; Wei JL, 2000, OTOLARYNG HEAD NECK, V123, P229, DOI 10.1067/mhn.2000.107454; Windfuhr JP, 2003, ANN OTO RHINOL LARYN, V112, P63, DOI 10.1177/000348940311200113; Worthington TC., 1907, JAMA-J AM MED ASSOC, V48, P1761, DOI [10.1001/jama.1907.25220470029003, DOI 10.1001/JAMA.1907.25220470029003]	11	168	177	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	2004	364	9435					697	702						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325834				2022-12-28	WOS:000223428900031
J	Car, J; Sheikh, A				Car, J; Sheikh, A			Email consultations in health care: 1-scope and effectiveness	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; ELECTRONIC COMMUNICATION; E-MAIL; INTERNET; INTERVENTIONS; TECHNOLOGY; PHYSICIANS; PATIENT; SYSTEM; RATES		Univ Edinburgh, Div Community Hlth Sci, GP Sect, Edinburgh EH8 9DX, Midlothian, Scotland; Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Social Med, London W6 8RP, England	University of Edinburgh; Imperial College London	Sheikh, A (corresponding author), Univ Edinburgh, Div Community Hlth Sci, GP Sect, Edinburgh EH8 9DX, Midlothian, Scotland.	aziz.sheikh@ed.ac.uk	Sheikh, Aziz/D-2818-2009; Car, Josip/H-6755-2015	Sheikh, Aziz/0000-0001-7022-3056; Car, Josip/0000-0001-8969-371X				[Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Balas EA, 1997, JAMA-J AM MED ASSOC, V278, P152, DOI 10.1001/jama.278.2.152; CAMPBELL JR, 1994, CLIN PEDIATR, V33, P268, DOI 10.1177/000992289403300503; Car J, 2003, BMJ-BRIT MED J, V326, P966, DOI 10.1136/bmj.326.7396.966; Christensen H, 2004, BRIT MED J, V328, P265, DOI 10.1136/bmj.37945.566632.EE; Dunbar PJ, 2003, J AM MED INFORM ASSN, V10, P11, DOI 10.1197/jamia.M1047; Eysenbach G, 1999, ARCH DERMATOL, V135, P151, DOI 10.1001/archderm.135.2.151; Ezenkwele UA, 2003, J EMERG MED, V24, P125, DOI 10.1016/S0736-4679(02)00739-4; Hamilton W, 1999, BMJ-BRIT MED J, V318, P1392, DOI 10.1136/bmj.318.7195.1392; Katz SJ, 2003, J GEN INTERN MED, V18, P736, DOI 10.1046/j.1525-1497.2003.20756.x; Moyer CA, 1999, AM J MANAG CARE, V5, P1513; Stone EG, 2002, ANN INTERN MED, V136, P641, DOI 10.7326/0003-4819-136-9-200205070-00006; Tate DF, 2001, JAMA-J AM MED ASSOC, V285, P1172, DOI 10.1001/jama.285.9.1172; Van Harrison R, 2003, MED CARE, V41, P375, DOI 10.1097/00005650-200303000-00006; Yager J, 2001, INT J EAT DISORDER, V29, P125, DOI 10.1002/1098-108X(200103)29:2<125::AID-EAT1002>3.0.CO;2-S	15	127	128	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 21	2004	329	7463					435	438		10.1136/bmj.329.7463.435	http://dx.doi.org/10.1136/bmj.329.7463.435			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849EA	15321902	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000223520300021
J	Kim, H; Rogers, MJ; Richmond, JE; McIntire, SL				Kim, H; Rogers, MJ; Richmond, JE; McIntire, SL			SNF-6 is an acetylcholine transporter interacting with the dystrophin complex in Caenorhabditis elegans	NATURE			English	Article							NEUROMUSCULAR-JUNCTION; GLYCOPROTEIN COMPLEX; GENETIC-EVIDENCE; MUSCLE-FIBERS; TIME-COURSE; MUTATIONS; DYSTROBREVIN; PHENOTYPES; MUTANTS; CALCIUM	Muscular dystrophies are among the most common human genetic diseases and are characterized by progressive muscle degeneration. Muscular dystrophies result from genetic defects in components of the dystrophin-glycoprotein complex (DGC), a multimeric complex found in the muscle cell plasma membrane(1). The DGC links the intracellular cytoskeleton to the extracellular matrix and is thought to be important for maintaining the mechanical integrity of muscles(2) and organizing signalling molecules(3). The exact role of the DGC in the pathogenesis of disease has, however, remained uncertain(4). Mutations in Caenorhabditis elegans DGC genes lead to specific defects in coordinated movement and can also cause muscle degeneration(5-7). Here we show that mutations in the gene snf-6 result in phenotypes indistinguishable from those of the DGC mutants, and that snf-6 encodes a novel acetylcholine/choline transporter. SNF-6 mediates the uptake of acetylcholine at neuromuscular junctions during periods of increased synaptic activity. SNF-6 also interacts with the DGC, and mutations in DGC genes cause a loss of SNF-6 at neuromuscular junctions. Improper clearing of acetylcholine and prolonged excitation of muscles might contribute to the pathogenesis of muscular dystrophies.	Univ Calif San Francisco, Dept Neurol, Program Neurosci, Ernest Gallo & Res Ctr, Emeryville, CA 94608 USA; Univ Calif San Francisco, Dept Neurol, Program Biomed Sci, Ernest Gallo & Res Ctr, Emeryville, CA 94608 USA; Univ Illinois, Dept Biol Sci, Chicago, IL 60607 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	McIntire, SL (corresponding author), Univ Calif San Francisco, Dept Neurol, Program Neurosci, Ernest Gallo & Res Ctr, 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.	slm@itsa.ucsf.edu		Kim, Hongkyun/0000-0002-4879-7122; Rogers, Matthew/0000-0001-5908-7962	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041477] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS041477-03, R01 NS041477-02, R01 NS041477, R01 NS041477-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bessou C, 1998, NEUROGENETICS, V2, P61, DOI 10.1007/s100480050053; BRENNER S, 1974, GENETICS, V77, P71; Burton EA, 2001, CONT NEUROS, P239; Davies AG, 2003, CELL, V115, P655, DOI 10.1016/S0092-8674(03)00979-6; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Froehner SC, 1997, SOC GEN PHY, V52, P197; Gieseler K, 1999, FEBS LETT, V461, P59, DOI 10.1016/S0014-5793(99)01421-0; Gieseler K, 1999, NEUROGENETICS, V2, P87, DOI 10.1007/s100480050057; Gieseler K, 2000, CURR BIOL, V10, P1092, DOI 10.1016/S0960-9822(00)00691-6; Gieseler K, 2001, J MOL BIOL, V307, P107, DOI 10.1006/jmbi.2000.4480; Giugia JB, 1999, FEBS LETT, V463, P270, DOI 10.1016/S0014-5793(99)01651-8; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; Grisoni K, 2002, GENE, V294, P77, DOI 10.1016/S0378-1119(02)00762-X; JACKSON MJ, 1985, CLIN CHIM ACTA, V147, P215, DOI 10.1016/0009-8981(85)90202-5; KARPATI G, 1988, MUSCLE NERVE, V11, P795, DOI 10.1002/mus.880110802; Kramarcy NR, 2000, MOL CELL NEUROSCI, V15, P262, DOI 10.1006/mcne.1999.0823; LEONARD JP, 1979, J CELL BIOL, V82, P811, DOI 10.1083/jcb.82.3.811; Mariol MC, 2001, CURR BIOL, V11, P1691, DOI 10.1016/S0960-9822(01)00528-0; MCARDLE A, 1994, MUSCLE NERVE, V17, P1378, DOI 10.1002/mus.880171206; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; Miyabayashi T, 1999, DEV BIOL, V215, P314, DOI 10.1006/dbio.1999.9470; POTTER LT, 1970, J PHYSIOL-LONDON, V206, P145, DOI 10.1113/jphysiol.1970.sp009003; Richmond JE, 1999, NAT NEUROSCI, V2, P791, DOI 10.1038/12160; SAELENS JK, 1965, J PHARMACOL EXP THER, V147, P336; SALPETER MM, 1979, J NEUROCYTOL, V8, P95, DOI 10.1007/BF01206461; Shioi G, 2001, GENETICS, V157, P1611; WATERSTON RH, 1984, J MOL BIOL, V180, P473, DOI 10.1016/0022-2836(84)90023-8; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1	28	39	52	0	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					891	896		10.1038/nature02798	http://dx.doi.org/10.1038/nature02798			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318222				2022-12-28	WOS:000223369800042
J	Knutti, R; Fluckiger, J; Stocker, TF; Timmermann, A				Knutti, R; Fluckiger, J; Stocker, TF; Timmermann, A			Strong hemispheric coupling of glacial climate through freshwater discharge and ocean circulation	NATURE			English	Article							MIXED BOUNDARY-CONDITIONS; THERMOHALINE CIRCULATION; RAPID CHANGES; SCALE; ATLANTIC; ANTARCTICA; GREENLAND; TEMPERATURE; INSTABILITY; FLUCTUATIONS	The climate of the last glacial period was extremely variable, characterized by abrupt warming events in the Northern Hemisphere, accompanied by slower temperature changes in Antarctica and variations of global sea level. It is generally accepted that this millennial-scale climate variability was caused by abrupt changes in the ocean thermohaline circulation. Here we use a coupled ocean-atmosphere-sea ice model to show that freshwater discharge into the North Atlantic Ocean, in addition to a reduction of the thermohaline circulation, has a direct effect on Southern Ocean temperature. The related anomalous oceanic southward heat transport arises from a zonal density gradient in the subtropical North Atlantic caused by a fast wave-adjustment process. We present an extended and quantitative bipolar seesaw concept that explains the timing and amplitude of Greenland and Antarctic temperature changes, the slow changes in Antarctic temperature and its similarity to sea level, as well as a possible time lag of sea level with respect to Antarctic temperature during Marine Isotope Stage 3.	Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; Leibniz Inst Meereswissensch, IFM, GEOMAR, D-24105 Kiel, Germany	University of Bern; Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel	Knutti, R (corresponding author), Univ Bern, Inst Phys, Sidlerstr 5, CH-3012 Bern, Switzerland.	knutti@climate.unibe.ch	Timmermann, Axel/Y-2799-2019; Timmermann, Axel/F-4977-2011; Fluckiger, Jacqueline/G-3457-2011; Stocker, Thomas/B-1273-2013; Knutti, Reto/B-8763-2008	Timmermann, Axel/0000-0003-0657-2969; Timmermann, Axel/0000-0003-0657-2969; Knutti, Reto/0000-0001-8303-6700				Allen JRM, 1999, NATURE, V400, P740, DOI 10.1038/23432; Blunier T, 2004, EARTH PLANET SC LETT, V218, P379, DOI 10.1016/S0012-821X(03)00672-1; Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; Broecker WS, 1998, PALEOCEANOGRAPHY, V13, P119, DOI 10.1029/97PA03707; Broecker WS, 1997, SCIENCE, V278, P1582, DOI 10.1126/science.278.5343.1582; Burns SJ, 2003, SCIENCE, V301, P1365, DOI 10.1126/science.1086227; Chappell J, 2002, QUATERNARY SCI REV, V21, P1229, DOI 10.1016/S0277-3791(01)00141-X; CLARK PU, 1999, MECH GLOBAL CLIMATE, P1; Crowley TJ, 1992, PALEOCEANOGRAPHY, V7, P489, DOI 10.1029/92PA01058; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; ENTING IG, 1987, J GEOPHYS RES-ATMOS, V92, P10977, DOI 10.1029/JD092iD09p10977; Ganopolski A, 2001, NATURE, V409, P153, DOI 10.1038/35051500; Goosse H, 1999, J GEOPHYS RES-OCEANS, V104, P23337, DOI 10.1029/1999JC900215; HEINRICH H, 1988, QUATERNARY RES, V29, P142, DOI 10.1016/0033-5894(88)90057-9; Hemming SR, 2004, REV GEOPHYS, V42, DOI 10.1029/2003RG000128; HSIEH WW, 1983, J PHYS OCEANOGR, V13, P1383, DOI 10.1175/1520-0485(1983)013<1383:TFKWIF>2.0.CO;2; Huang RX, 2000, GEOPHYS RES LETT, V27, P759, DOI 10.1029/1999GL002365; IPCC Climate Change, 2001, CLIM CHANG SCI BAS C; JOHNSEN SJ, 1972, NATURE, V235, P429, DOI 10.1038/235429a0; Johnson HL, 2002, J PHYS OCEANOGR, V32, P1121, DOI 10.1175/1520-0485(2002)032<1121:ATFTSA>2.0.CO;2; JOUZEL J, 2003, J GEOPHYS RES, V108, DOI DOI 10.1029/2003JD002677; Kanfoush SL, 2000, SCIENCE, V288, P1815, DOI 10.1126/science.288.5472.1815; Lang C, 1999, SCIENCE, V286, P934, DOI 10.1126/science.286.5441.934; Manabe S, 1997, PALEOCEANOGRAPHY, V12, P321, DOI 10.1029/96PA03932; MIKOLAJEWICZ U, 1994, J GEOPHYS RES-OCEANS, V99, P22633, DOI 10.1029/94JC01989; Mulvaney R, 2000, GEOPHYS RES LETT, V27, P2673, DOI 10.1029/1999GL011254; Opsteegh JD, 1998, TELLUS A, V50, P348, DOI 10.1034/j.1600-0870.1998.t01-1-00007.x; Peterson LC, 2000, SCIENCE, V290, P1947, DOI 10.1126/science.290.5498.1947; RAHMSTORF S, 1994, NATURE, V372, P82, DOI 10.1038/372082a0; Rahmstorf S, 2002, NATURE, V419, P207, DOI 10.1038/nature01090; Roe GH, 2004, J CLIMATE, V17, P1929, DOI [10.1175/1520-0442(2004)017<1929:COMCV>2.0.CO;2, 10.1175/1520-0442(2004)017&lt;1929:COMCV&gt;2.0.CO;2]; Schiller A, 1997, CLIM DYNAM, V13, P325, DOI 10.1007/s003820050169; Schmittner A, 2002, SCIENCE, V295, P1489, DOI 10.1126/science.1066174; Schwander J, 1997, J GEOPHYS RES-ATMOS, V102, P19483, DOI 10.1029/97JD01309; Severinghaus JP, 1999, SCIENCE, V286, P930, DOI 10.1126/science.286.5441.930; Shackleton NJ, 2000, PALEOCEANOGRAPHY, V15, P565, DOI 10.1029/2000PA000513; Siddall M, 2003, NATURE, V423, P853, DOI 10.1038/nature01690; Steig EJ, 1998, SCIENCE, V282, P92, DOI 10.1126/science.282.5386.92; Stenni B, 2004, EARTH PLANET SC LETT, V217, P183, DOI 10.1016/S0012-821X(03)00574-0; Stocker TF, 1998, SCIENCE, V282, P61, DOI 10.1126/science.282.5386.61; Stocker TF, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2003PA000920; Stocker TF, 2000, P NATL ACAD SCI USA, V97, P1362, DOI 10.1073/pnas.97.4.1362; STOCKER TF, 1991, NATURE, V351, P729, DOI 10.1038/351729a0; Stocker TF, 1992, PALEOCEANOGRAPHY, V7, P529, DOI 10.1029/92PA01695; TIMMERMANN A, IN PRESS CLIM DYN; Voelker AHL, 2002, QUATERNARY SCI REV, V21, P1185, DOI 10.1016/S0277-3791(01)00139-1; Wang YJ, 2001, SCIENCE, V294, P2345, DOI 10.1126/science.1064618; Weaver AJ, 2003, SCIENCE, V299, P1709, DOI 10.1126/science.1081002; Wunsch C, 2003, QUATERNARY SCI REV, V22, P1631, DOI 10.1016/S0277-3791(03)00152-5; Yokoyama Y, 2001, EARTH PLANET SC LETT, V193, P579, DOI 10.1016/S0012-821X(01)00515-5	50	208	225	2	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					851	856		10.1038/nature02786	http://dx.doi.org/10.1038/nature02786			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318212				2022-12-28	WOS:000223369800032
J	D'Amico, AV; Manola, J; Loffredo, M; Renshaw, AA; DellaCroce, A; Kantoff, PW				D'Amico, AV; Manola, J; Loffredo, M; Renshaw, AA; DellaCroce, A; Kantoff, PW			6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHASE-III TRIAL; DEPRIVATION THERAPY; RADIOTHERAPY; NEOADJUVANT; CARCINOMA; MORTALITY; MEN	Context Survival benefit in the management of high-grade clinically localized prostate cancer has been shown for 70 Gy radiation therapy combined with 3 years of androgen suppression therapy (AST), but long-term AST is associated with many adverse events. Objective To assess the survival benefit of 3-dimensional conformal radiation therapy (3D-CRT) alone or in combination with 6 months of AST in patients with clinically localized prostate cancer. Design, Setting, and Patients A prospective randomized controlled trial of 206 patients with clinically localized prostate cancer who were randomized to receive 70 Gy 3D-CRT alone (n=104) or in combination with 6 months of AST (n=102) from December 1, 1995, to April 15, 2001. Eligible patients included those with a prostate-specific antigen (PSA) of at least 10 ng/mL, a Gleason score of at least 7, or radiographic evidence of extraprostatic disease. Main Outcome Measures Time to PSA failure (PSA >11.0 ng/mL and increasing >0.2 ng/mL on 2 consecutive visits) and overall survival. Results After a median follow-up of 4.52 years, patients randomized to receive 3D-CRT plus AST had a significantly higher survival (P=.04), lower prostate cancer-specific mortality (P=.02), and higher survival free of salvage AST (P=.002). Kaplan-Meier estimates of 5-year survival rates were 88% (95% confidence interval [Cl], 80%-95%) in the 3D-CRT plus AST group vs 78% (95% Cl, 68%-88%) in the 3D-CRT group. Rates of survival free of salvage AST at 5 years were 82% (95% Cl, 73%-90%) in the 3D-CRT plus AST group vs 57% (95% Cl, 46%-69%) in the 3D-CRT group. Conclusion The addition of 6 months of AST to 70 Gy 3D-CRT confers an overall survival benefit for patients with clinically localized prostate cancer.	Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Biostat, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med Oncol, Boston, MA 02215 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute	D'Amico, AV (corresponding author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St,L-2 Level, Boston, MA 02215 USA.	adamico@lroc.harvard.edu		Kantoff, Philip/0000-0001-7275-0597				*AG HLTH CAR POL R, 1999, REL EFF COST EFF MET; Beahrs O. H., 1992, AM JOINT COMMITTEE C; Bolla M, 1997, NEW ENGL J MED, V337, P295, DOI 10.1056/NEJM199707313370502; Bolla M, 2002, LANCET, V360, P103, DOI 10.1016/S0140-6736(02)09408-4; Chen Z, 2002, CANCER-AM CANCER SOC, V95, P2136, DOI 10.1002/cncr.10967; D'Amico AV, 2003, J CLIN ONCOL, V21, P2163, DOI 10.1200/JCO.2003.01.075; D'Amico AV, 2003, J NATL CANCER I, V95, P1376, DOI 10.1093/jnci/djg043; GAYNOR JJ, 1993, J AM STAT ASSOC, V88, P400, DOI 10.2307/2290318; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; Green HJ, 2002, BJU INT, V90, P427, DOI 10.1046/j.1464-410X.2002.02917.x; Hanks GE, 2003, J CLIN ONCOL, V21, P3972, DOI 10.1200/JCO.2003.11.023; Holzbeierlein JM, 2004, ONCOLOGY-NY, V18, P303; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klein JP, 1997, SURVIVAL ANAL TECHNI, P96; MEHTA CR, 1984, BIOMETRICS, V40, P819, DOI 10.2307/2530927; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Pollack A, 2002, INT J RADIAT ONCOL, V53, P1097, DOI 10.1016/S0360-3016(02)02829-8; Roach M, 2003, J CLIN ONCOL, V21, P1904, DOI 10.1200/JCO.2003.05.004; Roden DM, 2004, NEW ENGL J MED, V350, P1013, DOI 10.1056/NEJMra032426; Smith MR, 2002, CANCER METAST REV, V21, P159, DOI 10.1023/A:1020840311573; Trotti A, 2000, INT J RADIAT ONCOL, V47, P13, DOI 10.1016/S0360-3016(99)00559-3	21	630	642	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2004	292	7					821	827		10.1001/jama.292.7.821	http://dx.doi.org/10.1001/jama.292.7.821			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847FO	15315996				2022-12-28	WOS:000223378300022
J	Kuiken, T; Rimmelzwaan, G; van Riel, D; van Amerongen, G; Baars, M; Fouchier, R; Osterhaus, A				Kuiken, T; Rimmelzwaan, G; van Riel, D; van Amerongen, G; Baars, M; Fouchier, R; Osterhaus, A			Avian H5N1 influenza in cats	SCIENCE			English	Article							VIRUSES		Erasmus Med Ctr, Dept Virol, NL-3015 GE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Kuiken, T (corresponding author), Erasmus Med Ctr, Dept Virol, NL-3015 GE Rotterdam, Netherlands.	t.kuiken@erasmusmc.nl	Fouchier, Ron A/A-1911-2014	Fouchier, Ron A/0000-0001-8095-2869; van Riel, Debby/0000-0001-9753-3564; Osterhaus, Albert/0000-0002-6074-1172				HINSHAW VS, 1981, INFECT IMMUN, V34, P354, DOI 10.1128/IAI.34.2.354-361.1981; Rimmelzwaan GF, 2001, J VIROL, V75, P6687, DOI 10.1128/JVI.75.14.6687-6691.2001; Sturm-Ramirez KM, 2004, J VIROL, V78, P4892, DOI 10.1128/JVI.78.9.4892-4901.2004; Webby RJ, 2003, SCIENCE, V302, P1519, DOI 10.1126/science.1090350; *WHO, 2004, CONF HUM CAS AV INFL; [No title captured]	6	302	348	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	2004	306	5694					241	241		10.1126/science.1102287	http://dx.doi.org/10.1126/science.1102287			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861MC	15345779				2022-12-28	WOS:000224419700029
J	Mecklenbrauker, I; Kalled, SL; Leitges, M; Mackay, F; Tarakhovsky, A				Mecklenbrauker, I; Kalled, SL; Leitges, M; Mackay, F; Tarakhovsky, A			Regulation of B-cell survival by BAFF-dependent PKC delta-mediated nuclear signalling	NATURE			English	Article							KINASE-C-DELTA; REACTIVE LYMPHOCYTES-B; HISTONE H2B; PROTEOLYTIC ACTIVATION; AUTOIMMUNE-DISEASE; APOPTOTIC CELLS; TRANSGENIC MICE; PHOSPHORYLATION; IDENTIFICATION; NF-KAPPA-B2	Approximately 65% of B cells generated in human bone marrow are potentially harmful autoreactive B cells(1). Most of these cells are clonally deleted in the bone marrow, while those autoreactive B cells that escape to the periphery are anergized or perish before becoming mature B cells(2-5). Escape of self-reactive B cells from tolerance permits production of pathogenic auto-antibodies(6); recent studies suggest that extended B lymphocyte survival is a cause of autoimmune disease in mice and humans(7). Here we report a mechanism for the regulation of peripheral B-cell survival by serine/threonine protein kinase Cdelta (PKCdelta): spontaneous death of resting B cells is regulated by nuclear localization of PKCdelta that contributes to phosphorylation of histone H2B at serine 14 (S14-H2B). We show that treatment of B cells with the potent B-cell survival factor BAFF ('B-cell-activating factor belonging to the TNF family') prevents nuclear accumulation of PKCdelta. Our data suggest the existence of a previously unknown BAFF-induced and PKCdelta-mediated nuclear signalling pathway which regulates B-cell survival.	Rockefeller Univ, Lab Lymphocyte Signaling, New York, NY 10021 USA; Biogen Idec Inc, Cambridge, MA 02142 USA; Max Planck Inst Expt Endocrinol, D-30625 Hannover, Germany; St Vincent Hosp, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia	Rockefeller University; Biogen; Max Planck Society; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Tarakhovsky, A (corresponding author), Rockefeller Univ, Lab Lymphocyte Signaling, 1230 York Ave, New York, NY 10021 USA.	tarakho@mail.rockefeller.edu	Leitges, Michael/AAN-1953-2021; Mackay, Fabienne/B-7440-2008	Mackay, Fabienne/0000-0002-6074-2693				Ajiro K, 2000, J BIOL CHEM, V275, P439, DOI 10.1074/jbc.275.1.439; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; Fernandez-Capetillo O, 2004, J EXP MED, V199, P1671, DOI 10.1084/jem.20032247; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; Gross JA, 2000, NATURE, V404, P995, DOI 10.1038/35010115; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Karpusas M, 2002, J MOL BIOL, V315, P1145, DOI 10.1006/jmbi.2001.5296; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Khare SD, 2000, P NATL ACAD SCI USA, V97, P3370, DOI 10.1073/pnas.050580697; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; Mackay F, 2002, CURR OPIN IMMUNOL, V14, P783, DOI 10.1016/S0952-7915(02)00407-7; Mecklenbrauker I, 2002, NATURE, V416, P860, DOI 10.1038/416860a; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Pelletier M, 2003, J BIOL CHEM, V278, P33127, DOI 10.1074/jbc.M305754200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Saijo K, 2002, J EXP MED, V195, P1647, DOI 10.1084/jem.20020408; Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Woodland RT, 1996, J IMMUNOL, V156, P2143; Yan MH, 2001, CURR BIOL, V11, P1547, DOI 10.1016/S0960-9822(01)00481-X	30	121	128	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	2004	431	7007					456	461		10.1038/nature02955	http://dx.doi.org/10.1038/nature02955			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	855UN	15361883				2022-12-28	WOS:000224000500042
J	Rosengren, A; Hawken, S; Ounpuu, S; Sliwa, K; Zubaid, M; Almahmeed, WA; Blackett, KN; Sittih-amorn, C; Sato, H; Yusuf, S				Rosengren, A; Hawken, S; Ounpuu, S; Sliwa, K; Zubaid, M; Almahmeed, WA; Blackett, KN; Sittih-amorn, C; Sato, H; Yusuf, S		INTERHEART Investigators	Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study	LANCET			English	Article							CORONARY-HEART-DISEASE; PSYCHOLOGICAL STRESS; MENTAL STRESS; JOB STRAIN; ENDOTHELIAL DYSFUNCTION; PROSPECTIVE COHORT; ARTERY DISEASE; WORK STRESS; MORTALITY; WOMEN	Background Psychosocial factors have been reported to be independently associated with coronary heart disease. However, previous studies have been in mainly North American or European populations. The aim of the present analysis was to investigate the relation of psychosocial factors to risk of myocardial infarction in 24 767 people from 52 countries. Methods We used a case-control design with 11119 patients with a first myocardial infarction and 13 648 age-matched (up to 5 years older or younger) and sex-matched controls from 262 centres in Asia, Europe, the Middle East, Africa, Australia, and North and South America. Data for demographic factors, education, income, and cardiovascular risk factors were obtained by standardised approaches. Psychosocial stress was assessed by four simple questions about stress at work and at home, financial stress, and major life events in the past year. Additional questions assessed locus of control and presence of depression. Findings People with myocardial infarction (cases) reported higher prevalence of all four stress factors (p<0 . 0001). Of those cases still working, 23 . 0% (n=1249) experienced several periods of work stress compared with 17.9% (1324) of controls, and 10.0% (540) experienced permanent work stress during the previous year versus 5.0% (372) of controls. Odds ratios were 1 . 38 (99% CI 1 . 19-1.61) for several periods of work stress and 2.14 (1.73-2.64) for permanent stress at work, adjusted for age, sex, geographic region, and smoking. 11.6% (1288) of cases had several periods of stress at home compared with 8.6% (1179) of controls (odds ratio 1 . 52 [99% CI 1 . 34-1.72]), and 3.5% (384) of cases reported permanent stress at home versus 1 . 9% (253) of controls (2.12 [1.68-2.65]). General stress (work, home, or both) was associated with an odds ratio of 1 . 45 (99% CI 1 . 30-1.61) for several periods and 2.17 (1.84-2.55) for permanent stress. Severe financial stress was more typical in cases than controls (14.6% [1622] vs 12.2% [1659]; odds ratio 1.33 [99% CI 1.19-1.48]). Stressful life events in the past year were also more frequent in cases than controls (16.1% [1790] vs 13.0% [1771]; 1.48 [1.33-1.64]), as was depression (24.0% [2673] vs 17.6% [2404]; odds ratio 1.55 [1.42-1.69]). These differences were consistent across regions, in different ethnic groups, and in men and women. Interpretation Presence of psychosocial stressors is associated with increased risk of acute myocardial infarction, suggesting that approaches aimed at modifying these factors should be developed.	McMaster Univ, Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada; Sahlgrens Univ Hosp, Gothenburg, Sweden; Baragwanath Hosp, ZA-2013 Johannesburg, South Africa; Kuwait Univ, Kuwait, Kuwait; CHU, Yaounde, Cameroon; Al Jazeira Hosp, Abu Dhabi, U Arab Emirates; Cent Hosp, Abu Dhabi, U Arab Emirates; Chulalongkorn Univ, Dept Med, Bangkok, Thailand; Osaka Univ, Grad Sch Med, Suita, Osaka, Japan	McMaster University; Population Health Research Institute; Sahlgrenska University Hospital; Kuwait University; Chulalongkorn University; Osaka University	Yusuf, S (corresponding author), McMaster Univ, Hamilton Hlth Sci, Populat Hlth Res Inst, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	yusufs@mcmaster.ca		Hawken, Steven/0000-0002-3341-9022; Yusuf, Salim/0000-0003-4776-5601				ANDA R, 1993, EPIDEMIOLOGY, V4, P285, DOI 10.1097/00001648-199307000-00003; Barefoot JC, 1996, CIRCULATION, V93, P1976, DOI 10.1161/01.CIR.93.11.1976; BENICHOU J, 1990, BIOMETRICS, V46, P991, DOI 10.2307/2532443; Bobak M, 2000, SOC SCI MED, V51, P1343, DOI 10.1016/S0277-9536(00)00096-4; Brunner E, 1996, LANCET, V347, P1008, DOI 10.1016/S0140-6736(96)90147-6; CROYLE RT, 1988, J APPL SOC PSYCHOL, V18, P473, DOI 10.1111/j.1559-1816.1988.tb00030.x; Demyttenaere K, 2004, JAMA-J AM MED ASSOC, V291, P2581, DOI 10.1001/jama.291.21.2581; Eaker ED, 2004, AM J EPIDEMIOL, V159, P950, DOI 10.1093/aje/kwh127; Engel LS, 2003, J NATL CANCER I, V95, P1404, DOI 10.1093/jnci/djg047; Ferketich AK, 2000, ARCH INTERN MED, V160, P1261, DOI 10.1001/archinte.160.9.1261; Ghiadoni L, 2000, CIRCULATION, V102, P2473, DOI 10.1161/01.CIR.102.20.2473; Hemingway H, 1999, BMJ-BRIT MED J, V318, P1460, DOI 10.1136/bmj.318.7196.1460; Iso H, 2002, CIRCULATION, V106, P1229, DOI 10.1161/01.CIR.0000028145.58654.41; KAPLAN JR, 1991, CIRCULATION, V84, P23; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; Kivimaki M, 2002, BRIT MED J, V325, P857, DOI 10.1136/bmj.325.7369.857; Kop WJ, 2001, J AM COLL CARDIOL, V37, P1359, DOI 10.1016/S0735-1097(01)01136-6; Lee S, 2002, INT J EPIDEMIOL, V31, P1147, DOI 10.1093/ije/31.6.1147; Lewthwaite J, 2002, CIRCULATION, V106, P196, DOI 10.1161/01.CIR.0000021121.26290.2C; Li J, 2002, CIRCULATION, V106, P1634, DOI 10.1161/01.CIR.0000031569.45667.58; Macleod J, 2001, J EPIDEMIOL COMMUN H, V55, P878, DOI 10.1136/jech.55.12.878; Marmot M., 2001, STRESS HEART PSYCHOS; Matthews KA, 2002, ARCH INTERN MED, V162, P309, DOI 10.1001/archinte.162.3.309; Moore L, 1999, INT J EPIDEMIOL, V28, P652, DOI 10.1093/ije/28.4.652; Orth-Gomer K, 2000, JAMA-J AM MED ASSOC, V284, P3008, DOI 10.1001/jama.284.23.3008; Ounpuu S, 2001, AM HEART J, V141, P711, DOI 10.1067/mhj.2001.114974; Patten S B, 1997, Chronic Dis Can, V18, P109; Prescott E, 2003, INT J EPIDEMIOL, V32, P990, DOI 10.1093/ije/dyg235; ROSENGREN A, 1991, AM J CARDIOL, V68, P1171, DOI 10.1016/0002-9149(91)90189-R; Rugulies R, 2002, AM J PREV MED, V23, P51, DOI 10.1016/S0749-3797(02)00439-7; Sacker A, 2001, PSYCHOL MED, V31, P279, DOI 10.1017/S0033291701003270; Stansfeld SA, 2002, INT J EPIDEMIOL, V31, P248, DOI 10.1093/ije/31.1.248; STRAWN WB, 1991, CIRC RES, V68, P1270, DOI 10.1161/01.RES.68.5.1270; von Kanel R, 2001, PSYCHOSOM MED, V63, P531, DOI 10.1097/00006842-200107000-00003; Welin C, 1995, CARDIOVASC RISK FACT, V5, P30; WELIN C, 1994, CARDIOVASCULAR RISK, V4, P154; Yoshimasu K, 2001, PSYCHOSOM MED, V63, P797, DOI 10.1097/00006842-200109000-00013; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	38	1502	1577	1	142	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	2004	364	9438					953	962		10.1016/S0140-6736(04)17019-0	http://dx.doi.org/10.1016/S0140-6736(04)17019-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364186				2022-12-28	WOS:000223831000025
J	Watson, JT; Pertel, PE; Jones, RC; Siston, AM; Paul, WS; Austin, CC; Gerber, SI				Watson, JT; Pertel, PE; Jones, RC; Siston, AM; Paul, WS; Austin, CC; Gerber, SI			Clinical characteristics and functional outcomes of West Nile fever	ANNALS OF INTERNAL MEDICINE			English	Article							VIRUS-INFECTION; NEW-YORK; OUTBREAK; ENCEPHALITIS; EPIDEMIC	Background: West Nile fever, considered a nonsevere manifestation of West Nile virus infection, has not been clinically well described in the United States. In 2002, Illinois had 884 documented cases of West Nile virus infection with 66 associated deaths. Objective: To describe the symptoms and functional outcomes of West Nile fever. Design: Case series. Setting: Illinois. Patients: 98 community-dwelling patients with laboratory evidence of West Nile virus infection but no history of clinical evidence of meningitis, encephalitis, or acute flaccid paralysis. Intervention: Outpatient interviews. Measurements: Presence and duration of patient-reported symptoms of infection, symptom-associated absenteeism, health care use, and impact on daily activities. Results: Of 98 patients, 96% had fatigue for a median of 36 days, 81% had fever for a median of 5 days, 71% had headache for a median of 10 days, 61% had muscle weakness for a median of 28 days, and 53% had difficulty concentrating for a median of 14 days. Thirty respondents reported hospitalization, with a median stay of 5 days. At 30 days after onset, 63% of respondents continued to have symptoms. Duration did not vary significantly with increased age. Among the 72 patients who normally attended work or school, 57 (79%) could not attend because of illness (median absence, 10 days). Limitations: Recall bias could have been introduced by the delay between illness onset and interview and by self-reporting of illness information. Conclusions: West Nile fever is a more severe illness than has previously been documented. Mandatory reporting of West Nile fever cases in addition to West Nile meningoencephalitis cases could allow more accurate and timely recognition of the geographic distribution of West Nile virus infections and could inform public health interventions.	Chicago Dept Publ Hlth, Chicago, IL 60612 USA; Illinois Dept Publ Hlth, Springfield, IL 62761 USA; Ctr Dis Control & Prevent, Atlanta, GA USA	Chicago Department of Public Health; Centers for Disease Control & Prevention - USA	Watson, JT (corresponding author), Chicago Dept Publ Hlth, 2160 W Ogden, Chicago, IL 60612 USA.	watson_john@cdph.org						*CDCP, ENC MEN ARB 2001 CAS; *CDCP, 2004, W NIL VIR 2002 CAS C; Chowers MY, 2001, EMERG INFECT DIS, V7, P675; Hubalek Z, 1999, EMERG INFECT DIS, V5, P643, DOI 10.3201/eid0505.990505; Lanciotti RS, 2000, J CLIN MICROBIOL, V38, P4066, DOI 10.1128/JCM.38.11.4066-4071.2000; Martin DA, 2000, J CLIN MICROBIOL, V38, P1823, DOI 10.1128/JCM.38.5.1823-1826.2000; Mostashari F, 2001, LANCET, V358, P261, DOI 10.1016/S0140-6736(01)05480-0; Nash D, 2001, NEW ENGL J MED, V344, P1807, DOI 10.1056/NEJM200106143442401; Petersen LR, 2001, EMERG INFECT DIS, V7, P611; Petersen LR, 2003, JAMA-J AM MED ASSOC, V290, P524, DOI 10.1001/jama.290.4.524; Petersen LR, 2002, ANN INTERN MED, V137, P173, DOI 10.7326/0003-4819-137-3-200208060-00009; Platonov AE, 2001, EMERG INFECT DIS, V7, P128, DOI 10.3201/eid0701.010118; Sejvar JJ, 2003, JAMA-J AM MED ASSOC, V290, P511, DOI 10.1001/jama.290.4.511; *SER W NIL VIR INF, 2001, MMWR-MORBID MORTAL W, V50, P37; SMITHBURN K. C, 1940, AMER JOUR TROP MED, V20, P471; Tsai TF, 1998, LANCET, V352, P767, DOI 10.1016/S0140-6736(98)03538-7; 2000, MMWR MORB MORTAL WKL, V49, P1044; 2002, MMWR MORB MORTAL WKL, V51, P1072; 2002, MMWR MORB MORTAL WKL, V51, P497	19	135	148	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	2004	141	5					360	365		10.7326/0003-4819-141-5-200409070-00010	http://dx.doi.org/10.7326/0003-4819-141-5-200409070-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CW	15353427				2022-12-28	WOS:000223733800004
J	Opdal, SH; Rognum, TO				Opdal, SH; Rognum, TO			New insight into sudden infant-death syndrome	LANCET			English	Editorial Material							SEROTONIN TRANSPORTER GENE; RISK		Rikshosp Univ Hosp, Inst Forens Med, N-0027 Oslo, Norway	University of Oslo; National Hospital Norway	Opdal, SH (corresponding author), Rikshosp Univ Hosp, Inst Forens Med, N-0027 Oslo, Norway.	siriop@ulrik.uio.no						Blackwell CC, 1999, FEMS IMMUNOL MED MIC, V25, P1, DOI 10.1111/j.1574-695X.1999.tb01320.x; Guntheroth WG, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e64; Heininger U, 2004, PEDIATRICS, V114, pE9, DOI 10.1542/peds.114.1.e9; Hunt CE, 2001, AM J RESP CRIT CARE, V164, P346, DOI 10.1164/ajrccm.164.3.9910045; Kinney HC, 2001, J NEUROPATH EXP NEUR, V60, P228, DOI 10.1093/jnen/60.3.228; Krous HF, 2004, PEDIATRICS, V114, P234, DOI 10.1542/peds.114.1.234; Lindgren C, 1997, EUR J PEDIATR, V156, P405, DOI 10.1007/s004310050626; Narita N, 2001, PEDIATRICS, V107, P690, DOI 10.1542/peds.107.4.690; Opdal SH, 2003, HUM IMMUNOL, V64, P1183, DOI 10.1016/j.humimm.2003.08.359; Opdal SH, 1999, EUR J PEDIATR, V158, P210, DOI 10.1007/s004310051051; Puffenberger EG, 2004, P NATL ACAD SCI USA, V101, P11689, DOI 10.1073/pnas.0401194101; ROGNUM TO, 1993, ACTA PAEDIATR, V82, P82, DOI 10.1111/j.1651-2227.1993.tb12886.x; Vege A, 1999, FEMS IMMUNOL MED MIC, V25, P67, DOI 10.1111/j.1574-695X.1999.tb01328.x; VEGE A, 1995, ACTA PAEDIATR, V84, P193, DOI 10.1111/j.1651-2227.1995.tb13608.x; Weese-Mayer DE, 2004, PEDIATR RES, V56, P391, DOI 10.1203/01.PDR.0000136285.91048.4A; Weese-Mayer DE, 2003, AM J MED GENET A, V117A, P268, DOI 10.1002/ajmg.a.20005	16	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2004	364	9437					825	826		10.1016/S0140-6736(04)16998-5	http://dx.doi.org/10.1016/S0140-6736(04)16998-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351175				2022-12-28	WOS:000223685200009
J	Van Ranst, M				Van Ranst, M			Chandipura virus: an emerging human pathogen?	LANCET			English	Editorial Material									Katholieke Univ Leuven, Rega Inst Med Res, BE-3000 Louvain, Belgium	KU Leuven	Van Ranst, M (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, BE-3000 Louvain, Belgium.	Marc.vanranst@uz.kuleuven.ac.be	Van Ranst, Marc/P-7522-2017	Van Ranst, Marc/0000-0002-1674-4157				BHATT PN, 1967, INDIAN J MED RES, V55, P1295; CLEWLEY JP, 1977, J VIROL, V23, P152, DOI 10.1128/JVI.23.1.152-166.1977; DHANDA V, 1970, INDIAN J MED RES, V58, P179; FONTENILLE D, 1994, AM J TROP MED HYG, V50, P570, DOI 10.4269/ajtmh.1994.50.570; RODRIGUES JJ, 1983, INDIAN J MED RES, V77, P303	5	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	2004	364	9437					821	822		10.1016/S0140-6736(04)16995-X	http://dx.doi.org/10.1016/S0140-6736(04)16995-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351172	Bronze, Green Published			2022-12-28	WOS:000223685200006
J	Fortney, JJ				Fortney, JJ			Looking into the giant planets	SCIENCE			English	Editorial Material							EQUATION-OF-STATE; PHASE-SEPARATION; HELIUM; JUPITER; SATURN; DEUTERIUM; EVOLUTION; HYDROGEN		NASA, Planetary Syst Branch, Ames Res Ctr, Moffett Field, CA 94035 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Fortney, JJ (corresponding author), NASA, Planetary Syst Branch, Ames Res Ctr, Moffett Field, CA 94035 USA.	jfortney@arc.nasa.gov	Fortney, Jonathan/F-8813-2014	Fortney, Jonathan/0000-0002-9843-4354				CASTILLO JF, COMMUNICATION; Collins GW, 1998, SCIENCE, V281, P1178, DOI 10.1126/science.281.5380.1178; Conrath BJ, 2000, ICARUS, V144, P124, DOI 10.1006/icar.1999.6265; FLASAR FM, COMMUNICATION; Fortney JJ, 2003, ICARUS, V164, P228, DOI 10.1016/S0019-1035(03)00130-1; Hubbard WB, 1999, PLANET SPACE SCI, V47, P1175, DOI 10.1016/S0032-0633(99)00042-2; Knudson MD, 2003, J PHYS A-MATH GEN, V36, P6149, DOI 10.1088/0305-4470/36/22/342; PFAFFENZELLER O, 1995, PHYS REV LETT, V74, P2599, DOI 10.1103/PhysRevLett.74.2599; SALPETER EE, 1973, ASTROPHYS J, V181, pL83, DOI 10.1086/181190; Saumon D, 2004, ASTROPHYS J, V609, P1170, DOI 10.1086/421257; SMOLUCHO.R, 1967, NATURE, V215, P691, DOI 10.1038/215691a0; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P239, DOI 10.1086/190479; von Zahn U, 1998, J GEOPHYS RES-PLANET, V103, P22815, DOI 10.1029/98JE00695	15	15	15	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	2004	305	5689					1414	1415		10.1126/science.1101352	http://dx.doi.org/10.1126/science.1101352			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353790	Green Published			2022-12-28	WOS:000223761900033
J	Fyles, AW; McCready, DR; Manchul, LA; Trudeau, ME; Merante, P; Pintilie, M; Weir, LM; Olivotto, IA				Fyles, AW; McCready, DR; Manchul, LA; Trudeau, ME; Merante, P; Pintilie, M; Weir, LM; Olivotto, IA			Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CLINICAL-TRIAL; POSTOPERATIVE RADIOTHERAPY; AXILLARY DISSECTION; CONSERVING SURGERY; TUMOR RECURRENCE; LYMPH-NODES; STAGE-I; LUMPECTOMY; THERAPY; MASTECTOMY	BACKGROUND: We determined the effect of breast irradiation plus tamoxifen on disease-free survival and local relapse in women 50 years of age or older who had T1 or T2 node-negative breast cancer. METHODS: Between December 1992 and June 2000, 769 women with early breast cancer (tumor diameter, 5 cm or less) were randomly assigned to receive breast irradiation plus tamoxifen (386 women) or tamoxifen alone (383 women). The median follow-up was 5.6 years. RESULTS: The rate of local relapse at five years was 7.7 percent in the tamoxifen group and 0.6 percent in the group given tamoxifen plus irradiation (hazard ratio, 8.3; 95 percent confidence interval, 3.3 to 21.2; P<0.001), with corresponding five-year disease-free survival rates of 84 percent and 91 percent (P=0.004). A planned subgroup analysis of 611 women with T1, receptor-positive tumors indicated a benefit from radiotherapy (five-year rates of local relapse, 0.4 percent with tamoxifen plus radiotherapy and 5.9 percent with tamoxifen alone; P<0.001). Overall, there was a significant difference in the rate of axillary relapse at five years (2.5 percent in the tamoxifen group and 0.5 percent in the group given tamoxifen plus irradiation, P=0.049), but no significant difference in the rates of distant relapse or overall survival. CONCLUSIONS: As compared with tamoxifen alone, radiotherapy plus tamoxifen significantly reduces the risk of breast and axillary recurrence after lumpectomy in women with small, node-negative, hormone-receptor-positive breast cancers.	Princess Margaret Hosp, Dept Radiat Oncol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON, Canada; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; British Columbia Cancer Agency	Fyles, AW (corresponding author), Princess Margaret Hosp, Dept Radiat Oncol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	anthony.fyles@rmp.uhn.on.ca		Fyles, Anthony/0000-0002-3633-2483				Clark RM, 1996, J NATL CANCER I, V88, P1659, DOI 10.1093/jnci/88.22.1659; CLARK RM, 1992, JNCI-J NATL CANCER I, V84, P683, DOI 10.1093/jnci/84.9.683; Fisher B, 2002, J CLIN ONCOL, V20, P4141, DOI 10.1200/JCO.2002.11.101; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; Fisher ER, 2001, CANCER-AM CANCER SOC, V91, P1679, DOI 10.1002/1097-0142(20010415)91:8+<1679::AID-CNCR1183>3.0.CO;2-8; FLEMING TR, 1990, J ACQ IMMUN DEF SYND, V3, pS82; Forrest AP, 1996, LANCET, V348, P708, DOI 10.1016/S0140-6736(96)02133-2; Freedman GM, 2002, J CLIN ONCOL, V20, P4015, DOI 10.1200/JCO.2002.03.155; Holli K, 2001, BRIT J CANCER, V84, P164, DOI 10.1054/bjoc.2000.1571; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Liljegren G, 1999, J CLIN ONCOL, V17, P2326, DOI 10.1200/JCO.1999.17.8.2326; McCormick B, 2002, J SURG ONCOL, V81, P12, DOI 10.1002/jso.10148; McCready DR, 2000, ANN SURG ONCOL, V7, P562, DOI 10.1007/BF02725334; Nattinger AB, 2000, LANCET, V356, P1148, DOI 10.1016/S0140-6736(00)02757-4; Rayan G, 2003, INT J RADIAT ONCOL, V55, P154, DOI 10.1016/S0360-3016(02)03826-9; Schlembach PJ, 2001, INT J RADIAT ONCOL, V51, P671, DOI 10.1016/S0360-3016(01)01684-4; VERONESI U, 1993, NEW ENGL J MED, V328, P1587, DOI 10.1056/NEJM199306033282202; Voogd AC, 2001, J CLIN ONCOL, V19, P1688, DOI 10.1200/JCO.2001.19.6.1688; Voogd AC, 2001, J CLIN ONCOL, V19, P2583; Yap KPL, 2003, CANCER-AM CANCER SOC, V97, P1369, DOI 10.1002/cncr.11218	21	458	462	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2004	351	10					963	970		10.1056/NEJMoa040595	http://dx.doi.org/10.1056/NEJMoa040595			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	850UB	15342804				2022-12-28	WOS:000223637400006
J	Malloy, MH				Malloy, MH			SIDS - A syndrome in search of a cause	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INFANT-DEATH-SYNDROME		Univ Texas, Med Branch, Dept Pediat, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston	Malloy, MH (corresponding author), Univ Texas, Med Branch, Dept Pediat, Galveston, TX 77550 USA.							*CDC WOND, COMPR MORT FIL UND C; KATTWINKEL J, 1992, PEDIATRICS, V89, P1120; KATTWINKEL J, 1992, PEDIATRICS, V90, P264; Krous HF, 2004, PEDIATRICS, V114, P234, DOI 10.1542/peds.114.1.234; WILLINGER M, 1994, PEDIATRICS, V93, P814	5	12	12	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2004	351	10					957	959		10.1056/NEJMp048194	http://dx.doi.org/10.1056/NEJMp048194			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	850UB	15342802				2022-12-28	WOS:000223637400004
J	Barratt, A; Trevena, L; Davey, HM; McCaffery, K				Barratt, A; Trevena, L; Davey, HM; McCaffery, K			Use of decision aids to support informed choices about screening	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; WOMEN; PROGRAMS		Univ Sydney, Sch Publ Hlth, Screening & Test Evaluat Program, Sydney, NSW 2006, Australia	University of Sydney	Barratt, A (corresponding author), Univ Sydney, Sch Publ Hlth, Screening & Test Evaluat Program, Sydney, NSW 2006, Australia.	alexb@health.usyd.edu.au	McCaffery, Kirsten/K-7945-2019; Barratt, Alexandra/A-7349-2011	McCaffery, Kirsten/0000-0003-2696-5006; Barratt, Alexandra/0000-0002-2561-3319; Trevena, Lyndal/0000-0003-1419-1832				*ACS, PREV EARL DET; ALDERMAN MH, 1990, J CLIN EPIDEMIOL, V43, P195, DOI 10.1016/0895-4356(90)90185-R; *AM MED ASS, 2002, US GUID MED LIT MAN, P387; Barratt A, 1999, JAMA-J AM MED ASSOC, V281, P2029, DOI 10.1001/jama.281.21.2029; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; Edwards A, 2003, BMJ-BRIT MED J, V327, P703, DOI 10.1136/bmj.327.7417.703; Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601; Ernster VL, 2002, J NATL CANCER I, V94, P1546; Etzioni R, 2002, J NATL CANCER I, V94, P981; Jepson R G, 2001, Health Expect, V4, P116, DOI 10.1046/j.1369-6513.2001.00143.x; Kavanagh AM, 1997, BRIT MED J, V314, P1388; KHAW KT, 1989, BRIT MED J, V299, P606, DOI 10.1136/bmj.299.6699.606; LEFEBVRE RC, 1988, ARCH INTERN MED, V148, P1993, DOI 10.1001/archinte.148.9.1993; Man-Son-Hing M, 1999, JAMA-J AM MED ASSOC, V282, P737, DOI 10.1001/jama.282.8.737; Montgomery AA, 1998, J EPIDEMIOL COMMUN H, V52, P520, DOI 10.1136/jech.52.8.520; MORRISON AS, 1992, SCREENING CHRONIC DI, P23; OConnor AM, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001431, DOI 10.1002/14651858.CD001431]; Oliver S, 1996, BMJ-BRIT MED J, V313, P1251, DOI 10.1136/bmj.313.7067.1251a; Olsen O, 2001, LANCET, V358, P1340, DOI 10.1016/S0140-6736(01)06449-2; PERNET AJ, 1992, PSYCHO-ONCOLOGY, V1, P217; Raffle A E, 2001, Health Expect, V4, P92, DOI 10.1046/j.1369-6513.2001.00138.x; Raffle AE, 2003, BRIT MED J, V326, P901, DOI 10.1136/bmj.326.7395.901; Scaf-Klomp W, 1997, J EPIDEMIOL COMMUN H, V51, P705, DOI 10.1136/jech.51.6.705; Schwartz LM, 2004, JAMA-J AM MED ASSOC, V291, P71, DOI 10.1001/jama.291.1.71; Slater DN, 2000, CYTOPATHOLOGY, V11, P166, DOI 10.1046/j.1365-2303.2000.00248.x; Towler B, 1998, BRIT MED J, V317, P559, DOI 10.1136/bmj.317.7158.559; Woloshin S, 2002, J NATL CANCER I, V94, P799, DOI 10.1093/jnci/94.11.799; YAMEY G, 2002, BRIT MED J, V324, P431; Zahl PH, 2004, BMJ-BRIT MED J, V328, P921, DOI 10.1136/bmj.38044.666157.63	29	64	64	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 28	2004	329	7464					507	510		10.1136/bmj.329.7464.507	http://dx.doi.org/10.1136/bmj.329.7464.507			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KS	15331483	Green Published			2022-12-28	WOS:000223684600028
J	Kim, WB; Voitl, T; Rodriguez-Rivera, GJ; Dumesic, JA				Kim, WB; Voitl, T; Rodriguez-Rivera, GJ; Dumesic, JA			Powering fuel cells with CO via aqueous polyoxometalates and gold catalysts	SCIENCE			English	Article							GAS-SHIFT REACTION; BIOMASS-DERIVED HYDROCARBONS; CARBON-MONOXIDE; WATER; OXIDATION; HYDROGEN; MEMBRANES; CLUSTERS; AU	Electricity was produced by catalytic oxidation of carbon monoxide (CO) by using gold catalysts at room temperature. The observed rates are faster than conventional processes operating at 500 kelvin or higher for the conversion of CO with water to produce hydrogen and carbon dioxide through the water-gas shift (WGS). By eliminating the WGS reaction, we remove the need to transport and vaporize liquid water in the production of energy for portable applications. This process can use CO-containing gas streams from the catalytic reforming of hydrocarbons to produce an aqueous solution of reduced polyoxometalate compounds that can be used to generate power. The reduced polyoxometalate can be reoxidized in fuel cells that contain simple carbon anodes.	Univ Wisconsin, Dept Biol & Chem Engn, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Dumesic, JA (corresponding author), Univ Wisconsin, Dept Biol & Chem Engn, Madison, WI 53706 USA.	dumesic@engr.wisc.edu		Kim, Won Bae/0000-0002-1251-9681				Bond GC, 2000, GOLD BULL, V33, P41, DOI 10.1007/BF03216579; Briand LE, 2003, APPL CATAL A-GEN, V256, P37, DOI 10.1016/S0926-860X(03)00387-9; BROWN GM, 1977, ACTA CRYSTALLOGR B, V33, P1038, DOI 10.1107/S0567740877005330; Cortright RD, 2002, NATURE, V418, P964, DOI 10.1038/nature01009; Date M, 2004, ANGEW CHEM INT EDIT, V43, P2129, DOI 10.1002/anie.200453796; Davda RR, 2003, ANGEW CHEM INT EDIT, V42, P4068, DOI 10.1002/anie.200351664; Deluga GA, 2004, SCIENCE, V303, P993, DOI 10.1126/science.1093045; Desai SK, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.075420; Fu Q, 2003, SCIENCE, V301, P935, DOI 10.1126/science.1085721; GomezRomero P, 1996, J PHYS CHEM-US, V100, P12448, DOI 10.1021/jp953326g; HARUTA M, 1987, CHEM LETT, P405, DOI 10.1246/cl.1987.405; Huber GW, 2003, SCIENCE, V300, P2075, DOI 10.1126/science.1085597; Koryabkina NA, 2003, J CATAL, V217, P233, DOI 10.1016/S0021-9517(03)00050-2; Kung HH, 2003, J CATAL, V216, P425, DOI 10.1016/S0021-9517(02)00111-2; Ovesen CV, 1996, J CATAL, V158, P170, DOI 10.1006/jcat.1996.0016; Rostrup-Nielsen JR, 2002, CATTECH, V6, P150, DOI 10.1023/A:1020163012266; Sakurai H, 1997, CHEM COMMUN, P271, DOI 10.1039/a606192c; Sanchez-Castillo MA, 2004, ANGEW CHEM INT EDIT, V43, P1140, DOI 10.1002/anie.200353238; Schubert MM, 2004, J CATAL, V222, P32, DOI 10.1016/j.jcat.2003.08.015; Steele BCH, 2001, NATURE, V414, P345, DOI 10.1038/35104620; Valden M, 1998, SCIENCE, V281, P1647, DOI 10.1126/science.281.5383.1647; Wang DN, 1998, ENERG FUEL, V12, P19, DOI 10.1021/ef970102j; Wang X, 2002, J CATAL, V212, P225, DOI 10.1006/jcat.2002.3789; Yu SF, 2003, NANO LETT, V3, P815, DOI 10.1021/nl0340576	24	251	256	10	190	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2004	305	5688					1280	1283		10.1126/science.1100860	http://dx.doi.org/10.1126/science.1100860			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850PJ	15333837				2022-12-28	WOS:000223624600038
J	Knutson, B				Knutson, B			Sweet revenge?	SCIENCE			English	Editorial Material							NUCLEUS-ACCUMBENS; REWARD; ANTICIPATION; DOPAMINE		Stanford Univ, Dept Psychol, Stanford, CA 94305 USA	Stanford University	Knutson, B (corresponding author), Stanford Univ, Dept Psychol, Stanford, CA 94305 USA.	knutson@psych.stanford.edu		Knutson, Brian/0000-0002-7669-426X				Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; de Quervain DJF, 2004, SCIENCE, V305, P1254, DOI 10.1126/science.1100735; Frank R. H., 1988, PASSIONS REASON STRA; Ikemoto S, 1999, BRAIN RES REV, V31, P6, DOI 10.1016/S0165-0173(99)00023-5; Knutson B, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0002.2001; Knutson B, 2001, NEUROREPORT, V12, P3683, DOI 10.1097/00001756-200112040-00016; MacLean P, 1990, TRIUNE BRAIN EVOLUTI; Martinez D, 2003, J CEREBR BLOOD F MET, V23, P285, DOI 10.1097/01.WCB.0000048520.34839.1A; O'Doherty JP, 2002, NEURON, V33, P815, DOI 10.1016/S0896-6273(02)00603-7; OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P219; Rilling JK, 2002, NEURON, V35, P395, DOI 10.1016/S0896-6273(02)00755-9; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755	12	58	59	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2004	305	5688					1246	1247		10.1126/science.1102822	http://dx.doi.org/10.1126/science.1102822			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850PJ	15333827				2022-12-28	WOS:000223624600027
J	Brasier, M; Antcliffe, J				Brasier, M; Antcliffe, J			Decoding the Ediacaran enigma	SCIENCE			English	Editorial Material							EVOLUTION		Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England	University of Oxford	Brasier, M (corresponding author), Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England.	martin.brasier@earth.ox.ac.uk		antcliffe, jonathan/0000-0001-8639-6998				[Anonymous], CRADLE LIFE; ANTCLIFFE J, 2004, THESIS U OXFORD; ANTCLIFFE J, 2004, WORKSH RIS FALL VEND; BASIER MD, 2002, NATURE, V416, P76; Brasier M.D., 1982, Journal of Micropalaeontology, V1, P95; Clapham ME, 2002, GEOLOGY, V30, P627, DOI 10.1130/0091-7613(2002)030<0627:EET>2.0.CO;2; FORTEY RA, 1987, PALEOBIOLOGY, V13, P1; GEHLING JG, 1991, MEMOIRS GEOLOGICAL S, V20, P181; Glaessner M.F., 1984, DAWN ANIMAL LIFE; Grazhdankin D, 2004, PALEOBIOLOGY, V30, P203, DOI 10.1666/0094-8373(2004)030<0203:PODITE>2.0.CO;2; JENKINS RJF, 1992, ORIGIN EARLY EVOLUTI, P131; MAYR E, 2002, WHAT EVOLUTION IS, P318; Narbonne GM, 2004, SCIENCE, V305, P1141, DOI 10.1126/science.1099727; Narbonne GM., 1998, GSA TODAY, V8, P1; SEILACHER A, 1992, J GEOL SOC LONDON, V149, P607, DOI 10.1144/gsjgs.149.4.0607; SEILACHER A, 2004, PALAEONTOL RES, V7, P44; SLACK J, 2003, THESIS U OXFORD	17	69	73	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2004	305	5687					1115	1117		10.1126/science.1102673	http://dx.doi.org/10.1126/science.1102673			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326344				2022-12-28	WOS:000223557400033
J	Malumbres, M; Sotillo, R; Santamaria, D; Galan, J; Cerezo, A; Ortega, S; Dubus, P; Barbacid, M				Malumbres, M; Sotillo, R; Santamaria, D; Galan, J; Cerezo, A; Ortega, S; Dubus, P; Barbacid, M			Mammalian cells cycle without the D-type cyclin-elependent kinases Cdk4 and Cdk6	CELL			English	Article							PROTEIN-KINASES; MICE; PROGRESSION; CANCER; G(1); IDENTIFICATION; PROLIFERATION; ONCOGENESIS; REGULATORS; DISRUPTION	Cdk4 and Cdk6 are thought to be essential for initiation of the cell cycle in response to mitogenic stimuli. Previous studies have shown that Cdk4 is dispensable for proliferation in most cell types, an observation attributed to a putative a compensatory role by Cdk6. Cdk6-null mice are viable and develop normally although hematopoiesis is slightly impaired. Embryos defective for Cdk4 and CdK6 die during the late stages of embryonic development due to severe anemia. However, these embryos display normal organogenesis and most cell types proliferate normally. In vitro, embryonic fibroblasts lacking Cdk4 and Cdk6 proliferate and become immortal upon serial passage. Moreover, quiescent Cdk4/Cdk6-null cells respond to serum stimulation and enter S phase with normal kinetics although with lower efficiency. These results indicate that D-type cyclin-dependent kinases are not essential for cell cycle entry and suggest the existence of alternative mechanisms to initiate cell proliferation upon mitogenic stimulation.	CNIO, Mol Oncol Program, E-28029 Madrid, Spain; Univ Bordeaux 2, EA2406, F-33076 Bordeaux, France	Centro Nacional de Investigaciones Oncologicas (CNIO); UDICE-French Research Universities; Universite de Bordeaux	Malumbres, M (corresponding author), CNIO, Mol Oncol Program, E-28029 Madrid, Spain.	malumbres@cnio.es; barbacid@cnio.es	Santamaria, David/D-3930-2011; Holt, Janet E/B-2415-2013; Cerezo, Ana/F-4403-2011; Malumbres, Marcos/E-8834-2011	Santamaria, David/0000-0002-4711-3569; Malumbres, Marcos/0000-0002-0829-6315; Galan, Javier/0000-0002-1160-8279; Cerezo Montemayor, Ana/0000-0003-0275-0844; Sotillo, Rocio/0000-0002-0855-7917; Dubus, Pierre/0000-0003-1803-4711				Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Amanatullah DF, 2001, METHOD ENZYMOL, V333, P116; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; LUKAS J, 1995, ONCOGENE, V10, P2125; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Martin J, 2003, ONCOGENE, V22, P5261, DOI 10.1038/sj.onc.1206506; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Matushansky I, 2000, P NATL ACAD SCI USA, V97, P14317, DOI 10.1073/pnas.250488697; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Moons DS, 2002, ENDOCRINOLOGY, V143, P3001, DOI 10.1210/en.143.8.3001; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Park M, 1999, DEVELOPMENT, V126, P4849; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Stacey D, 2002, CURR OPIN GENET DEV, V12, P44, DOI 10.1016/S0959-437X(01)00262-3; Steinman RA, 2002, ONCOGENE, V21, P3403, DOI 10.1038/sj.onc.1205325; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951; Traver D, 2001, BLOOD, V98, P627, DOI 10.1182/blood.V98.3.627; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Ye X, 2001, P NATL ACAD SCI USA, V98, P1682, DOI 10.1073/pnas.041596198	42	595	613	2	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2004	118	4					493	504		10.1016/j.cell.2004.08.002	http://dx.doi.org/10.1016/j.cell.2004.08.002			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	850YS	15315761	Bronze			2022-12-28	WOS:000223650900011
J	Hemingway, J				Hemingway, J			Taking aim at mosquitoes	NATURE			English	Article							INSECTICIDE RESISTANCE; GENOME SEQUENCE; PLASMODIUM		Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England	Liverpool School of Tropical Medicine; University of Liverpool	Hemingway, J (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.			Hemingway, Janet/0000-0002-3200-7173				Abraham EG, 2004, J BIOL CHEM, V279, P5573, DOI 10.1074/jbc.M307582200; Brooke BD, 2001, B ENTOMOL RES, V91, P265, DOI 10.1079/BER2001108; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Lindblade KA, 2004, JAMA-J AM MED ASSOC, V291, P2571, DOI 10.1001/jama.291.21.2571; McCarroll L, 2000, NATURE, V407, P961, DOI 10.1038/35039671; Osta MA, 2004, SCIENCE, V303, P2030, DOI 10.1126/science.1091789; Ranson H, 2002, SCIENCE, V298, P179, DOI 10.1126/science.1076781; Srinivasan P, 2004, J BIOL CHEM, V279, P5581, DOI 10.1074/jbc.M307587200	9	16	20	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2004	430	7002					936	936		10.1038/430936a	http://dx.doi.org/10.1038/430936a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318236	Green Accepted			2022-12-28	WOS:000223369800059
J	Mandavilli, A				Mandavilli, A			Struggling to make an impact	NATURE			English	Editorial Material																		2002, NATURE, V419, P422; 2004, NATURE, V429, P588	2	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2004	430	7002					935	935		10.1038/430935a	http://dx.doi.org/10.1038/430935a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318235	Bronze			2022-12-28	WOS:000223369800058
J	Mocumbi, P				Mocumbi, P			Plague of my people	NATURE			English	Editorial Material																			0	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2004	430	7002					925	925		10.1038/430925a	http://dx.doi.org/10.1038/430925a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318229	Bronze			2022-12-28	WOS:000223369800052
J	Zou, SM; Dodd, RY; Stramer, SL; Strong, DM				Zou, SM; Dodd, RY; Stramer, SL; Strong, DM		Tissue Safety Study Grp	Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD-DONORS; VIRAL-INFECTIONS; PREVALENCE; RISK; NAT; MARKERS; TIME	BACKGROUND: Tissue-banking organizations in the United States have introduced various review and testing procedures to reduce the risk of the transmission of viral infections from tissue grafts. We estimated the current probability of undetected viremia with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and human T-lymphotropic virus (HTLV) among tissue donors. METHODS: Rates of prevalence of hepatitis B surface antigen (HBsAg) and antibodies against HIV (anti-HIV), HCV (anti-HCV), and HTLV (anti-HTLV) were determined among 11,391 donors to five tissue banks in the United States. The data were compared with those of first-time blood donors in order to generate estimated incidence rates among tissue donors. The probability of viremia undetected by screening at the time of tissue donation was estimated on the basis of the incidence estimates and the window periods for these infections. RESULTS: The prevalence of confirmed positive tests among tissue donors was 0.093 percent for anti-HIV, 0.229 percent for HBsAg, 1.091 percent for anti-HCV, and 0.068 percent for anti-HTLV. The incidence rates were estimated to be 30.118, 18.325, 12.380, and 5.586 per 100,000 person-years, respectively. The estimated probability of viremia at the time of donation was 1 in 55,000, 1 in 34,000, 1 in 42,000, and 1 in 128,000, respectively. CONCLUSIONS: The prevalence rates of HBV, HCV, HIV, and HTLV infections are lower among tissue donors than in the general population. However, the estimated probability of undetected viremia at the time of tissue donation is higher among tissue donors than among first-time blood donors. The addition of nucleic acid-amplification testing to the screening of tissue donors should reduce the risk of these infections among recipients of donated tissues.	Amer Red Cross, Transmissible Dis Dept, Rockville, MD 20855 USA; Puget Sound Blood Ctr, NW Tissue Ctr, Seattle, WA 98104 USA	American Red Cross; Puget Sound Blood Center	Zou, SM (corresponding author), Amer Red Cross, Transmissible Dis Dept, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	zous@usa.redcross.org	Abrams, William R/A-5782-2008					Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; *AM ASS TISS BANKS, 2002, 2002 ANN REG SURV AC; [Anonymous], 2002, STAND TISS BANK; Busch MP, 2004, TRANSFUS CLIN BIOL, V11, P26, DOI 10.1016/j.tracli.2003.12.003; BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x; Dodd R Y, 2000, Dev Biol (Basel), V102, P19; Dodd RY, 2000, ANN MED, V32, P469, DOI 10.3109/07853890009002022; Dodd RY, 2002, TRANSFUSION, V42, P975, DOI 10.1046/j.1537-2995.2002.00174.x; Eastlund T., 2004, ADV TISSUE BANKING, V7, P51, DOI DOI 10.1142/9789812796646_0003; Glynn SA, 2000, JAMA-J AM MED ASSOC, V284, P229, DOI 10.1001/jama.284.2.229; Jackson BR, 2003, TRANSFUSION, V43, P721, DOI 10.1046/j.1537-2995.2003.00392.x; Janssen RS, 1999, JAMA-J AM MED ASSOC, V281, P1893; JOYCE MJ, 2004, AM AC ORTH SURG 71 A; Karon JM, 2001, AM J PUBLIC HEALTH, V91, P1060, DOI 10.2105/AJPH.91.7.1060; Korelitz JJ, 1997, TRANSFUSION, V37, P634, DOI 10.1046/j.1537-2995.1997.37697335159.x; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; McQuillan GM, 1999, AM J PUBLIC HEALTH, V89, P14, DOI 10.2105/AJPH.89.1.14; PETERSEN LR, 1994, TRANSFUSION, V34, P283, DOI 10.1046/j.1537-2995.1994.34494233574.x; Scardino MK, 2002, CORNEA, V21, P798, DOI 10.1097/00003226-200211000-00014; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Stramer SL, 2000, TRANSFUSION, V40, P1165, DOI 10.1046/j.1537-2995.2000.40101165.x; Stramer SL, 2001, TRANSFUSION, V41, P1079; 2003, MMWR MORB MORTAL WKL, V52, P273; 2000, CRYSTAL BALL SOFTWAR	24	143	151	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2004	351	8					751	759		10.1056/NEJMoa032510	http://dx.doi.org/10.1056/NEJMoa032510			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847CY	15317888				2022-12-28	WOS:000223367900007
J	Baker, MG; Graham, L				Baker, MG; Graham, L			The journey: Parkinson's disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review									European Parkinsons Dis Assoc, Sevenoaks TN13 3NJ, Kent, England		Graham, L (corresponding author), European Parkinsons Dis Assoc, Sevenoaks TN13 3NJ, Kent, England.	lizzie@epda.eu.com						AHO K, 2002, PARKINSONS DIS MY CO; ANDERSON S, 1989, HLTH IS BETWEEN YOUR; BAKER MG, 1999, PARKINSONS YOUR FING; *PARK DIS SOC, 2003, PARK AW PRIM CAR	4	33	33	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 11	2004	329	7466					611	614		10.1136/bmj.329.7466.611	http://dx.doi.org/10.1136/bmj.329.7466.611			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	854SK	15361447	Green Published			2022-12-28	WOS:000223923400021
J	Becerra-Posada, F; Berwick, D; Bhutta, Z; Chowdhury, M; de Savigny, D; Haines, A; Hyder, A; Lavis, J; Lumbiganon, P; Mills, A; Mshinda, H; Narayan, R; Oxman, A; Sanders, D; Sewankambo, N; Tomson, G; Victora, C				Becerra-Posada, F; Berwick, D; Bhutta, Z; Chowdhury, M; de Savigny, D; Haines, A; Hyder, A; Lavis, J; Lumbiganon, P; Mills, A; Mshinda, H; Narayan, R; Oxman, A; Sanders, D; Sewankambo, N; Tomson, G; Victora, C		Task Force Hlth Systems Res	Informed choices for attaining the Millennium Development Goals: towards an international cooperative agenda for health-systems research	LANCET			English	Article							PUBLIC-HEALTH; COUNTRIES; EXPENDITURE; EDUCATION; CHILDREN; IMPACT	Health systems constraints are impeding the implementation of major global initiatives for health and the attainment of the Millennium Development Goals (MDGs). Research could contribute to overcoming these barriers. An independent task force has been convened by WHO to suggest areas where international collaborative research could help to generate the knowledge necessary to improve health systems. Suggested topics encompass financial and human resources, organisation and delivery of health services, governance, stewardship, knowledge management, and global influences. These topics should be viewed as tentative suggestions that form a basis for further discussion. This article is part of a wide-ranging consultation and comment is invited. The potential agenda will be presented at the Ministerial Summit on Health Research in November, 2004, and revised in the light of responses. Subsequently, we hope that resources will be committed to generate the evidence needed to build the equitable, effective, and efficient health systems needed to achieve the MDGs.	Univ London London Sch Hyg & Trop Med, Deans Off, London WC1E 7HT, England; Minist Hlth, Coordinat Gen Natl Inst Hlth, Mexico City, DF, Mexico; Inst Healthcare Improvement, Boston, MA USA; Aga Khan Univ, Dept Paediat, Karachi, Pakistan; BRAC, Dhaka, Bangladesh; Swiss Trop Inst, CH-4002 Basel, Switzerland; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; McMaster Univ, Hlth Sci Ctr, Hamilton, ON, Canada; Khon Kaen Univ, Fac Med, Dept Obstet & Gynecol, Khon Kaen, Thailand; London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1, England; Ifakara Hlth Res & Dev Ctr, Ifakara, Tanzania; CHC Bangalore, Peoples Hlth Movement Secretariat Global, Bangalore, Karnataka, India; Norwegian Hlth Serv Res Ctr, Informed Choice Res Dept, Oslo, Norway; Univ Western Cape, Sch Publ Hlth, ZA-7535 Bellville, Cape, South Africa; Makerere Univ, Fac Med, Kampala, Uganda; Karolinska Inst, Dept Publ Hlth Sci, IHCAR Div Int Hlth, Stockholm, Sweden; Univ Fed Pelotas, Pelotas, RS, Brazil	University of London; London School of Hygiene & Tropical Medicine; Institute for Healthcare Improvement; Aga Khan University; Bangladesh Rural Advancement Committee BRAC; University of Basel; Swiss Tropical & Public Health Institute; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; Khon Kaen University; University of London; London School of Hygiene & Tropical Medicine; Ifakara Health Institute; University of the Western Cape; Makerere University; Karolinska Institutet; Universidade Federal de Pelotas	Haines, A (corresponding author), Univ London London Sch Hyg & Trop Med, Deans Off, Keppel St, London WC1E 7HT, England.	Andy.Haines@lshtm.ac.uk	Victora, Cesar Gomes/Y-2455-2019; Oxman, Andrew/Y-3004-2019; Hyder, Adnan/AAT-9503-2021; Victora, Cesar G/D-4476-2013	Victora, Cesar Gomes/0000-0002-2465-2180; Oxman, Andrew/0000-0002-5608-5061; Victora, Cesar G/0000-0002-2465-2180; Haines, Andy/0000-0002-8053-4605				Ashbolt NJ, 2004, TOXICOLOGY, V198, P229, DOI 10.1016/j.tox.2004.01.030; Beaglehole R., 2003, WORLD HLTH REPORT 20; Belsky L, 2004, HEALTH AFFAIR, V23, P137, DOI 10.1377/hlthaff.23.3.137; Block MAG, 1997, HEALTH POLICY, V42, P187, DOI 10.1016/S0168-8510(97)00072-9; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; BURNSIDE C, 2000, WORLD BANK STRUCTURE, P210; Carrin G., 2003, COMMUNITY BASED HLTH; Department for International Development, INCR ACC ESS MED DEV; Des Jarlais DC, 2004, AM J PUBLIC HEALTH, V94, P361, DOI 10.2105/AJPH.94.3.361; Filmer D, 1999, SOC SCI MED, V49, P1309, DOI 10.1016/S0277-9536(99)00150-1; Gbezo B E, 1999, World Work, P13; *GLOB FOR HLTH RES, 2004, 1090 GLO FOR HLTH RE; Gohou V, 2004, TROP MED INT HEALTH, V9, P406, DOI 10.1111/j.1365-3156.2004.01204.x; Gwatkin DR, SOCIOECONOMIC DIFFER; HAINES A, IN PRESS WORLD HLTH; Hanney Stephen R., 2003, HEALTH RES POLICY SY, V1, P1, DOI DOI 10.1186/1478-4505-1-2; Hanson K, 2003, J INT DEV, V15, P1, DOI DOI 10.1002/JID.963; HEYWOOD A, USING INFORMATION AC; *INT LAB ORG, 2002, EXT SOC PROT HLTH CO; JAFAREY SN, 1993, SOC SCI MED, V36, P371, DOI 10.1016/0277-9536(93)90021-U; JANOVSKY K, 1996, 961 WHOSNSNHP; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Katabarwa M, 1999, LANCET, V354, P1909, DOI 10.1016/S0140-6736(05)76878-1; LAVIS J, 2004, IN PRESS LANCET; LEHMANN U, 2004, 41 JLI; Lomas J, 2003, MILBANK Q, V81, P363, DOI 10.1111/1468-0009.t01-1-00060; Mabey D, 2004, NAT REV MICROBIOL, V2, P231, DOI 10.1038/nrmicro841; Macfarlane S, 2000, LANCET, V356, P841, DOI 10.1016/S0140-6736(00)02664-7; Martinez J, 1998, HEALTH POLICY PLANN, V13, P345, DOI 10.1093/heapol/13.4.345; MILLS A, 2000, REFORMING HLTH SECTO; *MIN HLTH TANZ, 2002, DISTR BURD DIS PROF; Oliveira-Cruz V., 2003, J INT DEV, V15, P41, DOI [10.1002/jid.965, DOI 10.1002/JID.965]; Pang T, 2002, BMJ-BRIT MED J, V324, P499, DOI 10.1136/bmj.324.7336.499; Pannarunothai S, 1997, SOC SCI MED, V44, P1781, DOI 10.1016/S0277-9536(96)00287-0; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; Puoane T, 2004, INT J QUAL HEALTH C, V16, P31, DOI 10.1093/intqhc/mzh002; Rivera JA, 2004, JAMA-J AM MED ASSOC, V291, P2563, DOI 10.1001/jama.291.21.2563; Roberts MJ., 2004, GETTING HLTH REFORM; Sanders D, 2001, SAMJ S AFR MED J, V91, P823; STOP TB, 2004, WHOHTMSTB200429; Temmerman M, 2003, AIDS, V17, P1239, DOI 10.1097/00002030-200305230-00016; TRAVIS P, IN PRESS LANCET; Van Damme W, 2003, LANCET, V362, P996, DOI 10.1016/S0140-6736(03)14375-9; Wagstaff A., 2004, MILLENNIUM DEVELOPME; Wertheimer Albert I, 2003, J Am Pharm Assoc (2003), V43, P710; *WHO, 1996, INV HLTH DEV REP AD; *WHO WTO JOINT STU, 2002, WTO AGR PUBL HLTH; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; Xu K, 2003, LANCET, V362, P111, DOI 10.1016/S0140-6736(03)13861-5; 2004, LANCET, V362, P2033	50	94	97	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	2004	364	9438					997	1003						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364193				2022-12-28	WOS:000223831000032
J	Levin, BR				Levin, BR			Noninherited resistance to antibiotics	SCIENCE			English	Editorial Material									Emory Univ, Dept Biol, Atlanta, GA 30322 USA	Emory University	Levin, BR (corresponding author), Emory Univ, Dept Biol, Atlanta, GA 30322 USA.	blevin@emory.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM091875] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40662] Funding Source: Medline; NIGMS NIH HHS [R01 GM091875, GM33782] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balaban NQ, 2004, SCIENCE, V305, P1622, DOI 10.1126/science.1099390; BARCLAY ML, 1992, ANTIMICROB AGENTS CH, V36, P1951, DOI 10.1128/AAC.36.9.1951; BIGGER WB, 1944, LANCET, V244, P497; Drusano GL, 2004, NAT REV MICROBIOL, V2, P289, DOI 10.1038/nrmicro862; EAGLE H, 1950, ANN INTERN MED, V33, P544, DOI 10.7326/0003-4819-33-3-544; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Gradelski E, 2001, INT J ANTIMICROB AG, V18, P43, DOI 10.1016/S0924-8579(01)00343-0; Lewis K, 2000, MICROBIOL MOL BIOL R, V64, P503, DOI 10.1128/MMBR.64.3.503-514.2000; Massey RC, 2001, CURR BIOL, V11, P1810, DOI 10.1016/S0960-9822(01)00507-3; Miller C, 2004, SCIENCE, V305, P1629, DOI 10.1126/science.1101630; REGOES RR, UNPUB; Tuomanen E, 1990, Scand J Infect Dis Suppl, V74, P102; WIUFF C, UNPUB	13	58	69	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	2004	305	5690					1578	1579		10.1126/science.1103077	http://dx.doi.org/10.1126/science.1103077			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361616				2022-12-28	WOS:000223891200032
J	Reilly, BM				Reilly, BM			In memoriam	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												breilly@cchil.org							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2004	292	10					1153	1154		10.1001/jama.292.10.1153	http://dx.doi.org/10.1001/jama.292.10.1153			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851ZA	15353516				2022-12-28	WOS:000223723800001
J	McAlister, FA; Ezekowitz, JA; Wiebe, N; Rowe, B; Spooner, C; Crumley, E; Hartling, L; Klassen, T; Abraham, W				McAlister, FA; Ezekowitz, JA; Wiebe, N; Rowe, B; Spooner, C; Crumley, E; Hartling, L; Klassen, T; Abraham, W			Systematic review: Cardiac resynchronization in patients with symptomatic heart failure	ANNALS OF INTERNAL MEDICINE			English	Review							INTRAVENTRICULAR-CONDUCTION DELAY; CHRONIC ATRIAL-FIBRILLATION; LEFT-VENTRICULAR DYSFUNCTION; QUALITY-OF-LIFE; CONTROLLED-TRIALS; TOTAL MORTALITY; ATLAS TRIAL; THERAPY; EXPERIENCE; LONG	Background: Even with optimal pharmacotherapy, symptomatic heart failure is associated with substantial morbidity and mortality. Purpose: To determine the efficacy and safety of cardiac resynchronization therapy in adults with advanced systolic heart failure. Data Sources: The Cochrane Central Register of Controlled Trials (2002, volume 4), MEDLINE (1980-2003), EMBASE (19802003), other electronic databases, and U.S. Food and Drug Administration reports. We contacted primary study authors and device manufacturers, and we hand searched bibliographies of relevant papers and conference proceedings. Study Selection: Randomized, controlled clinical trials for efficacy and controlled trials plus prospective cohort studies for safety. Data Extraction: Two reviewers chose studies and extracted data independently; random-effects models were used for analyses. Data Synthesis: Nine trials were included in the efficacy review (3216 patients). All trial participants had reduced ejection fraction and prolonged QRS duration, and 85% had New York Heart Association (NYHA) class III or IV symptoms. Cardiac resynchronization therapy improved ejection fraction (weighted mean difference, 0.035 [95% CI, 0.015 to 0.055]), quality of life (weighted mean reduction in score on the Minnesota Living with Heart Failure Questionnaire, 7.6 points [CI, 3.8 to 11.5 points]), and function (58% vs. 37% of patients improved by at least 1 NYHA class). Heart failure hospitalizations were reduced by 32% (relative risk [RR], 0.68 [CI, 0.41 to 1.12]), with benefits most marked in patients with NYHA class III or IV symptoms at baseline (RR, 0.65 [CI, 0.48 to 0.88]; number needed to treat for benefit [NNTB], 12). All-cause mortality was reduced by 21% (RR, 0.79 [CI, 0.66 to 0.96]; NNTB, 24), driven largely by reductions in death from progressive heart failure (RR, 0.60 [CI, 0.36 to 1.01]). Eighteen studies (total of 3701 patients with cardiac resynchronization devices) were included in the safety review. Implant success rate was 90% (CI, 89% to 91%), and 0.4% of patients died during implantation (CI, 0.2% to 0.7%). Over a median 6-month follow-up, leads dislodged in 9% of patients (CI, 7% to 10%) and mechanical malfunctions occurred in 7% (CI, 5% to 8%). Limitations: These trials enrolled only patients with heart failure with NYHA class III or IV symptoms despite medical therapy, a prolonged QRS duration, and reduced ejection fraction; in addition, experienced providers implanted the devices. Because all but one of these trials randomly assigned patients after device implantation, their results may overestimate the potential benefits of cardiac resynchronization. Finally, since few patients in these trials had bradyarrhythmias or atrial fibrillation, the role of cardiac resynchronization in such patients is uncertain. Conclusions: in selected patients with heart failure, cardiac resynchronization therapy improves functional and hemodynamic status, reduces heart failure hospitalizations, and reduces all-cause mortality.	Univ Alberta, Edmonton, AB, Canada; Capital Hlth Evidence Based Practice Ctr, Edmonton, AB, Canada; Ohio State Univ, Columbus, OH 43210 USA	University of Alberta; University System of Ohio; Ohio State University	McAlister, FA (corresponding author), Univ Alberta Hosp, 2E3-24,8440 112 St, Edmonton, AB T6G 2R7, Canada.	Finlay.McAlister@ualberta.ca	McAlister, Finlay/C-4151-2013; Ezekowitz, Justin A/C-4579-2013; Wiebe, Natasha/V-7803-2019	McAlister, Finlay/0000-0001-7435-3341; Ezekowitz, Justin A/0000-0002-2724-4086; Wiebe, Natasha/0000-0002-5613-1582; Klassen, Terry/0000-0002-5309-7091; Crumley, Ellen T./0000-0002-5198-6346				Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; Abraham WT, 2002, CURR OPIN CARDIOL, V17, P346, DOI 10.1097/00001573-200207000-00004; Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; *AM HEART ASS, 2002, HEART DIS STOK STAT; Auricchio A, 2002, J AM COLL CARDIOL, V39, P2026, DOI 10.1016/S0735-1097(02)01895-8; Baldasseroni S, 2002, AM HEART J, V143, P398, DOI 10.1067/mhj.2002.121264; Bradley DJ, 2003, JAMA-J AM MED ASSOC, V289, P730, DOI 10.1001/jama.289.6.730; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Brophy JM, 2001, ANN INTERN MED, V134, P550, DOI 10.7326/0003-4819-134-7-200104030-00008; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Cazeau S, 1996, PACE, V19, P1748, DOI 10.1111/j.1540-8159.1996.tb03218.x; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Curtin F, 2002, STAT MED, V21, P2131, DOI 10.1002/sim.1205; Ellenbogen KA, 2003, AM J CARDIOL, V92, P740, DOI 10.1016/S0002-9149(03)00844-0; Ezekowitz JA, 2003, ANN INTERN MED, V138, P445, DOI 10.7326/0003-4819-138-6-200303180-00007; FILHO MM, 2002, ARQ BRAS CARDIOL, V78, P110; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Garrigue S, 2002, HEART, V87, P529, DOI 10.1136/heart.87.6.529; Gras D, 2002, EUR J HEART FAIL, V4, P311, DOI 10.1016/S1388-9842(02)00018-1; Gregoratos G, 2002, J CARDIOVASC ELECTR, V13, P1183; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins SL, 2003, J AM COLL CARDIOL, V42, P1454, DOI 10.1016/S0735-1097(03)01042-8; Hjalmarson A, 2000, JAMA-J AM MED ASSOC, V283, P1295, DOI 10.1001/jama.283.10.1295; Jong P, 2002, ARCH INTERN MED, V162, P1689, DOI 10.1001/archinte.162.15.1689; Kass DA, 2003, J AM COLL CARDIOL, V42, P2125, DOI 10.1016/j.jacc.2003.09.021; Krahn AD, 2002, CAN J CARDIOL, V18, P380; Krum H, 2003, LANCET, V362, P147, DOI 10.1016/S0140-6736(03)13869-X; Kuhlkamp V, 2002, J AM COLL CARDIOL, V39, P790, DOI 10.1016/S0735-1097(01)01819-8; Leclercq C, 2000, AM HEART J, V140, P862, DOI 10.1067/mhj.2000.110570; Leclercq C, 2002, EUR HEART J, V23, P1780, DOI 10.1053/euhj.2002.3232; LECLERQ C, 2003, EUR SOC CARD C VIENN; Leon AR, 2002, J AM COLL CARDIOL, V39, P1258, DOI 10.1016/S0735-1097(02)01779-5; Lloyd-Jones DM, 2002, CIRCULATION, V106, P3068, DOI 10.1161/01.CIR.0000039105.49749.6F; MacIntyre K, 2000, CIRCULATION, V102, P1126, DOI 10.1161/01.CIR.102.10.1126; Massie BM, 1998, LANCET, V352, P29; MCALISTER FA, 2004, IN PRESS J AM COLL C; Medina-Ravell VA, 2003, CIRCULATION, V107, P740, DOI 10.1161/01.CIR.0000048126.07819.37; Mehra MR, 2004, J AM COLL CARDIOL, V43, P1145, DOI 10.1016/j.jacc.2003.10.050; Molhoek SG, 2002, AM J CARDIOL, V90, P379, DOI 10.1016/S0002-9149(02)02493-1; Mortensen PT, 2004, PACE, V27, P339, DOI 10.1111/j.1540-8159.2004.00438.x; Nichol G, 2004, ANN INTERN MED, V141, P343, DOI 10.7326/0003-4819-141-5-200409070-00102; Pablos-Mendez A, 1998, JAMA-J AM MED ASSOC, V279, P222, DOI 10.1001/jama.279.3.222; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Poole-Wilson PA, 2003, HEART, V89, P42, DOI 10.1136/heart.89.1.42; RECTOR TS, 1993, AM J CARDIOL, V71, P1106, DOI 10.1016/0002-9149(93)90582-W; RECTOR TS, 1992, AM HEART J, V124, P1017, DOI 10.1016/0002-8703(92)90986-6; RECTOR TS, 1993, CIRCULATION, V87, P71; Shamim W, 1999, INT J CARDIOL, V70, P171, DOI 10.1016/S0167-5273(99)00077-7; Uretsky BF, 2000, CIRCULATION, V102, P611, DOI 10.1161/01.CIR.102.6.611; Werling C, 2002, THORAC CARDIOV SURG, V50, P67, DOI 10.1055/s-2002-26702; Young JB, 2003, JAMA-J AM MED ASSOC, V289, P2685, DOI 10.1001/jama.289.20.2685	52	227	254	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	2004	141	5					381	390		10.7326/0003-4819-141-5-200409070-00101	http://dx.doi.org/10.7326/0003-4819-141-5-200409070-00101			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CW	15353430				2022-12-28	WOS:000223733800007
J	van Halteren, HK; Bongaerts, GPA; Wagener, DJT				van Halteren, HK; Bongaerts, GPA; Wagener, DJT			Cancer and psychosocial distress: frequent companions	LANCET			English	Editorial Material									Oosterschelde Hosp, Dept Internal Med, Goes, Netherlands; Univ Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands; Univ Med Ctr, Dept Med Oncol, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	van Halteren, HK (corresponding author), Oosterschelde Hosp, Dept Internal Med, Goes, Netherlands.	Hvanhalteren@soz.nl						Carlson LE, 2004, BRIT J CANCER, V90, P2297, DOI 10.1038/sj.bjc.6601887; Derogatis LR, 2001, BSI 18 BRIEF SYMPTOM; National Comprehensive Cancer Network, NCCN CLIN PRACT GUID; Ross L, 2002, EUR J CANCER, V38, P1447, DOI 10.1016/S0959-8049(02)00126-0	4	2	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2004	364	9437					824	825		10.1016/S0140-6736(04)16997-3	http://dx.doi.org/10.1016/S0140-6736(04)16997-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351174				2022-12-28	WOS:000223685200008
J	Ugalde, JA; Chang, BSW; Matz, MV				Ugalde, JA; Chang, BSW; Matz, MV			Evolution of coral pigments recreated	SCIENCE			English	Article							FEATURES		Univ Florida, Whitney Lab, Gainesville, FL 32611 USA; Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA; Univ Chile, Lab Bioinformat & Gene Express, Santiago, Chile; Univ Toronto, Dept Zool, Toronto, ON, Canada	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Universidad de Chile; University of Toronto	Matz, MV (corresponding author), Univ Florida, Whitney Lab, Gainesville, FL 32611 USA.	matz@whitney.ufl.edu	Ugalde, Juan Antonio/GLV-2034-2022; Ugalde, Juan/E-7070-2010; Matz, Mikhail V/K-4392-2017	Ugalde, Juan Antonio/0000-0001-6638-0817; Ugalde, Juan/0000-0001-6638-0817; Matz, Mikhail V/0000-0001-5453-9819				Kelmanson IV, 2003, MOL BIOL EVOL, V20, P1125, DOI 10.1093/molbev/msg130; Lenski RE, 2003, NATURE, V423, P139, DOI 10.1038/nature01568; Miyawaki A, 2003, CURR OPIN CHEM BIOL, V7, P557, DOI 10.1016/S1367-5931(03)00097-8; Shagin DA, 2004, MOL BIOL EVOL, V21, P841, DOI 10.1093/molbev/msh079; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555	5	96	99	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1433	1433		10.1126/science.1099597	http://dx.doi.org/10.1126/science.1099597			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353795				2022-12-28	WOS:000223761900038
J	Beatty, CD; Beirinckx, K; Sherratt, TN				Beatty, CD; Beirinckx, K; Sherratt, TN			The evolution of mullerian mimicry in multispecies communities	NATURE			English	Article							NATURAL-SELECTION; APOSEMATIC PREY; WARNING SIGNALS; COLOR	Prey species that are unprofitable to attack often share conspicuous colours and patterns with other coexisting defended species(1-6). This phenomenon, termed mullerian mimicry(2,3), has long been explained as a consequence of selection on defended prey to adopt a common way of advertising their unprofitability(7,8). However, studies using two unpalatable prey types have not always supported this theory(9-12). Here we show, using a system of humans hunting for computer-generated prey, that predators do not always generate strong selection for mimicry when there are two unprofitable prey types. By contrast, we demonstrate that when predators are faced with a range of different prey species, selection on unprofitable prey to resemble one another can be intense. Here the primary selective force is not one in which predators evaluate the profitabilities of distinct prey types independently, but one in which predators learn better to avoid unprofitable phenotypes that share traits distinguishing them from profitable prey(13,14). This need to simplify decision making readily facilitates the spread of imperfect mimetic forms from rarity, and suggests that mullerian mimicry is more likely to arise in multispecies communities.	Carleton Univ, Dept Biol, Ottawa, ON K1S 5B6, Canada	Carleton University	Sherratt, TN (corresponding author), Carleton Univ, Dept Biol, 1125 Colonel Dr, Ottawa, ON K1S 5B6, Canada.	sherratt@ccs.carleton.ca	Beatty, Christopher/ABE-6438-2020	Beatty, Christopher/0000-0003-2641-0000				Alatalo RV, 1996, NATURE, V382, P708, DOI 10.1038/382708a0; Bates H.W., 1862, T LINN SOC LOND, V23, P495; BEATTY CD, UNPUB ANIM BEHAV; BENSON WW, 1972, SCIENCE, V176, P936, DOI 10.1126/science.176.4037.936; Dukas R, 2002, PHILOS T R SOC B, V357, P1539, DOI 10.1098/rstb.2002.1063; Fisher R.A., 1930, GENETICAL THEORY NAT; Glanville PW, 1997, OIKOS, V80, P565, DOI 10.2307/3546630; Gotmark F, 1995, OIKOS, V74, P475, DOI 10.2307/3545993; GREENWOOD JJD, 1989, BIOL J LINN SOC, V36, P213, DOI 10.1111/j.1095-8312.1989.tb00491.x; GREENWOOD JJD, 1981, HEREDITY, V47, P27, DOI 10.1038/hdy.1981.56; Kapan DD, 2001, NATURE, V409, P338, DOI 10.1038/35053066; Lindstrom L, 2001, P NATL ACAD SCI USA, V98, P9181, DOI 10.1073/pnas.161071598; MacDougall A, 1998, ANIM BEHAV, V55, P1281, DOI 10.1006/anbe.1997.0702; MALLET J, 1995, BIOL J LINN SOC, V55, P159, DOI 10.1111/j.1095-8312.1995.tb01057.x; Mallet J, 1999, ANNU REV ECOL SYST, V30, P201, DOI 10.1146/annurev.ecolsys.30.1.201; Mallet J, 2001, P NATL ACAD SCI USA, V98, P8928, DOI 10.1073/pnas.171326298; MALLET J, 1989, EVOLUTION, V43, P421, DOI 10.1111/j.1558-5646.1989.tb04237.x; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; MULLER F, 1879, P ENTOMOL SOC LOND, pR20; Muller F., 1878, ZOOL ANZ, V1, P54; PEARCE JM, 1994, ANIMAL LEARNING COGN, P110; Poulton EB, 1890, COLOURS ANIMALS THEI; Rowe C, 2004, P ROY SOC B-BIOL SCI, V271, P407, DOI 10.1098/rspb.2003.2615; Ruxton GD, 1998, NATURE, V394, P833, DOI 10.1038/29652; SBORDONI V, 1979, ECOL ENTOMOL, V4, P83, DOI 10.1111/j.1365-2311.1979.tb00563.x; SHEPARD RN, 1961, PSYCHOL MONOGR, V75, P1, DOI 10.1037/h0093825; Sherratt TN, 2003, AM NAT, V162, P377, DOI 10.1086/378047; Shettleworth, 2010, COGNITION EVOLUTION; Symula R, 2001, P ROY SOC B-BIOL SCI, V268, P2415, DOI 10.1098/rspb.2001.1812; TURNER JRG, 1984, BIOL BUTTERFLIES, P141	30	85	85	0	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2004	431	7004					63	67		10.1038/nature02818	http://dx.doi.org/10.1038/nature02818			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343332				2022-12-28	WOS:000223641500041
J	Harbison, CT; Gordon, DB; Lee, TI; Rinaldi, NJ; Macisaac, KD; Danford, TW; Hannett, NM; Tagne, JB; Reynolds, DB; Yoo, J; Jennings, EG; Zeitlinger, J; Pokholok, DK; Kellis, M; Rolfe, PA; Takusagawa, KT; Lander, ES; Gifford, DK; Fraenkel, E; Young, RA				Harbison, CT; Gordon, DB; Lee, TI; Rinaldi, NJ; Macisaac, KD; Danford, TW; Hannett, NM; Tagne, JB; Reynolds, DB; Yoo, J; Jennings, EG; Zeitlinger, J; Pokholok, DK; Kellis, M; Rolfe, PA; Takusagawa, KT; Lander, ES; Gifford, DK; Fraenkel, E; Young, RA			Transcriptional regulatory code of a eukaryotic genome	NATURE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; BINDING-SITES; SEQUENCES; GCN4; PROTEINS; DATABASE; MOTIFS; GENES	DNA-binding transcriptional regulators interpret the genome's regulatory code by binding to specific sequences to induce or repress gene expression(1). Comparative genomics has recently been used to identify potential cis-regulatory sequences within the yeast genome on the basis of phylogenetic conservation(2-6), but this information alone does not reveal if or when transcriptional regulators occupy these binding sites. We have constructed an initial map of yeast's transcriptional regulatory code by identifying the sequence elements that are bound by regulators under various conditions and that are conserved among Saccharomyces species. The organization of regulatory elements in promoters and the environment-dependent use of these elements by regulators are discussed. We find that environment-specific use of regulatory elements predicts mechanistic models for the function of a large population of yeast's transcriptional regulators.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA; Broad Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Young, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	efraenkel@wi.mit.edu; young@wi.mit.edu	Kellis, Manolis/ABE-7385-2020; Rinaldi, Nicola J/J-5858-2017; Young, Richard A/F-6495-2012	Kellis, Manolis/0000-0001-7113-9630; Rinaldi, Nicola J/0000-0002-0358-0747; Young, Richard A/0000-0001-8855-8647; Tagne, Jean-Bosco/0000-0003-1830-9156; Fraenkel, Ernest/0000-0001-9249-8181	NHGRI NIH HHS [R01 HG002668-01, R01 HG002668, R01 HG004037] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002668, R01HG004037] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Albrecht G, 1998, J BIOL CHEM, V273, P12696, DOI 10.1074/jbc.273.21.12696; AXELROD JD, 1991, MOL CELL BIOL, V11, P564, DOI 10.1128/MCB.11.1.564; Bailey T L, 1995, Proc Int Conf Intell Syst Mol Biol, V3, P21; Baur M, 1997, MOL CELL BIOL, V17, P4330, DOI 10.1128/MCB.17.8.4330; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Blanchette M, 2003, NUCLEIC ACIDS RES, V31, P3840, DOI 10.1093/nar/gkg606; Chi Y, 2001, GENE DEV, V15, P1078, DOI 10.1101/gad.867501; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; CUNNINGHAM TS, 1993, J BACTERIOL, V175, P5851, DOI 10.1128/JB.175.18.5851-5861.1993; DONAHUE TF, 1983, CELL, V32, P89, DOI 10.1016/0092-8674(83)90499-3; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; KIRKPATRICK CR, 1995, MOL CELL BIOL, V15, P4021; Knuppel R, 1994, J Comput Biol, V1, P191, DOI 10.1089/cmb.1994.1.191; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Liu XS, 2002, NAT BIOTECHNOL, V20, P835, DOI 10.1038/nbt717; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Pritsker M, 2004, GENOME RES, V14, P99; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Wang T, 2003, BIOINFORMATICS, V19, P2369, DOI 10.1093/bioinformatics/btg329; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Zeitlinger J, 2003, CELL, V113, P395, DOI 10.1016/S0092-8674(03)00301-5; Zhu J, 1999, BIOINFORMATICS, V15, P607, DOI 10.1093/bioinformatics/15.7.607	30	1640	1691	1	115	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2004	431	7004					99	104		10.1038/nature02800	http://dx.doi.org/10.1038/nature02800			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343339	Green Accepted			2022-12-28	WOS:000223641500050
J	McCook, A				McCook, A			Paul H Silverman - Obituary	LANCET			English	Biographical-Item												abmccook@yahoo.com							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	2004	364	9436					752	752		10.1016/S0140-6736(04)16922-5	http://dx.doi.org/10.1016/S0140-6736(04)16922-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15338567				2022-12-28	WOS:000223569600014
J	Schmid, C; Nkunku, S; Merolle, A; Vounatsou, P; Burri, C				Schmid, C; Nkunku, S; Merolle, A; Vounatsou, P; Burri, C			Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness	LANCET			English	Article							TRYPANOSOMA-BRUCEI-GAMBIENSE	In 2000, we reported that a new short treatment schedule of melarsoprol was not worse than the longer and demanding standard treatment for late-stage human African trypanosomiasis. This alternative schedule was assessed in an open, randomised clinical equivalence trial of 500 patients in Angola. 24 h after treatment, all patients were parasite free. Of 442 patients, 12 (3%) had relapsed after 1 year, of whom seven (3%) had had standard treatment and five (2%) the alternative treatment. After 2 years, 23 (5%) relapsing patients were reported, 11 (5%) in the standard treatment group and 12 (6%) in the new group. The results at the 2-year follow-up support and strengthen our previous findings.	Swiss Trop Inst, CH-4002 Basel, Switzerland; WHO, EHA, DES, AFRO, Brazzaville, Rep Congo; Norwegians Peoples Aid, Luanda, Angola	University of Basel; Swiss Tropical & Public Health Institute; World Health Organization	Burri, C (corresponding author), Swiss Trop Inst, CH-4002 Basel, Switzerland.	Christian.Burri@unibas.ch		Vounatsou, Penelope/0000-0002-4904-5352; Burri, Christian/0000-0001-5418-1984				BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; Burri C, 2000, LANCET, V355, P1419, DOI 10.1016/S0140-6736(00)02141-3; Legros D, 1999, T ROY SOC TROP MED H, V93, P439, DOI 10.1016/S0035-9203(99)90151-7; Ruiz JA, 2002, B WORLD HEALTH ORGAN, V80, P738; SKAFF PJA, DESIGN ANAL EQUIVALE; *WHO, 1998, WHO TECH REP SER, V92, P829	6	53	54	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	2004	364	9436					789	+		10.1016/S0140-6736(04)16940-7	http://dx.doi.org/10.1016/S0140-6736(04)16940-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337407				2022-12-28	WOS:000223569600032
J	Goulielmakis, E; Uiberacker, M; Kienberger, R; Baltuska, A; Yakovlev, V; Scrinzi, A; Westerwalbesloh, T; Kleineberg, U; Heinzmann, U; Drescher, M; Krausz, F				Goulielmakis, E; Uiberacker, M; Kienberger, R; Baltuska, A; Yakovlev, V; Scrinzi, A; Westerwalbesloh, T; Kleineberg, U; Heinzmann, U; Drescher, M; Krausz, F			Direct measurement of light waves	SCIENCE			English	Article							ULTRASHORT OPTICAL PULSES; CYCLE REGIME; COMPRESSION; OSCILLATOR; GENERATION; MODULATION; FIELDS; FS	The electromagnetic field of visible light performs similar to10(15) oscillations per second. Although many instruments are sensitive to the amplitude and frequency (or wavelength) of these oscillations, they cannot access the light field itself. We directly observed how the field built up and disappeared in a short, few-cycle pulse of visible laser light by probing the variation of the field strength with a 250-attosecond electron burst. Our apparatus allows complete characterization of few-cycle waves of visible, ultraviolet, and/or infrared light, thereby providing the possibility for controlled and reproducible synthesis of ultrabroadband light waveforms.	Vienna Tech Univ, Inst Photon, A-1040 Vienna, Austria; Univ Bielefeld, Fak Phys, D-33615 Bielefeld, Germany; Max Planck Inst Quantum Opt, D-85748 Garching, Germany	Technische Universitat Wien; University of Bielefeld; Max Planck Society	Goulielmakis, E (corresponding author), Vienna Tech Univ, Inst Photon, Gusshausstr 27, A-1040 Vienna, Austria.		Goulielmakis, Eleftherios/F-1693-2011; Goulielmakis, Eleftherios/AAZ-1052-2020; Baltuska, ANDRIUS/ABE-2033-2020; Yakovlev, Vladislav S/C-4091-2015; Heinzmann, Ulrich/A-6248-2012	Goulielmakis, Eleftherios/0000-0003-3386-0245; Yakovlev, Vladislav S/0000-0002-0648-9375; Kienberger, Reinhard/0000-0001-8781-3685; Baltuska, Andrius/0000-0002-5267-0626				Albert O, 1999, APPL PHYS B-LASERS O, V69, P207, DOI 10.1007/s003400050795; Baltuska A, 2003, NATURE, V421, P611, DOI 10.1038/nature01414; Bandrauk AD, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.283903; Brabec T, 2000, REV MOD PHYS, V72, P545, DOI 10.1103/RevModPhys.72.545; Brabec T, 1997, PHYS REV LETT, V78, P3282, DOI 10.1103/PhysRevLett.78.3282; HANSCH TW, 1990, OPT COMMUN, V80, P71, DOI 10.1016/0030-4018(90)90509-R; Harris SE, 1998, PHYS REV LETT, V81, P2894, DOI 10.1103/PhysRevLett.81.2894; Iaconis C, 1998, OPT LETT, V23, P792, DOI 10.1364/OL.23.000792; KAPLAN AE, 1994, PHYS REV LETT, V73, P1243, DOI 10.1103/PhysRevLett.73.1243; Kienberger R, 2004, NATURE, V427, P817, DOI 10.1038/nature02277; Kobayashi Y, 2000, OPT LETT, V25, P856, DOI 10.1364/OL.25.000856; Nazarkin A, 1999, PHYS REV LETT, V83, P4748, DOI 10.1103/PhysRevLett.83.4748; Paulus GG, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.253004; SHIMODA K, 1995, JPN J APPL PHYS 1, V34, P3566, DOI 10.1143/JJAP.34.3566; SHVERDIN MY, 2004, OSA TRENDS OPTICS PH, V96; Sokolov AV, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.033402; Trebino R, 1997, REV SCI INSTRUM, V68, P3277, DOI 10.1063/1.1148286; Wittmann M, 2000, PHYS REV LETT, V84, P5508, DOI 10.1103/PhysRevLett.84.5508; Yamane K, 2003, OPT LETT, V28, P2258, DOI 10.1364/OL.28.002258; YAMANE K, OSA TRENDS OPTICS PH, V96; YOSHIKAWA S, 1993, OPT COMMUN, V96, P94, DOI 10.1016/0030-4018(93)90530-I	22	527	534	2	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2004	305	5688					1267	1269		10.1126/science.1100866	http://dx.doi.org/10.1126/science.1100866			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850PJ	15333834				2022-12-28	WOS:000223624600034
J	Stein, RS				Stein, RS			Tidat triggering caught in the act	SCIENCE			English	Editorial Material							EARTHQUAKES		US Geol Survey, Menlo Pk, CA 94025 USA	United States Department of the Interior; United States Geological Survey	Stein, RS (corresponding author), US Geol Survey, MS 977, Menlo Pk, CA 94025 USA.	rstein@usgs.gov						BEELER NM, 2003, J GEOPHYS RES, V108; COCHRAN ES, 2003, EOS T AGU S, V84; DIETERICH JH, 1987, TECTONOPHYSICS, V144, P127, DOI 10.1016/0040-1951(87)90012-6; Harris RA, 1998, J GEOPHYS RES-SOL EA, V103, P24347, DOI 10.1029/98JB01576; King GCP, 2001, ADV GEOPHYS, V44, P1, DOI 10.1016/S0065-2687(00)80006-0; KING GCP, 1994, B SEISMOL SOC AM, V84, P935; Scholz CH, 2003, NATURE, V425, P670, DOI 10.1038/425670a; Stein RS, 1999, NATURE, V402, P605, DOI 10.1038/45144; Tanaka S, 2004, EARTH PLANETS SPACE, V56, P511, DOI 10.1186/BF03352510; Tanaka S, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015386; Tolstoy M, 2002, GEOLOGY, V30, P503, DOI 10.1130/0091-7613(2002)030<0503:BOTSTC>2.0.CO;2; TSURUOKA H, 1995, GEOPHYS J INT, V122, P183, DOI 10.1111/j.1365-246X.1995.tb03546.x; Vidale JE, 1998, J GEOPHYS RES-SOL EA, V103, P24567, DOI 10.1029/98JB00594	13	22	26	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2004	305	5688					1248	1249		10.1126/science.1100726	http://dx.doi.org/10.1126/science.1100726			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850PJ	15333829				2022-12-28	WOS:000223624600029
J	Zhang, JS; Kalkum, M; Yamamura, S; Chait, BT; Roeder, RG				Zhang, JS; Kalkum, M; Yamamura, S; Chait, BT; Roeder, RG			E protein silencing by the leukemogenic AML1-ETO fusion protein	SCIENCE			English	Article							LOOP-HELIX PROTEINS; TRANSLOCATION; EXPANSION; LEUKEMIA; TRANSCRIPTION; REGULATORS; EXPRESSION; PROMOTES; BINDING; MODEL	The AML1-ETO fusion protein, generated by the t(8;21) chromosomal translocation, is causally involved in nearly 15% of acute myeloid leukemia (AML) cases. This study shows that AML1-ETO, as well as ETO, inhibits transcriptional activation by E proteins through stable interactions that preclude recruitment of p300/CREB-binding protein (CBP) coactivators. These interactions are mediated by a conserved ETO TAF4 homology domain and a 17-amino acid p300/CBP and ETO target motif within AD1 activation domains of E proteins. In t(8;21) leukemic cells, very stable interactions between AML1-ETO and E proteins underlie a t(8;21) translocation-specific silencing of E protein function through an aberrant cofactor exchange mechanism. These studies identify E proteins as AML1-ETO targets whose dysregulation may be important for t(8;21) leukemogenesis, as well as an E protein silencing mechanism that is distinct from that associated with differentiation-inhibitory proteins.	Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA	Rockefeller University; Rockefeller University	Roeder, RG (corresponding author), Rockefeller Univ, Biochem & Mol Biol Lab, 1230 York Ave, New York, NY 10021 USA.	roeder@mail.rockefeller.edu		Zhang, Jinsong/0000-0002-8798-7316; Kalkum, Markus/0000-0002-9506-671X				Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; Engel I, 2004, EMBO J, V23, P202, DOI 10.1038/sj.emboj.7600017; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Hug BA, 2004, ONCOGENE, V23, P4270, DOI 10.1038/sj.onc.1207674; Hug BA, 2002, CANCER RES, V62, P2906; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; Markus M, 2002, J BIOL CHEM, V277, P6469, DOI 10.1074/jbc.M110659200; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pagliuca A, 2000, CANCER RES, V60, P1376; Quong MW, 2002, ANNU REV IMMUNOL, V20, P301, DOI 10.1146/annurev.immunol.20.092501.162048; Rhoades KL, 2000, BLOOD, V96, P2108; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Scandura JM, 2002, ONCOGENE, V21, P3422, DOI 10.1038/sj.onc.1205315; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Sjogren H, 2000, CANCER RES, V60, P6832; ZHANG J, UNPUB	24	163	170	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2004	305	5688					1286	1289		10.1126/science.1097937	http://dx.doi.org/10.1126/science.1097937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850PJ	15333839				2022-12-28	WOS:000223624600040
J	Schulze, MB; Manson, JE; Ludwig, DS; Colditz, GA; Stampfer, MJ; Willett, WC; Hu, FB				Schulze, MB; Manson, JE; Ludwig, DS; Colditz, GA; Stampfer, MJ; Willett, WC; Hu, FB			Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FRUCTOSE CORN SYRUP; FOOD-FREQUENCY QUESTIONNAIRE; GLYCEMIC INDEX; BODY-WEIGHT; COFFEE CONSUMPTION; PHYSICAL-ACTIVITY; SOFT DRINK; MELLITUS; RISK; VALIDITY	Context Sugar-sweetened beverages like soft drinks and fruit punches contain large amounts of readily absorbable sugars and may contribute to weight gain and an increased risk of type 2 diabetes, but these relationships have been minimally addressed in adults. Objective To examine the association between consumption of sugar-sweetened beverages and weight change and risk of type 2 diabetes in women. Design, Setting, and Participants Prospective cohort analyses conducted from 1991 to 1999 among women in the Nurses' Health Study II. The diabetes analysis included 91249 women free of diabetes and other major chronic diseases at baseline in 1991. The weight change analysis included 51603 women for whom complete dietary information and body weight were ascertained in 1991, 1995, and 1999. We identified 741 incident cases of confirmed type 2 diabetes during 716300 person-years of follow-up. Main Outcome Measures Weight gain and incidence of type 2 diabetes. Results Those with stable consumption patterns had no difference in weight gain, but weight gain over a 4-year period was highest among women who increased their sugar-sweetened soft drink consumption from 1 or fewer drinks per week to 1 or more drinks per day (multivariate-adjusted means, 4.69 kg for 1991 to 1995 and 4.20 kg for 1995 to 1999) and was smallest among women who decreased their intake (1.34 and 0.15 kg for the 2 periods, respectively) after adjusting for lifestyle and dietary confounders. increased consumption of fruit punch was also associated with greater weight gain compared with decreased consumption. After adjustment for potential confounders, women consuming 1 or more sugar-sweetened soft drinks per day had a relative risk [RR] of type 2 diabetes of 1.83 (95% confidence interval [CI], 1.42-2.36; P<.001 for trend) compared with those who consumed less than 1 of these beverages per month. Similarly, consumption of fruit punch was associated with increased diabetes risk (RR for &GE;1 drink per day compared with <1 drink per month, 2.00; 95% Cl, 1.33-3.03; P=.001). Conclusion Higher consumption of sugar-sweetened beverages is associated with a greater magnitude of weight gain and an increased risk for development of type 2 diabetes in women, possibly by providing excessive calories and large amounts of rapidly absorbable sugars.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Div Prevent Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Childrens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Schulze, MB (corresponding author), German Inst Human Nutr, Dept Epidemiol, Arthur Scheunert Allee 114-116, D-14558 Nuthetal, Germany.	mschulze@channing.harvard.edu	Hu, Frank/C-1919-2013; Colditz, Graham/A-3963-2009; Schulze, Matthias B/AAH-6906-2021	Colditz, Graham/0000-0002-7307-0291; Schulze, Matthias B/0000-0002-0830-5277; Ludwig, David/0000-0003-3307-8544	NATIONAL CANCER INSTITUTE [R01CA050385] Funding Source: NIH RePORTER; NCI NIH HHS [CA50385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; AKGUN S, 1985, DIABETES CARE, V8, P279, DOI 10.2337/diacare.8.3.279; Almiron-Roig E, 2003, PHYSIOL BEHAV, V79, P767, DOI 10.1016/S0031-9384(03)00212-9; [Anonymous], 2003, MMWR-MORBID MORTAL W, V52, P833; Beridot-Therond ME, 1998, APPETITE, V31, P67, DOI 10.1006/appe.1997.0153; Bray GA, 2004, AM J CLIN NUTR, V79, P537; Centre for Disease Control and Prevention, 2002, NAT DIAB FACT SHEET; DECASTRO JM, 1993, PHYSIOL BEHAV, V53, P1133, DOI 10.1016/0031-9384(93)90370-U; DiMeglio DP, 2000, INT J OBESITY, V24, P794, DOI 10.1038/sj.ijo.0801229; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; Foster-Powell K, 2002, AM J CLIN NUTR, V76, P5, DOI 10.1093/ajcn/76.1.5; French SA, 2003, J AM DIET ASSOC, V103, P1326, DOI 10.1016/S0002-8223(03)01076-9; Gavin JR, 1997, DIABETES CARE, V20, P1183; HARRIS M, 1979, DIABETES, V28, P1039; Hofmann SM, 2002, DIABETES, V51, P2082, DOI 10.2337/diabetes.51.7.2082; Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849; Hu FB, 1999, AM J CLIN NUTR, V69, P243; Janssens JP, 1999, EUR J CANCER PREV, V8, P289, DOI 10.1097/00008469-199908000-00004; Kuczmarski MF, 2001, J AM DIET ASSOC, V101, P28, DOI 10.1016/S0002-8223(01)00008-6; Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Mokdad AH, 2000, DIABETES CARE, V23, P1278, DOI 10.2337/diacare.23.9.1278; PUTNAM JJ, STAT B FOOD RURAL EC, V965; Raben A, 2002, AM J CLIN NUTR, V76, P721, DOI 10.1093/ajcn/76.4.721; ROLLS BJ, 1990, PHYSIOL BEHAV, V48, P19, DOI 10.1016/0031-9384(90)90254-2; Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; Schulze MB, 2004, AM J CLIN NUTR, V80, P348, DOI 10.1093/ajcn/80.2.348; SCLAFANI A, 1991, BRAIN RES BULL, V27, P383, DOI 10.1016/0361-9230(91)90129-8; TORDOFF MG, 1990, AM J CLIN NUTR, V51, P963, DOI 10.1093/ajcn/51.6.963; *USDA, 1992, COMP FOODS RAW PROC; van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X; Vlassara H, 2002, P NATL ACAD SCI USA, V99, P15596, DOI 10.1073/pnas.242407999; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; Willett W, 2002, AM J CLIN NUTR, V76, p274S, DOI 10.1093/ajcn/76.1.274S; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991	38	1071	1112	3	213	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2004	292	8					927	934		10.1001/jama.292.8.927	http://dx.doi.org/10.1001/jama.292.8.927			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WR	15328324				2022-12-28	WOS:000223429200017
J	Biason-Lauber, A; Konrad, D; Navratil, F; Schoenle, EJ				Biason-Lauber, A; Konrad, D; Navratil, F; Schoenle, EJ			A WNT4 mutation associated with Mullerian-duct regression and virilization in a 46,XX woman	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANDROGEN; PROTEINS; DOMAIN; GENE	WNT4, a secreted protein that suppresses male sexual differentiation, is thought to repress the biosynthesis of gonadal androgen in female mammals. An 18-year-old woman presented with primary amenorrhea and an absence of mullerian-derived structures, unilateral renal agenesis, and clinical signs of androgen excess - a phenotype resembling the Mayer - Rokitansky - Kuster - Hauser syndrome and remarkably similar to that of female Wnt4 - knockout mice. A genetic evaluation revealed a loss-of-function mutation in the WNT4 gene. WNT4 appears to be important in the development and maintenance of the female phenotype in women, by means of the regulation of mullerian-duct formation and control of ovarian steroidogenesis.	Univ Childrens Hosp, Div Pediat Endocrinol & Diabetol, CH-8032 Zurich, Switzerland	University Children's Hospital Zurich	Biason-Lauber, A (corresponding author), Univ Childrens Hosp, Div Pediat Endocrinol & Diabetol, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	anna.lauber@kispi.unizh.ch		Konrad, Daniel/0000-0001-9067-4356				Biason-Lauber A, 2000, ENDOCRINOLOGY, V141, P1446, DOI 10.1210/en.141.4.1446; Biason-Lauber A, 2002, DIABETES, V51, P2301, DOI 10.2337/diabetes.51.7.2301; Brisken C, 2000, GENE DEV, V14, P650; BRYAN AL, 1949, SURG GYNECOL OBSTET, V88, P79; CUI KH, 1994, LANCET, V343, P79, DOI 10.1016/S0140-6736(94)90815-X; Domenice S, 2004, BRAZ J MED BIOL RES, V37, P145, DOI 10.1590/S0100-879X2004000100020; HAMILTON TC, 1983, CANCER RES, V43, P5379; Jeays-Ward K, 2003, DEVELOPMENT, V130, P3663, DOI 10.1242/dev.00591; Jordan BK, 2001, AM J HUM GENET, V68, P1102, DOI 10.1086/320125; Lindner TH, 1999, HUM MOL GENET, V8, P2001, DOI 10.1093/hmg/8.11.2001; MacLaughlin DT, 2004, NEW ENGL J MED, V350, P367, DOI 10.1056/NEJMra022784; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; OPITZ JM, 1987, AM J MED GENET, V26, P873, DOI 10.1002/ajmg.1320260414; Rosa S, 2002, J CLIN ENDOCR METAB, V87, P4378, DOI 10.1210/jc.2002-020139; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611	17	275	326	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2004	351	8					792	798		10.1056/NEJMoa040533	http://dx.doi.org/10.1056/NEJMoa040533			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847CY	15317892				2022-12-28	WOS:000223367900011
J	Wilga, CD; Lauder, GV				Wilga, CD; Lauder, GV			Biomechanics - Hydrodynamic function of the shark's tail	NATURE			English	Editorial Material							CAUDAL FIN LOCOMOTION; HETEROCERCAL TAIL; WAKE DYNAMICS; FISHES		Univ Rhode Isl, Dept Biol Sci, Kingston, RI 02881 USA; Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA	University of Rhode Island; Harvard University	Wilga, CD (corresponding author), Univ Rhode Isl, Dept Biol Sci, Kingston, RI 02881 USA.	cwilga@uri.edu						ALEXANDER RM, 1965, J EXP BIOL, V43, P131; Drucker EG, 1999, J EXP BIOL, V202, P2393; Ferry LA, 1996, J EXP BIOL, V199, P2253; GROVE A. J., 1936, ANN AND MAG NAT HIST, V17, P280; Lauder GV, 2000, AM ZOOL, V40, P101, DOI 10.1668/0003-1569(2000)040[0101:FOTCFD]2.0.CO;2; LAUDER GV, 1989, AM ZOOL, V29, P85; Nauen JC, 2002, J EXP BIOL, V205, P1709; THOMSON K S, 1976, Paleobiology, V2, P19; Webster DR, 1998, PHYS FLUIDS, V10, P400, DOI 10.1063/1.869531; Webster DR, 1997, PHYS FLUIDS, V9, P655, DOI 10.1063/1.869223; Wilga CD, 2002, J EXP BIOL, V205, P2365	11	78	80	9	164	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2004	430	7002					850	850		10.1038/430850a	http://dx.doi.org/10.1038/430850a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318211	Bronze			2022-12-28	WOS:000223369800031
J	Dellasega, C				Dellasega, C			Healing in spaces	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												cdellasega@psu.edu							0	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2004	292	7					780	780		10.1001/jama.292.7.780	http://dx.doi.org/10.1001/jama.292.7.780			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847FO	15315979				2022-12-28	WOS:000223378300001
J	Harling, R; Hayward, A; Watson, JM				Harling, R; Hayward, A; Watson, JM			Implications of the incidence of influenza-like illness in nursing homes for influenza chemoprophylaxis: descriptive study	BRITISH MEDICAL JOURNAL			English	Article									UCL, Royal Free Hosp, Ctr Infect Dis Epidemiol, Dept Primary Care & Populat Sci, London NW3 2PF, England; Hlth Protect Agcy, Ctr Communicable Dis Surveillance, Dept Resp Dis, London NW9 5EQ, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Health Protection Agency	Harling, R (corresponding author), UCL, Royal Free Hosp, Ctr Infect Dis Epidemiol, Dept Primary Care & Populat Sci, London NW3 2PF, England.	r.harling@pcps.ucl.ac.uk	Hayward, Andrew C/C-3268-2013	Hayward, Andrew C/0000-0002-3549-6232				Cooper NJ, 2003, BRIT MED J, V326, P1235, DOI 10.1136/bmj.326.7401.1235; Department of Health, 2002, RES CAR NURS HOM SEC; Govaert TME, 1998, FAM PRACT, V15, P16, DOI 10.1093/fampra/15.1.16; *HLTH PROT AG, HPA NAT SURV INFL WE; *NAT I CLIN EXC, 2003, TECHN APPR GUID, V67	5	12	12	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 18	2004	329	7467					663	664		10.1136/bmj.38204.674595.AE	http://dx.doi.org/10.1136/bmj.38204.674595.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	856JU	15333451	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000224042300022
J	Morrow, AL; Dawodu, A				Morrow, AL; Dawodu, A			Influencing birth outcomes in Nepal	LANCET			English	Editorial Material							HEALTH; MORTALITY		Childrens Hosp, Med Ctr, Ctr Biostat & Epidemiol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Morrow, AL (corresponding author), Childrens Hosp, Med Ctr, Ctr Biostat & Epidemiol, Cincinnati, OH 45229 USA.	ardythe.morrow@chmcc.org	Morrow, Ardythe/GQO-8482-2022; dawodu, adekunle/M-9985-2014	dawodu, adekunle/0000-0002-2050-800X				Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; Bhandari N, 2003, LANCET, V361, P1418, DOI 10.1016/S0140-6736(03)13134-0; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Claeson M, 2003, LANCET, V362, P323, DOI 10.1016/S0140-6736(03)13977-3; Ensor T, 2004, HEALTH POLICY PLANN, V19, P69, DOI 10.1093/heapol/czh009; HOWARDGRABMAN L, 2002, MOTHERCARE SAVE CHIL; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Morgan LM, 2001, HEALTH POLICY PLANN, V16, P221, DOI 10.1093/heapol/16.3.221; Morrow AL, 1999, LANCET, V353, P1226, DOI 10.1016/S0140-6736(98)08037-4; Pradhan Elizabeth Kimbrough, 1994, Controlled Clinical Trials, V15, P220; United Nations General Assembly, 2001, A56326 UN GEN ASS; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7	12	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	2004	364	9438					914	915		10.1016/S0140-6736(04)17036-0	http://dx.doi.org/10.1016/S0140-6736(04)17036-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364172				2022-12-28	WOS:000223831000005
J	Cho, BK; Jain, A; Gruner, SM; Wiesner, U				Cho, BK; Jain, A; Gruner, SM; Wiesner, U			Mesophase structure-mechanical and ionic transport correlations in extended amphiphilic dendrons	SCIENCE			English	Article							SPHERICAL SUPRAMOLECULAR DENDRIMERS; POLY(PROPYLENE IMINE) DENDRIMERS; DISORDERED MICELLE REGIME; DENDRITIC MACROMOLECULES; DIBLOCK COPOLYMERS; PHASE-BEHAVIOR; MICROPHASE SEPARATION; ORDER; POLYMERS; ELECTROLYTES	We have studied the self-assembly of amphiphilic dendrons extended with linear polyethylene oxide (PEO) chains and their ion complexes. Keeping the dendron core and linear PEO chain compatible allows for the combination of dendritic core-shell and conventional block copolymer characteristics for complex mesophase behavior. An unexpected sequence of crystalline lamellar, cubic micellar (Pm (3) over barn), hexagonal columnar, continuous cubic (la (3) over bard), and lamellar mesophases is observed. Multiple phase behavior within single compounds allows for the study of charge transport and mechanical property correlations as a function of structure. The results suggest an advanced molecular design concept for the next generation of nanostructured materials in applications involving charge transport.	Cornell Univ, Dept Mat Sci & Engn, Ithaca, NY 14853 USA; Cornell Univ, Dept Phys, Ithaca, NY 14853 USA	Cornell University; Cornell University	Wiesner, U (corresponding author), Cornell Univ, Dept Mat Sci & Engn, Ithaca, NY 14853 USA.	ubw1@cornell.edu	Gruner, Sol/G-2924-2010	Gruner, Sol/0000-0002-1171-4426				Balagurusamy VSK, 1997, J AM CHEM SOC, V119, P1539, DOI 10.1021/ja963295i; Borisch K, 1996, CHEM COMMUN, P237, DOI 10.1039/cc9960000237; Bosman AW, 1999, CHEM REV, V99, P1665, DOI 10.1021/cr970069y; BUHLEIER E, 1978, SYNTHESIS-STUTTGART, P155; Cameron JH, 1997, ADV MATER, V9, P398, DOI 10.1002/adma.19970090507; Cho BK, 2004, MACROMOLECULES, V37, P4227, DOI 10.1021/ma035745e; Cho BK, 2004, J AM CHEM SOC, V126, P4070, DOI 10.1021/ja0318986; Demus D., 2011, HDB LIQUID CRYSTALS; Dormidontova EE, 2001, MACROMOLECULES, V34, P9143, DOI 10.1021/ma010098h; Epps TH, 2003, MACROMOLECULES, V36, P2873, DOI 10.1021/ma021231o; GITSOV I, 1993, MACROMOLECULES, V26, P5621, DOI 10.1021/ma00073a014; Grason GM, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.058304; Grayson SM, 2001, CHEM REV, V101, P3819, DOI 10.1021/cr990116h; Hamley I. W., 1998, PHYS BLOCK COPOLYMER; HAWKER CJ, 1990, J AM CHEM SOC, V112, P7638, DOI 10.1021/ja00177a027; Hillmyer MA, 1996, SCIENCE, V271, P976, DOI 10.1126/science.271.5251.976; Hudson SD, 1997, SCIENCE, V278, P449, DOI 10.1126/science.278.5337.449; ISRAELACHVILI JN, 1976, J CHEM SOC FARAD T 2, V72, P1525, DOI 10.1039/f29767201525; Jayaraman M, 1998, J AM CHEM SOC, V120, P12996, DOI 10.1021/ja983229b; Johnson MA, 2004, MACROMOLECULES, V37, P2490, DOI 10.1021/ma030450m; Kishimoto K, 2003, J AM CHEM SOC, V125, P3196, DOI 10.1021/ja029750u; Kosonen H, 2002, MACROMOLECULES, V35, P10149, DOI 10.1021/ma0201577; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; Lorenz K, 1997, MACROMOLECULES, V30, P6860, DOI 10.1021/ma970282w; Mackay ME, 2002, MACROMOLECULES, V35, P8391, DOI 10.1021/ma0204608; Ohtake T, 2000, CHEM MATER, V12, P782, DOI 10.1021/cm990706w; Percec V, 1998, NATURE, V391, P161, DOI 10.1038/34384; Percec V, 2002, NATURE, V419, P384, DOI 10.1038/nature01072; Roman C, 1999, MACROMOLECULES, V32, P5525, DOI 10.1021/ma990212k; Ruokolainen J, 1998, SCIENCE, V280, P557, DOI 10.1126/science.280.5363.557; Soo PP, 1999, J ELECTROCHEM SOC, V146, P32, DOI 10.1149/1.1391560; Stupp SI, 1997, SCIENCE, V276, P384, DOI 10.1126/science.276.5311.384; TOMALIA DA, 1985, POLYM J, V17, P117, DOI 10.1295/polymj.17.117; Tsiourvas D, 2002, MACROMOLECULES, V35, P1746, DOI 10.1021/ma010933v; Ungar G, 2003, SCIENCE, V299, P1208, DOI 10.1126/science.1078849; Wang XH, 2002, MACROMOLECULES, V35, P9687, DOI 10.1021/ma021009j; Wright PV, 1998, POLYM INT, V47, P34, DOI 10.1002/(SICI)1097-0126(199809)47:1<34::AID-PI2>3.0.CO;2-G; Zeng XB, 2004, NATURE, V428, P157, DOI 10.1038/nature02368; Zhao J, 1996, MACROMOLECULES, V29, P1204, DOI 10.1021/ma9507251	39	357	360	4	175	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2004	305	5690					1598	1601		10.1126/science.1100872	http://dx.doi.org/10.1126/science.1100872			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361620				2022-12-28	WOS:000223891200037
J	Fisher, B; Jeong, JH; Bryant, J; Anderson, S; Dignam, J; Fisher, ER; Wolmark, N				Fisher, B; Jeong, JH; Bryant, J; Anderson, S; Dignam, J; Fisher, ER; Wolmark, N			Treatment of lymph-node-negative, oestrogen-recept-postive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials	LANCET			English	Article							PROGESTERONE-RECEPTOR; CHEMOTHERAPY; TAMOXIFEN; COMBINATION; REGRESSION; THERAPY; PATIENT	Background Findings from the National Surgical Adjuvant Breast and Bowel Project B-14 and B-20 trials showed that tamoxifen benefited women with oestrogen-receptor-positive tumours and negative axillary nodes, and that chemotherapy plus tamoxifen was more effective than tamoxifen alone. We present long-term findings from those trials and relate them to age, menopausal status, and tumour oestrogen-receptor concentrations. We also discuss the extent of progress made in the treatment of such patients. Methods B-14 patients were randomly assigned to placebo (n=1453) or tamoxifen (n=1439); B-20 patients to tamoxifen (n=788) or cyclophosphamide, methotrexate, fluorouracil, and tamoxifen (CMFT, n=789). Primary endpoints were recurrence-free survival and overall survival estimated according to patients' age, menopausal status, and tumour oestrogen-receptor concentration. Smoothed recurrence rates were used to measure patterns of recurrence as a continuous function of age. Findings Compared with placebo, tamoxifen benefited women in B-14 through 15 years, irrespective of age, menopausal status, or tumour oestrogen-receptor concentration (hazard ratio [HR] for recurrence-free survival 0.58, 95% CI 0.50-0.67, p<0.0001; HR for overall survival 0.80, 0.71-0.91, p=0.0008). In B-20, the benefit from CMFT over 12 years was greater than that from tamoxifen alone (HR for recurrence-free survival 0.52, 0.39-0.68, p<0.0001; HR for overall survival 0.78, 0.60-1.01, p=0.063). When CMFT was compared with placebo, there were reductions in treatment failure of about 65% in all age-groups. Interpretation Much benefit has been achieved in treatment of women with oestrogen-receptor-positive tumours and negative nodes. When planning systemic therapy for such patients of all ages, it should be understood that some have tumours with variable concentrations of oestrogen-receptors, a surrogate for other biomarkers associated with tumour growth and response to treatment. Older women tend to have higher tumour oestrogen-receptor concentrations and are more likely to benefit from tamoxifen than from chemotherapy; in younger women, the converse is true. Consequently, the notion that use of tamoxifen or chemotherapy should be based only on age is too restrictive.	Natl Surg Adjuvant Breast & Bowel Project, Operat Ctr, Pittsburgh, PA USA; Natl Surg Adjuvant Breast & Bowel Project, Ctr Biostat, Pittsburgh, PA USA; Natl Surg Adjuvant Breast & Bowel Project, Pathol Ctr, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project	Fisher, B (corresponding author), 4 Allegheny Ctr,Suite 602, Pittsburgh, PA 15212 USA.	bernard.fisher@nsabp.org		Anderson, Stewart/0000-0001-8948-0650; Jeong, Jong/0000-0003-0596-2201	NCI NIH HHS [U10-CA-37377, U10-CA-69974, U10-CA-69651, U10-CA-12027] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA037377, U10CA069651, U10CA069974, U10CA012027] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe O, 1998, LANCET, V352, P930; BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; Bonetti M, 2000, STAT MED, V19, P2595, DOI 10.1002/1097-0258(20001015)19:19<2595::AID-SIM562>3.0.CO;2-M; Bryant J, 1998, BREAST CANCER RES TR, V51, P239, DOI 10.1023/A:1006184428857; CARBONE PP, 1977, ADV RES TREATMENT, P165; CastiglioneGertsch M, 1997, J CLIN ONCOL, V15, P1385, DOI 10.1200/JCO.1997.15.4.1385; Clarke M, 1998, LANCET, V351, P1451; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; COX DR, 1972, J R STAT SOC B, V34, P187; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.2307/2334377; FISHER B, 1983, J CLIN ONCOL, V1, P227, DOI 10.1200/JCO.1983.1.4.227; FISHER B, 1990, J CLIN ONCOL, V8, P1005, DOI 10.1200/JCO.1990.8.6.1005; Fisher B, 1992, J Natl Cancer Inst Monogr, P105; Fisher B, 1997, JNCI-J NATL CANCER I, V89, P1673, DOI 10.1093/jnci/89.22.1673; FISHER B, 1983, J CLIN ONCOL, V1, P349, DOI 10.1200/JCO.1983.1.6.349; Fisher B, 2001, J Natl Cancer Inst Monogr, P62; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; FISHER B, 1983, BREAST CANCER RES TR, V3, P355, DOI 10.1007/BF01807588; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FISHER B, 1986, BREAST CANCER RES TR, V7, P147, DOI 10.1007/BF01806245; FISHER B, 1980, CANCER RES, V40, P3863; Fisher E R, 1992, J Natl Cancer Inst Monogr, P151; Fisher E R, 1981, Breast Cancer Res Treat, V1, P37, DOI 10.1007/BF01807890; Fisher E R, 1980, Pathol Annu, V15, P239; FISHER ER, 1983, CANCER-AM CANCER SOC, V51, P181, DOI 10.1002/1097-0142(19830115)51:2<181::AID-CNCR2820510202>3.0.CO;2-A; Goldhirsch A, 2002, JNCI-J NATL CANCER I, V94, P1054; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; LIPPMAN ME, 1978, NEW ENGL J MED, V298, P1223, DOI 10.1056/NEJM197806012982203; Lundin J, 2001, J CLIN ONCOL, V19, P28, DOI 10.1200/JCO.2001.19.1.28; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCGUIRE WL, 1977, CANCER-AM CANCER SOC, V39, P2934, DOI 10.1002/1097-0142(197706)39:6<2934::AID-CNCR2820390680>3.0.CO;2-P; MEYER JS, 1977, CANCER, V40, P2290, DOI 10.1002/1097-0142(197711)40:5<2290::AID-CNCR2820400541>3.0.CO;2-T; Mirza AN, 2002, ANN SURG, V235, P10, DOI 10.1097/00000658-200201000-00003	34	261	276	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2004	364	9437					858	868		10.1016/S0140-6736(04)16981-X	http://dx.doi.org/10.1016/S0140-6736(04)16981-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351193				2022-12-28	WOS:000223685200032
J	Welt, CK; Chan, JL; Bullen, J; Murphy, R; Smith, P; DePaoli, AM; Karalis, A; Mantzoros, CS				Welt, CK; Chan, JL; Bullen, J; Murphy, R; Smith, P; DePaoli, AM; Karalis, A; Mantzoros, CS			Recombinant human leptin in women with hypothalamic amenorrhea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GONADOTROPIN-RELEASING-HORMONE; ANOREXIA-NERVOSA; BONE METABOLISM; BODY-FAT; NEUROENDOCRINE; OBESITY; DEFICIENCY; THERAPY; WEIGHT; ONSET	BACKGROUND: Disruptions in hypothalamic-gonadal and other endocrine axes due to energy deficits are associated with low levels of the adipocyte-secreted hormone leptin and may result in hypothalamic amenorrhea. We hypothesized that exogenous recombinant leptin replacement would improve reproductive and neuroendocrine function in women with hypothalamic amenorrhea. METHODS: Eight women with hypothalamic amenorrhea due to strenuous exercise or low weight were studied for one month before receiving recombinant human leptin and then while receiving treatment for up to three months. Six control subjects with hypothalamic amenorrhea received no treatment and were studied for a mean (+/-SD) of 8.5+/-8.1 months. RESULTS: Luteinizing hormone (LH) pulsatility, body weight, ovarian variables, and hormone levels did not change significantly over time in the controls and during a one-month control period before recombinant leptin therapy in the treated subjects. In contrast, recombinant leptin treatment increased mean LH levels and LH pulse frequency after two weeks and increased maximal follicular diameter, the number of dominant follicles, ovarian volume, and estradiol levels over a period of three months. Three patients had an ovulatory menstrual cycle (P<0.05 for the comparison with an expected rate of spontaneous ovulation of 10 percent); two others had preovulatory follicular development and withdrawal bleeding during treatment (P<0.05). Recombinant leptin significantly increased levels of free triiodothyronine, free thyroxine, insulin-like growth factor 1, insulin-like growth factor-binding protein 3, bone alkaline phosphatase, and osteocalcin but not cortisol, corticotropin, or urinary N-telopeptide. CONCLUSIONS: Leptin administration for the relative leptin deficiency in women with hypothalamic amenorrhea appears to improve reproductive, thyroid, and growth hormone axes and markers of bone formation, suggesting that leptin, a peripheral signal reflecting the adequacy of energy stores, is required for normal reproductive and neuroendocrine function.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Endocrinol Diabet & Metab, Boston, MA 02215 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Reprod Endocrine Unit, Boston, MA USA; Amgen Inc, Thousand Oaks, CA 91320 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Amgen	Mantzoros, CS (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Endocrinol Diabet & Metab, 330 Brookline Ave,Stoneman 816, Boston, MA 02215 USA.	cmantzor@bidmc.harvard.edu	Mantzoros, Christos/Y-2902-2019; Karalis, Aspasia/GXH-9840-2022	Welt, Corrine/0000-0002-8219-5504	NCRR NIH HHS [M01-RR-01032, M01-RR-1066] Funding Source: Medline; NHLBI NIH HHS [K30-HL-04095] Funding Source: Medline; NIDDK NIH HHS [P30 DK40561, DK-58785] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066, M01RR001032] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K30HL004095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058785, P30DK040561, R56DK058785] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Barbieri RL, 2000, 6 STEPS INCREASED FE; Chan JL, 2003, J CLIN INVEST, V111, P1409, DOI 10.1172/JCI200317490; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cock TA, 2003, LANCET, V362, P1572, DOI 10.1016/S0140-6736(03)14747-2; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; FRISCH RE, 1974, SCIENCE, V185, P949, DOI 10.1126/science.185.4155.949; FRISCH RE, 1993, J CLIN ENDOCR METAB, V77, P471, DOI 10.1210/jc.77.2.471; Grinspoon S, 2002, J CLIN ENDOCR METAB, V87, P2883, DOI 10.1210/jc.87.6.2883; Hayes FJ, 1999, J CLIN ENDOCR METAB, V84, P1028, DOI 10.1210/jc.84.3.1028; Laughlin GA, 1997, J CLIN ENDOCR METAB, V82, P318, DOI 10.1210/jc.82.1.318; Laughlin GA, 1996, J CLIN ENDOCR METAB, V81, P4301, DOI 10.1210/jc.81.12.4301; Loucks AB, 1998, J APPL PHYSIOL, V84, P37, DOI 10.1152/jappl.1998.84.1.37; Macklon NS, 1999, HORM RES, V52, P161, DOI 10.1159/000023456; Miller KK, 1998, J CLIN ENDOCR METAB, V83, P2309, DOI 10.1210/jc.83.7.2309; Miller KK, 1999, J CLIN ENDOCR METAB, V84, P1775, DOI 10.1210/jc.84.6.1775; Misra M, 2003, J CLIN ENDOCR METAB, V88, P5615, DOI 10.1210/jc.2003-030532; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Oral EA, 2002, J CLIN ENDOCR METAB, V87, P3110, DOI 10.1210/jc.87.7.3110; PACHE TD, 1990, FERTIL STERIL, V54, P638; Perkins RB, 2001, HUM REPROD, V16, P2198, DOI 10.1093/humrep/16.10.2198; Perkins RB, 1999, J CLIN ENDOCR METAB, V84, P1905, DOI 10.1210/jc.84.6.1905; Plant TM, 2004, HUM REPROD UPDATE, V10, P67, DOI 10.1093/humupd/dmh001; REAME NE, 1985, J CLIN ENDOCR METAB, V61, P851, DOI 10.1210/jcem-61-5-851; REINDOLLAR RH, 1986, AM J OBSTET GYNECOL, V155, P531, DOI 10.1016/0002-9378(86)90274-7; Rosenbaum M, 2002, J CLIN ENDOCR METAB, V87, P2391, DOI 10.1210/jc.87.5.2391; SANTORO N, 1986, ENDOCR REV, V7, P11, DOI 10.1210/edrv-7-1-11; Simha V, 2002, J CLIN ENDOCR METAB, V87, P4942, DOI 10.1210/jc.2002-020792; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; TAYLOR AE, 1994, J CLIN ENDOCR METAB, V79, P240, DOI 10.1210/jc.79.1.240; Thong FSL, 2000, J APPL PHYSIOL, V88, P2037, DOI 10.1152/jappl.2000.88.6.2037; VELDHUIS JD, 1986, AM J PHYSIOL, V250, pE486, DOI 10.1152/ajpendo.1986.250.4.E486; Warren MP, 1999, J CLIN ENDOCR METAB, V84, P873, DOI 10.1210/jc.84.3.873; Welt CK, 1999, J CLIN ENDOCR METAB, V84, P105, DOI 10.1210/jc.84.1.105; Wong SL, 2004, J CLIN ENDOCR METAB, V89, P2672, DOI 10.1210/jc.2003-031931; YEN SSC, 1993, ENDOCRIN METAB CLIN, V22, P29, DOI 10.1016/S0889-8529(18)30179-8; ZHANG YY, 1995, NATURE, V374, P479, DOI 10.1038/374479a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	40	584	608	1	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2004	351	10					987	997		10.1056/NEJMoa040388	http://dx.doi.org/10.1056/NEJMoa040388			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	850UB	15342807				2022-12-28	WOS:000223637400009
J	Brennan, TA; Horwitz, RI; Duffy, FD; Cassel, CK; Goode, LD; Lipner, RS				Brennan, TA; Horwitz, RI; Duffy, FD; Cassel, CK; Goode, LD; Lipner, RS			The role of physician specialty board certification status in the quality movement	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CERTIFYING EXAMINATION; AMERICAN-BOARD; MEDICAL KNOWLEDGE; INTERNAL-MEDICINE; PATIENT OUTCOMES; RECERTIFICATION; PERFORMANCE; CARE; MORTALITY; SCORES	The Institute of Medicine's reports and discussions on quality of medical care have focused on a systems-based approach to quality improvement. Our objective is to summarize evidence and theory about the role of a physician's current board certification status in quality improvement. The first body of evidence includes the validity of board certification demonstrated by the testing process, the relationship of examination scores with other measures of physician competence, and the relationship between certification status and clinical outcomes. The second body of evidence involves the adaptation of error prevention theory to medical care. Patient safety is enhanced when problem-solving uses readily accessed habits of behavior, the same behavior necessary to achieve board certification. The third body of evidence, obtained through a Gallup poll, demonstrates that certification and maintenance of certification are highly valued by the public. The majority of respondents thought it important for physicians to be reevaluated on their qualifications every few years and that physicians should do more to demonstrate ongoing competence than is currently required by the profession. We conclude that a physician's current certification status should be among the evidence-based measures used in the quality movement.	Brigham & Womens Hosp, Brigham & Womens Phys Org, Boston, MA 02115 USA; Amer Board Internal Med, Philadelphia, PA USA; Case Western Reserve Univ, Sch Med, Cleveland, OH USA	Harvard University; Brigham & Women's Hospital; American Board of Internal Medicine; Case Western Reserve University	Brennan, TA (corresponding author), Brigham & Womens Hosp, Brigham & Womens Phys Org, 75 Francis St, Boston, MA 02115 USA.	tabrennan@partners.org						*AM BOARD MED SPEC, 2003, 2003 ANN REP REF HDB; *AM BOARD MED SPEC, 2002, ANN REP REF HDB; [Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Brennan T., 1996, NEW RULES REGULATION; Cizek G. J, 2001, SETTING PERFORMANCE; Epstein AM, 1998, JAMA-J AM MED ASSOC, V279, P1691, DOI 10.1001/jama.279.21.1691; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; GLASSOCK RJ, 1991, ANN INTERN MED, V114, P59, DOI 10.7326/0003-4819-114-1-59; Hibbard J H, 2001, Jt Comm J Qual Improv, V27, P591; Hofer TP, 1999, JAMA-J AM MED ASSOC, V281, P2098, DOI 10.1001/jama.281.22.2098; Horowitz SD, 2004, MED EDUC, V38, P10, DOI 10.1046/j.1365-2923.2004.01702.x; Kassirer JP, 1997, NEW ENGL J MED, V337, P43, DOI 10.1056/NEJM199707033370108; KELLY JV, 1986, MED CARE, V24, P785, DOI 10.1097/00005650-198609000-00001; Kohatsu ND, 2004, ARCH INTERN MED, V164, P653, DOI 10.1001/archinte.164.6.653; Kohn KT, 1999, ERR IS HUMAN BUILDIN; Lamb RM, 2003, HEALTH AFFAIR, V22, P73, DOI 10.1377/hlthaff.22.2.73; Landon BE, 2003, JAMA-J AM MED ASSOC, V290, P1183, DOI 10.1001/jama.290.9.1183; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; Leape LL, 2002, JAMA-J AM MED ASSOC, V288, P501, DOI 10.1001/jama.288.4.501; Lipner RS, 2002, ACAD MED, V77, pS64, DOI 10.1097/00001888-200210001-00021; Lynch DC, 2004, TEACH LEARN MED, V16, P85, DOI 10.1207/s15328015tlm1601_17; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; MELLOW MM, IN PRESS J HLTH POLI; Morrison J, 1998, JAMA-J AM MED ASSOC, V279, P1889, DOI 10.1001/jama.279.23.1889; Norcini J, 2001, ACAD MED, V76, pS21, DOI 10.1097/00001888-200110001-00008; NORCINI JJ, 1989, CRIT CARE MED, V17, P695, DOI 10.1097/00003246-198907000-00021; Norcini JJ, 1996, ACAD MED, V71, pS71, DOI 10.1097/00001888-199610000-00048; NORCINI JJ, 1989, JAMA-J AM MED ASSOC, V262, P2402, DOI 10.1001/jama.262.17.2402; NORCINI JJ, 1991, ANN INTERN MED, V114, P33, DOI 10.7326/0003-4819-114-1-33; NORCINI JJ, 1993, J GEN INTERN MED, V8, P82, DOI 10.1007/BF02599989; NORCINI JJ, 1987, J EDUC MEAS, V24, P56, DOI 10.1111/j.1745-3984.1987.tb00261.x; Norcini JJ, 2002, MED EDUC, V36, P853, DOI 10.1046/j.1365-2923.2002.01293.x; Norcini JJ, 2000, ACAD MED, V75, P1193, DOI 10.1097/00001888-200012000-00016; Norcini JJ, 2000, ACAD MED, V75, pS68, DOI 10.1097/00001888-200010001-00022; NORCINI JJ, 1985, ANN INTERN MED, V102, P385, DOI 10.7326/0003-4819-102-3-385; NORCINI JJ, 1987, J GEN INTERN MED, V2, P330, DOI 10.1007/BF02596169; Prystowsky JB, 2002, SURGERY, V132, P663, DOI 10.1067/msy.2002.127550; RAMSEY PG, 1989, ANN INTERN MED, V110, P719, DOI 10.7326/0003-4819-110-9-719; RASMUSSEN J, 1974, ERGONOMICS, V17, P293, DOI 10.1080/00140137408931355; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; ROUSE WB, 1983, AUTOMATICA, V19, P613, DOI 10.1016/0005-1098(83)90025-0; Sharp LK, 2002, ACAD MED, V77, P534, DOI 10.1097/00001888-200206000-00011; Shea J, 1992, APPL MEAS EDUC, V5, P63, DOI DOI 10.1207/S15324818AME0501_; SHEA JA, 1994, INT J TEACH LEARN ME, V6, P288; Silber JH, 2002, ANESTHESIOLOGY, V96, P1044, DOI 10.1097/00000542-200205000-00004; Studdert DM, 2004, NEW ENGL J MED, V350, P283, DOI 10.1056/NEJMhpr035470; Tamblyn R, 2002, JAMA-J AM MED ASSOC, V288, P3019, DOI 10.1001/jama.288.23.3019	47	212	215	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2004	292	9					1038	1043		10.1001/jama.292.9.1038	http://dx.doi.org/10.1001/jama.292.9.1038			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VH	15339894				2022-12-28	WOS:000223568700016
J	Bahatyrova, S; Frese, RN; Siebert, CA; Olsen, JD; van der Werf, KO; van Grondelle, R; Niederman, RA; Bullough, PA; Otto, C; Hunter, CN				Bahatyrova, S; Frese, RN; Siebert, CA; Olsen, JD; van der Werf, KO; van Grondelle, R; Niederman, RA; Bullough, PA; Otto, C; Hunter, CN			The native architecture of a photosynthetic membrane	NATURE			English	Article							LIGHT-HARVESTING COMPLEX; ATOMIC-FORCE MICROSCOPY; RHODOBACTER-SPHAEROIDES; CORE COMPLEX; RHODOPSEUDOMONAS-SPHAEROIDES; RHODOSPIRILLUM-RUBRUM; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; PROTEIN SUBUNITS; ANTENNA COMPLEX	In photosynthesis, the harvesting of solar energy and its subsequent conversion into a stable charge separation are dependent upon an interconnected macromolecular network of membrane-associated chlorophyll-protein complexes. Although the detailed structure of each complex has been determined(1-4), the size and organization of this network are unknown. Here we show the use of atomic force microscopy to directly reveal a native bacterial photosynthetic membrane. This first view of any multi-component membrane shows the relative positions and associations of the photosynthetic complexes and reveals crucial new features of the organization of the network: we found that the membrane is divided into specialized domains each with a different network organization and in which one type of complex predominates. Two types of organization were found for the peripheral light-harvesting LH2 complex. In the first, groups of 10-20 molecules of LH2 form light-capture domains that interconnect linear arrays of dimers of core reaction centre (RC)-light-harvesting 1 (RC-LH1-PufX) complexes; in the second they were found outside these arrays in larger clusters. The LH1 complex is ideally positioned to function as an energy collection hub, temporarily storing it before transfer to the RC where photochemistry occurs: the elegant economy of the photosynthetic membrane is demonstrated by the close packing of these linear arrays, which are often only separated by narrow 'energy conduits' of LH2 just two or three complexes wide.	Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Univ Twente, Biophys Tech Grp, Dept Sci & Technol, BMTI,MESA, NL-7500 AE Enschede, Netherlands; Vrije Univ Amsterdam, Fac Sci, NL-1081 HV Amsterdam, Netherlands	University of Sheffield; Rutgers State University New Brunswick; University of Twente; Vrije Universiteit Amsterdam	Hunter, CN (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	c.n.hunter@shef.ac.uk	Otto, Cees/H-8421-2019	frese, raoul/0000-0001-8243-9954; Bullough, Per/0000-0001-8147-1127; Siebert, charles/0000-0002-8126-1979				AAGAARD J, 1972, PHOTOCHEM PHOTOBIOL, V15, P209, DOI 10.1111/j.1751-1097.1972.tb06240.x; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P6162, DOI 10.1073/pnas.84.17.6162; Bahatyrova S, 2004, J BIOL CHEM, V279, P21327, DOI 10.1074/jbc.M313039200; BEEKMAN LMP, 1994, BIOCHEMISTRY-US, V33, P3143, DOI 10.1021/bi00177a001; BERRY EA, IN PRESS PHOTOSYN RE; Boekema EJ, 2000, J MOL BIOL, V301, P1123, DOI 10.1006/jmbi.2000.4037; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; Feniouk BA, 2002, BIOPHYS J, V82, P1115, DOI 10.1016/S0006-3495(02)75470-2; Fotiadis D, 2004, J BIOL CHEM, V279, P2063, DOI 10.1074/jbc.M310382200; Frese RN, 2000, P NATL ACAD SCI USA, V97, P5197, DOI 10.1073/pnas.090083797; Hess S, 1995, P NATL ACAD SCI USA, V92, P12333, DOI 10.1073/pnas.92.26.12333; HUNTER CN, 1985, BIOCHIM BIOPHYS ACTA, V807, P44, DOI 10.1016/0005-2728(85)90051-9; Jamieson SJ, 2002, EMBO J, V21, P3927, DOI 10.1093/emboj/cdf410; Katona G, 2003, J MOL BIOL, V331, P681, DOI 10.1016/S0022-2836(03)00751-4; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MONGER TG, 1977, BIOCHIM BIOPHYS ACTA, V460, P393, DOI 10.1016/0005-2728(77)90080-9; Muller DJ, 2003, J MOL BIOL, V327, P925, DOI 10.1016/S0022-2836(03)00206-7; NIEDERMAN RA, 1979, BIOCHIM BIOPHYS ACTA, V555, P210, DOI 10.1016/0005-2736(79)90161-5; Roszak AW, 2003, SCIENCE, V302, P1969, DOI 10.1126/science.1088892; Scheuring S, 2004, J BIOL CHEM, V279, P3620, DOI 10.1074/jbc.M310050200; Scheuring S, 2003, P NATL ACAD SCI USA, V100, P1690, DOI 10.1073/pnas.0437992100; Scheuring S, 2003, J MOL BIOL, V325, P569, DOI 10.1016/S0022-2836(02)01241-X; Siebert CA, 2004, EMBO J, V23, P690, DOI 10.1038/sj.emboj.7600092; Sturgis JN, 1996, ARCH MICROBIOL, V165, P235, DOI 10.1007/s002030050321; VANDERWERF KO, 1993, REV SCI INSTRUM, V64, P2892, DOI 10.1063/1.1144378; VISSCHER KJ, 1989, PHOTOSYNTH RES, V22, P211, DOI 10.1007/BF00048300; VOS M, 1988, BIOCHIM BIOPHYS ACTA, V933, P132, DOI 10.1016/0005-2728(88)90063-1; Walz T, 1998, J MOL BIOL, V282, P833, DOI 10.1006/jmbi.1998.2050	28	383	401	2	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2004	430	7003					1058	1062		10.1038/nature02823	http://dx.doi.org/10.1038/nature02823			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329728	Green Accepted			2022-12-28	WOS:000223514900050
J	Spragg, RG; Lewis, JF; Walmrath, H; Johannigman, J; Bellingan, G; Laterre, P; Witte, MC; Richards, GA; Rippin, G; Rathgeb, F; Hafner, D; Taut, FJH; Seeger, W				Spragg, RG; Lewis, JF; Walmrath, H; Johannigman, J; Bellingan, G; Laterre, P; Witte, MC; Richards, GA; Rippin, G; Rathgeb, F; Hafner, D; Taut, FJH; Seeger, W			Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PULMONARY SURFACTANT; LAVAGE MODEL; THERAPY	BACKGROUND: Preclinical studies suggest that exogenous surfactant may be of value in the treatment of the acute respiratory distress syndrome (ARDS), and two phase 2 clinical trials have shown a trend toward benefit. We conducted two phase 3 studies of a protein-containing surfactant in adults with ARDS. METHODS: In two multicenter, randomized, double-blind trials involving 448 patients with ARDS from various causes, we compared standard therapy alone with standard therapy plus up to four intratracheal doses of a recombinant surfactant protein C-based surfactant given within a period of 24 hours. RESULTS: The overall survival rate was 66 percent 28 days after treatment, and the median number of ventilator-free days was 0 (68 percent range, 0 to 26); there was no significant difference between the groups in terms of mortality or the need for mechanical ventilation. Patients receiving surfactant had a significantly greater improvement in blood oxygenation during the initial 24 hours of treatment than patients receiving standard therapy, according to both univariate and multivariate analyses. CONCLUSIONS: The use of exogenous surfactant in a heterogeneous population of patients with ARDS did not improve survival. Patients who received surfactant had a greater improvement in gas exchange during the 24-hour treatment period than patients who received standard therapy alone, suggesting the potential benefit of a longer treatment course.	Univ Calif San Diego, Vet Affairs Med Ctr, San Diego, CA 92014 USA; Univ Western Ontario, London, ON, Canada; Univ Giessen, Giessen, Germany; Univ Cincinnati Hosp, Cincinnati, OH USA; UCL, Dept Med, London WC1E 6BT, England; St Luc Univ Hosp, Brussels, Belgium; Mercy Med Ctr, Des Moines, IA USA; Univ Witwatersrand, Johannesburg, South Africa; Omnicare Clin Res, Cologne, Germany; Altana Pharma, Constance, Germany	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Western University (University of Western Ontario); Justus Liebig University Giessen; University System of Ohio; University of Cincinnati; University of London; University College London; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Witwatersrand; Altana	Spragg, RG (corresponding author), Univ Calif San Diego, Vet Affairs Med Ctr, 3350 La Jolla Village Dr, San Diego, CA 92014 USA.	rspragg@ucsd.edu; werner.seeger@innere.med.uni-giessen.de	Lewis, Jim/G-3320-2011; Lewis, James F./GVS-8247-2022	Seeger, Werner/0000-0003-1946-0894				*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Anzueto A, 1996, NEW ENGL J MED, V334, P1417, DOI 10.1056/NEJM199605303342201; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; ENHORNING G, 1995, AM J RESP CRIT CARE, V151, P554, DOI 10.1164/ajrccm.151.2.7842219; Gregory TJ, 1997, AM J RESP CRIT CARE, V155, P1309, DOI 10.1164/ajrccm.155.4.9105072; Hafner D, 1998, AM J RESP CRIT CARE, V158, P270; Herting E, 2001, PEDIATR RES, V50, P44, DOI 10.1203/00006450-200107000-00010; Hollander M., 1973, NONPARAMETRIC STAT M; JOBE AH, 1993, NEW ENGL J MED, V328, P861; Johnson R.A., 2002, APPL MULTIVARIATE ST; KESECIOGLU J, 2001, AM J RESP CRIT CARE, V165, pA819; Kleinbaum DG, 1994, LOGISTIC REGRESSION; Kleinbaum DG, 1996, SURVIVAL ANAL SELF L; McIntyre RC, 2000, CRIT CARE MED, V28, P3314, DOI 10.1097/00003246-200009000-00034; SPRAGG RG, 1994, CHEST, V105, P195, DOI 10.1378/chest.105.1.195; Spragg RG, 2003, AM J RESP CRIT CARE, V167, P1562, DOI 10.1164/rccm.200207-782OC; Spragg RG, 2000, J APPL PHYSIOL, V88, P674, DOI 10.1152/jappl.2000.88.2.674; Spragg RG, 2003, ACUTE RESP DISTRESS, P533; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Walmrath D, 1996, AM J RESP CRIT CARE, V154, P57, DOI 10.1164/ajrccm.154.1.8680699; WALTERS DV, 1992, PULMONARY SURFACTANT, P193; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Wiswell TE, 1999, AM J RESP CRIT CARE, V160, P1188, DOI 10.1164/ajrccm.160.4.9808118; Wright JR, 2003, J CLIN INVEST, V111, P1453, DOI 10.1172/JCI200318650	25	260	283	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2004	351	9					884	892		10.1056/NEJMoa033181	http://dx.doi.org/10.1056/NEJMoa033181			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849BM	15329426	Green Published			2022-12-28	WOS:000223512500010
J	Farkouh, ME; Kirshner, H; Harrington, RA; Ruland, S; Verheugt, FW; Schnitzer, T; Burmester, GR; Mysler, E; Hochberg, MC; Doherty, M; Ehrsam, E; Gitton, X; Krammer, G; Mellein, B; Gimona, A; Matchaba, P; Hawkey, CJ; Chesebro, JH				Farkouh, ME; Kirshner, H; Harrington, RA; Ruland, S; Verheugt, FW; Schnitzer, T; Burmester, GR; Mysler, E; Hochberg, MC; Doherty, M; Ehrsam, E; Gitton, X; Krammer, G; Mellein, B; Gimona, A; Matchaba, P; Hawkey, CJ; Chesebro, JH		TARGET Study Grp	Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SELECTIVE CYCLOOXYGENASE-2 INHIBITORS; ACUTE MYOCARDIAL-INFARCTION; LOW-DOSE ASPIRIN; BLOOD-PRESSURE; THROMBOTIC EVENTS; RISK; ROFECOXIB; COX-2; OSTEOARTHRITIS	Background The potential for cyclo-oxygenase 2 (COX2)-selective inhibitors to increase the risk for myocardial infarction is controversial. The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) aimed to assess gastrointestinal and cardiovascular safety of the COX2 inhibitor lumiracoxib compared with two non-steroidal anti-inflammatory drugs, naproxen and ibuprofen. Methods 18 325 patients age 50 years or older with osteoarthritis were randomised to lumiracoxib 400 mg once daily (n=9156), naproxen 500 mg twice daily (4754), or ibuprofen 800 mg three times daily (4415) in two substudies of identical design. Randomisation was stratified for low-dose aspirin use and age. The primary cardiovascular endpoint was the Antiplatelet Trialists' Collaboration endpoint of non-fatal and silent myocardial infarction, stroke, or cardiovascular death. Analysis was by intention to treat. Findings 81 (0.44%) patients did not start treatment and 7120 (39%) did not complete the study. At 1-year follow-up, incidence of the primary endpoint was low, both with lumiracoxib (59 events [0.65%]) and the non-steroidal anti-inflammatory drugs (50 events [0.55%]; hazard ratio 1.14 [95% CI 0.78-1.66], p=0.5074). Incidence of myocardial infarction (clinical and silent) in the overall population in the individual substudies was 0.38% with lumiracoxib (18 events) versus 0.21% with naproxen (ten) and 0.11% with lumiracoxib (five) versus 0.16% with ibuprofen (seven). In the naproxen substudy, rates of myocardial infarction (clinical and silent) did not differ significantly compared with lumiracoxib in the population not taking low-dose aspirin (hazard ratio 2.37 [95% CI 0.74-7.55], p=0.1454), overall (1.77 [0.82-3.84], p=0.1471), and in patients taking aspirin (1.36 [0.47-3.93], p=0.5658). In the ibuprofen substudy, these rates did not differ between lumiracoxib and ibuprofen in the population not taking low-dose aspirin (0.75 [0.20-2.79], p=0.6669), overall (0.66 [0.21-2.09], p=0.4833), and in patients taking aspirin (0.47 [0.04-5.14], p=0.5328). Interpretation The primary endpoint, including incidence of myocardial infarction, did not differ between lumiracoxib and either ibuprofen or naproxen, irrespective of aspirin use. This finding suggests that lumiracoxib is an appropriate treatment for patients with osteoarthritis, who are often at high cardiovascular risk and taking low-dose aspirin.	NYU, Sch Med, Cardiovasc Clin Res Ctr, New York, NY 10016 USA; Vanderbilt Univ, Sch Med, Dept Neurol, Nashville, TN 37212 USA; Duke Clin Res Inst, Durham, NC USA; Univ Illinois, Dept Neurol & Rehabil, Chicago, IL USA; Univ Med Ctr, Dept Cardiol, Nijmegen, Netherlands; Northwestern Univ, Off Clin Res & Training, Feinberg Sch Med, Chicago, IL 60611 USA; Humboldt Univ, Dept Rheumatol & Clin Immunol, Charite Univ Med Berlin, Berlin, Germany; Org Med Invest Buenos Aires, Dept Rheumatol, Buenos Aires, DF, Argentina; Univ Maryland, Sch Med, Div Clin Immunol & Rheumatol, Baltimore, MD 21201 USA; Univ Nottingham, City Hosp, Nottingham NG5 1PB, England; Univ Hosp, Inst Clin Trials Unit, Wolfson Digest Dis Ctr, Nottingham, England; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceut, E Hanover, NJ USA; Mayo Clin, Div Cardiol, Jacksonville, FL 32224 USA	New York University; Vanderbilt University; Duke University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Radboud University Nijmegen; Northwestern University; Feinberg School of Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University System of Maryland; University of Maryland Baltimore; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; Nottingham University Hospital NHS Trust; University of Nottingham; Novartis; Novartis; Mayo Clinic	Farkouh, ME (corresponding author), NYU, Sch Med, Cardiovasc Clin Res Ctr, 530 1st Ave, New York, NY 10016 USA.	michael.farkouh@med.nyu.edu	Verheugt, F.W.A./H-8105-2014; Burmester, Gerd R./AAY-7514-2020	Doherty, Michael/0000-0002-5763-8326				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Bruns W, 2002, ADV STU P M, V33, P1; Capone ML, 2004, CIRCULATION, V109, P1468, DOI 10.1161/01.CIR.0000124715.27937.78; Catella-Lawson F, 2001, NEW ENGL J MED, V345, P1809, DOI 10.1056/NEJMoa003199; Crofford LJ, 2000, ARTHRITIS RHEUM-US, V43, P4, DOI 10.1002/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V; Fisher LD, 2001, AM HEART J, V141, P26, DOI 10.1067/mhj.2001.111262; Grundy SM, 1999, J AM COLL CARDIOL, V34, P1348, DOI 10.1016/S0735-1097(99)00387-3; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HAWKEY CJ, 2004, ALIMENT PHARM THER, V19, P1; Howard PA, 2004, J AM COLL CARDIOL, V43, P519, DOI 10.1016/j.jacc.2003.09.043; Konstam MA, 2001, CIRCULATION, V104, P2280, DOI 10.1161/hc4401.100078; MacDonald TM, 2003, LANCET, V361, P573, DOI 10.1016/S0140-6736(03)12509-3; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Mamdani M, 2003, ARCH INTERN MED, V163, P481, DOI 10.1001/archinte.163.4.481; Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140-6736(04)16299-5; Mangold JB, 2002, DRUG METAB REV, V34, P141; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Rahme E, 2002, ARCH INTERN MED, V162, P1111, DOI 10.1001/archinte.162.10.1111; Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140-6736(02)11131-7; Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140-6736(04)16893-1; SCOTT G, 2002, ANN RHEUM DIS S1, V61, P242; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Singh G, 2002, AM J MANAG CARE, V8, pS383; Solomon DH, 2004, CIRCULATION, V109, P2068, DOI 10.1161/01.CIR.0000127578.21885.3E; Solomon DH, 2002, ARCH INTERN MED, V162, P1099, DOI 10.1001/archinte.162.10.1099; Strand V, 2002, ARTHRIT RHEUM-ARTHR, V47, P349, DOI 10.1002/art.10560; Van Hecken A, 2000, J CLIN PHARMACOL, V40, P1109; Watson DJ, 2002, ARCH INTERN MED, V162, P1105, DOI 10.1001/archinte.162.10.1105; Whelton A, 2002, AM J CARDIOL, V90, P959, DOI 10.1016/S0002-9149(02)02661-9; Whelton A, 2001, Am J Ther, V8, P85, DOI 10.1097/00045391-200103000-00003; Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646	33	372	398	0	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	2004	364	9435					675	684		10.1016/S0140-6736(04)16894-3	http://dx.doi.org/10.1016/S0140-6736(04)16894-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325832				2022-12-28	WOS:000223428900029
J	Gordon, P				Gordon, P			Numerical cognition without words: Evidence from Amazonia	SCIENCE			English	Article							NUMBER; REPRESENTATIONS; INFANTS; DISCRIMINATION; FOUNDATIONS; MAGNITUDES; KNOWLEDGE; ORIGINS	Members of the Piraha tribe use a "one-two-many" system of counting. I ask whether speakers of this innumerate language can appreciate larger numerosities without the benefit of words to encode them. This addresses the classic Whorfian question about whether language can determine thought. Results of numerical tasks with varying cognitive demands show that numerical cognition is clearly affected by the lack of a counting system in the language. Performance with quantities greater than three was remarkably poor, but showed a constant coefficient of variation, which is suggestive of an analog estimation process.	Columbia Univ, Dept Biobehav Sci, New York, NY 10027 USA	Columbia University	Gordon, P (corresponding author), Columbia Univ, Dept Biobehav Sci, 525 W 120th St, New York, NY 10027 USA.	pgordon@tc.columbia.edu						Barth H, 2003, COGNITION, V86, P201, DOI 10.1016/S0010-0277(02)00178-6; BROWN RW, 1954, J ABNORM SOC PSYCH, V49, P454, DOI 10.1037/h0057814; BUTTERWORTH B, 1999, WHAT COUNTS; Carey S, 2001, MIND LANG, V16, P37, DOI 10.1111/1468-0017.00155; Cordes S, 2001, PSYCHON B REV, V8, P698, DOI 10.3758/BF03196206; Dehaene S, 1999, SCIENCE, V284, P970, DOI 10.1126/science.284.5416.970; Dehaene S., 1997, NUMBER SENSE; Feigenson L, 2002, PSYCHOL SCI, V13, P150, DOI 10.1111/1467-9280.00427; Gallistel C. R., 1990, ORG LEARNING; Gelman R., 1978, CHILDS UNDERSTANDING; GORDON P, 1994, EUR SOC PHIL PSYCH P; GORDON P, 1993, BIENN M SOC RES CHIL; Hauser MD, 2003, P ROY SOC B-BIOL SCI, V270, P1441, DOI 10.1098/rspb.2003.2414; Levinson S.C., 1997, J LINGUISTIC ANTHR, V7, P98, DOI [10.1525/jlin.1997.7.1.98, DOI 10.1525/JLIN.1997.7.1.98]; LEVINSON SC, 2002, COGNITION, V4, P84; LI P, 2002, COGNITION, V3, P83; Lipton JS, 2003, PSYCHOL SCI, V14, P396, DOI 10.1111/1467-9280.01453; Lucy J.A., 1992, GRAMMATICAL CATEGORI; MECK WH, 1983, J EXP PSYCHOL ANIM B, V9, P320, DOI 10.1037/0097-7403.9.3.320; Menninger Karl., 1969, NUMBER WORDS NUMBER; PLATT J R, 1971, Learning and Motivation, V2, P386, DOI 10.1016/0023-9690(71)90020-8; Scholl BJ, 2001, COGNITION, V80, P1, DOI 10.1016/S0010-0277(00)00152-9; Simon TJ, 1997, COGNITIVE DEV, V12, P349, DOI 10.1016/S0885-2014(97)90008-3; TRICK LM, 1994, PSYCHOL REV, V101, P80, DOI 10.1037/0033-295X.101.1.80; Uller C, 1999, COGNITIVE DEV, V14, P1, DOI 10.1016/S0885-2014(99)80016-1; Whalen J, 1999, PSYCHOL SCI, V10, P130, DOI 10.1111/1467-9280.00120; Xu F, 2003, COGNITION, V89, pB15, DOI 10.1016/S0010-0277(03)00050-7; Zaslavsky, 1973, AFRICA COUNTS NUMBER	28	558	572	3	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	2004	306	5695					496	499		10.1126/science.1094492	http://dx.doi.org/10.1126/science.1094492			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15319490				2022-12-28	WOS:000224626500056
J	Ferbitz, L; Maier, T; Patzelt, H; Bukau, B; Deuerling, E; Ban, N				Ferbitz, L; Maier, T; Patzelt, H; Bukau, B; Deuerling, E; Ban, N			Trigger factor in complex with the ribosome forms a molecular cradle for nascent proteins	NATURE			English	Article							NEWLY SYNTHESIZED PROTEINS; ESCHERICHIA-COLI; PEPTIDE; DOMAINS; DNAK; ISOMERASE; CYTOSOL; BINDING; CHAINS	During protein biosynthesis, nascent polypeptide chains that emerge from the ribosomal exit tunnel encounter ribosome-associated chaperones, which assist their folding to the native state(1,2). Here we present a 2.7 Angstrom crystal structure of Escherichia coli trigger factor, the best-characterized chaperone of this type, together with the structure of its ribosome-binding domain in complex with the Haloarcula marismortui large ribosomal subunit. Trigger factor adopts a unique conformation resembling a crouching dragon with separated domains forming the amino-terminal ribosome-binding 'tail', the peptidylprolyl isomerase 'head', the carboxy-terminal 'arms' and connecting regions building up the 'back'. From its attachment point on the ribosome, trigger factor projects the extended domains over the exit of the ribosomal tunnel, creating a protected folding space where nascent polypeptides may be shielded from proteases and aggregation. This study sheds new light on our understanding of co-translational protein folding, and suggests an unexpected mechanism of action for ribosome-associated chaperones.	ETH Honggerberg, ETH Zurich, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland; Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Ruprecht Karls University Heidelberg	Ban, N (corresponding author), ETH Honggerberg, ETH Zurich, Inst Mol Biol & Biophys, HPK Gebaude, CH-8093 Zurich, Switzerland.	e.deuerling@zmbh.uni-heidelberg.de; ban@mol.biol.ethz.ch	Maier, Timm/A-8835-2016	Maier, Timm/0000-0002-7459-1363; Bukau, Bernd/0000-0003-0521-7199; Patzelt, Holger/0000-0001-9886-8374				Agashe VR, 2004, CELL, V117, P199, DOI 10.1016/S0092-8674(04)00299-5; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Behrens S, 2001, EMBO J, V20, P285, DOI 10.1093/emboj/20.1.285; Bitto E, 2003, J BIOL CHEM, V278, P49316, DOI 10.1074/jbc.M308853200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Halic M, 2004, NATURE, V427, P808, DOI 10.1038/nature02342; Hardesty B, 2001, PROG NUCLEIC ACID RE, V66, P41; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hesterkamp T, 1997, J BIOL CHEM, V272, P21865, DOI 10.1074/jbc.272.35.21865; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; Kramer G, 2004, J BACTERIOL, V186, P3777, DOI 10.1128/JB.186.12.3777-3784.2004; Kramer G, 2004, J BIOL CHEM, V279, P14165, DOI 10.1074/jbc.M313635200; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Kristensen O, 2003, STRUCTURE, V11, P1547, DOI 10.1016/j.str.2003.11.003; Maier R, 2003, J MOL BIOL, V326, P585, DOI 10.1016/S0022-2836(02)01427-4; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Nicola AV, 1999, NAT CELL BIOL, V1, P341, DOI 10.1038/14032; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patzelt H, 2002, BIOL CHEM, V383, P1611, DOI 10.1515/BC.2002.182; Pool MR, 2002, SCIENCE, V297, P1345, DOI 10.1126/science.1072366; Ramakrishnan V, 2002, CELL, V108, P557, DOI 10.1016/S0092-8674(02)00619-0; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Vogtherr M, 2002, J MOL BIOL, V318, P1097, DOI 10.1016/S0022-2836(02)00112-2	30	292	294	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	2004	431	7008					590	596		10.1038/nature02899	http://dx.doi.org/10.1038/nature02899			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	857YP	15334087	Green Published			2022-12-28	WOS:000224156700052
J	Giannini, O; Mayr, M				Giannini, O; Mayr, M			Finger pricking	LANCET			English	Editorial Material									Univ Basel Hosp, Div Neprol & Transplantat Immunol, CH-4031 Basel, Switzerland	University of Basel	Mayr, M (corresponding author), Univ Basel Hosp, Div Neprol & Transplantat Immunol, CH-4031 Basel, Switzerland.	mmayr@uhbs.ch		Mayr, Michael/0000-0002-1962-8186					0	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	2004	364	9438					980	980		10.1016/S0140-6736(04)17022-0	http://dx.doi.org/10.1016/S0140-6736(04)17022-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364189	Bronze			2022-12-28	WOS:000223831000028
J	Jeurissen, SER; Harinck, HIJ; Oepkes, D				Jeurissen, SER; Harinck, HIJ; Oepkes, D			Low dose synthetic prostaglandin E2: always safe for pregnancy termination?	LANCET			English	Editorial Material									Leiden Univ, Med Ctr, Dept Obstet & Gynecol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Oepkes, D (corresponding author), Leiden Univ, Med Ctr, Dept Obstet & Gynecol, NL-2300 RC Leiden, Netherlands.	D.Oepkes@lumc.nl						BROEKHUIZEN FF, 2003, BEEINDIGING ZWANGERS, P201; de Boer MA, 2001, EUR J OBSTET GYN R B, V99, P244, DOI 10.1016/S0301-2115(01)00406-7; Ravasia DJ, 2000, AM J OBSTET GYNECOL, V183, P1176, DOI 10.1067/mob.2000.109037	3	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	2004	364	9438					1010	1010		10.1016/S0140-6736(04)17031-1	http://dx.doi.org/10.1016/S0140-6736(04)17031-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364195				2022-12-28	WOS:000223831000037
J	Wallraff, A; Schuster, DI; Blais, A; Frunzio, L; Huang, RS; Majer, J; Kumar, S; Girvin, SM; Schoelkopf, RJ				Wallraff, A; Schuster, DI; Blais, A; Frunzio, L; Huang, RS; Majer, J; Kumar, S; Girvin, SM; Schoelkopf, RJ			Strong coupling of a single photon to a superconducting qubit using circuit quantum electrodynamics	NATURE			English	Article							COHERENCE; STATES; DOT	The interaction of matter and light is one of the fundamental processes occurring in nature, and its most elementary form is realized when a single atom interacts with a single photon. Reaching this regime has been a major focus of research in atomic physics and quantum optics(1) for several decades and has generated the field of cavity quantum electrodynamics(2,3). Here we perform an experiment in which a superconducting two-level system, playing the role of an artificial atom, is coupled to an on-chip cavity consisting of a superconducting transmission line resonator. We show that the strong coupling regime can be attained in a solid-state system, and we experimentally observe the coherent interaction of a superconducting two-level system with a single microwave photon. The concept of circuit quantum electrodynamics opens many new possibilities for studying the strong interaction of light and matter. This system can also be exploited for quantum information processing and quantum communication and may lead to new approaches for single photon generation and detection.	Yale Univ, Dept Appl Phys, New Haven, CT 06520 USA; Yale Univ, Dept Phys, New Haven, CT 06520 USA; Indiana Univ, Dept Phys, Bloomington, IN 47405 USA	Yale University; Yale University; Indiana University System; Indiana University Bloomington	Wallraff, A (corresponding author), Yale Univ, Dept Appl Phys, New Haven, CT 06520 USA.	andreas.wallraff@yale.edu	Wallraff, Andreas J/C-2130-2009; Majer, Johannes B/C-1864-2008; Schoelkopf, Robert J/J-8178-2012; Blais, Alexandre/E-3315-2010; Frunzio, Luigi/O-1573-2019	Wallraff, Andreas J/0000-0002-3476-4485; Majer, Johannes B/0000-0002-5192-1809; Blais, Alexandre/0000-0002-0591-2012; Frunzio, Luigi/0000-0002-0272-5481; schuster, david/0000-0002-0012-3874				Al-Saidi WA, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.224512; Berkley AJ, 2003, SCIENCE, V300, P1548, DOI 10.1126/science.1084528; Blais A, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.062320; Blais A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.127901; Bouchiat V, 1998, PHYS SCRIPTA, VT76, P165, DOI 10.1238/Physica.Topical.076a00165; BUISSON O, 2001, MACROSCOPIC QUANTUM; Childress L, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.042302; Chiorescu I, 2003, SCIENCE, V299, P1869, DOI 10.1126/science.1081045; Irish EK, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.155311; Kiraz A, 2001, APPL PHYS LETT, V78, P3932, DOI 10.1063/1.1379987; Lehnert KW, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.027002; Mabuchi H, 2002, SCIENCE, V298, P1372, DOI 10.1126/science.1078446; Makhlin Y, 2001, REV MOD PHYS, V73, P357, DOI 10.1103/RevModPhys.73.357; Marquardt F, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.054514; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; Nogues G, 1999, NATURE, V400, P239, DOI 10.1038/22275; Plastina F, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.224514; Raimond JM, 2001, REV MOD PHYS, V73, P565, DOI 10.1103/RevModPhys.73.565; RAU I, 2004, CAVITY QED SUPERCOND; SCHUSTER D, 2004, AC STARK SHIFT DEPHA; THOMPSON RJ, 1992, PHYS REV LETT, V68, P1132, DOI 10.1103/PhysRevLett.68.1132; Vion D, 2002, SCIENCE, V296, P886, DOI 10.1126/science.1069372; Vuckovic J, 2003, APPL PHYS LETT, V82, P3596, DOI 10.1063/1.1577828; Walls D. F., 1994, QUANTUM OPT; WEISBUCH C, 1992, PHYS REV LETT, V69, P3314, DOI 10.1103/PhysRevLett.69.3314; Yamamoto T, 2003, NATURE, V425, P941, DOI 10.1038/nature02015; Yang CP, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.042311; You JQ, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.064509	30	2849	2892	15	567	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2004	431	7005					162	167		10.1038/nature02851	http://dx.doi.org/10.1038/nature02851			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356625	Green Submitted			2022-12-28	WOS:000223746000038
J	Reinhardt, UE				Reinhardt, UE			The Swiss health system - Regulated competition without managed care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COUNTRIES; QUALITY; REFORM; PLAN		Princeton Univ, Dept Econ, Princeton, NJ 08540 USA; Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Princeton, NJ 08540 USA	Princeton University; Princeton University	Reinhardt, UE (corresponding author), Princeton Univ, Dept Econ, 351 Wallace Hall, Princeton, NJ 08540 USA.	reinhard@princeton.edu						Anderson GF, 2003, HEALTH AFFAIR, V22, P89, DOI 10.1377/hlthaff.22.3.89; Anderson GF, 1999, HEALTH AFFAIR, V18, P178, DOI 10.1377/hlthaff.18.3.178; [Anonymous], 2000, HLTH CARE SYSTEMS TR, P58; BECKER K, 2004, FLEXIBILISIERUNGSMOG, P18; Blendon RJ, 2001, HEALTH AFFAIR, V20, P233, DOI 10.1377/hlthaff.20.3.233; Blendon RJ, 2004, HEALTH AFFAIR, V23, P119, DOI 10.1377/hlthaff.23.3.119; Blendon RJ, 2001, HEALTH AFFAIR, V20, P10, DOI 10.1377/hlthaff.20.3.10; *CIVITAS I STUD CI, SWISS HEALTHC SYST; CRIVELLI L, 2004, 0407 DEC FS EC; CRIVELLI L, 2004, HLTH POLICY REFORM; ENTHOVEN AC, 1994, HEALTH AFFAIR, V13, P81, DOI 10.1377/hlthaff.13.1.81; FUCHS VR, 1994, HEALTH AFFAIR, V13, P102, DOI 10.1377/hlthaff.13.1.102; HADLEY J, 1994, HEALTH AFFAIR, V13, P115, DOI 10.1377/hlthaff.13.1.115; Herzlinger RE, 2004, JAMA-J AM MED ASSOC, V292, P1213, DOI 10.1001/jama.292.10.1213; Hussey PS, 2004, HEALTH AFFAIR, V23, P89, DOI 10.1377/hlthaff.23.3.89; Organization for Economic Cooperation and Development, 2004, OECD HLTH DAT 2004; Reinhardt UE, 2004, HEALTH AFFAIR, V23, P10, DOI 10.1377/hlthaff.23.3.10; van Doorslaer E, 1999, J HEALTH ECON, V18, P291, DOI 10.1016/S0167-6296(98)00043-5; VATERLAUS S, 2004, WAS LEISTET UNSER GE, P10; *WHO, 2000, WORLD HLTH REP 2000, P176; ZELMAN WA, 1994, HEALTH AFFAIR, V13, P9, DOI 10.1377/hlthaff.13.1.9	21	55	55	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2004	292	10					1227	1231		10.1001/jama.292.10.1227	http://dx.doi.org/10.1001/jama.292.10.1227			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	851ZA	15353536				2022-12-28	WOS:000223723800023
J	Majumdar, SR; Rowe, BH; Folk, D; Johnson, JA; Holroyd, BH; Morrish, DW; Maksymowych, WP; Steiner, IP; Harley, CH; Wirzba, BJ; Hanley, DA; Blitz, S; Russell, AS				Majumdar, SR; Rowe, BH; Folk, D; Johnson, JA; Holroyd, BH; Morrish, DW; Maksymowych, WP; Steiner, IP; Harley, CH; Wirzba, BJ; Hanley, DA; Blitz, S; Russell, AS			A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL WOMEN; MYOCARDIAL-INFARCTION; PRACTICE GUIDELINES; FOREARM FRACTURES; DISTAL FOREARM; HIP FRACTURE; FOLLOW-UP; INTERVENTION; QUALITY	Background: Despite the high risk for future fractures and the availability of effective treatments, fewer than 10% to 20% of patients who sustain a fragility fracture are tested or treated for osteoporosis. Objectives: To improve rates of testing and treatment for osteoporosis in patients with wrist fractures who are seen in the emergency department. Design: Nonrandomized, controlled trial with blinded ascertainment of outcomes. Setting: Emergency departments in Edmonton, Alberta, Canada. Patients: Persons 50 years of age or older who were treated for a wrist fracture and their physicians. Patients admitted to the hospital or treated for osteoporosis were excluded. Overall, 572 consecutive patients with fractures were screened, and 102 patients (55 intervention, 47 control) and 101 physicians were studied. Measurements: The primary end point was the prescription of osteoporosis treatment 6 months after fracture. Secondary end points included rates of testing for bone mineral density and patients' knowledge, satisfaction, and quality of life. Intervention: Faxed physician reminders that contained osteoporosis treatment guidelines endorsed by local opinion leaders and patient education. Control patients received usual care and information about falls and home safety. Results: The median patient age was 66 years. Most patients were female (78%) and white (79%); 70% of patients reported a previous fracture, and 22% had a fall with injury in the previous year. The intervention increased the rates of testing for bone mineral density to 62% (vs. 17% for controls; adjusted relative increase, 3.6 [P < 0.001]) and the rates of osteoporosis treatment to 40% (vs. 10% for controls; adjusted relative increase, 3.8 [P = 0.002]) within 6 months of fracture. Intervention patients were more likely to report a diagnosis of osteoporosis, but other patient-reported outcomes did not differ significantly between groups. Limitations: This was a small, nonrandomized, controlled study with process-based outcomes. Conclusions: in a multifaceted intervention directed at patients and their physicians, the rates of testing and treatment for osteoporosis after emergency department care for a fragility fracture were more than 3 times those of controls.	Univ Alberta, Univ Alberta Hosp, Walter Mackenzie Hlth Sci Ctr 2E307, Dept Med, Edmonton, AB T6G 2B7, Canada; Univ Calgary, Calgary, AB, Canada	University of Alberta; University of Calgary	Majumdar, SR (corresponding author), Univ Alberta, Univ Alberta Hosp, Walter Mackenzie Hlth Sci Ctr 2E307, Dept Med, 8440 112th St, Edmonton, AB T6G 2B7, Canada.	me2.majumdar@ualberta.ca	Golmohamad, Ramez/E-4848-2014	Golmohamad, Ramez/0000-0002-9958-7037; Johnson, Jeffrey/0000-0001-8290-2857; Maksymowych, Walter/0000-0002-1291-1755				Ailinger R L, 1998, Orthop Nurs, V17, P66; ALFFRAM P, 1964, ACTA ORTHOP SCAND S, V65, P64; *AM AC ORTH SURG, 1998, UPP LIMB DIS ARM SHO; Andrade SE, 2003, ARCH INTERN MED, V163, P2052, DOI 10.1001/archinte.163.17.2052; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; Brown JP, 2002, CAN MED ASSOC J, V167, pS1; Cuddihy MT, 1999, OSTEOPOROSIS INT, V9, P469, DOI 10.1007/s001980050172; Cuddihy MT, 2002, ARCH INTERN MED, V162, P421, DOI 10.1001/archinte.162.4.421; Earnshaw SA, 1998, OSTEOPOROSIS INT, V8, P53, DOI 10.1007/s001980050048; Ensrud KE, 1997, ARCH INTERN MED, V157, P2617, DOI 10.1001/archinte.157.22.2617; Freedman KB, 2000, J BONE JOINT SURG AM, V82A, P1063, DOI 10.2106/00004623-200008000-00001; GRIMSHAW JM, 2001, MED CARE S, V39, P112; Guyatt G, 2002, ENDOCR REV, V23, P496, DOI 10.1021/er.2001-1002; Hajcsar EE, 2000, CAN MED ASSOC J, V163, P819; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; Hawker G, 2003, OSTEOPOROSIS INT, V14, P171, DOI 10.1007/s00198-003-1377-4; HISS RG, 1978, P 17 ANN C RES MED E, V17, P283; Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L; Jaglal SB, 1996, CAN J SURG, V39, P105; Khan SA, 2001, ARCH INTERN MED, V161, P1309, DOI 10.1001/archinte.161.10.1309; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; Lydick E, 1997, J BONE MINER RES, V12, P456, DOI 10.1359/jbmr.1997.12.3.456; Majumdar SR, 2003, CAN MED ASSOC J, V169, P30; Majumdar SR, 2002, AM J MED, V113, P140, DOI 10.1016/S0002-9343(02)01166-X; Majumdar SR, 2001, J GEN INTERN MED, V16, P351, DOI 10.1046/j.1525-1497.2001.016006351.x; MALLMIN H, 1993, CALCIFIED TISSUE INT, V52, P269, DOI 10.1007/BF00296650; Maricic M, 2002, ARCH INTERN MED, V162, P1140, DOI 10.1001/archinte.162.10.1140; Marshall GN., 1994, PATIENT SATISFACTION; National Osteoporosis Foundation, 1999, PHYS GUID PREV TREAT; Naylor CD, 2002, AM J MED, V113, P161, DOI 10.1016/S0002-9343(02)01215-9; Robbins AS, 2002, ANN EPIDEMIOL, V12, P452, DOI 10.1016/S1047-2797(01)00278-2; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; Siris ES, 2003, J CLIN ENDOCR METAB, V88, P3482, DOI 10.1210/jc.2003-030568; Soumerai SB, 1998, JAMA-J AM MED ASSOC, V279, P1358, DOI 10.1001/jama.279.17.1358; Soumerai SB, 2000, PHARMACOEPIDEM DR S, P483; Torgerson DJ, 1998, ANN RHEUM DIS, V57, P378, DOI 10.1136/ard.57.6.378; Turner BJ, 2001, J GEN INTERN MED, V16, P422, DOI 10.1046/j.1525-1497.2001.016006422.x; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001	40	128	129	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	2004	141	5					366	373		10.7326/0003-4819-141-5-200409070-00011	http://dx.doi.org/10.7326/0003-4819-141-5-200409070-00011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CW	15353428				2022-12-28	WOS:000223733800005
J	Betancourt, JR				Betancourt, JR			Becoming a physician: Cultural competence - Marginal or mainstream movement?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Betancourt, JR (corresponding author), Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.							[Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Institute of Medicine Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care, 2003, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Stewart M, 1999, Cancer Prev Control, V3, P25	3	149	152	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2004	351	10					953	955		10.1056/NEJMp048033	http://dx.doi.org/10.1056/NEJMp048033			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	850UB	15342800				2022-12-28	WOS:000223637400002
J	Schmid, MF; Sherman, MB; Matsudaira, P; Chiu, W				Schmid, MF; Sherman, MB; Matsudaira, P; Chiu, W			Structure of the acrosomal bundle	NATURE			English	Article							LIMULUS SPERM; F-ACTIN; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; FILAMENTS; SCRUIN; STATE; TWIST; NUCLEOTIDE; RESOLUTION	In the unactivated Limulus sperm, a 60-mum-long bundle of actin filaments crosslinked by the protein scruin is bent and twisted into a coil around the base of the nucleus. At fertilization, the bundle uncoils and fully extends in five seconds to support a finger of membrane known as the acrosomal process. This biological spring is powered by stored elastic energy and does not require the action of motor proteins or actin polymerization(1). In a 9.5-Angstrom electron cryomicroscopic structure of the extended bundle, we show that twist, tilt and rotation of actin scruin subunits deviate widely from a 'standard' F-actin filament. This variability in structural organization allows filaments to pack into a highly ordered and rigid bundle in the extended state and suggests a mechanism for storing and releasing energy between coiled and extended states without disassembly.	Baylor Coll Med, Natl Ctr Macromol Imaging, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Whitehead Inst, Dept Biol, Cambridge, MA 02142 USA; MIT, Div Biol Engn, Cambridge, MA 02142 USA	Baylor College of Medicine; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Chiu, W (corresponding author), Baylor Coll Med, Natl Ctr Macromol Imaging, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.	wah@bcm.tmc.edu	Matsudaira, Paul/H-1475-2012	Matsudaira, Paul/0000-0002-8399-3276; Schmid, Michael/0000-0003-1077-5750				Borovikov YS, 2004, BIOPHYS J, V86, P3020, DOI 10.1016/S0006-3495(04)74351-9; BULLITT ESA, 1988, J CELL BIOL, V107, P597, DOI 10.1083/jcb.107.2.597; DEROSIER D, 1980, J MOL BIOL, V137, P375, DOI 10.1016/0022-2836(80)90163-1; Dominguez R, 2003, BIOPHYS J, V85, P2073, DOI 10.1016/S0006-3495(03)74635-9; Egelman EH, 2001, NAT STRUCT BIOL, V8, P735, DOI 10.1038/nsb0901-735; EGELMAN EH, 1982, NATURE, V298, P131, DOI 10.1038/298131a0; Galkin VE, 2003, J MOL BIOL, V325, P623, DOI 10.1016/S0022-2836(02)01309-8; Galkin VE, 2002, NAT STRUCT BIOL, V9, P518, DOI 10.1038/nsb811; Galkin VE, 2002, J CELL BIOL, V157, P243, DOI 10.1083/jcb.200111097; Galkin VE, 2001, J CELL BIOL, V153, P75, DOI 10.1083/jcb.153.1.75; Gardel ML, 2004, SCIENCE, V304, P1301, DOI 10.1126/science.1095087; Graceffa P, 2003, J BIOL CHEM, V278, P34172, DOI 10.1074/jbc.M303689200; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; Jiang W, 2001, J MOL BIOL, V308, P1033, DOI 10.1006/jmbi.2001.4633; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Mahadevan L, 2000, SCIENCE, V288, P95, DOI 10.1126/science.288.5463.95; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; Orlova A, 2001, J MOL BIOL, V312, P95, DOI 10.1006/jmbi.2001.4945; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Sablin EP, 2002, P NATL ACAD SCI USA, V99, P10945, DOI 10.1073/pnas.152329899; Sanders MC, 1996, J BIOL CHEM, V271, P2651, DOI 10.1074/jbc.271.5.2651; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; SCHMID MF, 1993, J MOL BIOL, V230, P384, DOI 10.1006/jmbi.1993.1155; Schmid MF, 2003, J STRUCT BIOL, V144, P195, DOI 10.1016/j.jsb.2003.09.024; Sherman MB, 1999, J MOL BIOL, V294, P139, DOI 10.1006/jmbi.1999.3222; Shin JH, 2004, J MOL BIOL, V337, P255, DOI 10.1016/j.jmb.2004.01.028; Shin JH, 2003, J CELL BIOL, V162, P1183, DOI 10.1083/jcb.200304006; TILNEY LG, 1975, J CELL BIOL, V64, P289, DOI 10.1083/jcb.64.2.289; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51	30	71	71	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2004	431	7004					104	107		10.1038/nature02881	http://dx.doi.org/10.1038/nature02881			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343340				2022-12-28	WOS:000223641500051
J	Gronthos, S				Gronthos, S			Reconstruction of human mandible by tissue engineering	LANCET			English	Editorial Material							HUMAN OSTEOGENIC PROTEIN-1; MINIATURE PIGS; STROMAL CELLS; DEFECTS; TRANSPLANTATION; REPAIR; MICE		Inst Med & Vet Sci, Div Haematol, Mesenchymal Stem Cell Grp, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia	Gronthos, S (corresponding author), Inst Med & Vet Sci, Div Haematol, Mesenchymal Stem Cell Grp, Adelaide, SA 5000, Australia.	stan.gronthos@imvs.sa.gov.au	Gronthos, Stan/Y-4419-2019	Gronthos, Stan/0000-0002-6225-3084				Campbell JH, 1999, CIRC RES, V85, P1173; Cao YL, 1997, PLAST RECONSTR SURG, V100, P297, DOI 10.1097/00006534-199708000-00001; Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958; Krebsbach PH, 1998, TRANSPLANTATION, V66, P1272, DOI 10.1097/00007890-199811270-00002; Lee JY, 2001, J BONE JOINT SURG AM, V83A, P1032, DOI 10.2106/00004623-200107000-00008; Rohner D, 2003, J BIOMED MATER RES B, V66B, P574, DOI 10.1002/jbm.b.10037; Shang QX, 2001, J CRANIOFAC SURG, V12, P586, DOI 10.1097/00001665-200111000-00017; Terheyden H, 2001, INT J ORAL MAX SURG, V30, P373, DOI 10.1054/ijom.2001.0032; Terheyden H, 2001, INT J ORAL MAX SURG, V30, P469, DOI 10.1054/ijom.2000.0008; Terheyden H, 1999, INT J ORAL MAX SURG, V28, P461, DOI 10.1034/j.1399-0020.1999.280613.x; Wright VJ, 2002, MOL THER, V6, P169, DOI 10.1006/mthe.2002.0654	11	27	28	2	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	2004	364	9436					735	736		10.1016/S0140-6736(04)16948-1	http://dx.doi.org/10.1016/S0140-6736(04)16948-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337383				2022-12-28	WOS:000223569600004
J	Monteleoni, C; Clark, E				Monteleoni, C; Clark, E			Using rapid-cycle quality improvement methodology to reduce feeding tubes in patients with advanced dementia: before and after study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NUTRITION; SURVIVAL; PROLONG	Problem Despite lack of evidence that enteral feeding tubes benefit patients with dementia, and often contrary to the wishes of patient and family, patients with dementia who have difficulty swallowing or reduced food intake often receive feeding tubes when hospitalised for an acute illness. Design We conducted a retrospective chart review of all patients receiving percutaneous endoscopic gastrostomy or jejunostomy tubes between March and September 2002. QI interventions including a palliative care consulting service and educational programmes were instituted. We conducted a second chart review for all patients receiving feeding tubes between March and September 2003. Setting 652 bed urban acute care hospital. Key measures for improvement We measured the number of feeding tubes placed in patients with dementia, the number of feeding tubes placed in patients with dementia capable of taking food by mouth, and the number of feeding tubes placed in patients with dementia with an advance directive stating the wish to forgo artificial nutrition and hydration. Strategies for change Medical and allied health staff received educational programmes on end of life care and on feeding management of patients with dementia. A palliative care consulting team was established. Effects of change After the interventions, the number of feeding tubes Placed in all patients and in patients with dementia was greatly reduced. Lessons learnt Multidisciplinary involvement, including participation by die administration, was essential to effect change in practice. The intensive focus on a particular issue and rapid change led to "culture shift" within the hospital community. The need to establish unified goals of care for each patient was highlighted. Background A growing body of research over the past decade has questioned the utility of placing feeding tubes (percutaneous endoscopic gastrostomy (PEG) or jejunostomy) in patients with advanced dementia.(1) Studies have found no evidence that feeding tubes in this population prevent aspiration,(2,3) prolong life,(4-6) improve overall function,(7) or reduce pressure sores.(8) Additionally, the quality of life of a patient with advanced dementia can be adversely affected when a feeding tube is inserted. The patient may require wrist restraints to prevent pulling on the tube(1-3) or may develop cellulitis at the gastrostomy site, develop decubitus ulcers,(1) be deprived of the social interaction and pleasure surrounding meals,(9,10) and require placement in a nursing home. Unfortunately, many doctors are unfamiliar with this literature or face barriers-attitudinal, institutional, or imposed by the healthcare industry-to applying its findings to their practice.(11) Thus feeding tubes are placed in patients who will not benefit from this intervention and whose quality of life in the terminal stage of their illness will be adversely affected. With the expected increase of elderly people with dementia,(12) a great change in doctors' knowledge, attitudes, and practice is necessary to prevent even greater numbers of patients receiving this futile treatment.	Lenox Hill Hosp, New York, NY 10021 USA	Northwell Health	Monteleoni, C (corresponding author), Lenox Hill Hosp, 100 E 77th St, New York, NY 10021 USA.	cmonteleoni@lenoxhill.net						Ahronheim JC, 1996, CLIN GERIATR MED, V12, P379; Berwick DM, 1996, BRIT MED J, V312, P619, DOI 10.1136/bmj.312.7031.619; CIOCON JO, 1988, ARCH INTERN MED, V148, P429, DOI 10.1001/archinte.148.2.429; COBBS EL, 2002, GERIATRICS REV SYLLA, P117; FINUCANE TE, 1995, J AM GERIATR SOC, V43, P447, DOI 10.1111/j.1532-5415.1995.tb05822.x; Finucane TE, 1996, LANCET, V348, P1421, DOI 10.1016/S0140-6736(96)03369-7; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; KAW M, 1995, DIGEST DIS SCI, V40, P921; Meier DE, 1997, ANN INTERN MED, V127, P225, DOI 10.7326/0003-4819-127-3-199708010-00008; Meier DE, 2001, ARCH INTERN MED, V161, P2386; Mitchell SL, 1998, J GERONTOL A-BIOL, V53, pM207, DOI 10.1093/gerona/53A.3.M207; Murphy LM, 2003, ARCH INTERN MED, V163, P1351, DOI 10.1001/archinte.163.11.1351; PECK A, 1991, J AM GERIATR SOC, V39, P732; *UN HOSP FUND, 2003, PALL CAR QUAL IMPR C; [No title captured]	15	75	79	1	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 28	2004	329	7464					491	494		10.1136/bmj.329.7464.491	http://dx.doi.org/10.1136/bmj.329.7464.491			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KS	15331474	Green Published			2022-12-28	WOS:000223684600016
J	de Quervain, DJF; Fischbacher, U; Treyer, V; Schelthammer, M; Schnyder, U; Buck, A; Fehr, E				de Quervain, DJF; Fischbacher, U; Treyer, V; Schelthammer, M; Schnyder, U; Buck, A; Fehr, E			The neural basis of altruistic punishment	SCIENCE			English	Article							INCREASING MONETARY REWARD; PREFRONTAL CORTEX; DORSAL STRIATUM; NEURONAL-ACTIVITY; DECISION-MAKING; BRAIN ACTIVITY; RESPONSES; EXPECTATION; COOPERATION; EVOLUTION	Many people voluntarily incur costs to punish violations of social norms. Evolutionary models and empirical evidence indicate that such altruistic punishment has been a decisive force in the evolution of human cooperation. We used (H2O)-O-15 positron emission tomography to examine the neural basis for altruistic punishment of defectors in an economic exchange. Subjects could punish defection either symbolically or effectively. Symbolic punishment did not reduce the defector's economic payoff, whereas effective punishment did reduce the payoff. We scanned the subjects' brains while they learned about the defector's abuse of trust and determined the punishment. Effective punishment, as compared with symbolic punishment, activated the dorsal striatum, which has been implicated in the processing of rewards that accrue as a result of goal-directed actions. Moreover, subjects with stronger activations in the dorsal striatum were willing to incur greater costs in order to punish. Our findings support the hypothesis that people derive satisfaction from punishing norm violations and that the activation in the dorsal striatum reflects the anticipated satisfaction from punishing defectors.	Univ Zurich, Div Psychiat Res, CH-8029 Zurich, Switzerland; Univ Zurich, Inst Empir Res Econ, CH-8006 Zurich, Switzerland; Univ Zurich Hosp, PET Ctr, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Psychiat, CH-8091 Zurich, Switzerland; Coll Helveticum, CH-8092 Zurich, Switzerland	University of Zurich; University of Zurich; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	de Quervain, DJF (corresponding author), Univ Zurich, Div Psychiat Res, Lenggstr 31, CH-8029 Zurich, Switzerland.	quervain@bti.unizh.ch; efehr@iew.unizh.ch	Treyer, Valerie/G-6986-2018; Fischbacher, Urs/H-2693-2014	Treyer, Valerie/0000-0002-4584-3031; Fischbacher, Urs/0000-0002-5115-8815; de Quervain, Dominique/0000-0001-7131-2464; Schnyder, Ulrich/0000-0003-3556-7990				Adolphs R, 2003, NAT REV NEUROSCI, V4, P165, DOI 10.1038/nrn1056; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; APICELLA P, 1991, EXP BRAIN RES, V85, P491; Arana FS, 2003, J NEUROSCI, V23, P9632; BATSON CD, 1987, J PERS SOC PSYCHOL, V53, P594, DOI 10.1037/0022-3514.53.3.594; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bowles S, 2004, THEOR POPUL BIOL, V65, P17, DOI 10.1016/j.tpb.2003.07.001; Boyd R, 2003, P NATL ACAD SCI USA, V100, P3531, DOI 10.1073/pnas.0630443100; Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8; Camerer C.F., 2011, BEHAV GAME THEORY EX, DOI 10.1257/jep.9.2.209; Delgado MR, 2003, COGN AFFECT BEHAV NE, V3, P27, DOI 10.3758/CABN.3.1.27; Delgado MR, 2004, CEREB CORTEX, V14, P1022, DOI 10.1093/cercor/bhh062; Delgado MR, 2000, J NEUROPHYSIOL, V84, P3072, DOI 10.1152/jn.2000.84.6.3072; Elliott R, 2003, J NEUROSCI, V23, P303; Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a; Fehr E, 2003, NATURE, V425, P785, DOI 10.1038/nature02043; Fehr E, 1999, Q J ECON, V114, P817, DOI 10.1162/003355399556151; Greene JD, 2001, SCIENCE, V293, P2105, DOI 10.1126/science.1062872; HIKOSAKA O, 1989, J NEUROPHYSIOL, V61, P814, DOI 10.1152/jn.1989.61.4.814; Hollerman JR, 1998, J NEUROPHYSIOL, V80, P947, DOI 10.1152/jn.1998.80.2.947; Kawagoe R, 1998, NAT NEUROSCI, V1, P411, DOI 10.1038/1625; Knutson B, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0002.2001; Knutson B, 2000, NEUROIMAGE, V12, P20, DOI 10.1006/nimg.2000.0593; Koepp MJ, 1998, NATURE, V393, P266, DOI 10.1038/30498; Krawczyk DC, 2002, NEUROSCI BIOBEHAV R, V26, P631, DOI 10.1016/S0149-7634(02)00021-0; Martin-Soelch C, 2003, EUR J NEUROSCI, V18, P680, DOI 10.1046/j.1460-9568.2003.02791.x; McCabe K, 2001, P NATL ACAD SCI USA, V98, P11832, DOI 10.1073/pnas.211415698; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Moll J, 2002, J NEUROSCI, V22, P2730, DOI 10.1523/JNEUROSCI.22-07-02730.2002; O'Doherty J, 2004, SCIENCE, V304, P452, DOI 10.1126/science.1094285; RABIN M, 1993, AM ECON REV, V83, P1281; Ramnani N, 2004, NAT REV NEUROSCI, V5, P184, DOI 10.1038/nrn1343; Rilling JK, 2002, NEURON, V35, P395, DOI 10.1016/S0896-6273(02)00755-9; Salinas JA, 1998, BEHAV NEUROSCI, V112, P812, DOI 10.1037/0735-7044.112.4.812; Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976; Schultz W, 2000, NAT REV NEUROSCI, V1, P199, DOI 10.1038/35044563; SCHULTZ W, 1988, EXP BRAIN RES, V71, P431; Singer T, 2004, NEURON, V41, P653, DOI 10.1016/S0896-6273(04)00014-5; Sober E., 1998, OTHERS EVOLUTION PSY; Stein EA, 1998, AM J PSYCHIAT, V155, P1009, DOI 10.1176/ajp.155.8.1009; Wagner AD, 2001, NEUROIMAGE, V14, P1337, DOI 10.1006/nimg.2001.0936	41	972	981	5	246	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2004	305	5688					1254	1258		10.1126/science.1100735	http://dx.doi.org/10.1126/science.1100735			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850PJ	15333831	Green Submitted			2022-12-28	WOS:000223624600031
J	Klein, DE; Nappi, VM; Reeves, GT; Shvartsman, SY; Lemmon, MA				Klein, DE; Nappi, VM; Reeves, GT; Shvartsman, SY; Lemmon, MA			Argos inhibits epidermal growth factor receptor signalling by ligand sequestration	NATURE			English	Article							SECRETED SPITZ; DROSOPHILA; PATHWAY; SULFATE; BINDING; ACTIVATION; PROTEINS	The epidermal growth factor receptor ( EGFR) has critical functions in development and in many human cancers(1-3). During development, the spatial extent of EGFR signalling is regulated by feedback loops comprising both well-understood activators and less well-characterized inhibitors(3,4). In Drosophila melanogaster the secreted protein Argos functions as the only known extracellular inhibitor of EGFR(5), with clearly identified roles in multiple stages of development(3). Argos is only expressed when the Drosophila EGFR (DER) is activated at high levels(6), and downregulates further DER signalling. Although there is ample genetic evidence that Argos inhibits DER activation, the biochemical mechanism has not been established. Here we show that Argos inhibits DER signalling without interacting directly with the receptor, but instead by sequestering the DER-activating ligand Spitz. Argos binds tightly to the EGF motif of Spitz and forms a 1:1 ( Spitz: Argos) complex that does not bind DER in vitro or at the cell surface. Our results provide an insight into the mechanism of Argos function, and suggest new strategies for EGFR inhibitor design.	Univ Penn, Sch Med, Dept Biochem & Biophys, Stellar Chance Labs 809C, Philadelphia, PA 19104 USA; Princeton Univ, Dept Chem Engn, Carl Icahn Lab, Princeton, NJ 08544 USA; Princeton Univ, Lewis Sigler Inst Integrat Genom, Carl Icahn Lab, Princeton, NJ 08544 USA	University of Pennsylvania; Princeton University; Princeton University	Lemmon, MA (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Stellar Chance Labs 809C, 422 Curie Blvd, Philadelphia, PA 19104 USA.	mlemmon@mail.med.upenn.edu	Shvartsman, Stanislav/GPP-4025-2022	Shvartsman, Stanislav/0000-0002-9152-9334; Lemmon, Mark/0000-0002-3379-5319; Klein, Daryl/0000-0002-7188-0450	NCI NIH HHS [R01 CA125432, R01 CA079992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079992, R01CA125432] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27; Barkai N, 2002, CURR BIOL, V12, pR493, DOI 10.1016/S0960-9822(02)00967-3; Duan C, 2002, J ENDOCRINOL, V175, P41, DOI 10.1677/joe.0.1750041; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Golembo M, 1996, DEVELOPMENT, V122, P223; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; Howes R, 1998, J BIOL CHEM, V273, P4275, DOI 10.1074/jbc.273.7.4275; Jin MH, 2000, MOL CELL BIOL, V20, P2098, DOI 10.1128/MCB.20.6.2098-2107.2000; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kramer KL, 2003, ANNU REV GENET, V37, P461, DOI 10.1146/annurev.genet.37.061103.090226; Mantovani A, 2001, TRENDS IMMUNOL, V22, P328, DOI 10.1016/S1471-4906(01)01941-X; Mattoon D, 2004, P NATL ACAD SCI USA, V101, P923, DOI 10.1073/pnas.0307286101; Paine-Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200; Powell AK, 2004, GLYCOBIOLOGY, V14, p17R, DOI 10.1093/glycob/cwh051; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SCHLESSINGER J, 1978, P NATL ACAD SCI USA, V75, P2659, DOI 10.1073/pnas.75.6.2659; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; Shilo BZ, 2003, EXP CELL RES, V284, P140, DOI 10.1016/S0014-4827(02)00094-0; Shvartsman SY, 2002, DEVELOPMENT, V129, P2577; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; Vinos J, 2000, ONCOGENE, V19, P3560, DOI 10.1038/sj.onc.1203702; Wasserman JD, 1998, CELL, V95, P355, DOI 10.1016/S0092-8674(00)81767-5; Wiley HS, 2003, TRENDS CELL BIOL, V13, P43; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	27	104	109	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2004	430	7003					1040	1044		10.1038/nature02840	http://dx.doi.org/10.1038/nature02840			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329724				2022-12-28	WOS:000223514900046
J	Nakamura, D; Gunjishima, I; Yamaguchi, S; Ito, T; Okamoto, A; Kondo, H; Onda, S; Takatori, K				Nakamura, D; Gunjishima, I; Yamaguchi, S; Ito, T; Okamoto, A; Kondo, H; Onda, S; Takatori, K			Ultrahigh-quality silicon carbide single crystals	NATURE			English	Article							SUBLIMATION GROWTH; DEGRADATION; MICROPIPES; PIN; 6H	Silicon carbide (SiC) has a range of useful physical, mechanical and electronic properties that make it a promising material for next-generation electronic devices(1,2). Careful consideration of the thermal conditions(3-6) in which SiC {0001} is grown has resulted in improvements in crystal diameter and quality: the quantity of macroscopic defects such as hollow core dislocations (micropipes)(7-9), inclusions, small-angle boundaries and long-range lattice warp has been reduced(10,11). But some macroscopic defects (about 1-10 cm(-2)) and a large density of elementary dislocations (similar to10(4) cm(-2)), such as edge, basal plane and screw dislocations, remain within the crystal, and have so far prevented the realization of high-efficiency, reliable electronic devices in SiC (refs 12-16). Here we report a method, inspired by the dislocation structure of SiC grown perpendicular to the c-axis (a-face growth)(17), to reduce the number of dislocations in SiC single crystals by two to three orders of magnitude, rendering them virtually dislocation-free. These substrates will promote the development of high-power SiC devices and reduce energy losses of the resulting electrical systems.	Toyota Cent Res & Dev Labs Inc, Aichi 4801192, Japan; DENSO Corp, Res Labs, Aichi 4700111, Japan	Toyota Central R&D Labs Inc; DENSO	Takatori, K (corresponding author), Toyota Cent Res & Dev Labs Inc, Aichi 4801192, Japan.	takatori@mosk.tytlabs.co.jp	Nakamura, Daisuke/AAT-8854-2021	Nakamura, Daisuke/0000-0002-7808-0528				BHATNAGAR M, 1993, IEEE T ELECTRON DEV, V40, P645, DOI 10.1109/16.199372; DASH WC, 1959, J APPL PHYS, V30, P459, DOI 10.1063/1.1702390; FRANK FC, 1951, ACTA CRYSTALLOGR, V4, P497, DOI 10.1107/S0365110X51001690; Gutkin MY, 2003, J APPL PHYS, V94, P7076, DOI 10.1063/1.1624481; Harris CI, 2001, APPL SURF SCI, V184, P393, DOI 10.1016/S0169-4332(01)00525-6; Heindl J, 1998, PHYS REV LETT, V80, P740, DOI 10.1103/PhysRevLett.80.740; Kato T, 2001, J CRYST GROWTH, V222, P579, DOI 10.1016/S0022-0248(00)00958-1; Lendenmann H, 2001, MATER SCI FORUM, V353-356, P727, DOI 10.4028/www.scientific.net/MSF.353-356.727; Malhan RK, 2002, MATER SCI FORUM, V433-4, P917, DOI 10.4028/www.scientific.net/MSF.433-436.917; Matsunami H, 1997, MAT SCI ENG R, V20, P125, DOI 10.1016/S0927-796X(97)00005-3; Muller St.G., 2003, MATER SCI FORUM, V433, P39; Neudeck PG, 1998, SOLID STATE ELECTRON, V42, P2157, DOI 10.1016/S0038-1101(98)00211-1; Oyanagi N, 2002, MATER SCI FORUM, V389-3, P87, DOI 10.4028/www.scientific.net/MSF.389-393.87; Selder M, 2001, J CRYST GROWTH, V226, P501, DOI 10.1016/S0022-0248(01)01401-4; SENZAKI J, 2004, 51 SPRING M JSAP, V1, P433; Stahlbush RE, 2002, MATER SCI FORUM, V389-3, P427, DOI 10.4028/www.scientific.net/MSF.389-393.427; STMULLER G, 2001, MATER SCI FORUM, V389, P23; TAIROV YM, 1978, J CRYST GROWTH, V43, P209, DOI 10.1016/0022-0248(78)90169-0; Takahashi J, 1997, J CRYST GROWTH, V181, P229, DOI 10.1016/S0022-0248(97)00289-3; TANIMOTO S, 2004, 51 SPRING M JSAP, V1, P434; Yakimova R, 1999, MAT SCI ENG B-SOLID, V61-2, P54, DOI 10.1016/S0921-5107(98)00444-9; Zulehner W, 2000, MAT SCI ENG B-SOLID, V73, P7, DOI 10.1016/S0921-5107(99)00427-4	22	312	337	13	232	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2004	430	7003					1009	1012		10.1038/nature02810	http://dx.doi.org/10.1038/nature02810			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329716				2022-12-28	WOS:000223514900038
J	Punckt, C; Bolscher, M; Rotermund, HH; Mikhailov, AS; Organ, L; Budiansky, N; Scully, JR; Hudson, JL				Punckt, C; Bolscher, M; Rotermund, HH; Mikhailov, AS; Organ, L; Budiansky, N; Scully, JR; Hudson, JL			Sudden onset of pitting corrosion on stainless steel as a critical phenomenon	SCIENCE			English	Article							COOPERATIVE STOCHASTIC-BEHAVIOR; LOCALIZED CORROSION; MNS INCLUSIONS; INITIATION; ALLOYS; MICROSCOPY; PASSIVITY; ALUMINUM; GROWTH; METALS	Stainless steels undergo a sharp rise in pitting corrosion rate as the potential, solution concentration, or temperature is changed only slightly. We report experiments using real-time microscopic in situ visualizations that resolve the nucleation and evolution of individual pits during the transition. They suggest that the sudden onset of corrosion is explained by an explosive autocatalytic growth in the number of metastable pits and that stabilization of individual pits takes place only later. This finding agrees with a theoretical approach treating the onset of pitting corrosion as a cooperative critical phenomenon resulting from interactions among metastable pits, and it extends perspectives on the control and prevention of corrosion onset.	Univ Virginia, Dept Chem Engn, Charlottesville, VA 22904 USA; Max Planck Gesell, Fritz Haber Inst, Phys Chem Abt, D-14195 Berlin, Germany; Univ Virginia, Dept Mat Sci & Engn, Charlottesville, VA 22904 USA	University of Virginia; Max Planck Society; Fritz Haber Institute of the Max Planck Society; University of Virginia	Hudson, JL (corresponding author), Univ Virginia, Dept Chem Engn, 102 Engineers Way, Charlottesville, VA 22904 USA.	hudson@virginia.edu	Punckt, Christian/A-1845-2011	Punckt, Christian/0000-0003-2120-5980				BAKER MA, 1993, CORROS SCI, V34, P667, DOI 10.1016/0010-938X(93)90279-P; BERTOCCI U, 1986, J ELECTROCHEM SOC, V133, P1782, DOI 10.1149/1.2109018; Buchler M, 2000, CORROS SCI, V42, P1661, DOI 10.1016/S0010-938X(00)00020-2; COLLINS JA, 1973, MATER PROT PERFORM, V12, P11; Frankel GS, 1998, J ELECTROCHEM SOC, V145, P2186, DOI 10.1149/1.1838615; Garfias LF, 2000, J ELECTROCHEM SOC, V147, P2525, DOI 10.1149/1.1393564; ISAACS HS, 1985, J ELECTROCHEM SOC, V132, P1288, DOI 10.1149/1.2114104; Isaacs HS, 2000, CORROSION, V56, P971, DOI 10.5006/1.3294386; Jones RL, 1996, MATER PERFORMANCE, V35, P63; KE R, 1992, J ELECTROCHEM SOC, V139, P1573, DOI 10.1149/1.2069458; Lim YS, 2001, CORROS SCI, V43, P53, DOI 10.1016/S0010-938X(00)00074-3; Lunt TT, 1997, J ELECTROCHEM SOC, V144, P1620, DOI 10.1149/1.1837651; Lunt TT, 2002, J ELECTROCHEM SOC, V149, pB163, DOI 10.1149/1.1466858; PISTORIUS PC, 1992, PHILOS T ROY SOC A, V341, P531, DOI 10.1098/rsta.1992.0114; REUTER M, 1990, ELECTROCHIM ACTA, V35, P1809, DOI 10.1016/0013-4686(90)87083-E; ROTERMUND HH, 1995, SCIENCE, V270, P608, DOI 10.1126/science.270.5236.608; Ryan MP, 1998, J ELECTROCHEM SOC, V145, P1566, DOI 10.1149/1.1838519; Ryan MP, 2002, NATURE, V415, P770, DOI 10.1038/415770a; Sasaki K, 2004, J ELECTROCHEM SOC, V151, pB124, DOI 10.1149/1.1641040; SUGIMOTO K, 1985, J ELECTROCHEM SOC, V132, P1791, DOI 10.1149/1.2114219; SZKLARSKASMIALO.Z, 1986, PITTING CORROSION ME; Tronstad L, 1929, NATURE, V124, P373, DOI 10.1038/124373a0; Tronstad L, 1929, Z PHYS CHEM A-CHEM T, V142, P241; WILLIAMS DE, 1991, NATURE, V350, P216, DOI 10.1038/350216a0; WILLIAMS DE, 1985, J ELECTROCHEM SOC, V132, P1796, DOI 10.1149/1.2114220; Wu B, 1997, J ELECTROCHEM SOC, V144, P1614, DOI 10.1149/1.1837650	26	208	217	17	219	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	2004	305	5687					1133	1136		10.1126/science.1101358	http://dx.doi.org/10.1126/science.1101358			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326349				2022-12-28	WOS:000223557400041
J	Leaning, J				Leaning, J			Diagnosing genocide - The case of Darfur	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Publ Hlth, Program Humanitarian Crises & Human Rights, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Leaning, J (corresponding author), Harvard Univ, Sch Publ Hlth, Program Humanitarian Crises & Human Rights, 665 Huntington Ave, Boston, MA 02115 USA.							[Anonymous], 1948, CONV PREV PUN CRIM G; *PHYS HUM RIGHTS, PHR CALLS INT SAV LI	2	12	12	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2004	351	8					735	738		10.1056/NEJMp048206	http://dx.doi.org/10.1056/NEJMp048206			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847CY	15317882				2022-12-28	WOS:000223367900001
J	Edamatsu, K; Oohata, G; Shimizu, R; Itoh, T				Edamatsu, K; Oohata, G; Shimizu, R; Itoh, T			Generation of ultraviolet entangled photons in a semiconductor	NATURE			English	Article							MOLECULES	Entanglement is one of the key features of quantum information and communications technology. The method that has been used most frequently to generate highly entangled pairs of photons(1,2) is parametric down-conversion. Short-wavelength entangled photons are desirable for generating further entanglement between three or four photons, but it is difficult to use parametric down-conversion to generate suitably energetic entangled photon pairs. One method that is expected to be applicable for the generation of such photons(3) is resonant hyper-parametric scattering (RHPS): a pair of entangled photons is generated in a semiconductor via an electronically resonant third-order non-linear optical process. Semiconductor-based sources of entangled photons would also be advantageous for practical quantum technologies, but attempts to generate entangled photons in semiconductors have not yet been successful(4,5). Here we report experimental evidence for the generation of ultraviolet entangled photon pairs by means of biexciton resonant RHPS in a single crystal of the semiconductor CuCl. We anticipate that our results will open the way to the generation of entangled photons by current injection, analogous to current-driven single photon sources(6,7).	Tohoku Univ, Elect Commun Res Inst, Sendai, Miyagi 9808577, Japan; Japan Sci & Technol Agcy, CREST, Tokyo, Japan; JST, ERATO, Semicond Spintron Project, Tokyo, Japan; Osaka Univ, Grad Sch Engn Sci, Toyonaka, Osaka 5608531, Japan	Tohoku University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Osaka University	Edamatsu, K (corresponding author), Tohoku Univ, Elect Commun Res Inst, Sendai, Miyagi 9808577, Japan.	eda@riec.tohoku.ac.jp						Boto AN, 2000, PHYS REV LETT, V85, P2733, DOI 10.1103/PhysRevLett.85.2733; HONERLAGE B, 1985, PHYS REP, V124, P161, DOI 10.1016/0370-1573(85)90025-0; ITOH T, 1978, J PHYS SOC JPN, V45, P1939, DOI 10.1143/JPSJ.45.1939; James DFV, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.052312; KUWATA M, 1982, OPT COMMUN, V40, P208, DOI 10.1016/0030-4018(82)90262-0; Kwiat PG, 1999, PHYS REV A, V60, pR773, DOI 10.1103/PhysRevA.60.R773; KWIAT PG, 1995, PHYS REV LETT, V75, P4337, DOI 10.1103/PhysRevLett.75.4337; Mitchell MW, 2004, NATURE, V429, P161, DOI 10.1038/nature02493; Munro WJ, 2001, J MOD OPTIC, V48, P1239, DOI 10.1080/095003400110034532; Saba M, 2001, NATURE, V414, P731, DOI 10.1038/414731a; Santori C, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.045308; Savasta S, 1999, SOLID STATE COMMUN, V111, P495, DOI 10.1016/S0038-1098(99)00233-1; Shimano R, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.233601; Stace TM, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.085317; Strekalov DV, 2002, J MOD OPTIC, V49, P519, DOI 10.1080/09500340110090846; UETA M, 1986, EXCITONIC PROCESSES, pCH3; Walther P, 2004, NATURE, V429, P158, DOI 10.1038/nature02552; WHITE AG, 2001, PHYS REV A, V65; Yuan ZL, 2002, SCIENCE, V295, P102, DOI 10.1126/science.1066790	20	156	158	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2004	431	7005					167	170		10.1038/nature02838	http://dx.doi.org/10.1038/nature02838			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356626				2022-12-28	WOS:000223746000039
J	Liu, BA; Juurlink, DN				Liu, BA; Juurlink, DN			Drugs and the QT interval - Caveat doctor	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Toronto, Dept Med, Toronto, ON, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Geriatr Med, Toronto, ON, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Gen Internal Med, Toronto, ON, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Clin Pharmacol, Toronto, ON, Canada	University of Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Liu, BA (corresponding author), Univ Toronto, Dept Med, Toronto, ON, Canada.							Al-Khatib SM, 2003, JAMA-J AM MED ASSOC, V289, P2120, DOI 10.1001/jama.289.16.2120; Alkhatib SM, 2003, JAMA-J AM MED ASSOC, V290, P1318; Dresser George K, 2002, Can J Clin Pharmacol, V9, P191; Roden DM, 2004, NEW ENGL J MED, V350, P1013, DOI 10.1056/NEJMra032426	4	43	46	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2004	351	11					1053	1056		10.1056/NEJMp048192	http://dx.doi.org/10.1056/NEJMp048192			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CX	15356302				2022-12-28	WOS:000223733900004
J	Pansegrau, GK; Gelmon, KA				Pansegrau, GK; Gelmon, KA			Lymph-node-negative oestrogen-receptor-positive breast cancer	LANCET			English	Editorial Material							RANDOMIZED-TRIAL; COMBINATION CHEMOTHERAPY; POSTMENOPAUSAL WOMEN; ADJUVANT TREATMENT; TAMOXIFEN THERAPY; OUTCOMES		British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada	British Columbia Cancer Agency	Gelmon, KA (corresponding author), British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.	kgelmon@bccancer.bc.ca						Baum M, 2003, Cancer, V98, P1802; BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; Chia SK, 2004, J CLIN ONCOL, V22, P1630, DOI 10.1200/JCO.2004.09.070; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331; FISHER B, 1990, J CLIN ONCOL, V8, P1005, DOI 10.1200/JCO.1990.8.6.1005; Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Joensuu H, 2003, CLIN CANCER RES, V9, P923; MARTIN M, 2003, SAN ANT BREAST CANC	10	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2004	364	9437					820	821		10.1016/S0140-6736(04)16994-8	http://dx.doi.org/10.1016/S0140-6736(04)16994-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351171				2022-12-28	WOS:000223685200005
J	Poole-Wilson, PA; Lubsen, J; Kirwan, BA; van Dalen, FJ; Wagener, G; Danchin, N; Just, H; Fox, KAA; Pocock, SJ; Clayton, TC; Motro, M; Parker, JD; Bourassa, MG; Dart, AM; Hildebrandt, P; Hjalmarson, A; Kragten, JA; Molhoek, GP; Otterstad, JE; Seabra-Gomes, R; Soler-Soler, J; Weber, S				Poole-Wilson, PA; Lubsen, J; Kirwan, BA; van Dalen, FJ; Wagener, G; Danchin, N; Just, H; Fox, KAA; Pocock, SJ; Clayton, TC; Motro, M; Parker, JD; Bourassa, MG; Dart, AM; Hildebrandt, P; Hjalmarson, A; Kragten, JA; Molhoek, GP; Otterstad, JE; Seabra-Gomes, R; Soler-Soler, J; Weber, S		ACTION investigators	Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial	LANCET			English	Article							CALCIUM-CHANNEL BLOCKER; ANTAGONISTS; RISK	Background Calcium antagonists are widely prescribed for angina pectoris but their effect on clinical outcome is controversial. We aimed to investigate the effect of the calcium antagonist nifedipine on long-term outcome in patients with stable angina pectoris. Methods We randomly assigned 3825 patients with treated stable symptomatic coronary disease to double-blind addition of nifedipine GITS (gastrointestinal therapeutic system) 60 mg once daily and 3840 to placebo. The primary endpoint was the combination of death, acute myocardial infarction, refractory angina, new overt heart failure, debilitating stroke, and peripheral revascularisation. Mean follow-up was 4.9 years (SD 1.1). Analysis was by intention to treat. Findings 310 patients allocated nifedipine died (1.64 per 100 patient-years) compared with 291 people allocated placebo (1.53 per 100 patient-years; hazard ratio 1.07 [95% CI 0.91-1.25], p=0.41). Primary endpoint rates were 4.60 per 100 patient-years for nifedipine and 4.75 per 100 patient-years for placebo (0.97 [0.88-1.07], p=0.54). With nifedipine, rate of death and any cardiovascular event or procedure was 9.32 per 100 patient-years versus 10.50 per 100 patient-years for placebo (0.89 [0.83-0.95], p=0.0012). The difference was mainly attributable to a reduction in the need for coronary angiography and interventions in patients assigned nifedipine, despite an increase in peripheral revascularisation. Nifedipine had no effect on the rate of myocardial infarction. Interpretation Addition of nifedipine GITS to conventional treatment of angina pectoris has no effect on major cardiovascular event-free survival. Nifedipine GITS is safe and reduces the need for coronary angiography and interventions.	Univ London Imperial Coll Sci Technol & Med, London SW3 6LY, England; Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands; SOCAR Res, Nyon, Switzerland; Bayer HealthCare, Pharma Res Ctr, Wuppertal, Germany; Georges Pompidou European Hosp, Dept Cardiol, Paris, France; Univ Freiburg, Freiburg, Germany; Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland; London Sch Hyg & Trop Med, Med Stat Unit, London WC1, England; Tel Aviv Univ, Chaim Sheba Med Ctr, Ringers Res Unit, IL-69978 Tel Aviv, Israel; Univ Hlth Network, Div Cardiol, Toronto, ON, Canada; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Montreal Heart Inst, Dept Med, Montreal, PQ H1T 1C8, Canada; Monash Univ, Alfred Hosp, Melbourne, Vic 3181, Australia; Frederiksberg Univ Hosp, Dept Cardiol & Endocrinol, Frederiksberg, Denmark; Sahlgrens Univ Hosp, Cardiovasc Inst, S-41345 Gothenburg, Sweden; Atrium Med Ctr, Heerlen, Netherlands; Med Spectrum Twente, Enschede, Netherlands; Vestfold Hosp, Div Cardiol, Tonsberg, Norway; Hosp Santa Cruz, Dept Cardiol, Lisbon, Portugal; Vall Hebron Univ Hosp, Dept Cardiol, Barcelona, Spain; Univ Paris 05, Dept Cardiol, Paris, France	Imperial College London; Erasmus University Rotterdam; Erasmus MC; Bayer AG; Bayer Healthcare Pharmaceuticals; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Freiburg; University of Edinburgh; University of London; London School of Hygiene & Tropical Medicine; Chaim Sheba Medical Center; Tel Aviv University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Universite de Montreal; Florey Institute of Neuroscience & Mental Health; Monash University; Sahlgrenska University Hospital; Atrium Medical Center; Medical Spectrum Twente; Universidade de Lisboa; Hospital Universitari Vall d'Hebron; UDICE-French Research Universities; Universite Paris Cite	Poole-Wilson, PA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dovehouse St, London SW3 6LY, England.	p.poole-wilson@imperial.ac.uk	Danchin, Nicolas/AAN-8291-2020; Dart, Anthony M/E-7461-2010; Fox, keith A A/I-3742-2013; Gonçalves, Sandro Cadaval/W-5228-2019	Dart, Anthony M/0000-0003-1360-3778; Parker, John/0000-0003-1949-2669; Bourassa, Martial G./0000-0002-4439-8650; Clayton, Tim/0000-0002-1266-3288; Kirwan, Bridget-Anne/0000-0002-3814-3598; Fox, Keith/0000-0002-0140-2752				Alderman MH, 1997, LANCET, V349, P594, DOI 10.1016/S0140-6736(96)08359-6; Brown MJ, 2000, LANCET, V356, P366, DOI 10.1016/S0140-6736(00)02527-7; Dargie HJ, 2002, LANCET, V359, P1269, DOI 10.1016/s0140-6736(02)08265-x; Dargie HJ, 1996, EUR HEART J, V17, P104; Fox KM, 2003, LANCET, V362, P782; Furberg CD, 1996, CIRCULATION, V93, P1475; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; HORTON R, 1995, LANCET, V346, P586, DOI 10.1016/S0140-6736(95)91429-3; LENFANT C, 1995, CIRCULATION, V91, P2855, DOI 10.1161/01.CIR.91.12.2855; Lubsen J, 2002, STAT MED, V21, P2959, DOI 10.1002/sim.1300; Lubsen J., 1998, European Heart Journal, V19, P120; Neal B, 2000, LANCET, V356, P1955; OPIE LH, 1995, CIRCULATION, V92, P1068, DOI 10.1161/01.CIR.92.5.1068; OPIE LH, 1995, LANCET, V346, P961; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; PEDERSEN TR, 1994, LANCET, V344, P1383; Poole-Wilson PA, 2002, LANCET, V359, P2199, DOI 10.1016/S0140-6736(02)09068-2; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; Turnbull F, 2003, LANCET, V362, P1527; Yusuf S, 2000, NEW ENGL J MED, V342, P145	21	406	460	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2004	364	9437					849	857		10.1016/S0140-6736(04)16980-8	http://dx.doi.org/10.1016/S0140-6736(04)16980-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351192				2022-12-28	WOS:000223685200031
J	Daly, ME				Daly, ME			Extending the use of the glycaemic index: beyond diabetes?	LANCET			English	Editorial Material							CORONARY-HEART-DISEASE; RISK; IMPROVES; INSULIN; GLUCOSE; PROFILE; WOMEN; LOAD; DIET; MEN		Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England	University of Exeter	Daly, ME (corresponding author), Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England.	M.E.Daly@exeter.ac.uk						BRANDMILLER JC, HOME GLYCAEMIC INDEX; Brynes AE, 2003, DIABETES CARE, V26, P548, DOI 10.2337/diacare.26.2.548; Brynes AE, 2003, BRIT J NUTR, V89, P207, DOI 10.1079/BJN2002769; Frost G, 1998, METABOLISM, V47, P1245, DOI 10.1016/S0026-0495(98)90331-6; Frost G, 1999, LANCET, V353, P1045, DOI 10.1016/S0140-6736(98)07164-5; FROST G, 1994, DIABETIC MED, V11, P397, DOI 10.1111/j.1464-5491.1994.tb00292.x; Liu SM, 2000, AM J CLIN NUTR, V71, P1455; Salmeron J, 1997, DIABETES CARE, V20, P545, DOI 10.2337/diacare.20.4.545	8	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	2004	364	9436					736	737		10.1016/S0140-6736(04)16949-3	http://dx.doi.org/10.1016/S0140-6736(04)16949-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337384				2022-12-28	WOS:000223569600005
J	Copeland, JG; Smith, RG; Arabia, FA; Nolan, PE; Sethi, GK; Tsau, PH; McClellan, D; Slepian, MJ; Foy, B; Long, J; Doty, D; Tector, A; Kormos, R				Copeland, JG; Smith, RG; Arabia, FA; Nolan, PE; Sethi, GK; Tsau, PH; McClellan, D; Slepian, MJ; Foy, B; Long, J; Doty, D; Tector, A; Kormos, R		CardioWest Total Artificial Heart	Cardiac replacement with a total artificial heart as a bridge to transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VENTRICULAR ASSIST SYSTEM; NOVACOR; THORATEC; SUPPORT; EXPERIENCE; DEVICE	BACKGROUND: The CardioWest Total Artificial Heart orthotopically replaces both native cardiac ventricles and all cardiac valves, thus eliminating problems commonly seen in the bridge to transplantation with left ventricular and biventricular assist devices, such as right heart failure, valvular regurgitation, cardiac arrhythmias, ventricular clots, intraventricular communications, and low blood flows. METHODS: We conducted a nonrandomized, prospective study in five centers with the use of historical controls. The purpose was to assess the safety and efficacy of the CardioWest Total Artificial Heart in transplant-eligible patients at risk for imminent death from irreversible biventricular cardiac failure. The primary end points included the rates of survival to heart transplantation and of survival after transplantation. RESULTS: Eighty-one patients received the artificial-heart device. The rate of survival to transplantation was 79 percent (95 percent confidence interval, 68 to 87 percent). Of the 35 control patients who met the same entry criteria but did not receive the artificial heart, 46 percent survived to transplantation (P<0.001). Overall, the one-year survival rate among the patients who received the artificial heart was 70 percent, as compared with 31 percent among the controls (P<0.001). One-year and five-year survival rates after transplantation among patients who had received a total artificial heart as a bridge to transplantation were 86 and 64 percent. CONCLUSIONS: Implantation of the total artificial heart improved the rate of survival to cardiac transplantation and survival after transplantation. This device prevents death in critically ill patients who have irreversible biventricular failure and are candidates for cardiac transplantation.	Univ Arizona, Sarver Heart Ctr, Tucson, AZ 85724 USA; Univ Arizona, Marshall Fdn Artificial Heart Program, Tucson, AZ 85724 USA; Univ Arizona, Coll Pharm, Tucson, AZ 85724 USA	University of Arizona; University of Arizona; University of Arizona	Copeland, JG (corresponding author), Univ Arizona, Sarver Heart Ctr, 1501 N Campbell Ave,4402, Tucson, AZ 85724 USA.	jgcbriez@aol.com	Slepian, Marvin/ABG-8305-2020	Slepian, Marvin/0000-0002-7864-6691				[Anonymous], 2001, 2001 ANN REP US ORG, V1, P439; Arabia FA, 1999, ANN THORAC SURG, V68, P698, DOI 10.1016/S0003-4975(99)00540-8; Copeland Jack G., 2003, Cardiology Clinics, V21, P101, DOI 10.1016/S0733-8651(02)00136-4; Copeland JG, 1998, ANN THORAC SURG, V66, P1662, DOI 10.1016/S0003-4975(98)00896-0; Copeland JG, 2001, ANN THORAC SURG, V71, pS92, DOI 10.1016/S0003-4975(00)02625-4; Copeland JG, 1996, J HEART LUNG TRANSPL, V15, P94; Copeland JG, 1999, ANN THORAC SURG, V68, P756, DOI 10.1016/S0003-4975(99)00526-3; Copeland JG, 2001, J HEART LUNG TRANSPL, V20, P654, DOI 10.1016/S1053-2498(01)00248-0; COPELAND JG, 2002, CLIN TRANSPLANTS 200, P203; Di Bella I, 2000, EUR J CARDIO-THORAC, V18, P112, DOI 10.1016/S1010-7940(00)00427-9; El-Banayosy A, 2000, J THORAC CARDIOV SUR, V119, P581, DOI 10.1016/S0022-5223(00)70140-1; Farrar DJ, 1997, J THORAC CARDIOV SUR, V113, P202, DOI 10.1016/S0022-5223(97)70416-1; Frazier OH, 2001, J THORAC CARDIOV SUR, V122, P1186, DOI 10.1067/mtc.2001.118274; HOGNES JR, 1991, ARTIFICIAL HEART PRO, P1; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; Leprince P, 2002, J HEART LUNG TRANSPL, V21, P822, DOI 10.1016/S1053-2498(01)00393-X; Minami K, 2000, ARTIF ORGANS, V24, P421, DOI 10.1046/j.1525-1594.2000.06621.x	17	335	341	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2004	351	9					859	867		10.1056/NEJMoa040186	http://dx.doi.org/10.1056/NEJMoa040186			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849BM	15329423				2022-12-28	WOS:000223512500007
J	Eschenbach, DA				Eschenbach, DA			Chronic vulvovaginal candidiasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Washington, Med Ctr, Dept Obstet & Gynecol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Eschenbach, DA (corresponding author), Univ Washington, Med Ctr, Dept Obstet & Gynecol, Seattle, WA 98195 USA.							Ferris DG, 2002, OBSTET GYNECOL, V99, P419, DOI 10.1016/S0029-7844(01)01759-8; Patel DA, 2004, AM J OBSTET GYNECOL, V190, P644, DOI 10.1016/j.ajog.2003.11.027; Sobel JD, 1997, NEW ENGL J MED, V337, P1896, DOI 10.1056/NEJM199712253372607	3	19	30	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2004	351	9					851	852		10.1056/NEJMp048152	http://dx.doi.org/10.1056/NEJMp048152			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849BM	15329419				2022-12-28	WOS:000223512500003
J	Rassenti, LZ; Huynh, L; Toy, TL; Chen, L; Keating, MJ; Gribben, JG; Neuberg, DS; Flinn, IW; Rai, KR; Byrd, JC; Kay, NE; Greaves, A; Weiss, A; Kipps, TJ				Rassenti, LZ; Huynh, L; Toy, TL; Chen, L; Keating, MJ; Gribben, JG; Neuberg, DS; Flinn, IW; Rai, KR; Byrd, JC; Kay, NE; Greaves, A; Weiss, A; Kipps, TJ			ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VARIABLE-REGION MUTATIONS; V-H GENES; CD38 EXPRESSION; B-CELLS; PHENOTYPE	BACKGROUND: The course of chronic lymphocytic leukemia (CLL) is variable. In aggressive disease, the CLL cells usually express an unmutated immunoglobulin heavy-chain variable-region gene (IgV(sub H)) and the 70-kD zeta-associated protein (ZAP-70), whereas in indolent disease, the CLL cells usually express mutated IgV(sub H) but lack expression of ZAP-70. METHODS: We evaluated the CLL B cells from 307 patients with CLL for ZAP-70 and mutations in the rearranged IgV(sub H) gene. We then investigated the association between the results and the time from diagnosis to initial therapy. RESULTS: We found that ZAP-70 was expressed above a defined threshold level in 117 of the 164 patients with an unmutated IgV(sub H) gene (71 percent), but in only 24 of the 143 patients with a mutated IgV(sub H) gene (17 percent, P<0.001). Among the patients with ZAP-70-positive CLL cells, the median time from diagnosis to initial therapy in those who had an unmutated IgV(sub H) gene (2.8 years) was not significantly different from the median time in those who had a mutated IgV(sub H) gene (4.2 years, P=0.07). However, the median time from diagnosis to initial treatment in each of these groups was significantly shorter than the time in patients with ZAP-70-negative CLL cells who had either mutated or unmutated IgV(sub H) genes (P<0.001). The median time from diagnosis to initial therapy among patients who did not have ZAP-70 was 11.0 years in those with a mutated IgV(sub H) gene and 7.1 years in those with an unmutated IgV(sub H) gene (P<0.001). CONCLUSIONS: Although the presence of an unmutated IgV(sub H) gene is strongly associated with the expression of ZAP-70, ZAP-70 is a stronger predictor of the need for treatment in B-cell CLL.	Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; Chron Lymphocyt Leukemia Res Consortium, La Jolla, CA USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Johns Hopkins, Kimmel Canc Ctr, Baltimore, MD USA; Long Isl Jewish Med Ctr, New Hyde Pk, NY 11042 USA; Ohio State Univ, Columbus, OH 43210 USA; Mayo Clin, Rochester, MN USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Diego; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Dana-Farber Cancer Institute; Johns Hopkins University; Northwell Health; University System of Ohio; Ohio State University; Mayo Clinic; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Kipps, TJ (corresponding author), Univ Calif San Diego, Sch Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	tkipps@ucsd.edu	Jones, Jeffrey A/E-9827-2013	Flinn, Ian/0000-0001-6724-290X	NATIONAL CANCER INSTITUTE [P01CA081534] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA81534] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen LG, 2002, BLOOD, V100, P4609, DOI 10.1182/blood-2002-06-1683; Cheson BD, 1996, BLOOD, V87, P4990, DOI 10.1182/blood.V87.12.4990.bloodjournal87124990; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Dighiero G, 1998, NEW ENGL J MED, V338, P1506, DOI 10.1056/NEJM199805213382104; Dighiero G, 2000, NEW ENGL J MED, V343, P1799, DOI 10.1056/NEJM200012143432410; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Fais F, 1998, J CLIN INVEST, V102, P1515, DOI 10.1172/JCI3009; Hamblin TJ, 2002, BLOOD, V99, P1023, DOI 10.1182/blood.V99.3.1023; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Kabat EA, 1991, SEQUENCES PROTEINS I; Keating Michael J, 2003, Hematology Am Soc Hematol Educ Program, P153, DOI 10.1182/asheducation-2003.1.153; KIPPS TJ, 2001, WILLIAMS HEMATOLOGY, P1163; Klein U, 2001, J EXP MED, V194, P1625, DOI 10.1084/jem.194.11.1625; Krober A, 2002, BLOOD, V100, P1410, DOI 10.1182/blood.V100.4.1410.h81602001410_1410_1416; Lin K, 2002, BLOOD, V100, P1404, DOI 10.1182/blood-2001-11-0066; Lin K, 2002, BLOOD, V100, P2291; Maloum K, 2000, BLOOD, V96, P377, DOI 10.1182/blood.V96.1.377.013k56f_377_379; Orchard JA, 2004, LANCET, V363, P105, DOI 10.1016/S0140-6736(03)15260-9; Oscier DG, 2002, BLOOD, V100, P1177, DOI 10.1182/blood.V100.4.1177.h81602001177_1177_1184; RAI KR, 2000, HEMATOLOGY BASIC PRI, P1350; Rassenti LZ, 1997, J EXP MED, V185, P1435, DOI 10.1084/jem.185.8.1435; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Tobin G, 2002, BLOOD, V99, P2262, DOI 10.1182/blood.V99.6.2262; Tobin G, 2003, BLOOD, V101, P4952, DOI 10.1182/blood-2002-11-3485; Wiestner A, 2003, BLOOD, V101, P4944, DOI 10.1182/blood-2002-10-3306	27	702	759	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2004	351	9					893	901		10.1056/NEJMoa040857	http://dx.doi.org/10.1056/NEJMoa040857			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849BM	15329427				2022-12-28	WOS:000223512500011
J	Williams, GD				Williams, GD			The fix-it man	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												gdwmesa@cox.net							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2004	292	8					903	904		10.1001/jama.292.8.903	http://dx.doi.org/10.1001/jama.292.8.903			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WR	15328310				2022-12-28	WOS:000223429200001
J	Keogh, B; Spiegelhalter, D; Bailey, A; Roxburgh, J; Magee, P; Hilton, C				Keogh, B; Spiegelhalter, D; Bailey, A; Roxburgh, J; Magee, P; Hilton, C			The legacy of Bristol: public disclosure of individual surgeons' results	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEW-YORK-STATE; IN-HOSPITAL MORTALITY; CARDIAC-SURGERY; PERFORMANCE REPORTS; HEALTH-CARE; QUALITY; OUTCOMES; VALIDATION; LOBECTOMY; VOLUME	Measurement of outcomes from medical or surgical interventions is part of good practice, but publication of individual doctors' results remains controversial. The authors discuss this issue in die context of cardiothoracic surgery.	Royal Coll Surgeons England, Soc Cardiothorac Surg Great Britain & Ireland, London WC2A 3PE, England; Limes, UK Cardiac Surg Register, Charfield GL12 8SR, Wotton Under Ed, England	Royal College of Surgeons of England	Keogh, B (corresponding author), Royal Coll Surgeons England, Soc Cardiothorac Surg Great Britain & Ireland, London WC2A 3PE, England.	Bruce.Keogh@uclh.org						Albert AA, 2004, EUR J CARDIO-THORAC, V25, P312, DOI 10.1016/j.ejcts.2003.12.009; Bridgewater B, 2003, BMJ-BRIT MED J, V327, P13, DOI 10.1136/bmj.327.7405.13; Burack JH, 1999, ANN THORAC SURG, V68, P1195, DOI 10.1016/S0003-4975(99)00907-8; Chassin MR, 1996, NEW ENGL J MED, V335, P1060, DOI 10.1056/NEJM199610033351413; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; *DEP HLTH, 2001, COR HEART DIS INF ST; *DEP HLTH, 2000, COR HEART DIS NAT SE; DRANOVE D, 8697 NAT BUR EC RES; FINE L, 2003, IMPROVING CREDIBILIT; Fine LG, 2003, BRIT MED J, V326, P25, DOI 10.1136/bmj.326.7379.25; Hannan EL, 2002, SURGERY, V131, P6, DOI 10.1067/msy.2002.120238; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HANNAN EL, 1994, ANN THORAC SURG, V58, P1852, DOI 10.1016/0003-4975(94)91726-4; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; *HEALTHC COMM, 2004, CLIN IND DEATHS FOLL; Iezzoni LI, 1997, JAMA-J AM MED ASSOC, V278, P1600, DOI 10.1001/jama.278.19.1600; KEOGH B, 2001, TIMES           1119; Keogh BE, 1998, BMJ-BRIT MED J, V316, P1759, DOI 10.1136/bmj.316.7147.1759; Khuri SF, 2002, ANN THORAC SURG, V74, P641, DOI 10.1016/S0003-4975(02)03795-5; Marshall MN, 2000, JAMA-J AM MED ASSOC, V283, P1866, DOI 10.1001/jama.283.14.1866; Marshall MN, 2000, DYING KNOW PUBLIC RE; OMOIGUI N, 1994, CIRCULATION, V90, P93; Schneider EC, 1996, NEW ENGL J MED, V335, P251, DOI 10.1056/NEJM199607253350406; Schneider EC, 1998, JAMA-J AM MED ASSOC, V279, P1638, DOI 10.1001/jama.279.20.1638; Schneider EC, 2001, QUAL HEALTH CARE, V10, P96, DOI 10.1136/qhc.10.2.96; Sergeant P, 1997, EUR J CARDIO-THORAC, V12, P1, DOI 10.1016/S1010-7940(97)00134-6; Shahian DM, 2001, ANN THORAC SURG, V72, P2155, DOI 10.1016/S0003-4975(01)03222-2; Shahian DM, 2000, J THORAC CARDIOV SUR, V120, P978, DOI 10.1067/mtc.2000.110461; Treasure T, 2003, BRIT MED J, V327, P73, DOI 10.1136/bmj.327.7406.73	29	61	61	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 21	2004	329	7463					450	454		10.1136/bmj.329.7463.450	http://dx.doi.org/10.1136/bmj.329.7463.450			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849EA	15321906	Green Published			2022-12-28	WOS:000223520300027
J	West, MA; Wallin, RPA; Matthews, SP; Svensson, HG; Zaru, R; Ljunggren, HG; Prescott, AR; Watts, C				West, MA; Wallin, RPA; Matthews, SP; Svensson, HG; Zaru, R; Ljunggren, HG; Prescott, AR; Watts, C			Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling	SCIENCE			English	Article							CLASS-I; MACROPINOCYTOSIS; MATURATION; PODOSOMES; CYTOSKELETON	Microbial products are sensed through Toll-like receptors (TLRs) and trigger a program of dendritic cell (DC) maturation that enables DCs to activate T cells. Although an accepted hallmark of this response is eventual down-regulation of DC endocytic capacity, we show that TLR ligands first acutely stimulate antigen macropinocytosis, leading to enhanced presentation on class I and class 11 major histocompatibility complex molecules. Simultaneously, actin-rich podosomes disappear, which suggests a coordinated redeployment of actin to fuel endocytosis. These reciprocal changes are transient and require p38 and extracellular signal-regulated kinase activation. Thus, the DC actin cytoskeleton can be rapidly mobilized in response to innate immune stimuli to enhance antigen capture and presentation.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland; Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Med, Ctr Infect Med, Stockholm, Sweden	University of Dundee; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Watts, C (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland.	c.watts@dundee.ac.uk	Prescott, Alan/Y-5956-2018	Prescott, Alan/0000-0002-0747-7317; Watts, Colin/0000-0001-6183-2087; Matthews, Stephen/0000-0003-3556-962X; Zaru, Rossana/0000-0002-3358-4423	Medical Research Council [G0100536] Funding Source: Medline; MRC [G0100536] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Boes M, 2003, J IMMUNOL, V171, P4081, DOI 10.4049/jimmunol.171.8.4081; Burns S, 2004, CELL MOTIL CYTOSKEL, V57, P118, DOI 10.1002/cm.10163; Burns S, 2001, BLOOD, V98, P1142, DOI 10.1182/blood.V98.4.1142; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Chow A, 2002, NATURE, V418, P988, DOI 10.1038/nature01006; Delamarre L, 2003, J EXP MED, V198, P111, DOI 10.1084/jem.20021542; Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02-07-0389; Evans JG, 2003, J CELL BIOL, V161, P697, DOI 10.1083/jcb.200212037; Garrett WS, 2000, CELL, V102, P325, DOI 10.1016/S0092-8674(00)00038-6; Granucci F, 2001, EUR J IMMUNOL, V31, P2539, DOI 10.1002/1521-4141(200109)31:9<2539::AID-IMMU2539>3.0.CO;2-9; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Kleijmeer M, 2001, J CELL BIOL, V155, P53, DOI 10.1083/jcb.200103071; Lanzavecchia A, 2001, CELL, V106, P263, DOI 10.1016/S0092-8674(01)00455-X; Lelouard H, 2002, NATURE, V417, P177, DOI 10.1038/417177a; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; West MA, 1999, EUR J IMMUNOL, V29, P3450, DOI 10.1002/(SICI)1521-4141(199911)29:11<3450::AID-IMMU3450>3.0.CO;2-A; West MA, 2000, CURR BIOL, V10, P839, DOI 10.1016/S0960-9822(00)00595-9	30	395	415	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	2004	305	5687					1153	1157		10.1126/science.1099153	http://dx.doi.org/10.1126/science.1099153			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326355				2022-12-28	WOS:000223557400048
J	Butler, D				Butler, D			Power to the people	NATURE			English	Article																			0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2004	430	7002					928	929		10.1038/430928a	http://dx.doi.org/10.1038/430928a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318231	Bronze			2022-12-28	WOS:000223369800054
J	Doms, RW				Doms, RW			Viral entry denied	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PROTEIN; FUSION		Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Doms, RW (corresponding author), Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.							Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; Moore JP, 2003, P NATL ACAD SCI USA, V100, P10598, DOI 10.1073/pnas.1932511100; Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101	3	6	9	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2004	351	8					743	744		10.1056/NEJMp048058	http://dx.doi.org/10.1056/NEJMp048058			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847CY	15317885				2022-12-28	WOS:000223367900004
J	Vennerstrom, JL; Arbe-Barnes, S; Brun, R; Charman, SA; Chiu, FCK; Chollet, J; Dong, YX; Dorn, A; Hunziker, D; Matile, H; McIntosh, K; Padmanilayam, M; Tomas, JS; Scheurer, C; Scorneaux, B; Tang, YQ; Urwyler, H; Wittlin, S; Charman, WN				Vennerstrom, JL; Arbe-Barnes, S; Brun, R; Charman, SA; Chiu, FCK; Chollet, J; Dong, YX; Dorn, A; Hunziker, D; Matile, H; McIntosh, K; Padmanilayam, M; Tomas, JS; Scheurer, C; Scorneaux, B; Tang, YQ; Urwyler, H; Wittlin, S; Charman, WN			Identification of an antimalarial synthetic trioxolane drug development candidate	NATURE			English	Article							PLASMODIUM-FALCIPARUM; QINGHAOSU ARTEMISININ; OZONIDES; PHARMACOKINETICS; ABSORPTION; RESISTANCE; PEROXIDES; DISCOVERY; INVITRO; DESIGN	The discovery of artemisinin more than 30 years ago provided a completely new antimalarial structural prototype; that is, a molecule with a pharmacophoric peroxide bond in a unique 1,2,4-trioxane heterocycle(1). Available evidence(2-4) suggests that artemisinin and related peroxidic antimalarial drugs exert their parasiticidal activity subsequent to reductive activation by haem, released as a result of haemoglobin digestion by the malaria-causing parasite. This irreversible redox reaction produces carbon-centred free radicals, leading to alkylation of haem(5) and proteins ( enzymes) 6, one of which-the sarcoplasmic-endoplasmic reticulum ATPase PfATP6 (ref. 7)-may be critical to parasite survival. Notably, there is no evidence of drug resistance to any member of the artemisinin family of drugs(8). The chemotherapy of malaria has benefited greatly from the semi-synthetic artemisinins artemether and artesunate as they rapidly reduce parasite burden, have good therapeutic indices and provide for successful treatment outcomes(9). However, as a drug class, the artemisinins suffer from chemical(10) ( semisynthetic availability, purity and cost), biopharmaceutical(11) (poor bioavailability and limiting pharmacokinetics) and treatment(8,11) (non-compliance with long treatment regimens and recrudescence) issues that limit their therapeutic potential. Here we describe how a synthetic peroxide antimalarial drug development candidate was identified in a collaborative drug discovery project.	Univ Nebraska, Med Ctr, Coll Pharm, Omaha, NE 68198 USA; Swiss Trop Inst, Hemel Hempstead HP1 1JY, Herts, England; Monash Univ, Victorian Coll Pharm, Parkville, Vic 3052, Australia; F Hoffmann La Roche & Co Ltd, CH-4070 Basel, Switzerland; Basilea Pharmaceut Ltd, CH-4058 Basel, Switzerland	University of Nebraska System; University of Nebraska Medical Center; Monash University; Roche Holding; Basilea Pharmaceutica Ltd.	Vennerstrom, JL (corresponding author), Univ Nebraska, Med Ctr, Coll Pharm, 986025 Nebraska Med Ctr, Omaha, NE 68198 USA.	jvenners@unmc.edu	Hua, QX/HGE-3640-2022; Charman, Susan A/E-2221-2011	Charman, Susan A/0000-0003-1753-8213; Charman, William/0000-0002-7051-2023				Abe M, 1999, J AM CHEM SOC, V121, P6556, DOI 10.1021/ja990807v; AVERY MA, 1992, J AM CHEM SOC, V114, P974, DOI 10.1021/ja00029a028; CHAWIRA AN, 1987, J TROP MED HYG, V90, P1; Crespi CL, 1997, ANAL BIOCHEM, V248, P188, DOI 10.1006/abio.1997.2145; CUMMING JN, 1997, ADV PHARMACOL, V37, P254; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; Eckstein-Ludwig U, 2003, NATURE, V424, P957, DOI 10.1038/nature01813; Gordi T, 2004, TOXICOL LETT, V147, P99, DOI 10.1016/j.toxlet.2003.12.009; Griesbaum K, 1997, LIEBIGS ANN-RECL, P1381; Jefford CW, 2001, CURR MED CHEM, V8, P1803, DOI 10.2174/0929867013371608; KEUL H, 1975, CHEM BER-RECL, V108, P1207, DOI 10.1002/cber.19751080427; KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571; LI AG, 1998, J PHARM PHARMACOL, V50, P173; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Meshnick SR, 2002, INT J PARASITOL, V32, P1655, DOI 10.1016/S0020-7519(02)00194-7; Nwaka S, 2003, NAT REV DRUG DISCOV, V2, P919, DOI 10.1038/nrd1230; Palm K, 1997, PHARMACEUT RES, V14, P568, DOI 10.1023/A:1012188625088; Ridley RG, 2002, NATURE, V415, P686, DOI 10.1038/415686a; Ridley RG, 1997, ANTIMICROB AGENTS CH, V41, P677, DOI 10.1128/AAC.41.3.677; Robert A, 2002, CHEM COMMUN, P414, DOI 10.1039/b110817b; Smith DA, 1996, MED RES REV, V16, P243; Tang YQ, 2004, MED RES REV, V24, P425, DOI 10.1002/med.10066; van de Waterbeemd H, 2001, J MED CHEM, V44, P1313, DOI 10.1021/jm000407e; Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n; Vennerstrom J. L., 2002, Patent No. [US6486- 199B1, 6486199]; VENNERSTROM JL, 2002, Patent No. 0219767; Vyas N, 2002, ANTIMICROB AGENTS CH, V46, P105, DOI 10.1128/AAC.46.1.105-109.2002; White N, 1999, PHILOS T R SOC B, V354, P739, DOI 10.1098/rstb.1999.0426; White NJ, 1997, ANTIMICROB AGENTS CH, V41, P1413, DOI 10.1128/AAC.41.7.1413; Wu YK, 2002, ACCOUNTS CHEM RES, V35, P255, DOI 10.1021/ar000080b	30	537	575	3	119	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					900	904		10.1038/nature02779	http://dx.doi.org/10.1038/nature02779			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	847DA	15318224				2022-12-28	WOS:000223369800044
J	Rosenberg, RN				Rosenberg, RN			West Nile virus encephalomyelitis in transplant recipients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INFECTION		Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rosenberg, RN (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	roger.rosenberg@utsouthwestern.edu						Kleinschmidt-DeMasters BK, 2004, ARCH NEUROL-CHICAGO, V61, P1210, DOI 10.1001/archneur.61.8.1210; Nash D, 2001, NEW ENGL J MED, V344, P1807, DOI 10.1056/NEJM200106143442401; Petersen LR, 2003, JAMA-J AM MED ASSOC, V290, P524, DOI 10.1001/jama.290.4.524; Sejvar JJ, 2003, JAMA-J AM MED ASSOC, V290, P511, DOI 10.1001/jama.290.4.511; Tyler KL, 2004, ARCH NEUROL-CHICAGO, V61, P1190, DOI 10.1001/archneur.61.8.1190	5	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2004	292	7					859	860		10.1001/jama.292.7.859	http://dx.doi.org/10.1001/jama.292.7.859			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847FO	15317142				2022-12-28	WOS:000223378300027
J	Kim, E; Chan, MHW				Kim, E; Chan, MHW			Observation of superflow in solid helium	SCIENCE			English	Article							BOSE-EINSTEIN CONDENSATION; SUPERSOLID HELIUM; LIQUID-HELIUM; HE-4; SUPERFLUIDITY; CRYSTALS; SEARCH; FLOW; PHASE	We report on the observation of nonclassical rotational inertia in solid helium-4 confined to an annular channel in a sample cell under torsional motion, demonstrating superfluid behavior. The effect shows up as a drop in the resonant oscillation period as the sample cell is cooled below 230 millikelvin. Measurement of 17 solid samples allows us to map out the boundary of this superfluid-like solid or supersotid phase from the melting tine up to 66 bars. This experiment indicates that superfluid behavior is found in all. three phases of matter.	Penn State Univ, Dept Phys, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Chan, MHW (corresponding author), Penn State Univ, Dept Phys, University Pk, PA 16802 USA.	chan@phys.psu.edu	Kim, Eunseong/D-4698-2009					Allen JF, 1938, NATURE, V141, P75, DOI 10.1038/141075a0; AMBEGAOKAR V, 1978, PHYS REV LETT, V40, P783, DOI 10.1103/PhysRevLett.40.783; ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; ANDREEV A, 1969, JETP LETT-USSR, V9, P306; ANDREEV AF, 1969, ZH EKSP TEOR FIZ, V29, P1107; Beamish J, 2004, NATURE, V427, P204, DOI 10.1038/427204a; BISHOP DJ, 1981, PHYS REV B, V24, P2844, DOI 10.1103/PhysRevB.24.2844; BISHOP DJ, 1978, PHYS REV LETT, V40, P1727, DOI 10.1103/PhysRevLett.40.1727; BONFAIT G, 1989, J PHYS-PARIS, V50, P1997, DOI 10.1051/jphys:0198900500150199700; CEPERLEY D, 1978, PHYS REV B, V17, P1070, DOI 10.1103/PhysRevB.17.1070; CHESTER GV, 1970, PHYS REV A, V2, P256, DOI 10.1103/PhysRevA.2.256; Chevy F, 2000, PHYS REV LETT, V85, P2223, DOI 10.1103/PhysRevLett.85.2223; Chikkatur AP, 2000, PHYS REV LETT, V85, P483, DOI 10.1103/PhysRevLett.85.483; DYUMIN NE, 1989, FIZ NIZK TEMP+, V15, P524; FERNANDEZ JF, 1974, J LOW TEMP PHYS, V17, P131, DOI 10.1007/BF00654549; FETTER AL, 1974, J LOW TEMP PHYS, V16, P533, DOI 10.1007/BF00654901; Feynman R. P, 1955, PROGR LOW TEMPERATUR, V1; Galli DE, 2001, J LOW TEMP PHYS, V124, P197, DOI 10.1023/A:1017582019606; Goodkind JM, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.095301; GREYWALL DS, 1977, PHYS REV B, V16, P1291, DOI 10.1103/PhysRevB.16.1291; GUYER RA, 1970, PHYS REV LETT, V26, P174; Kapitza P, 1938, NATURE, V141, P74, DOI 10.1038/141074a0; Kim E, 2004, NATURE, V427, P225, DOI 10.1038/nature02220; Kosterlitz JM, 1973, J PHYS C SOLID STATE, V6, P1181, DOI 10.1088/0022-3719/6/7/010; LEGGETT AJ, 1970, PHYS REV LETT, V25, P1543, DOI 10.1103/PhysRevLett.25.1543; LIU KS, 1973, J LOW TEMP PHYS, V10, P655, DOI 10.1007/BF00655458; LIU M, 1978, PHYS REV B, V18, P1165, DOI 10.1103/PhysRevB.18.1165; Matthews MR, 1999, PHYS REV LETT, V83, P2498, DOI 10.1103/PhysRevLett.83.2498; MEISEL MW, 1992, PHYSICA B, V178, P121, DOI 10.1016/0921-4526(92)90186-V; MUELLER E, COMMUNICATION; NOZIERES P, 1989, THEORY QUANTUM LIQUI, V2, pCH6; SASLOW WM, 1976, PHYS REV LETT, V36, P1151, DOI 10.1103/PhysRevLett.36.1151; TSYMBALENKO VL, 1976, JETP LETT+, V23, P653; [No title captured]	34	579	581	2	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	2004	305	5692					1941	1944		10.1126/science.1101501	http://dx.doi.org/10.1126/science.1101501			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	857RM	15345778				2022-12-28	WOS:000224136000041
J	Von Korff, M				Von Korff, M			Commentary: Can care management enhance integration of primary and specialty care?	BRITISH MEDICAL JOURNAL			English	Article							DEPRESSION		Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	Group Health Cooperative	Von Korff, M (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave, Seattle, WA 98101 USA.	vonkorff.m@ghc.org		VonKorff, Michael/0000-0001-5386-8477				Dietrich AJ, 2004, BMJ-BRIT MED J, V329, P602, DOI 10.1136/bmj.38219.481250.55; Gilbody S, 2003, JAMA-J AM MED ASSOC, V289, P3145, DOI 10.1001/jama.289.23.3145; Katon W, 2001, GEN HOSP PSYCHIAT, V23, P138, DOI 10.1016/S0163-8343(01)00136-0; Von Korff M, 2001, BRIT MED J, V323, P948, DOI 10.1136/bmj.323.7319.948	4	8	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 11	2004	329	7466					605	605		10.1136/bmj.329.7466.605	http://dx.doi.org/10.1136/bmj.329.7466.605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	854SK	15361444	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000223923400018
J	Zhou, RH; Huang, XH; Margulis, CJ; Berne, BJ				Zhou, RH; Huang, XH; Margulis, CJ; Berne, BJ			Hydrophobic collapse in multidomain protein folding	SCIENCE			English	Article							MOLECULAR-DYNAMICS; FREE-ENERGY; WATER; HYDRATION; DEPENDENCE; SIMULATION; SOLUTES	We performed molecular dynamics simulations of the collapse of a two-domain protein, the BphC enzyme, into a globular structure to examine how water molecules mediate hydrophobic collapse of proteins. in the interdomain region, liquid water persists with a density 10 to 15% lower than in the bulk, even at small domain separations. Water depletion and hydrophobic collapse occur on a nanosecond time scale, which is two orders of magnitude slower than that found in the collapse of idealized paraffin-like plates. When the electrostatic protein-water forces are turned off, a dewetting transition occurs in the interdomain region and the collapse speeds up by more than an order of magnitude. When attractive van der Waals forces are turned off as well, the dewetting in the interdomain region is more profound, and the collapse is even faster.	IBM Corp, Thomas J Watson Res Ctr, Computat Biol Ctr, Yorktown Hts, NY 10598 USA; Columbia Univ, Dept Chem, New York, NY 10027 USA	International Business Machines (IBM); Columbia University	Zhou, RH (corresponding author), IBM Corp, Thomas J Watson Res Ctr, Computat Biol Ctr, 1101 Kitchawan Rd, Yorktown Hts, NY 10598 USA.	ruhongz@us.ibm.com; berne@chem.columbia.edu	Huang, Xuhui/ABE-3207-2021	Huang, Xuhui/0000-0002-7119-9358; Zhou, Ruhong/0000-0001-8624-5591; Margulis, Claudio/0000-0003-1671-9784	NIGMS NIH HHS [GM4330] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashbaugh HS, 2001, J AM CHEM SOC, V123, P10721, DOI 10.1021/ja016324k; Ball P, 2003, NATURE, V423, P25, DOI 10.1038/423025a; Chandler D, 2002, NATURE, V417, P491, DOI 10.1038/417491a; Cheng YK, 1998, NATURE, V392, P696, DOI 10.1038/33653; Huang DM, 2000, P NATL ACAD SCI USA, V97, P8324, DOI 10.1073/pnas.120176397; Huang DM, 2002, J PHYS CHEM B, V106, P2047, DOI 10.1021/jp013289v; Huang X, 2003, P NATL ACAD SCI USA, V100, P11953, DOI 10.1073/pnas.1934837100; Hummer G, 2001, NATURE, V414, P188, DOI 10.1038/35102535; Hummer G, 2000, CHEM PHYS, V258, P349, DOI 10.1016/S0301-0104(00)00115-4; Jensen TR, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.086101; Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760; Leung K, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.065502; Leung K, 2000, J CHEM PHYS, V113, P5845, DOI 10.1063/1.1290479; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lum K, 1997, PHYS REV E, V56, pR6283, DOI 10.1103/PhysRevE.56.R6283; Lum K, 1998, INT J THERMOPHYS, V19, P845, DOI 10.1023/A:1022643006849; Lum K, 1999, J PHYS CHEM B, V103, P4570, DOI 10.1021/jp984327m; Mountain RD, 2003, J AM CHEM SOC, V125, P1950, DOI 10.1021/ja020496f; PANGALI C, 1979, J CHEM PHYS, V71, P2982, DOI 10.1063/1.438702; Paulaitis ME, 2002, ADV PROTEIN CHEM, V62, P283; Pratt LR, 2002, ANNU REV PHYS CHEM, V53, P409, DOI 10.1146/annurev.physchem.53.090401.093500; Steitz R, 2003, LANGMUIR, V19, P2409, DOI 10.1021/la026731p; Stillinger FH, 1973, J SOLUTION CHEM, V2, P141, DOI 10.1007/BF00651970; ten Wolde PR, 2002, P NATL ACAD SCI USA, V99, P6539, DOI 10.1073/pnas.052153299; WALLQVIST A, 1995, J PHYS CHEM-US, V99, P2885, DOI 10.1021/j100009a052; WALLQVIST A, 1995, J PHYS CHEM-US, V99, P2893, DOI 10.1021/j100009a053; Zhou RH, 2003, PROTEINS, V52, P561, DOI 10.1002/prot.10419	27	469	478	1	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2004	305	5690					1605	1609		10.1126/science.1101176	http://dx.doi.org/10.1126/science.1101176			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361621				2022-12-28	WOS:000223891200039
J	Ziegelstein, RC				Ziegelstein, RC			Near-syncope after exercise	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAROTID-SINUS HYPERSENSITIVITY; SEROTONIN REUPTAKE INHIBITORS; POSTEXERCISE HYPOTENSION; OLDER PATIENTS; RECURRENT SYNCOPE; HEART-DISEASE; COMPLICATIONS; HISTORY; MASSAGE; HYPERTENSION	Syncope and near-syncope are great diagnostic challenges in medicine. On the one hand, the symptom may result from a benign condition and pose little or no threat to health other than that related to falling. On the other hand, syncope or near-syncope can be the manifestation of a serious underlying condition that poses an imminent threat to life. Patients with a cardiac cause of syncope are at far greater risk of dying in the first year after an episode of syncope or near-syncope than individuals with a noncardiac cause. A cardiac cause of syncope should be considered in every patient with syncope or near-syncope, but it is particularly common in older patients or in patients with known structural heart disease, arrhythmia, or certain electrocardiographic abnormalities. Although many diagnostic tests may be helpful in the evaluation of syncope and near-syncope, the history, physical examination, and electrocardiogram pinpoint the cause in many circumstances. Syncope after exercise may be due to left ventricular outflow tract obstruction from aortic stenosis or hypertrophic obstructive cardiomyopathy but can also suggest the diagnosis of postexercise hypotension in which an abnormality in autonomic regulation of vascular tone or heart rate results in vasodilation or bradycardia after moderate-intensity aerobic activity. The patient discussed in this case highlights the importance of the clinical history in the evaluation of this condition, since the diagnosis was revealed as the patient's story was described and eventually acted out.	Johns Hopkins Univ, Sch Med, Dept Med,Div Cardiol, Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Ziegelstein, RC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med,Div Cardiol, Johns Hopkins Bayview Med Ctr, 4940 Eastern Ave, Baltimore, MD 21224 USA.	rziegel@jhmi.edu						Alboni P, 2001, J AM COLL CARDIOL, V37, P1921, DOI 10.1016/S0735-1097(01)01241-4; BOUDOULAS H, 2001, HURSTS HEART, P1003; BRIGNOLE M, 1992, AM J CARDIOL, V69, P1039, DOI 10.1016/0002-9149(92)90860-2; Brignole M, 2003, J CARDIOVASC ELECTR, V14, pS64, DOI 10.1046/j.1540-8167.14.s9.7.x; Brignole M, 2001, EUR HEART J, V22, P1256, DOI 10.1053/euhj.2001.2739; CLEROUX J, 1992, HYPERTENSION, V19, P183, DOI 10.1161/01.HYP.19.2.183; Dan D, 1997, PACE, V20, P1633, DOI 10.1111/j.1540-8159.1997.tb03532.x; Davies AJ, 1998, AM J CARDIOL, V81, P1256, DOI 10.1016/S0002-9149(98)00130-1; Davies AJ, 2001, AGE AGEING, V30, P289, DOI 10.1093/ageing/30.4.289; DAVIES KN, 1994, POSTGRAD MED J, V70, P433, DOI 10.1136/pgmj.70.824.433; EAGLE KA, 1985, AM J MED, V79, P455, DOI 10.1016/0002-9343(85)90032-4; FLORAS JS, 1989, HYPERTENSION, V14, P28, DOI 10.1161/01.HYP.14.1.28; FROELICHER VF, 1994, MANUAL EXERCISE TEST, P45; GAGGIOLI G, 1995, AM J CARDIOL, V75, P518, DOI 10.1016/S0002-9149(99)80596-7; Gregoratos Gabriel, 2002, Circulation, V106, P2145, DOI 10.1161/01.CIR.0000035996.46455.09; GRUBB BP, 1994, PACE, V17, P1434, DOI 10.1111/j.1540-8159.1994.tb02463.x; Haidet P, 2003, ARCH INTERN MED, V163, P1134, DOI 10.1001/archinte.163.10.1134; Halliwill J R, 2001, Exerc Sport Sci Rev, V29, P65, DOI 10.1097/00003677-200104000-00005; Halliwill JR, 1996, AM J PHYSIOL-REG I, V270, pR420, DOI 10.1152/ajpregu.1996.270.2.R420; Halliwill JR, 1996, J PHYSIOL-LONDON, V495, P279, DOI 10.1113/jphysiol.1996.sp021592; HUYCKE EC, 1987, ANN INTERN MED, V106, P844, DOI 10.7326/0003-4819-106-6-844; KAPOOR W, 1986, AM J MED, V80, P419, DOI 10.1016/0002-9343(86)90716-3; KAPOOR WN, 1983, NEW ENGL J MED, V309, P197, DOI 10.1056/NEJM198307283090401; KENNEY MJ, 1993, HYPERTENSION, V22, P653, DOI 10.1161/01.HYP.22.5.653; Kenny RAM, 2001, J AM COLL CARDIOL, V38, P1491, DOI 10.1016/S0735-1097(01)01537-6; Legramante JM, 2002, AM J PHYSIOL-REG I, V282, pR1037, DOI 10.1152/ajpregu.00603.2001; Linzer M, 1997, ANN INTERN MED, V126, P989, DOI 10.7326/0003-4819-126-12-199706150-00012; Lowe MD, 2000, POSTGRAD MED J, V76, P164, DOI 10.1136/pmj.76.893.164; MANOLIS AS, 1990, ANN INTERN MED, V112, P850, DOI 10.7326/0003-4819-112-11-850; MARK AL, 1983, J AM COLL CARDIOL, V1, P90, DOI 10.1016/S0735-1097(83)80014-X; Martin TP, 1997, ANN EMERG MED, V29, P459, DOI 10.1016/S0196-0644(97)70217-8; Mathias CJ, 2001, LANCET, V357, P348, DOI 10.1016/S0140-6736(00)03642-4; MUNRO NC, 1994, J AM GERIATR SOC, V42, P1248, DOI 10.1111/j.1532-5415.1994.tb06505.x; O'Shea D, 2001, J AM GERIATR SOC, V49, P236, DOI 10.1046/j.1532-5415.2001.49050.x; OSSWALD S, 1994, ANN INTERN MED, V120, P1008, DOI 10.7326/0003-4819-120-12-199406150-00007; Richardson DA, 2000, AGE AGEING, V29, P413, DOI 10.1093/ageing/29.5.413; Richardson DA, 1997, PACE, V20, P820, DOI 10.1111/j.1540-8159.1997.tb03912.x; SOMERS VK, 1985, J HYPERTENS, V3, pS129; Weiss S, 1933, MEDICINE, V12, P297, DOI 10.1097/00005792-193309000-00003	39	4	4	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2004	292	10					1221	1226		10.1001/jama.292.10.1221	http://dx.doi.org/10.1001/jama.292.10.1221			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851ZA	15353535				2022-12-28	WOS:000223723800022
J	Watts, G				Watts, G			Commentary: Golden rules	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							STAPHYLOCOCCUS-AUREUS				Watts, G (corresponding author), 28 New End Sq, London NW3 1LS, England.	geoff@scileg.freeserve.co.uk						Biant LC, 2004, BRIT MED J, V329, P149; Cooper BS, 2004, BMJ-BRIT MED J, V329, P533, DOI 10.1136/bmj.329.7465.533; Muto CA, 2003, INFECT CONT HOSP EP, V24, P362, DOI 10.1086/502213	3	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 4	2004	329	7465					538	539		10.1136/bmj.329.7465.538	http://dx.doi.org/10.1136/bmj.329.7465.538			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853DE	15345627	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000223805800017
J	Seo, HC; Edvardsen, RB; Maeland, AD; Bjordal, M; Jensen, MF; Hansen, A; Flaat, M; Weissenbach, J; Lehrach, H; Wincker, P; Reinhardt, R; Chourrout, D				Seo, HC; Edvardsen, RB; Maeland, AD; Bjordal, M; Jensen, MF; Hansen, A; Flaat, M; Weissenbach, J; Lehrach, H; Wincker, P; Reinhardt, R; Chourrout, D			Hox cluster disintegration with persistent anteroposterior order of expression in Oikopleura dioica	NATURE			English	Article							CIONA-INTESTINALIS; CAENORHABDITIS-ELEGANS; GENE; GENOME; VERTEBRATES; PHYLOGENY; EVOLUTION; CHORDATE; EMBRYOS; ORIGINS	Tunicate embryos and larvae have small cell numbers and simple anatomical features in comparison with other chordates, including vertebrates. Although they branch near the base of chordate phylogenetic trees(1), their degree of divergence from the common chordate ancestor remains difficult to evaluate. Here we show that the tunicate Oikopleura dioica has a complement of nine Hox genes in which all central genes are lacking but a full vertebrate-like set of posterior genes is present. In contrast to all bilaterians studied so far, Hox genes are not clustered in the Oikopleura genome. Their expression occurs mostly in the tail, with some tissue preference, and a strong partition of expression domains in the nerve cord, in the notochord and in the muscle. In each tissue of the tail, the anteroposterior order of Hox gene expression evokes spatial collinearity, with several alterations. We propose a relationship between the Hox cluster breakdown, the separation of Hox expression domains, and a transition to a determinative mode of development.	Bergen High Technol Ctr, Sars Ctr Marine Mol Biol, N-5008 Bergen, Norway; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Genoscope Ctr Natl Sequencage, F-91000 Evry, France; CNRS, UMR 8030, F-91000 Evry, France	Max Planck Society; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; CEA	Chourrout, D (corresponding author), Bergen High Technol Ctr, Sars Ctr Marine Mol Biol, Thormohlensgaten 55, N-5008 Bergen, Norway.	Daniel.Chourrout@sars.uib.no		Edvardsen, Rolf/0000-0001-8430-8042; Reinhardt, Richard/0000-0001-9376-2132				Aboobaker AA, 2003, CURR BIOL, V13, P37, DOI 10.1016/S0960-9822(02)01399-4; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; [Anonymous], 2002, PAUP 4 0 PHYLOGENETI; AVEROF M, 1995, NATURE, V376, P420, DOI 10.1038/376420a0; Balavoine G, 2002, MOL PHYLOGENET EVOL, V24, P366, DOI 10.1016/S1055-7903(02)00237-3; Bassham S, 2000, DEV BIOL, V220, P322, DOI 10.1006/dbio.2000.9647; Boutanaev AM, 2002, NATURE, V420, P666, DOI 10.1038/nature01216; BURGLIN TR, 1993, CURR OPIN GENET DEV, V3, P615, DOI 10.1016/0959-437X(93)90097-9; Cowing D, 1996, NATURE, V382, P353, DOI 10.1038/382353a0; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Ferrier DEK, 2000, EVOL DEV, V2, P284, DOI 10.1046/j.1525-142x.2000.00070.x; Ferrier DEK, 2002, MOL PHYLOGENET EVOL, V24, P412, DOI 10.1016/S1055-7903(02)00204-X; Finnerty JR, 2003, INT J DEV BIOL, V47, P523; Gionti M, 1998, DEV GENES EVOL, V207, P515, DOI 10.1007/s004270050142; Kmita M, 2003, SCIENCE, V301, P331, DOI 10.1126/science.1085753; Lacalli TC, 1999, BIOL REV, V74, P177, DOI 10.1017/S0006323199005319; Locascio A, 1999, DEVELOPMENT, V126, P4737; Nagatomo K, 2003, GENE EXPR PATTERNS, V3, P273, DOI 10.1016/S1567-133X(03)00051-6; Powers TP, 2004, CURR BIOL, V14, pR183, DOI 10.1016/j.cub.2004.02.015; Roy PJ, 2002, NATURE, V418, P975, DOI 10.1038/nature01012; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Seo HC, 2001, SCIENCE, V294, P2506, DOI 10.1126/science.294.5551.2506; Spada F, 2001, J BIOL CHEM, V276, P20624, DOI 10.1074/jbc.M100438200; Spagnuolo A, 2003, GENE, V309, P71, DOI 10.1016/S0378-1119(03)00488-8; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3; VonAllmen G, 1996, NATURE, V380, P116, DOI 10.1038/380116a0; Wada H, 1998, MOL BIOL EVOL, V15, P1189, DOI 10.1093/oxfordjournals.molbev.a026026; WELSCH U, 1969, Z ZELLFORSCH MIK ANA, V93, P547	28	243	252	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2004	431	7004					67	71		10.1038/nature02709	http://dx.doi.org/10.1038/nature02709			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343333				2022-12-28	WOS:000223641500042
J	Chaudhry, SI; Krumholz, HM; Foody, JM				Chaudhry, SI; Krumholz, HM; Foody, JM			Systolic hypertension in older persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							WHITE-COAT HYPERTENSION; PULSE PRESSURE; CARDIOVASCULAR RISK; ACTIVE TREATMENT; PLACEBO; PREVENTION; THERAPY; TRIAL; INTERVENTIONS; MORTALITY	Context The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure emphasizes the importance of systolic hypertension (SH), defined as systolic blood pressure (SBP) of at least 140 mm Hg and diastolic blood pressure of less than 90 mm Hg, in older persons (greater than or equal to60 years). Objective To systematically review the literature on clinical management of SH in older persons. Data Sources We performed a MEDLINE search of English-language literature from 1966-2004 to identify reports about SH in older persons, with particular emphasis on data from randomized clinical trials. Study Selection and Data Extraction We selected 1064 studies by using the search terms hypertension combined with the terms systole (or systolic) and aged. Data Synthesis There is strong evidence from clinical trials to support the treatment of SH in older persons with SBP of at least 160 mm Hg. Large-scale trials to assess the value of anti hypertensive therapy for older patients with SBP of 140 to 159 mm Hg have not been performed, and recommendations to treat these patients are based on observational studies that show a graded relationship of cardiovascular risk with increasing SBP. The studies most strongly support the use of thiazide diuretics and long-acting calcium channel blockers as first-line therapy to treat SH. Conclusions Treatment of SH in older patients with SBP of at least 160 mm Hg is supported by strong evidence. The evidence available to support treatment of patients to the level of 140 mm Hg or those with baseline SBP of 140 to 159 mm Hg is less strong; thus, these treatment decisions should be more sensitive to patient preferences and tolerance of therapy.	Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06520 USA; W Haven Vet Affairs Med Ctr, Dept Vet Affairs, West Haven, CT USA; Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT USA; Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Yale University; Yale University	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, 333 Cedar St,1-456 SHM,POB 208088, New Haven, CT 06520 USA.	harlan.krumholz@yale.edu	, Harlan/AAI-2875-2020		NATIONAL INSTITUTE ON AGING [K08AG020623, K23AG030986] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; [Anonymous], 1984, ARCH INTERN MED, V144, P1045; [Anonymous], 1993, ARCH INTERN MED, V153, P154, DOI DOI 10.1001/archinte.1993.00410020010002; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; BERTAKIS KD, 1977, J FAM PRACTICE, V5, P217; Berwick DM, 2002, HEALTH AFFAIR, V21, P80, DOI 10.1377/hlthaff.21.3.80; Blacher J, 2000, ARCH INTERN MED, V160, P1085, DOI 10.1001/archinte.160.8.1085; Black HR, 2001, HYPERTENSION, V38, P1118, DOI 10.1161/hy1101.095000; Borzecki AM, 2003, ARCH INTERN MED, V163, P2705, DOI 10.1001/archinte.163.22.2705; Bulpitt CJ, 2002, J HYPERTENS, V20, P339, DOI 10.1097/00004872-200202000-00026; Chang JJ, 2003, AM J MED, V115, P536, DOI 10.1016/j.amjmed.2003.07.002; Charles C, 1999, BRIT MED J, V319, P780, DOI 10.1136/bmj.319.7212.780; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cushman WC, 2001, HYPERTENSION, V38, P953, DOI 10.1161/hy1001.096212; Duthie EH, 1998, PRACTICE GERIATRICS; ENGLAND SL, 1992, SOC SCI MED, V34, P1217, DOI 10.1016/0277-9536(92)90314-G; Forette F, 1998, LANCET, V352, P1347, DOI 10.1016/S0140-6736(98)03086-4; Forette F, 2002, ARCH INTERN MED, V162, P2046, DOI 10.1001/archinte.162.18.2046; FRISHMAN WH, 1994, ARCH INTERN MED, V154, P1461, DOI 10.1001/archinte.154.13.1461; GOSSE P, 1993, HYPERTENSION, V22, P766, DOI 10.1161/01.HYP.22.5.766; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; Hollenberg NK, 2003, ARCH INTERN MED, V163, P1543, DOI 10.1001/archinte.163.13.1543; Hyman DJ, 2001, NEW ENGL J MED, V345, P479, DOI 10.1056/NEJMoa010273; *JOINT NAT COMM DE, 1980, ARCH INTERN MED, V140, P1280, DOI DOI 10.1001/ARCHINTE.1980.00330210028018; JULIUS S, 1990, HYPERTENSION, V16, P617, DOI 10.1161/01.HYP.16.6.617; Kjeldsen SE, 2002, JAMA-J AM MED ASSOC, V288, P1491, DOI 10.1001/jama.288.12.1491; Liu LS, 1998, J HYPERTENS, V16, P1823, DOI 10.1097/00004872-199816120-00016; MacGregor GA, 1997, J HUM HYPERTENS, V11, P249; MACGREGOR GA, 1982, BRIT MED J, V284, P693, DOI 10.1136/bmj.284.6317.693; Malacco E, 2003, BLOOD PRESSURE, V12, P160, DOI 10.1080/08037050310009545; Messerli FH, 1998, JAMA-J AM MED ASSOC, V279, P1903, DOI 10.1001/jama.279.23.1903; Moore TJ, 2001, HYPERTENSION, V38, P155, DOI 10.1161/01.HYP.38.2.155; MORRIS J, 1988, SOC SCI MED, V26, P583, DOI 10.1016/0277-9536(88)90021-4; Moser M, 2001, ARCH INTERN MED, V161, P2655, DOI 10.1001/archinte.161.22.2655; ODonnell CJ, 1997, CIRCULATION, V95, P1132; Psaty BM, 1999, ARCH INTERN MED, V159, P1339, DOI 10.1001/archinte.159.12.1339; Roter DL, 1998, MED CARE, V36, P1138, DOI 10.1097/00005650-199808000-00004; SAGIE A, 1993, NEW ENGL J MED, V329, P1912, DOI 10.1056/NEJM199312233292602; Savage PJ, 1998, ARCH INTERN MED, V158, P741, DOI 10.1001/archinte.158.7.741; SHEKELLE RB, 1974, STROKE, V5, P71, DOI 10.1161/01.STR.5.1.71; Sheridan SL, 2004, AM J PREV MED, V26, P56, DOI 10.1016/j.amepre.2003.09.011; Somes GW, 1999, ARCH INTERN MED, V159, P2004, DOI 10.1001/archinte.159.17.2004; Staessen JA, 1998, ARCH INTERN MED, V158, P1681, DOI 10.1001/archinte.158.15.1681; Staessen JA, 2000, LANCET, V355, P865, DOI 10.1016/S0140-6736(99)07330-4; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Sutton-Tyrrell K, 2003, ARCH INTERN MED, V163, P2728, DOI 10.1001/archinte.163.22.2728; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; *US BUR CENS, 1992, CURR POP REP PROJ US; Vaccarino V, 2001, AM J CARDIOL, V88, P980, DOI 10.1016/S0002-9149(01)01974-9; Whitlock EP, 2002, AM J PREV MED, V22, P267, DOI 10.1016/S0749-3797(02)00415-4; ZEZULKA AV, 1987, J CLIN PHARMACOL, V27, P41, DOI 10.1177/009127008702700106	52	79	83	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2004	292	9					1074	1080		10.1001/jama.292.9.1074	http://dx.doi.org/10.1001/jama.292.9.1074			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VH	15339901	Bronze			2022-12-28	WOS:000223568700023
J	Flore, O				Flore, O			Kaposi's sarcoma	LANCET			English	Editorial Material							EXPRESSION; CELLS; AIDS; INVITRO; GENE		NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Dept Dermatol, New York, NY 10016 USA	New York University; New York University	Flore, O (corresponding author), NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.	ornella.flore@med.nyu.edu						ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; BABA M, 1987, ANTIVIR RES, V7, P99, DOI 10.1016/0166-3542(87)90025-8; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Jussila L, 1998, CANCER RES, V58, P1599; Kaposi M., 1872, ARCH DERMATOL SYPHIL, V4, P265, DOI 10.1007/BF01830024; NICKOLOFF BJ, 1989, AM J PATHOL, V135, P793; Roizman B, 1996, FIELDS VIROLOGY, P2221; ROTH WK, 1988, INT J CANCER, V42, P767, DOI 10.1002/ijc.2910420523; RUTGERS JL, 1986, AM J PATHOL, V122, P493; Sturzl M, 1998, AIDS, V12, P1105; Wang HW, 2004, NAT GENET, V36, P687, DOI 10.1038/ng1384	11	6	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	2004	364	9436					740	741		10.1016/S0140-6736(04)16952-3	http://dx.doi.org/10.1016/S0140-6736(04)16952-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337387				2022-12-28	WOS:000223569600008
J	Rohling, EJ; Marsh, R; Wells, NC; Siddall, M; Edwards, NR				Rohling, EJ; Marsh, R; Wells, NC; Siddall, M; Edwards, NR			Similar meltwater contributions to glacial sea level changes from Antarctic and northern ice sheets	NATURE			English	Article							CLIMATE-CHANGE; GREENLAND; RECORD; CYCLE; INSTABILITY; MAXIMUM; EVENTS; PERIOD; MODEL; CORE	The period between 75,000 and 20,000 years ago was characterized by high variability in climate(1-12) and sea level(13,14). Southern Ocean records of ice-rafted debris(15) suggest a significant contribution to the sea level changes from melt water of Antarctic origin, in addition to likely contributions from northern ice sheets, but the relative volumes of melt water from northern and southern sources have yet to be established. Here we simulate the first-order impact of a range of relative meltwater releases from the two polar regions on the distribution of marine oxygen isotopes, using an intermediate complexity model. By comparing our simulations with oxygen isotope data from sediment cores, we infer that the contributions from Antarctica and the northern ice sheets to the documented sea level rises between 65,000 and 35,000 years ago(13) were approximately equal, each accounting for a rise of about 15 m. The reductions in Antarctic ice volume implied by our analysis are comparable to that inferred previously for the Antarctic contribution to meltwater pulse 1A (refs 16, 17), which occurred about 14,200 years ago, during the last deglaciation.	Southampton Oceanog Ctr, Southampton SO14 3ZH, Hants, England; Univ Bern, NCCR Climate, CH-3012 Bern, Switzerland	NERC National Oceanography Centre; University of Southampton; University of Bern	Rohling, EJ (corresponding author), Southampton Oceanog Ctr, Southampton SO14 3ZH, Hants, England.	e.rohling@soc.soton.ac.uk	Marsh, Robert/G-4988-2013; Rohling, Eelco J/B-9736-2008	Rohling, Eelco J/0000-0001-5349-2158; Marsh, Robert/0000-0002-1051-8749	Natural Environment Research Council [NER/T/S/2002/00455] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Anderson JB, 2002, QUATERNARY SCI REV, V21, P49, DOI 10.1016/S0277-3791(01)00083-X; ANNAN JD, IN PRESS OCEAN MODEL; Barrett P.J, 1996, TERRA ANTARCTICA, V3, P103; Blunier T, 1998, NATURE, V394, P739, DOI 10.1038/29447; Broecker WS, 2000, EARTH-SCI REV, V51, P137, DOI 10.1016/S0012-8252(00)00019-2; Clark PU, 2002, SCIENCE, V295, P2438; Cutler KB, 2003, EARTH PLANET SC LETT, V206, P253, DOI 10.1016/S0012-821X(02)01107-X; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Denton GH, 2002, QUATERNARY SCI REV, V21, P193, DOI 10.1016/S0277-3791(01)00090-7; EDWARDS NR, 2004, UNPUB CLIM DYN; Ganopolski A, 2001, NATURE, V409, P153, DOI 10.1038/35051500; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; Hemming SR, 2004, REV GEOPHYS, V42, DOI 10.1029/2003RG000128; Huybrechts P, 2002, QUATERNARY SCI REV, V21, P203, DOI 10.1016/S0277-3791(01)00082-8; Indermuhle A, 2000, GEOPHYS RES LETT, V27, P735, DOI 10.1029/1999GL010960; Kanfoush SL, 2000, SCIENCE, V288, P1815, DOI 10.1126/science.288.5472.1815; LANGWAY CC, 1985, GEOPHYS MONOGR AM GE, V33; Leuschner DC, 2000, QUATERNARY SCI REV, V19, P243, DOI 10.1016/S0277-3791(99)00064-5; Pahnke K, 2003, SCIENCE, V301, P948, DOI 10.1126/science.1084451; PELTIER WR, 1994, SCIENCE, V265, P195, DOI 10.1126/science.265.5169.195; RAHMSTORF S, 1994, NATURE, V372, P82, DOI 10.1038/372082a0; Rahmstorf S, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017115; RAHMSTORF S, 1995, NATURE, V378, P145, DOI 10.1038/378145a0; Rohling EJ, 2003, CLIM DYNAM, V20, P257, DOI 10.1007/s00382-002-0266-4; Shackleton NJ, 2000, PALEOCEANOGRAPHY, V15, P565, DOI 10.1029/2000PA000513; Siddall M, 2003, NATURE, V423, P853, DOI 10.1038/nature01690; Stenni B, 2004, EARTH PLANET SC LETT, V217, P183, DOI 10.1016/S0012-821X(03)00574-0; Stocker TF, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2003PA000920; Voelker AHL, 2002, QUATERNARY SCI REV, V21, P1185, DOI 10.1016/S0277-3791(01)00139-1; Weaver AJ, 2003, SCIENCE, V299, P1709, DOI 10.1126/science.1081002	30	71	73	1	387	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2004	430	7003					1016	1021		10.1038/nature02859	http://dx.doi.org/10.1038/nature02859			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329718				2022-12-28	WOS:000223514900040
J	Hogg, JC				Hogg, JC			Pathophysiology of airflow limitation in chronic obstructive pulmonary disease	LANCET			English	Review							GROWTH-FACTOR-BETA; TUMOR-NECROSIS-FACTOR; CHRONIC-BRONCHITIS; CIGARETTE-SMOKING; EPITHELIAL-CELLS; EXCISED HUMAN; SMALL AIRWAYS; TRANSFORMING GROWTH-FACTOR-BETA-1; PANLOBULAR EMPHYSEMA; NEUTROPHIL KINETICS	The airflow limitation that defines chronic obstructive pulmonary disease (COPD) is the result of a prolonged time constant for lung emptying, caused by increased resistance of the small conducting airways and increased compliance of the lung as a result of emphysematous destruction. These lesions are associated with a chronic innate and adaptive inflammatory immune response of the host to a lifetime exposure to inhaled toxic gases and particles. Processes contributing to obstruction in the small conducting airways include disruption of the epithelial barrier, interference with mucociliary clearance apparatus that results in accumulation of inflammatory mucous exudates in the small airway lumen, infiltration of the airway walls by inflammatory cells, and deposition of connective tissue in the airway wall. This remodelling and repair thickens the airway walls, reduces lumen calibre, and restricts the normal increase in calibre produced by lung inflation. Emphysematous lung destruction is associated with an infiltration of the same type of inflammatory cells found in the airways. The centrilobular pattern of emphysematous destruction is most closely associated with cigarette smoking, and although it is initially focused on respiratory bronchioles, separate lesions coalesce to destroy large volumes of lung tissue. The panacinar pattern of emphysema is characterised by a more even involvement of the acinus and is associated with alpha1 antitrypsin deficiency. The technology needed to diagnose and quantitate the individual small airway and emphysema phenotypes present in people with COPD is being developed, and should prove helpful in the assessment of therapeutic interventions designed to modify the progress of either phenotype.	Univ British Columbia, James Hogg ICAPTURE Ctr Cardiovasc & Pulm Res, Vancouver, BC V6Z 1Y6, Canada; St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada	University of British Columbia; St. Paul's Hospital; University of Saskatchewan	Hogg, JC (corresponding author), Univ British Columbia, James Hogg ICAPTURE Ctr Cardiovasc & Pulm Res, Room 166-1081,Burrard St, Vancouver, BC V6Z 1Y6, Canada.	jhogg@mrl.ubc.ca						ABBAS A, 2000, NEW ENGL J MED, V343, P338; ABBAS AK, 2000, CELLULAR MOL IMMUNOL, P291; [Anonymous], 1965, LANCET, V1, P775; [Anonymous], 1963, MORPHOMETRY HUMAN LU, DOI DOI 10.1007/978-3-642-87553-3_10; Bazzano LA, 2003, ANN INTERN MED, V138, P891, DOI 10.7326/0003-4819-138-11-200306030-00010; Becker S, 2002, TOXICOL IN VITRO, V16, P209, DOI 10.1016/S0887-2333(02)00015-2; Behzad AR, 1996, MICROVASC RES, V51, P303, DOI 10.1006/mvre.1996.0029; BEREND N, 1979, AM REV RESPIR DIS, V119, P695; BEREND N, 1982, J APPL PHYSIOL, V52, P346, DOI 10.1152/jappl.1982.52.2.346; BLANC PD, 1993, AM REV RESPIR DIS, V147, P134, DOI 10.1164/ajrccm/147.1.134; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; BOSKEN CH, 1990, AM REV RESPIR DIS, V142, P563, DOI 10.1164/ajrccm/142.3.563; BOSKEN CH, 1992, AM REV RESPIR DIS, V145, P911, DOI 10.1164/ajrccm/145.4_Pt_1.911; BOWMAN HG, 1999, ANNU REV IMMUNOL, V13, P61; BRUMFITT W, 1957, LANCET, V2, P1306; Burns AR, 2003, PHYSIOL REV, V83, P309, DOI 10.1152/physrev.00023.2002; BUTLER J, 1960, J CLIN INVEST, V39, P584, DOI 10.1172/JCI104071; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; Ciba Guest Symposium, 1959, THORAX, V14, P286, DOI 10.1136/thx.14.4.286; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; COSIO MG, 1980, AM REV RESPIR DIS, V122, P265; Coxson HO, 1999, AM J RESP CRIT CARE, V159, P851, DOI 10.1164/ajrccm.159.3.9805067; DAYMAN H, 1951, J CLIN INVEST, V30, P1175, DOI 10.1172/JCI102537; Dirksen A, 1999, AM J RESP CRIT CARE, V160, P1468, DOI 10.1164/ajrccm.160.5.9901055; DiStefano A, 1996, AM J RESP CRIT CARE, V153, P629, DOI 10.1164/ajrccm.153.2.8564109; Doerschuk CM, 2001, MICROCIRCULATION, V8, P71, DOI 10.1038/sj.mn.7300151; DOERSCHUK CM, 1994, J APPL PHYSIOL, V77, P2593, DOI 10.1152/jappl.1994.77.6.2593; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DUNNILL MS, 1982, PULMONARY PATHOLOGY, P81; EBERT RV, 1975, AM REV RESPIR DIS, V111, P4; Fletcher CM, 1976, NATURAL HIST CHRONIC; Fujii T, 2002, AM J RESP CELL MOL, V27, P34, DOI 10.1165/ajrcmb.27.1.4787; Fujii T, 2001, AM J RESP CELL MOL, V25, P265, DOI 10.1165/ajrcmb.25.3.4445; GEVENOIS PA, 1995, AM J RESP CRIT CARE, V152, P653, DOI 10.1164/ajrccm.152.2.7633722; Gilmour PS, 2001, AM J PHYSIOL-LUNG C, V281, pL598, DOI 10.1152/ajplung.2001.281.3.L598; *GOLD, 2001, NIH PUBL, V2701; Gorelik L, 2002, J EXP MED, V195, P1499, DOI 10.1084/jem.20012076; Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704; GREEN GM, 1977, AM REV RESPIR DIS, V115, P479; Guenther D, 2000, ACTA RADIOL, V41, P519, DOI 10.1080/028418500127346009; HALE KA, 1984, AM REV RESPIR DIS, V130, P716; HAYHURST MD, 1984, LANCET, V2, P320; HEARD BE, 1958, THORAX, V14, P58; HEPPLESTON A, 1961, AM J MED, V31, P279, DOI 10.1016/0002-9343(61)90116-4; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; HOGG JC, 1994, THORAX, V49, P473, DOI 10.1136/thx.49.5.473; Hogg JC, 2002, THORAX, V57, P830, DOI 10.1136/thorax.57.9.830; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; HOGG JC, 1987, PHYSIOL REV, V67, P1249, DOI 10.1152/physrev.1987.67.4.1249; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P421, DOI 10.1067/mai.2000.105010; HULBERT WC, 1981, AM REV RESPIR DIS, V123, P320; HUNNINGHAKE GW, 1983, AM REV RESPIR DIS, V128, P833; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; JONES JG, 1980, LANCET, V1, P66; Kanner RE, 2001, AM J RESP CRIT CARE, V164, P358, DOI 10.1164/ajrccm.164.3.2010017; Kauczor HU, 2001, EUR RESPIR J, V17, P1008, DOI 10.1183/09031936.01.17510080; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Kemeny DM, 1999, AM J RESP CRIT CARE, V160, pS33, DOI 10.1164/ajrccm.160.supplement_1.10; KIM PH, 1990, J IMMUNOL, V145, P3773; KIM WD, 1991, AM REV RESPIR DIS, V144, P1385, DOI 10.1164/ajrccm/144.6.1385; Kitagawa Y, 1997, J APPL PHYSIOL, V82, P1397, DOI 10.1152/jappl.1997.82.5.1397; KLUT ME, 1993, AM J RESP CELL MOL, V9, P82, DOI 10.1165/ajrcmb/9.1.82; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Kolb M, 2001, J CLIN INVEST, V107, P1529, DOI 10.1172/JCI12568; Kraal G, 1997, ADV IMMUNOL, V65, P347, DOI 10.1016/S0065-2776(08)60746-4; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; Laennec RTH, 1834, TREATISE DIS CHEST M, V4th; Lamm ME, 1997, ANNU REV MICROBIOL, V51, P311, DOI 10.1146/annurev.micro.51.1.311; LE JM, 1987, LAB INVEST, V56, P234; LEOPOLD J. G., 1957, THORAX, V12, P219, DOI 10.1136/thx.12.3.219; LeVine AM, 2001, MICROBES INFECT, V3, P161, DOI 10.1016/S1286-4579(00)01363-0; Liu YJ, 2001, CELL, V106, P259, DOI 10.1016/S0092-8674(01)00456-1; LUMSDEN AB, 1984, THORAX, V39, P844, DOI 10.1136/thx.39.11.844; MACNEE W, 1989, NEW ENGL J MED, V321, P924, DOI 10.1056/NEJM198910053211402; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V152, P1926, DOI 10.1164/ajrccm.152.6.8520757; Mai VM, 2001, J MAGN RESON IMAGING, V14, P574, DOI 10.1002/jmri.1221; MARKOS J, 1990, J APPL PHYSIOL, V69, P214, DOI 10.1152/jappl.1990.69.1.214; MARTIN CJ, 1970, AM REV RESPIR DIS, V102, P552; MATSUBA K, 1972, AM J PATHOL, V67, P265; MATSUBA K, 1989, EUR RESPIR J, V2, P834; McLEAN K. H., 1956, AUSTRALASIAN ANN MED, V5, P73; MEAD J, 1967, J APPL PHYSIOL, V22, P95, DOI 10.1152/jappl.1967.22.1.95; MEAD J, 1970, NEW ENGL J MED, V282, P1318, DOI 10.1056/NEJM197006042822311; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; MULLEN JBM, 1985, BMJ-BRIT MED J, V291, P1235, DOI 10.1136/bmj.291.6504.1235; MULLER NL, 1988, CHEST, V94, P782, DOI 10.1378/chest.94.4.782; Nakano Y, 2000, AM J RESP CRIT CARE, V162, P1102, DOI 10.1164/ajrccm.162.3.9907120; Neutra MR, 2001, NAT IMMUNOL, V2, P1004, DOI 10.1038/ni1101-1004; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; Ohno Y, 2001, AM J ROENTGENOL, V177, P185, DOI 10.2214/ajr.177.1.1770185; Ohno Yoshiharu, 2003, Top Magn Reson Imaging, V14, P237, DOI 10.1097/00002142-200306000-00004; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852, DOI 10.1164/ajrccm.155.3.9117016; OTIS AB, 1956, J APPL PHYSIOL, V8, P427, DOI 10.1152/jappl.1956.8.4.427; Oxenius A, 1998, ADV IMMUNOL, V70, P313, DOI 10.1016/S0065-2776(08)60390-9; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; PETO R, 1983, AM REV RESPIR DIS, V128, P491, DOI 10.1164/arrd.1983.128.3.491; PETTY TL, 1982, AM REV RESPIR DIS, V125, P535, DOI 10.1164/arrd.1982.125.5.535; PETTY TL, 1980, AM REV RESPIR DIS, V121, P449, DOI 10.1164/arrd.1980.121.3.449; Pride NB, 1995, CHRONIC OBSTRUCTIVE, P69; REID LYNNE, 1960, THORAX, V15, P132, DOI 10.1136/thx.15.2.132; REID LYNNE M., 1955, THORAX, V10, P199, DOI 10.1136/thx.10.3.199; Retamales I, 2001, AM J RESP CRIT CARE, V164, P469, DOI 10.1164/ajrccm.164.3.2007149; RICHMOND I, 1993, THORAX, V48, P1130, DOI 10.1136/thx.48.11.1130; SAETTA M, 1993, AM REV RESPIR DIS, V147, P301, DOI 10.1164/ajrccm/147.2.301; Saetta M, 1997, AM J RESP CRIT CARE, V156, P1633, DOI 10.1164/ajrccm.156.5.9701081; SAETTA M, 1985, AM REV RESPIR DIS, V132, P894; SALMON RB, 1982, AM REV RESPIR DIS, V126, P686; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Sethi S, 2001, CLIN MICROBIOL REV, V14, P336, DOI 10.1128/CMR.14.2.336-363.2001; SIMANI AS, 1974, LAB INVEST, V31, P75; Sime PJ, 1998, AM J PATHOL, V153, P825, DOI 10.1016/S0002-9440(10)65624-6; Sirianni FE, 2003, AM J RESP CRIT CARE, V168, P1532, DOI 10.1164/rccm.200303-371OC; SNIDER GL, 1985, AM REV RESPIR DIS, V132, P182; SONODA E, 1992, CELL IMMUNOL, V140, P158, DOI 10.1016/0008-8749(92)90184-Q; Soukup JM, 2001, TOXICOL APPL PHARM, V171, P20, DOI 10.1006/taap.2000.9096; Stick SA, 2003, AM J RESP CELL MOL, V28, P641, DOI 10.1165/rcmb.F271; Stolk J, 2001, INVEST RADIOL, V36, P648, DOI 10.1097/00004424-200111000-00004; TAKIZAWA T, 1971, AM REV RESPIR DIS, V104, P331, DOI 10.1164/arrd.1971.104.3.331; Terashima T, 1999, AM J RESP CELL MOL, V20, P171, DOI 10.1165/ajrcmb.20.1.3276; THOMPSON AB, 1989, AM REV RESPIR DIS, V140, P1527, DOI 10.1164/ajrccm/140.6.1527; THURLBECK W. M., 1964, THORAX, V19, P436, DOI 10.1136/thx.19.5.436; THURLBECK WM, 1975, AM REV RESPIR DIS, V112, P65; THURLBECK WM, 1963, AM REV RESPIR DIS, V87, P206; Topham MK, 1998, FASEB J, V12, P733, DOI 10.1096/fasebj.12.9.733; van Eeden SF, 2000, EUR RESPIR J, V15, P915, DOI 10.1034/j.1399-3003.2000.15e18.x; VANBRABANDT H, 1983, J APPL PHYSIOL, V55, P1733, DOI 10.1152/jappl.1983.55.6.1733; Vestbo J, 2002, AM J RESP CRIT CARE, V166, P329, DOI 10.1164/rccm.2112048; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Whitsett JA, 2002, J CLIN INVEST, V109, P565, DOI 10.1172/JCI200215209; WIGGS BR, 1990, J APPL PHYSIOL, V69, P849, DOI 10.1152/jappl.1990.69.3.849; WRIGHT JL, 1984, AM REV RESPIR DIS, V129, P989; WYATT JP, 1962, DIS CHEST, V41, P239, DOI 10.1378/chest.41.3.239; YANAI M, 1992, J APPL PHYSIOL, V72, P1016, DOI 10.1152/jappl.1992.72.3.1016	134	803	860	0	128	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	2004	364	9435					709	721		10.1016/S0140-6736(04)16900-6	http://dx.doi.org/10.1016/S0140-6736(04)16900-6			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325838				2022-12-28	WOS:000223428900035
J	Ho, TL				Ho, TL			Arrival of the fermion superfluid	SCIENCE			English	Editorial Material							CONDENSATION; GAS; ATOMS		Ohio State Univ, Dept Phys, Columbus, OH 43210 USA	Ohio State University	Ho, TL (corresponding author), Ohio State Univ, Dept Phys, 174 W 18th Ave, Columbus, OH 43210 USA.	ho@mps.ohio-state.edu						BARDEEN J, 1956, PHYS REV, V104, P844; Bartenstein M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.203201; Bourdel T, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.020402; Chin C, 2004, SCIENCE, V305, P1128, DOI 10.1126/science.1100818; Greiner M, 2003, NATURE, V426, P537, DOI 10.1038/nature02199; Holland M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.120406; Jochim S, 2003, SCIENCE, V302, P2101, DOI 10.1126/science.1093280; Kinast J, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.150402; Kinnunen J, 2004, SCIENCE, V305, P1131, DOI 10.1126/science.1100782; NOZIERES P, 1985, J LOW TEMP PHYS, V59, P195, DOI 10.1007/BF00683774; O'Hara KM, 2002, SCIENCE, V298, P2179, DOI 10.1126/science.1079107; Regal CA, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.040403; ZHANG J, IN PRESS PHYS REV LE; Zwierlein MW, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.120403; Zwierlein MW, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.250401	15	9	10	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2004	305	5687					1114	1115		10.1126/science.1102682	http://dx.doi.org/10.1126/science.1102682			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326343				2022-12-28	WOS:000223557400032
J	Attaran, A				Attaran, A			Where did it all go wrong?	NATURE			English	Article							ROLL BACK MALARIA		Univ Ottawa, Ottawa, ON K1N 6N5, Canada	University of Ottawa	Attaran, A (corresponding author), Univ Ottawa, Ottawa, ON K1N 6N5, Canada.							[Anonymous], 2003, AFR MAL REP 2003; Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6; MCCARTHY FD, 2000, 2303 WORLD BANK; Narasimhan V, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-8; Snow RW, 2003, TRENDS PARASITOL, V19, P363, DOI 10.1016/S1471-4922(03)00168-5; SPIELMAN A, 1993, J MED ENTOMOL, V30, P6, DOI 10.1093/jmedent/30.1.6; World Health Organization, 2001, MACR HLTH INV HLTH E; Yamey G, 2004, BRIT MED J, V328, P1086, DOI 10.1136/bmj.328.7448.1086	8	10	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					932	933		10.1038/430932a	http://dx.doi.org/10.1038/430932a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318233				2022-12-28	WOS:000223369800056
J	Clayton, J; Butler, D; Hull, K				Clayton, J; Butler, D; Hull, K			The long and winding road	NATURE			English	Article																			0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2004	430	7002					937	937		10.1038/430937a	http://dx.doi.org/10.1038/430937a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318237	Bronze			2022-12-28	WOS:000223369800060
J	Johnston, RE				Johnston, RE			A candidate vaccine for severe acute respiratory syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MICE		Univ N Carolina, Carolina Vaccine Inst, Chapel Hill, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill	Johnston, RE (corresponding author), Univ N Carolina, Carolina Vaccine Inst, Chapel Hill, NC 27514 USA.							[Anonymous], 2003, MMWR MORB MORTAL WKL, V52, P226; FLEMING JO, 1983, VIROLOGY, V131, P296, DOI 10.1016/0042-6822(83)90498-1; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; WILLIAMS RS, 1991, P NATL ACAD SCI USA, V88, P2726, DOI 10.1073/pnas.88.7.2726; Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463; 2003, MMWR MORB MORTAL WKL, V52, P284	6	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2004	351	8					827	828		10.1056/NEJMcibr041657	http://dx.doi.org/10.1056/NEJMcibr041657			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847CY	15317899				2022-12-28	WOS:000223367900019
J	Wood, MJ; Storz, G; Tjandra, N				Wood, MJ; Storz, G; Tjandra, N			Structural basis for redox regulation of Yap1 transcription factor localization	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR-LOCALIZATION; OXIDATIVE STRESS; RECEPTOR; DOMAIN; NMR; MACROMOLECULES; ACTIVATION; MECHANISM; TRANSPORT	The ability of organisms to alter their gene expression patterns in response to environmental changes is essential for viability. A central regulator of the response to oxidative stress in Saccharomyces cerevisiae is the Yap1 transcription factor. Upon activation by increased levels of reactive oxygen species, Yap1 rapidly redistributes to the nucleus where it regulates the expression of up to 70 genes(1-3). Here we identify a redox-regulated domain of Yap1 and determine its high-resolution solution structure. In the active oxidized form, a nuclear export signal (NES) in the carboxy-terminal cysteine-rich domain is masked by disulphide-bond-mediated interactions with a conserved amino-terminal alpha-helix. Point mutations that weaken the hydrophobic interactions between the N-terminal alpha-helix and the C-terminal NES-containing domain abolished redox-regulated changes in subcellular localization of Yap1. Upon reduction of the disulphide bonds, Yap1 undergoes a change to an unstructured conformation that exposes the NES and allows redistribution to the cytoplasm. These results reveal the structural basis of redox-dependent Yap1 localization and provide a previously unknown mechanism of transcription factor regulation by reversible intramolecular disulphide bond formation.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Biophys Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Storz, G (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.	storzg@mail.nih.gov; nico@helix.nih.gov		Storz, Gisela/0000-0001-6698-1241	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001608] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001608] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL001048, ZIAHL001048] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cavanagh J., 1995, PROTEIN NMR SPECTROS; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Coleman ST, 1999, MOL CELL BIOL, V19, P8302; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Graumann J, 2001, STRUCTURE, V9, P377, DOI 10.1016/S0969-2126(01)00599-8; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; Isoyama T, 2001, J BIOL CHEM, V276, P21863, DOI 10.1074/jbc.M009258200; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Kim PW, 2003, SCIENCE, V301, P1725, DOI 10.1126/science.1085643; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SIKORSKI RS, 1989, GENETICS, V122, P19; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Vijayalakshmi J, 2001, STRUCTURE, V9, P367, DOI 10.1016/S0969-2126(01)00597-4; Wood MJ, 2003, BIOCHEMISTRY-US, V42, P11982, DOI 10.1021/bi035003d; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	29	130	134	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					917	921		10.1038/nature02790	http://dx.doi.org/10.1038/nature02790			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318225				2022-12-28	WOS:000223369800048
J	Gao, M; Labuda, T; Xia, Y; Gallagher, E; Fang, D; Liu, YC; Karin, M				Gao, M; Labuda, T; Xia, Y; Gallagher, E; Fang, D; Liu, YC; Karin, M			Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase itch	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASES; N-TERMINAL KINASE; C-JUN; CELL DIFFERENTIATION; UBIQUITIN LIGASE; TRANSCRIPTION; EXPRESSION; APOPTOSIS; INHIBITOR	The turnover of Jun proteins, like that of other transcription factors, is regulated through ubiquitin-dependent proteolysis. Usually, such processes are regulated by extracellular stimuli through phosphorylation of the target protein, which allows recognition by F box-containing E3 ubiquitin ligases. In the case of c-Jun and JunB, we found that extracellular stimuli also modulate protein turnover by regulating the activity of an E3 ligase by means of its phosphorylation. Activation of the Jun amino-terminal kinase (JNK) mitogen-activated protein kinase cascade after T cell stimulation accelerated degradation of c-Jun and JunB through phosphorylation-dependent activation of the E3 ligase Itch. This pathway modulates cytokine production by effector T cells.	Univ Calif San Diego, Lab Gene Regulat & Signal Transduct, Dept Pharmacol, Sch Med, La Jolla, CA 92093 USA; Univ Copenhagen, Dept Med Microbiol & Immunol, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Inst Mol Biol, DK-2200 Copenhagen N, Denmark; La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA	University of California System; University of California San Diego; University of Copenhagen; University of Copenhagen; La Jolla Institute for Immunology	Karin, M (corresponding author), Univ Calif San Diego, Lab Gene Regulat & Signal Transduct, Dept Pharmacol, Sch Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu	Fang, Deyu/I-7245-2013	Fang, Deyu/0000-0002-4211-2751; LIU, YUN-CAI/0000-0002-0996-7109	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI048542, R01AI043477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES004151, R01ES004151, R01ES006376] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43477, R21AI48542] Funding Source: Medline; NIEHS NIH HHS [ES04151, ES06376] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Fuchs SY, 1996, ONCOGENE, V13, P1531; Gao M., UNPUB; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hartenstein B, 2002, EMBO J, V21, P6321, DOI 10.1093/emboj/cdf648; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Varshavsky A, 2003, NAT CELL BIOL, V5, P373, DOI 10.1038/ncb0503-373; Zhang L, 2003, EMBO J, V22, P4443, DOI 10.1093/emboj/cdg440	26	328	341	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	2004	306	5694					271	275		10.1126/science.1099414	http://dx.doi.org/10.1126/science.1099414			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861MC	15358865				2022-12-28	WOS:000224419700039
J	Stroscio, JA; Celotta, RJ				Stroscio, JA; Celotta, RJ			Controlling the dynamics of a single atom in lateral atom manipulation	SCIENCE			English	Article							SCANNING TUNNELING MICROSCOPE; SWITCH; TIP	We studied the dynamics of a single cobalt (Co) atom during lateral manipulation on a copper (111) surface in a low-temperature scanning tunneling microscope. The Co binding site locations were revealed in a detailed image that resulted from lateral Co atom motion within the trapping potential of the scanning tip. Random telegraph noise, corresponding to the Co atom switching between hexagonal close-packed (hcp) and face-centered cubic (fcc) sites, was seen when the tip was used to try to position the Co atom over the higher energy hcp site. Varying the probe tip height modified the normal copper (111) potential landscape and allowed the residence time of the Co atom in these sites to be varied. At low tunneling voltages (less than similar to5 millielectron volts), the transfer rate between sites was independent of tunneling voltage, current, and temperature. At higher voltages, the transfer rate exhibited a strong dependence on tunneling voltage, indicative of vibrational heating by inelastic electron scattering.	Natl Inst Stand & Technol, Electron Phys Grp, Gaithersburg, MD 20899 USA	National Institute of Standards & Technology (NIST) - USA	Stroscio, JA (corresponding author), Natl Inst Stand & Technol, Electron Phys Grp, Gaithersburg, MD 20899 USA.	joseph.stroscio@nist.gov						Bartels L, 1997, PHYS REV LETT, V79, P697, DOI 10.1103/PhysRevLett.79.697; Bouju X, 1999, PHYS REV B, V59, pR7845, DOI 10.1103/PhysRevB.59.R7845; BRANDBYGE M, 1994, PHYS REV LETT, V72, P2919, DOI 10.1103/PhysRevLett.72.2919; EIGLER DM, 1991, NATURE, V352, P600, DOI 10.1038/352600a0; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; Gao SW, 1997, PHYS REV B, V55, P4825, DOI 10.1103/PhysRevB.55.4825; GAO SW, 1992, SOLID STATE COMMUN, V84, P271, DOI 10.1016/0038-1098(92)90119-T; Heinrich AJ, 2002, SCIENCE, V298, P1381, DOI 10.1126/science.1076768; Hla SW, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.201402; Kogan S., 1996, ELECT NOISE FLUCTUAT; Kuhnle A, 2002, SURF SCI, V499, P15, DOI 10.1016/S0039-6028(01)01848-9; Lifshitz EM., 1977, QUANTUM MECH, V3rd; PERSSON BNJ, 1991, PHYS REV B, V44, P3277, DOI 10.1103/PhysRevB.44.3277; Repp J, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.206102; SHEN TC, 1995, SCIENCE, V268, P1590, DOI 10.1126/science.268.5217.1590; Stepanyuk VS, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.205410; Stipe BC, 1998, SCIENCE, V280, P1732, DOI 10.1126/science.280.5370.1732; STROSCIO JA, 1991, SCIENCE, V254, P1319, DOI 10.1126/science.254.5036.1319; STROSCIO JA, 1993, METHODS EXPT PHYS, V27, P13361; Tsivlin DV, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.205411; WADA Y, 1995, OPTOELECTRON-DEVICES, V10, P205; WALKUP RE, 1993, PHYS REV B, V48, P1858, DOI 10.1103/PhysRevB.48.1858; WEISSMAN MB, 1988, REV MOD PHYS, V60, P537, DOI 10.1103/RevModPhys.60.537	23	214	218	3	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	2004	306	5694					242	247		10.1126/science.1102370	http://dx.doi.org/10.1126/science.1102370			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861MC	15358867				2022-12-28	WOS:000224419700030
J	Stolow, A; Jonas, DM				Stolow, A; Jonas, DM			Multidimensional snapshots of chemical dynamics	SCIENCE			English	Editorial Material							RESOLVED PHOTOELECTRON-SPECTROSCOPY; MOLECULAR-DYNAMICS; CRYSTALLOGRAPHY; TRANSITION; PEPTIDE		Natl Res Council Canada, Steacie Inst Mol Sci, Ottawa, ON K1A 0R6, Canada; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	National Research Council Canada; University of Colorado System; University of Colorado Boulder	Stolow, A (corresponding author), Natl Res Council Canada, Steacie Inst Mol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	albert.stolow@nrc.ca; david.jonas@colorado.edu	Stolow, Albert/AAN-5609-2020; Jonas, David M/A-7491-2008	Jonas, David M/0000-0002-1085-8161				Benesch F, 2004, OPT LETT, V29, P1028, DOI 10.1364/OL.29.001028; Blanchet V, 1999, NATURE, V401, P52, DOI 10.1038/43410; Bredenbeck J, 2003, J PHYS CHEM B, V107, P8654, DOI 10.1021/jp034552q; Davies JA, 2000, PHYS REV LETT, V84, P5983, DOI 10.1103/PhysRevLett.84.5983; DeCamp MF, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.165502; Hanold KA, 1996, PHYS REV LETT, V77, P3335, DOI 10.1103/PhysRevLett.77.3335; Johnson SL, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.157403; Jonas DM, 2003, ANNU REV PHYS CHEM, V54, P425, DOI 10.1146/annurev.physchem.54.011002.103907; Jonas DM, 2003, SCIENCE, V300, P1515, DOI 10.1126/science.1085687; Kienberger R, 2004, NATURE, V427, P817, DOI 10.1038/nature02277; Lehr L, 1999, SCIENCE, V284, P635, DOI 10.1126/science.284.5414.635; Moffat K, 2003, FARADAY DISCUSS, V122, P65, DOI 10.1039/b201620f; Niikura H, 2003, NATURE, V421, P826, DOI 10.1038/nature01430; Ruan CY, 2004, P NATL ACAD SCI USA, V101, P1123, DOI 10.1073/pnas.0307302101; Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797; Siwick BJ, 2003, SCIENCE, V302, P1382, DOI 10.1126/science.1090052; Sporlein S, 2002, P NATL ACAD SCI USA, V99, P7998, DOI 10.1073/pnas.122238799; Stolow A, 2004, CHEM REV, V104, P1719, DOI 10.1021/cr020683w; 2004, S EM ULTR SPEC CHEM	19	28	28	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	2004	305	5690					1575	1577		10.1126/science.1103195	http://dx.doi.org/10.1126/science.1103195			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361614				2022-12-28	WOS:000223891200030
J	Elemans, CPH; Spierts, ILY; Muller, UK; van Leeuwen, JL; Goller, F				Elemans, CPH; Spierts, ILY; Muller, UK; van Leeuwen, JL; Goller, F			Superfast muscles control dove's trill	NATURE			English	Article							VOCALIZATIONS; SYRINX; SONG		Univ Wageningen & Res Ctr, Expt Zool Grp, NL-6709 PG Wageningen, Netherlands; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	Wageningen University & Research; Utah System of Higher Education; University of Utah	Elemans, CPH (corresponding author), Univ Wageningen & Res Ctr, Expt Zool Grp, NL-6709 PG Wageningen, Netherlands.	coen.elemans@wur.nl	van Leeuwen, Johan/N-3437-2019; van Leeuwen, Johan L/B-7897-2011	van Leeuwen, Johan/0000-0002-4433-880X; Elemans, Coen/0000-0001-6306-5715				Beckers GJL, 2003, J EXP BIOL, V206, P1833, DOI 10.1242/jeb.00364; Fee MS, 1998, NATURE, V395, P67, DOI 10.1038/25725; FLETCHER NH, 1988, J THEOR BIOL, V135, P455, DOI 10.1016/S0022-5193(88)80270-4; Gardner T, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.208101; Goller F, 1997, J EXP BIOL, V200, P2165; Goller F, 1998, NATURE, V395, P11, DOI 10.1038/25589; Goller F, 1996, J NEUROPHYSIOL, V75, P867, DOI 10.1152/jn.1996.75.2.867; Greenwalt C.H., 1968, BIRD SONG ACOUSTICS; Harris CM, 1998, NATURE, V394, P780, DOI 10.1038/29528; Larsen ON, 1999, P ROY SOC B-BIOL SCI, V266, P1609, DOI 10.1098/rspb.1999.0822; Rome LC, 1999, P NATL ACAD SCI USA, V96, P5826, DOI 10.1073/pnas.96.10.5826; Young IS, 2001, P ROY SOC B-BIOL SCI, V268, P1965, DOI 10.1098/rspb.2001.1731	12	52	55	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	2004	431	7005					146	146		10.1038/431146a	http://dx.doi.org/10.1038/431146a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356620	Bronze, Green Published			2022-12-28	WOS:000223746000033
J	Perneger, TV				Perneger, TV			Relation between online "hit counts" and subsequent citations: prospective study of research papers in the BMJ	BRITISH MEDICAL JOURNAL			English	Article							QUALITY		Univ Geneva, Inst Social & Prevent Med, CH-1211 Geneva, Switzerland	University of Geneva	Perneger, TV (corresponding author), Univ Geneva, Inst Social & Prevent Med, CH-1211 Geneva, Switzerland.	thomas.perneger@hcuge.ch						Adam D, 2002, NATURE, V415, P726, DOI 10.1038/415726a; Lee KP, 2002, JAMA-J AM MED ASSOC, V287, P2805, DOI 10.1001/jama.287.21.2805; Seglen PO, 1997, BRIT MED J, V314, P498; Walter G, 2003, MED J AUSTRALIA, V178, P280, DOI 10.5694/j.1326-5377.2003.tb05196.x	4	99	101	1	14	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 4	2004	329	7465					546	547		10.1136/bmj.329.7465.546	http://dx.doi.org/10.1136/bmj.329.7465.546			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853DE	15345629	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000223805800020
J	Park, HG; Kim, SH; Kwon, SH; Ju, YG; Yang, JK; Baek, JH; Kim, SB; Lee, YH				Park, HG; Kim, SH; Kwon, SH; Ju, YG; Yang, JK; Baek, JH; Kim, SB; Lee, YH			Electrically driven single-cell photonic crystal laser	SCIENCE			English	Article							OPTICAL MICROCAVITIES; SPONTANEOUS EMISSION; MICRODISK LASERS; MODE; DEFECT; OPERATION; PHYSICS; DEVICE	We report the experimental demonstration of an electrically driven, single-mode, low threshold current (similar to260 muA) photonic band gap laser operating at room temperature. The electrical current pulse is injected through a sub-micrometer-sized semiconductor wire at the center of the mode with minimal degradation of the quality factor. The actual mode of interest operates in a nondegenerate monopole mode, as evidenced through the comparison of the measurement with the computation based on the actual fabricated structural parameters. As a small step toward a thresholdless laser or a single photon source, this wavelength-size photonic crystal laser may be of interest to photonic crystals, cavity quantum electrodynamics, and quantum information communities.	Korea Adv Inst Sci & Technol, Dept Phys, Taejon 305701, South Korea; Elect & Telecommun Res Inst, Telecommun Basic Res Lab, Taejon 305600, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Electronics & Telecommunications Research Institute - Korea (ETRI)	Lee, YH (corresponding author), Korea Adv Inst Sci & Technol, Dept Phys, Taejon 305701, South Korea.	yhtee@kaist.ac.kr	Lee, Yong Hee/C-2015-2011; Kim, Se-Heon/C-5498-2008; kyu, yang jin/E-6200-2010					Coldren L.A., 1995, DIODE LASERS PHOTONI; Colombelli R, 2003, SCIENCE, V302, P1374, DOI 10.1126/science.1090561; DEPPE DG, 1988, J APPL PHYS, V64, P93; Fujita M, 2001, IEEE PHOTONIC TECH L, V13, P403, DOI 10.1109/68.920731; Happ TD, 2003, APPL PHYS LETT, V82, P4, DOI 10.1063/1.1527703; Kim J, 1999, NATURE, V397, P500, DOI 10.1038/17295; Kim S.O., UNPUB; Krauss TF, 1999, PROG QUANT ELECTRON, V23, P51, DOI 10.1016/S0079-6727(99)00004-X; LEVI AFJ, 1992, ELECTRON LETT, V28, P1010, DOI 10.1049/el:19920642; Loncar M, 2002, APPL PHYS LETT, V81, P2680, DOI 10.1063/1.1511538; Noda S, 2000, NATURE, V407, P608, DOI 10.1038/35036532; Noda S, 2001, SCIENCE, V293, P1123, DOI 10.1126/science.1061738; Painter O, 1999, SCIENCE, V284, P1819, DOI 10.1126/science.284.5421.1819; Park HG, 2003, IEEE PHOTONIC TECH L, V15, P1327, DOI 10.1109/LPT.2003.817992; Park HG, 2002, IEEE J QUANTUM ELECT, V38, P1353, DOI 10.1109/JQE.2002.802951; Park HG, 2001, APPL PHYS LETT, V79, P3032, DOI 10.1063/1.1416163; Ryu HY, 2002, APPL PHYS LETT, V80, P3883, DOI 10.1063/1.1480103; SLUSHER RE, 1993, APPL PHYS LETT, V63, P1310, DOI 10.1063/1.109714; Song DS, 2002, APPL PHYS LETT, V80, P3901, DOI 10.1063/1.1481984; Srinivasan K, 2003, APPL PHYS LETT, V83, P1915, DOI 10.1063/1.1606866; Vahala KJ, 2003, NATURE, V424, P839, DOI 10.1038/nature01939; Vuckovic J, 1999, IEEE J QUANTUM ELECT, V35, P1168, DOI 10.1109/3.777216; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; YOKOYAMA H, 1992, SCIENCE, V256, P66, DOI 10.1126/science.256.5053.66; Yuan ZL, 2002, SCIENCE, V295, P102, DOI 10.1126/science.1066790; Zhou WD, 2001, IEEE J QUANTUM ELECT, V37, P1153, DOI 10.1109/3.945320	26	703	727	2	217	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1444	1447		10.1126/science.1100968	http://dx.doi.org/10.1126/science.1100968			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353796				2022-12-28	WOS:000223761900042
J	Walensky, LD; Kung, AL; Escher, I; Malia, TJ; Barbuto, S; Wright, RD; Wagner, G; Verdine, GL; Korsmeyer, SJ				Walensky, LD; Kung, AL; Escher, I; Malia, TJ; Barbuto, S; Wright, RD; Wagner, G; Verdine, GL; Korsmeyer, SJ			Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix	SCIENCE			English	Article							CELL-PENETRATING PEPTIDES; CHROMOSOMAL BREAKPOINT; PROTEIN TRANSDUCTION; FOLLICULAR LYMPHOMA; NMR STRUCTURE; CYTOCHROME-C; DEATH; DOMAIN; BAK; MACROPINOCYTOSIS	BCL-2 family proteins constitute a critical control point for the regulation of apoptosis. Protein interaction between BCL-2 members is a prominent mechanism of control and is mediated through the amphipathic alpha-helical BH3 segment, an essential death domain. We used a chemical strategy, termed hydrocarbon stapling, to generate BH3 peptides with improved pharmacologic properties. The stapled peptides, called "stabilized alpha-helix of BCL-2 domains" (SAHBs), proved to be helical, protease-resistant, and cell-permeable molecules that bound with increased affinity to multidomain BCL-2 member pockets. A SAHB of the BH3 domain from the BID protein specifically activated the apoptotic pathway to kill leukemia cells. In addition, SAHB effectively inhibited the growth of human leukemia xenografts in vivo. Hydrocarbon stapling of native peptides may provide a useful strategy for experimental and therapeutic modulation of protein-protein interactions in many signaling pathways.	Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Hematol Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Childrens Hosp Boston, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; MIT, Dept Chem, Cambridge, MA 02139 USA	Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Verdine, GL (corresponding author), Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA.	verdine@chemistry.harvard.edu; stantey_korsmeyer@dfci.harvard.edu	Kung, Andrew/AAL-2384-2020; Kung, Andrew L/AEU-0826-2022	Kung, Andrew L/0000-0002-9091-488X	NATIONAL CANCER INSTITUTE [R37CA050239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL074049] Funding Source: NIH RePORTER; NCI NIH HHS [R37CA50239] Funding Source: Medline; NHLBI NIH HHS [K08 HL074049, K08HL074049] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Armstrong SA, 2003, CANCER CELL, V3, P173, DOI 10.1016/S1535-6108(03)00003-5; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Blackwell HE, 1998, ANGEW CHEM INT EDIT, V37, P3281, DOI 10.1002/(SICI)1521-3773(19981217)37:23<3281::AID-ANIE3281>3.0.CO;2-V; BRACKEN C, 1994, J AM CHEM SOC, V116, P6431, DOI 10.1021/ja00093a052; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEUC A, 2003, P NATL ACAD SCI USA, V100, P11273; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Phelan JC, 1997, J AM CHEM SOC, V119, P455, DOI 10.1021/ja9611654; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schafmeister CE, 2000, J AM CHEM SOC, V122, P5891, DOI 10.1021/ja000563a; Schleiff E, 1997, J BIOL CHEM, V272, P17784, DOI 10.1074/jbc.272.28.17784; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; WALENSKY LD, UNPUB; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WILLIAMS RM, 1991, J AM CHEM SOC, V113, P9276, DOI 10.1021/ja00024a038; YAN B, 2004, BIOORG MED CHEM LETT, V14, P1403	31	1049	1231	8	271	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1466	1470		10.1126/science.1099191	http://dx.doi.org/10.1126/science.1099191			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353804	Green Accepted			2022-12-28	WOS:000223761900050
J	Wang, A; Bashore, TM				Wang, A; Bashore, TM			Clinical problem-solving - Undercover and overlooked	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERICARDITIS PICKS-DISEASE; CONSTRICTIVE PERICARDITIS; DOPPLER-ECHOCARDIOGRAPHY; CARDIOMYOPATHY; RESECTION		Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA	Duke University	Wang, A (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA.			Wang, Andrew/0000-0001-8729-0933				Banerjee P, 2002, J AM COLL CARDIOL, V39, P138, DOI 10.1016/S0735-1097(01)01704-1; Felker GM, 2000, NEW ENGL J MED, V342, P1077, DOI 10.1056/NEJM200004133421502; HATLE LK, 1989, CIRCULATION, V79, P357, DOI 10.1161/01.CIR.79.2.357; Ling LH, 2000, ANN INTERN MED, V133, P659, DOI 10.7326/0003-4819-132-6-200003210-00004; Ling LH, 2000, ANN INTERN MED, V132, P444, DOI 10.7326/0003-4819-132-6-200003210-00004; Ling LH, 1999, CIRCULATION, V100, P1380, DOI 10.1161/01.CIR.100.13.1380; OH JK, 1994, J AM COLL CARDIOL, V23, P154, DOI 10.1016/0735-1097(94)90514-2; Talreja DR, 2003, CIRCULATION, V108, P1852, DOI 10.1161/01.CIR.0000087606.18453.FD; TYBERG TI, 1980, AM J CARDIOL, V46, P570, DOI 10.1016/0002-9149(80)90505-6; White PD, 1935, LANCET, V2, P597; White PD, 1935, LANCET, V2, P539	11	10	10	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2004	351	10					1014	1019		10.1056/NEJMcps033021	http://dx.doi.org/10.1056/NEJMcps033021			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	850UB	15342810				2022-12-28	WOS:000223637400013
J	Wang, YQ; Zhang, DX; Renner, SS; Chen, ZY				Wang, YQ; Zhang, DX; Renner, SS; Chen, ZY			A new self-pollination mechanism	NATURE			English	Editorial Material							ZINGIBERACEAE; POLLEN		Chinese Acad Sci, S China Bot Garden, Guangzhou 510650, Peoples R China; Zhongkai Agrotech Coll, Guangzhou 510225, Peoples R China; Univ Munich, Dept Biol, D-80638 Munich, Germany	Chinese Academy of Sciences; South China Botanical Garden, CAS; University of Munich	Wang, YQ (corresponding author), Chinese Acad Sci, S China Bot Garden, Guangzhou 510650, Peoples R China.	dx-zhang@scib.ac.cn		Zhang, Dianxiang/0000-0001-6549-8872				Barrett SCH, 2003, PHILOS T R SOC B, V358, P991, DOI 10.1098/rstb.2003.1301; DOBSON HEM, 1988, AM J BOT, V75, P170, DOI 10.2307/2443884; HESLOPHARRISON Y, 1977, ANN BOT-LONDON, V41, P1233, DOI 10.1093/oxfordjournals.aob.a085414; KRONESTEDT E, 1981, NORD J BOT, V1, P523; Larsen K, 2002, NORD J BOT, V22, P409, DOI 10.1111/j.1756-1051.2002.tb01392.x; LARSEN K, 1972, Notes from the Royal Botanic Garden Edinburgh, V31, P287; LARSEN KAI, 1964, BOT TIDSSKR, V60, P165; ROSE MJ, 1995, PLANT SYST EVOL, V195, P61, DOI 10.1007/BF00982315; Williams KJ, 2004, AM J BOT, V91, P100, DOI 10.3732/ajb.91.1.100	9	42	62	8	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2004	431	7004					39	40		10.1038/431039b	http://dx.doi.org/10.1038/431039b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343325				2022-12-28	WOS:000223641500032
J	Rennard, SI				Rennard, SI			Treatment of stable chronic obstructive pulmonary disease	LANCET			English	Review							SUSTAINED-RELEASE BUPROPION; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED CLINICAL-TRIAL; FORMOTEROL DRY POWDER; LONG-TERM TREATMENT; SMOKING-CESSATION; LUNG-FUNCTION; COPD PATIENTS; INHALED CORTICOSTEROIDS; FLUTICASONE PROPIONATE	Chronic obstructive pulmonary disease (COPD) is a readily diagnosable disorder that responds to treatment. Smoking cessation can reduce symptoms and prevent progression of disease. Bronchodilator therapy is key in improvement of lung function. Three classes of bronchodilators-beta agonists, anticholinergics, and theophylline-re available and can be used individually or in combination. Inhaled glucocorticoids can also improve airflow and can be combined with bronchodilators. Inhaled glucocorticoids, in addition, might reduce exacerbation frequency and severity as might some bronchodilators. Effective use of pharmacotherapy in COPD needs integration with a rehabilitation programme and successful treatment of co-morbidities, including depression and anxiety. Treatment for stable COPD can improve the function and quality of life of many patients, could reduce admissions to hospital, and has been suggested to improve survival.	Univ Nebraska, Med Ctr, Pulm & Crit Care Med Sect, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Rennard, SI (corresponding author), Univ Nebraska, Med Ctr, Pulm & Crit Care Med Sect, 600 S 42nd St, Omaha, NE 68198 USA.	srennard@unmc.edu						AbdelLatif AA, 1996, P SOC EXP BIOL MED, V211, P163; ALBERT RK, 1980, ANN INTERN MED, V92, P753, DOI 10.7326/0003-4819-92-6-753; Altose MD, 2000, NEW ENGL J MED, V343, P1902; [Anonymous], 1991, JAMA, V266, P3133; [Anonymous], [No title captured]; ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; Anthonisen NR, 2002, AM J RESP CRIT CARE, V166, P675, DOI 10.1164/rccm.2112096; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; ARGYROPOULOU P, 1993, RESPIRATION, V60, P216; Barnes PJ, 2003, AM J RESP CRIT CARE, V167, P813, DOI 10.1164/rccm.200210-1142PP; Bellia V, 2002, RESP MED, V96, P881, DOI 10.1053/rmed.2002.1380; BLACK P, 2003, COCHRANE LIB; BLEECKER ER, 1991, AM J MED, V91, pS24, DOI 10.1016/0002-9343(91)90258-Y; Blondal T, 1999, BRIT MED J, V318, P285, DOI 10.1136/bmj.318.7179.285; BONE R, 1994, CHEST, V105, P1411; Borak J, 1998, EUR RESPIR J, V12, P370; Borson, 1998, Semin Clin Neuropsychiatry, V3, P115; BORSON S, 1992, PSYCHOSOMATICS, V33, P190, DOI 10.1016/S0033-3182(92)71995-1; Brenes GA, 2003, PSYCHOSOM MED, V65, P963, DOI 10.1097/01.PSY.0000097339.75789.81; BUIST AS, 1976, AM REV RESPIR DIS, V114, P115; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Burge PS, 2003, THORAX, V58, P654, DOI 10.1136/thorax.58.8.654; Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Clary Greg L, 2002, Curr Psychiatry Rep, V4, P213, DOI 10.1007/s11920-002-0032-7; Corsico A, 2002, J APPL PHYSIOL, V93, P2053, DOI 10.1152/japplphysiol.00490.2002; Culpitt SV, 2002, AM J RESP CRIT CARE, V165, P1371, DOI 10.1164/rccm.2105106; Dahl R, 2001, AM J RESP CRIT CARE, V164, P778, DOI 10.1164/ajrccm.164.5.2007006; Daughton D, 1998, ARCH FAM MED, V7, P425, DOI 10.1001/archfami.7.5.425; Davies L, 1999, LANCET, V354, P456, DOI 10.1016/S0140-6736(98)11326-0; DAVIS RM, 1989, AM REV RESPIR DIS, V140, pS82, DOI 10.1164/ajrccm/140.3_Pt_2.S82; de Godoy DV, 2003, ARCH PHYS MED REHAB, V84, P1154, DOI 10.1016/S0003-9993(03)00239-9; Di Marco F, 2003, EUR RESPIR J, V21, P86, DOI 10.1183/09031936.03.00020102; Donohue JF, 2002, CHEST, V122, P47, DOI 10.1378/chest.122.1.47; EDWARDS KM, 1994, J INFECT DIS, V169, P68, DOI 10.1093/infdis/169.1.68; Fan VS, 2003, AM J RESP CRIT CARE, V168, P1488, DOI 10.1164/rccm.200301-019OC; Fiore M C, 2000, Respir Care, V45, P1200; Fiore MC, 1997, PUBLICATION US DEP H; Fletcher CM, 1976, NATURAL HIST CHRONIC; FrancoBronson K, 1996, PSYCHIAT CLIN N AM, V19, P329, DOI 10.1016/S0193-953X(05)70291-4; Friedman M, 2002, PHARMACOTHERAPY, V22, P1129, DOI 10.1592/phco.22.13.1129.33523; GILPIN EA, 1993, J GEN INTERN MED, V8, P549, DOI 10.1007/BF02599637; Gosselink R, 1996, AM J RESP CRIT CARE, V153, P976, DOI 10.1164/ajrccm.153.3.8630582; Gosselink R, 2000, J Cardiopulm Rehabil, V20, P353, DOI 10.1097/00008483-200011000-00004; Gourlay SG, 2000, COCHRANE LIB; Griffin MR, 2002, ARCH INTERN MED, V162, P1229, DOI 10.1001/archinte.162.11.1229; Hanania NA, 2003, CHEST, V124, P834, DOI 10.1378/chest.124.3.834; Hansel TT, 2002, DRUGS TODAY, V38, P585, DOI 10.1358/dot.2002.38.9.696535; Heishman S J, 1999, Nicotine Tob Res, V1 Suppl 2, pS143; HENNINGFIELD JE, 1985, J PHARMACOL EXP THER, V234, P1; HENNINGFIELD JE, 1993, J CONSULT CLIN PSYCH, V61, P743, DOI 10.1037/0022-006X.61.5.743; Highland KB, 2003, ANN INTERN MED, V138, P969, DOI 10.7326/0003-4819-138-12-200306170-00008; Hughes J R, 1999, Nicotine Tob Res, V1, P169, DOI 10.1080/14622299050011281; Hurt RD, 1997, NEW ENGL J MED, V337, P1195, DOI 10.1056/NEJM199710233371703; Irvin JE, 1999, J CONSULT CLIN PSYCH, V67, P563, DOI 10.1037/0022-006X.67.4.563; Jarvis B, 2001, DRUG AGING, V18, P441, DOI 10.2165/00002512-200118060-00006; Jo YH, 2002, J NEUROBIOL, V53, P618, DOI 10.1002/neu.10147; Johnell O, 2002, EUR RESPIR J, V19, P1058, DOI 10.1183/09031936.02.00276602; Johnson M, 2001, CHEST, V120, P258, DOI 10.1378/chest.120.1.258; JONES PW, 1995, CHEST, V107, pS187, DOI 10.1378/chest.107.5_Supplement.187S; Jones PW, 2003, EUR RESPIR J, V21, p13S, DOI 10.1183/09031936.03.00077803; Jones PW, 1997, AM J RESP CRIT CARE, V155, P1283, DOI 10.1164/ajrccm.155.4.9105068; Jorenby DE, 1999, NEW ENGL J MED, V340, P685, DOI 10.1056/NEJM199903043400903; Kenny PJ, 2001, PHARMACOL BIOCHEM BE, V70, P531, DOI 10.1016/S0091-3057(01)00651-7; KORNITZER M, 1995, PREV MED, V24, P41, DOI 10.1006/pmed.1995.1006; KRISTUFEK P, 2001, AM J RESP CRIT CARE, V163, P280; Liesker JJW, 2002, RESP MED, V96, P559, DOI 10.1053/rmed.2001.1335; Littner MR, 2000, AM J RESP CRIT CARE, V161, P1136, DOI 10.1164/ajrccm.161.4.9903044; Mahler DA, 1999, CHEST, V115, P957, DOI 10.1378/chest.115.4.957; Mahler DA, 2002, AM J RESP CRIT CARE, V166, P1084, DOI 10.1164/rccm.2112055; Mannino DM, 2000, ARCH INTERN MED, V160, P1683, DOI 10.1001/archinte.160.11.1683; Mannino DM, 2002, CHEST, V121, p121S, DOI 10.1378/chest.121.5_suppl.121S; Meyer PA, 2002, CHEST, V122, P2003, DOI 10.1378/chest.122.6.2003; Mumenthaler MS, 1998, PSYCHOPHARMACOLOGY, V140, P38, DOI 10.1007/s002130050736; MURPHY TF, 1992, AM REV RESPIR DIS, V146, P1067, DOI 10.1164/ajrccm/146.4.1067; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; NISHIMURA K, 1995, CHEST, V107, P718, DOI 10.1378/chest.107.3.718; O'Donnell DE, 1999, AM J RESP CRIT CARE, V160, P542, DOI 10.1164/ajrccm.160.2.9901038; O'Donnell DE, 2001, AM J RESP CRIT CARE, V164, P770, DOI 10.1164/ajrccm.164.5.2012122; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; On LS, 2001, AM J RESP CRIT CARE, V163, P1320, DOI 10.1164/ajrccm.163.6.2002129; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Piasecki TM, 2002, ADDICTION, V97, P1093, DOI 10.1046/j.1360-0443.2002.00216.x; Picciotto MR, 2002, NEUROREPORT, V13, P1097, DOI 10.1097/00001756-200207020-00006; Prescott E, 2002, EUR RESPIR J, V20, P539, DOI 10.1183/09031936.02.00532002; Rennard S, 2002, EUR RESPIR J, V20, P799, DOI 10.1183/09031936.02.03242002; Rennard S.I., 1998, PULMONARY DIS DISORD, P697; Rennard SI, 1996, CHEST, V110, P62, DOI 10.1378/chest.110.1.62; Rennard SI, 2003, EUR RESPIR J, V21, P916, DOI 10.1183/09031936.03.00111602; Rennard SI, 2000, LUNG BIOL HEALTH DIS, V145, P159; Ries AL, 1997, CHEST, V112, P1363, DOI 10.1378/chest.112.5.1363; ROFFEL AF, 1997, ROLE ANTICHOLINERGIC, P92; Rose C, 2002, PATIENT EDUC COUNS, V47, P311, DOI 10.1016/S0738-3991(02)00004-6; Rosenborg J, 2000, BRIT J CLIN PHARMACO, V49, P199; Rossi A, 2002, CHEST, V121, P1058, DOI 10.1378/chest.121.4.1058; Saey D, 2003, AM J RESP CRIT CARE, V168, P425, DOI 10.1164/rccm.200208-856OC; SAINT S, 1995, JAMA-J AM MED ASSOC, V273, P957, DOI 10.1001/jama.273.12.957; Salin-Pascual RJ, 2002, REV INVEST CLIN, V54, P36; SASSIDAMBRON DE, 1995, CHEST, V107, P724, DOI 10.1378/chest.107.3.724; Scanlon PD, 2000, AM J RESP CRIT CARE, V161, P381, DOI 10.1164/ajrccm.161.2.9901044; Schols AMWJ, 2001, EUR RESPIR J, V17, P337, DOI 10.1183/09031936.01.17303370; SCHOLS AMWJ, 1991, THORAX, V46, P695, DOI 10.1136/thx.46.10.695; SCHWARTZ JL, 1987, REV EVALUATION SMOKI; SHERWOOD N, 1995, NEUROPSYCHOBIOLOGY, V32, P161, DOI 10.1159/000119229; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; SILAGY C, 2001, PHYS ADVICE SMOKING; Sin DD, 2001, AM J RESP CRIT CARE, V164, P580, DOI 10.1164/ajrccm.164.4.2009033; Singer HK, 2001, CHEST, V120, P1246, DOI 10.1378/chest.120.4.1246; Smith SS, 2003, NICOTINE TOB RES, V5, P99, DOI 10.1080/1462220021000060437; Soriano JB, 2002, EUR RESPIR J, V20, P819, DOI 10.1183/09031936.02.00301302; Suissa S, 2003, AM J RESP CRIT CARE, V168, P49, DOI 10.1164/rccm.200210-1231OC; Sullivan F, 1999, COMPUT SCI ENG, V1, P2; Szafranski W, 2003, EUR RESPIR J, V21, P74, DOI 10.1183/09031936.03.00031402; Tashkin DP, 2001, LANCET, V357, P1571, DOI 10.1016/S0140-6736(00)04724-3; TAYLOR DR, 1985, AM REV RESPIR DIS, V131, P747; Thompson WH, 1996, AM J RESP CRIT CARE, V154, P407, DOI 10.1164/ajrccm.154.2.8756814; Tonnesen P, 1999, EUR RESPIR J, V13, P238, DOI 10.1034/j.1399-3003.1999.13b04.x; Tonnesen P, 2000, EUR RESPIR J, V16, P717, DOI 10.1034/j.1399-3003.2000.16d25.x; Ullman A, 1996, ALLERGY, V51, P745, DOI 10.1111/j.1398-9995.1996.tb02120.x; van Noord JA, 2000, EUR RESPIR J, V15, P878, DOI 10.1034/j.1399-3003.2000.15e11.x; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; Vincken W, 2002, EUR RESPIR J, V19, P209, DOI 10.1183/09031936.02.00238702; West R, 2000, THORAX, V55, P987, DOI 10.1136/thorax.55.12.987; Wise RA, 2003, CHEST, V124, P449, DOI 10.1378/chest.124.2.449; Wouters EFM, 2002, THORAX, V57, P1067, DOI 10.1136/thorax.57.12.1067; XIAO RP, 2001, SCI STKE 2001, P15; Yates SL, 1995, BIOCHEM PHARMACOL, V50, P2001, DOI 10.1016/0006-2952(95)02100-0; Yohannes AM, 2003, INT J GERIATR PSYCH, V18, P412, DOI 10.1002/gps.851; Yohannes AM, 2000, INT J GERIATR PSYCH, V15, P1090, DOI 10.1002/1099-1166(200012)15:12<1090::AID-GPS249>3.0.CO;2-L; Zarkovic JP, 2000, PEDIATR PULM, V29, P424; ZuWallack RL, 2001, CHEST, V119, P1661, DOI 10.1378/chest.119.6.1661; 2003, GLOBAL STRATEGY DIAG	135	66	69	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	2004	364	9436					791	802		10.1016/S0140-6736(04)16941-9	http://dx.doi.org/10.1016/S0140-6736(04)16941-9			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337408				2022-12-28	WOS:000223569600033
J	Tannen, T				Tannen, T			Sharon Mitchell, head of the Adult Industry Medical Clinic	LANCET			English	Editorial Material												asalea@sbcglobal.net							0	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	2004	364	9436					751	751		10.1016/S0140-6736(04)16921-3	http://dx.doi.org/10.1016/S0140-6736(04)16921-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15338566	Bronze			2022-12-28	WOS:000223569600013
J	Gutscher, MA				Gutscher, MA			What caused the Great Lisbon earthquake?	SCIENCE			English	Editorial Material							REGION; SUBDUCTION		IUEM, CNRS, UMR 6538, F-29280 Plouzane, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Universite de Bretagne Occidentale; Institut Universitaire Europeen de la Mer (IUEM)	Gutscher, MA (corresponding author), IUEM, CNRS, UMR 6538, Domaines Ocean, F-29280 Plouzane, France.	gutscher@univ-brest.fr	Gutscher, Marc-Andre/A-2137-2009	Gutscher, Marc-Andre/0000-0003-0123-4063				Baptista MA, 1998, J GEODYN, V25, P159, DOI 10.1016/S0264-3707(97)00020-3; Duggen S, 2004, EARTH PLANET SC LETT, V218, P91, DOI 10.1016/S0012-821X(03)00632-0; Faccenna C, 2004, TECTONICS, V23, DOI 10.1029/2002TC001488; GREVEMEYER I, 2004, GEOPH RES ABSTR, V6; Gutscher MA, 2002, GEOLOGY, V30, P1071, DOI 10.1130/0091-7613(2002)030<1071:EFASBG>2.0.CO;2; GUTSCHER MA, 2004, GEOPH RES ABSTR, V6; Jimenez-Munt I, 2001, EARTH PLANET SC LETT, V192, P175, DOI 10.1016/S0012-821X(01)00442-3; Lebreiro SM, 1997, J SEDIMENT RES, V67, P856; Lonergan L, 1997, TECTONICS, V16, P504, DOI 10.1029/96TC03937; MARTINEZSOLARES JM, 1979, TECTONOPHYSICS, V53, P301, DOI 10.1016/0040-1951(79)90075-1; Pinheiro LM, 2003, MAR GEOL, V195, P131, DOI 10.1016/S0025-3227(02)00685-0; PLATT JP, 1989, GEOLOGY, V17, P540, DOI 10.1130/0091-7613(1989)017<0540:ECOTCL>2.3.CO;2; Stich D, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002057	13	79	79	0	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2004	305	5688					1247	1248		10.1126/science.1101351	http://dx.doi.org/10.1126/science.1101351			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850PJ	15333828				2022-12-28	WOS:000223624600028
J	Tamura, K; Schimmel, P				Tamura, K; Schimmel, P			Chiral-selective aminoacylation of an RNA minihelix	SCIENCE			English	Article									Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	schimmel@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015539, R37GM015539] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bolli M, 1997, CHEM BIOL, V4, P309, DOI 10.1016/S1074-5521(97)90074-0; JOYCE GF, 1984, NATURE, V310, P602, DOI 10.1038/310602a0; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; Pizzarello S, 2004, SCIENCE, V303, P1151, DOI 10.1126/science.1093057; PROFY AT, 1984, J MOL EVOL, V20, P147, DOI 10.1007/BF02257375; Rodin S, 1996, P NATL ACAD SCI USA, V93, P4537, DOI 10.1073/pnas.93.10.4537	6	70	73	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2004	305	5688					1253	1253		10.1126/science.1099141	http://dx.doi.org/10.1126/science.1099141			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850PJ	15333830				2022-12-28	WOS:000223624600030
J	Sivakumar, B; Harry, LE; Paleolog, EM				Sivakumar, B; Harry, LE; Paleolog, EM			Modulating angiogenesis - More vs less	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ENDOTHELIAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; THERAPEUTIC ANGIOGENESIS; ISCHEMIC MYOCARDIUM; TUMOR ANGIOGENESIS; TENDON RUPTURES; GENE-TRANSFER; FACTOR-BETA; VEGF; INHIBITOR	The concept of manipulation of the vascular bed to either increase or decrease the number of blood vessels has attracted considerable interest. This review focuses on angiogenesis as a therapeutic target, particularly in the context of cancer and arthritis, as well as on promoting angiogenesis in cardiovascular disease and the healing of bone fractures. Although once touted almost as a panacea for treatment of tumors, as well as other diseases associated with angiogenesis, such as diabetic retinopathy or rheumatoid arthritis, it is now clear that such enthusiasm was somewhat premature. Similarly, some clinical trials of therapeutic angiogenesis for the management of cardiovascular disease have been disappointing. Nevertheless, this exciting field of research holds promise for more targeted therapies.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Kennedy Inst Rheumatol, London W6 8LH, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Surg Anaesthet & Intens Care, London W6 8LH, England; W Hertfordshire NHS Trust, Mt Vernon Hosp, Northwood, Middx, England	Imperial College London; University of Oxford; Imperial College London	Paleolog, EM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Kennedy Inst Rheumatol, Arthrit Res Campaign Bldg,1 Aspenlea Rd, London W6 8LH, England.	e.paleolog@imperial.ac.uk						Afuwape AO, 2002, HISTOL HISTOPATHOL, V17, P961, DOI 10.14670/HH-17.961; Afuwape AO, 2003, GENE THER, V10, P1950, DOI 10.1038/sj.gt.3302104; AJAGOPALAN S, 2003, CIRCULATION, V108, P1933; Ballara S, 2001, ARTHRITIS RHEUM, V44, P2055, DOI 10.1002/1529-0131(200109)44:9<2055::AID-ART355>3.0.CO;2-2; Berse B, 1999, CLIN EXP IMMUNOL, V115, P176; Brenchley PEC, 2000, CLIN EXP IMMUNOL, V121, P426, DOI 10.1046/j.1365-2249.2000.01299.x; BROWN FE, 1988, J HAND SURG-AM, V13A, P704, DOI 10.1016/S0363-5023(88)80129-1; CARRINGTON JL, 1988, J CELL BIOL, V107, P1969, DOI 10.1083/jcb.107.5.1969; Celletti FL, 2002, J VASC INTERV RADIOL, V13, P703, DOI 10.1016/S1051-0443(07)61847-8; Eckardt H, 2003, J ORTHOP RES, V21, P335, DOI 10.1016/S0736-0266(02)00159-6; Emery P, 2002, BRIT MED J, V324, P312, DOI 10.1136/bmj.324.7333.312; ERTEL AN, 1989, HAND CLIN, V5, P177; Eskens FALM, 2004, BRIT J CANCER, V90, P1, DOI 10.1038/sj.bjc.6601401; Etherington P J, 2002, Clin Exp Rheumatol, V20, P799; Fam NP, 2003, CIRCULATION, V108, P2613, DOI 10.1161/01.CIR.0000102939.04279.75; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; *GEN INC, FDA APPR AV TARG THE; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Glowacki J, 1998, CLIN ORTHOP RELAT R, pS82, DOI 10.1097/00003086-199810001-00010; Harry Lorraine E., 2003, Birth Defects Research, V69, P363, DOI 10.1002/bdrc.10024; Hausman MR, 2001, BONE, V29, P560, DOI 10.1016/S8756-3282(01)00608-1; Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A; Hiltunen MO, 2003, FASEB J, V17, P1147, DOI 10.1096/fj.02-0514fje; Hirohata S, 1999, LANCET, V353, P1331, DOI 10.1016/S0140-6736(98)05912-1; Huang JZ, 2003, P NATL ACAD SCI USA, V100, P7785, DOI 10.1073/pnas.1432908100; Jain A, 2001, ARTHRITIS RHEUM, V44, P1754, DOI 10.1002/1529-0131(200108)44:8<1754::AID-ART310>3.0.CO;2-8; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Kamihata H, 2001, CIRCULATION, V104, P1046, DOI 10.1161/hc3501.093817; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Lei Y, 2004, BASIC RES CARDIOL, V99, P121, DOI 10.1007/s00395-004-0447-x; Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1; Lu J, 2000, J IMMUNOL, V164, P5922, DOI 10.4049/jimmunol.164.11.5922; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Moulton K S, 2001, Curr Atheroscler Rep, V3, P225, DOI 10.1007/s11883-001-0065-0; Paleolog EM, 1998, ARTHRITIS RHEUM, V41, P1258, DOI 10.1002/1529-0131(199807)41:7<1258::AID-ART17>3.0.CO;2-1; Peters CL, 2004, ARTHRITIS RHEUM-US, V50, P291, DOI 10.1002/art.11473; Posey JA, 2003, CLIN CANCER RES, V9, P1323; Pufe T, 2002, CELL TISSUE RES, V309, P387, DOI 10.1007/s00441-002-0605-0; ROONEY M, 1988, ARTHRITIS RHEUM, V31, P956, DOI 10.1002/art.1780310803; SIMMONS DJ, 1985, CLIN ORTHOP RELAT R, V200, P100; Sone H, 2001, BIOCHEM BIOPH RES CO, V281, P562, DOI 10.1006/bbrc.2001.4395; Street J, 2000, CLIN ORTHOP RELAT R, P224, DOI 10.1097/00003086-200009000-00033; Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099; Street JT, 2001, J ORTHOP RES, V19, P1057, DOI 10.1016/S0736-0266(01)00048-1; Thomas AL, 2003, SEMIN ONCOL, V30, P32, DOI 10.1016/S0093-7754(03)00123-4; Tse HF, 2003, LANCET, V361, P47, DOI 10.1016/S0140-6736(03)12111-3; Vale PR, 2000, CIRCULATION, V102, P965, DOI 10.1161/01.CIR.102.9.965; Walsh DA, 1998, AM J PATHOL, V152, P691; WHITESIDE LA, 1978, CLIN ORTHOP RELAT R, V131, P266; WILLIAMSON SC, 1995, HAND CLIN, V11, P449; Zelzer E, 2002, DEVELOPMENT, V129, P1893	52	76	83	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2004	292	8					972	977		10.1001/jama.292.8.972	http://dx.doi.org/10.1001/jama.292.8.972			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WR	15328330				2022-12-28	WOS:000223429200023
J	Temel, J; Aquino, SL; Lynch, TJ; Wright, CD; Mark, EJ; Choi, NC				Temel, J; Aquino, SL; Lynch, TJ; Wright, CD; Mark, EJ; Choi, NC			Case 26-2004: A 56-year-old woman with cough and a lung nodule - Large-cell undifferentiated carcinoma of the lung, stage IIIA (T1N2M0)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							POSITRON-EMISSION-TOMOGRAPHY; INTENSITY-MODULATED RADIOTHERAPY; SOLITARY PULMONARY NODULES; RANDOMIZED-TRIAL; FLUORINE-18-FLUORODEOXYGLUCOSE UPTAKE; ADJUVANT CHEMOTHERAPY; COMPUTED-TOMOGRAPHY; FDG PET; CANCER; SURGERY		Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Thorac Surg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Surg, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Harvard University; Harvard University	Temel, J (corresponding author), Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA.							ALBAIN KS, 1995, J CLIN ONCOL, V13, P1880, DOI 10.1200/JCO.1995.13.8.1880; ALBAIN KS, 2003, P AN M AM SOC CLIN, V22, P621; ALBERTI W, 1995, BRIT MED J, V311, P899; Andre F, 2000, J CLIN ONCOL, V18, P2981, DOI 10.1200/JCO.2000.18.16.2981; Bakheet SMB, 1998, J NUCL MED, V39, P234; Choi NC, 1997, J CLIN ONCOL, V15, P712, DOI 10.1200/JCO.1997.15.2.712; Demarchi LMMF, 2000, MODERN PATHOL, V13, P511, DOI 10.1038/modpathol.3880089; Depierre A, 2002, J CLIN ONCOL, V20, P247, DOI 10.1200/JCO.20.1.247; DEWAN NA, 1993, CHEST, V104, P997, DOI 10.1378/chest.104.4.997; Elias AD, 1997, LUNG CANCER-J IASLC, V17, P147, DOI 10.1016/S0169-5002(97)00658-2; Erasmus JJ, 1998, AM J ROENTGENOL, V170, P1369, DOI 10.2214/ajr.170.5.9574618; Fleck J, 1993, P AN M AM SOC CLIN, V12, P333; Gephardt GN, 1996, ARCH PATHOL LAB MED, V120, P922; Goo JM, 2000, RADIOLOGY, V216, P117, DOI 10.1148/radiology.216.1.r00jl19117; Gotway MB, 2000, J THORAC IMAG, V15, P201, DOI 10.1097/00005382-200007000-00010; Gupta NC, 1996, J NUCL MED, V37, P943; Gupta NC, 2001, CHEST, V120, P521, DOI 10.1378/chest.120.2.521; Higashi K, 1998, J NUCL MED, V39, P1016; Kapucu LO, 1998, J NUCL MED, V39, P1267; Keller SM, 2000, NEW ENGL J MED, V343, P1217, DOI 10.1056/NEJM200010263431703; Kerr KM, 1998, HISTOPATHOLOGY, V33, P55; Lardinois D, 2003, NEW ENGL J MED, V348, P2500, DOI 10.1056/NEJMoa022136; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; Liu HH, 2004, INT J RADIAT ONCOL, V58, P1268, DOI 10.1016/j.ijrobp.2003.09.085; Lowe VJ, 1998, J CLIN ONCOL, V16, P1075, DOI 10.1200/JCO.1998.16.3.1075; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; MARTINI N, 1987, SURG CLIN N AM, V67, P1037; MARTINI N, 1983, ANN SURG, V198, P386, DOI 10.1097/00000658-198309000-00015; Mountain CF, 1997, CHEST, V111, P1718, DOI 10.1378/chest.111.6.1718; Murshed H, 2004, INT J RADIAT ONCOL, V58, P1258, DOI 10.1016/j.ijrobp.2003.09.086; Pieterman RM, 2000, NEW ENGL J MED, V343, P254, DOI 10.1056/NEJM200007273430404; ROSELL R, 1994, NEW ENGL J MED, V330, P153, DOI 10.1056/NEJM199401203300301; ROTH JA, 1994, J NATL CANCER I, V86, P673, DOI 10.1093/jnci/86.9.673; Scagliotti GV, 2003, JNCI-J NATL CANCER I, V95, P1453, DOI 10.1093/jnci/djg059; Scott WJ, 1996, J THORAC CARDIOV SUR, V111, P642, DOI 10.1016/S0022-5223(96)70317-3; Spira A, 2004, NEW ENGL J MED, V350, P379, DOI 10.1056/NEJMra035536; SUGARBAKER DJ, 1995, J THORAC CARDIOV SUR, V109, P473, DOI 10.1016/S0022-5223(95)70278-4; Suzuki K, 1999, J THORAC CARDIOV SUR, V118, P145, DOI 10.1016/S0022-5223(99)70153-4; Tan DF, 2003, HUM PATHOL, V34, P597, DOI 10.1016/S0046-8177(03)00180-1; Valk PE, 1995, ANN THORAC SURG, V60, P1573, DOI 10.1016/0003-4975(95)00752-0; 1995, AM J CLIN PATHOL, V104, P374	41	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2004	351	8					809	817		10.1056/NEJMcpc049012	http://dx.doi.org/10.1056/NEJMcpc049012			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847CY	15317895				2022-12-28	WOS:000223367900015
J	Mant, D; Del Mar, C; Glasziou, P; Knottnerus, A; Wallace, P; van Weel, C				Mant, D; Del Mar, C; Glasziou, P; Knottnerus, A; Wallace, P; van Weel, C			The state of primary-care research	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; ACUTE OTITIS-MEDIA; LOW-BACK-PAIN; GENERAL-PRACTICE; INTERVENTION; METAANALYSIS; ANTIBIOTICS; CHILDREN; EFFICACY; HEALTH		Univ Oxford, Dept Primary Hlth Care, Oxford OX2 7EY, England; Univ Maastricht, Netherlands Sch Primary Care Res, Maastricht, Netherlands; UCL Royal Free & UCL Med Sch, Dept Primary Care & Populat Sci, London, England; Univ Med Ctr Nijmegen, Dept Gen Practice, Nijmegen, Netherlands; Bond Univ, Fac Med & Hlth Sci, Gold Coast, Qld, Australia	University of Oxford; Maastricht University; University of London; University College London; Radboud University Nijmegen; Bond University	Mant, D (corresponding author), Univ Oxford, Dept Primary Hlth Care, Old Rd Campus, Oxford OX2 7EY, England.	david.mant@dphpc.ox.ac.uk	Glasziou, Paul/A-7832-2008; Knottnerus, Andre/F-4866-2013; Del Mar, Chris B/B-1136-2008; Mant, David CA/C-7763-2009; van Weel, Chris/D-4375-2009; Knottnerus, Johannes A/A-3829-2009	Glasziou, Paul/0000-0001-7564-073X; Del Mar, Chris B/0000-0003-3821-8163; van Weel, Chris/0000-0003-3653-4701; 				Allen C, 1999, LANCET, V354, P1229, DOI 10.1016/S0140-6736(98)10063-6; [Anonymous], 2003, LANCET, V361, P977; Askew DA, 2001, MED J AUSTRALIA, V175, P77, DOI 10.5694/j.1326-5377.2001.tb143534.x; Bradley F, 1999, BMJ-BRIT MED J, V318, P711; Capewell S, 2000, CIRCULATION, V102, P1511, DOI 10.1161/01.CIR.102.13.1511; Del Mar CB, 2003, MED J AUSTRALIA, V179, P26, DOI 10.5694/j.1326-5377.2003.tb05412.x; DelMar C, 1997, BRIT MED J, V314, P1526, DOI 10.1136/bmj.314.7093.1526; *DEP HLTH, 1997, R D PRIM CAR NAT WOR; Glasziou P, 2004, BRIT MED J, V328, P121, DOI 10.1136/bmj.328.7432.121; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GREEN LA, 1994, J FAM PRACTICE, V38, P400; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Grunfeld E, 1996, BMJ-BRIT MED J, V313, P665; Hopstaken RM, 2003, BRIT J GEN PRACT, V53, P358; Kendrick D, 2001, BRIT MED J, V322, P400, DOI 10.1136/bmj.322.7283.400; Kinmonth AL, 1998, BMJ-BRIT MED J, V317, P1202, DOI 10.1136/bmj.317.7167.1202; Morgan S, 1999, BRIT MED J, V318, P368, DOI 10.1136/bmj.318.7180.368; *NETH ORG HLTH RES, ENGL INTR; ROLAND M, 1983, SPINE, V8, P145, DOI 10.1097/00007632-198303000-00005; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; TASCHE M, 2001, HUISARTS WET, V44, P91; Thompson C, 2000, LANCET, V355, P185, DOI 10.1016/S0140-6736(99)03171-2; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; *UK DEP HLTH, 1999, NHS R D STRAT REV PR; *UK HIGH ED FUND C, 2001, 20014 RAE UK HIGH ED; van Weel C., 2004, ANN FAM MED, V2, pS5, DOI DOI 10.1370/AFM.194; VANBUCHEM FL, 1981, LANCET, V2, P883; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; WOOD DA, 1994, BRIT MED J, V308, P313, DOI 10.1136/bmj.308.6924.313	30	61	63	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 11	2004	364	9438					1004	1006		10.1016/S0140-6736(04)17027-X	http://dx.doi.org/10.1016/S0140-6736(04)17027-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364194	Green Submitted			2022-12-28	WOS:000223831000033
J	Koh, LP; Dunn, RR; Sodhi, NS; Colwell, RK; Proctor, HC; Smith, VS				Koh, LP; Dunn, RR; Sodhi, NS; Colwell, RK; Proctor, HC; Smith, VS			Species coextinctions and the biodiversity crisis	SCIENCE			English	Article							EVOLUTIONARY HISTORY; EXTINCTION; PHILOPTERIDAE; CONSERVATION; PHTHIRAPTERA; BUTTERFLIES; SINGAPORE; TAXONOMY	To assess the coextinction of species (the loss of a species upon the loss of another), we present a probabilistic model, scaled with empirical data. The model examines the relationship between coextinction levels (proportion of species extinct) of affiliates and their hosts across a wide range of coevolved interspecific systems: pollinating Ficus wasps and Ficus, parasites and their hosts, butterflies and their larval host plants, and ant butterflies and their host ants. Applying a nomographic method based on mean host specificity (number of host species per affiliate species), we estimate that 6300 affiliate species are "coendangered" with host species currently listed as endangered. Current extinction estimates need to be recalibrated by taking species coextinctions into account.	Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Curtin Univ Technol, Dept Environm Biol, Perth, WA 6845, Australia; Univ Connecticut, Dept Ecol & Evolutionary Biol, Storrs, CT 06269 USA; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	National University of Singapore; Curtin University; University of Connecticut; University of Alberta; University of Glasgow	Sodhi, NS (corresponding author), Natl Univ Singapore, Dept Biol Sci, 14 Sci Dr 4, Singapore 117543, Singapore.	dbsns@nus.edu.sg	Smith, Vincent/AAK-7335-2020; Colwell, Robert K/C-7276-2015; Koh, Lian Pin/A-5794-2010; Dunn, Robert/B-1360-2013; Proctor, Heather C./A-2677-2014	Smith, Vincent/0000-0001-5297-7452; Koh, Lian Pin/0000-0001-8152-3871; Proctor, Heather C./0000-0002-4920-9556; Dunn, Robert/0000-0002-6030-4837				Amaral LAN, 1999, PHYS REV LETT, V82, P652, DOI 10.1103/PhysRevLett.82.652; Boswell GP, 1998, P ROY SOC B-BIOL SCI, V265, P1921, DOI 10.1098/rspb.1998.0521; Brook BW, 2003, NATURE, V424, P420, DOI 10.1038/nature01795; Castelletta M, 2000, CONSERV BIOL, V14, P1870, DOI 10.1111/j.1523-1739.2000.99285.x; Clayton DH, 1999, ANN ENTOMOL SOC AM, V92, P675, DOI 10.1093/aesa/92.5.675; COLWELL RK, IN PRESS ECOLOGY; Colwell RK, ESTIMATES STAT ESTIM; Colwell Robert K., 1994, P23; Donovan TM, 1997, ECOLOGY, V78, P2064, DOI 10.1890/0012-9658(1997)078[2064:VILSEE]2.0.CO;2; Gilbert L. E., 1980, Conservation biology. An evolutionary-ecological perspective., P11; Gotwald WH, 1995, CORNELL SERIES ARTHR; HILTONTAYLOR C, 2000, 2000 INT UNION CONSE; Koh LP, 2004, BIOTROPICA, V36, P272, DOI 10.1111/j.1744-7429.2004.tb00319.x; Nee S, 1997, SCIENCE, V278, P692, DOI 10.1126/science.278.5338.692; Pimm SL, 2000, NATURE, V403, P843, DOI 10.1038/35002708; Price RD, 2000, J PARASITOL, V86, P948, DOI 10.2307/3284803; Purvis A, 2000, SCIENCE, V288, P328, DOI 10.1126/science.288.5464.328; STORK NE, 1993, NATURE, V366, P307, DOI 10.1038/366307a0; Thomas JA, 2004, SCIENCE, V303, P1879, DOI 10.1126/science.1095046; WINDSOR DA, 1995, CONSERV BIOL, V9, P1, DOI 10.1046/j.1523-1739.1995.09010001.x	20	375	390	9	247	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2004	305	5690					1632	1634		10.1126/science.1101101	http://dx.doi.org/10.1126/science.1101101			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361627				2022-12-28	WOS:000223891200047
J	Skaar, EP; Humayun, M; Bae, T; DeBord, KL; Schneewind, O				Skaar, EP; Humayun, M; Bae, T; DeBord, KL; Schneewind, O			Iron-source preference of Staphylococcus aureus infections	SCIENCE			English	Article							MODEL HOST; TRANSPORT; PROTEIN; IDENTIFICATION; SIDEROPHORE; VIRULENCE; MEMBRANE; GENES; HEMIN	Although bacteria use different iron compounds in vitro, the possibility that microbes distinguish between these iron sources during infection has hitherto not been examined. We applied stable isotope labeling to detect source-specific iron by mass spectrometry and show that Staphylococcus aureus preferentially imports heme iron over transferrin iron. By combining this approach with computational genome analysis, we identified hts (heme transport system), a gene cluster that promotes preferred heme iron import by S. aureus. Heme iron scavenging by means of hts is required for staphylococcal pathogenesis in animal hosts, indicating that heme iron is the preferred iron source during the initiation of infection.	Univ Chicago, Comm Microbiol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Schneewind, O (corresponding author), Univ Chicago, Comm Microbiol, 920 E 58th St, Chicago, IL 60637 USA.	oschnee@bsd.uchicago.edu	Humayun, Munir/A-1247-2007	Humayun, Munir/0000-0001-8516-9435; Bae, Taeok/0000-0002-0576-2851	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052474] Funding Source: NIH RePORTER; NIAID NIH HHS [AI52474] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBUS A, 1991, INFECT IMMUN, V59, P1008, DOI 10.1128/IAI.59.3.1008-1014.1991; ANBAR AD, 2004, FRONTIERS BOULDER, V217, P223; Beard BL, 1999, SCIENCE, V285, P1889, DOI 10.1126/science.285.5435.1889; BERNHEIMER AW, 1968, J BACTERIOL, V96, P487, DOI 10.1128/JB.96.2.487-491.1968; Braun V, 2002, CURR OPIN MICROBIOL, V5, P194, DOI 10.1016/S1369-5274(02)00298-9; Braun V, 2001, INT J MED MICROBIOL, V291, P67, DOI 10.1078/1438-4221-00103; Bullen J. J., 1999, IRON INFECT MOL PHYS; CRICHTON R, 2001, INORGANIC BIOCH IRON, V2; Dale SE, 2004, INFECT IMMUN, V72, P29, DOI 10.1128/IAI.72.1.29-37.2004; Drazek ES, 2000, MOL MICROBIOL, V36, P68, DOI 10.1046/j.1365-2958.2000.01818.x; Escolar L, 1999, J BACTERIOL, V181, P6223, DOI 10.1128/JB.181.20.6223-6229.1999; Garsin DA, 2001, P NATL ACAD SCI USA, V98, P10892, DOI 10.1073/pnas.191378698; Heinrichs JH, 1999, J BACTERIOL, V181, P1436, DOI 10.1128/JB.181.5.1436-1443.1999; Kloek AP, 1996, J MOL EVOL, V43, P101, DOI 10.1007/BF02337354; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; McKenney D, 1999, SCIENCE, V284, P1523, DOI 10.1126/science.284.5419.1523; Morrissey JA, 2000, INFECT IMMUN, V68, P6281, DOI 10.1128/IAI.68.11.6281-6288.2000; Posey JE, 2000, SCIENCE, V288, P1651, DOI 10.1126/science.288.5471.1651; Sebulsky MT, 2000, J BACTERIOL, V182, P4394, DOI 10.1128/JB.182.16.4394-4400.2000; Sifri CD, 2003, INFECT IMMUN, V71, P2208, DOI 10.1128/IAI.71.4.2208-2217.2003; Skaar EP, 2004, J BIOL CHEM, V279, P436, DOI 10.1074/jbc.M307952200; SMITH A, 1979, BIOCHEM J, V182, P47, DOI 10.1042/bj1820047; STOJILJKOVIC I, 1994, MOL MICROBIOL, V13, P719, DOI 10.1111/j.1365-2958.1994.tb00465.x; VONWACHENFELDT C, 1990, J BIOL CHEM, V265, P13939; Walczyk T, 2002, SCIENCE, V295, P2065, DOI 10.1126/science.1069389	26	321	336	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2004	305	5690					1626	1628		10.1126/science.1099930	http://dx.doi.org/10.1126/science.1099930			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361626				2022-12-28	WOS:000223891200045
J	Bowers, S				Bowers, S			COPD is not a death sentence	LANCET			English	Article												sgbowers@fast.net							0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	2004	364	9437					896	896		10.1016/S0140-6736(04)16985-7	http://dx.doi.org/10.1016/S0140-6736(04)16985-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351197				2022-12-28	WOS:000223685200036
J	Blanpain, C; Lowry, WE; Geoghegan, A; Polak, L; Fuchs, E				Blanpain, C; Lowry, WE; Geoghegan, A; Polak, L; Fuchs, E			Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche	CELL			English	Article							LABEL-RETAINING CELLS; HAIR FOLLICLE; MOUSE EPIDERMIS; IN-VIVO; GROWTH; SKIN; KERATINOCYTE; MULTIPLICATION; MORPHOGENESIS; INDUCTION	In adult skin, each hair follicle contains a reservoir of stem cells (the bulge), which can be mobilized to regenerate the new follicle with each hair cycle and to reepithelialize epidermis during wound repair. Here we report new methods that permit their clonal analyses and engraftment and demonstrate the two defining features of stem cells, namely self-renewal and multipotency. We also show that, within the bulge, there are two distinct populations, one of which maintains basal lamina contact and temporally precedes the other, which is suprabasal and arises only after the start of the first postnatal hair cycle. This spatial distinction endows them with discrete transcriptional programs, but surprisingly, both populations are growth inhibited in the niche but can self-renew in vitro and make epidermis and hair when grafted. These findings suggest that the niche microenvironment imposes intrinsic "stemness" features without restricting the establishment of epithelial polarity and changes in gene expression.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Fuchs, E (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.	fuchslb@rockefeller.edu	Blanpain, Cedric/ABD-8392-2021; Fuchs, Elaine/G-1565-2016		NIAMS NIH HHS [R01 AR050452-04, AR 31737, AR 050452] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR031737, R01AR050452] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Bennett WR, 2003, DEVELOPMENT, V130, P1079, DOI 10.1242/dev.00333; Braun KM, 2003, DEVELOPMENT, V130, P5241, DOI 10.1242/dev.00703; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; Li A, 2004, J CLIN INVEST, V113, P390, DOI 10.1172/JCI.200419140; LICHTI U, 1993, J INVEST DERMATOL, V101, pS124, DOI 10.1111/1523-1747.ep12363165; Lin HF, 2002, NAT REV GENET, V3, P931, DOI 10.1038/nrg952; Martin KH, 2002, SCIENCE, V296, P1652, DOI 10.1126/science.296.5573.1652; Morris RJ, 1999, J INVEST DERMATOL, V112, P470, DOI 10.1046/j.1523-1747.1999.00537.x; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; Panteleyev AA, 2001, J CELL SCI, V114, P3419; Poblet E, 2003, J INVEST DERMATOL, V121, P1220, DOI 10.1046/j.1523-1747.2003.12550_2.x; POTTEN CS, 1988, J CELL SCI, P45; POTTEN CS, 1974, CELL TISSUE KINET, V7, P77, DOI 10.1111/j.1365-2184.1974.tb00401.x; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Tani H, 2000, P NATL ACAD SCI USA, V97, P10960, DOI 10.1073/pnas.97.20.10960; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Triel C, 2004, EXP CELL RES, V295, P79, DOI 10.1016/j.yexcr.2003.11.032; TURNBAR T, 2004, SCIENCE, V303, P359; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Wagers AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092-8674(04)00208-9; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; WEINBERG WC, 1993, J INVEST DERMATOL, V100, P229, DOI 10.1111/1523-1747.ep12468971; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	37	1031	1098	1	91	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2004	118	5					635	648		10.1016/j.cell.2004.08.012	http://dx.doi.org/10.1016/j.cell.2004.08.012			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	852BN	15339667	Bronze			2022-12-28	WOS:000223730300013
J	Delprato, A; Merithew, E; Lambright, DG				Delprato, A; Merithew, E; Lambright, DG			Structure, exchange determinants, and family-wide rab specificity of the tandem helical bundle and Vps9 domains of Rabex-5	CELL			English	Article							SMALL GTPASE RAB5; NUCLEOTIDE-EXCHANGE; CRYSTAL-STRUCTURE; SPASTIC PARALYSIS; BINDING PROTEIN; PH DOMAIN; EFFECTOR; EEA1; ACTIVATION; RABAPTIN-5	The Rab5 GTPase, an essential regulator of endocytosis and endosome biogenesis, is activated by guanine-nucleotide exchange factors (GEFs) that contain a Vps9 domain. Here, we show that the catalytic core of the Rab GEF Rabex-5 has a tandem architecture consisting of a Vps9 domain stabilized by an indispensable helical bundle. A family-wide analysis of Rab specificity demonstrates high selectivity for Rab5 subfamily GTPases. Conserved exchange determinants map to a common surface of the Vps9 domain, which recognizes invariant aromatic residues in the switch regions of Rab GTPases and selects for for the Rab5 subfamily by requiring a small nonacidic residue preceding a critical phenylalanine in the switch I region. These and other observations reveal unexpected similarity with the Arf exchange site in the Sec7 domain.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Lambright, DG (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.	david.lambright@umassmed.edu			NIDDK NIH HHS [DK60564] Funding Source: Medline; NIGMS NIH HHS [GM56324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK060564] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056324] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Afar DEH, 1997, IMMUNITY, V6, P773, DOI 10.1016/S1074-7613(00)80452-5; Alexandrov K, 2001, METHOD ENZYMOL, V329, P14; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burd CG, 1996, MOL CELL BIOL, V16, P2369; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Devon RS, 2003, CLIN GENET, V64, P210, DOI 10.1034/j.1399-0004.2003.00138.x; Dhaka A, 2003, J NEUROSCI, V23, P748; Esters H, 2001, J MOL BIOL, V310, P141, DOI 10.1006/jmbi.2001.4735; Eymard-Pierre E, 2002, AM J HUM GENET, V71, P518, DOI 10.1086/342359; Gournier H, 1998, EMBO J, V17, P1930, DOI 10.1093/emboj/17.7.1930; Gros-Louis F, 2003, ANN NEUROL, V53, P144, DOI 10.1002/ana.10422; Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166; Hama H, 1999, J BIOL CHEM, V274, P15284, DOI 10.1074/jbc.274.21.15284; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kajiho H, 2003, J CELL SCI, V116, P4159, DOI 10.1242/jcs.00718; Kauppi M, 2002, J CELL SCI, V115, P899; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Lippe R, 2001, MOL BIOL CELL, V12, P2219, DOI 10.1091/mbc.12.7.2219; Macia E, 2001, J BIOL CHEM, V276, P24925, DOI 10.1074/jbc.M103284200; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Merithew E, 2003, J BIOL CHEM, V278, P8494, DOI 10.1074/jbc.M211514200; Mesa R, 2001, J CELL SCI, V114, P4041; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; Mossessova E, 2003, MOL CELL, V12, P1403, DOI 10.1016/S1097-2765(03)00475-1; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Nuoffer C, 1997, MOL BIOL CELL, V8, P1305, DOI 10.1091/mbc.8.7.1305; Opdam FJM, 2000, EUR J CELL BIOL, V79, P308, DOI 10.1078/S0171-9335(04)70034-5; Otomo A, 2003, HUM MOL GENET, V12, P1671, DOI 10.1093/hmg/ddg184; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; Pereira-Leal JB, 2000, J MOL BIOL, V301, P1077, DOI 10.1006/jmbi.2000.4010; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Renault L, 2003, NATURE, V426, P525, DOI 10.1038/nature02197; Rodriguez-Gabin AG, 2001, J NEUROSCI RES, V66, P1149, DOI 10.1002/jnr.1253.abs; Rossman KL, 2003, J BIOL CHEM, V278, P18393, DOI 10.1074/jbc.M300127200; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Rossman KL, 2002, J BIOL CHEM, V277, P50893, DOI 10.1074/jbc.M208580200; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Simon I, 1996, J BIOL CHEM, V271, P20470, DOI 10.1074/jbc.271.34.20470; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Yamanaka K, 2003, P NATL ACAD SCI USA, V100, P16041, DOI 10.1073/pnas.2635267100; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhu ZY, 2001, BIOCHEMISTRY-US, V40, P3027, DOI 10.1021/bi002680o	63	129	133	1	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2004	118	5					607	617		10.1016/j.cell.2004.08.009	http://dx.doi.org/10.1016/j.cell.2004.08.009			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	852BN	15339665	Bronze			2022-12-28	WOS:000223730300011
J	Mostoslavsky, R; Alt, FW; Rajewsky, K				Mostoslavsky, R; Alt, FW; Rajewsky, K			The lingering enigma of the allelic exclusion mechanism	CELL			English	Review							B-CELL DEVELOPMENT; LIGHT CHAIN GENES; KAPPA-L-CHAIN; V(D)J RECOMBINATION; EXPRESSION; REARRANGEMENTS; LOCUS; GENERATION; SELECTION; RECEPTORS	B lymphocytes produce diverse antibody specificities by "randomly" assembling antibody genes from germline segments. Yet, though each B lymphocyte has multiple allelic loci for the different antibody chains, each clonally derived mature B lymphocyte expresses a single species of antibody with a unique specificity via a process termed allelic exclusion. Despite some progress, the precise mechanism of allelic exclusion remains an enigma.	Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Alt, FW (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.	alt@enders.tch.harvard.edu; rajewsky@cbr.med.harvard.edu		Rajewsky, Klaus/0000-0002-6633-6370				ALT FW, 1980, CELL, V21, P1, DOI 10.1016/0092-8674(80)90109-9; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; ALVAREZ JD, 1995, J IMMUNOL, V155, P1191; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CEBRA JJ, 1966, J EXP MED, V123, P547, DOI 10.1084/jem.123.3.547; CHEN JZ, 1993, EMBO J, V12, P821, DOI 10.1002/j.1460-2075.1993.tb05722.x; COLECLOUGH C, 1983, NATURE, V303, P23, DOI 10.1038/303023a0; COLECLOUGH C, 1981, NATURE, V290, P372, DOI 10.1038/290372a0; Ferradini L, 1994, Semin Immunol, V6, P165, DOI 10.1006/smim.1994.1022; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; Goldmit M, 2004, IMMUNOL REV, V200, P197, DOI 10.1111/j.0105-2896.2004.00158.x; Gorman JR, 1998, ADV IMMUNOL, V69, P113, DOI 10.1016/S0065-2776(08)60607-0; Krangel MS, 2003, NAT IMMUNOL, V4, P624, DOI 10.1038/ni0703-624; Liang HE, 2004, CELL, V118, P19, DOI 10.1016/j.cell.2004.06.019; Melchers F, 1999, SEMIN IMMUNOL, V11, P307, DOI 10.1006/smim.1999.0187; Mostoslavsky R, 2001, NATURE, V414, P221, DOI 10.1038/35102606; Nemazee D, 2000, J EXP MED, V191, P1813, DOI 10.1084/jem.191.11.1813; Pelanda R, 1996, IMMUNITY, V5, P229, DOI 10.1016/S1074-7613(00)80318-0; PERNIS B, 1965, J EXP MED, V122, P853, DOI 10.1084/jem.122.5.853; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RAMSDEN DA, 1991, P NATL ACAD SCI USA, V88, P10721, DOI 10.1073/pnas.88.23.10721; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; ROLINK A, 1993, J EXP MED, V178, P1263, DOI 10.1084/jem.178.4.1263; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Von Boehmer H, 2004, ADV IMMUNOL, V84, P201, DOI 10.1016/S0065-2776(04)84006-9; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Yamagami T, 1999, IMMUNITY, V11, P317, DOI 10.1016/S1074-7613(00)80107-7; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; ZOU YR, 1993, EMBO J, V12, P811, DOI 10.1002/j.1460-2075.1993.tb05721.x	31	101	103	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2004	118	5					539	544		10.1016/j.cell.2004.08.023	http://dx.doi.org/10.1016/j.cell.2004.08.023			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	852BN	15339659	Bronze			2022-12-28	WOS:000223730300005
J	Capriotti, JA				Capriotti, JA			Clinic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												jcapriotti@nyee.edu							0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2004	292	9					1017	1018		10.1001/jama.292.9.1017	http://dx.doi.org/10.1001/jama.292.9.1017			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VH	15339884				2022-12-28	WOS:000223568700001
J	Fyhn, M; Molden, S; Witter, MP; Moser, EI; Moser, MB				Fyhn, M; Molden, S; Witter, MP; Moser, EI; Moser, MB			Spatial representation in the entorhinal cortex	SCIENCE			English	Article							POSITIONAL FIRING PROPERTIES; HEAD-DIRECTION CELLS; FREELY-MOVING RATS; PARAHIPPOCAMPAL REGION; HIPPOCAMPAL-LESIONS; UNIT-ACTIVITY; PLACE CELLS; MEMORY; NEURONS; ORGANIZATION	As the interface between hippocampus and neocortex, the entorhinal cortex is likely to play a pivotal role in memory. To determine how information is represented in this area, we measured spatial modulation of neural activity in layers of medial entorhinal cortex projecting to the hippocampus. Close to the postrhinal-entorhinal border, entorhinal neurons had stable and discrete multipeaked place fields, predicting the rat's location as accurately as place cells in the hippocampus. Precise positional modulation was not observed more ventromedially in the entorhinal cortex or upstream in the postrhinal cortex, suggesting that sensory input is transformed into durable allocentric spatial representations internally in the dorsocaudal medial entorhinal cortex.	Norwegian Univ Sci & Technol, Med Tech Res Ctr, Ctr Biol Memory, N-7489 Trondheim, Norway; Vrije Univ Amsterdam Med Ctr, Dept Anat, Neurosci Res Inst, Amsterdam, Netherlands	Norwegian University of Science & Technology (NTNU); Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Moser, EI (corresponding author), Norwegian Univ Sci & Technol, Med Tech Res Ctr, Ctr Biol Memory, N-7489 Trondheim, Norway.	edvard.moser@cbm.ntnu.no						BARNES CA, 1990, PROG BRAIN RES, V83, P287; Bostock E, 1991, Hippocampus, V1, P193, DOI 10.1002/hipo.450010207; Brun VH, 2002, SCIENCE, V296, P2243, DOI 10.1126/science.1071089; Burwell RD, 1998, NEUROREPORT, V9, P3013, DOI 10.1097/00001756-199809140-00017; Burwell RD, 2003, NEUROSCIENCE, V119, P577, DOI 10.1016/S0306-4522(03)00160-X; Burwell RD, 2000, ANN NY ACAD SCI, V911, P25; Calton JL, 2003, J NEUROSCI, V23, P9719; CHEN LL, 1994, EXP BRAIN RES, V101, P8, DOI 10.1007/BF00243212; Dolorfo CL, 1998, J COMP NEUROL, V398, P49, DOI 10.1002/(SICI)1096-9861(19980817)398:1<49::AID-CNE4>3.0.CO;2-9; Dolorfo CL, 1998, J COMP NEUROL, V398, P25; Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213; Frank LM, 2000, NEURON, V27, P169, DOI 10.1016/S0896-6273(00)00018-0; Iijima T, 1996, SCIENCE, V272, P1176, DOI 10.1126/science.272.5265.1176; JUNG MW, 1993, HIPPOCAMPUS, V3, P165, DOI 10.1002/hipo.450030209; JUNG MW, 1994, J NEUROSCI, V14, P7347; Lavenex P, 2000, HIPPOCAMPUS, V10, P420, DOI 10.1002/1098-1063(2000)10:4<420::AID-HIPO8>3.3.CO;2-X; LEE I, 2003, SOC NEUR ABSTR, V91, P11; LEUTGEB S, 2003, SOC NEUR ABSTR, V91, P5; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; MCNAUGHTON BL, 1989, NEUROSCIENCE CONNECT, P1; MOSER E, 1993, J NEUROSCI, V13, P3916; Moser MB, 1998, HIPPOCAMPUS, V8, P608, DOI 10.1002/(SICI)1098-1063(1998)8:6<608::AID-HIPO3>3.0.CO;2-7; Nadel L, 2000, HIPPOCAMPUS, V10, P352, DOI 10.1002/1098-1063(2000)10:4<352::AID-HIPO2>3.3.CO;2-4; Nakazawa K, 2002, SCIENCE, V297, P211, DOI 10.1126/science.1071795; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; QUIRK GJ, 1992, J NEUROSCI, V12, P1945; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; TAUBE JS, 1990, J NEUROSCI, V10, P420; van Haeften T, 2003, HIPPOCAMPUS, V13, P943, DOI 10.1002/hipo.10144; vanHaeften T, 1997, J NEUROSCI, V17, P862; Wirth S, 2003, SCIENCE, V300, P1578, DOI 10.1126/science.1084324; WITTER MP, 1989, PROG NEUROBIOL, V33, P161, DOI 10.1016/0301-0082(89)90009-9; Witter MP, 2000, ANN NY ACAD SCI, V911, P1; Wood ER, 2000, NEURON, V27, P623, DOI 10.1016/S0896-6273(00)00071-4	37	815	843	10	146	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2004	305	5688					1258	1264		10.1126/science.1099901	http://dx.doi.org/10.1126/science.1099901			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850PJ	15333832				2022-12-28	WOS:000223624600032
J	Bekhof, J; Norbruis, O; Scheenstra, R; Dikkers, F; de Langen, R; de Weerd, W				Bekhof, J; Norbruis, O; Scheenstra, R; Dikkers, F; de Langen, R; de Weerd, W			Babies and batteries	LANCET			English	Editorial Material									Isala Clin, Dept Pediat, NL-8025 AB Zwolle, Netherlands; Beatrix Childrens Hosp, Groningen, Netherlands; Univ Groningen Hosp, Dept Otorhinolaryngol, Groningen, Netherlands; Univ Groningen Hosp, Dept Surg, Groningen, Netherlands	Isala Clinics; University of Groningen; University of Groningen; University of Groningen	Bekhof, J (corresponding author), Isala Clin, Dept Pediat, NL-8025 AB Zwolle, Netherlands.	j.bekhof@isala.nl		Dikkers, Frederik G/0000-0001-5265-3722					0	8	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	2004	364	9435					708	708		10.1016/S0140-6736(04)16899-2	http://dx.doi.org/10.1016/S0140-6736(04)16899-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325837				2022-12-28	WOS:000223428900034
J	Seckl, MJ; Gillmore, R; Foskett, M; Sebire, NJ; Rees, H; Newlands, ES				Seckl, MJ; Gillmore, R; Foskett, M; Sebire, NJ; Rees, H; Newlands, ES			Routine terminations of pregnancy - should we screen for gestational trophoblastic neoplasia?	LANCET			English	Article							METHOTREXATE; EPIDEMIOLOGY; TUMORS	After termination of pregnancy for non-medical reasons, the products of conception are often not routinely examined for gestational trophoblastic neoplasia. Between 1995 and 2001 we identified 15 women without and 36 women with a pathological diagnosis of gestational trophoblastic neoplasia at the time of their pregnancy termination. Women without a diagnosis were significantly more likely to have subsequent life-threatening complications of gestational trophoblastic neoplasia (four of 15 vs none of 36; p=0.003), and to require surgical intervention (15 of 15 vs one of 36; p<0.0001) and chemotherapy (nine of 15 vs two of 36; p<0.0001). All women should be screened for gestational trophoblastic neoplasia after termination of pregnancy.	Univ London Imperial Coll Sci Technol & Med, Gestat Trophoblast Dis Unit, Dept Med Oncol, London W6 8RF, England	Imperial College London	Seckl, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Gestat Trophoblast Dis Unit, Dept Med Oncol, Charing Cross & Hammersmith Hosp Campus,Fulham Pa, London W6 8RF, England.	m.seckl@imperial.co.uk	sebire, neil J/C-4960-2008	Sebire, Neil/0000-0001-5348-9063				JACOBS PA, 1982, BRIT J OBSTET GYNAEC, V89, P258, DOI 10.1111/j.1471-0528.1982.tb04693.x; McNeish IA, 2002, J CLIN ONCOL, V20, P1838, DOI 10.1200/JCO.2002.07.166; Papadopoulos AJ, 2002, J REPROD MED, V47, P460; Rustin GJS, 1996, J CLIN ONCOL, V14, P2769, DOI 10.1200/JCO.1996.14.10.2769; Seckl MJ, 2000, LANCET, V356, P36, DOI 10.1016/S0140-6736(00)02432-6; Steigrad SJ, 2003, BEST PRACT RES CL OB, V17, P837, DOI 10.1016/S1521-6934(03)00049-X; THOMAS J, 2001, NATL AUDIT INDUCED A	7	31	33	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	2004	364	9435					705	707		10.1016/S0140-6736(04)16898-0	http://dx.doi.org/10.1016/S0140-6736(04)16898-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325836				2022-12-28	WOS:000223428900033
J	Tannen, T				Tannen, T			Edward B Lewis - Obituary	LANCET			English	Biographical-Item												ttannen@sbcglobal.net						LEWIS EB, PUBLICATION LIST	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	2004	364	9435					658	658		10.1016/S0140-6736(04)16878-5	http://dx.doi.org/10.1016/S0140-6736(04)16878-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15341018				2022-12-28	WOS:000223428900013
J	Koster, RD; Dirmeyer, PA; Guo, ZC; Bonan, G; Chan, E; Cox, P; Gordon, CT; Kanae, S; Kowalczyk, E; Lawrence, D; Liu, P; Lu, CH; Malyshev, S; McAvaney, B; Mitchell, K; Mocko, D; Oki, T; Oleson, K; Pitman, A; Sud, YC; Taylor, CM; Verseghy, D; Vasic, R; Xue, YK; Yamada, T				Koster, RD; Dirmeyer, PA; Guo, ZC; Bonan, G; Chan, E; Cox, P; Gordon, CT; Kanae, S; Kowalczyk, E; Lawrence, D; Liu, P; Lu, CH; Malyshev, S; McAvaney, B; Mitchell, K; Mocko, D; Oki, T; Oleson, K; Pitman, A; Sud, YC; Taylor, CM; Verseghy, D; Vasic, R; Xue, YK; Yamada, T		GLACE Team	Regions of strong coupling between soil moisture and precipitation	SCIENCE			English	Article							CLIMATE; PREDICTABILITY; VARIABILITY; TEMPERATURE; PREDICTION; SIMULATION; RAINFALL	Previous estimates of land-atmosphere interaction (the impact of soil moisture on precipitation) have been limited by a lack of observational data and by the model dependence of computational estimates. To counter the second limitation, a dozen climate-modeling groups have recently performed the same highly controlled numerical experiment as part of a coordinated comparison project. This allows a multimodel estimation of the regions on Earth where precipitation is affected by soil moisture anomalies during Northern Hemisphere summer. Potential bene its of this estimation may include improved seasonal rainfall forecasts.	NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Ctr Ocean Land Atmosphere Studies, Calverton, MD 20705 USA; Natl Ctr Atmospher Res, Boulder, CO 80307 USA; Meteorol Serv Canada, Toronto, ON M34 5T4, Canada; Hadley Ctr Climate Predict & Res, Exeter EX1 3PB, Devon, England; Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA; Res Inst Human & Nat, Kyoto 6020878, Japan; CSIRO Atmospher Res, Aspendale, Vic 3195, Australia; Univ Reading, Reading RG6 6BB, Berks, England; Sci Applicat Int Corp, Beltsville, MD 20705 USA; Natl Ctr Environm Predict, Camp Springs, MD 20746 USA; Princeton Univ, Princeton, NJ 08544 USA; Bur Meteorol Res Ctr, Melbourne, Vic 3001, Australia; Univ Tokyo, Tokyo 1538505, Japan; Macquarie Univ, N Ryde, NSW 2109, Australia; Ctr Ecol & Hydrol, Wallingford OX10 8BB, Oxon, England; Univ Calif Los Angeles, Los Angeles, CA 90095 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; National Center Atmospheric Research (NCAR) - USA; Environment & Climate Change Canada; Meteorological Service of Canada; Met Office - UK; Hadley Centre; National Oceanic Atmospheric Admin (NOAA) - USA; Research Institute for Humanity & Nature (RIHN); Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Reading; Science Applications International Corporation (SAIC); National Oceanic Atmospheric Admin (NOAA) - USA; Princeton University; Bureau of Meteorology - Australia; University of Tokyo; Macquarie University; UK Centre for Ecology & Hydrology (UKCEH); University of California System; University of California Los Angeles	Koster, RD (corresponding author), NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA.	randal.d.koster@nasa.gov	Kanae, Shinjiro/E-5606-2010; Lawrence, David M/C-4026-2011; Koster, Randal D/F-5881-2012; Taylor, Christopher/Y-7529-2019; Taylor, Chris/K-2319-2012; Oleson, Keith/A-9328-2008; Malyshev, Sergey/N-6422-2019; Dirmeyer, Paul/B-6553-2016; Oki, Taikan/E-5778-2010; Dirmeyer, Paul/P-3275-2019; Cox, Peter Michae;/B-3299-2012; Pitman, Andrew J/A-7353-2011; xue, yongkang/M-6756-2018	Kanae, Shinjiro/0000-0002-3176-4957; Lawrence, David M/0000-0002-2968-3023; Koster, Randal D/0000-0001-6418-6383; Taylor, Chris/0000-0002-0120-3198; Oleson, Keith/0000-0002-0057-9900; Malyshev, Sergey/0000-0001-6259-1043; Dirmeyer, Paul/0000-0003-3158-1752; Oki, Taikan/0000-0003-4067-4678; Dirmeyer, Paul/0000-0003-3158-1752; Cox, Peter Michae;/0000-0002-0679-2219; Pitman, Andrew J/0000-0003-0604-3274; xue, yongkang/0000-0002-6169-9631; Chan, Edmond/0000-0003-1160-1090; Lu, Cheng-hsuan/0000-0001-9960-5584				Beljaars ACM, 1996, MON WEATHER REV, V124, P362, DOI 10.1175/1520-0493(1996)124<0362:TAROTU>2.0.CO;2; CHARNEY J, 1977, J ATMOS SCI, V34, P1366, DOI 10.1175/1520-0469(1977)034<1366:ACSOTE>2.0.CO;2; DICKINSON RE, 1988, Q J ROY METEOR SOC, V114, P439, DOI 10.1002/qj.49711448009; Dirmeyer PA, 2001, J HYDROMETEOROL, V2, P329, DOI 10.1175/1525-7541(2001)002<0329:AEOTSO>2.0.CO;2; Dirmeyer PA, 2000, J CLIMATE, V13, P2900, DOI 10.1175/1520-0442(2000)013<2900:UAGSWD>2.0.CO;2; Douville H, 2000, CLIM DYNAM, V16, P719, DOI 10.1007/s003820000080; DRUFUCA G, 1975, J APPL METEOROL, V14, P1419, DOI 10.1175/1520-0450(1975)014<1419:SORD>2.0.CO;2; KEDEM B, 1990, J GEOPHYS RES-ATMOS, V95, P1965, DOI 10.1029/JD095iD02p01965; Kirtman BP, 1998, J CLIMATE, V11, P2804, DOI 10.1175/1520-0442(1998)011<2804:DVIEPA>2.0.CO;2; Koster RD, 2003, J HYDROMETEOROL, V4, P408, DOI 10.1175/1525-7541(2003)4<408:IOLSIO>2.0.CO;2; Koster RD, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016571; Koster RD, 2002, J HYDROMETEOROL, V3, P363, DOI 10.1175/1525-7541(2002)003<0363:CTDOLA>2.0.CO;2; Koster RD, 2000, J HYDROMETEOROL, V1, P26, DOI 10.1175/1525-7541(2000)001<0026:VAPOPA>2.0.CO;2; RASMUSSON EM, 1982, MON WEATHER REV, V110, P354, DOI 10.1175/1520-0493(1982)110<0354:VITSST>2.0.CO;2; Robock A, 2000, B AM METEOROL SOC, V81, P1281, DOI [10.1175/1520-0477(2000)081<1281:TGSMDB>2.3.CO;2, 10.1175/1520-0477(2000)081&lt;1281:TGSMDB&gt;2.3.CO;2]; Schlosser CA, 2002, J HYDROMETEOROL, V3, P483, DOI 10.1175/1525-7541(2002)003<0483:AMBIOS>2.0.CO;2; SHUKLA J, 1982, SCIENCE, V215, P1498, DOI 10.1126/science.215.4539.1498; SUD YC, 1993, J ARID ENVIRON, V25, P5, DOI 10.1006/jare.1993.1038; Vinnikov KY, 1996, J GEOPHYS RES-ATMOS, V101, P7163, DOI 10.1029/95JD02753; Wallace JM, 1998, J GEOPHYS RES-OCEANS, V103, P14241, DOI 10.1029/97JC02905; Xue YK, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD003556	21	1950	2036	35	530	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	2004	305	5687					1138	1140		10.1126/science.1100217	http://dx.doi.org/10.1126/science.1100217			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326351				2022-12-28	WOS:000223557400043
J	Hashimoto, A; Suenaga, K; Gloter, A; Urita, K; Iijima, S				Hashimoto, A; Suenaga, K; Gloter, A; Urita, K; Iijima, S			Direct evidence for atomic defects in graphene layers	NATURE			English	Article							CARBON NANOTUBE; GRAPHITE; STM; RELAXATION; VACANCIES	Atomic-scale defects in graphene layers alter the physical and chemical properties of carbon nanostructures(1,2). Theoretical predictions have recently shown that energetic particles such as electrons and ions can induce polymorphic atomic defects in graphene layers as a result of knock-on atom displacements(3,4). However, the number of experimental reports on these defects is limited(5,6). The graphite network in single-walled carbon nanotubes has been visualized by transmission electron microscopy (TEM) and their chiral indices have been determined(7,8). But the methods used require a long image acquisition time and intensive numerical treatments after observations to find an 'average' image, which prevents the accurate detection and investigation of defect structures. Here we report observations in situ of defect formation in single graphene layers by high-resolution TEM. The observed structures are expected to be of use when engineering the properties of carbon nanostructures for specific device applications.	Natl Inst Adv Ind Sci & Technol, Res Ctr Adv Carbon Mat, Tsukuba, Ibaraki 3058565, Japan; Univ Paris 11, CNRS, UMR 8502, Phys Solides Lab, F-91405 Orsay, France; Chiba Univ, Grad Sch Sci & Technol, Chiba 2638522, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Universite Paris Saclay; Chiba University	Suenaga, K (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Adv Carbon Mat, Tsukuba, Ibaraki 3058565, Japan.	suenaga-kazu@aist.go.jp	Suenaga, Kazu/E-2339-2014; HASHIMOTO, Ayako/H-2648-2011; GLOTER, Alexandre/F-7130-2017; Gloter, Alexandre/ABE-2539-2020; URITA, KOKI/Q-3065-2017	Suenaga, Kazu/0000-0002-6107-1123; HASHIMOTO, Ayako/0000-0002-1985-7667; Gloter, Alexandre/0000-0002-4813-3799; URITA, KOKI/0000-0002-2647-8702				Ajayan PM, 1998, PHYS REV LETT, V81, P1437, DOI 10.1103/PhysRevLett.81.1437; ASARI E, 1993, PHYS REV B, V47, P11143, DOI 10.1103/PhysRevB.47.11143; Banhart F, 1999, REP PROG PHYS, V62, P1181, DOI 10.1088/0034-4885/62/8/201; El-Barbary AA, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.144107; Ewels CP, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.025505; Ewels CP, 2002, CHEM PHYS LETT, V351, P178, DOI 10.1016/S0009-2614(01)01371-9; Hahn JR, 1996, PHYS REV B, V53, pR1725, DOI 10.1103/PhysRevB.53.R1725; Hansson A, 2000, PHYS REV B, V62, P7639, DOI 10.1103/PhysRevB.62.7639; Hjort M, 2000, PHYS REV B, V61, P14089, DOI 10.1103/PhysRevB.61.14089; Kelly KF, 1998, SURF SCI, V416, pL1085, DOI 10.1016/S0039-6028(98)00622-0; Kociak M, 2003, EUR PHYS J B, V32, P457, DOI 10.1140/epjb/e2003-00127-2; Kociak M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.155501; Krasheninnikov AV, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.245405; Krasheninnikov AV, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.073402; Krasheninnikov AV, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.165423; Lehtinen PO, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.017202; Lu AJ, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.105504; Meyer RR, 2003, J MICROSC-OXFORD, V212, P152, DOI 10.1046/j.1365-2818.2003.01240.x; Nordlund K, 1996, PHYS REV LETT, V77, P699, DOI 10.1103/PhysRevLett.77.699; Odom TW, 1998, NATURE, V391, P62, DOI 10.1038/34145; Orlikowski D, 2000, PHYS REV B, V61, P14194, DOI 10.1103/PhysRevB.61.14194; Ouyang M, 2001, SCIENCE, V291, P97, DOI 10.1126/science.291.5501.97; Smith BW, 2001, J APPL PHYS, V90, P3509, DOI 10.1063/1.1383020; STONE AJ, 1986, CHEM PHYS LETT, V128, P501, DOI 10.1016/0009-2614(86)80661-3; Telling RH, 2003, NAT MATER, V2, P333, DOI 10.1038/nmat876; Wildoer JWG, 1998, NATURE, V391, P59, DOI 10.1038/34139; Yakobson BI, 2000, CARBON, V38, P1675, DOI 10.1016/S0008-6223(00)00093-2; Zuo JM, 2003, SCIENCE, V300, P1419, DOI 10.1126/science.1083887	29	1394	1431	26	1204	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					870	873		10.1038/nature02817	http://dx.doi.org/10.1038/nature02817			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318216				2022-12-28	WOS:000223369800036
J	Prescher, JA; Dube, DH; Bertozzi, CR				Prescher, JA; Dube, DH; Bertozzi, CR			Chemical remodelling of cell surfaces in living animals	NATURE			English	Article							SIALIC-ACID; STAUDINGER LIGATION; GLYCOSYLATION; BIOSYNTHESIS; IDENTIFICATION; GLYCOPROTEINS; EXPRESSION; CHEMISTRY; PROTEINS; MOLECULE	Cell surfaces are endowed with biological functionality designed to mediate extracellular communication. The cell-surface repertoire can be expanded to include abiotic functionality through the biosynthetic introduction of unnatural sugars into cellular glycans, a process termed metabolic oligosaccharide engineering(1,2). This technique has been exploited in fundamental studies of glycan-dependent cell-cell and virus-cell interactions(3-5) and also provides an avenue for the chemical remodelling of living cells(6-8). Unique chemical functional groups can be delivered to cell-surface glycans by metabolism of the corresponding unnatural precursor sugars. These functional groups can then undergo covalent reaction with exogenous agents bearing complementary functionality. The exquisite chemical selectivity required of this process is supplied by the Staudinger ligation of azides and phosphines, a reaction that has been performed on cultured cells without detriment to their physiology(7,9). Here we demonstrate that the Staudinger ligation can be executed in living animals, enabling the chemical modification of cells within their native environment. The ability to tag cell-surface glycans in vivo may enable therapeutic targeting and noninvasive imaging of changes in glycosylation during disease progression.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; Howard Hughes Medical Institute; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Bertozzi, CR (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	crb@berkeley.edu						Buttner B, 2002, J NEUROSCI, V22, P8869; Charter NW, 2002, J BIOL CHEM, V277, P9255, DOI 10.1074/jbc.M111619200; CODINGTON JF, 1979, BIOCHEMISTRY-US, V18, P2145, DOI 10.1021/bi00578a002; Dube DH, 2003, CURR OPIN CHEM BIOL, V7, P616, DOI 10.1016/j.cbpa.2003.08.006; Fukuda M, 1996, CANCER RES, V56, P2237; Hang HC, 2003, P NATL ACAD SCI USA, V100, P14846, DOI 10.1073/pnas.2335201100; Jurisson SS, 1999, CHEM REV, V99, P2205, DOI 10.1021/cr980435t; Kavarana MJ, 1999, J MED CHEM, V42, P221, DOI 10.1021/jm9708036; KAYSER H, 1992, J BIOL CHEM, V267, P16934; Keppler OT, 2001, GLYCOBIOLOGY, V11, p11R, DOI 10.1093/glycob/11.2.11R; KEPPLER OT, 1995, J BIOL CHEM, V270, P1308, DOI 10.1074/jbc.270.3.1308; Kiick KL, 2002, P NATL ACAD SCI USA, V99, P19, DOI 10.1073/pnas.012583299; Kim YJ, 1997, GLYCOCONJUGATE J, V14, P569, DOI 10.1023/A:1018580324971; Kohn M, 2004, ANGEW CHEM INT EDIT, V43, P3106, DOI 10.1002/anie.200401744; Kolb HC, 2003, DRUG DISCOV TODAY, V8, P1128, DOI 10.1016/S1359-6446(03)02933-7; Luchansky SJ, 2003, METHOD ENZYMOL, V362, P249; LUCHANSKY SJ, IN PRESS BIOCHEMISTR; Mahal LK, 1997, SCIENCE, V276, P1125, DOI 10.1126/science.276.5315.1125; Martin DC, 1999, J CELL BIOL, V146, P881, DOI 10.1083/jcb.146.4.881; Morton CL, 2000, CANCER RES, V60, P4206; Ovaa H, 2003, ANGEW CHEM INT EDIT, V42, P3626, DOI 10.1002/anie.200351314; REICHNER JS, 1988, J BIOL CHEM, V263, P16316; Renkonen J, 2002, AM J PATHOL, V161, P543, DOI 10.1016/S0002-9440(10)64210-1; Saxon E, 2002, J AM CHEM SOC, V124, P14893, DOI 10.1021/ja027748x; Saxon E, 2000, SCIENCE, V287, P2007, DOI 10.1126/science.287.5460.2007; SELL S, 1990, HUM PATHOL, V21, P1003, DOI 10.1016/0046-8177(90)90250-9; Shaw CF, 1999, CHEM REV, V99, P2589, DOI 10.1021/cr980431o; SOARES ER, 1979, BIOCHEM GENET, V17, P577, DOI 10.1007/BF00502119; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319; Vocadlo DJ, 2003, P NATL ACAD SCI USA, V100, P9116, DOI 10.1073/pnas.1632821100	30	553	596	22	260	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					873	877		10.1038/nature02791	http://dx.doi.org/10.1038/nature02791			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318217				2022-12-28	WOS:000223369800037
J	March, J; Silva, S; Petrycki, S; Curry, J; Wells, K; Fairbank, J; Burns, B; Domino, M; Vitiello, B; Severe, J				March, J; Silva, S; Petrycki, S; Curry, J; Wells, K; Fairbank, J; Burns, B; Domino, M; Vitiello, B; Severe, J		TADS Team	Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression - Treatment for adolescents with depression study (TADS) randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-TRIALS; DOUBLE-BLIND; CHILDREN; PLACEBO; PSYCHOTHERAPY; PHARMACOTHERAPY; MEDICATIONS; CHILDHOOD; SYMPTOMS; SSRIS	Context Initial treatment of major depressive disorder in adolescents may include cognitive-behavioral therapy (CBT) or a selective serotonin reuptake inhibitor (SSRI). However, little is known about their relative or combined effectiveness. Objective To evaluate the effectiveness of 4 treatments among adolescents with major depressive disorder. Design, Setting, and Participants Randomized controlled trial of a volunteer sample of 439 patients between the ages of 12 to 17 years with a primary Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis of major depressive disorder. The trial was conducted at 13 US academic and community clinics between spring 2000 and summer 2003. Interventions Twelve weeks of (1) fluoxetine alone (10 to 40 mg/d), (2) CBT alone, (3) CBT with fluoxetine (10 to 40 mg/d), or (4) placebo (equivalent to 10 to 40 mg/d). Placebo and fluoxetine alone were administered double-blind; CBT alone and CBT with fluoxetine were administered unblinded. Main Outcome Measures Children's Depression Rating Scale-Revised total score and, for responder analysis, a (dichotomized) Clinical Global Impressions improvement score. Results Compared with placebo, the combination of fluoxetine with CBT was statistically significant (P=.001) on the Children's Depression Rating Scale-Revised. Compared with fluoxetine alone (P=.02) and CBT alone (P=.01), treatment of fluoxetine with CBT was superior. Fluoxetine alone is a superior treatment to CBT alone (P=.01). Rates of response for fluoxetine with CBT were 71.0% (95% confidence interval [Cl], 62%-80%); fluoxetine alone, 60.6% (95% Cl, 51%-70%); CBT alone, 43.2% (95% Cl, 34%-52%); and placebo, 34.8% (95% Cl, 26%-44%). On the Clinical Global Impressions improvement responder analysis, the 2 fluoxetine-containing conditions were statistically superior to CBT and to placebo. Clinically significant suicidal thinking, which was present in 29% of the sample at baseline, improved significantly in all 4 treatment groups. Fluoxetine with CBT showed the greatest reduction (P=.02). Seven (1.6%) of 439 patients attempted suicide; there were no completed suicides. Conclusion The combination of fluoxetine with CBT offered the most favorable tradeoff between benefit and risk for adolescents with major depressive disorder.	Duke Univ, Med Ctr, Dept Psychiat, Duke Clin Res Inst, Durham, NC 27710 USA; NIMH, Rockville, MD 20857 USA	Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	March, J (corresponding author), Duke Univ, Med Ctr, Dept Psychiat, Duke Clin Res Inst, 718 Rutherford St,Box 3527, Durham, NC 27710 USA.	jsmarch@acpub.duke.edu	Vitiello, Benedetto/AAC-1758-2022; Fairbank, John/F-8972-2013	Fairbank, John/0000-0003-2604-7256	DS NIH HHS [98-DS-0008] Funding Source: Medline	DS NIH HHS		Ahmoi C, 1999, DEPRESSIVE DISORDERS, P69; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Angold A, 1998, AM J PUBLIC HEALTH, V88, P75, DOI 10.2105/AJPH.88.1.75; [Anonymous], 1990, STAT ISSUES DRUG RES; Arias E, 2003, PEDIATRICS, V112, P1215, DOI 10.1542/peds.112.6.1215; Barbe RP, 2004, SUICIDE LIFE-THREAT, V34, P44, DOI 10.1521/suli.34.1.44.27768; Birmaher B, 1998, J AM ACAD CHILD PSY, V37, P1234, DOI 10.1097/00004583-199811000-00029; Brent D., 1997, COGNITIVE THERAPY TR; Brent DA, 1997, ARCH GEN PSYCHIAT, V54, P877; Brent DA, 2004, J AM ACAD CHILD PSY, V43, P379, DOI 10.1097/01.chi.0000120018.48166.57; Brown H., 1999, APPL MIXED MODELS ME; Clarke G. N., 1990, INSTRUCTORS MANUAL A; Costello EJ, 2002, BIOL PSYCHIAT, V52, P529, DOI 10.1016/S0006-3223(02)01372-0; Curry JE, 2003, J AM ACAD CHILD PSY, V42, P656, DOI 10.1097/01.CHI.0000046861.56865.6C; Curry JF, 2001, BIOL PSYCHIAT, V49, P1091, DOI 10.1016/S0006-3223(01)01130-1; Emslie GJ, 2002, J AM ACAD CHILD PSY, V41, P1205, DOI 10.1097/00004583-200210000-00010; Emslie GJ, 1997, ARCH GEN PSYCHIAT, V54, P1031; EMSLIE GJ, 2000, 39 ANN M AM COLL NEU; Fost N, 2001, BIOL PSYCHIAT, V49, P1015, DOI 10.1016/S0006-3223(01)01181-7; Friedman MA, 2004, CLIN PSYCHOL-SCI PR, V11, P47, DOI 10.1093/clipsy/bph052; Gould MS, 1998, J AM ACAD CHILD PSY, V37, P915, DOI 10.1097/00004583-199809000-00011; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310; Guy W., 1976, ECDEU ASSESSMENT MAN, VRev; HAZELL P, 2002, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD002317; Hughes CW, 2000, NEUROPSYCHOPHARMACOL, V23, P591, DOI 10.1016/S0893-133X(00)00098-1; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Keller MB, 2000, NEW ENGL J MED, V342, P1462, DOI 10.1056/NEJM200005183422001; Khan A, 2003, AM J PSYCHIAT, V160, P790, DOI 10.1176/appi.ajp.160.4.790; Khan A, 2001, INT J NEUROPSYCHOPH, V4, P113, DOI 10.1017/S1461145701002322; Koch G, 1996, DRUG INF J, V30, P523, DOI DOI 10.1177/009286159603000228; Kraemer HC, 2002, ARCH GEN PSYCHIAT, V59, P877, DOI 10.1001/archpsyc.59.10.877; Lewinsohn PM, 1999, CLIN PSYCHOL REV, V19, P329, DOI 10.1016/S0272-7358(98)00055-5; March J, 2004, J AM ACAD CHILD PSY, V43, P1046, DOI 10.1097/01.chi.0000129606.83206.77; March J, 2003, J AM ACAD CHILD PSY, V42, P531, DOI 10.1097/01.CHI.0000046839.90931.0D; MARCH J, 2003, PEDIAT PSYCHOPHARMAC, P326; Negron R, 1997, J AM ACAD CHILD PSY, V36, P1512, DOI 10.1016/S0890-8567(09)66559-X; Pampallona S, 2004, ARCH GEN PSYCHIAT, V61, P714, DOI 10.1001/archpsyc.61.7.714; Poznanski EO, 1995, CHILDRENS DEPRESSION; Reinecke MA, 1998, J AM ACAD CHILD PSY, V37, P26, DOI 10.1097/00004583-199801000-00013; Reynolds W. M., 1987, REYNOLDS ADOLESCENT; Rosenthal R., 2000, CONTRASTS EFFECT SIZ; Sackett DL, 2000, EVIDENCE BASED MED; Safer DJ, 1997, J CHILD ADOL PSYCHOP, V7, P267, DOI 10.1089/cap.1997.7.267; Shaffer D, 1996, ARCH GEN PSYCHIAT, V53, P339; SHEA MT, 1992, ARCH GEN PSYCHIAT, V49, P782, DOI 10.1001/archpsyc.1992.01820100026006; *TADS, IN PRESS J AM ACAD C; TEICHER MH, 1993, DRUG SAFETY, V8, P186, DOI 10.2165/00002018-199308030-00002; *US FDA WEB SIT, WORS DEPR SUIC PAT B; Vitiello B, 2004, NEW ENGL J MED, V350, P1489, DOI 10.1056/NEJMp038248; Weinfurt K. P, 2000, READING UNDERSTANDIN, P317; Whittington CJ, 2004, LANCET, V363, P1341, DOI 10.1016/S0140-6736(04)16043-1	51	1209	1222	5	361	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2004	292	7					807	820						14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	847FO	15315995				2022-12-28	WOS:000223378300021
J	Dietrich, AJ; Oxman, TE; Williams, JW; Schulberg, HC; Bruce, ML; Lee, PW; Barry, S; Raue, PJ; Lefever, JJ; Heo, M; Rost, K; Kroenke, K; Gerrity, M; Nutting, PA				Dietrich, AJ; Oxman, TE; Williams, JW; Schulberg, HC; Bruce, ML; Lee, PW; Barry, S; Raue, PJ; Lefever, JJ; Heo, M; Rost, K; Kroenke, K; Gerrity, M; Nutting, PA			Re-engineering systems for the treatment of depression in primary care: cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COLLABORATIVE CARE; MANAGEMENT; IMPROVE; QUALITY; DISORDERS; SYMPTOMS; PROGRAMS; OUTCOMES; DISEASE; UTILITY	Objective To test the effectiveness of an evidence based model for management of depression in primary care with support from quality improvement resources. Design Cluster randomised controlled trial. Setting Five healthcare organisations in the United States and 60 affiliated practices. Patients 405 patients, aged greater than or equal to18 years, starting or changing treatment for depression. Intervention Care provided by clinicians, with staff providing telephone support under supervision from a psychiatrist. Main outcome measures Severity of depression at three and six months (Hopkins symptom checklist-20): response to treatment (greater than or equal to50% decrease in scores) and remission (score of <0.5). Results At six months, 60% (106 of 177) of patients in intervention practices had responded to treatment compared with 47% (68 of 146) of patients in usual care practices (P=0.02). At six months, 37% of intervention patients showed remission compared with 27% for usual care patients (P=0.014). 90% of intervention patients rated their depression care as good or excellent at six months compared with 75% of usual care patients (P=0.0003). Conclusion Resources such as quality improvement programmes can be used effectively in primary care to implement evidence based management of depression and improve outcomes for patients with depression.	Dartmouth Coll, Sch Med, Hanover, NH 03755 USA; Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res, Durham, NC 27705 USA; Cornell Univ, Weill Med Coll, White Plains, NY 10605 USA; Univ Colorado, Hlth Sci Ctr, UCHSC Fitzsimmons, Aurora, CO 80010 USA; Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA; Vet Adm Med Ctr, Portland, OR 97207 USA; Ctr Res Strategies, Denver, CO 80203 USA	Dartmouth College; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Cornell University; University of Colorado System; University of Colorado Anschutz Medical Campus; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Dietrich, AJ (corresponding author), Dartmouth Coll, Sch Med, HB 7250, Hanover, NH 03755 USA.	allen.j.dietrich@dartmouth.edu	Williams, John/AAM-4572-2020; anand, amit/A-7222-2009; Williams, John W/A-3696-2008	Williams, John/0000-0002-5267-5558; Williams, John W/0000-0002-5267-5558; Kroenke, Kurt/0000-0002-0114-4669; Heo, Moonseong/0000-0001-7711-1209; Gerrity, Martha/0000-0002-8772-4591				Badamgarav E, 2003, AM J PSYCHIAT, V160, P2080, DOI 10.1176/appi.ajp.160.12.2080; Bruce ML, 2004, JAMA-J AM MED ASSOC, V291, P1081, DOI 10.1001/jama.291.9.1081; Dietrich AJ, 2004, ANN FAM MED, V2, P301, DOI 10.1370/afm.102; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Eisenberg JM, 2000, JAMA-J AM MED ASSOC, V284, P2100, DOI 10.1001/jama.284.16.2100; Ford DE, 2000, J GEN INTERN MED, V15, P344, DOI 10.1046/j.1525-1497.2000.03011.x; Gilbody S, 2003, JAMA-J AM MED ASSOC, V289, P3145, DOI 10.1001/jama.289.23.3145; Hedrick SC, 2003, J GEN INTERN MED, V18, P9, DOI 10.1046/j.1525-1497.2003.11109.x; HSIEH FY, 1988, STAT MED, V7, P1195, DOI 10.1002/sim.4780071113; Hunkeler EM, 2000, ARCH FAM MED, V9, P700, DOI 10.1001/archfami.9.8.700; Katon W, 1999, ARCH GEN PSYCHIAT, V56, P1109, DOI 10.1001/archpsyc.56.12.1109; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Leatherman S, 2004, BRIT MED J, V328, P288; Lewis R, 2004, BMJ-BRIT MED J, V328, P220, DOI 10.1136/bmj.328.7433.220; Lin EHB, 1999, AM J PSYCHIAT, V156, P643; LIPMAN RS, 1979, J AFFECT DISORDERS, V1, P9, DOI 10.1016/0165-0327(79)90021-1; Moynihan R, 2004, BRIT MED J, V328, P303, DOI 10.1136/bmj.328.7435.303-a; Nutting PA, 2002, J GEN INTERN MED, V17, P103, DOI 10.1046/j.1525-1497.2002.10128.x; Oxman TE, 2002, PSYCHOSOMATICS, V43, P441, DOI 10.1176/appi.psy.43.6.441; Raudenbush SW, 2002, HIERARCHICAL LINEAR; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; Rost K, 2002, BMJ-BRIT MED J, V325, P934, DOI 10.1136/bmj.325.7370.934; Rost K, 2001, J GEN INTERN MED, V16, P644, DOI 10.1046/j.1525-1497.2001.016009641.x; Simon GE, 2000, BRIT MED J, V320, P550, DOI 10.1136/bmj.320.7234.550; Smith R, 2000, BRIT MED J, V321, P1428, DOI 10.1136/bmj.321.7274.1428; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Thompson C, 2000, LANCET, V355, P185, DOI 10.1016/S0140-6736(99)03171-2; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; VERBEKE G, 1997, LINEAR MIXED MODELS, P222; Von Korff M, 2001, BRIT MED J, V323, P948, DOI 10.1136/bmj.323.7319.948; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212	34	215	217	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 11	2004	329	7466					602	605		10.1136/bmj.38219.481250.55	http://dx.doi.org/10.1136/bmj.38219.481250.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	854SK	15345600	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000223923400017
J	Falkowski, PG; Davis, CS				Falkowski, PG; Davis, CS			Natural proportions	NATURE			English	Article									Rutgers State Univ, Inst Marine & Coastal Sci, Princeton, NJ 08540 USA; Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	Rutgers State University New Brunswick; Woods Hole Oceanographic Institution	Falkowski, PG (corresponding author), Rutgers State Univ, Inst Marine & Coastal Sci, Princeton, NJ 08540 USA.							Falkowski PG, 2004, SCIENCE, V305, P354, DOI 10.1126/science.1095964; Hedin LO, 2004, P NATL ACAD SCI USA, V101, P10849, DOI 10.1073/pnas.0404222101; Redfield A. C., 1934, P176; Sterner R.W, 2002, ECOLOGICAL STOICHIOM, DOI DOI 10.1086/382444	4	42	46	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2004	431	7005					131	131		10.1038/431131a	http://dx.doi.org/10.1038/431131a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356609	Bronze			2022-12-28	WOS:000223746000019
J	Ross, N				Ross, N			Improving surgical consent	LANCET			English	Editorial Material											Ross, N (corresponding author), POB 999, London, England.	nickross@lineone.net						*DEP HLTH, CONS; *DEP HLTH, CONS OV GEN INF; *NAT AUD OFF, 2003, NAT HLTH SERV ENGL S	3	6	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	2004	364	9436					812	813		10.1016/S0140-6736(04)16943-2	http://dx.doi.org/10.1016/S0140-6736(04)16943-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337410				2022-12-28	WOS:000223569600035
J	Noakes, TD				Noakes, TD			Tainted glory - Doping and athletic performance	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Cape Town, Dept Human Biol, Univ Cape Town Med Res Council Res Unit Exercise, Newlands, South Africa; Sports Sci Inst S Africa, Newlands, South Africa	University of Cape Town	Noakes, TD (corresponding author), Univ Cape Town, Dept Human Biol, Univ Cape Town Med Res Council Res Unit Exercise, Newlands, South Africa.		Noakes, Tim/AAD-3162-2020; Noakes, Timothy D./E-7253-2011	Noakes, Tim/0000-0001-7244-2375; Noakes, Timothy D./0000-0001-7244-2375				Franke WW, 1997, CLIN CHEM, V43, P1262; Hoberman J., 2001, DOPING ELITE SPORTS, P241; Hoberman J., 1984, MORTAL ENGINES SCI P; REITERER W, 2000, POSITIVE AUSTR OLYMP; VOET W, 2001, BREAKING CHAIN DRUGS	5	43	44	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2004	351	9					847	849		10.1056/NEJMp048208	http://dx.doi.org/10.1056/NEJMp048208			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849BM	15329417				2022-12-28	WOS:000223512500001
J	Renlund, DG				Renlund, DG			Building a bridge to heart transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Utah, Sch Med, Dept Cardiol, Salt Lake City, UT 84112 USA; Latter Day St Hosp, Salt Lake City, UT 84143 USA	Utah System of Higher Education; University of Utah	Renlund, DG (corresponding author), Univ Utah, Sch Med, Dept Cardiol, Salt Lake City, UT 84112 USA.								0	9	10	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2004	351	9					849	851		10.1056/NEJMp048176	http://dx.doi.org/10.1056/NEJMp048176			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849BM	15329418				2022-12-28	WOS:000223512500002
J	Rubinstein, SM; Cohen, G; Fineberg, J				Rubinstein, SM; Cohen, G; Fineberg, J			Detachment fronts and the onset of dynamic friction	NATURE			English	Article							DEPENDENT FRICTION; CRACK-PROPAGATION; SLIP-PULSE; RUPTURE; EARTHQUAKE; FAULT; STABILITY; INSIGHTS; VELOCITY; LAWS	The dynamics of friction have been studied for hundreds of years, yet many aspects of these everyday processes are not understood. One such aspect is the onset of frictional motion ( slip). First described more than 200 years ago as the transition from static to dynamic friction, the onset of slip is central to fields as diverse as physics(1-3), tribology(4,5), mechanics of earthquakes(6-11) and fracture(12-14). Here we show that the onset of frictional slip is governed by three different types of coherent crack-like fronts: these are observed by real-time visualization of the net contact area that forms the interface separating two blocks of like material. Two of these fronts, which propagate at subsonic and intersonic velocities, have been the subject of intensive recent interest(12-17). We show that a third type of front, which propagates an order of magnitude more slowly, is the dominant mechanism for the rupture of the interface. No overall motion ( sliding) of the blocks occurs until either of the slower two fronts traverses the entire interface.	Hebrew Univ Jerusalem, Racah Inst Phys, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Fineberg, J (corresponding author), Hebrew Univ Jerusalem, Racah Inst Phys, IL-91904 Jerusalem, Israel.	jay@vms.huji.ac.il		Fineberg, Jay/0000-0002-8381-6675				ANDREWS DJ, 1976, J GEOPHYS RES, V81, P5679, DOI 10.1029/JB081i032p05679; Andrews DJ, 1997, J GEOPHYS RES-SOL EA, V102, P553, DOI 10.1029/96JB02856; Anooshehpoor A, 1999, GEOPHYS RES LETT, V26, P2025, DOI 10.1029/1999GL900397; Baumberger T, 1999, PHYS REV B, V60, P3928, DOI 10.1103/PhysRevB.60.3928; Baumberger T, 2003, EUR PHYS J E, V11, P85, DOI 10.1140/epje/i2003-10009-7; Ben-Zion Y, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000254; Ben-Zion Y, 2001, J MECH PHYS SOLIDS, V49, P2209, DOI 10.1016/S0022-5096(01)00036-9; BERSSON BNJ, 2000, SLIDING FRICTION PHY; Bodin P, 1998, J GEOPHYS RES-SOL EA, V103, P29931, DOI 10.1029/98JB02733; Bouchon M, 2001, GEOPHYS RES LETT, V28, P2723, DOI 10.1029/2001GL013112; Bowden F, 2001, AM J PHYS, DOI DOI 10.1119/1.1933017; Ciliberto S, 1999, EUR PHYS J B, V9, P551, DOI 10.1007/s100510050795; Cochard A, 2000, J GEOPHYS RES-SOL EA, V105, P25891, DOI 10.1029/2000JB900230; Crescentini L, 1999, SCIENCE, V286, P2132, DOI 10.1126/science.286.5447.2132; DIETERICH JH, 1994, PURE APPL GEOPHYS, V143, P283, DOI 10.1007/BF00874332; FREUND LB, 1979, J GEOPHYS RES, V84, P2199, DOI 10.1029/JB084iB05p02199; Gao HJ, 2001, J MECH PHYS SOLIDS, V49, P2113, DOI 10.1016/S0022-5096(01)00032-1; Gerde E, 2001, NATURE, V413, P285, DOI 10.1038/35095018; HEATON TH, 1990, PHYS EARTH PLANET IN, V64, P1, DOI 10.1016/0031-9201(90)90002-F; Kanamori H, 1998, SCIENCE, V279, P839, DOI 10.1126/science.279.5352.839; KILGORE BD, 1993, GEOPHYS RES LETT, V20, P903, DOI 10.1029/93GL00368; Linde AT, 2002, EARTH PLANET SC LETT, V203, P265, DOI 10.1016/S0012-821X(02)00849-X; Muser MH, 2001, PHYS REV LETT, V86, P1295, DOI 10.1103/PhysRevLett.86.1295; Ohnaka M, 1999, J GEOPHYS RES-SOL EA, V104, P817, DOI 10.1029/1998JB900007; Rice JR, 2001, J MECH PHYS SOLIDS, V49, P1865, DOI 10.1016/S0022-5096(01)00042-4; RICE JR, 1983, J APPL MECH-T ASME, V50, P343, DOI 10.1115/1.3167042; Rogers G, 2003, SCIENCE, V300, P1942, DOI 10.1126/science.1084783; Rosakis AJ, 1999, SCIENCE, V284, P1337, DOI 10.1126/science.284.5418.1337; Scholz CH, 1998, NATURE, V391, P37, DOI 10.1038/34097; Xia KW, 2004, SCIENCE, V303, P1859, DOI 10.1126/science.1094022	30	290	294	8	103	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2004	430	7003					1005	1009		10.1038/nature02830	http://dx.doi.org/10.1038/nature02830			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329715				2022-12-28	WOS:000223514900037
J	Kalisz, S; Vogler, DW; Hanley, KM				Kalisz, S; Vogler, DW; Hanley, KM			Context-dependent autonomous self-fertilization yields reproductive assurance and mixed mating	NATURE			English	Article							INBREEDING DEPRESSION; CROSS-FERTILIZATION; EVOLUTION; PLANTS; POLLINATION; ECOLOGY; SYSTEMS; COST	The evolution of self-fertilization in hermaphrodites is opposed by costs that decrease the value of self progeny relative to that of outcross progeny1-3. However, self-fertilization is common in plants(4); 20% are highly selfing and 33% are intermediate between selfing and outcrossing(5). Darwin(6) proposed an adaptive benefit of self-pollination in providing reproductive assurance when outcrossing is impossible(6-9). Moreover, if outcross pollen receipt is inconsistent within or between years, these conditions likewise favour self-pollination(10), and this can result in a mixture of self and outcross seed production ( mixed mating). Despite wide acceptance, the reproductive assurance hypothesis has lacked the support of complete empirical evidence to show that variable pollination can create both the ecological and genetic conditions favouring self-pollination. We recently showed in Collinsia verna that during periods of infrequent pollinator visits, autonomous self-pollination boosted seed output per flower(11), the key ecological condition. Here we show low inbreeding depression and marker-based estimates of selfing, demonstrating that when the pollination environment in wild populations necessitates reproductive assurance, selfing rates increase. We provide a complete demonstration of reproductive assurance under variable pollination environments and mechanistically link reproductive assurance to intermediate selfing rates through mixed mating.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; SUNY Coll Oneonta, Dept Biol, Oneonta, NY 13820 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University of New York (SUNY) System	Kalisz, S (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.	kalisz@pitt.edu						BAKER HG, 1955, EVOLUTION, V9, P347, DOI 10.2307/2405656; Barrett SCH, 2002, NAT REV GENET, V3, P274, DOI 10.1038/nrg776; Barrett SCH, 1996, PHILOS T R SOC B, V351, P1271, DOI 10.1098/rstb.1996.0110; Barrett SCH, 2003, PHILOS T R SOC B, V358, P991, DOI 10.1098/rstb.2003.1301; BURD M, 1994, BOT REV, V60, P83, DOI 10.1007/BF02856594; Byers DL, 1999, ANNU REV ECOL SYST, V30, P479, DOI 10.1146/annurev.ecolsys.30.1.479; Cruden R.W., 1989, EVOLUTIONARY ECOLOGY, P171; Darwin C. R., 1876, EFFECTS CROSS SELF F; Fausto JA, 2001, AM J BOT, V88, P1794, DOI 10.2307/3558355; Fisher RA, 1941, ANN EUGENIC, V11, P53, DOI 10.1111/j.1469-1809.1941.tb02272.x; HARDER LD, 1995, NATURE, V373, P512, DOI 10.1038/373512a0; Herlihy CR, 2002, NATURE, V416, P320, DOI 10.1038/416320a; HOLSINGER KE, 1991, TRENDS ECOL EVOL, V6, P307, DOI 10.1016/0169-5347(91)90033-T; HOLSINGER KE, 1991, AM NAT, V138, P606, DOI 10.1086/285237; Holsinger KE, 2000, P NATL ACAD SCI USA, V97, P7037, DOI 10.1073/pnas.97.13.7037; Husband BC, 1996, EVOLUTION, V50, P54, DOI [10.1111/j.1558-5646.1996.tb04472.x, 10.2307/2410780]; JARNE P, 1993, ANNU REV ECOL SYST, V24, P441, DOI 10.1146/annurev.es.24.110193.002301; Johnston MO, 1998, GENETICA, V102-3, P267, DOI 10.1023/A:1017039010191; KALISZ S, 1989, EVOLUTION, V43, P1263, DOI 10.1111/j.1558-5646.1989.tb02573.x; Kalisz S, 2003, ECOLOGY, V84, P2928, DOI 10.1890/02-0519; Kalisz S, 1999, AM J BOT, V86, P1239, DOI 10.2307/2656771; LANDE R, 1985, EVOLUTION, V39, P24, DOI [10.2307/2408514, 10.1111/j.1558-5646.1985.tb04077.x]; LLOYD DG, 1992, INT J PLANT SCI, V153, P370, DOI 10.1086/297041; LLOYD DG, 1992, INT J PLANT SCI, V153, P358, DOI 10.1086/297040; Ritland K., MULTILOCUS MATING SY; Schoen DJ, 1996, PHILOS T R SOC B, V351, P1281, DOI 10.1098/rstb.1996.0111; SCHOEN DJ, 1992, INT J PLANT SCI, V153, P381, DOI 10.1086/297042; SCHOEN DJ, 1991, EVOLUTION, V45, P1651, DOI [10.1111/j.1558-5646.1991.tb02670.x, 10.2307/2409786]; Stebbins G.L., 1974, FLOWERING PLANTS EVO, DOI 10.4159/harvard.9780674864856; Vogler DW, 2001, EVOLUTION, V55, P202, DOI 10.1111/j.0014-3820.2001.tb01285.x	30	327	349	2	92	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					884	887		10.1038/nature02776	http://dx.doi.org/10.1038/nature02776			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318220				2022-12-28	WOS:000223369800040
J	Lubinski, SM; Hendrix, T				Lubinski, SM; Hendrix, T			VIPoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Johns Hopkins Univ, Baltimore, MD 21287 USA	Johns Hopkins University	Lubinski, SM (corresponding author), Johns Hopkins Univ, Baltimore, MD 21287 USA.								0	2	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2004	351	8					808	808		10.1056/NEJMicm960440	http://dx.doi.org/10.1056/NEJMicm960440			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847CY	15317894				2022-12-28	WOS:000223367900013
J	Dimick, JB; Welch, HG; Birkmeyer, JD				Dimick, JB; Welch, HG; Birkmeyer, JD			Surgical mortality as an indicator of hospital quality - The problem with small sample size	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context Surgical mortality rates are increasingly used to measure hospital quality. It is not clear, however, how many hospitals have sufficient caseloads to reliably identify quality problems. Objective To determine whether the 7 operations for which mortality has been advocated as a quality indicator by the Agency for Healthcare Research and Quality (coronary artery bypass graft [CABG] surgery, repair of abdominal aortic aneurysm, pancreatic resection, esophageal resection, pediatric heart surgery, craniotomy, hip replacement) are performed frequently enough to reliably identify hospitals with increased mortality rates. Design and Setting The US national average mortality rates and hospital caseloads of the 7 operations were determined using the 2000 Nationwide Inpatient Sample (NIS), and sample size calculations were performed to determine the minimum case-load necessary to reliably detect increased mortality rates in poorly performing hospitals. A 3-year hospital caseload was used for the baseline analysis, and poor performance was defined as a mortality rate double the national average. Main Outcome Measure Proportion of hospitals in the United States that performed more than the minimum caseload for each operation. Results The national average mortality rates for the 7 procedures examined ranged from 0.3% for hip replacement to 10.7% for craniotomy. Minimum hospital caseloads necessary to detect a doubling of the mortality rate were 64 cases for craniotomy, 77 for esophageal resection, 86 for pancreatic resection, 138 for pediatric heart surgery, 195 for repair of abdominal aortic aneurysm, 219 for CABG surgery, and 2668 for hip replacement. For only 1 operation did the majority of hospitals exceed the minimum caseload, with 90% of hospitals performing CABG surgery having a caseload of 219 or higher. For the remaining operations, only a small proportion of hospitals met the minimum caseload: craniotomy (33%), pediatric heart surgery (25%), repair of abdominal aortic aneurysm (8%), pancreatic resection (2%), esophageal resection (1%), and hip replacement (<1%). Conclusion Except for CABG surgery, the operations for which surgical mortality has been advocated as a quality indicator are not performed frequently enough to judge hospital quality.	Dept Vet Affairs Med Ctr, VA Outcomes Grp 111B, White River Jct, VT 05009 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Ctr Evaluat Clin Sci, Hanover, NH 03756 USA; Univ Michigan, Med Ctr, Dept Surg, Michigan Surg Collaborat Outcomes Res & Evaluat, Ann Arbor, MI 48109 USA	VA Outcomes Group; Dartmouth College; University of Michigan System; University of Michigan	Dimick, JB (corresponding author), Dept Vet Affairs Med Ctr, VA Outcomes Grp 111B, 215 N Main St, White River Jct, VT 05009 USA.	justin.b.dimick@dartmouth.edu						Agency for healthcare research and quality, 2002, AHRQ PUBL, V02-EO16; Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; *HEALTHC COST UT P, 2000, NAT INP SAMPL REL 9; Khuri SF, 2002, ARCH SURG-CHICAGO, V137, P20, DOI 10.1001/archsurg.137.1.20; Milstein A, 2000, Eff Clin Pract, V3, P313; *NJ DEP HLTH SEN S, 1997, COR ART BYP GRAFT SU; *NY STAT DEP HLTH, 1992, COR ART BYP SURG NEW; *PA HLTH CAR COST, 1991, CONS GUID COR ART BY; *PAC BUS GROUP HLT, 2001, CAL REP COR ART BYP; *PHS US DEP HHS, 1988, INT CLASS DIS 9 REV	11	372	374	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2004	292	7					847	851		10.1001/jama.292.7.847	http://dx.doi.org/10.1001/jama.292.7.847			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847FO	15315999	Bronze			2022-12-28	WOS:000223378300025
J	Heinrich, AJ; Gupta, JA; Lutz, CP; Eigler, DM				Heinrich, AJ; Gupta, JA; Lutz, CP; Eigler, DM			Single-atom spin-flip spectroscopy	SCIENCE			English	Article							BIAS TUNNELING ANOMALIES; MAGNETIC-FIELD; KONDO RESONANCE; SCATTERING; MICROSCOPY; JUNCTIONS; STATES; MODEL	We demonstrate the ability to measure the energy required to flip the spin of single adsorbed atoms. A low-temperature, high-magnetic field. scanning tunneling microscope was used to measure the spin excitation spectra of individual manganese atoms adsorbed on Al2O3 islands on a NiAl surface. We find pronounced variations of the spin-flip spectra for manganese atoms in different local environments.	IBM Corp, Almaden Res Ctr, Div Res, San Jose, CA 95120 USA	International Business Machines (IBM)	Heinrich, AJ (corresponding author), IBM Corp, Almaden Res Ctr, Div Res, 650 Harry Rd, San Jose, CA 95120 USA.	heinrich@almaden.ibm.com	Gupta, Jay/AGK-0162-2022	Gupta, Jay/0000-0002-3908-7719				ANDERSON PW, 1966, PHYS REV LETT, V17, P95, DOI 10.1103/PhysRevLett.17.95; APPELBAUM JA, 1967, PHYS REV, V154, P633, DOI 10.1103/PhysRev.154.633; BERMON S, 1978, PHYS REV B, V17, P2110, DOI 10.1103/PhysRevB.17.2110; Durkan C, 2002, APPL PHYS LETT, V80, P458, DOI 10.1063/1.1434301; GREGORY S, 1992, PHYS REV LETT, V68, P2070, DOI 10.1103/PhysRevLett.68.2070; Hansma P. K., 1982, TUNNELING SPECTROSCO; Heinrich AJ, 2002, SCIENCE, V298, P1381, DOI 10.1126/science.1076768; Heinze S, 2000, SCIENCE, V288, P1805, DOI 10.1126/science.288.5472.1805; Knorr N, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.096804; Kulawik M, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.256101; Li JT, 1998, PHYS REV LETT, V80, P2893, DOI 10.1103/PhysRevLett.80.2893; Liang WJ, 2002, NATURE, V417, P725, DOI 10.1038/nature00790; Madhavan V, 1998, SCIENCE, V280, P567, DOI 10.1126/science.280.5363.567; MANASSEN Y, 1989, PHYS REV LETT, V62, P2531, DOI 10.1103/PhysRevLett.62.2531; Nagaoka K, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.077205; Nilius N, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.046808; Park J, 2002, NATURE, V417, P722, DOI 10.1038/nature00791; RALPH DC, 1994, PHYS REV LETT, V72, P3401, DOI 10.1103/PhysRevLett.72.3401; Rosch A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.076804; SHEN LYL, 1968, PHYS REV, V165, P566, DOI 10.1103/PhysRev.165.566; Song Z, 2001, SURF SCI, V491, P39, DOI 10.1016/S0039-6028(01)01434-0; Stierle A, 2004, SCIENCE, V303, P1652, DOI 10.1126/science.1094060; Stipe BC, 1998, SCIENCE, V280, P1732, DOI 10.1126/science.280.5370.1732; WALLIS RH, 1974, J PHYS C SOLID STATE, V7, P1293, DOI 10.1088/0022-3719/7/7/022; WYATT AFG, 1964, PHYS REV LETT, V13, P401, DOI 10.1103/PhysRevLett.13.401	25	528	532	6	191	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	2004	306	5695					466	469		10.1126/science.1101077	http://dx.doi.org/10.1126/science.1101077			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	864IF	15358866				2022-12-28	WOS:000224626500046
J	Scott, MP; Lawrence, PA				Scott, MP; Lawrence, PA			Obituary - Edward B. Lewis (1918-2004)	NATURE			English	Biographical-Item									Stanford Univ, Sch Med, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Bioengn, Howard Hughes Med Inst, Stanford, CA 94305 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; MRC Laboratory Molecular Biology	Scott, MP (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA.	scott@pmgm2.stanford.edu; pal@mrc-lmb.cam.ac.uk			Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)			0	0	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	2004	431	7005					143	143		10.1038/431143a	http://dx.doi.org/10.1038/431143a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356617	Bronze			2022-12-28	WOS:000223746000026
J	Rao, BL; Basu, A; Wairagkar, NS; Gore, MM; Arankalle, VA; Thakare, JP; Jadi, RS; Rao, KA; Mishra, AC				Rao, BL; Basu, A; Wairagkar, NS; Gore, MM; Arankalle, VA; Thakare, JP; Jadi, RS; Rao, KA; Mishra, AC			A large outbreak of acute encephalitis with high fatality rate in children in Andhra Pradesh, India, in 2003, associated with Chandipura virus	LANCET			English	Article							FEBRILE ILLNESS; ASSAY; TRANSMISSION; ANIMALS; PCR	Background An outbreak of acute encephalitis of unknown origin with high case fatality (183 of 329 cases) was reported in children from Andhra Pradesh state in southern India during 2003. We investigated the causative agent. Methods Cell lines and peripheral blood lymphocyte co-cultures were used to isolate the causative agent from clinical samples. Identity of the agent was established by electron microscopy and serological and molecular assays. Findings Clinical samples tested negative for IgM antibodies to Japanese encephalitis, West Nile, dengue, and measles viruses, and for RNA of coronavirus, paramyxovirus, enterovirus, and influenza viruses. Virus was isolated from six patients with encephalitis and was identified as Chandipura virus by electron microscopy, complement fixation, and neutralisation tests. Chandipura virus RNA was detected in clinical samples from nine patients. Sequencing of five of these RNA samples showed 96.7-97.5% identity with the reference strain of 1965. Chandipura viral antigen and RNA were detected in brain tissue of a deceased child by immunofluorescent antibody test and PCR. Neutralising, IgG, and IgM antibodies to Chandipura virus were present in some patients' serum samples. Serum samples obtained after 4 days of illness were more frequently positive for IgM to Chandipura virus than were those obtained earlier (p<0.001). A similar trend was noted for neutralising antibodies. Interpretation Our findings suggest that this outbreak of acute encephalitis in Andhra Pradesh was associated with Chandipura virus, adding to the evidence suggesting that this virus should be considered as an important emerging pathogen.	Natl Inst Virol, Pune 411001, Maharashtra, India; Karimnagar Dist Hosp, Karimnagar, Andhra Pradesh, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Virology (NIV)	Mishra, AC (corresponding author), Natl Inst Virol, 20A Dr Ambedkar Rd, Pune 411001, Maharashtra, India.	acm1750@rediffmail.com	Jadi, Ramesh/AAV-2059-2020	Jadi, Ramesh/0000-0002-5710-4893; Arankalle, Vidya/0000-0002-9940-3437				BANERJEE K, 1984, VIRUS ECOLOGY, P109; BHATT PN, 1967, INDIAN J MED RES, V55, P1295; Chua KB, 2000, SCIENCE, V288, P1432, DOI 10.1126/science.288.5470.1432; de Mattos C, 2001, FIELDS VIROLOGY, P1245; DHANDA V, 1970, INDIAN J MED RES, V58, P179; GORE MM, 1985, INDIAN J MED RES, V81, P343; ILKAL MA, 1991, ACTA VIROL, V35, P27, DOI 10.1016/0166-0934(91)90082-B; John T Jacob, 2003, Indian Pediatr, V40, P863; KELKAR SD, 1976, INDIAN J MED RES, V64, P814; KEMP GE, 1975, B WORLD HEALTH ORGAN, V52, P615; KUMAR S, 2001, MEGA2 1 MOL EVOLUTIO; NAJIB KHAN, 1954, Indian Journal of Medical Sciences, V8, P597; NERURKAR LS, 1984, J CLIN MICROBIOL, V20, P109, DOI 10.1128/JCM.20.1.109-114.1984; Poddar SK, 2002, J CLIN LAB ANAL, V16, P163, DOI 10.1002/jcla.10036; RAO TR, 1967, INDIAN J MED RES, V55, P1306; Read SJ, 1999, J CLIN MICROBIOL, V37, P1352, DOI 10.1128/JCM.37.5.1352-1355.1999; RODRIGUE.FM, 1972, B WORLD HEALTH ORGAN, V46, P173; RODRIGUES FM, 1984, INDIAN J MED RES S, P1; RODRIGUES JJ, 1983, INDIAN J MED RES, V77, P303; SEVER JL, 1962, J IMMUNOL, V88, P320; Stephensen CB, 1999, VIRUS RES, V60, P181, DOI 10.1016/S0168-1702(99)00017-9; TESH RB, 1993, AM J TROP MED HYG, V32, P621; Traore-Lamizana M, 2001, J MED ENTOMOL, V38, P480, DOI 10.1603/0022-2585-38.4.480	23	131	142	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2004	364	9437					869	874		10.1016/S0140-6736(04)16982-1	http://dx.doi.org/10.1016/S0140-6736(04)16982-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351194	Green Published, Bronze			2022-12-28	WOS:000223685200033
J	Jahan, R; Germain, A				Jahan, R; Germain, A			Mobilising support to sustain political will is the key to progress in reproductive health	LANCET			English	Editorial Material									Int Womens Hlth Coalit, New York, NY 10010 USA; Columbia Univ, Sch Int & Publ Affairs, New York, NY USA	Columbia University	Germain, A (corresponding author), Int Womens Hlth Coalit, New York, NY 10010 USA.	shornik@iwhc.org						AHMED N, 2003, HLTH POLICY RES S AS, V14, P369; *GOV BANGL, 1997, BANGL HLTH POP SECT; *ICDDR B, 2000, INV STAK HLTH POP SE; Jahan R, 2003, REPROD HEALTH MATTER, V11, P183, DOI 10.1016/S0968-8080(03)02173-6; Ministry of Health and Family Welfare Government of Bangladesh, 1998, HLTH POP SECT PROGR; STREATFIELD PK, 2003, HPSP 1998 2003 BANGL; *WHO, 2004, REPR HLTH REP SECR	7	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	2004	364	9436					742	744		10.1016/S0140-6736(04)16954-7	http://dx.doi.org/10.1016/S0140-6736(04)16954-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337389				2022-12-28	WOS:000223569600010
J	Jaffe, H				Jaffe, H			Whatever happened to the US AIDS epidemic?	SCIENCE			English	Editorial Material							HIV; MEN		Univ Oxford, Dept Publ Hlth, Oxford OX3 7LF, England	University of Oxford	Jaffe, H (corresponding author), Univ Oxford, Dept Publ Hlth, Old Rd Campus, Oxford OX3 7LF, England.	harold.jaffe@dphpc.ox.ac.uk						Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; BOZZETTE SA, 2003, NEW ENGL J MED, V344, P817; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; *CDC, 2003, MMWR-MORBID MORTAL W, V52, P329; *CDCP, 2002, CAS HIV INF AIDS US; *CDCP, FACT SHEET PUBLIC HL; Centers for Disease Control and Prevention, UNPUB; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P1229; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1013; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1051; FLEMING PL, 2002, 9 C RETR OPP INF SEA; *KAIS FAM FDN, 2004, SURV AM HIV AIDS 1; KAMIMOTO L, 2004, 11 C RETR OPP INF SA; LYTER DW, 1987, PUBLIC HEALTH REP, V102, P468; MECKLER L, 2002, WASHINGTON POST 0123, pA15; Montgomery JP, 2003, AIDS CARE, V15, P829, DOI 10.1080/09540120310001618676; Stoneburner RL, 2004, SCIENCE, V304, P714, DOI 10.1126/science.1093166; American Medical Association, 2004, MMWR Recomm Rep, V53, P1; Urbina A, 2004, CLIN INFECT DIS, V38, P890, DOI 10.1086/381975; *US BUR JUST, US DEP JUST BUR JUST; Valdiserri RO, 2004, AIDS EDUC PREV, V16, P426, DOI 10.1521/aeap.16.5.426.48738; *WASH POST KAIS FA, 2002, NAT SURV PUBL ATT HI; WATTERS JK, 1994, JAMA-J AM MED ASSOC, V271, P115, DOI 10.1001/jama.271.2.115	23	25	26	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2004	305	5688					1243	1244		10.1126/science.1101136	http://dx.doi.org/10.1126/science.1101136			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850PJ	15333825				2022-12-28	WOS:000223624600025
J	Leonard, MB; Feldman, HI; Shults, J; Zemel, BS; Foster, BJ; Stallings, VA				Leonard, MB; Feldman, HI; Shults, J; Zemel, BS; Foster, BJ; Stallings, VA			Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							X-RAY ABSORPTIOMETRY; GLOMERULAR-FILTRATION RATE; CHILDREN; DENSITY; DISEASE; OSTEOPENIA; FRACTURES; GROWTH; RISK; OSTEOPOROSIS	BACKGROUND: Glucocorticoids suppress bone formation, impair growth, and induce obesity. We determined the effects of long-term treatment with glucocorticoids on bone mineral content in children with glucocorticoid-sensitive nephrotic syndrome, a disorder with minimal known independent effects on bone. METHODS: We performed dual-energy x-ray absorptiometry of the whole body and spine in 60 children and adolescents with the nephrotic syndrome and 195 control subjects. We used linear regression analysis of log-transformed values to compare the bone mineral content in patients with that in controls. RESULTS: Patients had received an average of 23,000 mg of glucocorticoids and were shorter (P=0.008) and had a greater body-mass index (P<0.001) than controls. The bone mineral content of the spine, adjusted for bone area, age, sex, degree of maturation (Tanner stage), and race, did not differ significantly between patients and controls (ratio, 0.99; 95 percent confidence interval, 0.96 to 1.02; P=0.51). After adjustment for the z score for body-mass index, the bone mineral content of the spine was significantly lower in patients than in controls (0.96; 95 percent confidence interval, 0.92 to 0.99; P=0.01). Whole-body bone mineral content, adjusted for height, age, sex, degree of maturation, and race, was significantly higher in patients than in controls (ratio, 1.11; 95 percent confidence interval, 1.05 to 1.18; P<0.001); however, the addition of the z score for body-mass index to the model eliminated the association with the nephrotic syndrome (ratio, 0.99; 95 percent confidence interval, 0.94 to 1.03; P=0.55). CONCLUSIONS: Intermittent treatment with high-dose glucocorticoids during growth does not appear to be associated with deficits in the bone mineral content of the spine or whole body relative to age, bone size, sex, and degree of maturation. Glucocorticoid-induced increases in body-mass index were associated with increased whole-body bone mineral content and maintenance of the bone mineral content of the spine.	Childrens Hosp Philadelphia, Dept Pediat, CHOP N, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Leonard, MB (corresponding author), Childrens Hosp Philadelphia, Dept Pediat, CHOP N, Rm 1564, Philadelphia, PA 19104 USA.	leonard@email.chop.edu	Zemel, Babette S./D-1117-2009	Zemel, Babette S./0000-0002-6164-7348	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK058200, K08DK002523, T32DK007785] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00240] Funding Source: Medline; NIDDK NIH HHS [T32 DK007785, 1-R03-DK058200, K08-DK02523] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhudhikanok GS, 1996, PEDIATRICS, V97, P103; Boot AM, 1998, GUT, V42, P188, DOI 10.1136/gut.42.2.188; BRODEHL J, 1991, EUR J PEDIATR, V150, P380, DOI 10.1007/BF02093714; Canalis E, 2002, J PEDIATR ENDOCR MET, V15, P1341; CARTER DR, 1992, J BONE MINER RES, V7, P137; Daniel V, 1997, CLIN NEPHROL, V47, P289; Ellis KJ, 2001, J BONE MINER RES, V16, P1658, DOI 10.1359/jbmr.2001.16.9.1658; Ferraris JR, 2000, PEDIATR NEPHROL, V14, P682, DOI 10.1007/s004670000337; Freundlich M, 2004, PEDIATR NEPHROL, V19, P400, DOI 10.1007/s00467-003-1378-8; FREUNDLICH M, 1985, PEDIATRICS, V76, P280; Gafni RI, 2004, J PEDIATR-US, V144, P253, DOI 10.1016/j.jpeds.2003.08.054; Gafni RI, 2002, FASEB J, V16, P736, DOI 10.1096/fj.01-0640fje; Goulding A, 1998, J BONE MINER RES, V13, P143, DOI 10.1359/jbmr.1998.13.1.143; GRYMONPREZ A, 1995, PEDIATR NEPHROL, V9, P278, DOI 10.1007/BF02254183; Gulati S, 2003, AM J KIDNEY DIS, V41, P1163, DOI 10.1016/S0272-6386(03)00348-2; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Krebs NF, 2003, PEDIATRICS, V112, P424, DOI 10.1542/peds.112.2.424; LAAN RF, 1994, ANN INTERN MED, V119, P963; Landin LA, 1997, J PEDIATR ORTHOP B, V6, P79, DOI 10.1097/01202412-199704000-00002; Leonard MB, 1998, J BONE MINER RES, V13, P1687, DOI 10.1359/jbmr.1998.13.11.1687; Leonard MB, 2004, BONE, V34, P1044, DOI 10.1016/j.bone.2003.12.003; Leonard MB, 2004, AM J CLIN NUTR, V80, P514, DOI 10.1093/ajcn/80.2.514; Leonard MB, 2002, PEDIATR CLIN N AM, V49, P143, DOI 10.1016/S0031-3955(03)00113-5; Leonard MB, 1999, J PEDIATR-US, V135, P182, DOI 10.1016/S0022-3476(99)70020-X; Lien G, 2003, ARTHRITIS RHEUM-US, V48, P2214, DOI 10.1002/art.11097; Ma DQ, 2003, J BONE MINER RES, V18, P1970, DOI 10.1359/jbmr.2003.18.11.1970; Ogden CL, 2002, PEDIATRICS, V109, P45, DOI 10.1542/peds.109.1.45; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Parfitt AM, 1996, J BONE MINER RES, V11, P150; Petit MA, 2002, J BONE MINER RES, V17, P363, DOI 10.1359/jbmr.2002.17.3.363; PRENTICE A, 1994, AM J CLIN NUTR, V60, P837; SCHWARTZ GJ, 1984, J PEDIATR-US, V104, P849, DOI 10.1016/S0022-3476(84)80479-5; Seeman E, 1997, J BONE MINER RES, V12, P509, DOI 10.1359/jbmr.1997.12.4.509; Stewart WA, 2003, ARTHRITIS RHEUM, V48, P2294, DOI 10.1002/art.11211; Tanner JM, 1962, GROWTH ADOLESCENCE, V2nd; Taylor A, 1997, J BONE MINER RES, V12, P652, DOI 10.1359/jbmr.1997.12.4.652; van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108; Van Staa TP, 2003, J BONE MINER RES, V18, P913, DOI 10.1359/jbmr.2003.18.5.913; 1981, J PEDIAT, V98, P561	39	144	152	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2004	351	9					868	875		10.1056/NEJMoa040367	http://dx.doi.org/10.1056/NEJMoa040367			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849BM	15329424				2022-12-28	WOS:000223512500008
J	Schlossmacher, MG; Hamann, C; Cole, AG; Gonzalez, RG; Frosch, MP				Schlossmacher, MG; Hamann, C; Cole, AG; Gonzalez, RG; Frosch, MP			A 79-year-old woman with disturbances in gait, cognition, and autonomic function - Multiple-system atrophy. Cerebral arteriolar sclerosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							GLIAL CYTOPLASMIC INCLUSIONS; ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; STRIATONIGRAL DEGENERATION; ALZHEIMERS-DISEASE; DEMENTIA; MUTATION		Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Geriatr Med Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Div Neuropathol, Boston, MA 02114 USA; MetroW Med Ctr, Dept Med, Natick, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Schlossmacher, MG (corresponding author), Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.		Frosch, Matthew P/ABD-7456-2021	Frosch, Matthew P/0000-0002-3940-9861; Schlossmacher, Michael/0000-0002-0394-0300				Bendszus M, 2001, AM J NEURORADIOL, V22, P1926; Billings JA, 2000, BMJ-BRIT MED J, V321, P555, DOI 10.1136/bmj.321.7260.555; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; CLARKE C, 2002, CLIN EVIDENCE CONCIS, V8, P264; Dichgans M, 2002, J NEUROL SCI, V203, P77, DOI 10.1016/S0022-510X(02)00270-8; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Duda JE, 2000, J NEUROPATH EXP NEUR, V59, P830, DOI 10.1093/jnen/59.9.830; Eustice S, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.cd002113, DOI 10.1002/14651858.CD002113]; Filley CM, 2001, NEW ENGL J MED, V345, P425, DOI 10.1056/NEJM200108093450606; Gai WP, 2003, EXP NEUROL, V181, P68, DOI 10.1016/S0014-4886(03)00004-9; GILLESPIE LD, 2001, COCHRANE DB SYST REV, V3; Gilman S, 1999, J NEUROL SCI, V163, P94, DOI 10.1016/S0022-510X(98)00304-9; Gilman S, 2003, NEUROLOGY, V61, P29, DOI 10.1212/01.WNL.0000073745.68744.94; Golbe LI, 2004, ANN NEUROL, V55, P153, DOI 10.1002/ana.20036; Ham RJ, 1999, ALZ DIS ASSOC DIS, V13, pS27, DOI 10.1097/00002093-199911002-00005; Herrmann N, 2002, CAN J PSYCHIAT, V47, P715, DOI 10.1177/070674370204700802; Hijdra Albert, 1996, P1602; Jozefowicz-Korczynska Magdalena, 1994, Materia Medica Polona, V26, P123; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Lang Anthony E., 1996, P299; Larson EB, 1998, AM J GERIAT PSYCHIAT, V6, pS34, DOI 10.1097/00019442-199821001-00005; Lee EA, 2002, MOVEMENT DISORD, V17, P1242, DOI 10.1002/mds.10225; Longstreth WT, 2001, ARCH NEUROL-CHICAGO, V58, P635, DOI 10.1001/archneur.58.4.635; MARK MH, 1995, MOVEMENT DISORD, V10, P450, DOI 10.1002/mds.870100408; McCarthy Micheline, 1996, P1293; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; Mukamal KJ, 2003, JAMA-J AM MED ASSOC, V289, P1405, DOI 10.1001/jama.289.11.1405; O'Riordan S, 2002, NEUROLOGY, V59, P1108, DOI 10.1212/WNL.59.7.1108; Ozawa T, 1999, NEUROSCI LETT, V270, P110, DOI 10.1016/S0304-3940(99)00475-9; PAPP MI, 1994, BRAIN, V117, P235, DOI 10.1093/brain/117.2.235; PAPP MI, 1989, J NEUROL SCI, V94, P79, DOI 10.1016/0022-510X(89)90219-0; Pusey H, 2001, AGING MENT HEALTH, V5, P107, DOI 10.1080/13607860120038302; Seppi K, 2003, NEUROLOGY, V60, P922, DOI 10.1212/01.WNL.0000049911.91657.9D; So Yuen T., 1996, P1373; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Spruill SC, 2002, OBSTET GYNECOL, V99, P875, DOI 10.1016/S0029-7844(01)01603-9; Trojanowski JQ, 2002, NEUROTOXICOLOGY, V23, P457, DOI 10.1016/S0161-813X(02)00065-7; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; VICTOR M, 1993, NEUROL CLIN, V11, P639, DOI 10.1016/S0733-8619(18)30144-0; Volicer L, 1998, HOSPICE CARE PATIENT; Wenning GK, 2002, J NEURAL TRANSM, V109, P307, DOI 10.1007/s007020200025; Wenning GK, 1999, MOVEMENT DISORD, V14, P947, DOI 10.1002/1531-8257(199911)14:6<947::AID-MDS1006>3.0.CO;2-O	42	5	5	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2004	351	9					912	922		10.1056/NEJMcpc049018	http://dx.doi.org/10.1056/NEJMcpc049018			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849BM	15329430				2022-12-28	WOS:000223512500015
J	Topol, EJ; Falk, GW				Topol, EJ; Falk, GW			A coxib a day won't keep the doctor away	LANCET			English	Editorial Material							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GASTROINTESTINAL TOXICITY; RHEUMATOID-ARTHRITIS; INHIBITORS; COX-2; RISK; CELECOXIB; DISEASE; TRIAL; OSTEOARTHRITIS		Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Gastroenterol & Hepatol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Topol, EJ (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	TOPOLE@ccf.org		Falk, Gary/0000-0002-7143-1436; Topol, Eric/0000-0002-1478-4729				Bogaty P, 2004, CIRCULATION, V110, P934, DOI 10.1161/01.CIR.0000139338.12464.5F; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Chan FKL, 2002, NEW ENGL J MED, V347, P2104, DOI 10.1056/NEJMoa021907; Chenevard R, 2003, CIRCULATION, V107, P405, DOI 10.1161/01.CIR.0000051361.69808.3A; Cipollone F, 2004, ARTERIOSCL THROM VAS, V24, P246, DOI 10.1161/01.ATV.0000104005.92603.f2; FitzGerald G, 2003, NAT REV DRUG DISCOV, V2, P879, DOI 10.1038/nrd1225; Hawkey CJ, 2004, ALIMENT PHARM THER, V20, P51, DOI 10.1111/j.1365-2036.2004.02026.x; Howard PA, 2004, J AM COLL CARDIOL, V43, P519, DOI 10.1016/j.jacc.2003.09.043; Juni P, 2002, BRIT MED J, V324, P1287, DOI 10.1136/bmj.324.7349.1287; Mamdani M, 2004, BRIT MED J, V328, P1415, DOI 10.1136/bmj.38068.716262.F7; Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140-6736(04)16299-5; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Ott E, 2003, J THORAC CARDIOV SUR, V125, P1481, DOI 10.1016/S0022-5223(03)00125-9; Ray WA, 2002, LANCET, V359, P118, DOI 10.1016/S0140-6736(02)07370-1; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Solomon DH, 2004, CIRCULATION, V109, P2068, DOI 10.1161/01.CIR.0000127578.21885.3E; Spiegel BMR, 2003, ANN INTERN MED, V138, P795, DOI 10.7326/0003-4819-138-10-200305200-00007; Whelton A, 2002, AM J CARDIOL, V90, P959, DOI 10.1016/S0002-9149(02)02661-9	18	67	69	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	2004	364	9435					639	640		10.1016/S0140-6736(04)16906-7	http://dx.doi.org/10.1016/S0140-6736(04)16906-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325809				2022-12-28	WOS:000223428900003
J	Cristofanilli, M; Budd, GT; Ellis, MJ; Stopeck, A; Matera, J; Miller, MC; Reuben, JM; Doyle, GV; Allard, WJ; Terstappen, LWMM; Hayes, DF				Cristofanilli, M; Budd, GT; Ellis, MJ; Stopeck, A; Matera, J; Miller, MC; Reuben, JM; Doyle, GV; Allard, WJ; Terstappen, LWMM; Hayes, DF			Circulating tumor cells, disease progression, and survival in metastatic breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERIPHERAL-BLOOD; PROGNOSTIC FACTORS; CARCINOMA-CELLS; CARCINOCYTHEMIA; LEUKEMIA	BACKGROUND: We tested the hypothesis that the level of circulating tumor cells can predict survival in metastatic breast cancer. METHODS: In a prospective, multicenter study, we tested 177 patients with measurable metastatic breast cancer for levels of circulating tumor cells both before the patients were to start a new line of treatment and at the first follow-up visit. The progression of the disease or the response to treatment was determined with the use of standard imaging studies at the participating centers. RESULTS: Outcomes were assessed according to levels of circulating tumor cells at baseline, before the patients started a new treatment for metastatic disease. Patients in a training set with levels of circulating tumor cells equal to or higher than 5 per 7.5 ml of whole blood, as compared with the group with fewer than 5 circulating tumor cells per 7.5 ml, had a shorter median progression-free survival (2.7 months vs. 7.0 months, P<0.001) and shorter overall survival (10.1 months vs. >18 months, P<0.001). At the first follow-up visit after the initiation of therapy, this difference between the groups persisted (progression-free survival, 2.1 months vs. 7.0 months; P<0.001; overall survival, 8.2 months vs. >18 months; P<0.001), and the reduced proportion of patients (from 49 percent to 30 percent) in the group with an unfavorable prognosis suggested that there was a benefit from therapy. The multivariate Cox proportional-hazards regression showed that, of all the variables in the statistical model, the levels of circulating tumor cells at baseline and at the first follow-up visit were the most significant predictors of progression-free and overall survival. CONCLUSIONS: The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; Cleveland Clin, Cleveland, OH 44106 USA; Duke Univ, Durham, NC USA; Univ Arizona, Tucson, AZ USA; Immunicon, Huntingdon, PA USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Texas System; UTMD Anderson Cancer Center; Cleveland Clinic Foundation; Duke University; University of Arizona; University of Michigan System; University of Michigan	Cristofanilli, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, 1515 Holcombe Blvd,Box 424, Houston, TX 77030 USA.	mcristof@mdanderson.org	Hayes, Daniel/ABE-1129-2020; terstappen, leon/O-4923-2018	terstappen, leon/0000-0001-5944-3787				ALLARD WJ, IN PRESS CLIN CANC R; ALLARD WJ, 2003, P 39 ANN M AM SOC CL, V22, P851; Ashworth T. R, 1869, AUST MED J, V14, P146, DOI DOI 10.1038/SJ.BJC.6604218; CAREY RW, 1976, AM J MED, V60, P273, DOI 10.1016/0002-9343(76)90437-X; Ellis MJ, 2004, DIS BREAST, P1101; ENGELL H C, 1955, Acta Chir Scand Suppl, V201, P1; Fehm T, 2002, CLIN CANCER RES, V8, P2073; *FOOD DRUG ADM, 510K PREM NOT DAT PL; *FOOD DRUG ADM, 510K PREM NOT DAT BA; *FOOD DRUG ADM, 510K PREM NOT DAT PR; Gaforio JJ, 2003, INT J CANCER, V107, P984, DOI 10.1002/ijc.11479; GALLIVAN MVE, 1984, CANCER, V53, P1100, DOI 10.1002/1097-0142(19840301)53:5<1100::AID-CNCR2820530514>3.0.CO;2-K; Guller U, 2002, ANN SURG, V236, P768, DOI 10.1097/00000658-200212000-00009; HORTOBAGYI GN, 1983, J CLIN ONCOL, V1, P776, DOI 10.1200/JCO.1983.1.12.776; Kagan M, 2002, J CLIN LIGAND ASSAY, V25, P104; Kagan M, 2002, TUMOR MARKERS PHYSL, P495; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MORENO JG, 1992, CANCER RES, V52, P6110; MYEROWITZ RL, 1977, CANCER, V40, P3107, DOI 10.1002/1097-0142(197712)40:6<3107::AID-CNCR2820400653>3.0.CO;2-5; Racila E, 1998, P NATL ACAD SCI USA, V95, P4589, DOI 10.1073/pnas.95.8.4589; RAO C, 2002, P 93 ANN M AM ASS CA, V3, P734; Rodriguez-Salas N, 2000, ACTA CYTOL, V44, P237, DOI 10.1159/000326367; Seronie-Vivien S, 2001, ANN ONCOL, V12, P1019, DOI 10.1023/A:1011184706281; Sile CC, 1999, ARCH PATHOL LAB MED, V123, P426; SWENERTON KD, 1979, CANCER RES, V39, P1552; Terstappen LWMM, 2000, INT J ONCOL, V17, P573; YAM LT, 1987, ACTA CYTOL, V31, P68	27	3384	3598	10	574	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2004	351	8					781	791		10.1056/NEJMoa040766	http://dx.doi.org/10.1056/NEJMoa040766			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847CY	15317891				2022-12-28	WOS:000223367900010
J	Gregory, R				Gregory, R			The blind leading the sighted	NATURE			English	Editorial Material									Univ Bristol, Dept Expt Psychol, Bristol BS8 1TN, Avon, England	University of Bristol	Gregory, R (corresponding author), Univ Bristol, Dept Expt Psychol, Bristol BS8 1TN, Avon, England.								0	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2004	430	7002					836	836		10.1038/430836a	http://dx.doi.org/10.1038/430836a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318199	Bronze			2022-12-28	WOS:000223369800021
J	Haugan, T; Barnes, PN; Wheeler, R; Meisenkothen, F; Sumption, M				Haugan, T; Barnes, PN; Wheeler, R; Meisenkothen, F; Sumption, M			Addition of nanoparticle dispersions to enhance flux pinning of the YBa2Cu3O7-x superconductor	NATURE			English	Article							SELF-ORGANIZED GROWTH; COATED CONDUCTORS; RECENT PROGRESS; CURRENT-DENSITY; THIN-FILMS; FABRICATION; DEPOSITION; YBCO; SUPERLATTICES; SUBSTRATE	Following the discovery of type-II high-temperature superconductors in 1986 (refs 1, 2), work has proceeded to develop these materials for power applications. One of the problems, however, has been that magnetic flux is not completely expelled, but rather is contained within magnetic fluxons, whose motion prevents larger supercurrents. It is known that the critical current of these materials can be enhanced by incorporating a high density of extended defects to act as pinning centres for the fluxons(3,4). YBa2Cu3O7 (YBCO or 123) is the most promising material for such applications at higher temperatures ( liquid nitrogen) 3-13. Pinning is optimized when the size of the defects approaches the superconducting coherence length (similar to2-4 nm for YBCO at temperatures less than or equal to77 K) and when the areal number density of defects is of the order of (H/2) x 10(11) cm(-2), where H is the applied magnetic field in tesla(3,4). Such a high density has been difficult to achieve by material-processing methods that maintain a nanosize defect, except through irradiation(5). Here we report a method for achieving a dispersion of similar to8-nm-sized nanoparticles in YBCO with a high number density, which increases the critical current ( at 77 K) by a factor of two to three for high magnetic fields.	USAF, Res Lab, Wright Patterson AFB, OH 45433 USA; Ohio State Univ, Dept Mat Sci & Engn, Columbus, OH 43210 USA	United States Department of Defense; United States Air Force; US Air Force Research Laboratory; University System of Ohio; Ohio State University	Haugan, T (corresponding author), USAF, Res Lab, Wright Patterson AFB, OH 45433 USA.	timothy.haugan@wpafb.af.mil	Sumption, Mike D/N-5913-2016	Sumption, Mike D/0000-0002-4243-8380				Balachandran U, 2003, PHYSICA C, V392, P806, DOI 10.1016/S0921-4534(03)00790-1; BEDNORZ JG, 1986, Z PHYS B CON MAT, V64, P189, DOI 10.1007/BF01303701; CIVALE L, 1991, PHYS REV LETT, V67, P648, DOI 10.1103/PhysRevLett.67.648; Dam B, 1999, NATURE, V399, P439, DOI 10.1038/20880; FEENSTRA R, 1992, PHYS REV B, V45, P7555, DOI 10.1103/PhysRevB.45.7555; Goyal A, 2001, PHYSICA C, V357, P903, DOI 10.1016/S0921-4534(01)00437-3; Gross RE, 1996, PHYSICA C, V260, P188, DOI 10.1016/0921-4534(96)00113-X; Groves JR, 2002, PHYSICA C, V382, P43, DOI 10.1016/S0921-4534(02)01194-2; Haugan T, 2003, J MATER RES, V18, P2618, DOI 10.1557/JMR.2003.0366; Haugan T, 2003, PHYSICA C, V397, P47, DOI 10.1016/S0921-4534(03)01088-8; Kakimoto K, 2003, PHYSICA C, V392, P783, DOI 10.1016/S0921-4534(03)01129-8; Larbalestier D, 2001, NATURE, V414, P368, DOI 10.1038/35104654; LARBALESTIER DC, 1993, MRS BULL, V18, P50, DOI 10.1557/S0883769400037775; Liu P, 2002, APPL PHYS LETT, V80, P3910, DOI 10.1063/1.1481541; Matsushita T, 2000, SUPERCOND SCI TECH, V13, P730, DOI 10.1088/0953-2048/13/6/320; Pan VM, 2003, PHYSICA C, V388, P431, DOI 10.1016/S0921-4534(02)02556-X; Redl FX, 2003, NATURE, V423, P968, DOI 10.1038/nature01702; REICHELT K, 1988, VACUUM, V38, P1083, DOI 10.1016/0042-207X(88)90004-8; Selvamanickam V, 2003, PHYSICA C, V392, P859, DOI 10.1016/S0921-4534(03)00789-5; Springholz G, 1998, SCIENCE, V282, P734, DOI 10.1126/science.282.5389.734; Verebelyi DT, 2003, SUPERCOND SCI TECH, V16, pL19, DOI 10.1088/0953-2048/16/5/101; Yamasaki H, 2002, PHYSICA C, V372, P1885, DOI 10.1016/S0921-4534(02)01001-8; ZHU YM, 1993, PHYS REV B, V48, P6436, DOI 10.1103/PhysRevB.48.6436	24	621	629	9	205	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					867	870		10.1038/nature02792	http://dx.doi.org/10.1038/nature02792			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318215				2022-12-28	WOS:000223369800035
J	Loh, AN; Bauer, JE; Druffel, ERM				Loh, AN; Bauer, JE; Druffel, ERM			Variable ageing and storage of dissolved organic components in the open ocean	NATURE			English	Article							PACIFIC-OCEAN; BLACK CARBON; MATTER; RADIOCARBON; SEDIMENTS; WATER; SEA; ENVIRONMENTS; FRACTIONS	Seawater dissolved organic matter (DOM) is the largest reservoir of exchangeable organic carbon in the ocean, comparable in quantity to atmospheric carbon dioxide(1,2). The composition, turnover times and fate of all but a few planktonic constituents of this material are, however, largely unknown(3,4). Models of ocean carbon cycling are thus limited by the need for information on temporal scales of carbon storage in DOM subcomponents, produced via the 'biological pump', relative to their recycling by bacteria(3,4). Here we show that carbohydrate- and protein-like substances in the open Atlantic and Pacific oceans, though often significantly aged, comprise younger fractions of the DOM, whereas dissolved lipophilic material exhibits up to similar to90 per cent fossil character. In contrast to the millennial mean ages of DOM observed throughout the water column, weighted mean turnover times of DOM in the surface ocean are only decadal in magnitude. An observed size-age continuum further demonstrates that small dissolved molecules are the most highly aged forms of organic matter, cycling much more slowly than larger, younger dissolved and particulate precursors, and directly links oceanic organic matter age and size with reactivity(3,5).	Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA; Coll William & Mary, Sch Marine Sci, Gloucester Point, VA 23062 USA	University of California System; University of California Irvine; William & Mary	Loh, AN (corresponding author), Florida Gulf Coast Univ, Coll Arts & Sci, Div Ecol Studies, 10501 FGCU Blvd S, Ft Myers, FL 33965 USA.	anloh@fgcu.edu						Aluwihare LI, 2002, DEEP-SEA RES PT II, V49, P4421, DOI 10.1016/S0967-0645(02)00124-8; Aluwihare LI, 1997, NATURE, V387, P166, DOI 10.1038/387166a0; Amon RMW, 1996, LIMNOL OCEANOGR, V41, P41, DOI 10.4319/lo.1996.41.1.0041; BAUER JE, 1992, NATURE, V357, P667, DOI 10.1038/357667a0; Benner R., 2002, BIOGEOCHEMISTRY MARI, P5990, DOI DOI 10.1016/B978-012323841-2/50005-1; Carlson C., 2002, BIOGEOCHEMISTRY MARI, P91, DOI DOI 10.1016/B978-012323841-2/50006-3; Clark LL, 1998, NATURE, V393, P426, DOI 10.1038/30881; Druffel ERM, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017423; DRUFFEL ERM, 1992, J GEOPHYS RES-OCEANS, V97, P15639, DOI 10.1029/92JC01511; Eglinton TI, 1997, SCIENCE, V277, P796, DOI 10.1126/science.277.5327.796; Eglinton TI, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000269; GOERICKE R, 1994, STABLE ISOTOPES ECOL, P181; Hedges JI, 2000, ORG GEOCHEM, V31, P945, DOI 10.1016/S0146-6380(00)00096-6; HEDGES JI, 1995, MAR CHEM, V49, P81, DOI 10.1016/0304-4203(95)00008-F; HEDGES JI, 1992, MAR CHEM, V39, P67, DOI 10.1016/0304-4203(92)90096-S; Hwang JS, 2003, SCIENCE, V299, P881, DOI 10.1126/science.1078508; LOH AN, 2002, THESIS COLL WILLIAM; Masiello CA, 1998, SCIENCE, V280, P1911, DOI 10.1126/science.280.5371.1911; Masiello CA, 2002, GEOCHIM COSMOCHIM AC, V66, P1025, DOI 10.1016/S0016-7037(01)00831-6; SANTSCHI PH, 1995, GEOCHIM COSMOCHIM AC, V59, P625, DOI 10.1016/0016-7037(94)00378-Y; SOFER Z, 1980, ANAL CHEM, V52, P1389, DOI 10.1021/ac50058a063; STUIVER M, 1983, SCIENCE, V219, P849, DOI 10.1126/science.219.4586.849; STUIVER M, 1977, RADIOCARBON, V19, P355, DOI 10.1017/S0033822200003672; Trumbore SE, 1995, DAHL WS ENV, V16, P7; VOGEL JS, 1987, NUCL INSTRUM METH B, V29, P50, DOI 10.1016/0168-583X(87)90202-3; Wakeham SG, 1997, DEEP-SEA RES PT II, V44, P2131, DOI 10.1016/S0967-0645(97)00035-0; Wang XC, 2001, GEOPHYS RES LETT, V28, P3313, DOI 10.1029/2001GL013430; Wang XC, 1998, GEOCHIM COSMOCHIM AC, V62, P1365, DOI 10.1016/S0016-7037(98)00074-X; Whelan J.K., 1993, ORG GEOCHEM, P289; WILLIAMS PM, 1987, NATURE, V330, P246, DOI 10.1038/330246a0	30	134	140	8	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					877	881		10.1038/nature02780	http://dx.doi.org/10.1038/nature02780			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318218	Green Published			2022-12-28	WOS:000223369800038
J	Mulliken, JB				Mulliken, JB			The changing faces of children with cleft lip and palate	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Childrens Hosp, Craniofacial Ctr, Div Plast Surg, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital	Mulliken, JB (corresponding author), Childrens Hosp, Craniofacial Ctr, Div Plast Surg, 300 Longwood Ave, Boston, MA 02115 USA.							Clinical Research Services, 1998, REP CLIFT LIP PAL, P1; SHAW WC, 1992, CLEFT PALATE-CRAN J, V29, P413, DOI 10.1597/1545-1569(1992)029<0413:ASCISO>2.3.CO;2; Strauss RP, 1998, CLEFT PALATE-CRAN J, V35, P473, DOI 10.1597/1545-1569-35.6.473	3	32	33	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2004	351	8					745	747		10.1056/NEJMp048157	http://dx.doi.org/10.1056/NEJMp048157			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847CY	15317886				2022-12-28	WOS:000223367900005
J	Piffanelli, P; Ramsay, L; Waugh, R; Benabdelmouna, A; D'Hont, A; Hollricher, K; Jorgensen, JH; Schulze-Lefert, P; Panstruga, R				Piffanelli, P; Ramsay, L; Waugh, R; Benabdelmouna, A; D'Hont, A; Hollricher, K; Jorgensen, JH; Schulze-Lefert, P; Panstruga, R			A barley cultivation-associated polymorphism conveys resistance to powdery mildew	NATURE			English	Article							MLO FAMILY; DIVERSITY; GENE; DEFENSE; PROTEIN; GENOME; PLANTS	Barley ( Hordeum vulgare) has played a pivotal role in Old World agriculture since its domestication about 10,000 yr ago(1). Barley plants carrying loss-of-function alleles (mlo) of the Mlo locus are resistant against all known isolates of the widespread powdery mildew fungus(2). The sole mlo resistance allele recovered so far from a natural habitat, mlo-11, was originally retrieved from Ethiopian landraces and nowadays controls mildew resistance in the majority of cultivated European spring barley elite varieties(2). Here we use haplotype analysis to show that the mlo-11 allele probably arose once after barley domestication. Resistance in mlo-11 plants is linked to a complex tandem repeat array inserted upstream of the wild-type gene. The repeat units consist of a truncated Mlo gene comprising 3.5 kilobases (kb) of 50-regulatory sequence plus 1.1 kb of coding sequence. These generate aberrant transcripts that impair the accumulation of both Mlo wild-type transcript and protein. We exploited the meiotic instability of mlo-11 resistance and recovered susceptible revertants in which restoration of Mlo function was accompanied by excision of the repeat array. We infer cis-dependent perturbation of transcription machinery assembly by transcriptional interference in mlo-11 plants as a likely mechanism leading to disease resistance.	Max Planck Inst Zuchtungsforsch, Dept Plant Microbe Interact, D-50829 Cologne, Germany; John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; Scottish Crop Res Inst, Genome Unit, Dundee DD2 5DA, Scotland; CIRAD, F-34398 Montpellier 5, France; Max Planck Inst Zuchtungsforsch, Dept Plant Breeding & Yield Physiol, D-50829 Cologne, Germany; Riso Natl Lab, Res Dept, DK-4000 Roskilde, Denmark; Max Planck Inst Zuchtungsforsch, Dept Plant Microbe Interact, D-50829 Cologne, Germany	Max Planck Society; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; James Hutton Institute; CIRAD; Max Planck Society; Technical University of Denmark; Max Planck Society	Schulze-Lefert, P (corresponding author), Max Planck Inst Zuchtungsforsch, Dept Plant Microbe Interact, Carl von Linne Weg 10, D-50829 Cologne, Germany.	schlef@mpiz-koeln.mpg.de	DHONT, Angélique/AAL-8074-2021; Schulze-Lefert, Paul/A-7746-2008; Bruening, Stefan/B-8505-2011; Panstruga, Ralph/F-3340-2011; Schulze-Lefert, Paul/B-6707-2011	Panstruga, Ralph/0000-0002-3756-8957; Benabdelmouna, Abdellah/0000-0003-1910-219X				Badr A, 2000, MOL BIOL EVOL, V17, P499, DOI 10.1093/oxfordjournals.molbev.a026330; Benabdelmouna A, 2001, THEOR APPL GENET, V103, P668, DOI 10.1007/s001220100596; Buschges R, 1997, CELL, V88, P695, DOI 10.1016/S0092-8674(00)81912-1; Chopra S, 2003, GENETICS, V163, P1135; Collins NC, 2003, NATURE, V425, P973, DOI 10.1038/nature02076; Devoto A, 1999, J BIOL CHEM, V274, P34993, DOI 10.1074/jbc.274.49.34993; Devoto A, 2003, J MOL EVOL, V56, P77, DOI 10.1007/s00239-002-2382-5; Eszterhas SK, 2002, MOL CELL BIOL, V22, P469, DOI 10.1128/MCB.22.2.469-479.2002; Fransz PF, 1996, PLANT J, V9, P421, DOI 10.1046/j.1365-313X.1996.09030421.x; GIESSEN J. E., 1956, Zeitschrift fur Pflanzenzuchtung, V35, P377; Gutierrez C, 1999, CELL MOL LIFE SCI, V56, P313, DOI 10.1007/s000180050433; Henikoff S, 1998, BIOESSAYS, V20, P532, DOI 10.1002/(SICI)1521-1878(199807)20:7<532::AID-BIES3>3.3.CO;2-0; JORGENSEN JH, 1994, CRIT REV PLANT SCI, V13, P97, DOI 10.1080/713608055; JORGENSEN JH, 1992, EUPHYTICA, V63, P141, DOI 10.1007/BF00023919; JORGENSEN JH, 1976, BARLEY GENET, V3, P446; Kapitonov VV, 2001, P NATL ACAD SCI USA, V98, P8714, DOI 10.1073/pnas.151269298; Kim MC, 2002, NATURE, V416, P447, DOI 10.1038/416447a; Matus IA, 2002, GENOME, V45, P1095, DOI 10.1139/G02-071; NEGASSA M, 1985, HEREDITAS, V102, P113, DOI 10.1111/j.1601-5223.1985.tb00472.x; NEI M, 1972, AM NAT, V106, P283, DOI 10.1086/282771; Pakniyat H, 1997, GENOME, V40, P332, DOI 10.1139/g97-046; Panstruga R, 2003, MICROBES INFECT, V5, P429, DOI 10.1016/S1286-4579(03)00053-4; Panstruga R, 1998, NUCLEIC ACIDS RES, V26, P1056, DOI 10.1093/nar/26.4.1056; Piffanelli P, 2002, PLANT PHYSIOL, V129, P1076, DOI 10.1104/pp.010954; Simons G, 1997, GENOMICS, V44, P61, DOI 10.1006/geno.1997.4844; Stam M, 2002, GENE DEV, V16, P1906, DOI 10.1101/gad.1006702; Thomas WTB, 1998, MOL BREEDING, V4, P381, DOI 10.1023/A:1009646115967	27	126	143	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					887	891		10.1038/nature02781	http://dx.doi.org/10.1038/nature02781			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318221				2022-12-28	WOS:000223369800041
J	Rennie, D				Rennie, D			Trial registration - A great idea switches from ignored to irresistible	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CLINICAL-TRIALS; INFORMATION; DEPRESSION; INDUSTRY; COMPANY		JAMA, Chicago, IL 60610 USA		Rennie, D (corresponding author), JAMA, 515 N State St, Chicago, IL 60610 USA.	drummond_rennie@jama-archives.org						ABBOUD L, 2004, WALL STREET J   0803; *AM MED ASS COUNC, INFL FUND SOURC OUTC; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; *CMR INT, PHARM IND CLIN TRIAL; DeAngelis CD, 2004, JAMA-J AM MED ASSOC, V292, P1363, DOI 10.1001/jama.292.11.1363; Dickersin K, 2003, JAMA-J AM MED ASSOC, V290, P516, DOI 10.1001/jama.290.4.516; DURMAN P, 2004, TIMES LONDON    0606; FURBERG CD, 1983, AM J CARDIOL, V52, pC32, DOI 10.1016/0002-9149(83)90629-X; Garland EJ, 2004, CAN MED ASSOC J, V170, P489; Gibson L, 2004, BRIT MED J, V328, P1513, DOI 10.1136/bmj.328.7455.1513-a; Glass RM, 2004, JAMA-J AM MED ASSOC, V292, P861, DOI 10.1001/jama.292.7.861; GROPPE M, 2004, INDIANAPOLIS ST 0805; Herxheimer A, 2004, BRIT MED J, V329, P64, DOI 10.1136/bmj.329.7457.64; HIRSCH L, 2004, CMAJ, V170, P477; HOLMER AF, 2004, USA TODAY       0810, pA10; Kondro W, 2004, CAN MED ASSOC J, V170, P783, DOI 10.1503/cmaj.1040213; KUSMER K, 2004, ASS PRESS       0803; Manheimer E, 2002, BRIT MED J, V325, P528, DOI 10.1136/bmj.325.7363.528; March J, 2004, JAMA-J AM MED ASSOC, V292, P807; Mathews Anna Wilde, 2004, Wall St J (East Ed), pA7; MATTHEWS AW, 2004, WALL STREET J   1101, pA1; *MED HEALTHC PROD, 2003, INT REP COMM SAF MED; MEIER B, 2004, NY TIMES        0804; MEIER B, 2004, NY TIMES        0930, pC1; PEAR R, 2004, NY TIMES        0725; PESTON R, 2004, SUNDAY TELEGRAP 0606; *PHARM RES MAN AM, 2004, UPD PRINC COND CLIN; *PHARM RES MAN AM, 2002, PHRMA PRINC COND CLI; Rennie D, 1999, JAMA-J AM MED ASSOC, V282, P1766, DOI 10.1001/jama.282.18.1766; Sykes R, 1998, BRIT MED J, V317, P1172, DOI 10.1136/bmj.317.7167.1172; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; *US FDA, 2004, FDA UPC M ANN JOINT; Wadman M, 2004, NATURE, V430, P495, DOI 10.1038/430495a; Wessely S, 2004, JAMA-J AM MED ASSOC, V292, P379, DOI 10.1001/jama.292.3.379; Whittington CJ, 2004, LANCET, V363, P1341, DOI 10.1016/S0140-6736(04)16043-1	35	93	95	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2004	292	11					1359	1362		10.1001/jama.292.11.1359	http://dx.doi.org/10.1001/jama.292.11.1359			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853YL	15355937				2022-12-28	WOS:000223866800030
J	Burls, A; Jobanputra, P				Burls, A; Jobanputra, P			The trials of anakinra	LANCET			English	Editorial Material							RHEUMATOID-ARTHRITIS		Univ Birmingham, Dept Epidemiol & Publ Hlth, W Midlands Hlth Technol Assessment Collaborat, Birmingham B15 2TT, W Midlands, England; Univ Hosp Birmingham NHS Trust, Selly Oak Hosp, Dept Rheumatol, Birmingham, W Midlands, England	University of Birmingham	Burls, A (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, W Midlands Hlth Technol Assessment Collaborat, Birmingham B15 2TT, W Midlands, England.	A.J.Burls@bham.ac.uk	Burls, Amanda J.E./D-7641-2011; Jobanputra, Paresh/R-2311-2019	Jobanputra, Paresh/0000-0002-2712-667X; Burls, Amanda/0000-0001-9540-622X				Braddock M, 2004, NAT REV DRUG DISCOV, V3, P1, DOI 10.1038/nrd1342; Buch MH, 2004, ARTHRITIS RHEUM-US, V50, P725, DOI 10.1002/art.20115; CLARK W, 2004, HLTH TECH ASSESS, V8; Fleischmann RM, 2003, ARTHRITIS RHEUM-US, V48, P927, DOI 10.1002/art.10870; *FOOD DRUG ADM CTR, 103950 BLA STN FOOD; Genovese MC, 2004, ARTHRITIS RHEUM-US, V50, P1412, DOI 10.1002/art.20221; JOBANPUTRA P, 2002, HLTH TECH ASSESS, V6; NICE, 2002, GUID US ET INFL TREA; *NICE, 2003, AN RHEUM ARTHR; Parmar MKB, 1996, J NATL CANCER I, V88, P1645, DOI 10.1093/jnci/88.22.1645	10	14	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2004	364	9437					827	828		10.1016/S0140-6736(04)16999-7	http://dx.doi.org/10.1016/S0140-6736(04)16999-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351176				2022-12-28	WOS:000223685200010
J	Hallam, SJ; Putnam, N; Preston, CM; Detter, JC; Rokhsar, D; Richardson, PM; DeLong, EF				Hallam, SJ; Putnam, N; Preston, CM; Detter, JC; Rokhsar, D; Richardson, PM; DeLong, EF			Reverse methanogenesis: Testing the hypothesis with environmental genomics	SCIENCE			English	Article							METHANE-OXIDIZING ARCHAEA; MARINE-SEDIMENTS; ANAEROBIC OXIDATION; CARBONATES; PATHWAYS; BACTERIA; GENES	Microbial methane consumption in anoxic sediments significantly impacts the global environment by reducing the flux of greenhouse gases from ocean to atmosphere. Despite its significance, the biological mechanisms controlling anaerobic methane oxidation are not well characterized. One current model suggests that relatives of methane-producing Archaea, developed the capacity to reverse methanogenesis and thereby to consume methane to produce cellular carbon and energy. We report here a test of the "reverse-methanogenesis" hypothesis by genomic analyses of methane-oxidizing Archaea, from deep-sea sediments. Our results show that nearly all genes typically associated with methane production are present in one specific group of archaeal methanotrophs. These genome-based observations support previous hypotheses and provide an informed foundation for metabolic modeling of anaerobic methane oxidation.	Monterey Bay Aquarium Res Inst, Moss Landing, CA 95064 USA; Joint Genome Inst, Walnut Creek, CA 94598 USA	Monterey Bay Aquarium Research Institute; United States Department of Energy (DOE); Joint BioEnergy Institute - JBEI; Joint Genome Institute - JGI	DeLong, EF (corresponding author), MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	delong@mit.edu	Putnam, Nicholas/B-9968-2008	Putnam, Nicholas/0000-0002-1315-782X; Rokhsar, Daniel/0000-0002-8704-2224				Angelaccio S, 2003, J BIOL CHEM, V278, P41789, DOI 10.1074/jbc.M306747200; Boetius A, 2000, NATURE, V407, P623, DOI 10.1038/35036572; Borowski WS, 1999, MAR GEOL, V159, P131, DOI 10.1016/S0025-3227(99)00004-3; Chistoserdova L, 2000, MICROBIOL-SGM, V146, P233, DOI 10.1099/00221287-146-1-233; D'Hondt S, 2002, SCIENCE, V295, P2067, DOI 10.1126/science.1064878; DeLong EF, 2002, CURR OPIN MICROBIOL, V5, P520, DOI 10.1016/S1369-5274(02)00353-3; Hallam SJ, 2003, APPL ENVIRON MICROB, V69, P5483, DOI 10.1128/AEM.69.9.5483-5491.2003; Hinrichs KU, 1999, NATURE, V398, P802, DOI 10.1038/19751; Hoehler TM, 1996, MICROBIAL GROWTH ON C(1) COMPOUNDS, P326; IVERSEN N, 1985, LIMNOL OCEANOGR, V30, P944, DOI 10.4319/lo.1985.30.5.0944; Jiang GQ, 2003, NATURE, V426, P822, DOI 10.1038/nature02201; Kruger M, 2003, NATURE, V426, P878, DOI 10.1038/nature02207; KUHNER CH, 1993, J BACTERIOL, V175, P3195, DOI 10.1128/JB.175.10.3195-3203.1993; KULM LD, 1986, SCIENCE, V231, P561, DOI 10.1126/science.231.4738.561; Marx CJ, 2004, J BACTERIOL, V186, P2173, DOI 10.1128/JB.186.7.2173-2178.2004; Michaelis W, 2002, SCIENCE, V297, P1013, DOI 10.1126/science.1072502; Orphan VJ, 2002, P NATL ACAD SCI USA, V99, P7663, DOI 10.1073/pnas.072210299; Orphan VJ, 2001, SCIENCE, V293, P484, DOI 10.1126/science.1061338; Orphan VJ, 2001, APPL ENVIRON MICROB, V67, P1922, DOI 10.1128/AEM.67.4.1922-1934.2001; PAULL CK, 1992, PALAIOS, V7; Reeburgh WS, 1996, MICROBIAL GROWTH ON C(1) COMPOUNDS, P334; Reeve JN, 1997, J BACTERIOL, V179, P5975, DOI 10.1128/jb.179.19.5975-5986.1997; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; ZEHNDER AJB, 1979, J BACTERIOL, V137, P420, DOI 10.1128/JB.137.1.420-432.1979	24	471	515	11	177	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1457	1462		10.1126/science.1100025	http://dx.doi.org/10.1126/science.1100025			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353801				2022-12-28	WOS:000223761900047
J	Wojtowicz, WM; Flanagan, JJ; Millard, SS; Zipursky, SL				Wojtowicz, WM; Flanagan, JJ; Millard, SS; Zipursky, SL			Alternative splicing of Drosophila Dscam generates axon guidance receptors that exhibit isoform-specific homophilic binding	CELL			English	Article							CELL-ADHESION MOLECULE; SUPERFAMILY; EXPRESSION; DIVERSITY; NEUREXINS; NEURONS; FAMILY; GROWTH; MEMBER	Dscam is an immunoglobulin (Ig) superfamily protein required for the formation of neuronal connections in Drosophila. Through alternative splicing, Dscam potentially gives rise to 19,008 different extracellular domains linked to one of two alternative transmembrane segments, resulting in 38,016 isoforms. All isoforms share the same domain structure but contain variable amino acid sequences within three Ig domains in the extracellular region. We demonstrate that different isoforms exhibit different binding specificity. Each isoform binds to itself but does not bind or binds poorly to other isoforms. The amino acid sequences of all three variable Ig domains determine binding specificity. Even closely related isoforms sharing nearly identical amino acid sequences exhibit isoform-specific binding. We propose that this preferential homophilic binding specificity regulates interactions between cells and contributes to the formation of complex patterns of neuronal connections.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Howard Hughes Med Inst, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Zipursky, SL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.	zipursky@hhmi.ucla.edu	Millard, Sean/A-8522-2013	Millard, Sean/0000-0001-8573-4625; Zipursky, Stephen/0000-0001-5630-7181	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS044582, T32NS007101] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [GM07185, T32 GM007185] Funding Source: Medline; NINDS NIH HHS [F31 NS044582, F31NS044582, 5 T32 NS07101, T32 NS007101] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agarwala KL, 2001, BIOCHEM BIOPH RES CO, V285, P760, DOI 10.1006/bbrc.2001.5214; Agarwala KL, 2000, MOL BRAIN RES, V79, P118, DOI 10.1016/S0169-328X(00)00108-X; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; De Angelis E, 1999, EMBO J, V18, P4744, DOI 10.1093/emboj/18.17.4744; Feinstein P, 2004, CELL, V117, P817, DOI 10.1016/j.cell.2004.05.011; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; GRAVELEY BR, 2004, IN PRESS ORG EVOLUTI; Hansen MJ, 2004, NEURON, V42, P717, DOI 10.1016/j.neuron.2004.05.009; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Higashijima S, 1996, DEVELOPMENT, V122, P527; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Huh GS, 2000, SCIENCE, V290, P2155, DOI 10.1126/science.290.5499.2155; Hummel T, 2003, NEURON, V37, P221, DOI 10.1016/S0896-6273(02)01183-2; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; McLaughlin T, 2003, DEVELOPMENT, V130, P2407, DOI 10.1242/dev.00467; McLaughlin T, 2003, CURR OPIN NEUROBIOL, V13, P57, DOI 10.1016/S0959-4388(03)00014-X; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; Neves G, 2004, NAT GENET, V36, P240, DOI 10.1038/ng1299; Price SR, 2002, CELL, V109, P205, DOI 10.1016/S0092-8674(02)00695-5; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Uemura T, 1998, CELL, V93, P1095, DOI 10.1016/S0092-8674(00)81452-X; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Wang J, 2004, NEURON, V43, P663, DOI 10.1016/j.neuron.2004.06.033; Wang J, 2002, NEURON, V33, P559, DOI 10.1016/S0896-6273(02)00570-6; Winberg ML, 1998, CELL, V93, P581, DOI 10.1016/S0092-8674(00)81187-3; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Yamakawa K, 1998, HUM MOL GENET, V7, P227, DOI 10.1093/hmg/7.2.227; Zhan XL, 2004, NEURON, V43, P673, DOI 10.1016/j.neuron.2004.07.020	31	235	242	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2004	118	5					619	633		10.1016/j.cell.2004.08.021	http://dx.doi.org/10.1016/j.cell.2004.08.021			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	852BN	15339666	Green Accepted, Bronze			2022-12-28	WOS:000223730300012
J	Murta, EFC; Nomelini, RS				Murta, EFC; Nomelini, RS			Is repeated caesarean section a consequence of elective caesarean section?	LANCET			English	Editorial Material							UTERINE RUPTURE; RISK-FACTORS; PREGNANCY; REQUEST; WOMEN; RATES		Fac Med Triangulo Mineiro, Discipline Gynaecol & Obstet, BR-38025440 Uberlandia, MG, Brazil	Universidade Federal do Triangulo Mineiro	Murta, EFC (corresponding author), Fac Med Triangulo Mineiro, Discipline Gynaecol & Obstet, BR-38025440 Uberlandia, MG, Brazil.	eddiemurta@mednet.com.br	Murta, Eddie FC/C-5696-2013; Murta, Eddie/AAU-7749-2020	Murta, Eddie FC/0000-0003-4014-1345; Murta, Eddie/0000-0003-4014-1345				Bergholt T, 2004, ACTA OBSTET GYN SCAN, V83, P262, DOI 10.1111/j.0001-6349.2004.0312.x; Devendra K, 2003, ANN ACAD MED SINGAP, V32, P577; Ecker JL, 2004, AM J OBSTET GYNECOL, V190, P314, DOI 10.1016/S0002-9378(03)00869-X; Fabri RH, 2002, INT J GYNECOL OBSTET, V76, P87, DOI 10.1016/S0020-7292(01)00544-6; Guise JM, 2004, BMJ-BRIT MED J, V329, P19, DOI 10.1136/bmj.329.7456.19; Hager RME, 2004, AM J OBSTET GYNECOL, V190, P428, DOI 10.1016/j.ajog.2003.08.037; Hannah ME, 2004, CAN MED ASSOC J, V170, P813, DOI 10.1503/cmaj.1032002; Juntunen K, 2004, BJOG-INT J OBSTET GY, V111, P561, DOI 10.1111/j.1471-0528.2004.00154.x; Kalish RB, 2004, OBSTET GYNECOL, V103, P1137, DOI 10.1097/01.AOG.0000128118.37737.df; Ofir K, 2003, AM J OBSTET GYNECOL, V189, P1042, DOI 10.1067/S0002-9378(03)01052-4; Singer B, 2004, CAN MED ASSOC J, V170, P775, DOI 10.1503/cmaj.1040209; Stone C, 2000, PAEDIATR PERINAT EP, V14, P340, DOI 10.1046/j.1365-3016.2000.00299.x	12	6	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	2004	364	9435					649	650		10.1016/S0140-6736(04)16913-4	http://dx.doi.org/10.1016/S0140-6736(04)16913-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325816				2022-12-28	WOS:000223428900010
J	Wertheim, HFL; Vos, MC; Ott, A; van Belkum, A; Voss, A; Kluytmans, JAJW; van Keulen, PHJ; Vandenbroucke-Grauls, CMJE; Meester, MHM; Verbrugh, HA				Wertheim, HFL; Vos, MC; Ott, A; van Belkum, A; Voss, A; Kluytmans, JAJW; van Keulen, PHJ; Vandenbroucke-Grauls, CMJE; Meester, MHM; Verbrugh, HA			Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers	LANCET			English	Article							INFECTIONS; CARRIAGE	Staphylococcus aureus is the second most frequent cause of nosocomial blood infections. We screened 14 008 nonbacteraemic, non-surgical patients for S aureus nasal carriage at admission, and monitored them for development of bacteraemia. Nosocomial S aureus bacteraemia was three times more frequent in S aureus carriers (40/3420, 1.2%) than in non-carriers (41/10588, 0.4%; relative risk 3.0, 95% CI 2.0-4.7). However, in bacteraemic patients, all-cause mortality was significantly higher in non-carriers (19/41, 46%) than in carriers (seven/40, 18%, p=0.005). Additionally, S aureus bacteraemia-related death was significantly higher in non-carriers than in carriers (13/41 [32%] vs three/40 [8%], p=0.006). S aureus nasal carriers and non-carriers differ significantly in risk and outcome of nosocomial S aureus bacteraemia. Genotyping revealed that 80% of strains causing bacteraemia in carriers were endogenous.	Univ Med Ctr, Erasmus MC, Dept Med Microbiol & Infect Dis, NL-3015 GD Rotterdam, Netherlands; Radboud Univ Nijmegen Med Ctr, Dept Med Microbiol & Infect Dis, Nijmegen, Netherlands; Amphia Hosp, Dept Med Microbiol & Infect Control, Breda, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Med Microbiol & Infect Control, Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Radboud University Nijmegen; Amphia Hospital; Vrije Universiteit Amsterdam	Wertheim, HFL (corresponding author), Univ Med Ctr, Erasmus MC, Dept Med Microbiol & Infect Dis, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands.	h.wertheim@erasmusmc.nl	Vandenbroucke-Grauls, Christina/AAO-7953-2020; Wertheim, Heiman FL/F-3338-2016; Voss, A./H-8111-2014	Vandenbroucke-Grauls, Christina/0000-0003-2074-1597; Wertheim, Heiman FL/0000-0002-5003-5565; 				GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505, DOI 10.1128/CMR.10.3.505; PITTET D, 1995, ARCH INTERN MED, V155, P1177, DOI 10.1001/archinte.155.11.1177; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; von Eiff C, 2001, NEW ENGL J MED, V344, P11, DOI 10.1056/NEJM200101043440102; WERTHEIM HFL, IN PRESS ANN INTERN	6	618	638	0	35	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	2004	364	9435					703	705		10.1016/S0140-6736(04)16897-9	http://dx.doi.org/10.1016/S0140-6736(04)16897-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325835				2022-12-28	WOS:000223428900032
J	Benkler, Y				Benkler, Y			Intellectual property - Commons-based strategies and the problems of patents	SCIENCE			English	Editorial Material							INNOVATION		Yale Univ, Yale Law Sch, New Haven, CT 06520 USA	Yale University	Benkler, Y (corresponding author), Yale Univ, Yale Law Sch, 127 Wall St, New Haven, CT 06520 USA.	yochai.benkler@yale.edu						Arrow K., 1962, RATE DIRECTION INVEN, P609, DOI DOI 10.1515/9781400879762-024; Atkinson RC, 2003, SCIENCE, V301, P174, DOI 10.1126/science.1085553; Benkler Y, 2002, YALE LAW J, V112, P369, DOI 10.2307/1562247; COHEN WM, 2000, NBER WORK PAP SER; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; Jaffe AB, 2000, RES POLICY, V29, P531, DOI 10.1016/S0048-7333(99)00088-8; KANEFSKY B, 2001, 32 LUN PLAN SCI C HO, P1272; Lerner J, 2002, AM ECON REV, V92, P221, DOI 10.1257/000282802320189294; LERNER J, IN PRESS J LAW EC OR, V21; LERNER J, 2002, NBER WORK PAP SER; Lessig Lawrence, 2004, FREE CULTURE; LEVIN RC, 1987, BROOKINGS PAP ECO AC, P783; Maurer S, 2004, BIOTECHNOLOGY ESSAYS, P33; MERTON R, 1973, SOCIOLOY SCI; Raymond E. S., 2001, CATHEDRAL BAZAAR; Sincell M, 2001, SCIENCE, V293, P419, DOI 10.1126/science.293.5529.419; Snow CD, 2002, NATURE, V420, P102, DOI 10.1038/nature01160; Varmus H, 1999, E BIOMED PROPOSAL EL	18	59	59	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2004	305	5687					1110	1111		10.1126/science.1100526	http://dx.doi.org/10.1126/science.1100526			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326340				2022-12-28	WOS:000223557400029
J	Wolfe, MS; Kopan, R				Wolfe, MS; Kopan, R			Intramembrane proteotysis: Theme and variations	SCIENCE			English	Review							SIGNAL PEPTIDE PEPTIDASE; GAMMA-SECRETASE COMPLEX; ALZHEIMERS-DISEASE; SUBSTRATE-SPECIFICITY; SREBP PATHWAY; BETA-APP; PRESENILIN; PROTEIN; CLEAVAGE; NICASTRIN	Proteases that reside in cellular membranes apparently wield water to hydrolyze the peptide bonds of substrates despite their water-excluding environment. Although these intramembrane proteases bear little or no sequence resemblance to classical water-soluble proteases, they have ostensibly converged on similar hydrolytic mechanisms. Identification of essential amino acid residues of these proteases suggests that they use residue combinations for catalysis in the same way as their soluble cousins. In contrast to classical proteases, however, the catalytic residues of intramembrane proteases lie within predicted hydrophobic transmembrane domains. Elucidating the biological functions of intramembrane proteases, identifying their substrates, and understanding how they hydrolyze peptide bonds within membranes will shed light on the ways these proteases regulate crucial biological processes and contribute to disease.	Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Washington Univ, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Dept Med, St Louis, MO 63110 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Washington University (WUSTL); Washington University (WUSTL)	Wolfe, MS (corresponding author), Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA.	mwolfe@rics.bwh.harvard.edu; kopan@wustl.edu	Kopan, Raphael/AFG-3275-2022; Kopan, Raphael/AAF-1357-2022	Kopan, Raphael/0000-0002-0350-2730				Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Berezovska O, 2003, J NEUROSCI, V23, P4560; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; Das C, 2003, J AM CHEM SOC, V125, P11794, DOI 10.1021/ja037131v; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Duncan EA, 1998, J BIOL CHEM, V273, P17801, DOI 10.1074/jbc.273.28.17801; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Esser K, 2002, J MOL BIOL, V323, P835, DOI 10.1016/S0022-2836(02)01000-8; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; GOLDE T, COMMUNICATION; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Goutte C, 2000, DEVELOPMENT, V127, P2481; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Herlan M, 2003, J BIOL CHEM, V278, P27781, DOI 10.1074/jbc.M211311200; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Kanehara K, 2001, GENE, V281, P71, DOI 10.1016/S0378-1119(01)00823-X; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kornilova AY, 2003, J BIOL CHEM, V278, P16470, DOI 10.1074/jbc.C300019200; Laudon H, 2004, J NEUROCHEM, V89, P44, DOI 10.1046/j.1471-4159.2003.02298.x; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee JR, 2001, CELL, V107, P161, DOI 10.1016/S0092-8674(01)00526-8; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Lohi O, 2004, CURR BIOL, V14, P236, DOI 10.1016/j.cub.2004.01.025; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; McQuibban GA, 2003, NATURE, V423, P537, DOI 10.1038/nature01633; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Nyborg AC, 2004, J BIOL CHEM, V279, P15153, DOI 10.1074/jbc.M309305200; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; Rudner DZ, 1999, P NATL ACAD SCI USA, V96, P14765, DOI 10.1073/pnas.96.26.14765; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Urban S, 2003, MOL CELL, V11, P1425, DOI 10.1016/S1097-2765(03)00181-3; Urban S, 2002, CURR BIOL, V12, P1507, DOI 10.1016/S0960-9822(02)01092-8; Urban S, 2001, CELL, V107, P173, DOI 10.1016/S0092-8674(01)00525-6; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Ye J, 2000, P NATL ACAD SCI USA, V97, P5123, DOI 10.1073/pnas.97.10.5123; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zelenski NG, 1999, J BIOL CHEM, V274, P21973, DOI 10.1074/jbc.274.31.21973; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	73	295	317	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	2004	305	5687					1119	1123		10.1126/science.1096187	http://dx.doi.org/10.1126/science.1096187			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326347				2022-12-28	WOS:000223557400036
J	Snow, RW				Snow, RW			The invisible victims	NATURE			English	Article							MALARIA; FUTURE		Kenya Med Res Inst Wellcome Trust Collaborat Prog, Nairobi, Kenya	Kenya Medical Research Institute	Snow, RW (corresponding author), Kenya Med Res Inst Wellcome Trust Collaborat Prog, Nairobi, Kenya.		Snow, Robert William/AFR-1436-2022	Snow, Robert William/0000-0003-3725-6088				Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6; MONASCH R, IN PRESS AM J TROP M; Rogers DJ, 2002, NATURE, V415, P710, DOI 10.1038/415710a; Snow RW, 2001, TRENDS PARASITOL, V17, P593, DOI 10.1016/S1471-4922(01)02031-1; SNOW RW, 2003, 11 DCPP; United Nations Development Program, 2003, HUM DEV REP 2003 MIL; 2000, ABUJA DECLARATION RO	7	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2004	430	7002					934	935		10.1038/430934a	http://dx.doi.org/10.1038/430934a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318234	Bronze			2022-12-28	WOS:000223369800057
J	Wang, Y; Wysocka, J; Sayegh, J; Lee, YH; Perlin, JR; Leonelli, L; Sonbuchner, LS; McDonald, CH; Cook, RG; Dou, Y; Roeder, RG; Clarke, S; Stallcup, MR; Allis, CD; Coonrod, SA				Wang, Y; Wysocka, J; Sayegh, J; Lee, YH; Perlin, JR; Leonelli, L; Sonbuchner, LS; McDonald, CH; Cook, RG; Dou, Y; Roeder, RG; Clarke, S; Stallcup, MR; Allis, CD; Coonrod, SA			Human PAD4 regulates histone arginine methylation levels via demethylimination	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATION; RECEPTOR; RNA; DIMETHYLAMINOHYDROLASE; ACETYLATION; RESIDUES; PRMT1; H4	Methylation of arginine (Arg) and lysine residues in histories has been correlated with epigenetic forms of gene regulation. Although histone methyltransferases are known, enzymes that demethylate histories have not been identified. Here, we demonstrate that human peptidylarginine deiminase 4 (PAD4) regulates histone Arg methylation by converting methyl-Arg to citrulline and releasing methylamine. PAD4 targets multiple sites in histones H3 and H4, including those sites methylated by coactivators CARM1 (H3 Arg(17)) and PRMT1 (H4 Arg(3)). A decrease of histone Arg methylation, with a concomitant increase of citrullination, requires PAD4 activity in human HL-60 granulocytes. Moreover, PAD4 activity is linked with the transcriptional regulation of estrogen-responsive genes in MCF-7 cells. These data suggest that PAD4 mediates gene expression by regulating Arg methylation and citrullination in histories.	Rockefeller Univ, Lab Chromatin Biol, New York, NY 10021 USA; Cornell Univ, Dept Med Genet, Weill Med Coll, New York, NY 10021 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	Rockefeller University; Cornell University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Southern California; Baylor College of Medicine; Rockefeller University	Allis, CD (corresponding author), Rockefeller Univ, Lab Chromatin Biol, Box 78,1230 York Ave, New York, NY 10021 USA.	alliscd@rockefeller.edu; scc2003@med.cornell.edu	Leonelli, Lauriebeth/GYU-8762-2022; Lee, Young-Ho/G-2361-2014; zhang, shijun/K-3688-2013	Leonelli, Lauriebeth/0000-0001-7536-523X; Lee, Young-Ho/0000-0001-6415-4912; Wang, Yanming/0000-0002-0710-043X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK055274, R01DK055274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020] Funding Source: NIH RePORTER; NICHD NIH HHS [HD R01 38353] Funding Source: Medline; NIDDK NIH HHS [DK55274] Funding Source: Medline; NIGMS NIH HHS [GM R01 50659, GM R01 26020] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Arita K, 2004, NAT STRUCT MOL BIOL, V11, P777, DOI 10.1038/nsmb799; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Barber CM, 2004, CHROMOSOMA, V112, P360, DOI 10.1007/s00412-004-0281-9; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; Boisvert FM, 2003, MOL CELL PROTEOMICS, V2, P1319, DOI 10.1074/mcp.M300088-MCP200; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Georgieva EI, 1999, ANAL BIOCHEM, V269, P399, DOI 10.1006/abio.1999.4050; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hagiwara T, 2002, BIOCHEM BIOPH RES CO, V290, P979, DOI 10.1006/bbrc.2001.6303; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Murray-Rust J, 2001, NAT STRUCT BIOL, V8, P679, DOI 10.1038/90387; Nakatani T, 2002, J BIOL CHEM, V277, P9562, DOI 10.1074/jbc.M110132200; OGAWA T, 1989, J BIOL CHEM, V264, P10205; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SAYEGH J, UNPUB; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Vossenaar ER, 2003, BIOESSAYS, V25, P1106, DOI 10.1002/bies.10357; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; WANG Y, UNPUB; XIE H, 1990, Methods (Orlando), V1, P276, DOI 10.1016/S1046-2023(05)80328-7; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	31	706	744	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	2004	306	5694					279	283		10.1126/science.1101400	http://dx.doi.org/10.1126/science.1101400			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	861MC	15345777				2022-12-28	WOS:000224419700041
J	Pikarsky, E; Porat, RM; Stein, I; Abramovitch, R; Amit, S; Kasem, S; Gutkovich-Pyest, E; Urieli-Shoval, S; Galun, E; Ben-Neriah, Y				Pikarsky, E; Porat, RM; Stein, I; Abramovitch, R; Amit, S; Kasem, S; Gutkovich-Pyest, E; Urieli-Shoval, S; Galun, E; Ben-Neriah, Y			NF-kappa B functions as a tumour promoter in inflammation-associated cancer	NATURE			English	Article							HEPATOCELLULAR-CARCINOMA; MOUSE MODEL; DNA-DAMAGE; IKK-BETA; LIVER; APOPTOSIS; MICE; ACTIVATION; INHIBITION; TARGET	The causes of sporadic human cancer are seldom recognized, but it is estimated that carcinogen exposure and chronic inflammation are two important underlying conditions for tumour development, the latter accounting for approximately 20% of human cancer(1). Whereas the causal relationship between carcinogen exposure and cancer has been intensely investigated(2), the molecular and cellular mechanisms linking chronic inflammation to tumorigenesis remain largely unresolved(1). We proposed that activation of the nuclear factor kappaB (NF-kappaB), a hallmark of inflammatory responses(3) that is frequently detected in tumours(4,5), may constitute a missing link between inflammation and cancer. To test this hypothesis, we studied the Mdr2-knockout mouse strain, which spontaneously develops cholestatic hepatitis followed by hepatocellular carcinoma(6), a prototype of inflammation-associated cancer(7). We monitored hepatitis and cancer progression in Mdr2-knockout mice, and here we show that the inflammatory process triggers hepatocyte NF-kappaB through upregulation of tumour-necrosis factor-alpha (TNFalpha) in adjacent endothelial and inflammatory cells. Switching off NF-kappaB in mice from birth to seven months of age, using a hepatocyte-specific inducible IkappaB-super-repressor transgene, had no effect on the course of hepatitis, nor did it affect early phases of hepatocyte transformation. By contrast, suppressing NF-kappaB inhibition through anti-TNFalpha treatment or induction of IkappaB-superrepressor in later stages of tumour development resulted in apoptosis of transformed hepatocytes and failure to progress to hepatocellular carcinoma. Our studies thus indicate that NF-kappaB is essential for promoting inflammation-associated cancer, and is therefore a potential target for cancer prevention in chronic inflammatory diseases.	Hadassah Hebrew Univ Med Ctr, Dept Pathol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91120 Jerusalem, Israel; Goldyne Savad Inst Gene Therapy, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Hematol Unit, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Pikarsky, E (corresponding author), Hadassah Hebrew Univ Med Ctr, Dept Pathol, IL-91120 Jerusalem, Israel.	peli@hadassah.org.il; yinon@cc.huji.ac.il	pikarsky, eli/GXV-7099-2022; Ben-Neriah, Yinon/L-6285-2019; Galun, Eithan/AAD-9117-2022	Galun, Eithan/0000-0002-6243-6702; pikarsky, eli/0000-0003-4186-7105				Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557; Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3; Chaisson ML, 2002, J CLIN INVEST, V110, P193, DOI 10.1172/JCI200215295; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; De Vree JML, 2000, GASTROENTEROLOGY, V119, P1720, DOI 10.1053/gast.2000.20222; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Friedberg EC, 2004, CURR OPIN GENET DEV, V14, P5, DOI 10.1016/j.gde.2003.11.001; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Gupta S, 2000, SEMIN CANCER BIOL, V10, P161; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Lavon I, 2000, NAT MED, V6, P573, DOI 10.1038/75057; Lavon I, 2003, CANCER RES, V63, P25; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; MAUAD TH, 1994, AM J PATHOL, V145, P1237; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Nakamoto Y, 1998, J EXP MED, V188, P341, DOI 10.1084/jem.188.2.341; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Radisky D, 2001, SEMIN CANCER BIOL, V11, P87, DOI 10.1006/scbi.2000.0360; Staudt LM, 2003, NEW ENGL J MED, V348, P1777, DOI 10.1056/NEJMra020067; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Wang JS, 1999, MUTAT RES-FUND MOL M, V424, P167, DOI 10.1016/S0027-5107(99)00017-2; Wilson J, 2002, SEMIN CANCER BIOL, V12, P113, DOI 10.1006/scbi.2001.0419	27	1998	2128	10	202	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	2004	431	7007					461	466		10.1038/nature02924	http://dx.doi.org/10.1038/nature02924			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	855UN	15329734				2022-12-28	WOS:000224000500043
J	Morgan, WJ; Crain, EF; Gruchalla, RS; O'Connor, GT; Kattan, M; Evans, RI; Stout, J; Malindzak, G; Smartt, E; Plaut, M; Walter, M; Vaughn, B; Mitchell, H				Morgan, WJ; Crain, EF; Gruchalla, RS; O'Connor, GT; Kattan, M; Evans, RI; Stout, J; Malindzak, G; Smartt, E; Plaut, M; Walter, M; Vaughn, B; Mitchell, H		Inner-City Asthma Study Grp	Results of a home-based environmental intervention among urban children with asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOUSE-DUST-MITE; INNER-CITY CHILDREN; COCKROACH ALLERGEN EXPOSURE; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND TRIAL; AVOIDANCE MEASURES; TOBACCO-SMOKE; RISK-FACTORS; LOW-INCOME; REDUCTION	Background: Children with asthma who live in the inner city are exposed to multiple indoor allergens and environmental tobacco smoke in their homes. Reductions in these triggers of asthma have been difficult to achieve and have seldom been associated with decreased morbidity from asthma. The objective of this study was to determine whether an environmental intervention tailored to each child's allergic sensitization and environmental risk factors could improve asthma-related outcomes. Methods: We enrolled 937 children with atopic asthma (age, 5 to 11 years) in seven major U.S. cities in a randomized, controlled trial of an environmental intervention that lasted one year (intervention year) and included education and remediation for exposure to both allergens and environmental tobacco smoke. Home environmental exposures were assessed every six months, and asthma-related complications were assessed every two months during the intervention and for one year after the intervention. Results: For every 2-week period, the intervention group had fewer days with symptoms than did the control group both during the intervention year (3.39 vs. 4.20 days, P<0.001) and the year afterward (2.62 vs. 3.21 days, P<0.001), as well as greater declines in the levels of allergens at home, such as Dermatophagoides farinae (Derf1) allergen in the bed (P<0.001) and on the bedroom floor (P=0.004), D. pteronyssinus in the bed (P=0.007), and cockroach allergen on the bedroom floor (P<0.001). Reductions in the levels of cockroach allergen and dust-mite allergen (Derf1) on the bedroom floor were significantly correlated with reduced complications of asthma (P<0.001). Conclusions: Among inner-city children with atopic asthma, an individualized, home-based, comprehensive environmental intervention decreases exposure to indoor allergens, including cockroach and dust-mite allergens, resulting in reduced asthma-associated morbidity.	Univ Arizona, Arizona Resp Ctr, Coll Med, Tucson, AZ 85724 USA; Albert Einstein Coll Med, Jacobi Med Ctr, Bronx, NY 10467 USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Boston Univ, Sch Med, Boston, MA 02118 USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Childrens Mem Hosp, Chicago, IL 60614 USA; Univ Washington, Sch Med & Publ Hlth, Seattle, WA USA; NIEHS, Res Triangle Pk, NC 27709 USA; NIAID, Bethesda, MD 20892 USA; Rho, Chapel Hill, NC USA	University of Arizona; Jacobi Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Boston University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Ann & Robert H. Lurie Children's Hospital of Chicago; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Rho	Morgan, WJ (corresponding author), Univ Arizona, Arizona Resp Ctr, Coll Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA.			O'Connor, George/0000-0002-6476-3926; Walter, Michelle/0000-0002-3251-487X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI039761, U01AI039901, U01AI039776, U01AI039902, U01AI039900, U01AI039785, U01AI039789, U01AI039769] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00533] Funding Source: Medline; NIAID NIH HHS [AI-39769, AI-39776, AI-39901, AI-39785, AI-39900, AI-39902, AI-39789, AI-39761] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; BANDURA A, 1986, SOCIAL FDN THOUGHT A; Bandura A, 1986, SOCIAL LEARNING THEO; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; Cook DG, 1997, THORAX, V52, P1081, DOI 10.1136/thx.52.12.1081; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939, DOI 10.1289/ehp.02110939; DORWARD AJ, 1988, THORAX, V43, P98, DOI 10.1136/thx.43.2.98; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Elder JP, 1999, AM J PREV MED, V17, P275, DOI 10.1016/S0749-3797(99)00094-X; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; Gotzsche PC, 2001, COCHRANE DB SYST REV, V3; Hamilton RG, 1997, METHODS, V13, P53, DOI 10.1006/meth.1997.0495; Hovell MF, 2002, PEDIATRICS, V110, P946, DOI 10.1542/peds.110.5.946; Htut T, 2001, J ALLERGY CLIN IMMUN, V107, P55, DOI 10.1067/mai.2001.111240; *I MED, 2000, CLEAR AIR ASTHM IND, P124; Irvine L, 1999, BRIT MED J, V318, P1456, DOI 10.1136/bmj.318.7196.1456; Jalaludin B, 1998, J ALLERGY CLIN IMMUN, V102, P382, DOI 10.1016/S0091-6749(98)70124-1; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; MARKS GB, 1994, CLIN EXP ALLERGY, V24, P1078, DOI 10.1111/j.1365-2222.1994.tb02746.x; McDonald E, 2002, CHEST, V122, P1535, DOI 10.1378/chest.122.5.1535; *NAT KIDN FDN INC, 1997, DIAL OUTC QUAL IN CL, P42; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Platts-Mills TAE, 2003, NEW ENGL J MED, V349, P207, DOI 10.1056/NEJMp030082; Rijssenbeek-Nouwens LHM, 2002, THORAX, V57, P784, DOI 10.1136/thorax.57.9.784; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; *THOM HEALTHC, 2004, DRUG TOP RED BOOK; vanderHeide S, 1997, ALLERGY, V52, P921, DOI 10.1111/j.1398-9995.1997.tb01252.x; Vojta PJ, 2001, ENVIRON HEALTH PERSP, V109, P815, DOI 10.2307/3454824; Wakefield M, 2002, PREV MED, V34, P58, DOI 10.1006/pmed.2001.0953; WALSHAW MJ, 1986, Q J MED, V58, P199; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, P75, DOI 10.1016/S0091-6749(00)90181-7; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; Williams LW, 1999, J ALLERGY CLIN IMMUN, V104, P702, DOI 10.1016/S0091-6749(99)70346-5; Wood RA, 2001, ANN ALLERG ASTHMA IM, V87, P60, DOI 10.1016/S1081-1206(10)62324-1; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175	45	776	802	2	79	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2004	351	11					1068	1080		10.1056/NEJMoa032097	http://dx.doi.org/10.1056/NEJMoa032097			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CX	15356304				2022-12-28	WOS:000223733900006
J	Talbot, TR; Stapleton, JT; Brady, RC; Winokur, PL; Bernstein, DI; Germanson, T; Yoder, SM; Rock, MT; Crowe, JE; Edwards, KM				Talbot, TR; Stapleton, JT; Brady, RC; Winokur, PL; Bernstein, DI; Germanson, T; Yoder, SM; Rock, MT; Crowe, JE; Edwards, KM			Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	42nd Annual Meeting of the Infectious-Diseases-Society-of-America	SEP 30-OCT 03, 2004	Boston, MA	Infect Dis Soc Amer			ADVERSE EVENTS; RESPONSES	Context Additional smallpox vaccine doses are needed to augment current US national stockpile. Aventis Pasteur smallpox vaccine (APSV), initially manufactured in the 1950s from the New York Board of Health vaccinia strain in a frozen preparation, appears as effective as lyophilized vaccine but the effectiveness of diluted doses of APSV is unclear. Objective To compare the vaccination success rate and the reaction profile of various APSV dilutions. Design, Setting, and Participants A double-blind, randomized controlled trial of 340 healthy vaccinia-naive adults aged 18 to 32 years from 3 academic medical centers who were vaccinated with 1 of 3 strengths of APSV dilutions (undiluted, 1:5, and 1: 10) between October 9, 2002, and February 24, 2003. Volunteers were followed up every 3 to 5 days until the vaccination site healed for bandage changes, vaccine response assessment, and adverse event evaluation, followed by 1- and 2-month clinic evaluations and 6-month telephone interview. Main Outcome Measures Successful vaccination, defined by presence of a vesicle or pustule at the inoculation site 6 to 11 days postvaccination, and local and systemic reactions to vaccination. Results A total of 340 volunteers were vaccinated (vaccine dose: undiluted, n=113; 1:5 dilution, n=114; and 1:10 dilution, n=113). Following vaccination, 99.4% (95% confidence interval [CI], 97.9%-99.9%) of all volunteers had successful vaccinations. Success rates did not differ between the dilution groups (undiluted, 100.0%; 95% CI, 96.8%-100.0%; 1:5 dilution, 98.2%; 95% CI, 93.8%-99.8%; 1:10 dilution, 100.0% 95% CI, 96.8%-100.0%; P=33). Overall, 99.7% of volunteers reported at least 1 local symptom at the vaccination site, and 61.8% had axillary lymphadenopathy, 15.0% developed satellite lesions, and 7.6% developed a rash away from the vaccination site. Fever developed in 21.5%. No differences were noted in local or systemic reactions between the 3 dilution groups (P>.05 for each comparison). A total of 25% of volunteers missed scheduled duties due to vaccine-related symptoms. Conclusions Even at diluted doses, APSV is an effective smallpox vaccine, allowing for expansion of the current stockpile. However, reactogenicity was not reduced with dilution of the vaccine and, as with other smallpox vaccines, may impair daily activities.	Vanderbilt Univ, Sch Med, Dept Pediat, Pediat Clin Res Off, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Univ Iowa, Dept Med, Iowa City, IA 52242 USA; Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH USA; EMMES Corp, Rockville, MD USA	Vanderbilt University; Vanderbilt University; University of Iowa; Cincinnati Children's Hospital Medical Center; Emmes Corporation	Edwards, KM (corresponding author), Vanderbilt Univ, Sch Med, Dept Pediat, Pediat Clin Res Off, CCC-5323,MCN,1161 21st Ave S, Nashville, TN 37232 USA.	kathryn.edwards@vanderbilt.edu	Crowe, James/B-5549-2009	Crowe, James/0000-0002-0049-1079; Talbot, Thomas/0000-0002-6139-212X; Winokur, Patricia/0000-0002-4826-1790; Stapleton, Jack/0000-0002-2302-9055	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000059, M01RR000095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025462, N01AI025459, R01AI057661, N01AI065298] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR-00095, M01 RR-00059] Funding Source: Medline; NIAID NIH HHS [N01 AI-25462, N01 AI-25459, N01 AI-15448, N01 AI-65298, R01 AI-57661] Funding Source: Medline; ODCDC CDC HHS [U50/CCU416123] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ODCDC CDC HHS		Aragon TJ, 2003, ANN EMERG MED, V42, P681, DOI 10.1016/S0196-0644(03)00811-4; Belshe RB, 2004, J INFECT DIS, V189, P493, DOI 10.1086/380906; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P639; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P191; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P180; *CDCP, SMALLP VACC PROGR ST; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P248; CHARATAN F, 2003, BMJ-BRIT MED J, V327, P414; Enserink M, 2003, SCIENCE, V300, P880; Frey SE, 2002, NEW ENGL J MED, V346, P1265, DOI 10.1056/NEJMoa020534; Grabenstein JD, 2003, JAMA-J AM MED ASSOC, V289, P3278, DOI 10.1001/jama.289.24.3278; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; Jezek Z, 1988, HUMAN MONKEYPOX; Newman FK, 2003, J CLIN MICROBIOL, V41, P3154, DOI 10.1128/JCM.41.7.3154-3157.2003; Pittman PR, 2002, VACCINE, V20, pS48, DOI 10.1016/S0264-410X(02)00172-X; Rock MT, 2004, J INFECT DIS, V189, P1401, DOI 10.1086/382510; Seli E, 2002, IMMUNOL ALLERGY CLIN, V22, P407, DOI 10.1016/S0889-8561(02)00017-6; Talbot TR, 2004, CLIN INFECT DIS, V38, P536, DOI 10.1086/381205; Talbot TR, 2003, JAMA-J AM MED ASSOC, V289, P3290, DOI 10.1001/jama.289.24.3290; Wharton Melinda, 2003, MMWR Recomm Rep, V52, P1	20	43	45	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2004	292	10					1205	1212		10.1001/jama.292.10.1205	http://dx.doi.org/10.1001/jama.292.10.1205			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	851ZA	15353533				2022-12-28	WOS:000223723800020
J	Levey, DJ; Duncan, RS; Levins, CF				Levey, DJ; Duncan, RS; Levins, CF			Use of dung as a tool by burrowing owls	NATURE			English	Editorial Material							CALEDONIAN CROWS; ECOLOGY		Univ Florida, Dept Zool, Gainesville, FL 32611 USA; Birmingham So Coll, Div Sci & Math, Birmingham, AL 35254 USA	State University System of Florida; University of Florida	Levey, DJ (corresponding author), Univ Florida, Dept Zool, POB 118525, Gainesville, FL 32611 USA.	dlevey@zoo.ufl.edu						Cristol DA, 1997, AUK, V114, P296, DOI 10.2307/4089172; HAUG EA, 1993, BURROWING OWL; HENRICH B, 1988, CONDOR, V90, P270; Hunt GR, 1996, NATURE, V379, P249, DOI 10.1038/379249a0; MARTIN DJ, 1973, CONDOR, V75, P446, DOI 10.2307/1366565; ROBINSON SK, 1994, WILSON BULL, V106, P567; Tebbich S, 2002, ECOL LETT, V5, P656, DOI 10.1046/j.1461-0248.2002.00370.x; Weir AAS, 2002, SCIENCE, V297, P981, DOI 10.1126/science.1073433; Woodruff R. E., 1973, SCARAB BEETLES FLORI	9	40	45	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2004	431	7004					39	39		10.1038/431039a	http://dx.doi.org/10.1038/431039a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343324				2022-12-28	WOS:000223641500031
J	Heathcote, J				Heathcote, J			Abnormal liver function found after an unplanned consultation: case outcome	BRITISH MEDICAL JOURNAL			English	Editorial Material									S View Lodge, Bromley BR1 3DR, Kent, England		Heathcote, J (corresponding author), S View Lodge, Bromley BR1 3DR, Kent, England.	james.heathcote@gp-G84001.nhs.uk							0	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 28	2004	329	7464					500	500		10.1136/bmj.329.7464.500	http://dx.doi.org/10.1136/bmj.329.7464.500			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KS	15331476	Green Published			2022-12-28	WOS:000223684600021
J	Wong, GWK; Ko, FWS; Hui, DSC; Fok, TF; Carr, D; von Mutius, E; Zhong, NS; Chen, YZ; Lai, CKW				Wong, GWK; Ko, FWS; Hui, DSC; Fok, TF; Carr, D; von Mutius, E; Zhong, NS; Chen, YZ; Lai, CKW			Factors associated with difference in prevalence of asthma in children from three cities in China: multicentre epidemiological survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; HOME-ENVIRONMENT; LUNG-FUNCTION; YOUNG-ADULTS; SCHOOLCHILDREN; POPULATION; RISK	Objective To determine the factors associated with difference in prevalence of asthma in children in different regions of China. Design Multicentre epidemiological survey. Setting Three cities in china. Participants 10 902 schoolchildren aged 10 years. Main outcome measures Asthma and atopic symptoms, atopic sensitisation, and early and current exposure to environmental factors. Results Children from Hong Kong had a significantly higher prevalence of wheeze in the past year than those from Guangzhou and Beijing (odds ratio 1.64, 95% confidence interval 1.35 to 1.99). Factors during the first year of life and currently that were significantly associated with wheeze were cooking with gas (odds ratio 2.04, 1.34 to 3.13), foam pillows (2.58, 1.66 to 3.99), and damp housing (1.89,1.26 to 2.83). Factors protecting against wheeze were cotton quilts and the consumption of fruit and raw vegetables. Conclusion Environmental factors and diet may explain the differences in prevalence of asthma between children living in different regions of China.	Chinese Univ Hong Kong, Dept Paediat, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; Univ Childrens Hosp, Munich, Germany; Guangzhou Inst Resp Dis, Guangzhou, Peoples R China; Capital Inst Paediat, Clin & Educ Ctr Asthma, Beijing, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich	Wong, GWK (corresponding author), Chinese Univ Hong Kong, Dept Paediat, Hong Kong, Hong Kong, Peoples R China.	wingkunvong@cuhk.edu.hk	Wong, Gary WK/AAY-9207-2020; Ko, Fanny W. S./B-8958-2016; Hui, David Shu-Cheong/O-2754-2015	Wong, Gary WK/0000-0001-5939-812X; Ko, Fanny W. S./0000-0001-8454-0087; Hui, David Shu-Cheong/0000-0003-4382-2445; von Mutius, Erika/0000-0002-8893-4515				ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363, DOI 10.1164/ajrccm/140.5.1363; Burr ML, 1999, THORAX, V54, P27, DOI 10.1136/thx.54.1.27; Burr ML, 1989, ARCH DIS CHILD, V64, P1118; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; DEKKER C, 1991, CHEST, V100, P922, DOI 10.1378/chest.100.4.922; Goren AI, 1997, EUR RESPIR J, V10, P2279, DOI 10.1183/09031936.97.10102279; Greenland S, 1998, MODERN EPIDEMIOLOGY; HSIEH KH, 1988, J ASTHMA, V25, P73, DOI 10.3109/02770908809071357; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; Leung R, 1997, EUR RESPIR J, V10, P354, DOI 10.1183/09031936.97.10020354; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Ponsonby AL, 2001, CLIN EXP ALLERGY, V31, P1544, DOI 10.1046/j.1365-2222.2001.01163.x; Shaheen SO, 2001, AM J RESP CRIT CARE, V164, P1823, DOI 10.1164/ajrccm.164.10.2104061; SHAW RA, 1990, ARCH DIS CHILD, V65, P1319, DOI 10.1136/adc.65.12.1319; Strachan D, 1997, BRIT MED J, V314, P518, DOI 10.1136/bmj.314.7079.518; STRACHAN DP, 1995, BRIT MED J, V311, P1053, DOI 10.1136/bmj.311.7012.1053; The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee, 1998, LANCET, V351, P1125; Williamson IJ, 1997, THORAX, V52, P229, DOI 10.1136/thx.52.3.229; Wong GWK, 2002, EUR RESPIR J, V19, P288, DOI 10.1183/09031936.02.002319.02; Wong GWK, 2001, CLIN EXP ALLERGY, V31, P1225, DOI 10.1046/j.1365-2222.2001.01140.x; Woods RK, 2003, AM J CLIN NUTR, V78, P414, DOI 10.1093/ajcn/78.3.414	23	91	93	1	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 28	2004	329	7464					486	488B		10.1136/bmj.329.7464.486	http://dx.doi.org/10.1136/bmj.329.7464.486			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KS	15331473	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000223684600014
J	Sun, HM; Ringdahl, U; Homeister, JW; Fay, WP; Engleberg, NC; Yang, AY; Rozek, LS; Wang, XX; Sjobring, U; Ginsburg, D				Sun, HM; Ringdahl, U; Homeister, JW; Fay, WP; Engleberg, NC; Yang, AY; Rozek, LS; Wang, XX; Sjobring, U; Ginsburg, D			Plasminogen is a critical host pathogenicity factor for group A streptococcal infection	SCIENCE			English	Article							LIGNEOUS CONJUNCTIVITIS; PLASMIN(OGEN) SYSTEM; PROTEIN PAM; VIRULENCE; MICE; DEFICIENCY; STREPTOKINASE; THROMBOSIS; ACTIVATION; PYOGENES	Group A streptococci, a common human pathogen, secrete streptokinase, which activates the host's blood clot-dissolving protein, plasminogen. Streptokinase is highly specific for human plasminogen, exhibiting little or no activity against other mammalian species, including mouse. Here, a transgene expressing human plasminogen markedly increased mortality in mice infected with streptococci, and this susceptibility was dependent on bacterial streptokinase expression. Thus, streptokinase is a key pathogenicity factor and the primary determinant of host species specificity for group A streptococcal infection. In addition, local fibrin clot formation may be implicated in host defense against microbial pathogens.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Lund Univ, Dept Lab Med, Sect Microbiol Immunol & Glycobiol, SE-22184 Lund, Sweden	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Lund University	Ginsburg, D (corresponding author), Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.	ginsburg@umich.edu			NHLBI NIH HHS [P01HL057346] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057346] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; Boyle MDP, 2000, METHODS, V21, P99, DOI 10.1006/meth.2000.0980; Braunwald E, 1996, NEW ENGL J MED, V334, P51, DOI 10.1056/NEJM199601043340113; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Coleman JL, 1997, CELL, V89, P1111, DOI 10.1016/S0092-8674(00)80298-6; Collen D, 1998, NAT MED, V4, P279, DOI 10.1038/nm0398-279; Drew AF, 1998, BLOOD, V91, P1616, DOI 10.1182/blood.V91.5.1616.1616_1616_1624; Gladysheva IP, 2003, P NATL ACAD SCI USA, V100, P9168, DOI 10.1073/pnas.1631716100; Heath A, 1999, INFECT IMMUN, V67, P5298, DOI 10.1128/IAI.67.10.5298-5305.1999; Herwald H, 2004, CELL, V116, P367, DOI 10.1016/S0092-8674(04)00057-1; Johansson L, 2003, SCIENCE, V301, P373, DOI 10.1126/science.1086476; Khil J, 2003, J INFECT DIS, V188, P497, DOI 10.1086/377100; Lahteenmaki K, 2001, FEMS MICROBIOL REV, V25, P531, DOI 10.1111/j.1574-6976.2001.tb00590.x; Li ZQ, 1999, J INFECT DIS, V179, P907, DOI 10.1086/314654; LIJNEN HR, 1994, EUR J BIOCHEM, V224, P863, DOI 10.1111/j.1432-1033.1994.00863.x; Lijnen HR, 1999, BLOOD, V93, P2274, DOI 10.1182/blood.V93.7.2274.407a30_2274_2281; MCCOY HE, 1991, J INFECT DIS, V164, P515, DOI 10.1093/infdis/164.3.515; MCKILLOP C, 1975, NATURE, V255, P638, DOI 10.1038/255638a0; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; Ringdahl U, 1998, J BIOL CHEM, V273, P6424, DOI 10.1074/jbc.273.11.6424; Schott D, 1998, NEW ENGL J MED, V339, P1679, DOI 10.1056/NEJM199812033392305; SODEINDE OA, 1992, SCIENCE, V258, P1004, DOI 10.1126/science.1439793; Wistedt AC, 1998, J BIOL CHEM, V273, P24420, DOI 10.1074/jbc.273.38.24420	24	300	310	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2004	305	5688					1283	1286		10.1126/science.1101245	http://dx.doi.org/10.1126/science.1101245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850PJ	15333838				2022-12-28	WOS:000223624600039
J	Powers, R; Fisher, M				Powers, R; Fisher, M			Tenosynovitis due to Mycobacterium marinum	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									W Virginia Univ, Morgantown, WV 26506 USA	West Virginia University	Powers, R (corresponding author), W Virginia Univ, Morgantown, WV 26506 USA.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2004	351	9					911	911		10.1056/NEJMicm990217	http://dx.doi.org/10.1056/NEJMicm990217			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849BM	15329429				2022-12-28	WOS:000223512500013
J	Nalbant, P; Hodgson, L; Kraynov, V; Toutchkine, A; Hahn, KM				Nalbant, P; Hodgson, L; Kraynov, V; Toutchkine, A; Hahn, KM			Activation of endogenous Cdc42 visualized in living cells	SCIENCE			English	Article							ALDRICH-SYNDROME PROTEIN; RHO-GTPASES; COMPLEX; RAC; BINDING; WASP; FIBROBLASTS; NEUTROPHILS; FILOPODIA; POLARITY	Signaling proteins are tightly regulated spatially and temporally to perform multiple functions. For Cdc42 and other guanosine triphosphatases, the subcellular location of activation is a critical determinant of cell behavior. However, current approaches are limited in their ability to examine the dynamics of Cdc42 activity in living cells. We report the development of a biosensor capable of visualizing the changing activation of endogenous, unlabeled Cdc42 in living cells. With the use of a dye that reports protein interactions, the biosensor revealed localized activation in the trans-Golgi apparatus, microtubule-dependent Cdc42 activation at the cell periphery, and activation kinetics precisely coordinated with cell extension and retraction.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Hahn, KM (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA.	khahn@med.unc.edu	Krainov, Vladimir P./D-9224-2014; Toutchkine, Alexei/A-7600-2009	Hahn, Klaus/0000-0002-1970-7562; Hodgson, Louis/0000-0001-9188-7580	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM064346, R01GM057464, R55GM057464] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM64346, GM57464, R01 GM057464] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BRIGHT GR, 1989, METHOD CELL BIOL, V30, P157; Cerione RA, 2004, TRENDS CELL BIOL, V14, P127, DOI 10.1016/j.tcb.2004.01.008; Erickson JW, 2001, CURR OPIN CELL BIOL, V13, P153, DOI 10.1016/S0955-0674(00)00192-7; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Higashida C, 2004, SCIENCE, V303, P2007, DOI 10.1126/science.1093923; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; MANDEVILLE JTH, 1995, BIOPHYS J, V68, P1207, DOI 10.1016/S0006-3495(95)80336-X; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; Nabi IR, 1999, J CELL SCI, V112, P1803; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Palazzo Alexander F, 2002, Sci STKE, V2002, ppe31, DOI 10.1126/stke.2002.139.pe31; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Seth A, 2003, BIOCHEMISTRY-US, V42, P3997, DOI 10.1021/bi026881z; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174; Toutchkine A, 2003, J AM CHEM SOC, V125, P4132, DOI 10.1021/ja0290882; Vignal E, 2000, J BIOL CHEM, V275, P36457, DOI 10.1074/jbc.M003487200; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Wedlich-Soldner R, 2003, SCIENCE, V299, P1231, DOI 10.1126/science.1080944; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585	32	300	309	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2004	305	5690					1615	1619		10.1126/science.1100367	http://dx.doi.org/10.1126/science.1100367			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361624				2022-12-28	WOS:000223891200042
J	Renwick, WH; Smith, SV; Sleezer, RO; Buddemeier, RW				Renwick, WH; Smith, SV; Sleezer, RO; Buddemeier, RW			Comment on "Managing soil carbon" (II)	SCIENCE			English	Editorial Material							EROSION; DEPOSITION; SEDIMENTS		Miami Univ, Dept Geog, Oxford, OH 45056 USA; Ctr Invest Cient & Educ Super Ensenada, Ensenada, Baja California, Mexico; Emporia State Univ, Dept Earth Sci, Emporia, KS 66801 USA; Univ Kansas, Kansas Geol Survey, Lawrence, KS 66047 USA	Miami University; CICESE - Centro de Investigacion Cientifica y de Educacion Superior de Ensenada; University of Kansas	Renwick, WH (corresponding author), Miami Univ, Dept Geog, Oxford, OH 45056 USA.	renwicwh@muohio.edu; svsmith@cicese.mx; sleezerr@emporia.edu; buddrw@ku.edu						Lal R, 2004, SCIENCE, V304, P1623, DOI 10.1126/science.1097396; Lal R, 2004, SCIENCE, V304, P393, DOI 10.1126/science.1093079; Lal R, 2003, ENVIRON INT, V29, P437, DOI 10.1016/S0160-4120(02)00192-7; Lal R., 1995, SOILS GLOBAL CHANGE, P131; Liu SG, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2002GB002010; RENWICK WH, IN PRESS GEOMORPHOLO; Rice CW, 2002, GEOTIMES, V47, P14; RITCHIE JC, 1989, WATER RESOUR BULL, V25, P301; Schlesinger W.H., 1995, BIOTIC FEEDBACKS GLO, V1st, P159; Smith SV, 2002, SCI TOTAL ENVIRON, V299, P21, DOI 10.1016/S0048-9697(02)00222-X; Smith SV, 2001, GLOBAL BIOGEOCHEM CY, V15, P697, DOI 10.1029/2000GB001341	11	27	34	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2004	305	5690												1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361609				2022-12-28	WOS:000223891200022
J	Yki-Jarvinen, H				Yki-Jarvinen, H			Drug therapy: Thiazolidinediones	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACTIVATED RECEPTOR-GAMMA; POLYCYSTIC-OVARY-SYNDROME; HEPATIC FAT-CONTENT; HAART-ASSOCIATED LIPODYSTROPHY; IMPROVES GLYCEMIC CONTROL; TYPE-2 DIABETES-MELLITUS; ADIPOSE-SPECIFIC PROTEIN; CORONARY-ARTERY-DISEASE; INSULIN-RESISTANCE; PPAR-GAMMA		Univ Helsinki, Dept Med, Div Diabet, Helsinki 00029, Finland	University of Helsinki	Yki-Jarvinen, H (corresponding author), Univ Helsinki, Dept Med, Div Diabet, POB 340, Helsinki 00029, Finland.	ykijarvi@cc.helsinki.fi						Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; Addy CL, 2003, J CLIN ENDOCR METAB, V88, P627, DOI 10.1210/jc.2002-020795; Arioglu E, 2000, ANN INTERN MED, V133, P263, DOI 10.7326/0003-4819-133-4-200008150-00009; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Aronoff S, 2000, DIABETES CARE, V23, P1605, DOI 10.2337/diacare.23.11.1605; Azziz R, 2001, J CLIN ENDOCR METAB, V86, P1626, DOI 10.1210/jc.86.4.1626; Bajaj M, 2004, J CLIN ENDOCR METAB, V89, P200, DOI 10.1210/jc.2003-031315; Bajaj M, 2003, DIABETES, V52, P1364, DOI 10.2337/diabetes.52.6.1364; Barbier O, 2002, ARTERIOSCL THROM VAS, V22, P717, DOI 10.1161/01.ATV.0000015598.86369.04; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Berger J, 2001, J BIOL CHEM, V276, P12629, DOI 10.1074/jbc.M003592200; Berger JP, 2003, MOL ENDOCRINOL, V17, P662, DOI 10.1210/me.2002-0217; Caballero AE, 2003, METABOLISM, V52, P173, DOI 10.1053/meta.2003.50023; Carey DG, 2002, OBES RES, V10, P1008, DOI 10.1038/oby.2002.137; Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3; Cavaghan MK, 1997, J CLIN INVEST, V100, P530, DOI 10.1172/JCI119562; Charbonnel B, 2002, DIABETOLOGIA, V45, pA107; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chinetti G, 2000, INFLAMM RES, V49, P497, DOI 10.1007/s000110050622; Clark JM, 2002, GASTROENTEROLOGY, V122, P1649, DOI 10.1053/gast.2002.33573; Clark JM, 2003, AM J GASTROENTEROL, V98, P960, DOI [10.1016/S0002-9270(03)00265-X, 10.1111/j.1572-0241.2003.07486.x]; Combs TP, 2002, ENDOCRINOLOGY, V143, P998, DOI 10.1210/endo.143.3.8662; Czoski-Murray C, 2004, HEALTH TECHNOL ASSES, V8, P1; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; *DIAB ATH INT STUD, 2001, LANCET, V357, P1890; Dubois M, 2000, DIABETOLOGIA, V43, P1165, DOI 10.1007/s001250051508; Duez H, 2002, J BIOL CHEM, V277, P48051, DOI 10.1074/jbc.M206966200; Einhorn D, 2000, CLIN THER, V22, P1395, DOI 10.1016/S0149-2918(00)83039-8; Fonseca V, 2000, JAMA-J AM MED ASSOC, V284, P1384; Fonseca V, 2000, JAMA-J AM MED ASSOC, V283, P1695, DOI 10.1001/jama.283.13.1695; Franks S, 1999, ENDOCRIN METAB CLIN, V28, P361, DOI 10.1016/S0889-8529(05)70074-8; Gale EAM, 2001, LANCET, V357, P1870, DOI 10.1016/S0140-6736(00)04960-6; Gavrilova O, 2003, J BIOL CHEM, V278, P34268, DOI 10.1074/jbc.M300043200; Ghazeeri G, 2003, FERTIL STERIL, V79, P562, DOI 10.1016/S0015-0282(02)04843-4; Gomez-Perez FJ, 2002, DIABETES-METAB RES, V18, P127, DOI 10.1002/dmrr.264; Guan HP, 2002, NAT MED, V8, P1122, DOI 10.1038/nm780; Haffner SM, 2002, CIRCULATION, V106, P679, DOI 10.1161/01.CIR.0000025403.20953.23; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Haque WA, 2002, J CLIN ENDOCR METAB, V87, P2395, DOI 10.1210/jc.87.5.2395; He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100; Henke BR, 1998, J MED CHEM, V41, P5020, DOI 10.1021/jm9804127; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Hirose H, 2002, METABOLISM, V51, P314, DOI 10.1053/meta.2002.30506; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Iuorno MJ, 2001, OBSTET GYN CLIN N AM, V28, P153, DOI 10.1016/S0889-8545(05)70191-1; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Khan MA, 2002, DIABETES CARE, V25, P708, DOI 10.2337/diacare.25.4.708; Kipnes MS, 2001, AM J MED, V111, P10, DOI 10.1016/S0002-9343(01)00713-6; Knochenhauer ES, 1998, J CLIN ENDOCR METAB, V83, P3078, DOI 10.1210/jc.83.9.3078; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kumada M, 2003, ARTERIOSCL THROM VAS, V23, P85, DOI 10.1161/01.ATV.0000048856.22331.50; Lebovitz HE, 2002, DIABETES CARE, V25, P815, DOI 10.2337/diacare.25.5.815; Lebovitz HE, 2001, J CLIN ENDOCR METAB, V86, P1659; Lebovitz HE, 2001, J CLIN ENDOCR METAB, V86, P280, DOI 10.1210/jc.86.1.280; LEBOVITZ HE, 2002, J CLIN ENDOCR METAB, V87, pR4; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Ljung B, 2002, J LIPID RES, V43, P1855, DOI 10.1194/jlr.M200127-JLR200; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Malmstrom R, 1997, DIABETOLOGIA, V40, P454, DOI 10.1007/s001250050700; Marx N, 2003, ARTERIOSCL THROM VAS, V23, P283, DOI 10.1161/01.ATV.0000054195.35121.5E; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Matsuda M, 2002, J BIOL CHEM, V277, P37487, DOI 10.1074/jbc.M206083200; Mayerson AB, 2002, DIABETES, V51, P797, DOI 10.2337/diabetes.51.3.797; Michalik L, 2003, CURR OPIN LIPIDOL, V14, P129, DOI 10.1097/00041433-200304000-00003; Miyazaki Y, 2002, DIABETES CARE, V25, P517, DOI 10.2337/diacare.25.3.517; Miyazaki Y, 2002, J CLIN ENDOCR METAB, V87, P2784, DOI 10.1210/jc.87.6.2784; Miyazaki Y, 2001, DIABETOLOGIA, V44, P2210, DOI 10.1007/s001250100031; Miyazaki Y, 2001, DIABETES CARE, V24, P710, DOI 10.2337/diacare.24.4.710; Mynarcik DC, 2002, JAIDS-J ACQ IMM DEF, V31, P514, DOI 10.1097/00126334-200212150-00009; Nathan DM, 2002, NEW ENGL J MED, V347, P1342, DOI 10.1056/NEJMcp021106; NESTLER JE, 1991, J CLIN ENDOCR METAB, V72, P83, DOI 10.1210/jcem-72-1-83; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V38, P1008, DOI 10.1053/jhep.2003.50420; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; Phillips SA, 2003, DIABETES, V52, P667, DOI 10.2337/diabetes.52.3.667; Picard F, 2002, ANNU REV NUTR, V22, P167, DOI 10.1146/annurev.nutr.22.010402.102808; Promrat K, 2004, HEPATOLOGY, V39, P188, DOI 10.1002/hep.20012; Raskin P, 2001, DIABETES CARE, V24, P1226, DOI 10.2337/diacare.24.7.1226; Reitman ML, 2000, TRENDS ENDOCRIN MET, V11, P410, DOI 10.1016/S1043-2760(00)00309-X; Rieusset J, 1999, BIOCHEM BIOPH RES CO, V265, P265, DOI 10.1006/bbrc.1999.1657; Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219; RIGGS BL, 2003, NEW ENGL J MED, V348, P1192; Rosenblatt S, 2001, CORONARY ARTERY DIS, V12, P413, DOI 10.1097/00019501-200108000-00011; Rosenstock J, 2002, INT J CLIN PRACT, V56, P251; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Ryysy L, 2000, DIABETES, V49, P749, DOI 10.2337/diabetes.49.5.749; Sakamoto J, 2000, BIOCHEM BIOPH RES CO, V278, P704, DOI 10.1006/bbrc.2000.3868; Scherbaum WA, 2002, HORM METAB RES, V34, P589, DOI 10.1055/s-2002-35421; Seppala-Lindroos A, 2002, J CLIN ENDOCR METAB, V87, P3023, DOI 10.1210/jc.87.7.3023; Sidhu JS, 2004, ARTERIOSCL THROM VAS, V24, P930, DOI 10.1161/01.ATV.0000124890.40436.77; Smith U, 2001, FASEB J, V15, P215, DOI 10.1096/fj.00-0020com; Solomon CG, 1999, ENDOCRIN METAB CLIN, V28, P247, DOI 10.1016/S0889-8529(05)70069-4; Steiner G, 2001, LANCET, V357, P905; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; SUTER SL, 1992, DIABETES CARE, V15, P193, DOI 10.2337/diacare.15.2.193; Sutinen J, 2003, ANTIVIR THER, V8, P199; Sutinen J, 2003, J CLIN ENDOCR METAB, V88, P1907, DOI 10.1210/jc.2002-021922; Tack CJJ, 1998, DIABETOLOGIA, V41, P569, DOI 10.1007/s001250050948; Tiikkainen M, 2004, DIABETES, V53, P2169, DOI 10.2337/diabetes.53.8.2169; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; *UKPDS GROUP, 1998, LANCET, V352, P1557; Unger RH, 2003, TRENDS ENDOCRIN MET, V14, P398, DOI 10.1016/j.tem.2003.09.008; Viberti G, 2002, DIABETES CARE, V25, P1737, DOI 10.2337/diacare.25.10.1737; Vongthavaravat V, 2002, CURR MED RES OPIN, V18, P456, DOI 10.1185/030079902125001236; Vozarova B, 2002, DIABETES, V51, P1889, DOI 10.2337/diabetes.51.6.1889; Walker BR, 2000, CLIN ENDOCRINOL, V52, P401, DOI 10.1046/j.1365-2265.2000.00969.x; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Yang WS, 2002, DIABETES CARE, V25, P376, DOI 10.2337/diacare.25.2.376; Yki-Jarvinen H, 2003, ARTERIOSCL THROM VAS, V23, P688, DOI 10.1161/01.ATV.0000062885.61917.A5; Yki-Jarvinen H, 2001, DIABETES CARE, V24, P758, DOI 10.2337/diacare.24.4.758; YKIJARVINEN H, 1994, LANCET, V343, P91, DOI 10.1016/S0140-6736(94)90821-4; YKIJARVINEN H, 2003, TXB DIABETES; Yu JG, 2002, DIABETES, V51, P2968, DOI 10.2337/diabetes.51.10.2968	118	1629	1696	0	74	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2004	351	11					1106	1118		10.1056/NEJMra041001	http://dx.doi.org/10.1056/NEJMra041001			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CX	15356308				2022-12-28	WOS:000223733900010
J	Eigenmann, PA; Haenggeli, CA				Eigenmann, PA; Haenggeli, CA			Food colourings and preservatives - allergy and hyperactivity	LANCET			English	Editorial Material							CHILDREN		Childrens Univ Hosp, CH-1211 Geneva 14, Switzerland	University of Geneva	Eigenmann, PA (corresponding author), Childrens Univ Hosp, CH-1211 Geneva 14, Switzerland.	Philippe.Eigenmann@hcuge.ch	Eigenmann, Philippe/A-6569-2017	Eigenmann, Philippe/0000-0003-1738-1826				Avery NJ, 2003, PEDIAT ALLERG IMM-UK, V14, P378, DOI 10.1034/j.1399-3038.2003.00072.x; Bateman B, 2004, ARCH DIS CHILD, V89, P506, DOI 10.1136/adc.2003.031435; EGGER J, 1992, LANCET, V339, P1150, DOI 10.1016/0140-6736(92)90742-L; Feingold B F, 1975, Am J Nurs, V75, P797, DOI 10.2307/3423460; Homer CJ, 2000, PEDIATRICS, V105, P1158; POLLOCK I, 1990, ARCH DIS CHILD, V65, P74, DOI 10.1136/adc.65.1.74; Warner J O, 1993, Pediatr Allergy Immunol, V4, P112, DOI 10.1111/j.1399-3038.1993.tb00078.x	7	22	22	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	2004	364	9437					823	824		10.1016/S0140-6736(04)16996-1	http://dx.doi.org/10.1016/S0140-6736(04)16996-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351173				2022-12-28	WOS:000223685200007
J	Holland, NJ; Weiner, GM				Holland, NJ; Weiner, GM			Recent developments in Bell's palsy	BMJ-BRITISH MEDICAL JOURNAL			English	Review							FACIAL PARALYSIS; ACYCLOVIR; PREDNISONE; THERAPY; DIAGNOSIS; STEROIDS; SURGERY		Royal Devon & Exeter NHS Fdn Trust, Dept Otolaryngol, Exeter EX2 5DW, Devon, England	University of Exeter	Holland, NJ (corresponding author), Royal Devon & Exeter NHS Fdn Trust, Dept Otolaryngol, Exeter EX2 5DW, Devon, England.	njulianholland@hotmail.com						ADOUR KK, 1982, NEW ENGL J MED, V307, P348, DOI 10.1056/NEJM198208053070605; Axelsson S, 2003, ANN OTO RHINOL LARYN, V112, P197, DOI 10.1177/000348940311200301; Beurskens CHG, 2003, OTOL NEUROTOL, V24, P677, DOI 10.1097/00129492-200307000-00024; BURGESS LPA, 1984, LARYNGOSCOPE, V94, P1472; De Diego JI, 1998, LARYNGOSCOPE, V108, P573, DOI 10.1097/00005537-199804000-00020; DEMIRANDA P, 1983, J ANTIMICROB CHEMOTH, V12, P29, DOI 10.1093/jac/12.suppl_B.29; DOBIE RA, 1998, OTOLARYNGOLOGY HEAD, P2757; DRESNER SC, 2000, FOCAL POINTS     JAN; FISCH U, 1981, ARCH OTOLARYNGOL, V107, P1; Grogan PM, 2001, NEUROLOGY, V56, P830, DOI 10.1212/WNL.56.7.830; Hato N, 2003, OTOL NEUROTOL, V24, P948, DOI 10.1097/00129492-200311000-00022; HOUSE JW, 1985, OTOLARYNG HEAD NECK, V93, P146, DOI 10.1177/019459988509300202; Lagalla G, 2002, NEUROL SCI, V23, P107, DOI 10.1007/s100720200035; Murakami S, 1997, ANN NEUROL, V41, P353, DOI 10.1002/ana.410410310; Murakami S, 1996, ANN INTERN MED, V124, P27, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00005; Peitersen E, 2002, ACTA OTO-LARYNGOL, V122, P4, DOI 10.1080/000164802320401694; Ramsey MJ, 2000, LARYNGOSCOPE, V110, P335, DOI 10.1097/00005537-200003000-00001; Rowlands S, 2002, EUR J NEUROL, V9, P63, DOI 10.1046/j.1468-1331.2002.00343.x; SALINAS RA, 2002, COCHRANE DB SYST REV; Salman MS, 2001, J CHILD NEUROL, V16, P565, DOI 10.2310/7010.2001.16848; SHAFSHAK TS, 1994, J LARYNGOL OTOL, V108, P940, DOI 10.1017/S0022215100128580; SIPE J, 2001, COCHRANE DB SYST REV; Snoeck R, 1999, DRUGS, V57, P187, DOI 10.2165/00003495-199957020-00005; Stanek G, 2003, LANCET, V362, P1639, DOI 10.1016/S0140-6736(03)14798-8; Sweeney CJ, 2001, J NEUROL NEUROSUR PS, V71, P149, DOI 10.1136/jnnp.71.2.149; Williamson IG, 1996, BRIT J GEN PRACT, V46, P743	26	185	197	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 4	2004	329	7465					553	557		10.1136/bmj.329.7465.553	http://dx.doi.org/10.1136/bmj.329.7465.553			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853DE	15345630	Green Published			2022-12-28	WOS:000223805800025
J	Bilkey, DK				Bilkey, DK			In the place space	SCIENCE			English	Editorial Material							CELLS		Univ Otago, Dept Psychol, Dunedin, New Zealand	University of Otago	Bilkey, DK (corresponding author), Univ Otago, Dept Psychol, Dunedin, New Zealand.	dbilkey@psy.otago.ac.nz						Brun VH, 2002, SCIENCE, V296, P2243, DOI 10.1126/science.1071089; Fyhn M, 2004, SCIENCE, V305, P1258, DOI 10.1126/science.1099901; Jeffery KJ, 2004, NEUROSCI BIOBEHAV R, V28, P201, DOI 10.1016/j.neubiorev.2003.12.002; Lee I, 2004, HIPPOCAMPUS, V14, P301, DOI 10.1002/hipo.10177; Lee I, 2004, NATURE, V430, P456, DOI 10.1038/nature02739; Leutgeb S, 2004, SCIENCE, V305, P1295, DOI 10.1126/science.1100265; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; MULLER RU, 1987, J NEUROSCI, V7, P1951; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; QUIRK GJ, 1992, J NEUROSCI, V12, P1945	10	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	2004	305	5688					1245	1246		10.1126/science.1102895	http://dx.doi.org/10.1126/science.1102895			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850PJ	15333826				2022-12-28	WOS:000223624600026
J	Dormitzer, PR; Nason, EB; Prasad, BVV; Harrison, SC				Dormitzer, PR; Nason, EB; Prasad, BVV; Harrison, SC			Structural rearrangements in the membrane penetration protein of a non-enveloped virus	NATURE			English	Article							RHESUS ROTAVIRUS VP4; CRYOELECTRON MICROSCOPY; 3-DIMENSIONAL STRUCTURE; CELL ENTRY; FUSION; HEMAGGLUTININ; RECONSTRUCTION; CLEAVAGE; BINDING; PERMEABILIZATION	Non-enveloped virus particles (those that lack a lipid-bilayer membrane) must breach the membrane of a target host cell to gain access to its cytoplasm. So far, the molecular mechanism of this membrane penetration step has resisted structural analysis. The spike protein VP4 is a principal component in the entry apparatus of rotavirus, a non-enveloped virus that causes gastroenteritis and kills 440,000 children each year(1). Trypsin cleavage of VP4 primes the virus for entry by triggering a rearrangement that rigidifies the VP4 spikes(2). We have determined the crystal structure, at 3.2 Angstrom resolution, of the main part of VP4 that projects from the virion. The crystal structure reveals a coiled-coil stabilized trimer. Comparison of this structure with the two-fold clustered VP4 spikes in a similar to12 Angstrom resolution image reconstruction from electron cryomicroscopy of trypsin-primed virions shows that VP4 also undergoes a second rearrangement, in which the oligomer reorganizes and each subunit folds back on itself, translocating a potential membrane-interaction peptide from one end of the spike to the other. This rearrangement resembles the conformational transitions of membrane fusion proteins of enveloped viruses(3-6).	Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA; Baylor Coll Med, Berna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Baylor College of Medicine	Dormitzer, PR (corresponding author), Harvard Univ, Sch Med, Dept Pediat, 320 Longwood Ave, Boston, MA 02115 USA.	dormitze@crystal.harvard.edu		Prasad, B.V.Venkataram/0000-0002-1172-2071	NIAID NIH HHS [R01 AI053174-01A1, R01 AI053174-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053174] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arias CF, 1996, J VIROL, V70, P5832, DOI 10.1128/JVI.70.9.5832-5839.1996; Crawford SE, 2001, J VIROL, V75, P6052, DOI 10.1128/JVI.75.13.6052-6061.2001; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; Dormitzer PR, 2001, J VIROL, V75, P7339, DOI 10.1128/JVI.75.16.7339-7350.2001; Dormitzer PR, 2002, EMBO J, V21, P885, DOI 10.1093/emboj/21.5.885; Dowling W, 2000, J VIROL, V74, P6368, DOI 10.1128/JVI.74.14.6368-6376.2000; Gibbons DL, 2004, NATURE, V427, P320, DOI 10.1038/nature02239; Gilbert JM, 1998, J VIROL, V72, P5323, DOI 10.1128/JVI.72.6.5323-5327.1998; Graham KL, 2003, J VIROL, V77, P9969, DOI 10.1128/JVI.77.18.9969-9978.2003; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lawton JA, 1996, J STRUCT BIOL, V116, P209, DOI 10.1006/jsbi.1996.0032; Liemann S, 2002, CELL, V108, P283, DOI 10.1016/S0092-8674(02)00612-8; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; MACKOW ER, 1988, P NATL ACAD SCI USA, V85, P645, DOI 10.1073/pnas.85.3.645; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OFFIT PA, 1986, J VIROL, V58, P700, DOI 10.1128/JVI.58.2.700-703.1986; Padilla JE, 2003, ACTA CRYSTALLOGR D, V59, P1124, DOI 10.1107/S0907444903007947; Parashar UD, 2003, EMERG INFECT DIS, V9, P565, DOI 10.3201/eid0905.020562; RUGGERI FM, 1991, J VIROL, V65, P2211, DOI 10.1128/JVI.65.5.2211-2219.1991; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; SHAW AL, 1993, CELL, V74, P693, DOI 10.1016/0092-8674(93)90516-S; TANIGUCHI K, 1988, J VIROL, V62, P2421, DOI 10.1128/JVI.62.7.2421-2426.1988; Tihova M, 2001, J MOL BIOL, V314, P985, DOI 10.1006/jmbi.2000.5238; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Weissenhorn W, 1996, EMBO J, V15, P1507, DOI 10.1002/j.1460-2075.1996.tb00494.x; Wriggers W, 1999, J STRUCT BIOL, V125, P185, DOI 10.1006/jsbi.1998.4080; YEAGER M, 1994, EMBO J, V13, P1011, DOI 10.1002/j.1460-2075.1994.tb06349.x; YEAGER M, 1990, J CELL BIOL, V110, P2133, DOI 10.1083/jcb.110.6.2133	30	164	178	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2004	430	7003					1053	1058		10.1038/nature02836	http://dx.doi.org/10.1038/nature02836			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329727	Green Accepted, Bronze			2022-12-28	WOS:000223514900049
J	Lloyd, S				Lloyd, S			Going into reverse	NATURE			English	Editorial Material									MIT, Dept Mech Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lloyd, S (corresponding author), MIT, Dept Mech Engn, 3-160, Cambridge, MA 02139 USA.							Landauer R., 2003, MAXWELLS DEMON, VII	1	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2004	430	7003					971	971		10.1038/430971a	http://dx.doi.org/10.1038/430971a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329700	Bronze			2022-12-28	WOS:000223514900022
J	Silverstein, M; Mack, C; Reavis, N; Koepsell, TD; Gross, GS; Grossman, DC				Silverstein, M; Mack, C; Reavis, N; Koepsell, TD; Gross, GS; Grossman, DC			Effect of a clinic-based referral system to head start - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLLOW-UP; CHILDREN; CARE; INTERVENTION; ACHIEVEMENT; ADOLESCENTS	Context Early childhood development programs such as Head Start have proven benefits for impoverished children. However, few physicians assist families with enrollment. Objective To test if a primary care-based intervention is efficacious in increasing Head Start attendance. Design, Setting, and Participants Randomized controlled trial of 246 Head Start-eligible children aged 0 through 4 years recruited in spring 2003 from 4 health clinics in Seattle, Wash. Interventions List of Head Start telephone contacts provided to families of all children and, for those in the intervention group, a computer-generated packet containing a physician referral letter (and a physical examination form and immunization record, if available) mailed directly to Head Start by study personnel. Main Outcome Measure Head Start attendance by January 2004. Results The 123 children analyzed in each study group were similar at baseline. Overall, 72 children (29%) were successfully connected with Head Start (ie, actively attending or on a waiting list) by January 2004. Among the intervention group, 50 children (41%) were successfully connected with Head Start, contrasted with 22 (18%) in the control group (adjusted difference, 17%; 95% confidence interval (01, 8%-27%). Among the intervention group, 31 children (25%) were actively attending Head Start, contrasted with 14 (11%) in the control group (adjusted difference, 12%; 95% Cl, 3% -21%). Only 2 clinics contributed children to Head Start waiting lists. Among children from these clinics, 19 of 87 (22%) in the intervention group got onto a Head Start waiting list, vs 8 of 94 (9%) in the control group (adjusted difference, 13%; 95% Cl, 5%-21%). To get 1 child either into Head Start or onto a waiting list, we needed to refer 4 children. Conclusion Facilitating an initial connection to Head Start on families' behalf substantially increased Head Start attendance.	Boston Univ, Sch Med, Boston Med Ctr, Dept Pediat, Boston, MA 02118 USA; Univ Washington, Robert Wood Johnson Clin Scholars Program, Seattle, WA 98195 USA; Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA	Boston Medical Center; Boston University; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Silverstein, M (corresponding author), Boston Univ, Sch Med, Boston Med Ctr, Dept Pediat, Matern Bldg,4th Floor,91 E Concord St, Boston, MA 02118 USA.	michael.silverstein@bmc.org		Silverstein, Michael/0000-0002-9474-7548				Anderson Laurie M, 2002, MMWR Recomm Rep, V51, P1; CAMPBELL FA, 1994, CHILD DEV, V65, P684, DOI 10.1111/j.1467-8624.1994.tb00777.x; Deddens JA, 2004, AM J EPIDEMIOL, V159, P213, DOI 10.1093/aje/kwh022; Forrest CB, 1999, ARCH PEDIAT ADOL MED, V153, P705, DOI 10.1001/archpedi.153.7.705; Forrest CB, 1999, PEDIATRICS, V104, P28, DOI 10.1542/peds.104.1.28; Glasgow RE, 2001, MILBANK Q, V79, P579, DOI 10.1111/1468-0009.00222; JOHNSON DL, 1991, J EARLY INTERVENTION, V15, P226, DOI 10.1177/105381519101500302; LALLY J, 1997, LONG RANGE IMPACT EA; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; LOVE JM, MAKING DIFFERENCE LI; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; NEEDLMAN R, 1999, AMBULATORY CHILD HLT, V5, P61; Reynolds AJ, 2001, JAMA-J AM MED ASSOC, V285, P2339, DOI 10.1001/jama.285.18.2339; Rushton J, 2002, ARCH PEDIAT ADOL MED, V156, P592, DOI 10.1001/archpedi.156.6.592; Schweinhart L.J., 1993, SIGNIFICANT BENEFITS; Silverstein M, 2003, PEDIATRICS, V111, P1351, DOI 10.1542/peds.111.6.1351; *US DEP HHS, 2000, HEAD STAR PROGR PERF; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; ZORITCH B, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000564; Zuckerman B, 2003, PEDIATRICS, V111, P1433, DOI 10.1542/peds.111.6.1433	20	32	32	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2004	292	8					968	971		10.1001/jama.292.8.968	http://dx.doi.org/10.1001/jama.292.8.968			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WR	15328329				2022-12-28	WOS:000223429200022
J	Car, J; Sheikh, A				Car, J; Sheikh, A			Email consultations in health care: 2-acceptability and safe application	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PATIENT-PHYSICIAN COMMUNICATION; WORLD-WIDE-WEB; RANDOMIZED CONTROLLED-TRIAL; E-MAIL CONSULTATIONS; ELECTRONIC COMMUNICATION; MEDICAL ADVICE; INTERNET; TELEPHONE; INFORMATION; GUIDELINES	Electronic communication promises to revolutionise the delivery of health care. In the second of two articles considering the potential for email consultations, Car and Sheikh summarise the evidence about public and professional attitudes to them and discuss how to ensure their safe use	Univ Edinburgh, Div Community Hlth Sci, GP Sect, Edinburgh EH8 9DX, Midlothian, Scotland; Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Social Med, London W6 8RP, England	University of Edinburgh; Imperial College London	Sheikh, A (corresponding author), Univ Edinburgh, Div Community Hlth Sci, GP Sect, Edinburgh EH8 9DX, Midlothian, Scotland.	aziz.sheikh@ed.ac.uk	Car, Josip/H-6755-2015; Sheikh, Aziz/D-2818-2009	Car, Josip/0000-0001-8969-371X; Sheikh, Aziz/0000-0001-7022-3056				AKIBA T, 2002, JPN J LUNG CANC, V42, P589; Anderson R, 1996, BRIT MED J, V312, P109; Anderson R, 1996, SECURITY CLIN INFORM; Andersson G, 2003, HEADACHE, V43, P353, DOI 10.1046/j.1526-4610.2003.03070.x; Andersson G, 2002, PSYCHOSOM MED, V64, P810, DOI 10.1097/01.PSY.0000031577.42041.F8; Andreassen Hege, 2002, Tidsskr Nor Laegeforen, V122, P1640; [Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Bachman JW, 2003, MAYO CLIN PROC, V78, P67, DOI 10.4065/78.1.67; Baker L, 2003, JAMA-J AM MED ASSOC, V289, P2400, DOI 10.1001/jama.289.18.2400; Baur C, 2000, HEALTH COMMUN, V12, P239, DOI 10.1207/S15327027HC1203_02; Borowitz SM, 1998, JAMA-J AM MED ASSOC, V280, P1321, DOI 10.1001/jama.280.15.1321; Car J, 2004, BMJ-BRIT MED J, V329, P435, DOI 10.1136/bmj.329.7463.435; Car J, 2004, QUAL SAF HEALTH CARE, V13, P2, DOI 10.1136/qshc.2003.009241; Car J, 2003, BMJ-BRIT MED J, V326, P966, DOI 10.1136/bmj.326.7396.966; Carlbring P, 2001, BEHAV THER, V32, P751, DOI 10.1016/S0005-7894(01)80019-8; *COLL AM PATH, MY HLTH TEST REM; Couchman GR, 2001, J FAM PRACTICE, V50, P414; Department of Health, 2003, CONF NHS COD PRACT; DONALDSON MS, 1996, PRIMARY CARE AM HLTH, P3; Eggar M, 2001, SYSTEMATIC REV HLTH; Ellis JE, 1999, J CLIN ANESTH, V11, P136, DOI 10.1016/S0952-8180(99)00005-7; Eysenbach G, 2002, BMJ-BRIT MED J, V324, P573, DOI 10.1136/bmj.324.7337.573; Eysenbach G, 2000, ARCH DERMATOL, V136, P121; Eysenbach G, 1998, LANCET, V352, P1526, DOI 10.1016/S0140-6736(05)60334-0; Eysenbach G, 1998, JAMA-J AM MED ASSOC, V280, P1333, DOI 10.1001/jama.280.15.1333; EYSENBACH G, 2000, J MED INTERNET RES, V2, pE1; Ferguson T, 1998, JAMA-J AM MED ASSOC, V280, P1361, DOI 10.1001/jama.280.15.1361; Ferguson T, 2000, BRIT MED J, V321, P1129, DOI 10.1136/bmj.321.7269.1129; Flanagan A., 2003, EUROPEAN PHYS INTERN; FRIDSMA DB, 1994, J AM MED INFORM ASSN, P15; Gaster B, 2003, J GEN INTERN MED, V18, P385, DOI 10.1046/j.1525-1497.2003.20627.x; *GEN PRACT COMM, 2001, CONS MOD WORLD GUID; Gordon C, 2003, LANCET, V362, P1768, DOI 10.1016/S0140-6736(03)14872-6; *HARR INT ARIA MAR, 2000, HARR INT ARIA MARK H; Herreria J, 1999, Profiles Healthc Mark, V15, P31; Hjortdahl P, 1999, Tidsskr Nor Laegeforen, V119, P4339; Hobbs J, 2003, INT J MED INFORM, V70, P1, DOI 10.1016/S1386-5056(03)00007-8; Houston TK, 2003, HEALTH COMMUN, V15, P515, DOI 10.1207/S15327027HC1504_08; Johnston C, 1996, CAN MED ASSOC J, V155, P1606; Kane B, 1998, J AM MED INFORM ASSN, V5, P104, DOI 10.1136/jamia.1998.0050104; Kassirer JP, 2000, HEALTH AFFAIR, V19, P115, DOI 10.1377/hlthaff.19.6.115; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; Katz SJ, 2003, J GEN INTERN MED, V18, P736, DOI 10.1046/j.1525-1497.2003.20756.x; Kleiner KD, 2002, PEDIATRICS, V109, P740, DOI 10.1542/peds.109.5.740; Leslie S, 2001, J TELEMED TELECARE, V7, P78, DOI 10.1258/1357633011937236; Liederman EM, 2003, J AM MED INFORM ASSN, V10, P260, DOI 10.1197/jamia.M1259; MAJEED A, FINDING MED INFORMAT; Mandl KD, 1998, ANN INTERN MED, V129, P495, DOI 10.7326/0003-4819-129-6-199809150-00012; Mason B W, 2000, Commun Dis Public Health, V3, P67; Mechanic D, 1998, MILBANK Q, V76, P281, DOI 10.1111/1468-0009.00089; *MED, MED NETW CONN PHYS P; *MED, MED US TERMS SERV; Mold J W, 1998, J Okla State Med Assoc, V91, P331; Moyer CA, 2002, AM J MANAG CARE, V8, P427; Moyer CA, 1999, AM J MANAG CARE, V5, P1513; Neill R A, 1994, Arch Fam Med, V3, P268, DOI 10.1001/archfami.3.3.268; Neinstein L, 2000, J ADOLESCENT HEALTH, V27, P6, DOI 10.1016/S1054-139X(99)00119-6; Neville R, 2000, BRIT J GEN PRACT, V50, P256; *NHS INF AUTH, NHSNET SAF COMP GUID; Partridge MR, 2004, PATIENT EDUC COUNS, V54, P11, DOI 10.1016/S0738-3991(03)00166-6; Patt MR, 2003, J MED INTERNET RES, V5, DOI 10.2196/jmir.5.2.e9; Perlemuter L, 2002, DIABETIC MED, V19, P701, DOI 10.1046/j.1464-5491.2002.00688_6.x; Prady SL, 2001, J AM MED INFORM ASSN, V8, P344, DOI 10.1136/jamia.2001.0080344; *RELAYHEALTH, SEC ONL COMM HEALTHC; Sarkar IN, 2002, J AM MED INFORM ASSN, V9, P209, DOI 10.1197/jamia.M1037; SCHORN H, 2000, J FERTIL REPROD, V10, P32; Sellu D, 1996, BRIT MED J, V312, P49, DOI 10.1136/bmj.312.7022.49a; Sharp D, 2001, BRIT MED J, V323, P1081, DOI 10.1136/bmj.323.7321.1081; Sittig DF, 2001, INT J MED INFORM, V61, P71, DOI 10.1016/S1386-5056(00)00134-9; Skinner CS, 1999, ANN BEHAV MED, V21, P290, DOI 10.1007/BF02895960; Strom L, 2000, J CONSULT CLIN PSYCH, V68, P722, DOI 10.1037//0022-006X.68.4.722; Tate DF, 2003, JAMA-J AM MED ASSOC, V289, P1833, DOI 10.1001/jama.289.14.1833; Turner CF, 1998, SCIENCE, V280, P867, DOI 10.1126/science.280.5365.867; United States Department of Health Human Services, MED PRIV NAT STAND P; Von Knoop C, 2003, VITAL SIGNS E HLTH U; Wedderburn A W, 1996, Ann R Coll Surg Engl, V78, P70; Widman LE, 1997, ARCH INTERN MED, V157, P209, DOI 10.1001/archinte.157.2.209	77	102	104	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 21	2004	329	7463					439	+		10.1136/bmj.329.7463.439	http://dx.doi.org/10.1136/bmj.329.7463.439			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	849EA	15321903	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000223520300024
J	Ahn, S; Joyner, AL				Ahn, S; Joyner, AL			Dynamic changes in the response of cells to positive hedgehog signaling during mouse limb patterning	CELL			English	Article							APICAL ECTODERMAL RIDGE; SONIC-HEDGEHOG; CUBITUS-INTERRUPTUS; SPINAL-CORD; INDIAN-HEDGEHOG; TRANSCRIPTIONAL ACTIVATOR; RECOMBINASE ACTIVITY; POLARIZING ACTIVITY; CRE RECOMBINASE; NEURAL-TUBE	In the vertebrate limb, the posteriorly located zone of polarizing activity (ZPA) regulates digit identity through the morphogen Sonic Hedgehog (Shh). By genetically marking Shh-responding cells in mice, we have addressed whether the cumulative influence of positive Shh signaling over time and space reflects a linear gradient of Shh responsiveness and whether Shh could play additional roles in limb patterning. Our results show that all posterior limb mesenchyme cells, as well as the ectoderm, respond to Shh from the ZPA and become the bone, muscle, and skin of the posterior limb. Further, the readout of Shh activator function integrated over time and space does not display a stable and linear gradient along the A-P axis, as in a classical morphogen view. Finally, by fate mapping Shh-responding cells in Gli2 and Gli3 mutant limbs, we demonstrate that a specific level of positive Hh signaling is not required to specify digit identities.	NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA; NYU, Sch Med, Dev Genet Program, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA	Howard Hughes Medical Institute; New York University; New York University; New York University; New York University	Joyner, AL (corresponding author), NYU, Sch Med, Howard Hughes Med Inst, 540 1st Ave, New York, NY 10016 USA.	joyner@saturn.med.nyu.edu						AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bai CB, 2004, DEV CELL, V6, P103, DOI 10.1016/S1534-5807(03)00394-0; Bai CB, 2002, DEVELOPMENT, V129, P4753; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Bren-Mattison Y, 2002, DEV BIOL, V242, P130, DOI 10.1006/dbio.2001.0528; Buckingham M, 2003, J ANAT, V202, P59, DOI 10.1046/j.1469-7580.2003.00139.x; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Chiang C, 2001, DEV BIOL, V236, P421, DOI 10.1006/dbio.2001.0346; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960-9822(07)00562-3; Duprez D, 1999, MECH DEVELOP, V82, P151, DOI 10.1016/S0925-4773(99)00040-4; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124; Grindley JC, 1997, DEV BIOL, V188, P337, DOI 10.1006/dbio.1997.8644; Gritli-Linde A, 2001, DEV BIOL, V236, P364, DOI 10.1006/dbio.2001.0336; Guo QX, 2003, DEV BIOL, V264, P166, DOI 10.1016/j.ydbio.2003.08.012; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Iwasaki M, 1997, MECH DEVELOP, V69, P197, DOI 10.1016/S0925-4773(97)00145-7; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Karp SJ, 2000, DEVELOPMENT, V127, P543; Kimmel RA, 2000, GENE DEV, V14, P1377; Kraus P, 2001, MECH DEVELOP, V100, P45, DOI 10.1016/S0925-4773(00)00492-5; Lee J, 1997, DEVELOPMENT, V124, P2537; Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092-8674(01)00369-5; Litingtung Y, 2002, NATURE, V418, P979, DOI 10.1038/nature01033; LOPEZMARTINEZ A, 1995, CURR BIOL, V5, P791, DOI 10.1016/S0960-9822(95)00156-4; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; MASUYA H, 1995, GENE DEV, V9, P1645, DOI 10.1101/gad.9.13.1645; MATISE MP, 2001, GENE TARGETING, P101; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Methot N, 2001, DEVELOPMENT, V128, P733; Mo R, 1997, DEVELOPMENT, V124, P113; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; Park HL, 2000, DEVELOPMENT, V127, P1593; Persson M, 2002, GENE DEV, V16, P2865, DOI 10.1101/gad.243402; Platt KA, 1997, MECH DEVELOP, V62, P121, DOI 10.1016/S0925-4773(96)00648-X; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROBINSON SP, 1991, DRUG METAB DISPOS, V19, P36; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Welscher PT, 2002, SCIENCE, V298, P827, DOI 10.1126/science.1075620; Wijgerde M, 2002, GENE DEV, V16, P2849, DOI 10.1101/gad.1025702; Yang Y, 1997, DEVELOPMENT, V124, P4393; Ying LT, 2000, NAT NEUROSCI, V3, P979, DOI 10.1038/79916; Zervas M, 2004, NEURON, V43, P345, DOI 10.1016/j.neuron.2004.07.010	50	377	391	1	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2004	118	4					505	516		10.1016/j.cell.2004.07.023	http://dx.doi.org/10.1016/j.cell.2004.07.023			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	850YS	15315762	Bronze			2022-12-28	WOS:000223650900012
J	Parkin, G				Parkin, G			Zinc-zinc bonds: A new frontier	SCIENCE			English	Editorial Material							ATOMS		Columbia Univ, Dept Chem, New York, NY 10027 USA	Columbia University	Parkin, G (corresponding author), Columbia Univ, Dept Chem, New York, NY 10027 USA.	parkin@chem.columbia.edu						Bardaji M, 1999, J CHEM EDUC, V76, P201, DOI 10.1021/ed076p201; Bravo-Zhivotovskii D, 1999, ANGEW CHEM INT EDIT, V38, P1100, DOI 10.1002/(SICI)1521-3773(19990419)38:8<1100::AID-ANIE1100>3.0.CO;2-N; Cotton F.A., 1993, MULTIPLE BONDS METAL; FAGGIANI R, 1986, CHEM COMMUN, P517; Hao HJ, 2001, CHEM COMMUN, P1118, DOI 10.1039/b102275j; KERSTEN JL, 1992, ANGEW CHEM INT EDIT, V31, P1341, DOI 10.1002/anie.199213411; LOBBIA GG, 1991, GAZZ CHIM ITAL, V121, P355; REGER DL, 1993, J AM CHEM SOC, V115, P10406, DOI 10.1021/ja00075a085; Resa I, 2004, SCIENCE, V305, P1136, DOI 10.1126/science.1101356; SCHNEIDER JJ, 1991, ANGEW CHEM INT EDIT, V30, P1124, DOI 10.1002/anie.199111241; Tian Y, 2003, J AM CHEM SOC, V125, P6622, DOI 10.1021/ja0343757	11	58	58	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2004	305	5687					1117	1118		10.1126/science.1102500	http://dx.doi.org/10.1126/science.1102500			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326345				2022-12-28	WOS:000223557400034
J	Meydani, SN; Leka, LS; Fine, BC; Dallal, GE; Keusch, GT; Singh, MF; Hamer, DH				Meydani, SN; Leka, LS; Fine, BC; Dallal, GE; Keusch, GT; Singh, MF; Hamer, DH			Vitamin E and respiratory tract infections in elderly nursing home residents - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TERM-CARE FACILITIES; HEALTHY OLDER-ADULTS; NOSOCOMIAL INFECTIONS; E SUPPLEMENTATION; SURVEILLANCE; POPULATION; MORTALITY; RISK; PREVALENCE; RHINOVIRUS	Context Respiratory tract infections are prevalent in elderly individuals, resulting in increased morbidity, mortality, and use of health care services. Vitamin E supplementation has been shown to improve immune response in elderly persons. However, the clinical importance of these findings has not been determined. Objective To determine the effect of 1 year of vitamin E supplementation on respiratory tract infections in elderly nursing home residents. Design, Setting, and Participants A randomized, double-blind, placebo-controlled trial was conducted from April 1998 to August 2001 at 33 long-term care facilities in the Boston, Mass, area. A total of 617 persons aged at least 65 years and who met the study's eligibility criteria were enrolled; 451 (73%) completed the study. Intervention Vitamin E (200 IU) or placebo capsule administered daily; all participants received a capsule containing half the recommended daily allowance of essential vitamins and minerals. Main Outcome Measures incidence of respiratory tract infections, number of persons and number of days with respiratory tract infections (upper and lower), and number of new antibiotic prescriptions for respiratory tract infections among all participants randomized and those who completed the study. Results Vitamin E had no significant effect on incidence or number of days with infection for all, upper, or lower respiratory tract infections. However, fewer participants receiving vitamin E acquired 1 or more respiratory tract infections (60% vs 68%; risk ratio [RR], 0.88; 95% confidence interval [0], 0.76-1.00; P=.048 for all participants; and 65% vs 74%; RR, 0.88; 95% Cl, 0.75-0.99; P=.04 for completing participants), or upper respiratory tract infections (44% vs 52%; RR, 0.84; 95% Cl, 0.69-1.00; P=.05 for all participants; and 50% vs 62%; RR, 0.81; 95% Cl, 0.66-0.96; P=.01 for completing participants). When common colds were analyzed in a post hoc subgroup analysis, the vitamin E group had a lower incidence of common cold (0.67 vs 0.81 per person-year; RR, 0.83; 95% Cl, 0.68-1.01; P=.06 for all participants; and 0.66 vs 0.83 per person-year; RR, 0.80; 95% Cl, 0.64-0.98;, P=.04 for completing participants) and fewer participants in the vitamin E group acquired 1 or more colds (40% vs 48%; RR, 0.83; 95% Cl, 0.67-1.00; P=.05 for all participants; and 46% vs 57%; RR, 0.80; 95% Cl, 0.64-0.96; P=.02 for completing participants). Vitamin E had no significant effect on antibiotic use. Conclusions Supplementation with 200 IU per day of vitamin E did not have a statistically significant effect on lower respiratory tract infections in elderly nursing home residents. However, we observed a protective effect of vitamin E supplementation on upper respiratory tract infections, particularly the common cold, that merits further investigation.	Tufts Univ, Jean Mayer USDA HNRCA, Nutr Immunol Lab, Boston, MA 02111 USA; Tufts Univ, Jean Mayer USDA HNRCA, Biostat Unit, Boston, MA 02111 USA; Tufts Univ, Sackler Grad Sch Biochem Sci, Dept Pathol, Boston, MA 02111 USA; Mt Auburn Hosp, Dept Med, Cambridge, MA USA; Boston Univ, Sch Publ Hlth, Dept Int Hlth, Boston, MA USA; Univ Sydney, Lidcombe, Australia; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Boston Univ, Sch Publ Hlth, Ctr Int Hlth & Dev, Boston, MA USA	Tufts University; United States Department of Agriculture (USDA); Tufts University; United States Department of Agriculture (USDA); Tufts University; Harvard University; Mount Auburn Hospital; Boston University; University of Sydney; Tufts University; Boston University	Meydani, SN (corresponding author), Tufts Univ, Jean Mayer USDA HNRCA, Nutr Immunol Lab, 711 Washington St, Boston, MA 02111 USA.	simin.meydani@tufts.edu		/0000-0001-5724-2965; Hamer, Davidson/0000-0002-4700-1495	NATIONAL INSTITUTE ON AGING [R01AG013975] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG013975-05, 1R01-AG13975] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALVAREZ S, 1988, J GERONTOL, V43, pM9, DOI 10.1093/geronj/43.1.M9; Arruda E, 1997, J CLIN MICROBIOL, V35, P2864, DOI 10.1128/JCM.35.11.2864-2868.1997; BLAND JM, I MEASURE OBSERVER A; CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C; CHANDRA RK, 1990, PROG CLIN BIOL RES, V326, P321; CHAVANCE M, 1989, EUR J CLIN NUTR, V43, P827; CHRISTOU NV, 1989, ANN SURG, V210, P69, DOI 10.1097/00000658-198907000-00011; COHN JR, 1983, J AM GERIATR SOC, V31, P808, DOI 10.1111/j.1532-5415.1983.tb03404.x; Crossley KB, 1996, CLIN INFECT DIS, V22, P209, DOI 10.1093/clinids/22.2.209; DRINKA PJ, 1991, J AM GERIATR SOC, V39, P1008, DOI 10.1111/j.1532-5415.1991.tb04050.x; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P478, DOI 10.1016/S1081-1206(10)63155-9; Falsey AR, 1997, J AM GERIATR SOC, V45, P706, DOI 10.1111/j.1532-5415.1997.tb01474.x; FARBER BF, 1984, J AM GERIATR SOC, V32, P499, DOI 10.1111/j.1532-5415.1984.tb02234.x; FIATARONE M, 1990, HOSP PRACT, V25, P38; Gabrel C S, 2000, Adv Data, P1; GARIBALDI RA, 1981, NEW ENGL J MED, V305, P731, DOI 10.1056/NEJM198109243051304; Gay R, 2004, FASEB J, V18, pA162; Graat JM, 2002, JAMA-J AM MED ASSOC, V288, P715, DOI 10.1001/jama.288.6.715; Gugliotti R, 1987, Conn Med, V51, P287; HASLEY PB, 1993, MED CARE, V31, P649, DOI 10.1097/00005650-199307000-00007; HAYEK MG, 1996, FASEB J, V9, pA500; JACKSON MM, 1992, AM J EPIDEMIOL, V135, P685, DOI 10.1093/oxfordjournals.aje.a116348; Loeb M, 2001, INFECT CONT HOSP EP, V22, P120, DOI 10.1086/501875; MANDELL G, 1995, PRINCIPLES PRACTICE; Markus H, 1996, STROKE, V27, P1249, DOI 10.1161/01.STR.27.7.1249; Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709; MCGEER A, 1991, AM J INFECT CONTROL, V19, P1, DOI 10.1016/0196-6553(91)90154-5; MEHR DR, 1992, J FAM PRACTICE, V34, P585; MEYDANI SN, 1990, AM J CLIN NUTR, V52, P557, DOI 10.1093/ajcn/52.3.557; Meydani SN, 1997, JAMA-J AM MED ASSOC, V277, P1380, DOI 10.1001/jama.277.17.1380; MEYDANI SN, 1994, AM J CLIN NUTR, V60, P704, DOI 10.1093/ajcn/60.5.704; Meydani SN, 1998, AM J CLIN NUTR, V68, P311, DOI 10.1093/ajcn/68.2.311; MEYDANI SN, 1989, HUMAN NUTR COMPREHEN, V7, P61; Muder Robert R., 1998, American Journal of Medicine, V105, P319, DOI 10.1016/S0002-9343(98)00262-9; *NAT RES COUNC, 1989, REC DIET ALL, P284; NICOLLE LE, 1984, J AM GERIATR SOC, V32, P513, DOI 10.1111/j.1532-5415.1984.tb02236.x; PLEWA M C, 1990, Emergency Medicine Clinics of North America, V8, P193; Ramsey F. L., 2002, STAT SLEUTH COURSE M; RUBEN FL, 1995, AM J EPIDEMIOL, V141, P145, DOI 10.1093/oxfordjournals.aje.a117402; SAHYOUN NR, 1988, AM J CLIN NUTR, V47, P524, DOI 10.1093/ajcn/47.3.524; SCHNEIDER EL, 1983, ANN INTERN MED, V98, P395, DOI 10.7326/0003-4819-98-3-395; TYRRELL DAJ, 1993, EPIDEMIOL INFECT, V111, P143, DOI 10.1017/S0950268800056764; WAYNE SJ, 1990, J GERONTOL, V45, pM45, DOI 10.1093/geronj/45.2.M45; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; [No title captured]; [No title captured]	46	200	208	1	93	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2004	292	7					828	836		10.1001/jama.292.7.828	http://dx.doi.org/10.1001/jama.292.7.828			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847FO	15315997	Green Accepted, Bronze			2022-12-28	WOS:000223378300023
J	Metcalf, B; Voss, L; Jeffery, A; Perkins, J; Wilkin, T				Metcalf, B; Voss, L; Jeffery, A; Perkins, J; Wilkin, T			Physical activity cost of the school run: impact on schoolchildren of being driven to school (EarlyBird 22)	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Med, Peninsula Med Sch, Derriford Hosp, Plymouth PL6 8DH, Devon, England	Derriford Hospital; University of Plymouth	Wilkin, T (corresponding author), Univ Med, Peninsula Med Sch, Derriford Hosp, Plymouth PL6 8DH, Devon, England.	T.Wilkin@pms.ac.uk		Jeffery, Alison/0000-0001-7539-5957				Cooper AR, 2003, AM J PREV MED, V25, P273, DOI 10.1016/S0749-3797(03)00205-8; *DEP ENV TRANSP RE, 2000, 199799 DEP ENV TRANS; Department for Education and Skills, 2003, TRAV SCH GOOD PRACT; Metcalf BS, 2002, MED SCI SPORT EXER, V34, P1533, DOI 10.1097/00005768-200209000-00022; Voss LD, 2003, J PEDIATR ENDOCR MET, V16, P1211	5	88	89	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 9	2004	329	7470					832	833		10.1136/bmj.38169.688102.F71	http://dx.doi.org/10.1136/bmj.38169.688102.F71			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	862EK	15317729	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000224472800019
J	Qi, Y; Gregory, MA; Li, ZL; Brousal, JP; West, K; Hann, SR				Qi, Y; Gregory, MA; Li, ZL; Brousal, JP; West, K; Hann, SR			p19(ARF) directly and differentially controls the functions of c-Myc independently of p53	NATURE			English	Article							CELL-CYCLE PROGRESSION; INDUCED APOPTOSIS; TUMOR-SUPPRESSOR; P53-INDEPENDENT APOPTOSIS; FIBROBLASTS; INDUCTION; PROTEOLYSIS; EXPRESSION; INK4A/ARF; TARGET	Increased expression of the oncogenic transcription factor c-Myc causes unregulated cell cycle progression(1). c-Myc can also cause apoptosis, but it is not known whether the activation and/or repression of c-Myc target genes mediates these diverse functions of c-Myc. Because unchecked cell cycle progression leads to hyperproliferation and tumorigenesis, it is essential for tumour suppressors, such as p53 and p19(ARF) (ARF), to curb cell cycle progression in response to increased c-Myc (refs 2, 3). Increased c-Myc has previously been shown to induce ARF expression, which leads to cell cycle arrest or apoptosis through the activation of p53 (ref. 4). Here we show that ARF can inhibit c-Myc by a unique and direct mechanism that is independent of p53. When c-Myc increases, ARF binds with c-Myc and dramatically blocks c-Myc's ability to activate transcription and induce hyperproliferation and transformation. In contrast, c-Myc's ability to repress transcription is unaffected by ARF and c-Myc-mediated apoptosis is enhanced. These differential effects of ARF on c-Myc function suggest that separate molecular mechanisms mediate c-Myc-induced hyperproliferation and apoptosis. This direct feedback mechanism represents a p53-independent checkpoint to prevent c-Myc-mediated tumorigenesis.	Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Vanderbilt University	Hann, SR (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, 221 Kirkland Hall, Nashville, TN 37232 USA.	steve.hann@vanderbilt.edu						Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fukatsu K, 1997, SEN-I GAKKAISHI, V53, P15, DOI 10.2115/fiber.53.15; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Haviernik P, 2003, ONCOGENE, V22, P1600, DOI 10.1038/sj.onc.1206268; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Lenahan MK, 1996, ONCOGENE, V12, P1847; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Oster SK, 2000, MOL CELL BIOL, V20, P6768, DOI 10.1128/MCB.20.18.6768-6778.2000; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Soucek L, 2002, CANCER RES, V62, P3507; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; Tsuji K, 2002, BIOCHEM BIOPH RES CO, V295, P621, DOI 10.1016/S0006-291X(02)00723-4; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	30	178	190	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	2004	431	7009					712	717		10.1038/nature02958	http://dx.doi.org/10.1038/nature02958			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	859WS	15361884				2022-12-28	WOS:000224299300046
J	Thompson, WW; Shay, DK; Weintraub, E; Brammer, I; Bridges, CB; Cox, NJ; Fukuda, K				Thompson, WW; Shay, DK; Weintraub, E; Brammer, I; Bridges, CB; Cox, NJ; Fukuda, K			Influenza-associated hospitalizations in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY SYNCYTIAL VIRUS; PANDEMIC INFLUENZA; OUTPATIENT VISITS; IMPACT; VACCINATION; EPIDEMICS; MORTALITY; CHILDREN; INFECTIONS; PNEUMONIA	Context Respiratory viral infections are responsible for a large number of hospitalizations in the United States each year. Objective To estimate annual influenza-associated hospitalizations in the United States by hospital discharge category, discharge type, and age group. Design, Setting, and Participants National Hospital Discharge Survey (NHDS) data and World Health Organization Collaborating Laboratories influenza surveillance data were used to estimate annual average numbers of hospitalizations associated with the circulation of influenza viruses from the 1979-1980 through the 2000-2001 seasons in the United States using age-specific Poisson regression models. Main Outcome Measures We estimated influenza-associated hospitalizations for primary and any listed pneumonia and influenza and respiratory and circulatory hospitalizations. Results Annual averages of 94735 (range, 18908-193561) primary and 133 900 (range, 30757-271529) any listed pneumonia and influenza hospitalizations were associated with influenza virus infections. Annual averages of 226 054 (range, 54523-430960) primary and 294128 (range, 86494-544909) any listed respiratory and circulatory hospitalizations were associated with influenza virus infections. Persons 85 years or older had the highest rates of influenza-associated primary respiratory and circulatory hospitalizations (1194.9 per 100000 persons). Children younger than 5 years (107.9 primary respiratory and circulatory hospitalizations per 100000 persons) had rates similar to persons aged 50 through 64 years. Estimated rates of influenza-associated hospitalizations were highest during seasons in which A(H3N2) viruses predominated, followed by B and A(H1N1) seasons. After adjusting for the length of each influenza season, influenza-associated primary pneumonia and influenza hospitalizations increased over time among the elderly. There were no significant increases in influenza-associated primary respiratory and circulatory hospitalizations after adjusting for the length of the influenza season. Conclusions Significant numbers of influenza-associated hospitalizations in the United States occur among the elderly, and the numbers of these hospitalizations have increased substantially over the last 2 decades due in part to the aging of the population. Children younger than 5 years had rates of influenza-associated hospitalizations similar to those among individuals aged 50 through 64 years. These findings highlight the need for improved influenza prevention efforts for both young and older US residents.	Ctr Dis Control & Prevent, Immunizat Safety Branch, Epidemiol & Surveillance Div, Natl Immunizat Program, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Thompson, WW (corresponding author), Ctr Dis Control & Prevent, Immunizat Safety Branch, Epidemiol & Surveillance Div, Natl Immunizat Program, 1600 Clifton Rd NE,MS E61, Atlanta, GA 30333 USA.	wct2@cdc.gov		Fukuda, Keiji/0000-0002-9598-9565; Shay, David/0000-0001-9619-4820				BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; BARKER WH, 1986, AM J PUBLIC HEALTH, V76, P761, DOI 10.2105/AJPH.76.7.761; Brammer T L, 2000, MMWR CDC Surveill Summ, V49, P13; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P547; Dennison C, 2000, Vital Health Stat 1, P1; *EDW BROTH, 1978, INT CLASS DIS 9 REV, V1; FRANK AL, 1983, AM J EPIDEMIOL, V118, P313, DOI 10.1093/oxfordjournals.aje.a113638; Fukuda K, 2000, INT J CLIN PRACT, P37; Gensheimer KF, 2002, VACCINE, V20, pS63, DOI 10.1016/S0264-410X(02)00135-4; Gillum B.S., 1998, VITAL HLTH STAT 13, V133, p[i, 1]; Glezen WP, 2000, NEW ENGL J MED, V342, P1752; GLEZEN WP, 1980, AM J EPIDEMIOL, V111, P13, DOI 10.1093/oxfordjournals.aje.a112865; GLEZEN WP, 1982, EPIDEMIOL REV, V4, P25, DOI 10.1093/oxfordjournals.epirev.a036250; GRAVES EJ, 1997, VITAL HLTH STAT 13, V128, P1; Hall Margaret J, 2002, Adv Data, P1; Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3; HAUPT BJ, 1992, VITAL HLTH STAT 13, V111, P1; Iwane MK, 2004, PEDIATRICS, V113, P1758, DOI 10.1542/peds.113.6.1758; Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402; KOZAK LJ, 2002, VITAL HLTH STAT 13, V153, P1; LAWRENCE L, 1999, ADV DATA, V308, P1; McBean AM, 2004, INT J INFECT DIS, V8, P227, DOI 10.1016/j.ijid.2004.04.013; MCBEAN AM, 1993, ARCH INTERN MED, V153, P2105, DOI 10.1001/archinte.153.18.2105; Meltzer MI, 1999, EMERG INFECT DIS, V5, P659, DOI 10.3201/eid0505.990507; Meyer KC, 2001, RESP PHYSIOL, V128, P23, DOI 10.1016/S0034-5687(01)00261-4; Miller RA, 1996, SCIENCE, V273, P70, DOI 10.1126/science.273.5271.70; MULLOOLY JP, 1982, AM J PUBLIC HEALTH, V72, P1008, DOI 10.2105/AJPH.72.9.1008; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; Neuzil KM, 2000, J PEDIATR-US, V137, P856, DOI 10.1067/mpd.2000.110445; Neuzil KM, 2002, J INFECT DIS, V185, P147, DOI 10.1086/338363; Nichol KL, 2003, VACCINE, V21, P1769, DOI 10.1016/S0264-410X(03)00070-7; Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028; Nichol KL, 1999, ANN INTERN MED, V130, P397, DOI 10.7326/0003-4819-130-5-199903020-00003; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; Nichols G, 1999, J ASIAN EARTH SCI, V17, P47, DOI 10.1016/S0743-9547(98)00034-8; Nordin J, 2001, J INFECT DIS, V184, P665, DOI 10.1086/323085; Simonsen L, 2000, J INFECT DIS, V181, P831, DOI 10.1086/315320; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; *US BUR CENS, 1990, INT EST POP AG SEX R; *US DEP HHS, 1999, 991232 PHS US DEP HH; Vu T, 2002, VACCINE, V20, P1831, DOI 10.1016/S0264-410X(02)00041-5	41	1682	1781	3	164	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2004	292	11					1333	1340		10.1001/jama.292.11.1333	http://dx.doi.org/10.1001/jama.292.11.1333			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853YL	15367555				2022-12-28	WOS:000223866800025
J	Hruska, AJ				Hruska, AJ			The Global Fund's principal recipients ... or neglected partners	LANCET			English	Editorial Material											Hruska, AJ (corresponding author), Arrayan 2702,Dpto 304, Santiago, Chile.	ajhruska@umich.edu	Hruska, Allan/AAV-7547-2020	Hruska, Allan/0000-0003-0984-3816				RIVERS R, 2004, NEWSLETTER      0607; 2003, GLOBAL FUND FIGHT AI; 2004, AGUA BUENA ASOCIACIO	3	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	2004	364	9438					918	920		10.1016/S0140-6736(04)17039-6	http://dx.doi.org/10.1016/S0140-6736(04)17039-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364175				2022-12-28	WOS:000223831000008
J	Aurigemma, GP; Gaasch, WH				Aurigemma, GP; Gaasch, WH			Diastolic heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VENTRICULAR EJECTION FRACTION; PRESERVED SYSTOLIC FUNCTION; PRIOR MYOCARDIAL-INFARCTION; ASSOCIATION TASK-FORCE; NATRIURETIC PEPTIDE; PRACTICE GUIDELINES; AMERICAN-COLLEGE; DYSFUNCTION; REGRESSION; REDUCTION	A 78-year-old woman with a history of hypertension is admitted to the hospital with congestive heart failure. Physical examination reveals a blood pressure of 180/90 mm Hg, increased jugular venous pressure, peripheral edema, and pulmonary rales. A chest radiograph shows pulmonary edema and mild cardiomegaly. An echocardiogram (Fig. 1) shows increased thickness of the left ventricular wall, a left ventricular cavity of normal size, left atrial enlargement, and a left ventricular ejection fraction of 70 percent. The left ventricular Doppler filling pattern is abnormal and consistent with an elevated pulmonary-capillary wedge pressure. How should this patient be treated?	Univ Massachusetts, Sch Med, Dept Med, Div Cardiol, Worcester, MA 01655 USA; Lahey Clin Fdn, Dept Cardiovasc Med, Burlington, MA USA	University of Massachusetts System; University of Massachusetts Worcester; Lahey Hospital & Medical Center	Aurigemma, GP (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Div Cardiol, 55 Lake Ave N, Worcester, MA 01655 USA.	aurigemg@ummhc.org						*ACC AHA, 1999, ACCAHA GUID MAN PAT; [Anonymous], 2001, CIRCULATION, V104, P2118; Aronow WS, 1997, AM J CARDIOL, V80, P207, DOI 10.1016/S0002-9149(97)00320-2; ARONOW WS, 1993, AM J CARDIOL, V71, P602, DOI 10.1016/0002-9149(93)90520-M; August P, 2003, NEW ENGL J MED, V348, P610, DOI 10.1056/NEJMcp010357; AURIGEMMA GP, 1995, AM J CARDIOL, V76, P702, DOI 10.1016/S0002-9149(99)80201-X; Aurigemma GP, 2001, J AM COLL CARDIOL, V37, P1042, DOI 10.1016/S0735-1097(01)01110-X; AURIGEMMA GP, 1995, J AM COLL CARDIOL, V26, P195, DOI 10.1016/0735-1097(95)00153-Q; Banerjee P, 2002, J AM COLL CARDIOL, V39, P138, DOI 10.1016/S0735-1097(01)01704-1; Brilla CG, 2000, CIRCULATION, V102, P1388, DOI 10.1161/01.CIR.102.12.1388; BROGAN WC, 1992, AM J MED, V92, P627, DOI 10.1016/0002-9343(92)90781-6; Caruana L, 2000, BRIT MED J, V321, P215, DOI 10.1136/bmj.321.7255.215; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Dao Q, 2001, J AM COLL CARDIOL, V37, P379, DOI 10.1016/S0735-1097(00)01156-6; Dauterman KW, 1998, AM HEART J, V135, pS310, DOI 10.1016/S0002-8703(98)70258-3; Diez J, 2002, CIRCULATION, V105, P2512, DOI 10.1161/01.CIR.0000017264.66561.3D; FRENNEAUX MP, 1989, J AM COLL CARDIOL, V13, P1521, DOI 10.1016/0735-1097(89)90342-2; Gaasch WH, 2004, ANNU REV MED, V55, P373, DOI 10.1146/annurev.med.55.091902.104417; GAASCH WH, 1994, JAMA-J AM MED ASSOC, V271, P1276; GAASCH WH, 1994, LEFT VENTRICULAR DIA, P245; GAASCH WH, 1996, CARDIOVASCULAR THERA, P237; Gandhi SK, 2001, NEW ENGL J MED, V344, P17, DOI 10.1056/NEJM200101043440103; Garcia MJ, 1998, J AM COLL CARDIOL, V32, P865, DOI 10.1016/S0735-1097(98)00345-3; Gottdiener JS, 1997, CIRCULATION, V95, P2007, DOI 10.1161/01.CIR.95.8.2007; Gottdiener JS, 2000, J AM COLL CARDIOL, V35, P1628, DOI 10.1016/S0735-1097(00)00582-9; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; JUDGE KW, 1991, J AM COLL CARDIOL, V18, P377, DOI 10.1016/0735-1097(91)90589-2; KITZMAN DW, 1991, J AM COLL CARDIOL, V17, P1065, DOI 10.1016/0735-1097(91)90832-T; Kitzman DW, 2002, JAMA-J AM MED ASSOC, V288, P2144, DOI 10.1001/jama.288.17.2144; Kitzman DW, 2001, AM J CARDIOL, V87, P413, DOI 10.1016/S0002-9149(00)01393-X; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; Kramer K, 2000, AM HEART J, V140, P451, DOI 10.1067/mhj.2000.108828; MANCINI DM, 1992, CIRCULATION, V86, P909, DOI 10.1161/01.CIR.86.3.909; MASSIE B, 1987, CIRCULATION, V76, P1009, DOI 10.1161/01.CIR.76.5.1009; Mathew J, 2001, CIRCULATION, V104, P1615, DOI 10.1161/hc3901.096700; Nagueh SF, 1997, J AM COLL CARDIOL, V30, P1527, DOI 10.1016/S0735-1097(97)00344-6; Nesto RW, 2004, DIABETES CARE, V27, P256, DOI 10.2337/diacare.27.1.256; Nishimura RA, 1997, J AM COLL CARDIOL, V30, P8, DOI 10.1016/S0735-1097(97)00144-7; O'Connor CM, 2000, AM J CARDIOL, V86, P863, DOI 10.1016/S0002-9149(00)01107-3; Paulus WJ, 1998, EUR HEART J, V19, P990; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Redfield MM, 2003, JAMA-J AM MED ASSOC, V289, P194, DOI 10.1001/jama.289.2.194; Remme WJ, 2001, EUR HEART J, V22, P2217; Senni M, 1998, CIRCULATION, V98, P2282, DOI 10.1161/01.CIR.98.21.2282; SETARO JF, 1990, AM J CARDIOL, V66, P981, DOI 10.1016/0002-9149(90)90937-V; SETARO JF, 1992, AM J CARDIOL, V69, P1212, DOI 10.1016/0002-9149(92)90938-U; Tsuyuki RT, 2001, ARCH INTERN MED, V161, P2337, DOI 10.1001/archinte.161.19.2337; Vasan RS, 2000, CIRCULATION, V101, P2118, DOI 10.1161/01.CIR.101.17.2118; Vasan RS, 1999, J AM COLL CARDIOL, V33, P1948, DOI 10.1016/S0735-1097(99)00118-7; VASAN RS, 1995, J AM COLL CARDIOL, V26, P1565, DOI 10.1016/0735-1097(95)00381-9; Vinch CS, 2003, AM J CARDIOL, V91, P1140, DOI 10.1016/S0002-9149(03)00170-X; Warner JG, 1999, J AM COLL CARDIOL, V33, P1567, DOI 10.1016/S0735-1097(99)00048-0; Yusuf S, 2003, LANCET, V362, P777, DOI 10.1016/S0140-6736(03)14285-7; Zile MR, 2004, NEW ENGL J MED, V350, P1953, DOI 10.1056/NEJMoa032566; Zile MR, 2001, CIRCULATION, V104, P779, DOI 10.1161/hc3201.094226; Zile MR, 2002, CIRCULATION, V105, P1387, DOI 10.1161/hc1102.105289	56	351	376	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2004	351	11					1097	1105		10.1056/NEJMcp022709	http://dx.doi.org/10.1056/NEJMcp022709			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CX	15356307				2022-12-28	WOS:000223733900009
J	Demaerel, P; Van Paesschen, W				Demaerel, P; Van Paesschen, W			Images in clinical medicine: Marchiafava-Bignami disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Katholieke Univ Leuven, B-3000 Louvain, Belgium	KU Leuven	Demaerel, P (corresponding author), Katholieke Univ Leuven, B-3000 Louvain, Belgium.		Van Paesschen, Wim/A-4540-2010	Van Paesschen, Wim/0000-0002-8535-1699					0	6	7	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2004	351	11					E10	E10		10.1056/NEJMicm030414	http://dx.doi.org/10.1056/NEJMicm030414			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CX	15356319				2022-12-28	WOS:000223733900012
J	Ray, WA; Murray, KT; Meredith, S; Narasimhulu, SS; Hall, K; Stein, CM				Ray, WA; Murray, KT; Meredith, S; Narasimhulu, SS; Hall, K; Stein, CM			Oral erythromycin and the risk of sudden death from cardiac causes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TORSADES-DE-POINTES; PROLONGATION; ITRACONAZOLE; TERFENADINE; CISAPRIDE; MIDAZOLAM; PHARMACOEPIDEMIOLOGY; PHARMACOKINETICS; CLARITHROMYCIN; KETOCONAZOLE	Background: Oral erythromycin prolongs cardiac repolarization and is associated with case reports of torsades de pointes. Because erythromycin is extensively metabolized by cytochrome P-450 3A (CYP3A) isozymes, commonly used medications that inhibit the effects of CYP3A may increase plasma erythromycin concentrations, thereby increasing the risk of ventricular arrhythmias and sudden death. We studied the association between the use of erythromycin and the risk of sudden death from cardiac causes and whether this risk was increased with the concurrent use of strong inhibitors of CYP3A. Methods: We studied a previously identified Tennessee Medicaid cohort that included 1,249,943 person-years of follow-up and 1476 cases of confirmed sudden death from cardiac causes. The CYP3A inhibitors used in the study were nitroimidazole antifungal agents, diltiazem, verapamil, and troleandomycin; each doubles, at least, the area under the time-concentration curve for a CYP3A substrate. Amoxicillin, an antimicrobial agent with similar indications but which does not prolong cardiac repolarization, and former use of erythromycin also were studied, to assess possible confounding by indication. Results: The multivariate adjusted rate of sudden death from cardiac causes among patients currently using erythromycin was twice as high (incidence-rate ratio, 2.01; 95 percent confidence interval, 1.08 to 3.75; P=0.03) as that among those who had not used any of the study antibiotic medications. There was no significant increase in the risk of sudden death among former users of erythromycin (incidence-rate ratio, 0.89; 95 percent confidence interval, 0.72 to 1.09; P=0.26) or among those who were currently using amoxicillin (incidence-rate ratio, 1.18; 95 percent confidence interval, 0.59 to 2.36; P=0.65). The adjusted rate of sudden death from cardiac causes was five times as high (incidence-rate ratio, 5.35; 95 percent confidence interval, 1.72 to 16.64; P=0.004) among those who concurrently used CYP3A inhibitors and erythromycin as that among those who had used neither CYP3A inhibitors nor any of the study antibiotic medications. In contrast, there was no increase in the risk of sudden death among those who concurrently used amoxicillin and CYP3A inhibitors or those currently using any of the study antibiotic medications who had formerly used CYP3A inhibitors. Conclusions: The concurrent use of erythromycin and strong inhibitors of CYP3A should be avoided.	Vanderbilt Univ, Sch Med, Dept Prevent Med, Div Pharmacoepidemiol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Div Cardiol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Div Rheumatol, Nashville, TN 37212 USA; Nashville Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Geriatric Research Education & Clinical Center	Ray, WA (corresponding author), Vanderbilt Univ, Sch Med, Dept Prevent Med, Div Pharmacoepidemiol, Nashville, TN 37212 USA.	cindy.naron@vanderbilt.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031304] Funding Source: NIH RePORTER; AHRQ HHS [HS1-0384] Funding Source: Medline; NIGMS NIH HHS [GM-31304] Funding Source: Medline; FDA HHS [FD-U-001641] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FDA HHS		Abernethy DR, 2001, CLIN PHARMACOL THER, V69, P96, DOI 10.1067/mcp.2001.114230; Ahonen J, 1997, EUR J CLIN PHARMACOL, V51, P415, DOI 10.1007/s002280050223; Albert CM, 1998, JAMA-J AM MED ASSOC, V279, P23, DOI 10.1001/jama.279.1.23; Curtis LH, 2003, AM J MED, V114, P135, DOI 10.1016/S0002-9343(02)01455-9; Damkier P, 1999, BRIT J CLIN PHARMACO, V48, P829, DOI 10.1046/j.1365-2125.1999.00099.x; De Ponti F, 2000, EUR J CLIN PHARMACOL, V56, P1, DOI 10.1007/s002280050714; Desta Z, 1998, J PHARMACOL EXP THER, V285, P428; Drici MD, 1998, JAMA-J AM MED ASSOC, V280, P1774, DOI 10.1001/jama.280.20.1774; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; Gil M, 2003, AM J CARDIOL, V92, P995, DOI 10.1016/S0002-9149(03)00906-8; Goldschmidt N, 2001, ANN PHARMACOTHER, V35, P1396; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; HOFER CA, 1993, AM J MED, V95, P431, DOI 10.1016/0002-9343(93)90314-F; JOHNSON RE, 1991, J AM GERIATR SOC, V39, P1079, DOI 10.1111/j.1532-5415.1991.tb02872.x; KIRCH W, 1989, THER DRUG MONIT, V11, P411; Kivisto KT, 1997, CLIN PHARMACOL THER, V62, P348, DOI 10.1016/S0009-9236(97)90038-2; Koh TW, 2001, PACE, V24, P1575, DOI 10.1046/j.1460-9592.2001.01575.x; Lam YWF, 2003, J CLIN PHARMACOL, V43, P1274, DOI 10.1177/0091270003259216; Lamberg TS, 1998, CLIN PHARMACOL THER, V63, P640, DOI 10.1016/S0009-9236(98)90087-X; LANDRY JA, 1988, GERONTOLOGIST, V28, P672, DOI 10.1093/geront/28.5.672; LEISTER KA, 1981, MED CARE, V19, P658, DOI 10.1097/00005650-198106000-00008; MARCUS FI, 1988, AM J CARDIOL, V61, P8, DOI 10.1016/0002-9149(88)91295-7; Matsumoto S, 2001, BRIT J CLIN PHARMACO, V51, P133, DOI 10.1111/j.1365-2125.2001.01292.x; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; MURRAY KT, 2004, CARDIOLOGY, P765; NICOLAU DP, 1992, J HEART LUNG TRANSPL, V11, P564; OLKKOLA KT, 1994, CLIN PHARMACOL THER, V55, P481, DOI 10.1038/clpt.1994.60; Ouellet D, 1998, CLIN PHARMACOL THER, V64, P355, DOI 10.1016/S0009-9236(98)90065-0; Paine MF, 2002, CLIN PHARMACOL THER, V72, P524, DOI 10.1067/mcp.2002.128387; PIPER JM, 1990, AM J EPIDEMIOL, V132, P561, DOI 10.1093/oxfordjournals.aje.a115692; Rawson NSB, 1995, STAT MED, V14, P2627, DOI 10.1002/sim.4780142404; Ray WA, 2004, CLIN PHARMACOL THER, V75, P234, DOI 10.1016/j.clpt.2003.09.019; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; Ray WA, 2001, ARCH GEN PSYCHIAT, V58, P1161, DOI 10.1001/archpsyc.58.12.1161; Shaffer D, 2002, CLIN INFECT DIS, V35, P197, DOI 10.1086/340861; Simard C, 2001, EUR J CLIN PHARMACOL, V57, P229, DOI 10.1007/s002280100298; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; Stanat SJC, 2003, MOL CELL BIOCHEM, V254, P1, DOI 10.1023/A:1027309703313; STROM BL, 1990, EPIDEMIOL REV, V12, P87, DOI 10.1093/oxfordjournals.epirev.a036064; Tschida SJ, 1996, PHARMACOTHERAPY, V16, P663; Varis T, 2000, CLIN PHARMACOL THER, V67, P215, DOI 10.1067/mcp.2000.104611; Vogt AW, 1997, ANESTH ANALG, V85, P1011, DOI 10.1097/00000539-199711000-00010; WAROT D, 1987, EUR J CLIN PHARMACOL, V32, P389, DOI 10.1007/BF00543975; WEST SL, 1995, AM J EPIDEMIOL, V142, P1103, DOI 10.1093/oxfordjournals.aje.a117563; WISEMAN LR, 1994, DRUGS, V47, P116, DOI 10.2165/00003495-199447010-00008	45	331	349	1	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2004	351	11					1089	1096		10.1056/NEJMoa040582	http://dx.doi.org/10.1056/NEJMoa040582			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CX	15356306				2022-12-28	WOS:000223733900008
J	Wessel, TR; Arant, CB; Olson, MB; Johnson, BD; Reis, SL; Sharaf, BL; Shaw, LJ; Handberg, E; Sopko, G; Kelsey, SF; Pepine, CJ; Merz, CNB				Wessel, TR; Arant, CB; Olson, MB; Johnson, BD; Reis, SL; Sharaf, BL; Shaw, LJ; Handberg, E; Sopko, G; Kelsey, SF; Pepine, CJ; Merz, CNB			Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYNDROME EVALUATION WISE; FOLLOW-UP; MYOCARDIAL-INFARCTION; RISK-FACTORS; WEIGHT-LOSS; ENDOTHELIAL DYSFUNCTION; FUNCTIONAL-CAPACITY; OBESE WOMEN; LIFE-STYLE; MORTALITY	Context Individual contributions of obesity and physical fitness (physical activity and functional capacity) to risk of coronary heart disease in women remain unclear. Objective To investigate the relationships of measures of obesity (body mass index [BMI], waist circumference, waist-hip ratio, and waist-height ratio) and physical fitness (self-reported Duke Activity Status Index [DASI] and Postmenopausal Estrogen-Progestin Intervention questionnaire [PEPI-Q] scores) with coronary artery disease (CAD) risk factors, angiographic CAD, and adverse cardiovascular (CV) events in women evaluated for suspected myocardial ischemia. Design, Setting, and Participants The National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) is a multicenter prospective cohort study. From 1996-2000, 936 women were enrolled at 4 US academic medical centers at the time of clinically indicated coronary angiography and then assessed (mean follow-up, 3.9 [SD, 1.8] years) for adverse outcomes. Main Outcome Measures Prevalence of obstructive CAD (any angiographic stenosis greater than or equal to50%) and incidence of adverse CV events (all-cause death or hospitalization for nonfatal myocardial infarction, stroke, congestive heart failure, unstable angina, or other vascular events) during follow-up. Results Of 906 women (mean age, 58 [SD, 12] years) with complete data, 19% were of nonwhite race, 76% were overweight (BMI greater than or equal to25), 70% had low functional capacity (DASI scores <25, equivalent to <= 7 metabolic equivalents [METs]), and 39% had obstructive CAD. During follow-up, 337 (38%) women had a first adverse event, 118 (13%) had a major adverse event, and 68 (8%) died. Overweight women were more likely than normal weight women to have CAD risk factors, but neither BMI nor abdominal obesity measures were significantly associated with obstructive CAD or adverse CV events after adjusting for other risk factors (P=.05 to .88). Conversely, women with lower DASI scores were significantly more likely to have CAD risk factors and obstructive CAD (44% vs 26%, P<.001) at baseline, and each 1-MET increase in DASI score was independently associated with an 8% (hazard ratio, 0.92; 95% confidence interval, 0.85-0.99; P=.02) decrease in risk of major adverse CV events during follow-up. Conclusions Among women undergoing coronary angiography for suspected ischemia, higher self-reported physical fitness scores were independently associated with fewer CAD risk factors, less angiographic CAD, and lower risk for adverse CV events. Measures of obesity were not independently associated with these outcomes.	Univ Florida, Coll Med, Div Cardiovasc Med, Gainesville, FL 32610 USA; Univ Pittsburgh, Med Ctr, Cardiovasc Inst, Pittsburgh, PA USA; Univ Pittsburgh, Med Ctr, Dept Epidemiol, Pittsburgh, PA USA; Rhode Isl Hosp, Div Cardiol, Providence, RI USA; Atlanta Cardiovasc Res Inst, Atlanta, GA USA; NHLBI, Div Heart & Vasc Dis, NIH, Bethesda, MD 20892 USA; Cedars Sinai Med Ctr, Cedars Sinai Res Inst, Dept Med, Div Cardiol, Los Angeles, CA 90048 USA	State University System of Florida; University of Florida; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Lifespan Health Rhode Island; Rhode Island Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Cedars Sinai Medical Center	Wessel, TR (corresponding author), Univ Florida, Coll Med, Div Cardiovasc Med, POB 100277, Gainesville, FL 32610 USA.	twessel@ufl.edu		Handberg, Eileen/0000-0002-7805-9577; Reis, Steven/0000-0001-8023-0102	NHLBI NIH HHS [U01-HL64829-01, U01-HL64924-01, N01-HV-68163, N01-HV-68161, N01-HV-68164, U01-HL64914-01, N01-HV-68162] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV068161, N01HV068163, N01HV068164, N01HV068162] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL064829, U01HL064914, U01HL064924] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al Suwaidi J, 2001, J AM COLL CARDIOL, V37, P1523, DOI 10.1016/S0735-1097(01)01212-8; Bertsias G, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-3; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Esposito K, 2003, JAMA-J AM MED ASSOC, V289, P1799, DOI 10.1001/jama.289.14.1799; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Gulati M, 2003, CIRCULATION, V108, P1554, DOI 10.1161/01.CIR.0000091080.57509.E9; Halcox J, 2004, J AM COLL CARDIOL, V43, p485A, DOI 10.1016/S0735-1097(04)92050-5; Hambrecht R, 2004, CIRCULATION, V109, P1371, DOI 10.1161/01.CIR.0000121360.31954.1F; Hedblad B, 2002, J INTERN MED, V252, P542, DOI 10.1046/j.1365-2796.2002.01069.x; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; Huang KC, 2002, INT J OBESITY, V26, P1060, DOI 10.1038/sj.ijo.0802047; Johansson S, 2003, EUR HEART J, V24, P704, DOI 10.1016/S0195-668X(02)00811-4; Jonsson S, 2002, INT J OBESITY, V26, P1046, DOI 10.1038/sj.ijo.0802060; Kanaya AM, 2003, AM J EPIDEMIOL, V158, P1161, DOI 10.1093/aje/kwg271; Kannel WB, 2002, AM J CARDIOL, V90, P697, DOI 10.1016/S0002-9149(02)02592-4; Kip KE, 2004, CIRCULATION, V109, P706, DOI 10.1161/01.CIR.0000115514.44135.A8; Lakka HM, 2002, EUR HEART J, V23, P706, DOI 10.1053/euhj.2001.2889; Linfante A, 2004, CIRCULATION, V110, P664; Manson JE, 2004, ARCH INTERN MED, V164, P249, DOI 10.1001/archinte.164.3.249; Manson JE, 2002, NEW ENGL J MED, V347, P716, DOI 10.1056/NEJMoa021067; Merz CNB, 1999, J AM COLL CARDIOL, V33, P1453; Merz CNB, 2002, AM J MED, V113, P723, DOI 10.1016/S0002-9343(02)01366-9; Merz CNB, 2000, J WOMEN HEALTH GEN-B, V9, P769, DOI 10.1089/15246090050147745; Mora S, 2003, JAMA-J AM MED ASSOC, V290, P1600, DOI 10.1001/jama.290.12.1600; Okura T, 2002, OBES RES, V10, P757, DOI 10.1038/oby.2002.103; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; Olson MB, 2000, J AM COLL CARDIOL, V36, P1565, DOI 10.1016/S0735-1097(00)00901-3; Pischon T, 2003, OBES RES, V11, P1055, DOI 10.1038/oby.2003.145; Pradhan AD, 2002, J CARDIOVASC RISK, V9, P323, DOI 10.1097/00043798-200212000-00005; Raikkonen K, 1999, INT J OBESITY, V23, P775, DOI 10.1038/sj.ijo.0800917; Rea TD, 2001, AM J CARDIOL, V88, P467, DOI 10.1016/S0002-9149(01)01720-9; Schunkert H, 2002, INT J OBESITY, V26, pS15, DOI 10.1038/sj.ijo.0802214; Sharaf BL, 2001, AM J CARDIOL, V87, P937, DOI 10.1016/S0002-9149(01)01424-2; Sowers JR, 2003, AM J MED, V115, P37, DOI 10.1016/j.amjmed.2003.08.012; Stevens J, 2002, AM J EPIDEMIOL, V156, P832, DOI 10.1093/aje/kwf114; Taylor RW, 1998, AM J CLIN NUTR, V67, P44, DOI 10.1093/ajcn/67.1.44; Tchernof A, 2002, CIRCULATION, V105, P564, DOI 10.1161/hc0502.103331; Wei M, 1999, JAMA-J AM MED ASSOC, V282, P1547, DOI 10.1001/jama.282.16.1547; Wolk R, 2003, CIRCULATION, V108, P2206, DOI 10.1161/01.CIR.0000095270.85646.E8; Ziccardi P, 2002, CIRCULATION, V105, P804, DOI 10.1161/hc0702.104279	42	232	238	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2004	292	10					1179	1187		10.1001/jama.292.10.1179	http://dx.doi.org/10.1001/jama.292.10.1179			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851ZA	15353530	Bronze			2022-12-28	WOS:000223723800017
J	Siok, WT; Perfetti, CA; Jin, Z; Tan, LH				Siok, WT; Perfetti, CA; Jin, Z; Tan, LH			Biological abnormality of impaired reading is constrained by culture	NATURE			English	Article							LEFT PREFRONTAL CORTEX; HUMAN FRONTAL-CORTEX; WORKING-MEMORY; BRAIN ACTIVATION; NATIVE LANGUAGE; NEURAL SYSTEMS; FUNCTIONAL MRI; WORD FORM; DYSLEXIA; CHINESE	Developmental dyslexia is characterized by a severe reading problem in people who have normal intelligence and schooling(1-3). Impaired reading of alphabetic scripts is associated with dysfunction of left temporoparietal brain regions(2-5). These regions perform phonemic analysis and conversion of written symbols to phonological units of speech (grapheme-to-phoneme conversion); two central cognitive processes that mediate reading acquisition(6-7). Furthermore, it has been assumed that, in contrast to cultural diversities, dyslexia in different languages has a universal biological origin(1,8). Here we show using functional magnetic resonance imaging with reading-impaired Chinese children and associated controls, that functional disruption of the left middle frontal gyrus is associated with impaired reading of the Chinese language ( a logographic rather than alphabetic writing system). Reading impairment in Chinese is manifested by two deficits: one relating to the conversion of graphic form ( orthography) to syllable, and the other concerning orthography-to-semantics mapping. Both of these processes are critically mediated by the left middle frontal gyrus, which functions as a centre for fluent Chinese reading(9-11) that coordinates and integrates various information about written characters in verbal and spatial working memory. This finding provides an insight into the fundamental pathophysiology of dyslexia by suggesting that rather than having a universal origin, the biological abnormality of impaired reading is dependent on culture.	Univ Hong Kong, Dept Linguist, Cognit Neurosci Lab, Hong Kong, Hong Kong, Peoples R China; Univ Pittsburgh, Ctr Learning Res & Dev, Pittsburgh, PA 15260 USA; Beijing 306 Hosp, MRI Div, Beijing 100101, Peoples R China; NIMH, Neuropsychol Lab, NIH, Bethesda, MD 20892 USA	University of Hong Kong; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Tan, LH (corresponding author), Univ Hong Kong, Dept Linguist, Cognit Neurosci Lab, Hong Kong, Hong Kong, Peoples R China.	lihaitan@intra.nimh.nih.gov	Siok, Wai Ting/A-8392-2010	Siok, Wai Ting/0000-0002-2154-5996				Aylward EH, 2003, NEUROLOGY, V61, P212, DOI 10.1212/01.WNL.0000068363.05974.64; Cohen L, 2000, BRAIN, V123, P291, DOI 10.1093/brain/123.2.291; Courtney SM, 1998, SCIENCE, V279, P1347, DOI 10.1126/science.279.5355.1347; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Eden GF, 2002, NAT NEUROSCI, V5, P1080, DOI 10.1038/nn946; Fiez JA, 2000, NAT NEUROSCI, V3, P3, DOI 10.1038/71078; Fox PT, 1996, NATURE, V382, P158, DOI 10.1038/382158a0; Fu SM, 2002, NEUROIMAGE, V17, P1538, DOI 10.1006/nimg.2002.1155; Gabrieli JDE, 1998, P NATL ACAD SCI USA, V95, P906, DOI 10.1073/pnas.95.3.906; Gold BT, 2002, NEURON, V35, P803, DOI 10.1016/S0896-6273(02)00800-0; Horwitz B, 1998, P NATL ACAD SCI USA, V95, P8939, DOI 10.1073/pnas.95.15.8939; Kochunov P, 2003, NEUROREPORT, V14, P961, DOI 10.1097/01.wnr.0000075417.59944.00; Mattingly I, 1972, LANGUAGE EAR EYE, P133; Paulesu E, 2001, SCIENCE, V291, P2165, DOI 10.1126/science.1057179; Perfetti CA, 1999, READING CHINESE SCRIPT, P115; PERFETTI CA, IN PRESS PSYCHOL REV; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; Price CJ, 1997, J COGNITIVE NEUROSCI, V9, P727, DOI 10.1162/jocn.1997.9.6.727; Rayner K, 2001, PSYCHOL SCI, P31, DOI 10.1111/1529-1006.00004; Shaywitz SE, 1998, P NATL ACAD SCI USA, V95, P2636, DOI 10.1073/pnas.95.5.2636; Siok WT, 2003, HUM BRAIN MAPP, V18, P201, DOI 10.1002/hbm.10094; Siok WT, 2001, DEV PSYCHOL, V37, P886, DOI 10.1037//0012-1649.37.6.886; SNYDER PJ, 1993, CORTEX, V29, P115, DOI 10.1016/S0010-9452(13)80216-X; Talairach J., 1988, COPLANAR STEREOTAXIC; Tan LH, 2001, NEUROIMAGE, V13, P836, DOI 10.1006/nimg.2001.0749; Tan LH, 2000, HUM BRAIN MAPP, V10, P16; Tan LH, 2003, HUM BRAIN MAPP, V18, P158, DOI 10.1002/hbm.10089; Temple E, 2003, P NATL ACAD SCI USA, V100, P2860, DOI 10.1073/pnas.0030098100; Turkeltaub PE, 2003, NAT NEUROSCI, V6, P767, DOI 10.1038/nn1065; Wagner AD, 2001, NEURON, V31, P329, DOI 10.1016/S0896-6273(01)00359-2; WANG WSY, 1973, SCI AM, V228, P50, DOI 10.1038/scientificamerican0273-50	31	330	369	6	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2004	431	7004					71	76		10.1038/nature02865	http://dx.doi.org/10.1038/nature02865			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343334				2022-12-28	WOS:000223641500043
J	Carney, PA; Nierenberg, DW; Pipas, CF; Brooks, WB; Stukel, TA; Keller, AM				Carney, PA; Nierenberg, DW; Pipas, CF; Brooks, WB; Stukel, TA; Keller, AM			Educational epidemiology - Applying population-based design and analytic approaches to stuffy medical education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; KNOWLEDGE; EXPOSURE	Conducting educational research in medical schools is challenging partly because interventional controlled research designs are difficult to apply. In addition, strict accreditation requirements and student/faculty concerns about educational inequality reduce the flexibility needed to plan and execute educational experiments. Consequently, there is a paucity of rigorous and generalizable educational research to provide an evidence-guided foundation to support educational effectiveness. "Educational epidemiology," ie, the application across the physician education continuum of observational designs (eg, cross-sectional, longitudinal, cohort, and case-control studies) and randomized experimental designs (eg, randomized controlled trials, randomized crossover designs), could revolutionize the conduct of research in medical education. Furthermore, the creation of a comprehensive national network of educational epidemiologists could enhance collaboration and the development of a strong educational research foundation.	Dartmouth Coll, Sch Med, Dept Community & Family Med, Lebanon, NH 03756 USA; Dartmouth Coll, Sch Med, Dept Med, Lebanon, NH 03756 USA; Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA; Dartmouth Coll, Sch Med, Dept Community & Family Med, Hanover, NH 03755 USA; Dartmouth Coll, Sch Med, Dept Med, Hanover, NH 03755 USA; Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Univ Toronto, Fac Med, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Inst Clin Evaluat Sci, Toronto, ON, Canada; Dartmouth Coll, Off Vice President & Treasurer, Hanover, NH USA	Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College; University of Toronto; University of Toronto; Dartmouth College	Carney, PA (corresponding author), Dartmouth Coll, Sch Med, Dept Community & Family Med, 1 Med Ctr Dr HB 7925, Lebanon, NH 03756 USA.	patricia.a.carney@dartmouth.edu		Stukel, Therese/0000-0002-2951-1360				Albanese M, 2000, MED EDUC, V34, P729, DOI 10.1046/j.1365-2923.2000.00753.x; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Association of American Medical Colleges, MED SCH OBJ PROJ; Boissel Jean-Pierre, 2003, Stud Health Technol Inform, V95, P554; Carney PA, 2004, ACAD MED, V79, P580, DOI 10.1097/00001888-200406000-00017; COHEN JJ, 2004, 0407 ASS AM MED COLL; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; EATON WW, 1984, ARCH GEN PSYCHIAT, V41, P942; Elnicki DM, 1998, TEACH LEARN MED, V10, P223, DOI 10.1207/S15328015TLM1004_5; Engehausen DG, 2000, ANTICANCER RES, V20, P5145; Furney SL, 2001, J GEN INTERN MED, V16, P620, DOI 10.1046/j.1525-1497.2001.016009620.x; Goodwin RD, 2003, J CLIN EPIDEMIOL, V56, P914, DOI 10.1016/S0895-4356(03)00126-4; *GRAD MED ED OUTC, GEN COMP MIN PROGR R; HOUN F, 1995, RADIOL CLIN N AM, V33, P1059; Jekel J. F., 1996, EPIDEMIOLOGY BIOSTAT; LIND J, 1953, LINDS TREATISE SCURV; LINZER M, 1988, JAMA-J AM MED ASSOC, V260, P2537, DOI 10.1001/jama.260.17.2537; Lurie SJ, 2003, JAMA-J AM MED ASSOC, V290, P1210, DOI 10.1001/jama.290.9.1210; Maclure M, 2000, ANNU REV PUBL HEALTH, V21, P193, DOI 10.1146/annurev.publhealth.21.1.193; McManus IC, 1998, BRIT MED J, V316, P345, DOI 10.1136/bmj.316.7128.345; Quinn MJ, 2003, JNCI-J NATL CANCER I, V95, P1258, DOI 10.1093/jnci/djg063; Reed VA, 1999, ACAD MED, V74, pS96, DOI 10.1097/00001888-199910000-00052; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Smits PBA, 2002, BMJ-BRIT MED J, V324, P153, DOI 10.1136/bmj.324.7330.153; Smorenburg CH, 2003, J CLIN ONCOL, V21, P197, DOI 10.1200/JCO.2003.01.058; Swan SH, 2000, APMIS, V108, P793, DOI 10.1111/j.1600-0463.2000.tb00001.x; Torgerson CJ, 2002, BRIT MED J, V324, P1156; Torgerson CJ, 2002, MED EDUC, V36, P1002, DOI 10.1046/j.1365-2923.2002.01335.x; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV; Walsh CR, 2002, ARCH INTERN MED, V162, P1007, DOI 10.1001/archinte.162.9.1007; WANF PS, 2000, J GEN INTERN MED, V15, P284	31	100	102	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2004	292	9					1044	1050		10.1001/jama.292.9.1044	http://dx.doi.org/10.1001/jama.292.9.1044			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VH	15339895				2022-12-28	WOS:000223568700017
J	Banks, E; Reeves, G; Beral, V; Bull, D; Crossley, B; Simmonds, M; Hilton, E; Bailey, S; Barrett, N; Briers, P; English, R; Jackson, A; Kutt, E; Lavelle, J; Rockall, L; Wallis, MG; Wilson, M; Patnick, J				Banks, E; Reeves, G; Beral, V; Bull, D; Crossley, B; Simmonds, M; Hilton, E; Bailey, S; Barrett, N; Briers, P; English, R; Jackson, A; Kutt, E; Lavelle, J; Rockall, L; Wallis, MG; Wilson, M; Patnick, J			Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HORMONE REPLACEMENT THERAPY; BREAST DENSITY; PARENCHYMAL PATTERNS; SCREENING-PROGRAM; CANCER; INTERVAL; ESTROGEN; AGE; PREDICTORS; PROGESTIN	Objectives To examine how lifestyle, hormonal, and other factors influence the sensitivity and specificity of mammography. Methods Women recruited into the Million Women Study completed a questionnaire about various personal factors before routine mammographic screening. A sample of 12355 women aged 50-64 years were followed for outcome of screening and incident breast cancer in the next 12 months. Sensitivity and specificity were calculated by using standard definitions, with adjustment for potential confounding factors. Results Breast cancer was diagnosed in 726 (0.6%) women, 629 in screen positive and 97 in screen negative women; 3885 (3.2%) were screen positive but had no subsequent diagnosis of breast cancer. Overall sensitivity was 86.6% and specificity was 96.8%. Three factors had an adverse effect on both measures: use of hormone replacement therapy (sensitivity: 83.0% (95% confidence interval 77.4% to 87.6%), 84.7% (73.9% to 91.6%), and 92.1% (87.6% to 95.0%); specificity: 96.8% (96.6% to 97.0%), 97.8% (97.5% to 98.0%), and 98.1% (98.0% to 98.2%), respectively, for current, past, and never use); previous breast surgery v no previous breast surgery (sensitivity: 83.5% (75.7% to 89.1%) v 89.4% (86.5% to 91.8%); specificity: 96.2% (95.8% to 96.5%) v 97.4% (97.3% to 97.5%), respectively); and body mass index <25 v >= 25 (sensitivity: 85.7% (81.2% to 89.3%) v 91.0% (87.5% to 93.6%); specificity: 97.2% (97.0% to 97.3%) v 97.4% (97.3% to 97.6%), respectively). Neither sensitivity nor specificity varied significantly according to age, family history of breast cancer, parity, past oral contraceptive use, tubal ligation, physical activity, smoking, or alcohol consumption. Conclusions The efficiency, and possibly the effectiveness, of mammographic screening is lower in users of hormone replacement therapy, in women with previous breast surgery, and in thin women compared with other women.	Radcliffe Infirm, Canc Res UK, Epidemiol Unit, Oxford OX2 6HE, England; Princess Wales Community Hosp, Breast Screening Serv, Bromsgrove B61 0BB, Worcs, England; Charing Cross Hosp, W London Breast Screening Serv, London W6 8RF, England; Gloucestershire Breast Screening Serv, Cheltenham GL53 7AS, Glos, England; Churchill Hosp, Oxford Radcliffe Hosp NHS Trust, Breast Care Unit, Oxford OX3 7JH, England; Queen Alexandra Hosp, Patricia Massey Breast Screening Unit, Portsmouth PO6 3LY, Hants, England; Cent Hlth Clin, Avon Breast Screening, Bristol BS2 0JD, Avon, England; Royal Lancaster Infirm, N Lancashire Breast Screening Serv, Lancaster LA1 4GG, England; Worthing Dist Hosp, W Sussex Breast Screening Serv, Worthing BN11 2DH, W Sussex, England; Coventry & Warwick Hosp, Breast Screening Unit, Coventry CV1 4FH, W Midlands, England; Withington Hosp, Greater Manchester Breast Screening Serv, Nightingale Ctr, Manchester M20 0PT, Lancs, England; NHS Breast Screening Programme, Sheffield S11 9PS, S Yorkshire, England	Cancer Research UK; Radcliffe Infirmary; Imperial College London; Oxford University Hospitals NHS Foundation Trust; University of Oxford; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital	Banks, E (corresponding author), Radcliffe Infirm, Canc Res UK, Epidemiol Unit, Gibson Bldg, Oxford OX2 6HE, England.	emily.banks@anu.edu.au		Banks, Emily/0000-0002-4617-1302				Abbott S, 2002, BJOG-INT J OBSTET GY, V109, P1319; Banks E, 2004, BMJ-BRIT MED J, V328, P1291, DOI 10.1136/bmj.328.7451.1291; Banks E, 2002, J MED SCREEN, V9, P74, DOI 10.1136/jms.9.2.74; Banks E, 2001, J Epidemiol Biostat, V6, P357; Banks E, 2001, J MED SCREEN, V8, P29, DOI 10.1136/jms.8.1.29; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; BERAL V, IN PRESS MENOPAUSE H; Carney PA, 2003, ANN INTERN MED, V138, P168, DOI 10.7326/0003-4819-138-3-200302040-00008; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Crane CEB, 2002, BREAST, V11, P131, DOI 10.1054/brst.2001.0371; DESTAVOLA BL, 1990, INT J EPIDEMIOL, V19, P247, DOI 10.1093/ije/19.2.247; Fisher MD, 2001, CLIN LYMPHOMA, V2, P84, DOI 10.1016/S1526-9655(11)70134-8; Greendale GA, 1999, ANN INTERN MED, V130, P262, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00003; Kerlikowske K, 2000, ANN INTERN MED, V133, P855, DOI 10.7326/0003-4819-133-11-200012050-00009; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P33, DOI 10.1001/jama.276.1.33; MA L, 1992, J NATL CANCER I, V84, P781, DOI 10.1093/jnci/84.10.781; Mandelson MT, 2000, J NATL CANCER I, V92, P1081, DOI 10.1093/jnci/92.13.1081; Porter PL, 1999, J NATL CANCER I, V91, P2020, DOI 10.1093/jnci/91.23.2020; Rosenberg RD, 1998, RADIOLOGY, V209, P511, DOI 10.1148/radiology.209.2.9807581; Sala E, 1998, J MED SCREEN, V5, P207, DOI 10.1136/jms.5.4.207; Schouten LJ, 1997, LANCET, V349, P1104, DOI 10.1016/S0140-6736(05)62329-X; The Million Women Study Collaborative Group, 1999, BREAST CANCER RES, V1, P73, DOI DOI 10.1186/BCR16; Wang HG, 2001, INT J CANCER, V94, P594, DOI 10.1002/ijc.1511	23	77	81	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 28	2004	329	7464					477	479		10.1136/bmj.329.7464.477	http://dx.doi.org/10.1136/bmj.329.7464.477			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KS	15331472	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000223684600011
J	Warnke, PH; Springer, ING; Wiltfang, J; Acil, Y; Eufinger, H; Wehmoller, M; Russo, PAJ; Bolte, H; Sherry, E; Behrens, E; Terheyden, H				Warnke, PH; Springer, ING; Wiltfang, J; Acil, Y; Eufinger, H; Wehmoller, M; Russo, PAJ; Bolte, H; Sherry, E; Behrens, E; Terheyden, H			Growth and transplantation of a custom vascularised bone graft in a man	LANCET			English	Article							HUMAN OSTEOGENIC PROTEIN-1; MANDIBULAR RECONSTRUCTION; MORPHOGENETIC PROTEIN-7; MINIATURE PIGS; RHOP-1; TISSUE	Background A major goal of research in bone transplantation is the ability to avoid creation of secondary bone defects. We aimed to repair an extended mandibular discontinuity defect by growth of a custom bone transplant inside the latissimus dorsi muscle of an adult male patient. Methods Three-dimensional computed tomography (CT) scanning and computer-aided design techniques were used to produce an ideal virtual replacement for the mandibular defect. These data were used to create a titanium mesh cage that was filled with bone mineral blocks and infiltrated with 7 mg recombinant human bone morphogenetic protein 7 and 20 mL of the patient's bone marrow. Thus prepared, the transplant was implanted into the latissimus dorsi muscle and 7 weeks later transplanted as a free bone-muscle flap to repair the mandibular defect. Findings In-vivo skeletal scintigraphy showed bone remodelling and mineralisation inside the mandibular transplant both before and after transplantation. CT provided radiological evidence of new bone formation. Postoperatively, the patient had an improved degree of mastication and was satisfied with the aesthetic outcome of the procedure. Interpretation Heterotopic bone induction to form a mandibular replacement inside the latissimus dorsi muscle in a human being is possible. This technique allows for a lower operative burden compared with conventional techniques by avoiding creation of a secondary bone defect. It also provides a good three-dimensional outcome.	Univ Kiel, Dept Oral & Maxillofacial Surg, D-24105 Kiel, Germany; Knappschaftskrankenhaus, Dept Oral & Maxillofacial Surg, Recklinghausen, Germany; Australian Natl Univ, Dept Rheumatol, Canberra, ACT, Australia; Univ Kiel, Dept Diagnost Radiol, Kiel, Germany; Univ Sydney, Dept Orthopaed Surg, Penrith, Australia	University of Kiel; Australian National University; University of Kiel; University of Sydney	Warnke, PH (corresponding author), Univ Kiel, Dept Oral & Maxillofacial Surg, Arnold Heller Str 16, D-24105 Kiel, Germany.	warnke@mkg.uni-kiel.de	Terheyden, Hendrik/HDM-7610-2022; Wiltfang, Jörg/B-1767-2010; Cruz e Silva, Odete/AAH-5595-2020	Terheyden, Hendrik/0000-0002-0709-114X; 				Cao YL, 1997, PLAST RECONSTR SURG, V100, P297, DOI 10.1097/00006534-199708000-00001; Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151; Springer ING, 2002, BONE, V31, P230, DOI 10.1016/S8756-3282(02)00809-8; Terheyden H, 2001, INT J ORAL MAX SURG, V30, P373, DOI 10.1054/ijom.2001.0032; Terheyden H, 2004, INT J ORAL MAX SURG, V33, P164, DOI 10.1054/ijom.2003.0500; Terheyden H, 2003, INT J ORAL MAX SURG, V32, P528, DOI 10.1054/ijom.2002.0408; Terheyden H, 2001, INT J ORAL MAX SURG, V30, P469, DOI 10.1054/ijom.2000.0008; Terheyden H, 1999, INT J ORAL MAX SURG, V28, P461, DOI 10.1034/j.1399-0020.1999.280613.x; Vacanti JP, 2003, J GASTROINTEST SURG, V7, P831, DOI 10.1016/S1091-255X(03)00135-5; Vacanti JP, 1999, LANCET S1, V354, pSI32; Wang HM, 2004, J BIOMED MATER RES A, V68A, P219, DOI 10.1002/jbm.a.10129; Warnke PH, 2003, PLAST RECONSTR SURG, V111, P2471, DOI 10.1097/01.PRS.0000063110.10932.9B	12	505	536	0	65	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	2004	364	9436					766	770		10.1016/S0140-6736(04)16935-3	http://dx.doi.org/10.1016/S0140-6736(04)16935-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337402				2022-12-28	WOS:000223569600027
J	Clark, JM; Xu, X; Forster, CA; Wang, Y				Clark, JM; Xu, X; Forster, CA; Wang, Y			A Middle Jurassic 'sphenosuchian' from China and the origin of the crocodylian skull	NATURE			English	Article							BASAL CROCODYLOMORPH ARCHOSAURS; EVOLUTION; ONTOGENY	The skull of living crocodylians is highly solidified and the jaw closing muscles are enlarged(1), allowing for prey capture by prolonged crushing between the jaws. Living species are all semi-aquatic, with sprawling limbs and a broad body that moves mainly from side-to-side(2); however, fossils indicate that they evolved from terrestrial forms. The most cursorial of these fossils(3-6) are small, gracile forms often grouped together as the Sphenosuchia, with fully erect, slender limbs; their relationships, however, are poorly understood(5,7-10). A new crocodylomorph from deposits in northwestern China of the poorly known Middle Jurassic epoch possesses a skull with several adaptations typical of living crocodylians. Postcranially it is similar to sphenosuchians but with even greater adaptations for cursoriality in the forelimb. Here we show, through phylogenetic analysis, that it is the closest relative of the large group Crocodyliformes, including living crocodylians. Thus, important features of the modern crocodylian skull evolved during a phase when the postcranial skeleton was evolving towards greater cursoriality, rather than towards their current semi-aquatic habitus.	George Washington Univ, Dept Biol Sci, Washington, DC 20052 USA; Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Beijing 100044, Peoples R China; SUNY Stony Brook, Dept Anat Sci, Stony Brook, NY 11794 USA	George Washington University; Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Clark, JM (corresponding author), George Washington Univ, Dept Biol Sci, Washington, DC 20052 USA.	jclark@gwu.edu						AGUE JJ, 1995, AM J SCI, V295, P1, DOI 10.2475/ajs.295.1.1; Benton M.J., 1988, PHYLOGENY CLASSIFICA, V35A, P295, DOI DOI 10.1017/S0016756800006476; Benton MJ, 2002, ZOOL J LINN SOC-LOND, V136, P25, DOI 10.1046/j.1096-3642.2002.00024.x; Brochu CA, 1996, J VERTEBR PALEONTOL, V16, P49, DOI 10.1080/02724634.1996.10011283; Chen Pei-ji, 1996, Museum of Northern Arizona Bulletin, V60, P395; CLARK JM, 1994, IN THE SHADOW OF THE DINOSAURS, P84; Clark JM, 2002, ZOOL J LINN SOC-LOND, V136, P77, DOI 10.1046/j.1096-3642.2002.00026.x; Clark JM, 2000, J VERTEBR PALEONTOL, V20, P683, DOI 10.1671/0272-4634(2000)020[0683:ANSOHA]2.0.CO;2; CLARK JM, 2001, DINOSAURS XINJIANG; Eberth DA, 2001, CAN J EARTH SCI, V38, P1627, DOI 10.1139/e01-067; Goslow, 2001, ANAL VERTEBRATE STRU; Iordansky N.N., 1973, P201; JENKINS FA, 1993, AM J SCI, V293A, P253, DOI 10.2475/ajs.293.A.253; Lucas S.G., 2002, CHINESE FOSSIL VERTE; MULLER GB, 1990, J MORPHOL, V203, P151, DOI 10.1002/jmor.1052030204; Osmolska H, 1997, ACTA PALAEONTOL POL, V42, P257; PARRISH JM, 1987, PALEOBIOLOGY, V13, P396; Salisbury SW, 2001, CROCODILIAN BIOLOGY AND EVOLUTION, P85; Sereno P.C., 1992, Journal of Vertebrate Paleontology, V12, P435; Sues HD, 2003, J VERTEBR PALEONTOL, V23, P329, DOI 10.1671/0272-4634(2003)023[0329:ANCAFT]2.0.CO;2; SWOFFORD DL, 2003, PAUP BETA 10 SOFTWAR; WALKER AD, 1970, PHILOS T ROY SOC B, V257, P323, DOI 10.1098/rstb.1970.0028; Wu Xiao-Chun, 1993, Journal of Vertebrate Paleontology, V13, P58	23	87	92	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2004	430	7003					1021	1024		10.1038/nature02802	http://dx.doi.org/10.1038/nature02802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329719				2022-12-28	WOS:000223514900041
J	Douma, S; van Laar, T; Zevenhoven, J; Meuwissen, R; van Garderen, E; Peeper, DS				Douma, S; van Laar, T; Zevenhoven, J; Meuwissen, R; van Garderen, E; Peeper, DS			Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB	NATURE			English	Article							HUMAN NEUROBLASTOMAS; SIGNAL-TRANSDUCTION; KINASE RECEPTOR; EXPRESSION; APOPTOSIS; SURVIVAL; PATHWAY; ACTIVATION; MECHANISMS; INTEGRINS	Metastasis is a major factor in the malignancy of cancers, and is often responsible for the failure of cancer treatment. Anoikis ( apoptosis resulting from loss of cell-matrix interactions) has been suggested to act as a physiological barrier to metastasis; resistance to anoikis may allow survival of cancer cells during systemic circulation, thereby facilitating secondary tumour formation in distant organs(1-3). In an attempt to identify metastasis-associated oncogenes, we designed an unbiased, genome-wide functional screen solely on the basis of anoikis suppression. Here, we report the identification of TrkB, a neurotrophic tyrosine kinase receptor(4,5), as a potent and specific suppressor of caspase-associated anoikis of non-malignant epithelial cells. By activating the phosphatidylinositol-3-OH kinase/protein kinase B pathway, TrkB induced the formation of large cellular aggregates that survive and proliferate in suspension. In mice, these cells formed rapidly growing tumours that infiltrated lymphatics and blood vessels to colonize distant organs. Consistent with the ability of TrkB to suppress anoikis, metastases-whether small vessel infiltrates or large tumour nodules-contained very few apoptotic cells. These observations demonstrate the potent oncogenic effects of TrkB and uncover a specific pro-survival function that may contribute to its metastatic capacity, providing a possible explanation for the aggressive nature of human tumours that overexpress TrkB.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Dept Expt Anim Pathol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Peeper, DS (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	d.peeper@nki.nl	Peeper, Daniel/AAA-2430-2020	van Laar, Theo/0000-0002-0990-6234				Aoyama M, 2001, CANCER LETT, V164, P51, DOI 10.1016/S0304-3835(00)00715-1; Banks GB, 2002, INT J DEV BIOL, V46, P551; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Eggert A, 2001, J CLIN ONCOL, V19, P689, DOI 10.1200/JCO.2001.19.3.689; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Ho R, 2002, CANCER RES, V62, P6462; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Jaboin J, 2003, CANCER LETT, V193, P109, DOI 10.1016/S0304-3835(02)00723-1; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; Koh EY, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf142; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Peeper DS, 2002, NAT CELL BIOL, V4, P148, DOI 10.1038/ncb742; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Ruggeri BA, 1999, CURR MED CHEM, V6, P845; Ruoslahti E, 1997, CURR OPIN CELL BIOL, V9, P605, DOI 10.1016/S0955-0674(97)80112-3; Schmidt M, 2002, BRIT J CANCER, V87, P924, DOI 10.1038/sj.bjc.6600566; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; Vooijs M, 2002, CANCER RES, V62, P1862; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	30	438	495	4	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2004	430	7003					1034	1040		10.1038/nature02765	http://dx.doi.org/10.1038/nature02765			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329723	Bronze			2022-12-28	WOS:000223514900045
J	Malinina, L; Malakhova, ML; Teplov, A; Brown, RE; Patel, DJ				Malinina, L; Malakhova, ML; Teplov, A; Brown, RE; Patel, DJ			Structural basis for glycosphingolipid transfer specificity	NATURE			English	Article							GLYCOLIPID TRANSFER PROTEIN; PHOSPHOLIPID TRANSFER PROTEINS; MACROMOLECULAR STRUCTURES; CRYSTAL-STRUCTURE; PIG BRAIN; PURIFICATION; RECOGNITION; REFINEMENT; ANGSTROM; COMPLEX	Lipid transfer proteins are important in membrane vesicle biogenesis and trafficking, signal transduction and immunological presentation processes(1-3). The conserved and ubiquitous mammalian glycolipid transfer proteins (GLTPs) serve as potential regulators of cell processes mediated by glycosphingolipids, ranging from differentiation and proliferation to invasive adhesion, neurodegeneration and apoptosis(4,5). Here we report crystal structures of apo-GLTP (1.65 Angstrom resolution) and lactosylceramide-bound (1.95 Angstrom) GLTP, in which the bound glycosphingolipid is sandwiched, after adaptive recognition, within a previously unknown two-layer all-alpha-helical topology. Glycosphingolipid binding specificity is achieved through recognition and anchoring of the sugar-amide headgroup to the GLTPlipid recognition centre and within the hydrophobic tunnel support a framework for understanding how GLTPs acquire and release glycosphingolipids during lipid intermembrane transfer and presentation processes.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10021 USA	University of Minnesota System; Memorial Sloan Kettering Cancer Center	Brown, RE (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	reb@umn.edu; pateld@mskcc.org	Malinina, Lucy/B-8161-2013	Malinina, Lucy/0000-0001-7973-1831; Brown, Rhoderick/0000-0002-7337-3604; Teplov, Alexei/0000-0003-4826-4518	NIGMS NIH HHS [R01 GM045928-13, R01 GM045928-08, R01 GM045928, R01 GM045928-11, R01 GM045928-10, R01 GM045928-12, R01 GM045928-07, R01 GM045928-09, R01 GM045928-14A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045928] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE A, 1985, J BIOL CHEM, V260, P1231; Brodersen P, 2002, GENE DEV, V16, P490, DOI 10.1101/gad.218202; BROWN RE, 1990, BIOCHIM BIOPHYS ACTA, V1044, P77, DOI 10.1016/0005-2760(90)90221-I; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Dwek RA, 2002, NAT REV DRUG DISCOV, V1, P65, DOI 10.1038/nrd708; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Gadola SD, 2002, NAT IMMUNOL, V3, P721, DOI 10.1038/ni821; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Li XM, 2002, BIOPHYS J, V83, P1535, DOI 10.1016/S0006-3495(02)73923-4; Lin X, 2000, J BIOL CHEM, V275, P5104, DOI 10.1074/jbc.275.7.5104; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; Mattjus P, 2003, BIOCHEMISTRY-US, V42, P535, DOI 10.1021/bi026896x; METZ RJ, 1982, J BIOL CHEM, V257, P2901; Min KC, 2003, P NATL ACAD SCI USA, V100, P14713, DOI 10.1073/pnas.2136684100; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; Rogers DP, 2000, INT REV CYTOL, V197, P35, DOI 10.1016/S0074-7696(00)97002-5; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353; Wright CS, 2003, J MOL BIOL, V331, P951, DOI 10.1016/S0022-2836(03)00794-0; YAMADA K, 1985, J BIOL CHEM, V260, P4615; Zajonc DM, 2003, NAT IMMUNOL, V4, P808, DOI 10.1038/ni948; Zhou DP, 2004, SCIENCE, V303, P523, DOI 10.1126/science.1092009	30	102	103	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	2004	430	7003					1048	1053		10.1038/nature02856	http://dx.doi.org/10.1038/nature02856			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329726	Green Accepted			2022-12-28	WOS:000223514900048
J	Ahuja, RB; Bhattacharya, S				Ahuja, RB; Bhattacharya, S			ABC of burns - Burns in the developing world and burn disasters	BRITISH MEDICAL JOURNAL			English	Review									Lok Nayak Hosp, Dept Burns Plast Maxillofacial & Microvasc Surg, New Delhi, India; Maulana Azad Med Coll, New Delhi, India	Maulana Azad Medical College	Ahuja, RB (corresponding author), Lok Nayak Hosp, Dept Burns Plast Maxillofacial & Microvasc Surg, New Delhi, India.							Ahuja RB, 2002, BURNS, V28, P555, DOI 10.1016/S0305-4179(02)00069-4; Ahuja RB, 1995, INDIAN J BURNS, V3, P1; DAVIES JWL, 1990, BURNS S1, V17, pS2; HADJIISKI O, 1996, ANN BURN FIRE DISAST, V9, P232; Masellis M, 1991, ANN BURN FIRE DISAST, V4, P215; Sawhney CP, 1993, IND J BURNS, V1, P1; WACHTEL TL, 1998, TOTAL BURN CARE, P19	7	105	105	1	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 21	2004	329	7463					447	449		10.1136/bmj.329.7463.447	http://dx.doi.org/10.1136/bmj.329.7463.447			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849EA	15321905	Green Published			2022-12-28	WOS:000223520300026
J	Tsuruta, D; Sowa, J; Higashi, N; Kobayashi, H; Ishii, M				Tsuruta, D; Sowa, J; Higashi, N; Kobayashi, H; Ishii, M			A red tattoo and a sword-fish supper	LANCET			English	Editorial Material									Osaka City Univ, Dept Dermatol, Grad Sch Med, Abeno Ku, Osaka 5458585, Japan	Osaka Metropolitan University	Tsuruta, D (corresponding author), Osaka City Univ, Dept Dermatol, Grad Sch Med, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.	dtsuruta@med.osaka-cu.ac.jp		xiao lin, yu mei/0000-0002-2246-117X				Boyd AS, 2000, J AM ACAD DERMATOL, V43, P81, DOI 10.1067/mjd.2000.106360; Rietschel R.L, 2001, FISHERS CONTACT DERM, P607; GOVT AGENCIES WARN S	3	7	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	2004	364	9435					730	730		10.1016/S0140-6736(04)16903-1	http://dx.doi.org/10.1016/S0140-6736(04)16903-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325840				2022-12-28	WOS:000223428900038
J	Diggs, C; Ewart, S; Moree, M				Diggs, C; Ewart, S; Moree, M			Strength in unity	NATURE			English	Article									USAID Malaria Vaccine Dev Program, Washington, DC 20523 USA	United States Agency for International Development (USAID)	Diggs, C (corresponding author), USAID Malaria Vaccine Dev Program, Washington, DC 20523 USA.								0	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2004	430	7002					938	939		10.1038/430938a	http://dx.doi.org/10.1038/430938a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318238	Bronze			2022-12-28	WOS:000223369800061
J	Hayward, R				Hayward, R			Historical keywords - Lifestyle	LANCET			English	Editorial Material												Rhodri.Hayward@ucl.ac.uk			Wellcome Trust [068387] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)			0	3	3	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	2004	364	9433					495	495		10.1016/S0140-6736(04)16792-5	http://dx.doi.org/10.1016/S0140-6736(04)16792-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844BS	15323016				2022-12-28	WOS:000223132700014
J	Chiorescu, I; Bertet, P; Semba, K; Nakamura, Y; Harmans, CJPM; Mooij, JE				Chiorescu, I; Bertet, P; Semba, K; Nakamura, Y; Harmans, CJPM; Mooij, JE			Coherent dynamics of a flux qubit coupled to a harmonic oscillator	NATURE			English	Article							MACROSCOPIC QUANTUM STATES; CHARGE QUBITS; ENTANGLEMENT; ATOMS	In the emerging field of quantum computation(1) and quantum information, superconducting devices are promising candidates for the implementation of solid-state quantum bits (qubits). Single-qubit operations(2-6), direct coupling between two qubits(7-10) and the realization of a quantum gate(11) have been reported. However, complex manipulation of entangled states-such as the coupling of a two-level system to a quantum harmonic oscillator, as demonstrated in ion/atom-trap experiments(12,13) and cavity quantum electrodynamics(14)-has yet to be achieved for superconducting devices. Here we demonstrate entanglement between a superconducting flux qubit (a two-level system) and a superconducting quantum interference device (SQUID). The latter provides the measurement system for detecting the quantum states; it is also an effective inductance that, in parallel with an external shunt capacitance, acts as a harmonic oscillator. We achieve generation and control of the entangled state by performing microwave spectroscopy and detecting the resultant Rabi oscillations of the coupled system.	Delft Univ Technol, Kavli Inst NanoSci, Quantum Transport Grp, NL-2628 CJ Delft, Netherlands; Delft Univ Technol, Delft Inst Microelect & Submicron Technol, NL-2628 CJ Delft, Netherlands; NTT Corp, NTT Basic Res Labs, Atsugi, Kanagawa 2430198, Japan; NEC Fundamental Res Labs, Tsukuba, Ibaraki 3058501, Japan	Delft University of Technology; Delft University of Technology; Nippon Telegraph & Telephone Corporation; NEC Corporation	Chiorescu, I (corresponding author), Michigan State Univ, Dept Phys & Astron, E Lansing, MI 48824 USA.	chiorescu@pa.msu.edu; mooij@qt.tn.tudelft.nl	Nakamura, Yasunobu/H-1300-2012; Mooij, Johan/B-1371-2012	Nakamura, Yasunobu/0000-0003-0424-630X; 				Berkley AJ, 2003, SCIENCE, V300, P1548, DOI 10.1126/science.1084528; BURKARD G, 2004, ASYMMETRY DECOHERENC; Chiorescu I, 2003, SCIENCE, V299, P1869, DOI 10.1126/science.1081045; COHENTANNOUDJI C, 1992, ATOM PHOTON INTERACT, pCHE2; GOORDEN MC, 2004, ENTANGLEMENT SPECTRO; IZMALKOV A, 2003, EXPT EVIDENCE ENTANG; Leibfried D, 2003, REV MOD PHYS, V75, P281, DOI 10.1103/RevModPhys.75.281; MAJER JB, 2003, SPECTROSCOPY 2 COUPL; Mandel O, 2003, NATURE, V425, P937, DOI 10.1038/nature02008; Mooij JE, 1999, SCIENCE, V285, P1036, DOI 10.1126/science.285.5430.1036; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Pashkin YA, 2003, NATURE, V421, P823, DOI 10.1038/nature01365; Raimond JM, 2001, REV MOD PHYS, V73, P565, DOI 10.1103/RevModPhys.73.565; Tinkham M., 1996, INTRO SUPERCONDUCTIV, V2nd ed.; van der Wal CH, 2000, SCIENCE, V290, P773, DOI 10.1126/science.290.5492.773; Vion D, 2002, SCIENCE, V296, P886, DOI 10.1126/science.1069372; Yamamoto T, 2003, NATURE, V425, P941, DOI 10.1038/nature02015; Yu Y, 2002, SCIENCE, V296, P889, DOI 10.1126/science.1069452	20	614	628	1	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2004	431	7005					159	162		10.1038/nature02831	http://dx.doi.org/10.1038/nature02831			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356624	Green Submitted			2022-12-28	WOS:000223746000037
J	Court, FA; Sherman, DL; Pratt, T; Garry, EM; Ribchester, RR; Cottrell, DF; Fleetwood-Walker, SM; Brophy, PJ				Court, FA; Sherman, DL; Pratt, T; Garry, EM; Ribchester, RR; Cottrell, DF; Fleetwood-Walker, SM; Brophy, PJ			Restricted growth of Schwann cells lacking Cajal bands slows conduction in myelinated nerves	NATURE			English	Article							PROTEIN MESSENGER-RNA; MICE; OLIGODENDROCYTES; MICROTUBULES; EXPRESSION; JUNCTION; PERIAXIN; FIBERS	Nerve impulses are propagated at nodes of Ranvier in the myelinated nerves of vertebrates. Internodal distances have been proposed to affect the velocity of nerve impulse conduction(1); however, direct evidence is lacking, and the cellular mechanisms that might regulate the length of the myelinated segments are unknown. Ramon y Cajal described longitudinal and transverse bands of cytoplasm or trabeculae in internodal Schwann cells and suggested that they had a nutritive function(2). Here we show that internodal growth in wild-type nerves is precisely matched to nerve extension, but disruption of the cytoplasmic bands in Periaxin-null mice impairs Schwann cell elongation during nerve growth. By contrast, myelination proceeds normally. The capacity of wild-type and mutant Schwann cells to elongate is cell-autonomous, indicating that passive stretching can account for the lengthening of the internode during limb growth. As predicted on theoretical grounds, decreased internodal distances strikingly decrease conduction velocities and so affect motor function. We propose that microtubule-based transport in the longitudinal bands of Cajal permits internodal Schwann cells to lengthen in response to axonal growth, thus ensuring rapid nerve impulse transmission.	Univ Edinburgh, Neurosci Res Ctr, Edinburgh EH9 1QH, Midlothian, Scotland	University of Edinburgh	Brophy, PJ (corresponding author), Univ Edinburgh, Neurosci Res Ctr, Edinburgh EH9 1QH, Midlothian, Scotland.	peter.brophy@ed.ac.uk	Court, Felipe/C-5911-2015	Ribchester, Richard/0000-0003-2670-6995; Pratt, Thomas/0000-0002-7105-3527; Court, Felipe/0000-0002-9394-7601; Court, Felipe/0000-0002-1384-2552				Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; Anzini P, 1997, J NEUROSCI, V17, P4545; BRILL MH, 1977, J NEUROL NEUROSUR PS, V40, P769, DOI 10.1136/jnnp.40.8.769; Carson JH, 1997, CELL MOTIL CYTOSKEL, V38, P318, DOI 10.1002/(SICI)1097-0169(1997)38:4<318::AID-CM2>3.0.CO;2-#; Collinson JM, 1998, GLIA, V23, P11, DOI 10.1002/(SICI)1098-1136(199805)23:1<11::AID-GLIA2>3.0.CO;2-7; COLMAN DR, 1982, J CELL BIOL, V95, P598, DOI 10.1083/jcb.95.2.598; Fernan M., 1933, HISTOLOGY; Gillespie CS, 2000, NEURON, V26, P523, DOI 10.1016/S0896-6273(00)81184-8; GILLESPIE CS, 1994, NEURON, V12, P497, DOI 10.1016/0896-6273(94)90208-9; GRIFFITHS IR, 1989, J NEUROCYTOL, V18, P345, DOI 10.1007/BF01190837; HISCOE HB, 1947, ANAT REC, V99, P447, DOI 10.1002/ar.1090990404; Hursh JB, 1939, AM J PHYSIOL, V127, P131, DOI 10.1152/ajplegacy.1939.127.1.131; HUXLEY AF, 1949, J PHYSIOL-LONDON, V108, P315, DOI 10.1113/jphysiol.1949.sp004335; Komada M, 2002, J CELL BIOL, V156, P337, DOI 10.1083/jcb.200110003; McIntyre CC, 2002, J NEUROPHYSIOL, V87, P995, DOI 10.1152/jn.00353.2001; Pratt T, 2000, DEV BIOL, V228, P19, DOI 10.1006/dbio.2000.9935; RANVIER L, 1872, CR HEBD ACAD SCI, V75, P1129; SCHLAEPFER WW, 1973, J COMP NEUROL, V147, P255, DOI 10.1002/cne.901470207; Sherman DL, 2001, NEURON, V30, P677, DOI 10.1016/S0896-6273(01)00327-0; Tait S, 2000, J CELL BIOL, V150, P657, DOI 10.1083/jcb.150.3.657; TRAPP BD, 1995, J NEUROSCI, V15, P1797, DOI 10.1523/JNEUROSCI.15-03-01797.1995	21	168	174	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2004	431	7005					191	195		10.1038/nature02841	http://dx.doi.org/10.1038/nature02841			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356632	Green Published			2022-12-28	WOS:000223746000046
J	Hierro, A; Sun, J; Rusnak, AS; Kim, J; Prag, G; Emr, SD; Hurley, JH				Hierro, A; Sun, J; Rusnak, AS; Kim, J; Prag, G; Emr, SD; Hurley, JH			Structure of the ESCRT-II endosomal trafficking complex	NATURE			English	Article							RECEPTOR DOWN-REGULATION; MULTIVESICULAR-BODY; UBIQUITIN LIGASE; PROTEIN; TSG101; MACHINERY; PATHWAY; SYSTEM; BODIES; DELTA	The multivesicular-body (MVB) pathway delivers transmembrane proteins and lipids to the lumen of the endosome. The multivesicular-body sorting pathway has crucial roles in growth-factor-receptor downregulation(1), developmental signalling(2-4), regulation of the immune response(5) and the budding of certain enveloped viruses such as human immunodeficiency virus(6). Ubiquitination is a signal for sorting into the MVB pathway(7,8), which also requires the functions of three protein complexes, termed ESCRT-I, -II and -III (endosomal sorting complex required for transport)(7,9,10). Here we report the crystal structure of the core of the yeast ESCRT-II complex, which contains one molecule of the Vps protein Vps22, the carboxy-terminal domain of Vps36 and two molecules of Vps25, and has the shape of a capital letter 'Y'. The amino-terminal coiled coil of Vps22 and the flexible linker leading to the ubiquitin-binding NZF domain of Vps36 both protrude from the tip of one branch of the 'Y'. Vps22 and Vps36 form nearly equivalent interactions with the two Vps25 molecules at the centre of the 'Y'. The structure suggests how ubiquitinated cargo could be passed between ESCRT components of the MVB pathway through the sequential transfer of ubiquitinated cargo from one complex to the next.	NIDDKD, Mol Biol Lab, NIH, US Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Hurley, JH (corresponding author), NIDDKD, Mol Biol Lab, NIH, US Dept Hlth & Human Serv, Bethesda, MD 20892 USA.	hurley@helix.nih.gov	Hierro, Aitor/F-9998-2011	Hierro, Aitor/0000-0002-7721-1581	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036118] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam SL, 2004, EMBO J, V23, P1411, DOI 10.1038/sj.emboj.7600114; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Deblandre GA, 2001, DEV CELL, V1, P795, DOI 10.1016/S1534-5807(01)00091-0; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kleijmeer M, 2001, J CELL BIOL, V155, P53, DOI 10.1083/jcb.200103071; Lai EC, 2001, DEV CELL, V1, P783, DOI 10.1016/S1534-5807(01)00092-2; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Pavlopoulos E, 2001, DEV CELL, V1, P807, DOI 10.1016/S1534-5807(01)00093-4; RAYMOND CK, 1992, INT REV CYTOL, V139, P59, DOI 10.1016/S0074-7696(08)61410-2; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Rost B, 2003, NUCLEIC ACIDS RES, V31, P3300, DOI 10.1093/nar/gkg508; Sundquist WI, 2004, MOL CELL, V13, P783, DOI 10.1016/S1097-2765(04)00129-7; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Tan S, 2001, PROTEIN EXPRES PURIF, V21, P224, DOI 10.1006/prep.2000.1363; TEO H, IN PRESS J BIOL CHEM; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072	30	119	127	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2004	431	7005					221	225		10.1038/nature02914	http://dx.doi.org/10.1038/nature02914			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15329733	Green Published			2022-12-28	WOS:000223746000052
J	Greenhalgh, RM; Brown, LC; Kwong, GPS; Powell, JT; Thompson, SG				Greenhalgh, RM; Brown, LC; Kwong, GPS; Powell, JT; Thompson, SG			Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial	LANCET			English	Article							EUROSTAR EXPERIENCE; SURGICAL REPAIR; RISK-FACTORS; SURVEILLANCE; DESIGN; SUITABILITY; REGISTRY; SURGERY; DEATH	Background Endovascular aneurysm repair (EVAR) is a new technology to treat patients with abdominal aortic aneurysm (AAA) when the anatomy is suitable. Uncertainty exists about how endovascular repair compares with conventional open surgery. EVAR trial 1 was instigated to compare these treatments in patients judged fit for open AAA repair. Methods Between 1999 and 2003, 1082 elective (non-emergency) patients were randomised to receive either EVAR (n=543) or open AAA repair (n=539). Patients aged at least 60 years with aneurysms of diameter 5.5 cm or more, who were fit enough for open surgical repair (anaesthetically and medically well enough for the procedure), were recruited for the study at 41 British hospitals proficient in the EVAR technique. The primary outcome measure is all-cause mortality and these results will be released in 2005. The primary analysis presented here is operative mortality by intention to treat and a secondary analysis was done in per-protocol patients. Findings Patients (983 men, 99 women) had a mean age of 74 years (SD 6) and mean AAA diameter of 6.5 cm (SD 1). 1047 (97%) patients underwent AAA repair and 1008 (93%) received their allocated treatment. 30-day mortality in the EVAR group was 1.7% (9/531) versus 4.7% (24/516) in the open repair group (odds ratio 0.35 [95% CI 0.16-0.77], p=0.009). By per-protocol analysis, 30-day mortality for EVAR was 1.6% (8/512) versus 4.6% (23/496) for open repair (0.33 [0.15-0.74], p=0.007). Secondary interventions were more common in patients allocated EVAR (9.8% vs 5.8%, p=0.02). Interpretation In patients with large AAAs, treatment by EVAR reduced the 30-day operative mortality by two-thirds compared with open repair. Any change in clinical practice should await durability and longer term results.	Univ London Imperial Coll Sci Technol & Med, Dept Vasc Surg, London W6 8RP, England	Imperial College London	Greenhalgh, RM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Vasc Surg, 4th Floor,Charing Cross Campus,St Dunstans Rd, London W6 8RP, England.	r.greenhalgh@imperial.ac.uk	Russell, Ian T/H-1181-2012					Adriaensen MEAPM, 2002, RADIOLOGY, V224, P739, DOI 10.1148/radiol.2243011675; Anderson PL, 2004, J VASC SURG, V39, P10, DOI 10.1016/j.jvs.2003.07.020; Arko FR, 2004, J ENDOVASC THER, V11, P33, DOI 10.1583/1545-1550(2004)011<0033:HMPWIA>2.0.CO;2; Armon MP, 1997, BRIT J SURG, V84, P178, DOI 10.1002/bjs.1800840210; Blankensteijn JD, 1998, BRIT J SURG, V85, P1624; Brady AR, 2000, BRIT J SURG, V87, P742, DOI 10.1046/j.1365-2168.2000.01410.x; Brady AR, 2002, NEW ENGL J MED, V346, P1445; Brown LC, 2004, EUR J VASC ENDOVASC, V27, P372, DOI 10.1016/j.ejvs.2003.12.019; BROWN LC, 2004, ENDOVASCULAR INTERVE, P27; DUBOST C, 1951, Mem Acad Chir (Paris), V77, P381; Harris PL, 1997, J ENDOVASC SURG, V4, P72, DOI 10.1583/1074-6218(1997)004<0072:TNFCTO>2.0.CO;2; Harris PL, 2000, J VASC SURG, V32, P739, DOI 10.1067/mva.2000.109990; Lederle FA, 2002, NEW ENGL J MED, V346, P1437, DOI 10.1056/NEJMoa012573; *MED DEV AG AL, 2000, ANEURX STENT GRAFT S; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; Poldermans D, 2003, CIRCULATION, V107, P1848, DOI 10.1161/01.CIR.0000066286.15621.98; Powell JT, 1998, LANCET, V352, P1649; Prinssen M, 2002, J CARDIOVASC SURG, V43, P379; Thomas S, 2004, ENDOVASCULAR INTERVE, P37; Thomas SM, 2001, EUR J VASC ENDOVASC, V21, P57, DOI 10.1053/ejvs.2000.1268; Vallabhaneni SR, 2001, EUR J RADIOL, V39, P34, DOI 10.1016/S0720-048X(01)00340-0; van Marrewijk C, 2002, J VASC SURG, V35, P461, DOI 10.1067/mva.2002.118823; VOLODOS NL, 1986, VESTN KHIR IM GREKOV, V137, P123; Woodburn KR, 2001, BRIT J SURG, V88, P77, DOI 10.1046/j.1365-2168.2001.01616.x	24	1465	1524	1	54	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	2004	364	9437					843	848		10.1016/S0140-6736(04)16979-1	http://dx.doi.org/10.1016/S0140-6736(04)16979-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351191				2022-12-28	WOS:000223685200030
J	Cuthbert, GL; Daujat, S; Snowden, AW; Erdjument-Bromage, H; Hagiwara, T; Yamada, M; Schneider, R; Gregory, PD; Tempst, P; Bannister, AJ; Kouzarides, T				Cuthbert, GL; Daujat, S; Snowden, AW; Erdjument-Bromage, H; Hagiwara, T; Yamada, M; Schneider, R; Gregory, PD; Tempst, P; Bannister, AJ; Kouzarides, T			Histone deimination antagonizes arginine methylation	CELL			English	Article							IN-VIVO; GENE ACTIVATION; H3; RECEPTOR; PROMOTER; ACETYLATION; RESIDUES; H4	Methylation of arginine residues within histone H3 has been linked to active transcription. This modification appears on the estrogen-regulated pS2 promoter when the CARM1 methyltransferase is recruited during transcriptional activation. Here we describe a process, deimination, that converts histone arginine to citrulline and antagonizes arginine methylation. We show that peptidyl arginine deiminase 4 (PADI4) specifically deiminates, arginine residues R2, R8, R17, and R26 in the H3 tail. Deimination by PADI4 prevents arginine methylation by CARM1. Dimethylation of arginines prevents deimination by PADI4 although monomethylation still allows deimination to take place. In vivo targeting experiments on an endogenous promoter demonstrate that PADI4 can repress hormone receptor-mediated gene induction. Consistent with a repressive role for PADI4, this enzyme is recruited to the pS2 promoter following hormone induction when the gene is transcriptionally downregulated. The recruitment of PADI4 coincides with deimination of the histone H3 N-terminal tail. These results define deimination as a novel mechanism for antagonizing the transcriptional induction mediated by arginine methylation.	Univ Cambridge, Gurdon Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QR, England; Sangamo Biosci Inc, Point Richmond Tech Ctr 2, Richmond, CA 94804 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Yokohama City Univ, Grad Sch Integrated Sci, Kanazawa Ku, Yokohama, Kanagawa 2360027, Japan	University of Cambridge; University of Cambridge; Sangamo Therapeutics, Inc.; Memorial Sloan Kettering Cancer Center; Yokohama City University	Kouzarides, T (corresponding author), Univ Cambridge, Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	tk106@mole.bio.cam.ac.uk	Daujat, Sylvain/A-6070-2017; zhang, shijun/K-3688-2013	Daujat, Sylvain/0000-0001-5107-119X; Bannister, Andrew/0000-0002-6312-4436; Gregory, Philip/0000-0001-9249-2468; Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Kouzarides, Tony/0000-0002-8918-4162	NCI NIH HHS [P30 CA08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; Daujat S, 2002, CURR BIOL, V12, P2090, DOI 10.1016/S0960-9822(02)01387-8; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Hagiwara T, 2002, BIOCHEM BIOPH RES CO, V290, P979, DOI 10.1006/bbrc.2001.6303; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; Martens JHA, 2003, MOL CELL BIOL, V23, P1808, DOI 10.1128/MCB.23.5.1808-1816.2003; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Nakatani T, 2002, J BIOL CHEM, V277, P9562, DOI 10.1074/jbc.M110132200; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; SENSHU T, 1992, ANAL BIOCHEM, V203, P94, DOI 10.1016/0003-2697(92)90047-B; Snowden AW, 2002, CURR BIOL, V12, P2159, DOI 10.1016/S0960-9822(02)01391-X; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; Vossenaar ER, 2003, BIOESSAYS, V25, P1106, DOI 10.1002/bies.10357; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6	21	609	640	1	76	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2004	118	5					545	553		10.1016/j.cell.2004.08.020	http://dx.doi.org/10.1016/j.cell.2004.08.020			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	852BN	15339660	Bronze			2022-12-28	WOS:000223730300006
J	Franz, M				Franz, M			Crystalline electron pairs	SCIENCE			English	Editorial Material							PHASE FLUCTUATIONS; BI2SR2CACU2O8+DELTA; SUPERCONDUCTORS; STATE		Univ British Columbia, Dept Phys & Astron, Vancouver, BC V6T 1Z1, Canada	University of British Columbia	Franz, M (corresponding author), Univ British Columbia, Dept Phys & Astron, Vancouver, BC V6T 1Z1, Canada.	franz@physics.ubc.ca						Anderson P. W., 1997, THEORY SUPERCONDUCTI; Bonn DA, 2001, NATURE, V414, P887, DOI 10.1038/414887a; Franz M, 1998, PHYS REV B, V58, P14572, DOI 10.1103/PhysRevB.58.14572; Hanaguri T, 2004, NATURE, V430, P1001, DOI 10.1038/nature02861; Hoffman JE, 2002, SCIENCE, V295, P466, DOI 10.1126/science.1066974; Howald C, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.014533; Norman M, 2004, SCIENCE, V303, P1985, DOI 10.1126/science.1096341; Vershinin M, 2004, SCIENCE, V303, P1995, DOI 10.1126/science.1093384	9	17	17	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	2004	305	5689					1410	1411		10.1126/science.1099569	http://dx.doi.org/10.1126/science.1099569			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353787	Green Submitted			2022-12-28	WOS:000223761900030
J	Galik, K; Senut, B; Pickford, M; Gommery, D; Treil, J; Kuperavage, AJ; Eckhardt, RB				Galik, K; Senut, B; Pickford, M; Gommery, D; Treil, J; Kuperavage, AJ; Eckhardt, RB			External and internal morphology of the BAR 1002 ' 00 Orrorin tugenensis femur	SCIENCE			English	Article							CORTICAL BONE; FEMORAL-NECK; HOMINID; MIOCENE	Late Miocene fossils from the Lukeino Formation in Kenya's Tugen Hills are assigned to Orrorin tugenensis. Of 20 fossils recovered there to date, 3 are proximal femurs. One of these, BAR 1002'00, preserves an intact head connected to the proximal shaft by an elongated neck. Although this fossil is comparable in size to Pan troglodytes, computerized tomography scans of the neck-shaft junction of BAR 1002'00 reveal that the cortex is markedly thinner superiorly than inferiorly, differing from the approximately equal cortical thicknesses observed in extant African apes, approaching the condition in later hominids, and indicating that O. tugenensis was bipedal.	Penn State Univ, Dept Kinesiol, Lab Comparat Morphol & Mech, University Pk, PA 16802 USA; Allegheny Gen Hosp, Orthopaed Biomech Lab, Pittsburgh, PA 15212 USA; Museum Natl Hist Nat, CNRS, UMR 5143, Dept Hist Terr, F-75231 Paris 05, France; Coll France, Chaire Paleonanthropol & Prehist, F-75231 Paris 05, France; CNRS, UPR 2147, F-75014 Paris, France; CNRS, GDR 983, F-75005 Paris, France; CNRS, UMR 8555, Serv Radiol, F-31300 Toulouse, France; Clin Pasteur, Serv Radiol, F-31300 Toulouse, France	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Allegheny General Hospital; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Eckhardt, RB (corresponding author), Penn State Univ, Dept Kinesiol, Lab Comparat Morphol & Mech, University Pk, PA 16802 USA.	eyl@psu.edu						BEGUN D, 2004, SCIENCE, V303, P1503; Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; Haile-Selassie Y, 2004, SCIENCE, V303, P1503, DOI 10.1126/science.1092978; Lovejoy CO, 2002, AM J PHYS ANTHROPOL, V119, P97, DOI 10.1002/ajpa.10111; Meijering EHW, 2001, MED IMAGE ANAL, V5, P111, DOI 10.1016/S1361-8415(00)00040-2; Ohman JC, 1997, AM J PHYS ANTHROPOL, V104, P117, DOI 10.1002/(SICI)1096-8644(199709)104:1<117::AID-AJPA8>3.0.CO;2-O; Pickford M, 2002, C R PALEVOL, V1, P191, DOI 10.1016/S1631-0683(02)00028-3; Rafferty KL, 1998, J HUM EVOL, V34, P361, DOI 10.1006/jhev.1997.0202; Sawada Y, 2002, CR PALEVOL, V1, P293, DOI 10.1016/S1631-0683(02)00036-2; Senut B, 2001, CR ACAD SCI II A, V332, P137, DOI 10.1016/S1251-8050(01)01529-4; SPOOR CF, 1993, AM J PHYS ANTHROPOL, V91, P469, DOI 10.1002/ajpa.1330910405	11	91	98	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1450	1453		10.1126/science.1098807	http://dx.doi.org/10.1126/science.1098807			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353798				2022-12-28	WOS:000223761900044
J	Kleinman, A				Kleinman, A			Culture and depression	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Dept Anthropol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Social Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Psychiat, Boston, MA USA	Harvard University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kleinman, A (corresponding author), Harvard Univ, Dept Anthropol, Cambridge, MA 02138 USA.								0	321	331	1	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2004	351	10					951	953		10.1056/NEJMp048078	http://dx.doi.org/10.1056/NEJMp048078			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	850UB	15342799				2022-12-28	WOS:000223637400001
J	Brotherton, SE; Rockey, PH; Etzel, SI				Brotherton, SE; Rockey, PH; Etzel, SI			US graduate medical education, 2003-2004	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SATISFACTION; FUTURE; TRENDS; CARE	Context Information about recent graduates of medical schools and the characteristics of physicians training in graduate medical education (GME) portends the size and composition of the US physician workforce of the near future. Objectives To examine trends in training programs and career choices of graduating male and female residents and to monitor trends in the size of the entire residency population. Design, Setting, and Participants The American Medical Association and Association of American Medical Colleges jointly surveyed residency programs during the academic year 2003-2004 about active, transferred, and graduated residents, as well as about program characteristics. The 8192 programs confirmed the status of 94.6% of residents. Nearly 86% of program directors (n=7040) completed the accompanying program survey. Main Outcome Measures Overall trends during the last 6 years in the number and characteristics of residents and programs, as well as the specialty of male and female graduating residents. Results There were 99964 active residents during the 2003-2004 academic year, the highest ever recorded by the National GME Census. The number of residents (n=22444) entering US graduate medical education programs for the first time is also the highest on record. In 1999, 28773 physicians completed training, 10546 (36.7%) of whom were women. In 2003, there were 29745 graduates, 11681 (39.3%) of whom were women, representing a 10.8% increase. The number of obstetrics/gynecology male graduates decreased 31.3%, while female graduates increased 18.2%. Other specialties that lost men and gained women were dermatology, family medicine, internal medicine, ophthalmology, pathology, psychiatry, and general surgery. The proportion of graduates who pursued additional training increased; percentages were 27.2% in 1999, 29.6% in 2001, and 32.1% in 2003. In 2000, 35.7% of programs provided opportunities to develop cultural competence; the percentage in 2003 was 50.7%. The percentage of programs with complementary/alternative medicine curriculum has held steady at 24%. Conclusions The number of physicians in GME is at its highest, and nearly one third of physicians completing training in one program continue on in another. The choices of female residents parallel those of male residents in many respects, but there are important differences.	Amer Med Assoc, Div Grad Med Educ, Chicago, IL 60610 USA	American Medical Association	Brotherton, SE (corresponding author), Amer Med Assoc, Div Grad Med Educ, 515 N State St, Chicago, IL 60610 USA.	sarah_brotherton@ama-assn.org						Barnes PM., 2004, COMPLEMENTARY ALTERN; BARZANSKY B, 2004, JAMA-J AM MED ASSOC, V291, P1025; BIOLA H, 2003, AM FAM PHYSICIAN, V68, P1496; BIOLA H, 2003, AM FAM PHYSICIAN, V68, P1500; BIOLA H, 2003, AM FAM PHYSICIAN, V68, P1494; Brotherton SE, 2003, JAMA-J AM MED ASSOC, V290, P1197, DOI 10.1001/jama.290.9.1197; BUCKLEY LM, 2004, ACAD MED, V79, P310; Cooper RA, 2002, HEALTH AFFAIR, V21, P140, DOI 10.1377/hlthaff.21.1.140; Dorsey ER, 2003, JAMA-J AM MED ASSOC, V290, P1173, DOI 10.1001/jama.290.9.1173; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Gorey TM, 2004, ANN FAM MED, V2, pS3, DOI 10.1370/afm.130; Health UDo Services H. Office for Civil Rights, 2019, FED REGISTER, V68, P47311; Landon BE, 2003, JAMA-J AM MED ASSOC, V289, P442, DOI 10.1001/jama.289.4.442; Larson EB, 2004, J GEN INTERN MED, V19, P69, DOI 10.1111/j.1525-1497.2004.31337.x; Miller RS, 1999, JAMA-J AM MED ASSOC, V282, P855, DOI 10.1001/jama.282.9.855; Nelson AR, 2002, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Oldendick R, 2000, SOUTH MED J, V93, P375; PARK E, 2004, AC HLTH ANN RES M JU; Seltzer VL, 1999, AM J OBSTET GYNECOL, V180, P837, DOI 10.1016/S0002-9378(99)70654-X; Shipman SA, 2004, PEDIATRICS, V113, P435, DOI 10.1542/peds.113.3.435; United States Department of Health and Human Services, 2001, NAT STAND CULT LING; WEINER JP, 2004, HLTH AFF MILLWO 0204; FREIDA ONLINE FELLOW	23	80	83	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2004	292	9					1032	1037		10.1001/jama.292.9.1032	http://dx.doi.org/10.1001/jama.292.9.1032			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VH	15339893				2022-12-28	WOS:000223568700015
J	Kwok, S				Kwok, S			The synthesis of organic and inorganic compounds in evolved stars	NATURE			English	Review							HYDROGENATED AMORPHOUS-CARBON; INTERPLANETARY DUST PARTICLES; RICH PROTOPLANETARY NEBULAE; INFRARED-EMISSION SPECTRA; 21 MICRON FEATURE; MU-M FEATURE; INTERSTELLAR-MEDIUM; PLANETARY-NEBULAE; AROMATIC-HYDROCARBONS; PRIMITIVE METEORITES	Recent isotopic analysis of meteorites and interplanetary dust has identified solid-state materials of pro-solar origin. We can now,trace the origin of these inorganic grains to the circumstellar envelopes of evolved stars. Moreover, organic (aromatic and aliphatic) compounds have been detected in proto-planetary nebulae and planetary nebulae, which are the descendants of carbon stars. This implies that molecular synthesis is actively happening in the circumstellar environment on timescales as short as several hundred years. The detection of stellar grains in the Solar System suggests that they can survive their journey through the interstellar medium and that they are a major contributor of interstellar grains.	Acad Sinica, Inst Astron & Astrophys, Taipei 106, Taiwan	Academia Sinica - Taiwan	Kwok, S (corresponding author), Acad Sinica, Inst Astron & Astrophys, POB 23-141, Taipei 106, Taiwan.	kwok@asiaa.sinica.edu.tw	Kwok, Sun/D-3080-2009	Kwok, Sun/0000-0001-7708-081X				ALEON J, 2003, GEOPHYS COSMOPHYS AC, V67, P3373; ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; BERNATOWICZ T, 1987, NATURE, V330, P728, DOI 10.1038/330728a0; Brownlee DE, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002087; BUSS RH, 1990, ASTROPHYS J, V365, pL23, DOI 10.1086/185879; Cernicharo J, 2001, ASTROPHYS J, V546, pL123, DOI 10.1086/318871; CLEMETT SJ, 1993, SCIENCE, V262, P721, DOI 10.1126/science.262.5134.721; Cody GD, 2002, GEOCHIM COSMOCHIM AC, V66, P1851, DOI 10.1016/S0016-7037(01)00888-2; COLANGELI L, 1995, ASTRON ASTROPHYS SUP, V113, P561; CRONIN JR, 1987, GEOCHIM COSMOCHIM AC, V51, P299, DOI 10.1016/0016-7037(87)90242-0; DAVIES JK, 1993, MON NOT R ASTRON SOC, V265, P1022, DOI 10.1093/mnras/265.4.1022; DEMUIZON MJ, 1990, ASTRON ASTROPHYS, V235, P367; DULEY WW, 1981, MON NOT R ASTRON SOC, V196, P269, DOI 10.1093/mnras/196.2.269; Flynn GJ, 2003, GEOCHIM COSMOCHIM AC, V67, P4791, DOI 10.1016/j.gca.2003.09.001; FLYNN GJ, 2003, LUNAR PLANET SCI, V34, P1652; FORREST WJ, 1981, ASTROPHYS J, V248, P195, DOI 10.1086/159143; GEBALLE TR, 1992, ASTROPHYS J, V387, pL89, DOI 10.1086/186312; GOEBEL JH, 1985, ASTROPHYS J, V290, pL35, DOI 10.1086/184437; Guillois O, 1996, ASTROPHYS J, V464, P810, DOI 10.1086/177366; Hasegawa T, 2000, ASTROPHYS J, V532, P994, DOI 10.1086/308610; Herlin N, 1998, ASTRON ASTROPHYS, V330, P1127; Hill HGM, 1998, ASTRON ASTROPHYS, V336, pL41; Hony S, 2001, ASTRON ASTROPHYS, V370, P1030, DOI 10.1051/0004-6361:20010242; Hrivnak BJ, 2000, ASTROPHYS J, V535, P275, DOI 10.1086/308823; Jager C, 1998, ASTRON ASTROPHYS, V339, P904; JONES AP, 1994, ASTROPHYS J, V433, P797, DOI 10.1086/174689; JONES AP, 1990, Q J ROY ASTRON SOC, V31, P567; Kwok S, 1999, ASTRON ASTROPHYS, V350, pL35; KWOK S, 1989, ASTROPHYS J, V345, pL51, DOI 10.1086/185550; KWOK S, 1993, ANNU REV ASTRON ASTR, V31, P63, DOI 10.1146/annurev.aa.31.090193.000431; Kwok S, 1997, ASTROPHYS J SUPPL S, V112, P557, DOI 10.1086/313038; Kwok S, 2001, ASTROPHYS J, V554, pL87, DOI 10.1086/320913; KWOK S, 1999, IAU S, V191, P297; KWOK S, 1987, PHYS REP, V156, P113; Lattanzio J, 2003, IAU SYMP, P73; LEWIS RS, 1987, NATURE, V326, P160, DOI 10.1038/326160a0; LODDERS K, 1995, METEORITICS, V30, P661, DOI 10.1111/j.1945-5100.1995.tb01164.x; Messenger S, 2003, SCIENCE, V300, P105, DOI 10.1126/science.1080576; Messenger S, 2000, NATURE, V404, P968, DOI 10.1038/35010053; Nagashima K, 2004, NATURE, V428, P921, DOI 10.1038/nature02510; Nguyen AN, 2004, SCIENCE, V303, P1496, DOI 10.1126/science.1094389; Nittler LR, 1997, ASTROPHYS J, V483, P475, DOI 10.1086/304234; OLOFSSON H, 1997, P IAU S, V178, P457; OMONT A, 1995, ASTROPHYS J, V454, P819, DOI 10.1086/176534; Papoular R, 1996, ASTRON ASTROPHYS, V315, P222; PAPOULAR R, 1989, ASTRON ASTROPHYS, V217, P204; Papoular R, 2001, ASTRON ASTROPHYS, V378, P597, DOI 10.1051/0004-6361:20011224; Pendleton YJ, 2002, ASTROPHYS J SUPPL S, V138, P75, DOI 10.1086/322999; Posch T, 1999, ASTRON ASTROPHYS, V352, P609; Posch T, 2002, ASTRON ASTROPHYS, V393, pL7, DOI 10.1051/0004-6361:20021127; PUGET JL, 1989, ANNU REV ASTRON ASTR, V27, P161; RUSSELL RW, 1977, ASTROPHYS J, V217, pL149, DOI 10.1086/182559; SAKATA A, 1984, ASTROPHYS J, V287, pL51, DOI 10.1086/184396; SAKATA A, 1987, ASTROPHYS J, V320, pL63, DOI 10.1086/184977; Scott A, 1996, ASTROPHYS J, V472, pL123, DOI 10.1086/310365; Scott AD, 1997, ASTROPHYS J, V490, pL175, DOI 10.1086/311030; Sellgren K, 2001, SPECTROCHIM ACTA A, V57, P627, DOI 10.1016/S1386-1425(00)00433-9; Sloan GC, 1996, ASTROPHYS J, V463, P310, DOI 10.1086/177243; Speck AK, 2004, ASTROPHYS J, V600, P986, DOI 10.1086/379973; Van Winckel H, 2003, ANNU REV ASTRON ASTR, V41, P391, DOI 10.1146/annurev.astro.41.071601.170018; Volk K, 1999, ASTROPHYS J, V516, pL99, DOI 10.1086/312007; von Helden G, 2000, SCIENCE, V288, P313, DOI 10.1126/science.288.5464.313; Wallerstein G, 1997, REV MOD PHYS, V69, P995, DOI 10.1103/RevModPhys.69.995; Webster A, 1995, MON NOT R ASTRON SOC, V277, P1555, DOI 10.1093/mnras/277.4.1555; Wooden DH, 1999, ASTROPHYS J, V517, P1034, DOI 10.1086/307206; Woods PM, 2003, ASTRON ASTROPHYS, V402, P189, DOI 10.1051/0004-6361:20030215; ZHANG CY, 1991, ASTRON ASTROPHYS, V250, P179; Zinner E, 1998, ANNU REV EARTH PL SC, V26, P147, DOI 10.1146/annurev.earth.26.1.147	68	120	123	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	2004	430	7003					985	991		10.1038/nature02862	http://dx.doi.org/10.1038/nature02862			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849CD	15329712				2022-12-28	WOS:000223514900033
J	Allen, D; Westerblad, H				Allen, D; Westerblad, H			Lactic acid - The latest performance-enhancing drug	SCIENCE			English	Editorial Material							MUSCLE; FATIGUE; FORCE; PH		Univ Sydney, Inst Biomed Res, Sydney, NSW 2006, Australia; Karolinska Inst, S-17177 Stockholm, Sweden	University of Sydney; Karolinska Institutet	Allen, D (corresponding author), Univ Sydney, Inst Biomed Res, Sydney, NSW 2006, Australia.	davida@physiol.usyd.edu.au; hakan.westerblad@fyfa.ki.se		Westerblad, Hakan/0000-0002-8180-3029				Bruton JD, 1998, J APPL PHYSIOL, V85, P478, DOI 10.1152/jappl.1998.85.2.478; CADY EB, 1989, J PHYSIOL-LONDON, V418, P311, DOI 10.1113/jphysiol.1989.sp017842; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; Hill AV, 1929, P R SOC LOND B-CONTA, V105, P313, DOI 10.1098/rspb.1929.0045; Nielsen OB, 2001, J PHYSIOL-LONDON, V536, P161, DOI 10.1111/j.1469-7793.2001.t01-1-00161.x; PATE E, 1995, J PHYSIOL-LONDON, V486, P689, DOI 10.1113/jphysiol.1995.sp020844; Pedersen TH, 2004, SCIENCE, V305, P1144, DOI 10.1126/science.1101141; Westerblad H, 2002, NEWS PHYSIOL SCI, V17, P17	8	45	47	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	2004	305	5687					1112	1113		10.1126/science.1103078	http://dx.doi.org/10.1126/science.1103078			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326341				2022-12-28	WOS:000223557400030
J	Orgel, LE				Orgel, LE			Francis Crick (1916-2004)	SCIENCE			English	Biographical-Item									Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Orgel, LE (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	orgel@salk.edu						CRICK FH, PUBLICATION LIST	1	3	5	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2004	305	5687					1118	1118		10.1126/science.1103634	http://dx.doi.org/10.1126/science.1103634			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326346				2022-12-28	WOS:000223557400035
J	Rajkovic, A; Pangas, SA; Ballow, D; Suzumori, N; Matzuk, MM				Rajkovic, A; Pangas, SA; Ballow, D; Suzumori, N; Matzuk, MM			NOBOX deficiency disrupts early folliculogenesis and oocyte-specific gene expression	SCIENCE			English	Article							TRANSCRIPTION FACTOR; GERM-CELLS; C-KIT; MICE; DIFFERENTIATION; LOCUS; MSY2	Primordial ovarian follicles in mice form when somatic cells surround individual oocytes. We show that lack of Nobox, an oocyte-specific homeobox gene, accelerates postnatal oocyte loss and abolishes the transition from primordial to growing follicles in mice. Follicles are replaced by fibrous tissue in female mice lacking Nobox in a manner similar to nonsyndromic ovarian failure in women. Genes preferentially expressed in oocytes, including Oct4 and Gdf9, are down-regulated in Nobox(-/-) mice, whereas ubiquitous genes such as Bmp4, Kit, and Bax remain unaffected. Therefore, Nobox is critical for specifying an oocyte-restricted gene expression pattern essential for postnatal follicle development.	Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Rajkovic, A (corresponding author), Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA.	rajkovic@bcm.tmc.edu		Suzumori, Nobuhiro/0000-0001-9003-1289; Pangas, Stephanie/0000-0001-5748-5844	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD033438] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD033438, R01HD042500, K12HD001426] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01426, HD42500, HD007165, HD33438] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bachvarova R, 1985, Dev Biol (N Y 1985), V1, P453; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; ENDERS GC, 1994, DEV BIOL, V163, P331, DOI 10.1006/dbio.1994.1152; Gu W, 1998, BIOL REPROD, V59, P1266, DOI 10.1095/biolreprod59.5.1266; MANOVA K, 1991, DEV BIOL, V146, P312, DOI 10.1016/0012-1606(91)90233-S; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; Pepling ME, 2001, DEV BIOL, V234, P339, DOI 10.1006/dbio.2001.0269; Pesce M, 1998, MECH DEVELOP, V71, P89, DOI 10.1016/S0925-4773(98)00002-1; Soyal SM, 2000, DEVELOPMENT, V127, P4645; Suzumori N, 2002, MECH DEVELOP, V111, P137, DOI 10.1016/S0925-4773(01)00620-7; Tong ZB, 2000, NAT GENET, V26, P267, DOI 10.1038/81547; Wu XM, 2003, NAT GENET, V33, P187, DOI 10.1038/ng1079; Yan CN, 2001, MOL ENDOCRINOL, V15, P854, DOI 10.1210/me.15.6.854; Yu JY, 2001, BIOL REPROD, V65, P1260, DOI 10.1095/biolreprod65.4.1260	15	380	413	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2004	305	5687					1157	1159		10.1126/science.1099755	http://dx.doi.org/10.1126/science.1099755			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15326356				2022-12-28	WOS:000223557400049
J	Bouzat, C; Gumilar, F; Spitzmaul, G; Wang, HL; Rayes, D; Hansen, SB; Taylor, P; Sine, SM				Bouzat, C; Gumilar, F; Spitzmaul, G; Wang, HL; Rayes, D; Hansen, SB; Taylor, P; Sine, SM			Coupling of agonist binding to channel gating in an ACh-binding protein linked to an ion channel	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; LIGAND-BINDING; MOLECULAR DISSECTION; SUBUNIT INTERFACES; IDENTIFICATION; RESIDUES; KINETICS; REVEALS; DOMAIN	Neurotransmitter receptors from the Cys-loop superfamily couple the binding of agonist to the opening of an intrinsic ion pore in the final step in rapid synaptic transmission. Although atomic resolution structural data have recently emerged for individual binding(1) and pore domains(2), how they are linked into a functional unit remains unknown. Here we identify structural requirements for functionally coupling the two domains by combining acetylcholine (ACh)-binding protein, whose structure was determined at atomic resolution(1), with the pore domain from the serotonin type-3A (5-HT3A) receptor. Only when amino-acid sequences of three loops in ACh-binding protein are changed to their 5-HT3A counterparts does ACh bind with low affinity characteristic of activatable receptors, and trigger opening of the ion pore. Thus functional coupling requires structural compatibility at the interface of the binding and pore domains. Structural modelling reveals a network of interacting loops between binding and pore domains that mediates this allosteric coupling process.	Mayo Clin Coll Med, Dept Physiol & Biomed Engn, Receptor Biol Lab, Rochester, MN 55905 USA; Univ Nacl Sur, CONICET, Inst Invest Bioquim, RA-8000 Bahia Blanca, Buenos Aires, Argentina; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	Mayo Clinic; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of the South; University of California System; University of California San Diego	Sine, SM (corresponding author), Mayo Clin Coll Med, Dept Physiol & Biomed Engn, Receptor Biol Lab, Rochester, MN 55905 USA.	sine@mayo.edu	Spitzmaul, Guillermo/AAM-4785-2021; , Diego/AAH-4523-2020	Spitzmaul, Guillermo/0000-0001-5123-8914; Gumilar, Fernanda/0000-0002-7789-2647				Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; Gao F, 2003, J BIOL CHEM, V278, P23020, DOI 10.1074/jbc.M301151200; Grosman C, 2000, J GEN PHYSIOL, V116, P327, DOI 10.1085/jgp.116.3.327; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hansen SB, 2002, J BIOL CHEM, V277, P41299, DOI 10.1074/jbc.C200462200; JACKSON MB, 1989, P NATL ACAD SCI USA, V86, P2199, DOI 10.1073/pnas.86.7.2199; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Kelley SP, 2003, NATURE, V424, P321, DOI 10.1038/nature01788; LEE BS, 1991, J BIOL CHEM, V266, P11448; LIU Y, 1991, BIOPHYS J, V60, P424, DOI 10.1016/S0006-3495(91)82068-9; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; Quiram PA, 1998, J BIOL CHEM, V273, P11001, DOI 10.1074/jbc.273.18.11001; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; Sine SM, 2002, J NEUROBIOL, V53, P431, DOI 10.1002/neu.10139; Sine SM, 2002, J BIOL CHEM, V277, P29210, DOI 10.1074/jbc.M203396200; Spitzmaul G, 2001, MOL PHARMACOL, V60, P235, DOI 10.1124/mol.60.2.235; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; Wang HL, 1999, NAT NEUROSCI, V2, P226, DOI 10.1038/6326	27	230	234	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					896	900		10.1038/nature02753	http://dx.doi.org/10.1038/nature02753			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318223				2022-12-28	WOS:000223369800043
J	Goldacre, MJ; Davidson, JM; Lambert, TW				Goldacre, MJ; Davidson, JM; Lambert, TW			Country of training and ethnic origin of UK doctors: database and survey studies	BRITISH MEDICAL JOURNAL			English	Article							UNITED-KINGDOM	Objectives To report on the country of training and ethnicity of consultants in different specialties in the NHS, on trends in intake to UK medical schools by ethnicity, and on the specialty choices made by UK graduates in different ethnic groups. Design Analysis of official databases of consultants and of students accepted to study medicine; survey data about career choices made by newly qualified doctors. Setting and subjects England and Wales (consultants), United Kingdom (students and newly qualified doctors). Results Of consultants appointed before 1992, 15% had trained abroad; of those appointed in 1992-2001, 24% had trained abroad. The percentage of consultants who had trained abroad and were non-white was significantly high, compared with their overall percentage among consultants, in geriatric medicine, genitourinary medicine, paediatrics, old age psychiatry, and learning disability UK trained non-white doctors had specialty destinations similar to those of UK trained white doctors. The percentage of UK medical graduates who are non-white has increased substantially from about 2% in 1974 and will approach 30% by 2005. White men now comprise little more than a quarter of all UK medical students. White and non-white UK graduates make similar choices of specialty. Conclusions Specialist medical practice in the NHS has been heavily dependent on doctors who have trained abroad, particularly in specialties where posts have been hard to fill. By contrast, UK trained doctors from ethnic minorities are not over-represented in the less popular specialties. Ethnic minorities are well represented in UK medical school intakes; and white men, but not white women, are now substantially under-represented.	Univ Oxford, Dept Publ Hlth, UK Med Careers Res Grp, Oxford OX3 7LF, England	University of Oxford	Goldacre, MJ (corresponding author), Univ Oxford, Dept Publ Hlth, UK Med Careers Res Grp, Oxford OX3 7LF, England.	michael.goldacre@dphpc.ox.ac.uk						British Medical Association, 2004, DEM MED SCH DISC PAP; *GEN MED COUNC, 2003, MED REG 2003; Lambert TW, 2004, BMJ-BRIT MED J, V328, P1347, DOI 10.1136/bmj.38062.639190.44; Lambert TW, 1996, BRIT MED J, V313, P19, DOI 10.1136/bmj.313.7048.19; Lambert TW, 2003, BRIT MED J, V326, P194, DOI 10.1136/bmj.326.7382.194; *MED WORKF STAND A, 1997, PLANN MED WORKF 3 RE; *NAT STAT, CENSUS 2001 ETHN; *ROYAL COMM NAT HL, 1907, REP, P217; Taylor DH, 1999, BRIT MED J, V318, P306, DOI 10.1136/bmj.318.7179.306	9	45	45	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 11	2004	329	7466					597	600		10.1136/bmj.38202.364271.BE	http://dx.doi.org/10.1136/bmj.38202.364271.BE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	854SK	15347580	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000223923400015
J	Hof, B; van Doorne, CWH; Westerweel, J; Nieuwstadt, FTM; Faisst, H; Eckhardt, B; Wedin, H; Kerswell, RR; Waleffe, F				Hof, B; van Doorne, CWH; Westerweel, J; Nieuwstadt, FTM; Faisst, H; Eckhardt, B; Wedin, H; Kerswell, RR; Waleffe, F			Experimental observation of nonlinear traveling waves in turbulent pipe flow	SCIENCE			English	Article							EXACT COHERENT STRUCTURES; PLANE COUETTE-FLOW; SHEAR FLOWS; TRANSITION	Transition to turbulence in pipe flow is one of the most fundamental and longest-standing problems in fluid dynamics. Stability theory suggests that the flow remains laminar for all flow rates, but in practice pipe flow becomes turbulent even at moderate speeds. This transition drastically affects the transport efficiency of mass, momentum, and heat. On the basis of the recent discovery of unstable traveling waves in computational studies of the Navier-stokes equations and ideas from dynamical systems theory, a model, for the transition process has been suggested. We report experimental observation of these traveling waves in pipe flow, confirming the proposed transition scenario and suggesting that the dynamics associated with these unstable states may indeed capture the nature of fluid turbulence.	Delft Univ Technol, Lab Aerodynam & Hydrodynam, NL-2628 CA Delft, Netherlands; Univ Marburg, Fachbereich Phys, D-35032 Marburg, Germany; Univ Bristol, Dept Math, Bristol BS8 1TW, Avon, England; Univ Wisconsin, Dept Math, Madison, WI 53706 USA; Univ Wisconsin, Dept Engn Phys, Madison, WI 53706 USA	Delft University of Technology; Philipps University Marburg; University of Bristol; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Hof, B (corresponding author), Delft Univ Technol, Lab Aerodynam & Hydrodynam, Leeghwaterstr 21, NL-2628 CA Delft, Netherlands.	b.hof@wbmt.tudelft.nl	Westerweel, Jerry/G-9087-2011; Eckhardt, Bruno/D-5948-2012	Eckhardt, Bruno/0000-0003-4050-3254; Westerweel, Jerry/0000-0002-2799-5242				CHOI H, 1994, J FLUID MECH, V262, P75, DOI 10.1017/S0022112094000431; Clever RM, 1997, J FLUID MECH, V344, P137, DOI 10.1017/S0022112097005818; DARBYSHIRE AG, 1995, J FLUID MECH, V289, P83, DOI 10.1017/S0022112095001248; Draad AA, 1998, J FLUID MECH, V377, P267, DOI 10.1017/S0022112098003139; Drazin P.G., 1982, HYDRODYNAMIC STABILI; Eckhardt B, 1999, PHYS REV E, V60, P509, DOI 10.1103/PhysRevE.60.509; EGGELS JGM, 1994, J FLUID MECH, V268, P175, DOI 10.1017/S002211209400131X; Faisst H, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.224502; Faisst H, 2004, J FLUID MECH, V504, P343, DOI 10.1017/S0022112004008134; HAMILTON JM, 1995, J FLUID MECH, V287, P317, DOI 10.1017/S0022112095000978; Hof B, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.244502; Kawahara G, 2001, J FLUID MECH, V449, P291, DOI 10.1017/S0022112001006243; NAGATA M, 1990, J FLUID MECH, V217, P519, DOI 10.1017/S0022112090000829; Pfenninger W., 1961, BOUNDARY LAYER FLOW, P970; Prasad AK, 2000, EXP FLUIDS, V29, P103, DOI 10.1007/s003480000143; PROCACCIA I, 1988, NATURE, V333, P498, DOI 10.1038/333498a0; Reynolds O., 1883, P R SOC LOND, V35, P84, DOI [10.1098/rspl.1883.0018, DOI 10.1098/RSPL.1883.0018]; Schmiegel A, 1997, PHYS REV LETT, V79, P5250, DOI 10.1103/PhysRevLett.79.5250; SHINBROT T, 1993, NATURE, V363, P411, DOI 10.1038/363411a0; VANDOOME CWH, 2003, P EUROPIV, V2; VANDOORNE CWH, 2004, THESIS DELFT U TECHN; Waleffe F, 1997, PHYS FLUIDS, V9, P883, DOI 10.1063/1.869185; Waleffe F, 2003, PHYS FLUIDS, V15, P1517, DOI 10.1063/1.1566753; Waleffe F, 2001, J FLUID MECH, V435, P93, DOI 10.1017/S0022112001004189; Waleffe F, 1998, PHYS REV LETT, V81, P4140, DOI 10.1103/PhysRevLett.81.4140; Wedin H, 2004, J FLUID MECH, V508, P333, DOI 10.1017/S0022112004009346; WYGNANSKI IJ, 1973, J FLUID MECH, V59, P281, DOI 10.1017/S0022112073001576	27	333	338	5	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2004	305	5690					1594	1598		10.1126/science.1100393	http://dx.doi.org/10.1126/science.1100393			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361619				2022-12-28	WOS:000223891200036
J	Kim, HJ; Graham, DW; DiSpirito, AA; Alterman, MA; Galeva, N; Larive, CK; Asunskis, D; Sherwood, PMA				Kim, HJ; Graham, DW; DiSpirito, AA; Alterman, MA; Galeva, N; Larive, CK; Asunskis, D; Sherwood, PMA			Methanobactin, a copper-acquisition compound from methane-oxidizing bacteria	SCIENCE			English	Article							METHYLOSINUS-TRICHOSPORIUM OB3B; METHYLOCOCCUS-CAPSULATUS BATH; FORMALDEHYDE DEHYDROGENASE; MONOOXYGENASE ACTIVITY; SIDEROPHORE; EXPRESSION; PROTEIN; IONS	Siderophores are extracellular iron-binding compounds that mediate iron transport into many cells. We present evidence of analogous molecules for copper transport from methane-oxidizing bacteria, represented here by a small fluorescent chromopeptide (C45N12O14H62Cu, 1216 daltons) produced by Methylosinus trichosporium OB3b. The crystal structure of this compound, methanobactin, was resolved to 1.15 angstroms. It is composed of a tetrapeptide, a tripeptide, and several unusual moieties, including two 4-thionyl-5-hydroxy-imidazole chromophores that coordinate the copper, a pyrrolidine that confers a bend in the overall chain, and an amino-terminal isopropylester group. The copper coordination environment includes a dual nitrogen- and sulfur-donating system derived from the thionyl imidazolate moieties. Structural elucidation of this molecule has broad implications in terms of organo-copper chemistry, biological methane oxidation, and global carbon cycling.	Univ Kansas, Dept Civil Environm & Architectural Engn, Lawrence, KS 66045 USA; Univ Kansas, Biochem Res Serv Lab, Lawrence, KS 66045 USA; Univ Kansas, Mass Spectrometry Lab, Lawrence, KS 66045 USA; Univ Kansas, Dept Chem, Lawrence, KS 66045 USA; Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Kansas State Univ, Dept Chem, Manhattan, KS 66506 USA	University of Kansas; University of Kansas; University of Kansas; University of Kansas; Iowa State University; Kansas State University	Graham, DW (corresponding author), Univ Kansas, Dept Civil Environm & Architectural Engn, Lawrence, KS 66045 USA.	dwgraham@ku.edu	Larive, Cynthia K/E-4640-2012	Sherwood, Peter/0000-0001-6487-0724; Graham, David W/0000-0002-9753-496X; Larive, Cynthia/0000-0003-3458-0771				BERSON O, 1998, ENVIRON SCI TECHNOL, V30, P802; Brantner CA, 1997, CAN J MICROBIOL, V43, P672, DOI 10.1139/m97-095; Bruckner C, 2000, INORG CHEM, V39, P6100, DOI 10.1021/ic0004636; Choi DW, 2003, J BACTERIOL, V185, P5755, DOI 10.1128/JB.185.19.5755-5764.2003; Claycomb GD, 2002, J VAC SCI TECHNOL A, V20, P1230, DOI 10.1116/1.1479357; Dalton H, 1984, MICROBIAL GROWTH C C, P1; DEMANGE P, 1988, BIOCHEMISTRY-US, V27, P2745, DOI 10.1021/bi00408a014; DEMANGE P, 1990, BIOCHEMISTRY-US, V29, P11041, DOI 10.1021/bi00502a005; DiSpirito AA, 1998, J BACTERIOL, V180, P3606, DOI 10.1128/JB.180.14.3606-3613.1998; DISPIRITO AA, 2004, Patent No. 60434873; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; FITCH MW, 1993, APPL ENVIRON MICROB, V59, P2771, DOI 10.1128/AEM.59.9.2771-2776.1993; Grabarse WG, 2000, J MOL BIOL, V303, P329, DOI 10.1006/jmbi.2000.4136; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Karlsen OA, 2003, APPL ENVIRON MICROB, V69, P2386, DOI 10.1128/AEM.69.4.2386-2388.2003; Kim H.-J., UNPUB; Kim HJ, 2001, FEMS MICROBIOL LETT, V201, P133, DOI 10.1016/S0378-1097(01)00257-9; KIM HJ, 2003, THESIS U KANSAS; KNOSP O, 1984, J BACTERIOL, V159, P341, DOI 10.1128/JB.159.1.341-347.1984; Lontoh S, 1998, APPL ENVIRON MICROB, V64, P1106; NGUYEN HHT, 1994, J BIOL CHEM, V269, P14995; PELTOLA P, 1993, ARCH MICROBIOL, V159, P521, DOI 10.1007/BF00249029; PRIOR SD, 1985, J GEN MICROBIOL, V131, P155; Puig S, 2002, STRUCTURE, V10, P1292, DOI 10.1016/S0969-2126(02)00863-8; Rensing C, 2003, FEMS MICROBIOL REV, V27, P197, DOI 10.1016/S0168-6445(03)00049-4; Rosenzweig AC, 2002, CHEM BIOL, V9, P673, DOI 10.1016/S1074-5521(02)00156-4; Selmer T, 2000, J BIOL CHEM, V275, P3755, DOI 10.1074/jbc.275.6.3755; Sheldrick G. M., 1994, SHELXTL VERSION 5 RE; Stafford GP, 2003, MICROBIOL-SGM, V149, P1771, DOI 10.1099/mic.0.26060-0; Tate S, 1999, MICROBIOL-UK, V145, P159, DOI 10.1099/13500872-145-1-159; Tellez CM, 1998, APPL ENVIRON MICROB, V64, P1115; Vorholt JA, 1999, J BACTERIOL, V181, P5750, DOI 10.1128/JB.181.18.5750-5757.1999; Zahn JA, 1996, J BACTERIOL, V178, P1018, DOI 10.1128/jb.178.4.1018-1029.1996; Zahn JA, 2001, J BACTERIOL, V183, P6832, DOI 10.1128/JB.183.23.6832-6840.2001	34	246	261	3	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2004	305	5690					1612	1615		10.1126/science.1098322	http://dx.doi.org/10.1126/science.1098322			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	854GV	15361623				2022-12-28	WOS:000223891200041
J	Rivera, MC; Lake, JA				Rivera, MC; Lake, JA			The ring of life provides evidence for a genome fusion origin of eukaryotes	NATURE			English	Article							EVOLUTIONARY TREES; GENE-TRANSFER; PHYLOGENY; SEQUENCES; ARCHAEA; ARCHAEBACTERIA; NUCLEUS; RECONSTRUCTION; PROKARYOTES; EUBACTERIA	Genomes hold within them the record of the evolution of life on Earth. But genome fusions and horizontal gene transfer seem to have obscured sufficiently the gene sequence record such that it is difficult to reconstruct the phylogenetic tree of life. Here we determine the general outline of the tree using complete genome data from representative prokaryotes and eukaryotes and a new genome analysis method that makes it possible to reconstruct ancient genome fusions and phylogenetic trees. Our analyses indicate that the eukaryotic genome resulted from a fusion of two diverse prokaryotic genomes, and therefore at the deepest levels linking prokaryotes and eukaryotes, the tree of life is actually a ring of life. One fusion partner branches from deep within an ancient photosynthetic clade, and the other is related to the archaeal prokaryotes. The eubacterial organism is either a proteobacterium, or a member of a larger photosynthetic clade that includes the Cyanobacteria and the Proteobacteria.	Univ Calif Los Angeles, MCD Biol, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, IGPP, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Astrobiol Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Lake, JA (corresponding author), Univ Calif Los Angeles, MCD Biol, Inst Mol Biol, Los Angeles, CA 90095 USA.	lake@mbi.ucla.edu	Rivera, Maria/GYU-2150-2022					Adams KL, 2000, NATURE, V408, P354, DOI 10.1038/35042567; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Brochier C, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r17; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; Campbell AM, 2000, THEOR POPUL BIOL, V57, P71, DOI 10.1006/tpbi.2000.1454; COLLURA RV, 1995, NATURE, V378, P485, DOI 10.1038/378485a0; Daubin V, 2002, GENOME RES, V12, P1080, DOI 10.1101/gr.187002; Dayhoff MO, 1978, ATLAS PROTEIN SEQUEN, V5; DICKERSON RE, 1980, DIFFRACTION RELATED, P227; Doolittle WF, 1999, SCIENCE, V284, P2124, DOI 10.1126/science.284.5423.2124; ESSER C, 2004, MOL BIOL EVOL; Feng DF, 1997, P NATL ACAD SCI USA, V94, P13028, DOI 10.1073/pnas.94.24.13028; Fitz-Gibbon ST, 1999, NUCLEIC ACIDS RES, V27, P4218, DOI 10.1093/nar/27.21.4218; Gabaldon T, 2003, SCIENCE, V301, P609, DOI 10.1126/science.1085463; Galtier N, 1999, SCIENCE, V283, P220, DOI 10.1126/science.283.5399.220; Gogarten JP, 1997, ASM NEWS, V63, P404; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; Gray MW, 1999, CURR OPIN GENET DEV, V9, P678, DOI 10.1016/S0959-437X(99)00030-1; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Gupta RS, 1998, MICROBIOL MOL BIOL R, V62, P1435, DOI 10.1128/MMBR.62.4.1435-1491.1998; GUPTA RS, 1994, P NATL ACAD SCI USA, V91, P2895, DOI 10.1073/pnas.91.8.2895; Horiike T, 2001, NAT CELL BIOL, V3, P210, DOI 10.1038/35055129; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; Karlin S, 1997, J BACTERIOL, V179, P3899, DOI 10.1128/jb.179.12.3899-3913.1997; LAKE JA, 1988, NATURE, V331, P184, DOI 10.1038/331184a0; LAKE JA, 1995, P NATL ACAD SCI USA, V92, P9662, DOI 10.1073/pnas.92.21.9662; Lake JA, 1998, MOL BIOL EVOL, V15, P1224, DOI 10.1093/oxfordjournals.molbev.a026030; LAKE JA, 1982, P NATL ACAD SCI-BIOL, V79, P5948, DOI 10.1073/pnas.79.19.5948; LAKE JA, 1994, P NATL ACAD SCI USA, V91, P1455, DOI 10.1073/pnas.91.4.1455; Lake JA, 2004, MOL BIOL EVOL, V21, P681, DOI 10.1093/molbev/msh061; LAKE JA, 1994, P NATL ACAD SCI USA, V91, P2880, DOI 10.1073/pnas.91.8.2880; LAKE JA, 1974, RIBOSOMES, P543; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; Margulis L, 1970, ORIGIN EUKARYOTIC CE; Martin W, 1996, PLANT MOL BIOL, V32, P485, DOI 10.1007/BF00019100; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; Montague MG, 2000, P NATL ACAD SCI USA, V97, P5334, DOI 10.1073/pnas.97.10.5334; Moreira D, 1998, J MOL EVOL, V47, P517, DOI 10.1007/PL00006408; Ochman H, 2000, EMBO J, V19, P6637, DOI 10.1093/emboj/19.24.6637; PACE NR, 1986, CELL, V45, P325, DOI 10.1016/0092-8674(86)90315-6; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; RIVERA MC, 1992, SCIENCE, V257, P74, DOI 10.1126/science.1621096; Snel B, 1999, NAT GENET, V21, P108, DOI 10.1038/5052; Tekaia F, 1999, GENOME RES, V9, P550; Timmis JN, 2004, NAT REV GENET, V5, P123, DOI 10.1038/nrg1271; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1981, SCI AM, V244, P98, DOI 10.1038/scientificamerican0681-98; Wolf YI, 2001, BMC EVOL BIOL, V1, DOI 10.1186/1471-2148-1-8; ZISCHLER H, 1995, NATURE, V378, P489, DOI 10.1038/378489a0	49	329	356	1	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2004	431	7005					152	155		10.1038/nature02848	http://dx.doi.org/10.1038/nature02848			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356622				2022-12-28	WOS:000223746000035
J	Rosenblatt, RA				Rosenblatt, RA			A view from the periphery - Health care in rural America	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Washington, Sch Med, Dept Family Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Rosenblatt, RA (corresponding author), Univ Washington, Sch Med, Dept Family Med, Seattle, WA 98195 USA.							Larson EH, 2003, STATE HLTH WORKFORCE; Rabinowitz HK, 2001, JAMA-J AM MED ASSOC, V286, P1041, DOI 10.1001/jama.286.9.1041; Ricketts III TC, 1999, RURAL HLTH US; ROSENBLATT RA, 1992, JAMA-J AM MED ASSOC, V268, P1559, DOI 10.1001/jama.268.12.1559	4	52	53	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2004	351	11					1049	1051		10.1056/NEJMp048073	http://dx.doi.org/10.1056/NEJMp048073			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CX	15356300				2022-12-28	WOS:000223733900002
J	Gilbert, N; Boyle, S; Fiegler, H; Woodfine, K; Carter, NP; Bickmore, WA				Gilbert, N; Boyle, S; Fiegler, H; Woodfine, K; Carter, NP; Bickmore, WA			Chromatin architecture of the human genome: Gene-rich domains are enriched in open chromatin fibers	CELL			English	Article							HIGHER-ORDER STRUCTURE; HUMAN TRANSCRIPTOME MAP; BETA-GLOBIN GENE; INTERPHASE NUCLEI; EXPRESSED GENES; ACTIVE GENES; CHROMOSOMES; HYBRIDIZATION; LOCALIZATION; SEQUENCE	We present an analysis of chromatin fiber structure across the human genome. Compact and open chromatin fiber structures were separated by sucrose sedimentation and their distributions analyzed by hybridization to metaphase chromosomes and genomic microarrays. We show that compact chromatin fibers originate from some sites of heterochromatin (C-bands), and G-bands (euchromatin). Open chromatin fibers correlate with regions of highest gene density, but not with gene expression since inactive genes can be in domains of open chromatin, and active genes in regions of low gene density can be embedded in compact chromatin fibers. Moreover, we show that chromatin fiber structure impacts on further levels of chromatin condensation. Regions of open chromatin fibers are cytologically decondensed and have a distinctive nuclear organization. We suggest that domains of open chromatin may create an environment that facilitates transcriptional activation and could provide an evolutionary constraint to maintain clusters of genes together along chromosomes.	MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	University of Edinburgh; Wellcome Trust Sanger Institute	Bickmore, WA (corresponding author), MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.	w.bickmore@hgu.mrc.ac.uk	Bickmore, Wendy A/C-7314-2013	Bickmore, Wendy A/0000-0001-6660-7735; Gilbert, Nick/0000-0003-0505-6081				BELLARD M, 1977, COLD SPRING HARB SYM, V42, P779, DOI 10.1101/SQB.1978.042.01.078; BELMONT AS, 1994, J CELL BIOL, V127, P287, DOI 10.1083/jcb.127.2.287; CAPLAN A, 1987, J MOL BIOL, V193, P57, DOI 10.1016/0022-2836(87)90626-7; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; Croft JA, 1999, J CELL BIOL, V145, P1119, DOI 10.1083/jcb.145.6.1119; Fan JY, 2002, NAT STRUCT BIOL, V9, P172, DOI 10.1038/nsb767; FANTES J, 1995, HUM MOL GENET, V4, P415, DOI 10.1093/hmg/4.3.415; FANTES JA, 1992, AM J HUM GENET, V51, P1286; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; FISHER EA, 1986, BIOCHEMISTRY-US, V25, P8010, DOI 10.1021/bi00372a033; Furey TS, 2003, HUM MOL GENET, V12, P1037, DOI 10.1093/hmg/ddg113; Ghirlando R, 2004, J MOL BIOL, V336, P597, DOI 10.1016/j.jmb.2003.12.049; Gilbert N, 2003, EMBO J, V22, P5540, DOI 10.1093/emboj/cdg520; Gilbert N, 2001, P NATL ACAD SCI USA, V98, P11949, DOI 10.1073/pnas.211322798; GREULICH KO, 1987, J MOL BIOL, V193, P709, DOI 10.1016/0022-2836(87)90353-6; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Jolly C, 2004, J CELL BIOL, V164, P25, DOI 10.1083/jcb.200306104; Kim Y, 2002, P NATL ACAD SCI USA, V99, P15381, DOI 10.1073/pnas.242536699; KIMURA T, 1983, NATURE, V306, P709, DOI 10.1038/306709a0; LANGMORE JP, 1983, J CELL BIOL, V96, P1120, DOI 10.1083/jcb.96.4.1120; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; Mahy NL, 2002, J CELL BIOL, V159, P753, DOI 10.1083/jcb.200207115; MCGHEE JD, 1983, CELL, V33, P831, DOI 10.1016/0092-8674(83)90025-9; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; Muller WG, 2001, J CELL BIOL, V154, P33, DOI 10.1083/jcb.200011069; NOLL H, 1989, METHOD ENZYMOL, V170, P55; Nye AC, 2002, MOL CELL BIOL, V22, P3437, DOI 10.1128/MCB.22.10.3437-3449.2002; Rizzi N, 2004, MOL BIOL CELL, V15, P543, DOI 10.1091/mbc.E03-07-0487; SACCONE S, 1993, P NATL ACAD SCI USA, V90, P11929, DOI 10.1073/pnas.90.24.11929; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Shaw-Smith C, 2004, J MED GENET, V41, P241, DOI 10.1136/jmg.2003.017731; Shiels C, 1997, GENOMICS, V44, P35, DOI 10.1006/geno.1997.4817; Sun FL, 2001, MOL CELL BIOL, V21, P2867, DOI 10.1128/MCB.21.8.2867-2879.2001; TAGARRO I, 1994, HUM GENET, V93, P383; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Tsukamoto T, 2000, NAT CELL BIOL, V2, P871, DOI 10.1038/35046510; Tumbar T, 1999, J CELL BIOL, V145, P1341, DOI 10.1083/jcb.145.7.1341; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vermaak D, 2003, CURR OPIN CELL BIOL, V15, P266, DOI 10.1016/S0955-0674(03)00043-7; Versteeg R, 2003, GENOME RES, V13, P1998, DOI 10.1101/gr.1649303; Volpi EV, 2000, J CELL SCI, V113, P1565; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; Wolffe A., 1998, CHROMATIN STRUCTURE; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42; Woodfine K, 2004, HUM MOL GENET, V13, P191, DOI 10.1093/hmg/ddh016; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; Yokota H, 1997, CHROMOSOME RES, V5, P157, DOI 10.1023/A:1018438729203	54	372	383	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2004	118	5					555	566		10.1016/j.cell.2004.08.011	http://dx.doi.org/10.1016/j.cell.2004.08.011			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	852BN	15339661	Bronze			2022-12-28	WOS:000223730300007
J	Cowan, CR; Hyman, AA				Cowan, CR; Hyman, AA			Centrosomes direct cell polarity independently of microtubule assembly in C-elegans embryos	NATURE			English	Article							CAENORHABDITIS-ELEGANS; ANTEROPOSTERIOR AXIS; PROTEIN SPD-2; GAMMA-TUBULIN; SPINDLE; POLARIZATION; MATURATION; ESTABLISHMENT; DUPLICATION; DOMAINS	Polarity establishment requires a symmetry-breaking event, resulting in an axis along which determinants are segregated. In Caenorhabditis elegans, oocytes are apolar and are triggered to polarize rapidly along one axis after fertilization. The establishment of this first polarity axis is revealed by the asymmetric distribution of PAR proteins and cortical activity in the one-celled embryo. Current evidence suggests that the centrosome pronucleus complex contributed by the sperm is involved in defining the polarization axis(1-6). Here we directly assess the contribution of the centrosome to polarity establishment by laser ablating the centrosome before and during polarization. We find that the centrosome is required to initiate polarity but not to maintain it. Initiation of polarity coincides with the proximity of the centrosome to the cortex and the assembly of pericentriolar material on the immature sperm centrosome. Depletion of microtubules or the microtubule nucleator gamma-tubulin did not affect polarity establishment. These results demonstrate that the centrosome provides an initiating signal that polarizes C. elegans embryos and indicate that this signalling event might be independent of the role of the centrosome as a microtubule nucleator.	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	Max Planck Society	Cowan, CR (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.	cowan@mpi-cbg.de	Hyman, Anthony A/B-3917-2017; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; Cowan, Carrie/0000-0002-2867-1733				ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; Berdnik D, 2002, CURR BIOL, V12, P640, DOI 10.1016/S0960-9822(02)00766-2; Boyd L, 1996, DEVELOPMENT, V122, P3075; Cuenca AA, 2003, DEVELOPMENT, V130, P1255, DOI 10.1242/dev.00284; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Goldstein B, 1996, DEVELOPMENT, V122, P1467; Gonczy P, 1999, J CELL BIOL, V144, P927, DOI 10.1083/jcb.144.5.927; Grill SW, 2003, SCIENCE, V301, P518, DOI 10.1126/science.1086560; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hamill DR, 2002, DEV CELL, V3, P673, DOI 10.1016/S1534-5807(02)00327-1; Hannak E, 2002, J CELL BIOL, V157, P591, DOI 10.1083/jcb.200202047; Hung TJ, 1999, DEVELOPMENT, V126, P127; Kemp CA, 2004, DEV CELL, V6, P511, DOI 10.1016/S1534-5807(04)00066-8; Kirkham M, 2003, CELL, V112, P575, DOI 10.1016/S0092-8674(03)00117-X; O'Connell KF, 2000, DEV BIOL, V222, P55, DOI 10.1006/dbio.2000.9714; Oegema K, 2001, J CELL BIOL, V153, P1209, DOI 10.1083/jcb.153.6.1209; Pelletier L, 2004, CURR BIOL, V14, P863, DOI 10.1016/j.cub.2004.04.012; Pichler S, 2000, DEVELOPMENT, V127, P2063; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; Praitis V, 2001, GENETICS, V157, P1217; Sadler PL, 2000, DEVELOPMENT, V127, P355; Stevenson VA, 2001, NAT CELL BIOL, V3, P68, DOI 10.1038/35050579; Strome S, 2001, MOL BIOL CELL, V12, P1751, DOI 10.1091/mbc.12.6.1751; Wallenfang MR, 2000, NATURE, V408, P89, DOI 10.1038/35040562	24	162	168	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2004	431	7004					92	96		10.1038/nature02825	http://dx.doi.org/10.1038/nature02825			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343338				2022-12-28	WOS:000223641500048
J	Steinbrook, R				Steinbrook, R			Conflicts of interest at the NIH - Resolving the problem	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Steinbrook R, 2004, NEW ENGL J MED, V350, P327, DOI 10.1056/NEJMp038247; WILLMAN D, 2004, LOS ANGELES TIM 1222, pA1; Willman David, 2003, Los Angeles Times, pA32; 2004, REPORT NATL I HLTH B	4	14	14	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2004	351	10					955	957		10.1056/NEJMp048235	http://dx.doi.org/10.1056/NEJMp048235			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	850UB	15342801				2022-12-28	WOS:000223637400003
J	Holman, H				Holman, H			Chronic disease - The need for a new clinical education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SELF-MANAGEMENT; CHRONIC ILLNESS; REGIONAL-VARIATIONS; CARE; OUTCOMES		Stanford Univ, Sch Med, Palo Alto, CA 94304 USA	Stanford University	Holman, H (corresponding author), Stanford Univ, Sch Med, 1000 Welch Rd,Suite 203, Palo Alto, CA 94304 USA.	Holman@stanford.edu						Adams K, 2003, PRIOR AR NAT ACT TRA; *AM HEALTHW, 2004, DEF PAT PHYS REL 21; Ashton CM, 2003, NEW ENGL J MED, V349, P1637, DOI 10.1056/NEJMsa003299; Beck A, 1997, J AM GERIATR SOC, V45, P543, DOI 10.1111/j.1532-5415.1997.tb03085.x; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; CHRISTAKIS NA, 1995, JAMA-J AM MED ASSOC, V274, P706, DOI 10.1001/jama.274.9.706; Cuff N., 2004, IMPROVING MEDICAL ED; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Gerteis M., 1993, PATIENTS EYES UNDERS; Glasgow Russell E, 2003, Jt Comm J Qual Saf, V29, P563; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; Institute of Medicine, 2001, CROSSING QUALITY CHA; Institute of Medicine, 2003, HLTH PROF ED BRIDG Q; Kaplan SH, 1996, ANN INTERN MED, V124, P497, DOI 10.7326/0003-4819-124-5-199603010-00007; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; Ludmerer K., 1999, TIME HEAL AM MED ED; PAWLSON LG, 1994, JOINT COMM J QUAL IM, V20, P33, DOI 10.1016/S1070-3241(16)30051-7; Pham HH, 2004, ACAD MED, V79, P32, DOI 10.1097/00001888-200401000-00009; Scott J, 1998, GERIATRICS, V53, P68; Starr P, 1982, SOCIAL TRANSFORMATIO; Stewart M, 2000, J FAM PRACTICE, V49, P796; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788	26	99	101	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2004	292	9					1057	1059		10.1001/jama.292.9.1057	http://dx.doi.org/10.1001/jama.292.9.1057			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VH	15339897				2022-12-28	WOS:000223568700019
J	Simon, GE; Ludman, EJ; Tutty, S; Operskalski, B; Von Korff, M				Simon, GE; Ludman, EJ; Tutty, S; Operskalski, B; Von Korff, M			Telephone psychotherapy and telephone care management for primary care patients starting antidepressant treatment - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MAJOR DEPRESSION; COLLABORATIVE CARE; IMPROVE TREATMENT; UNITED-STATES; OUTCOMES; INTERVENTION; PREDICTORS; DISORDERS; SEVERITY; ILLNESS	Context Both antidepressant medication and structured psychotherapy have been proven efficacious, but less than one third of people with depressive disorders receive effective levels of either treatment. Objective To compare usual primary care for depression with 2 intervention programs: telephone care management and telephone care management plus telephone psychotherapy. Design Three-group randomized controlled trial with allocation concealment and blinded outcome assessment conducted between November 2000 and May 2002. Setting and Participants A total of 600 patients beginning antidepressant treatment for depression were systematically sampled from 7 group-model primary care clinics; patients already receiving psychotherapy were excluded. Interventions Usual primary care; usual care plus a telephone care management program including at least 3 outreach calls, feedback to the treating physician, and care coordination; usual care plus care management integrated with a structured 8-session cognitive-behavioral psychotherapy program delivered by telephone. Main Outcome Measures Blinded telephone interviews at 6 weeks, 3 months, and 6 months assessed depression severity (Hopkins Symptom Checklist Depression Scale and the Patient Health Questionnaire), patient-rated improvement, and satisfaction with treatment. Computerized administrative data examined use of antidepressant medication and outpatient visits. Results Treatment participation rates were 97% for telephone care management and 93% for telephone care management plus psychotherapy. Compared with usual care, the telephone psychotherapy intervention led to lower mean Hopkins Symptom Checklist Depression Scale depression scores (P=.02), a higher proportion of patients reporting that depression was "much improved" (80% vs 55%, P<.001), and a higher proportion of patients "very satisfied" with depression treatment (59% vs 29%, P<.001). The telephone care management program had smaller effects on patient-rated improvement (66% vs 55%, P=.04) and satisfaction (47% vs 29%, P=.001); effects on mean depression scores were not statistically significant. Conclusions For primary care patients beginning antidepressant treatment, a telephone program integrating care management and structured cognitive-behavioral psychotherapy can significantly improve satisfaction and clinical outcomes. These findings suggest a new public health model of psychotherapy for depression including active outreach and vigorous efforts to improve access to and motivation for treatment.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	Group Health Cooperative	Simon, GE (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,1600, Seattle, WA 98101 USA.	simon.g@ghc.org		VonKorff, Michael/0000-0001-5386-8477	PHS HHS [R0151338] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Addis ME, 2002, CLIN PSYCHOL-SCI PR, V9, P367, DOI 10.1093/clipsy/9.4.367; [Anonymous], 2000, AM J PSYCHIAT S, V157, P1; BECK AT, 1987, COGNITIVE THERAPY DE; Bull SA, 2002, JAMA-J AM MED ASSOC, V288, P1403, DOI 10.1001/jama.288.11.1403; Derogatis LR, 1974, PSYCHOL MEASUREMENTS, P79; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; HAYS S, 1999, ACCEPTANCE COMMITMEN; Horvitz-Lennon M, 2003, AM J PSYCHIAT, V160, P720, DOI 10.1176/appi.ajp.160.4.720; Hunkeler EM, 2000, ARCH FAM MED, V9, P700, DOI 10.1001/archfami.9.8.700; Institute of Medicine, 2001, CROSS QUAL CHASM; Jaycox Lisa H, 2003, Ment Health Serv Res, V5, P109, DOI 10.1023/A:1023233612022; Katon W, 1999, ARCH GEN PSYCHIAT, V56, P1109, DOI 10.1001/archpsyc.56.12.1109; Katon W, 1996, ARCH GEN PSYCHIAT, V53, P924; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Katzelnick DJ, 2000, ARCH FAM MED, V9, P345, DOI 10.1001/archfami.9.4.345; Keller MB, 2000, NEW ENGL J MED, V342, P1462, DOI 10.1056/NEJM200005183422001; Lewinsohn P., 1986, CONTROL YOUR DEPRESS; Ludman E, 2000, INT J PSYCHIAT MED, V30, P229, DOI 10.2190/44LK-28E9-RRJ5-KQVW; Miranda J, 2003, JAMA-J AM MED ASSOC, V290, P57, DOI 10.1001/jama.290.1.57; Olfson M, 2002, JAMA-J AM MED ASSOC, V287, P203, DOI 10.1001/jama.287.2.203; Rollnick S., 1999, HLTH BEHAV CHANGE GU, V1st; Rollnick S, 1995, BEHAV COGN PSYCHOTH, V23, P325, DOI DOI 10.1017/S135246580001643X; Schulberg HC, 1996, ARCH GEN PSYCHIAT, V53, P913; Simon GE, 2001, ARCH GEN PSYCHIAT, V58, P395, DOI 10.1001/archpsyc.58.4.395; SIMON GE, 1993, J PSYCHIAT RES, V27, P247, DOI 10.1016/0022-3956(93)90035-Z; Simon GE, 1995, J GEN INTERN MED, V10, P663, DOI 10.1007/BF02602759; Simon GE, 2000, BRIT MED J, V320, P550, DOI 10.1136/bmj.320.7234.550; Simon GE, 1996, J CLIN EPIDEMIOL, V49, P1067, DOI 10.1016/0895-4356(96)00139-4; Sirey JA, 2001, PSYCHIAT SERV, V52, P1615, DOI 10.1176/appi.ps.52.12.1615; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Thase ME, 1997, ARCH GEN PSYCHIAT, V54, P1009; Tutty S, 2000, Eff Clin Pract, V3, P170; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; *US DEP HHS AHCPR, AHCPR PUBL; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; Wang PS, 2000, J GEN INTERN MED, V15, P284, DOI 10.1046/j.1525-1497.2000.9908044.x; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Whooley MA, 2000, NEW ENGL J MED, V343, P1942, DOI 10.1056/NEJM200012283432607; Young AS, 2001, ARCH GEN PSYCHIAT, V58, P55, DOI 10.1001/archpsyc.58.1.55; COMMERCIAL HEDIS 200	40	306	309	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2004	292	8					935	942		10.1001/jama.292.8.935	http://dx.doi.org/10.1001/jama.292.8.935			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WR	15328325	Bronze			2022-12-28	WOS:000223429200018
J	Banatvala, J				Banatvala, J			Unhealthy airports	LANCET			English	Editorial Material									Guys Kings & St Thomas Sch Med & Dent, London SE1 7EH, England	University of London; King's College London	Banatvala, J (corresponding author), Guys Kings & St Thomas Sch Med & Dent, London SE1 7EH, England.	jangu@btopenworld.com						*DEP TRANSP, 2003, FUT AIR TRANSP; *HLTH COUNC NETH, 1999, COMM HLTH IMP LARG A; HYGGE S, 1996, P INT 96, V1, P2189; King DA, 2004, SCIENCE, V303, P176, DOI 10.1126/science.1094329; Nemmar A, 2002, CIRCULATION, V105, P411, DOI 10.1161/hc0402.104118; Peters A, 2002, LANCET, V360, P1184, DOI 10.1016/S0140-6736(02)11289-X; *ROYAL COMM ENV PO, 2002, ENV EFF CIV AIRCR FL; Stansfeld S, 2000, Rev Environ Health, V15, P43; TAYLOR L, 2002, INFORMING DECISION M; *WHO, 1999, JUN 1999 CHART TRANS; 2004, PRIME MINISTERS STAT	11	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	2004	364	9435					646	648		10.1016/S0140-6736(04)16911-0	http://dx.doi.org/10.1016/S0140-6736(04)16911-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325814				2022-12-28	WOS:000223428900008
J	Dietzschold, B; Koprowski, H				Dietzschold, B; Koprowski, H			Rabies transmission from organ transplants in the USA	LANCET			English	Editorial Material							BAT RABIES		Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Dietzschold, B (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.	b_dietzschold@mail.jci.tju.edu						*CDCP, 2004, MMWR-MORBID MORTAL W, V53, P586; Dietzschold B, 2000, J HUMAN VIROL, V3, P50; Morimoto K, 1996, P NATL ACAD SCI USA, V93, P5653, DOI 10.1073/pnas.93.11.5653; MURPHY FA, 1973, LAB INVEST, V28, P361; RAY NB, 1995, J VIROL, V69, P764, DOI 10.1128/JVI.69.2.764-772.1995; RUPPRECHT CE, 1995, EMERG INFECT DIS, V1, P107, DOI 10.3201/eid0104.950401; WARRELL MJ, 1995, LANCET, V346, P65, DOI 10.1016/S0140-6736(95)92106-0	7	25	27	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	2004	364	9435					648	649		10.1016/S0140-6736(04)16912-2	http://dx.doi.org/10.1016/S0140-6736(04)16912-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325815				2022-12-28	WOS:000223428900009
J	Resa, I; Carmona, E; Gutierrez-Puebla, E; Monge, A				Resa, I; Carmona, E; Gutierrez-Puebla, E; Monge, A			Decamethyldizincocene, a stable compound of Zn(I) with a Zn-Zn bond	SCIENCE			English	Article							RAY CRYSTAL-STRUCTURE; ZINC; REACTIVITY; COMPLEXES; HYDRIDE; ATOMS	Unlike mercury, which has an extensive +1 oxidation state chemistry, zinc usually adopts the +2 oxidation state. Decamethyldizincocene, Zn-2(eta(5)-C5Me5)(2), an organometallic compound of Zn(I) formally derived from the dimetallic [Zn-Zn](2+) unit, has been isolated from the low-temperature (-10degreesC) reaction of Zn(C5Me5)(2) and Zn(C,H,), in diethyl ether. X-ray studies show that it contains two eclipsed Zn(eta(5)-C5Me5) fragments with a Zn-Zn distance (+/- standard deviation) of 2.305(+/-3) angstroms, indicative of a metal-metal bonding interaction.	Univ Sevilla, CSIC, Dept Quim Inorgan, Inst Invest Quim, Seville 41092, Spain; CSIC, Inst Ciencia Mat, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-USE - Instituto de Investigaciones Quimicas (IIQ); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Ciencia de Materiales de Madrid (ICMM); CSIC - Instituto de Ciencias Matematicas (ICMAT); Instituto de Ciencia de Materiales de Sevilla (ICMS-CSIC)	Carmona, E (corresponding author), Univ Sevilla, CSIC, Dept Quim Inorgan, Inst Invest Quim, Am Vespucio 49, Seville 41092, Spain.	guzman@us.es	Monge, M. Angeles/A-5389-2011; Carmona, Ernesto/K-4177-2014; Gutierrez-Puebla, Enrique/A-5392-2011	Monge, M. Angeles/0000-0003-2242-7593; Carmona, Ernesto/0000-0003-2449-5848; Gutierrez-Puebla, Enrique/0000-0002-2878-3540				BLOM R, 1986, ACTA CHEM SCAND A, V40, P113, DOI 10.3891/acta.chem.scand.40a-0113; COATES GE, 1967, J CHEM SOC A, P1233, DOI 10.1039/j19670001233; COTTON FA, 1999, ADV INORG CHEM, pCH15; DORN E, 1971, J CHEM SOC CHEM COMM, P466; FAGGIANI R, 1986, J CHEM SOC CHEM COMM, P517, DOI 10.1039/c39860000517; HAN R, 1991, J CHEM SOC CHEM COMM, P717, DOI 10.1039/c39910000717; Hao HJ, 2001, CHEM COMMUN, P1118, DOI 10.1039/b102275j; JASTRZEBSKI JTBH, 1988, RECL TRAV CHIM PAY B, V107, P263; Jutzi P, 1999, CHEM REV, V99, P969, DOI 10.1021/cr941099t; KERRIDGE DH, 1967, J CHEM SOC A, P1122, DOI 10.1039/j19670001122; KERSTEN JL, 1992, ANGEW CHEM INT EDIT, V31, P1341, DOI 10.1002/anie.199213411; OBRIEN P, 1995, COMPREHENSIVE ORGA 2, V3, pCH4; Pauling L., 1960, NATURE CHEM BOND; REGER DL, 1993, J AM CHEM SOC, V115, P10406, DOI 10.1021/ja00075a085; Rittner F, 1998, MICROPOR MESOPOR MAT, V24, P127, DOI 10.1016/S1387-1811(98)00154-1; SCHNEIDER JJ, 1991, ANGEW CHEM INT EDIT, V30, P1124, DOI 10.1002/anie.199111241; Tian Y, 2003, J AM CHEM SOC, V125, P6622, DOI 10.1021/ja0343757; WIBERG N, 2001, HOLLEMANWIBERG INORG, pCHR23	18	417	422	5	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	2004	305	5687					1136	1138		10.1126/science.1101356	http://dx.doi.org/10.1126/science.1101356			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	849RD	15326350				2022-12-28	WOS:000223557400042
J	Steinbrook, R				Steinbrook, R			After Bangkok - Expanding the global response to AIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Joint United Nations Program on HIV/AIDS, 2004, 2004 REP GLOB AIDS E; *US AID UNAIDS WHO, 2004, COV SEL SERV HIV AID; *WHO, 2004, WHO HIV AIDS PLAN JA; *WHO, 2004, 3 5 PROGR REP DEC 20	4	8	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2004	351	8					738	+		10.1056/NEJMp048186	http://dx.doi.org/10.1056/NEJMp048186			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847CY	15317883				2022-12-28	WOS:000223367900002
J	Christian, P; Khatry, SK; West, KP				Christian, P; Khatry, SK; West, KP			Antenatal anthelmintic treatment, birthweight, and infant survival in rural Nepal	LANCET			English	Article							PREGNANT-WOMEN; SUPPLEMENTATION; THERAPY; ANEMIA; PLAINS; TRIAL	Anthelmintic treatment, which is recommended during pregnancy in areas where there is a high rate of anaemia, needs further investigation. We examined prospectively the association between anthelmintic treatment and maternal anaemia, birthweight, and infant mortality in a study of prenatal supplements, in which women received albendazole twice during pregnancy. Women given albendazole in the second trimester of pregnancy had a lower rate of severe anaemia during the third trimester. Birthweight of infants of women who had received two doses of albendazole rose by 59 g (95% CI 19-98), and infant mortality at 6 months fell by 41% (RR 0 . 59; 95% Cl 0 . 43-0.82). Antenatal anthelmintics could be effective in reducing maternal anaemia and improving birthweight and infant survival in hookworm-endemic regions.	Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Program Human Nutr, Dept Int Hlth, Baltimore, MD 21205 USA; Ctr Human Nutr, Baltimore, MD USA; Soc Prevent Blindness, Nepal Nutr Intervent Project, Kathmandu, Nepal	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Christian, P (corresponding author), Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Program Human Nutr, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.	pchristi@jhsph.edu						ATUKORALA TMS, 1994, AM J CLIN NUTR, V60, P286, DOI 10.1093/ajcn/60.2.286; Christian P, 2003, AM J CLIN NUTR, V78, P1194, DOI 10.1093/ajcn/78.6.1194; Christian P, 2003, BMJ-BRIT MED J, V326, P571, DOI 10.1136/bmj.326.7389.571; de Silva NR, 1999, LANCET, V353, P1145, DOI 10.1016/S0140-6736(98)06308-9; Dreyfuss ML, 2000, J NUTR, V130, P2527, DOI 10.1093/jn/130.10.2527; Navitsky RC, 1998, J PARASITOL, V84, P647, DOI 10.2307/3284746; Stoltzfus RJ, 1998, GUIDELINES USE IRON	7	133	138	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	2004	364	9438					981	983		10.1016/S0140-6736(04)17023-2	http://dx.doi.org/10.1016/S0140-6736(04)17023-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364190				2022-12-28	WOS:000223831000029
J	Lin, HK; Bergmann, S; Pandolfi, PP				Lin, HK; Bergmann, S; Pandolfi, PP			Cytoplasmic PML function in TGF-beta signalling	NATURE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; MONOCYTIC DIFFERENTIATION; PREMATURE SENESCENCE; TUMOR SUPPRESSION; ANDROGEN RECEPTOR; PROTEIN ISOFORMS; ONCOGENIC RAS; CANCER-CELLS; GROWTH; ALPHA	Transforming growth factor beta (TGF-beta) is a pluripotent cytokine that controls key tumour suppressive functions(1-3), but cancer cells are often unresponsive to it(1,4). The promyelocytic leukaemia (PML) tumour suppressor of acute promyelocytic leukaemia (APL) accumulates in the PML nuclear body, but cytoplasmic PML isoforms of unknown function have also been described(5,6). Here we show that cytoplasmic Pml is an essential modulator of TGF-beta signalling. Pml-null primary cells are resistant to TGF-beta-dependent growth arrest, induction of cellular senescence and apoptosis. These cells also have impaired phosphorylation and nuclear translocation of the TGF-beta signalling proteins Smad2 and Smad3, as well as impaired induction of TGF-beta target genes. Expression of cytoplasmic Pml is induced by TGF-beta. Furthermore, cytoplasmic PML physically interacts with Smad2/3 and SARA (Smad anchor for receptor activation) and is required for association of Smad2/3 with SARA and for the accumulation of SARA and TGF-beta receptor in the early endosome. The PML-RARalpha oncoprotein of APL can antagonize cytoplasmic PML function and APL cells have defects in TGF-beta signalling similar to those observed in Pml-null cells. Our findings identify cytoplasmic PML as a critical TGF-beta regulator, and further implicate deregulated TGF-beta signalling in cancer pathogenesis.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, Canc Biol & Genet Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org						Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; ESCOLA JM, 1995, J CELL SCI, V108, P2337; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Ferbeyre G, 2000, GENE DEV, V14, P2015; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; Kim SJ, 2003, LEUKEMIA, V17, P1731, DOI 10.1038/sj.leu.2403069; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Panopoulou E, 2002, J BIOL CHEM, V277, P18046, DOI 10.1074/jbc.M107983200; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; TESTA U, 1993, J IMMUNOL, V150, P2418; TESTA U, 1994, CANCER RES, V54, P4508; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; Wang ZG, 1998, SCIENCE, V279, P1547; Zhu J, 2002, NAT REV CANCER, V2, P705, DOI 10.1038/nrc887	30	252	274	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2004	431	7005					205	211		10.1038/nature02783	http://dx.doi.org/10.1038/nature02783			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356634				2022-12-28	WOS:000223746000049
J	Greenberger, NJ; Sharma, P				Greenberger, NJ; Sharma, P			Update in gastroenterology and hepatology	ANNALS OF INTERNAL MEDICINE			English	Review							ASPIRIN		Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Univ Kansas, Med Ctr, Sch Med, Kansas City, KS 66103 USA	Harvard University; University of Kansas; University of Kansas Medical Center	Greenberger, NJ (corresponding author), Brigham & Womens Hosp, Div Gastroenterol, 75 Francis St, Boston, MA 02115 USA.	ngreenberger@partners.org						Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Francella A, 2003, GASTROENTEROLOGY, V124, P9, DOI 10.1053/gast.2003.50014; Imperiale TF, 2003, NEW ENGL J MED, V348, P879, DOI 10.1056/NEJMp030005	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	2004	141	5					374	380		10.7326/0003-4819-141-5-200409070-00012	http://dx.doi.org/10.7326/0003-4819-141-5-200409070-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CW	15353429				2022-12-28	WOS:000223733800006
J	Painter, TM; Diaby, KL; Matia, DM; Lin, LS; Sibailly, TS; Kouassi, MK; Ekpini, ER; Roels, TH; Wiktor, SZ				Painter, TM; Diaby, KL; Matia, DM; Lin, LS; Sibailly, TS; Kouassi, MK; Ekpini, ER; Roels, TH; Wiktor, SZ			Women's reasons for not participating in follow up visits before starting short course antiretroviral prophylaxis for prevention of mother to child transmission of HIV: qualitative interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SHORT-COURSE ZIDOVUDINE; COTE-DIVOIRE; PREGNANT-WOMEN; ORAL ZIDOVUDINE; BURKINA-FASO; ACCEPTABILITY; ABIDJAN; INTERVENTIONS; COHORT; RETURN	Objective To find out why pregnant women who receive HIV-1 positive test results and are offered short course antiretroviral prophylaxis to prevent transmission of HIV from mother to child do not participate in necessary follow up visits before starting prophylaxis. Design Qualitative interview study. Setting A programme aiming to prevent transmission of HIV from mother to child at a public antenatal clinic in Abidjan, Cote d'Ivoire. Participants Purposive sample of 27 women who had received HIV-1 positive test results and were invited to return for monthly follow up visits before starting prophylaxis with zidovudine at 36 weeks' gestation, but who had either refused or discontinued the visits. None of the women started prophylaxis. Results Most of the women explained their non-participation in follow up visits by referring to negative experiences that they had had while interacting with programme staff or to their views about the programme. Additional reasons concerned their disbelief of HIV positive test results and personal factors. Conclusions Difficulties experienced by women during their contacts with staff working on the prevention programme and negative views that they have about the programme can contribute to their non-participation in prophylaxis. Training and supervision of programme staff may increase the likelihood of positive interactions between staff and clients, thereby facilitating women's participation in preventing transmission of HIV from mother to child. Outreach and mobilisation in communities that are served by prevention programmes may complement these measures at programme level by contributing to increased social support for women's efforts to prevent transmission of HIV from mother to child.	Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA; US Embasy, CDC HIV, Projet RETRO CI, Abidjan 1712 01, Cote Ivoire; WHO, Div HIV AIDS, CH-1211 Geneva 27, Switzerland; US Embassy, Ctr Dis Control & Prevent, Global AIDS Program, Kigali, Rwanda; BOTUSA Project, Global AIDS Program, Gaborone, Botswana	Centers for Disease Control & Prevention - USA; World Health Organization	Painter, TM (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, 1600 Clifton Rd NE,Mail Stop E-37, Atlanta, GA 30333 USA.	tcp2@cdc.gov		Roels, Thierry/0000-0002-0886-5645				Allen S., 1999, PREVENTING HIV DEV C, P87; Carr R, 1998, FASEB J, V12, pA1; Cartoux M, 1998, AIDS, V12, P2489, DOI 10.1097/00002030-199818000-00019; Cartoux M, 1998, AIDS, V12, P2337, DOI 10.1097/00002030-199817000-00016; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; DEKONINCK M, 1997, RECHERCHES FEMINISTE, V10, P97; Ekouevi DK, 2004, JAIDS-J ACQ IMM DEF, V36, P755, DOI 10.1097/00126334-200406010-00014; EZOUA J, 2001, 12 INT C AIDS STD AF; Farquhar C., 2000, 13 INT AIDS C DURB S; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Issiaka S, 2001, AIDS CARE, V13, P123, DOI 10.1080/09540120020018224; Kiarie J, 2000, AIDS, V14, P1468, DOI 10.1097/00002030-200007070-00030; Ladner J, 1996, AIDS, V10, P69, DOI 10.1097/00002030-199601000-00010; Malonza IA, 2003, AIDS, V17, P113, DOI 10.1097/00002030-200301030-00015; McKenna SL, 1997, AIDS, V11, pS103; MOUZIN E, 2001, MTCT NEWS 2001, P2; Msellati P, 2001, B WORLD HEALTH ORGAN, V79, P641; MWAI C, 2001, 3 C GLOB STRAT PREV; Nebie Y, 2001, J ACQ IMMUN DEF SYND, V28, P367, DOI 10.1097/00126334-200112010-00010; Painter TM, 2001, SOC SCI MED, V53, P1397, DOI 10.1016/S0277-9536(00)00427-5; Prual A, 2000, HEALTH POLICY PLANN, V15, P11, DOI 10.1093/heapol/15.1.11; Seidel G, 2000, HEALTH POLICY PLANN, V15, P24, DOI 10.1093/heapol/15.1.24; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; SIBAILLY TS, 2000, 13 INT AIDS C DURB S; Songok EM, 2003, AM J TROP MED HYG, V69, P8, DOI 10.4269/ajtmh.2003.69.8; Stringer EM, 2003, AIDS, V17, P1377, DOI 10.1097/00002030-200306130-00012; Temmerman M, 2003, AIDS, V17, P1239, DOI 10.1097/00002030-200305230-00016; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; Wilkinson D, 1997, HEALTH POLICY PLANN, V12, P161, DOI 10.1093/heapol/12.2.161	29	76	77	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 4	2004	329	7465					543	546		10.1136/bmj.329.7465.543	http://dx.doi.org/10.1136/bmj.329.7465.543			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853DE	15345628	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000223805800019
J	Deehan, R; Heald, R				Deehan, R; Heald, R			Centromere glue provides spindle cue	CELL			English	Editorial Material							SISTER-CHROMATID COHESION; DROSOPHILA MEI-S332; PROTEIN MEI-S332; MEIOSIS-I; MAINTENANCE	During cell division, accurate distribution of the genome by the mitotic spindle requires that sister chromatids remain tethered until the right moment. Studies of an uncharacterized vertebrate protein, Sgo (Salic et al., 2004 [this issue of Cell]), reveal dual roles as a chromosome cohesion factor and a regulator of spindle microtubule dynamics.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Deehan, R (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 311 Life Sci & Cell Biol, Berkeley, CA 94720 USA.			Heald, Rebecca/0000-0001-6671-6528				Haering CH, 2003, BIOESSAYS, V25, P1178, DOI 10.1002/bies.10361; Katis VL, 2004, CURR BIOL, V14, P560, DOI 10.1016/j.cub.2004.03.001; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; Kitajima TS, 2004, NATURE, V427, P510, DOI 10.1038/nature02312; LeBlanc HN, 1999, CHROMOSOMA, V108, P401, DOI 10.1007/s004120050392; Lee JY, 2004, CURR BIOL, V14, P1277, DOI 10.1016/j.cub.2004.07.023; Marston AL, 2004, SCIENCE, V303, P1367, DOI 10.1126/science.1094220; Moore DP, 1998, J CELL BIOL, V140, P1003, DOI 10.1083/jcb.140.5.1003; Rabitsch KP, 2004, CURR BIOL, V14, P287, DOI 10.1016/j.cub.2004.01.051; Tang TTL, 1998, GENE DEV, V12, P3843, DOI 10.1101/gad.12.24.3843	10	0	0	1	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	2004	118	5					529	530		10.1016/j.cell.2004.08.018	http://dx.doi.org/10.1016/j.cell.2004.08.018			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	852BN	15339655	Bronze			2022-12-28	WOS:000223730300001
J	Li, L; Thomas, RM; Suzuki, H; De Brabander, JK; Wang, XD; Harran, PG				Li, L; Thomas, RM; Suzuki, H; De Brabander, JK; Wang, XD; Harran, PG			A small molecule Smac mimic potentiates TRAIL- and TNF alpha-mediated cell death	SCIENCE			English	Article							APOPTOSIS PROTEIN; STRUCTURAL BASIS; INHIBITOR; SMAC/DIABLO; EXPRESSION; BINDING; IDENTIFICATION; SUPPRESSION; ACTIVATION; C-IAP2	We describe the synthesis and properties of a small molecule mimic of Smac, a pro-apoptotic protein that functions by relieving inhibitor-of-apoptosis protein (IAP)-mediated suppression of caspase activity. The compound binds to X chromosome-encoded IAP (XIAP), cellular IAP 1 (clAP-1), and cellular IAP 2 (clAP-2) and synergizes with both tumor necrosis factor alpha (TNFalpha.) and TNF-related apoptosis-inducing ligand (TRAIL) to potently induce caspase activation and apoptosis in human cancer cells. The molecule has allowed a temporal, unbiased evaluation of the roles that IAP proteins play during signaling from TRAIL and TNF receptors. The compound is also a lead structure for the development of IAP antagonists potentially useful as therapy for cancer and inflammatory diseases.	Univ Texas, SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	De Brabander, JK (corresponding author), Univ Texas, SW Med Ctr Dallas, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jdebra@biochem.swmed.edu; xwang@biochem.swmed.edu; pharra@biochem.swmed.edu			NCI NIH HHS [P01 CA95471] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA095471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; BERSCHEID R, 1992, SYNTHESIS-STUTTGART, P58; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fox DA, 2000, ARCH INTERN MED, V160, P437, DOI 10.1001/archinte.160.4.437; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Hasegawa T, 2003, BLOOD, V101, P1164, DOI 10.1182/blood-2002-05-1505; Huang YH, 2003, J BIOL CHEM, V278, P49517, DOI 10.1074/jbc.M310061200; Imoto I, 2001, CANCER RES, V61, P6629; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XD, 2001, GENE DEV, V15, P2922; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yang LL, 2003, CANCER RES, V63, P831	25	565	629	7	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1471	1474		10.1126/science.1098231	http://dx.doi.org/10.1126/science.1098231			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	852NK	15353805				2022-12-28	WOS:000223761900051
J	Tzfira, T; Vaidya, M; Citovsky, V				Tzfira, T; Vaidya, M; Citovsky, V			Involvement of targeted proteolysis in plant genetic transformation by Agrobacterium	NATURE			English	Article							T-DNA TRANSFER; NUCLEAR-LOCALIZATION SIGNAL; NOPALINE STRAINS; BINDING-PROTEIN; VIRULENCE GENE; A-TUMEFACIENS; VIRD2 PROTEIN; CELLS; HOST; VIRE2	Genetic transformation of plant cells by Agrobacterium represents a unique case of trans-kingdom DNA transfer(1). During this process, Agrobacterium exports its transferred ( T) DNA and several virulence (Vir) proteins into the host cell(2), within which T-DNA nuclear import is mediated by VirD2 (ref. 3) and VirE2 ( ref. 4) and their host cell interactors AtKAP-alpha(5) and VIP1 (ref. 6), whereas its integration is mediated mainly by host cell proteins(7-9). The factors involved in the uncoating of T-DNA from its cognate proteins, which occurs before integration into the host genome, are still unknown. Here, we report that VirF - one of the few known exported Vir proteins whose function in the host cell remains unknown - is involved in targeted proteolysis of VIP1 and VirE2. We show that VirF localizes to the plant cell nucleus and interacts with VIP1, a nuclear protein. VirF, which contains an F-box motif(10), significantly destabilizes both VIP1 and VirE2 in yeast cells. Destabilization of VIP1 in the presence of VirF was then confirmed in planta. These results suggest that VIP1 and its cognate VirE2 are specifically targeted by the VirF-containing Skp1-Cdc53-cullin-F-box complex for proteolysis. The critical role of proteasomal degradation in Agrobacterium-mediated genetic transformation was also evident from inhibition of T-DNA expression by a proteasomal inhibitor.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Tzfira, T (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	ttzfira@ms.cc.sunysb.edu		Citovsky, Vitaly/0000-0003-2024-6844				Ballas N, 1997, P NATL ACAD SCI USA, V94, P10723, DOI 10.1073/pnas.94.20.10723; BUNDOCK P, 1995, EMBO J, V14, P3206, DOI 10.1002/j.1460-2075.1995.tb07323.x; CITOVSKY V, 1992, SCIENCE, V256, P1802, DOI 10.1126/science.1615325; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; del Pozo JC, 2000, PLANT MOL BIOL, V44, P123, DOI 10.1023/A:1006413007456; Deng WY, 1999, MOL MICROBIOL, V31, P1795, DOI 10.1046/j.1365-2958.1999.01316.x; DOMMISSE EM, 1990, PLANT SCI, V69, P249, DOI 10.1016/0168-9452(90)90124-7; Gelvin SB, 2000, ANNU REV PLANT PHYS, V51, P223, DOI 10.1146/annurev.arplant.51.1.223; Gelvin SB, 2003, MICROBIOL MOL BIOL R, V67, P16, DOI 10.1128/MMBR.67.1.16-37.2003; Goodin MM, 2002, PLANT J, V31, P375, DOI 10.1046/j.1365-313X.2002.01360.x; Gray WM, 2001, NATURE, V414, P271, DOI 10.1038/35104500; HOWARD EA, 1992, CELL, V68, P109, DOI 10.1016/0092-8674(92)90210-4; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; JARCHOW E, 1991, P NATL ACAD SCI USA, V88, P10426, DOI 10.1073/pnas.88.23.10426; Kunik T, 2001, P NATL ACAD SCI USA, V98, P1871, DOI 10.1073/pnas.041327598; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; MELCHERS LS, 1990, PLANT MOL BIOL, V14, P249, DOI 10.1007/BF00018565; Nagai H, 2003, CELL MICROBIOL, V5, P373, DOI 10.1046/j.1462-5822.2003.00285.x; Narasimhulu SB, 1996, PLANT CELL, V8, P873, DOI 10.1105/tpc.8.5.873; OTTEN L, 1984, MOL GEN GENET, V195, P159, DOI 10.1007/BF00332739; REGENSBURGTUINK AJG, 1993, NATURE, V363, P69, DOI 10.1038/363069a0; Schrammeijer B, 1998, MOL PLANT MICROBE IN, V11, P429, DOI 10.1094/MPMI.1998.11.5.429; Schrammeijer B, 2001, CURR BIOL, V11, P258, DOI 10.1016/S0960-9822(01)00069-0; STACHEL SE, 1989, NATURE, V340, P190, DOI 10.1038/340190a0; Tzfira T, 2001, EMBO J, V20, P3596, DOI 10.1093/emboj/20.13.3596; Tzfira T, 2002, P NATL ACAD SCI USA, V99, P10435, DOI 10.1073/pnas.162304099; Tzfira T, 2004, TRENDS GENET, V20, P375, DOI 10.1016/j.tig.2004.06.004; Tzfira T, 2002, TRENDS CELL BIOL, V12, P121, DOI 10.1016/S0962-8924(01)02229-2; Vergunst AC, 2000, SCIENCE, V290, P979, DOI 10.1126/science.290.5493.979; Zupan J, 2000, PLANT J, V23, P11, DOI 10.1046/j.1365-313x.2000.00808.x	30	186	207	3	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	2004	431	7004					87	92		10.1038/nature02857	http://dx.doi.org/10.1038/nature02857			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343337				2022-12-28	WOS:000223641500047
J	Pignone, M				Pignone, M			Faecal occult-blood screening in Burgundy	LANCET			English	Editorial Material							COLORECTAL-CANCER MORTALITY		Univ N Carolina, Dept Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27707 USA; Cecil Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27707 USA	University of North Carolina; University of North Carolina Chapel Hill	Pignone, M (corresponding author), Univ N Carolina, Dept Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27707 USA.	pignone@med.unc.edu		Pignone, Michael/0000-0002-6657-7342				Faivre J, 2004, GASTROENTEROLOGY, V126, P1674, DOI 10.1053/j.gastro.2004.02.018; KEWENTER J, 1994, SCAND J GASTROENTERO, V29, P468, DOI 10.3109/00365529409096840; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; Mandel JS, 1999, J NATL CANCER I, V91, P434, DOI 10.1093/jnci/91.5.434; Steele RJC, 2004, BMJ-BRIT MED J, V329, P133, DOI 10.1136/bmj.38153.491887.7C; Towler B, 1998, BRIT MED J, V317, P559, DOI 10.1136/bmj.317.7158.559	7	3	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	2004	364	9436					741	742		10.1016/S0140-6736(04)16953-5	http://dx.doi.org/10.1016/S0140-6736(04)16953-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337388				2022-12-28	WOS:000223569600009
J	Law, M; Sirbuly, DJ; Johnson, JC; Goldberger, J; Saykally, RJ; Yang, PD				Law, M; Sirbuly, DJ; Johnson, JC; Goldberger, J; Saykally, RJ; Yang, PD			Nanoribbon waveguides for subwavelength photonics integration	SCIENCE			English	Article							ROOM-TEMPERATURE; LASERS; ZNO; MANIPULATION; MICROSCOPE; CRYSTALS; EMISSION; WIRES	Although the electrical integration of chemically synthesized nanowires has been achieved with lithography, optical integration, which promises high speeds and greater device versatility, remains unexplored. We describe the properties and functions of individual crystalline oxide nanoribbons that act as subwaveiength optical waveguides and assess their applicability as nanoscale photonic elements. The length, flexibility, and strength of these structures enable their manipulation on surfaces, including the optical linking of nanoribbon waveguides and other nanowire elements to form networks and device components. We demonstrate the assembly of ribbon waveguides with nanowire light sources and detectors as a first step toward building nanowire photonic circuitry.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Yang, PD (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	p_yang@uclink.berkeley.edu	Goldberger, Joshua/N-8963-2016; Goldberger, Joshua/F-5484-2011; Johnson, Justin/Q-7439-2017	Goldberger, Joshua/0000-0003-4284-604X; Goldberger, Joshua/0000-0003-4284-604X; Law, Matt/0000-0001-7645-9908; SAYKALLY, RICHARD/0000-0001-8942-3656; Johnson, Justin/0000-0002-8874-6637				Almeida VR, 2004, OPT LETT, V29, P1209, DOI 10.1364/OL.29.001209; Barnes WL, 2003, NATURE, V424, P824, DOI 10.1038/nature01937; Duan XF, 2003, NATURE, V425, P274, DOI 10.1038/nature01996; Duan XF, 2003, NATURE, V421, P241, DOI 10.1038/nature01353; Egelhaaf HJ, 1996, J CRYST GROWTH, V161, P190, DOI 10.1016/0022-0248(95)00634-6; Eldada L, 2004, REV SCI INSTRUM, V75, P575, DOI 10.1063/1.1647701; Gmachl C, 1998, SCIENCE, V280, P1556, DOI 10.1126/science.280.5369.1556; Huang MH, 2001, SCIENCE, V292, P1897, DOI 10.1126/science.1060367; Johnson JC, 2003, J PHYS CHEM B, V107, P8816, DOI 10.1021/jp034482n; Kim KS, 2003, REV SCI INSTRUM, V74, P4021, DOI 10.1063/1.1597955; Kind H, 2002, ADV MATER, V14, P158, DOI 10.1002/1521-4095(20020116)14:2<158::AID-ADMA158>3.0.CO;2-W; Krenn JR, 2004, PHILOS T ROY SOC A, V362, P739, DOI 10.1098/rsta.2003.1344; Law M, 2002, ANGEW CHEM INT EDIT, V41, P2405, DOI 10.1002/1521-3773(20020703)41:13<2405::AID-ANIE2405>3.0.CO;2-3; Lopez C, 2003, ADV MATER, V15, P1679, DOI 10.1002/adma.200300386; McAlpine MC, 2003, NANO LETT, V3, P1531, DOI 10.1021/nl0346427; Noda S, 2000, SCIENCE, V289, P604, DOI 10.1126/science.289.5479.604; Okamoto K., 2000, FUNDAMENTALS OPTICAL; Pan ZW, 2001, SCIENCE, V291, P1947, DOI 10.1126/science.1058120; Postma HWC, 2000, ADV MATER, V12, P1299, DOI 10.1002/1521-4095(200009)12:17<1299::AID-ADMA1299>3.0.CO;2-O; Psaltis D, 2002, SCIENCE, V298, P1359, DOI 10.1126/science.1078823; Quidant R, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.066607; REDDICK RC, 1990, REV SCI INSTRUM, V61, P3669, DOI 10.1063/1.1141534; Snyder A.W., 1983, OPTICAL WAVEGUIDE TH; Tao A, 2003, NANO LETT, V3, P1229, DOI 10.1021/nl0344209; Tong LM, 2003, NATURE, V426, P816, DOI 10.1038/nature02193; Yan HQ, 2003, ADV MATER, V15, P1907, DOI 10.1002/adma.200305490; Yang PD, 2000, SCIENCE, V287, P465, DOI 10.1126/science.287.5452.465	27	847	905	7	351	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2004	305	5688					1269	1273		10.1126/science.1100999	http://dx.doi.org/10.1126/science.1100999			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850PJ	15333835				2022-12-28	WOS:000223624600035
J	Hamblin, TJ				Hamblin, TJ			Predicting progression - ZAP-70 in CLL	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CHRONIC LYMPHOCYTIC-LEUKEMIA; EXPRESSION		Univ Southampton, Dept Immunohaematol, Southampton, Hants, England	University of Southampton	Hamblin, TJ (corresponding author), Univ Southampton, Dept Immunohaematol, Southampton, Hants, England.							Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; Orchard JA, 2004, LANCET, V363, P105, DOI 10.1016/S0140-6736(03)15260-9	4	20	20	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2004	351	9					856	857		10.1056/NEJMp048184	http://dx.doi.org/10.1056/NEJMp048184			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849BM	15329421				2022-12-28	WOS:000223512500005
J	Neumann, HPH; Pawlu, C; Peczkowska, M; Bausch, B; MeWhinney, SR; Muresan, M; Buchta, M; Franke, G; Klisch, J; Bley, TA; Hoegerle, S; Boedeker, CC; Opocher, G; Schipper, J; Januszewicz, A; Eng, C				Neumann, HPH; Pawlu, C; Peczkowska, M; Bausch, B; MeWhinney, SR; Muresan, M; Buchta, M; Franke, G; Klisch, J; Bley, TA; Hoegerle, S; Boedeker, CC; Opocher, G; Schipper, J; Januszewicz, A; Eng, C		European-Amer Paraganglioma Study Grp	Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENDOCRINE NEOPLASIA TYPE-2; GERM-LINE MUTATIONS; COMPLEX-II GENE; HEREDITARY PARAGANGLIOMAS; PHEOCHROMOCYTOMA; MULTIPLE; SUSCEPTIBILITY; DISEASE; SURGERY; PET	Context Germline mutations of the genes encoding succinate dehydrogenase subunits B (SDHB) and D. (SDHD) predispose to paraganglioma syndromes type 4 (PGL-4) and type 1 (PGL-1), respectively. In both syndromes, pheochromocytomas as well as head and neck paragangliomas occur; however, details for individual risks and other clinical characteristics are unknown. Objective To determine the differences in clinical features in carriers of SDHB mutations and SDHD mutations. Design, Setting, and Patients Population-based genetic screening for SDHB and SDHD germline mutations in 417 unrelated patients with adrenal or extra-adrenal abdominal or thoracic pheochromocytomas (n =334) or head and neck paragangliomas (n =83), but without syndromic features, from 2 registries based in Germany and central Poland, conducted from April 1, 2000, until May 15, 2004. Main Outcome Measures Demographic and clinical findings with respect to gene mutation in SDHB vs SDHD compared with nonmutation carriers. Results A total of 49 (12%) of 417 registrants carried SDHB or SDHD mutations. In addition, 28 SDHB and 23 SDHD mutation carriers were newly detected among relatives of these carriers. Comparison of 53 SDHB and 47 SDHD total mutation carriers showed similar ages at diagnosis but differences in penetrance and of tumor manifestations. Head and neck paragangliomas (10/32 vs 27/34, respectively, P<.001) and multifocal (9/32 vs 25/34, respectively, P<.001) tumors were more frequent in carriers of SDHD mutations. In contrast, SDHB mutation carriers have an increased frequency of malignant disease (11/32 vs 0/34, P<.001). Renal cell cancer was observed in 2 SDHB mutation carriers and papillary thyroid cancer in 1 SDHB mutation carrier and 1 SDHD mutation carrier. Conclusions In contrast with SDHD mutation carriers (PGL-1) who have more frequent multifocal paragangliomas, SDHB mutation carriers (PGL-4) are more likely to develop malignant disease and possibly extraparaganglial neoplasias, including renal cell and thyroid carcinomas. Appropriate and timely clinical screening is recommended in all patients with PGL-1 and PGL-4.	Univ Freiburg, Med Klin, Dept Hypertens & Nephrol, D-79106 Freiburg, Germany; Univ Freiburg, Dept Neuroradiol, D-79106 Freiburg, Germany; Univ Freiburg, Dept Diagnost Radiol, D-79106 Freiburg, Germany; Univ Freiburg, Dept Nucl Med, D-79106 Freiburg, Germany; Univ Freiburg, Dept Otorhinolaryngol, D-79106 Freiburg, Germany; Inst Cardiol, Dept Hypertens, Warsaw, Poland; Ohio State Univ, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Univ Nancy, Hop Brabois, Dept Endocrinol, Nancy, France; Univ Padua, Dept Endocrinol, Padua, Italy	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Institute of Cardiology - Poland; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; CHU de Nancy; Universite de Lorraine; University of Padua	Neumann, HPH (corresponding author), Univ Freiburg, Med Klin, Dept Hypertens & Nephrol, Hugstetter Str 55, D-79106 Freiburg, Germany.	neumann@med1.ukl.uni-freiburg.de	Opocher, Giuseppe/F-3950-2014	Opocher, Giuseppe/0000-0002-9845-9623; Eng, Charis/0000-0002-3693-5145	NCI NIH HHS [P30CA16058] Funding Source: Medline; NICHD NIH HHS [R01HD39058-02S1, R01HD39058-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039058] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Badenhop RF, 2001, GENE CHROMOSOME CANC, V31, P255, DOI 10.1002/gcc.1142; Bauters C, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.6.e75; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178; Baysal BE, 2002, J MED GENET, V39, P617, DOI 10.1136/jmg.39.9.617; BAYSAL BE, IN PRESS J MED GENET; Cascon A, 2002, EUR J HUM GENET, V10, P457, DOI 10.1038/sj.ejhg.5200829; Eisenhofer G, 1999, NEW ENGL J MED, V340, P1872, DOI 10.1056/NEJM199906173402404; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; Gimenez-Roqueplo AP, 2003, CANCER RES, V63, P5615; Gimenez-Roqueplo AP, 2001, AM J HUM GENET, V69, P1186, DOI 10.1086/324413; Gimm O, 2000, CANCER RES, V60, P6822; HEUTINK P, 1992, HUM MOL GENET, V1, P7, DOI 10.1093/hmg/1.1.7; Hoegerle S, 2003, EUR J NUCL MED MOL I, V30, P689, DOI 10.1007/s00259-003-1115-3; Hoegerle S, 2002, RADIOLOGY, V222, P507, DOI 10.1148/radiol.2222010622; Janetschek G, 1998, J UROLOGY, V160, P330, DOI 10.1016/S0022-5347(01)62886-6; Maher ER, 2002, HUM MOL GENET, V11, P2347, DOI 10.1093/hmg/11.20.2347; Milunsky JM, 2001, AM J MED GENET, V100, P311, DOI 10.1002/ajmg.1270; NEUMANN HPH, 1993, NEW ENGL J MED, V329, P1531, DOI 10.1056/NEJM199311183292103; Neumann HPH, 1999, BRIT J SURG, V86, P94, DOI 10.1046/j.1365-2168.1999.00974.x; Neumann HPH, 1999, J CLIN ENDOCR METAB, V84, P2608, DOI 10.1210/jc.84.8.2608; Neumann HPH, 2002, NEW ENGL J MED, V346, P1459, DOI 10.1056/NEJMoa020152; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Niemann S, 2003, HUM GENET, V113, P92, DOI 10.1007/s00439-003-0938-0; Pacak K, 2001, HYPERTENSION, V38, P6, DOI 10.1161/01.HYP.38.1.6; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; Sawka AM, 2003, J CLIN ENDOCR METAB, V88, P553, DOI 10.1210/jc.2002-021251; Taschner PEM, 2001, GENE CHROMOSOME CANC, V31, P274, DOI 10.1002/gcc.1144; VANDERMEY AGL, 1989, LANCET, V2, P1291; Vanharanta S, 2004, AM J HUM GENET, V74, P153, DOI 10.1086/381054; Walz MK, 2002, WORLD J SURG, V26, P1005, DOI 10.1007/s00268-002-6632-x	33	657	683	2	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2004	292	8					943	951		10.1001/jama.292.8.943	http://dx.doi.org/10.1001/jama.292.8.943			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WR	15328326	Bronze			2022-12-28	WOS:000223429200019
J	Lewis, T				Lewis, T			10-minute consultation - Using the NO TEARS tool for medication review	BRITISH MEDICAL JOURNAL			English	Article									Carreg Wen Surg, Torfaen NP4 9AF, Wales		Lewis, T (corresponding author), Carreg Wen Surg, Torfaen NP4 9AF, Wales.	Tessa.Lewis@gp-w93015.wales.nhs.uk							0	30	30	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 21	2004	329	7463					434	434		10.1136/bmj.329.7463.434	http://dx.doi.org/10.1136/bmj.329.7463.434			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849EA	15321901	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000223520300020
J	Renault, AD; Sigal, YJ; Morris, AJ; Lehmann, R				Renault, AD; Sigal, YJ; Morris, AJ; Lehmann, R			Soma-germ line competition for lipid phosphate uptake regulates germ cell migration and survival	SCIENCE			English	Article							LYSOPHOSPHATIDIC ACID; DROSOPHILA; PLATELETS; RECEPTORS	Lipid phosphates can act as signaling molecules to influence cell division, apoptosis, and migration. wunen and wunen2 encode Drosophila lipid phosphate phosphohydrolases, integral membrane enzymes that dephosphorylate extracellular lipid phosphates. wun and wun2 act redundantly in somatic tissues to repel migrating germ cells, although the mechanism by which germ cells respond is unclear. Here, we report that wun2 also functions in germ cells, enabling them to perceive the wun/wun2-related signal from the soma. Upon Wun2 expression, cultured insect cells dephosphorylate and internalize exogenously supplied lipid phosphate. We propose that Drosophila germ cell migration and survival are controlled by competition for hydrolysis of a lipid phosphate between germ cells and soma.	NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA; NYU, Sch Med, Dev Genet Program, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	Howard Hughes Medical Institute; New York University; New York University; New York University; New York University; University of North Carolina; University of North Carolina Chapel Hill	Lehmann, R (corresponding author), NYU, Sch Med, Howard Hughes Med Inst, 540 1st Ave, New York, NY 10016 USA.	lehmann@saturn.med.nyu.edu	Morris, Andrew/B-7869-2010	Renault, Andrew/0000-0003-4313-9726; Lehmann, Ruth/0000-0002-8454-5651	NICHD NIH HHS [HD421900 RO1] Funding Source: Medline; NIGMS NIH HHS [GM54388] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burnett C, 2003, EMBO REP, V4, P793, DOI 10.1038/sj.embor.embor900; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Escalante-Alcalde D, 2003, DEVELOPMENT, V130, P4623, DOI 10.1242/dev.00635; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Martinho RG, 2004, CURR BIOL, V14, P159, DOI 10.1016/j.cub.2003.12.036; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Renault AD, 2002, MECH DEVELOP, V119, pS293, DOI 10.1016/S0925-4773(03)00131-X; Roberts R, 1998, J BIOL CHEM, V273, P22059, DOI 10.1074/jbc.273.34.22059; Santos AC, 2004, CURR BIOL, V14, pR578, DOI 10.1016/j.cub.2004.07.018; Siess W, 2002, BBA-MOL CELL BIOL L, V1582, P204, DOI 10.1016/S1388-1981(02)00173-7; Starz-Gaiano M, 2001, DEVELOPMENT, V128, P983; Van Doren M, 1998, CURR BIOL, V8, P243; Van Doren M, 1998, NATURE, V396, P466, DOI 10.1038/24871; WYLIE CR, COMMUNICATION; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0	19	69	70	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	2004	305	5692					1963	1966		10.1126/science.1102421	http://dx.doi.org/10.1126/science.1102421			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	857RM	15331773				2022-12-28	WOS:000224136000049
J	Aaby, P				Aaby, P			Being wrong in the right direction?	LANCET			English	Editorial Material									Danish Epidemiol Sci Ctr, Bandim Hlth Project, Bissau, Guinea Bissau	Aarhus University	Aaby, P (corresponding author), Danish Epidemiol Sci Ctr, Bandim Hlth Project, Apartado 861, Bissau, Guinea Bissau.	psb@mail.gtelecom.gw		Aaby, Peter/0000-0001-8331-1389					0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	2004	364	9438					984	984		10.1016/S0140-6736(04)17024-4	http://dx.doi.org/10.1016/S0140-6736(04)17024-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364191				2022-12-28	WOS:000223831000030
J	Manandhar, DS; Osrin, D; Shrestha, BP; Mesko, N; Morrison, J; Tumbahangphe, KM; Tamang, S; Thapa, S; Shrestha, D; Thapa, B; Shrestha, JR; Wade, A; Borghi, J; Standing, H; Manandhar, M; Costello, AMD				Manandhar, DS; Osrin, D; Shrestha, BP; Mesko, N; Morrison, J; Tumbahangphe, KM; Tamang, S; Thapa, S; Shrestha, D; Thapa, B; Shrestha, JR; Wade, A; Borghi, J; Standing, H; Manandhar, M; Costello, AMD		MIRA Makwanpur Trial Team	Effect of a participatory intervention with women' groups on birth outcomes in Nepal: cluster-randomised controlled trial	LANCET			English	Article							PRIMARY HEALTH-CARE; COMMUNITY PARTICIPATION; MORTALITY; MOTHERS	Background Neonatal deaths in developing countries make the largest contribution to global mortality in children younger than 5 years. 90% of deliveries in the poorest quintile of households happen at home. We postulated that a community-based participatory intervention could significantly reduce neonatal mortality rates. Methods We pair-matched 42 geopolitical clusters in Makwanpur district, Nepal, selected 12 pairs randomly, and randomly assigned one of each pair to intervention or control. in each intervention cluster (average population 7000), a female facilitator convened nine women's group meetings every month. The facilitator supported groups through an action-learning cycle in which they identified local perinatal. problems and formulated strategies to address them. We monitored birth outcomes in a cohort of 28 931 women, of whom 8% joined the groups. The primary outcome was neonatal mortality rate. Other outcomes included stillbirths and maternal deaths, uptake of antenatal and delivery services, home care practices, infant morbidity, and health-care seeking. Analysis was by intention to treat. The study is registered as an International Standard Randomised Controlled Trial, number ISRCTN31137309. Findings From 2001 to 2003, the neonatal mortality rate was 26.2 per 1000 (76 deaths per 2899 livebirths) in intervention clusters compared with 36.9 per 1000 (119 deaths per 3226 livebirths) in controls (adjusted odds ratio 0 . 70 [95% CI 0 . 53-0.94]). Stillbirth rates were similar in both groups. The maternal mortality ratio was 69 per 100000 (two deaths per 2899 livebirths) in intervention clusters compared with 341 per 100000 (11 deaths per 3226 livebirths) in control clusters (0.22 [0.05-0.90]). Women in intervention clusters were more likely to have antenatal care, institutional delivery, trained birth attendance, and hygienic care than were controls. Interpretation Birth outcomes in a poor rural population improved greatly through a low cost, potentially sustainable and scalable, participatory intervention with women's groups.	UCL, Inst Child Hlth, Int Perinatal Care Unit, London WC1N 1EH, England; UCL, Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England; Mother & Infant Res Act, Kathmandu, Nepal; Univ Sussex, Inst Dev Studies, Brighton BN1 9RE, E Sussex, England; Nepal Adm Staff Coll, Kathmandu, Nepal	University of London; University College London; University of London; University College London; University of Sussex	Costello, AMD (corresponding author), UCL, Inst Child Hlth, Int Perinatal Care Unit, 30 Guilford St, London WC1N 1EH, England.	ipu@ich.ucl.ac.uk	Trajman, Anete/C-7679-2016	Trajman, Anete/0000-0002-4000-4984; Osrin, David/0000-0001-9691-9684; Tamang, Suresh/0000-0002-9659-1700; Morrison, Joanna/0000-0002-9241-8863; Borghi, Josephine/0000-0002-0482-5451				Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; Bhandari N, 2003, LANCET, V361, P1418, DOI 10.1016/S0140-6736(03)13134-0; Bolam A, 1998, BRIT MED J, V316, P805, DOI 10.1136/bmj.316.7134.805; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; CARLOUGH M, 1998, J I MED KATHMANDU, V20, P20; Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786, DOI 10.1136/bmj.315.7111.786; *CENTR BUR STAT, 2001, STAT YB NEP 2001; DHUNGEL B, 1992, ANTHR NEPAL PEOPLES; Edwards SJL, 1999, BMJ-BRIT MED J, V318, P1407, DOI 10.1136/bmj.318.7195.1407; Ensor T, 2004, HEALTH POLICY PLANN, V19, P69, DOI 10.1093/heapol/czh009; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; HOBLEY M, 1990, PROJECTS PEOPLE PRAC; Hobley M., 1996, PARTICIPATORY FOREST; HOWARDGRABMAN L, 1993, 16B J SNOW INT MOTHE; HOWARDGRABMAN L, 2002, MOTHERCARE SAVE CHIL; HOWARDGRABMAN L, 1993, 16A J SNOW INT MOTHE; JUSTICE J, 1999, ANTHR PUBLIC HLTH BR; Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0; KUTZIN J, 1993, 13 HRO WORLD BANK; MANANDHAR M, 1996, EXPLORATORY STUDY LO; Mesko Natasha, 2003, BMC Int Health Hum Rights, V3, P3, DOI 10.1186/1472-698X-3-3; *MIN FIN, 2002, EC SURV FISC YEAR 20; *MIN FIN, 2002, NEP DEM HLTH SURV 20; Morgan LM, 2001, HEALTH POLICY PLANN, V16, P221, DOI 10.1093/heapol/16.3.221; Morrow AL, 1999, LANCET, V353, P1226, DOI 10.1016/S0140-6736(98)08037-4; Osrin D, 2002, BMJ-BRIT MED J, V325, P1063, DOI 10.1136/bmj.325.7372.1063; Osrin D, 2003, J NEPAL MED ASSOC, V41, P411; PAUL VK, 1999, SEMIN NEONATOL, V4, P141; Pradhan A., 1997, NEPAL FAMILY HLTH SU; Pradhan Elizabeth Kimbrough, 1994, Controlled Clinical Trials, V15, P220; Rifkin S. B., 1986, Health Policy and Planning, V1, P240, DOI 10.1093/heapol/1.3.240; RIFKIN SB, 1988, SOC SCI MED, V26, P931, DOI 10.1016/0277-9536(88)90413-3; Rifkin SB, 1990, COMMUNITY PARTICIPAT; *SAV CHILDR, 2001, SAV NEWB LIV STAT WO; Sepehri A, 1996, HEALTH POLICY PLANN, V11, P93, DOI 10.1093/heapol/11.1.93; SHARMA H, 2002, DISTRICT DEMOGRAPHIC; STONE L, 1986, SOC SCI MED, V22, P293, DOI 10.1016/0277-9536(86)90125-5; Tamang S, 2001, CONTRIBUTIONS NEPALE, V28, P10; Tipping G, 1995, HLTH CARE SEEKING BE; UN, MILL DEV GOALS; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7; *WHO, 2004, COMM PART ADV ACT; *WORLD BANK, 1993, WORLD DEV REP; World Health Organization, 1996, ESS NEWB CAR REP TEC	44	577	582	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	2004	364	9438					970	979		10.1016/S0140-6736(04)17021-9	http://dx.doi.org/10.1016/S0140-6736(04)17021-9			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853MF	15364188				2022-12-28	WOS:000223831000027
J	Watanabe, KN; Taeb, M; Okusu, H				Watanabe, KN; Taeb, M; Okusu, H			Japanese controversies over transgenic crop regulation	SCIENCE			English	Editorial Material									Univ Tsukuba, Ctr Gene Res, Tsukuba 3058572, Japan; Int Plant Genet Resources Inst, Rome, Italy; United Nations Univ, Inst Adv Studies, Yokohama, Kanagawa 2200012, Japan	University of Tsukuba; Alliance; Bioversity International; United Nations University	Watanabe, KN (corresponding author), Univ Tsukuba, Ctr Gene Res, Tsukuba 3058572, Japan.	nabechan@gene.tsukuba.ac.jp		WATANABE, KAZUO/0000-0003-1499-9989				Barru N., 2003, GLOBAL STATUS COMMER; *DEP ENV FOOD RUR, GEN MOD; *JAP BIOIND ASS, BIOT Q A; Kapuscinski AR, 2003, NAT BIOTECHNOL, V21, P599, DOI 10.1038/nbt0603-599; MENON P, 2002, FRONTLINE, V19; Watanabe K.N., 2004, INTELLECTUAL PROPERT, P187; Watanabe KN, 2004, NAT BIOTECHNOL, V22, P943, DOI 10.1038/nbt0804-943a; Watanabe KN, 2003, NATURE, V421, P689, DOI 10.1038/421689a; 2004, KYOTO SHIMBUN N 0611; 2004, GUIDELINE PLANTING G	10	11	11	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2004	305	5690					1572	1572		10.1126/science.1100734	http://dx.doi.org/10.1126/science.1100734			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361611				2022-12-28	WOS:000223891200027
J	Bai, YF; Han, XG; Wu, JG; Chen, ZZ; Li, LH				Bai, YF; Han, XG; Wu, JG; Chen, ZZ; Li, LH			Ecosystem stability and compensatory effects in the Inner Mongolia grassland	NATURE			English	Article							BIODIVERSITY; DIVERSITY; DYNAMICS; ECOLOGY	Numerous studies have suggested that biodiversity reduces variability in ecosystem productivity through compensatory effects(1-6); that is, a species increases in its abundance in response to the reduction of another in a fluctuating environment(1,7). But this view has been challenged on several grounds(8-10). Because most studies have been based on artificially constructed grasslands with short duration, long-term studies of natural ecosystems are needed. On the basis of a 24-year study of the Inner Mongolia grassland, here we present three key findings. First, that January-July precipitation is the primary climatic factor causing fluctuations in community biomass production; second, that ecosystem stability (conversely related to variability in community biomass production) increases progressively along the hierarchy of organizational levels (that is, from species to functional group to whole community); and finally, that the community-level stability seems to arise from compensatory interactions among major components at both species and functional group levels. From a hierarchical perspective, our results corroborate some previous findings of compensatory effects(1,4,7,11). Undisturbed mature steppe ecosystems seem to culminate with high biodiversity, productivity and ecosystem stability concurrently. Because these relationships are correlational, further studies are necessary to verify the causation among these factors. Our study provides new insights for better management and restoration of the rapidly degrading Inner Mongolia grassland.	Chinese Acad Sci, Inst Bot, Lab Quantitat Vegetat Ecol, Beijing 100093, Peoples R China; Arizona State Univ, Sch Life Sci, Fac Ecol Evolut & Environm Sci, Tempe, AZ 85287 USA	Chinese Academy of Sciences; Institute of Botany, CAS; Arizona State University; Arizona State University-Tempe	Wu, JG (corresponding author), Chinese Acad Sci, Inst Bot, Lab Quantitat Vegetat Ecol, Beijing 100093, Peoples R China.	Jingle.Wu@asu.edu	Han, Xingguo/B-3980-2012; Han, Xingguo/K-7552-2016; Wu, Jianguo/G-6267-2010	Han, Xingguo/0000-0002-1836-975X; Wu, Jianguo/0000-0002-1182-3024				Bai Y.F., 1999, ACTA PHYTOECOL SIN, V23, P155; Brown JH, 2001, SCIENCE, V293, P643, DOI 10.1126/science.293.5530.643; Chen S.H., 2001, ROOT SYSTEMS GRASSLA; Chen Z., 2000, TYPICAL STEPPE ECOSY; CHEN ZZ, 1985, RES GRASSLAND ECOSYS, V1, P112; GIVNISH TJ, 1994, NATURE, V371, P113, DOI 10.1038/371113b0; Hooper DU, 1997, SCIENCE, V277, P1302, DOI 10.1126/science.277.5330.1302; Huston M A, 2000, Science, V289, P1255; Huston MA, 1997, OECOLOGIA, V110, P449, DOI 10.1007/s004420050180; JIANG S, 1985, RES GRASSLAND ECOSYS, V1; Knapp AK, 2001, SCIENCE, V291, P481, DOI 10.1126/science.291.5503.481; Knapp AK, 2002, SCIENCE, V298, P2202, DOI 10.1126/science.1076347; LI B, 1988, RES GRASSLAND ECOSYS, V3, P84; Loreau M, 2000, OIKOS, V91, P3, DOI 10.1034/j.1600-0706.2000.910101.x; Loreau M, 1998, P NATL ACAD SCI USA, V95, P5632, DOI 10.1073/pnas.95.10.5632; McCann KS, 2000, NATURE, V405, P228, DOI 10.1038/35012234; MCNAUGHTON SJ, 1985, ECOL MONOGR, V55, P259, DOI 10.2307/1942578; MCNAUGHTON SJ, 1977, AM NAT, V111, P515, DOI 10.1086/283181; Naeem S, 1997, NATURE, V390, P507, DOI 10.1038/37348; O'Connor TG, 2001, J ECOL, V89, P850, DOI 10.1046/j.0022-0477.2001.00605.x; Pfisterer AB, 2002, NATURE, V416, P84, DOI 10.1038/416084a; Tilman D, 1997, SCIENCE, V277, P1300, DOI 10.1126/science.277.5330.1300; Tilman D, 1999, ECOLOGY, V80, P1455, DOI 10.1890/0012-9658(1999)080[1455:TECOCI]2.0.CO;2; TILMAN D, 1994, NATURE, V367, P363, DOI 10.1038/367363a0; Tong C, 2004, J ARID ENVIRON, V59, P133, DOI 10.1016/j.jaridenv.2004.01.004; Wardle DA, 2000, OIKOS, V89, P11, DOI 10.1034/j.1600-0706.2000.890102.x; WU JG, 1994, ECOL MONOGR, V64, P447, DOI 10.2307/2937145; Wu JG, 1995, Q REV BIOL, V70, P439, DOI 10.1086/419172; Wu Jianguo, 1992, P67; Yachi S, 1999, P NATL ACAD SCI USA, V96, P1463, DOI 10.1073/pnas.96.4.1463	30	835	1122	77	972	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2004	431	7005					181	184		10.1038/nature02850	http://dx.doi.org/10.1038/nature02850			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356630				2022-12-28	WOS:000223746000043
J	Goldenberg, NA; Knapp-Clevenger, R; Manco-Johnson, MJ				Goldenberg, NA; Knapp-Clevenger, R; Manco-Johnson, MJ		Mt States Regional Thrombophilia G	Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	45th Annual Meeting and Exhibition of the American-Society-of-Hematology	DEC 06-09, 2003	San Diego, CA	Amer Soc Hematol			RECURRENT VENOUS THROMBOEMBOLISM; DEEP-VEIN THROMBOSIS; POSTTHROMBOTIC SYNDROME; RISK-FACTORS; THROMBOPHILIA; ANTICOAGULATION; CHILDHOOD; REGISTRY; THERAPY; DISEASE	Background: Elevated levels of plasma factor VIII and D-dimer predict recurrent venous thromboembolism in adults. We sought to determine whether an elevation of factor VIII, D-dimer, or both at diagnosis and persistence of the laboratory abnormality after three to six months of anticoagulant therapy correlate with poor outcomes of thrombosis in children. Methods: We evaluated levels of factor VIII and D-dimer and additional components of an extensive laboratory thrombophilia (i.e., hypercoagulability) panel at the time of diagnosis in 144 children with a radiologically confirmed acute thrombotic event. All patients were treated initially with heparin and then with either warfarin or low-molecular-weight heparin for at least three to six months, according to the current standard of care. Patients were examined at follow-up visits 3, 6, and 12 months after diagnosis and then annually, at which times testing was repeated in children with previously abnormal factor VIII and D-dimer test results and a uniform evaluation for the post-thrombotic syndrome was performed. Results: Among 82 children for whom complete data were available regarding laboratory test results at diagnosis and thrombotic outcomes during follow-up, 67 percent had factor VIII levels above the cutoff value of 150 IU per deciliter, D-dimer levels above 500 ng per milliliter, or both at diagnosis, and at least one of the two laboratory values was persistently elevated in 43 percent of the 75 patients in whom testing was performed after three to six months of anticoagulant therapy. Fifty-one percent of the 82 patients had a poor outcome (i.e., a lack of thrombus resolution, recurrent thrombosis, or the post-thrombotic syndrome) during a median follow-up of 12 months (range, 3 months to 5 years). Elevated levels of factor VIII, D-dimer, or both at diagnosis were highly predictive of a poor outcome (odds ratio, 6.1; P=0.008), as was the persistence of at least one laboratory abnormality at three to six months (odds ratio, 4.7; P=0.002). The combination of a factor VIII level above 150 IU per deciliter and a D-dimer level above 500 ng per milliliter at diagnosis was 91 percent specific for a poor outcome, and after three to six months of standard anticoagulation, the combination was 88 percent specific. Conclusions: Elevated levels of plasma factor VIII, D-dimer, or both at diagnosis and a persistent elevation of at least one of these factors after standard-duration anticoagulant therapy predict a poor outcome in children with thrombosis.	Univ Colorado, Hlth Sci Ctr, Dept Pediat, Sect Hematol Oncol & Bone Marrow Transplantat, Denver, CO 80218 USA; Childrens Hosp, Denver, CO 80218 USA; Mt States Reg Hemophilia & Thrombosis Ctr, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado	Goldenberg, NA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pediat, Sect Hematol Oncol & Bone Marrow Transplantat, 1056 E 19th Ave,B-115, Denver, CO 80218 USA.	neil.goldenberg@uchsc.edu			PHS HHS [M01-R00069] Funding Source: Medline; ODCDC CDC HHS [UR6/CCU820552-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); ODCDC CDC HHS		Bick RL, 2003, HEMATOL ONCOL CLIN N, V17, P9, DOI 10.1016/S0889-8588(02)00101-6; Eichinger S, 2003, JAMA-J AM MED ASSOC, V290, P1071, DOI 10.1001/jama.290.8.1071; Kahn SR, 2003, BLOOD, V102, p57A; KOSTER T, 1994, THROMB HAEMOSTASIS, V71, P719; Kraaijenhagen RA, 2000, THROMB HAEMOSTASIS, V83, P5; Kyrle PA, 2000, NEW ENGL J MED, V343, P457, DOI 10.1056/NEJM200008173430702; Male C, 1999, J PEDIATR-US, V134, P199, DOI 10.1016/S0022-3476(99)70416-6; Manco-Johnson MJ, 2003, BLOOD, V102, p553A; Manco-Johnson MJ, 2000, J PEDIATR-US, V136, P446, DOI 10.1016/S0022-3476(00)90006-4; Manco-Johnson MJ, 2002, THROMB HAEMOSTASIS, V88, P155; MANCOJOHNSON MJ, 1995, AM J HEMATOL, V48, P240, DOI 10.1002/ajh.2830480407; MARZINOTTO V, 2001, THROMB HAEMOST S2, V78, pOC962; Mathew P, 2003, BLOOD, V102, p548A; Meijers JCM, 2000, NEW ENGL J MED, V342, P696, DOI 10.1056/NEJM200003093421004; MEISSNER MH, 1993, J VASC SURG, V18, P596, DOI 10.1016/0741-5214(93)90069-X; Monagle P, 2000, PEDIATR RES, V47, P763, DOI 10.1203/00006450-200006000-00013; Monagle P, 2001, CHEST, V119, p344S, DOI 10.1378/chest.119.1_suppl.344S; Nowak-Gottl U, 2001, BLOOD, V97, P858, DOI 10.1182/blood.V97.4.858; Palareti G, 2002, THROMB HAEMOSTASIS, V87, P7; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; Rutherford RB, 2000, J VASC SURG, V31, P1307, DOI 10.1016/S0741-5214(00)90143-5; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; Van Ommen CH, 2003, J THROMB HAEMOST, V1, P2516, DOI 10.1046/j.1538-7836.2003.00465.x; van Ommen CH, 2001, J PEDIATR-US, V139, P676, DOI 10.1067/mpd.2001.118192; Vlieg AV, 2000, BLOOD, V95, P3678; Wong D L, 1988, Pediatr Nurs, V14, P9	26	165	169	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2004	351	11					1081	1088		10.1056/NEJMoa040161	http://dx.doi.org/10.1056/NEJMoa040161			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	852CX	15356305	Bronze			2022-12-28	WOS:000223733900007
J	Graham, JS; Rothwell, BC				Graham, JS; Rothwell, BC			Images in clinical medicine: Gallstone ileus	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Rockyview Gen Hosp, Calgary, AB T2V 1P9, Canada; Calgary Gen Hosp, Calgary, AB T1Y 6J4, Canada	University of Calgary	Graham, JS (corresponding author), Rockyview Gen Hosp, Calgary, AB T2V 1P9, Canada.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2004	351	11					1119	1119		10.1056/NEJMicm980833	http://dx.doi.org/10.1056/NEJMicm980833			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CX	15356309				2022-12-28	WOS:000223733900011
J	Hynek, BM				Hynek, BM			Implications for hydrologic processes on Mars from extensive bedrock outcrops throughout Terra Meridiani	NATURE			English	Article								Grey haematite was recently detected in the Terra Meridiani region of Mars(1,2) by the Thermal Emission Spectrometer onboard the Mars Global Surveyor spacecraft. The formation of haematite on Earth often requires liquid water to be present for long periods of time, making this an important target for deciphering the history of water on Mars. The Mars Exploration Rover Opportunity landed in Meridiani early in 2004 and has since discovered light-toned bedrock outcrops rich in chemical and textural signatures of long-term water interaction locally at the landing site(3). Here I use remote sensing data to show that the light-toned outcrops at the landing site are not a local phenomenon. Instead, they are observable throughout the haematite-bearing plains in both visible and thermal infrared remote sensing data. Moreover, the light-toned material outcrops around much of the margin and is mappable for hundreds of kilometres to the north, east and west of the plains. I infer that 3 x 10(5) km(2) of this material is exposed over 20degrees of longitude, indicating the extended presence of surface or near-surface water over a large region of Mars.	Univ Colorado, Atmospher & Space Phys Lab, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Hynek, BM (corresponding author), Univ Colorado, Atmospher & Space Phys Lab, Campus Box 392, Boulder, CO 80309 USA.	brian.hynek@lasp.colorado.edu						Arvidson RE, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE001982; Christensen PR, 2001, J GEOPHYS RES-PLANET, V106, P23873, DOI 10.1029/2000JE001415; Christensen PR, 2000, J GEOPHYS RES-PLANET, V105, P9623, DOI 10.1029/1999JE001093; CHRISTENSEN PR, 2004, LUNAR PLANET SCI C, V35, P2186; Edgett KS, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL016515; Hynek BM, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002062; Hynek BM, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2002JE001891; HYNEK BM, 2004, LUNAR PLANET SCI C, V35, P1899; JAKOSKY BM, 2004, UNPUB J GEOPHYS RES; Lane MD, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017183; Malin MC, 2000, SCIENCE, V290, P1927, DOI 10.1126/science.290.5498.1927; Malin MC, 2001, J GEOPHYS RES-PLANET, V106, P23429, DOI 10.1029/2000JE001455; Mellon MT, 2000, ICARUS, V148, P437, DOI 10.1006/icar.2000.6503; PALLUCONI FD, 1981, ICARUS, V45, P415, DOI 10.1016/0019-1035(81)90044-0; PUTZIG NE, 2004, LUN PLAN SCI C, V35, P1863; Squyres S. W., 2004, LUNAR PLANET SCI C, VXXXV, P2187; Tanaka KL, 2000, ICARUS, V144, P254, DOI 10.1006/icar.1999.6297	17	72	73	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2004	431	7005					156	159		10.1038/nature02902	http://dx.doi.org/10.1038/nature02902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356623				2022-12-28	WOS:000223746000036
J	Nichol, G; Kaul, P; Huszti, E; Bridges, JFP				Nichol, G; Kaul, P; Huszti, E; Bridges, JFP			Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure	ANNALS OF INTERNAL MEDICINE			English	Article							IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; CONVENIENT APPROXIMATION; SECONDARY PREVENTION; LIFE EXPECTANCY; CLINICAL-TRIALS; CONDUCTION; UNCERTAINTY; MORBIDITY; DEALE	Background: Heart failure is a common, costly, and debilitating illness. Resynchronization of ventricular contraction in patients with heart failure improves ejection fraction. The long-term morbidity and costs associated with such cardiac resynchronization therapy remain unclear. Objective: To assess the incremental cost-effectiveness of cardiac resynchronization therapy. Design: Markov model with Monte Carlo simulation. Future costs and effects were discounted at 3%. Data Sources: Effects data were obtained from a concurrent systematic review. Health-related quality-of-life and cost data were obtained from publicly available data or from surveys. Target Population: Patients with reduced ventricular function and prolonged QRS. Time Horizon: Lifetime. Perspective: U.S. health care system. Interventions: Cardiac resynchronization therapy versus medical therapy. Outcome Measures: Quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness. Results of Base-Case Analysis: Medical therapy yielded a median of 2.64 (interquartile range, 2.47 to 2.82) discounted QALYs and a median discounted lifetime cost of $34400 (interquartile range, $31100 to $37700). Cardiac resynchronization therapy was associated with a median incremental cost of $107800 (interquartile range, $79800 to $156500) per additional QALY. Results of Sensitivity Analysis: Results were sensitive to changes in several variables, including the relative risk for death or hospitalization. Limitations: These results apply to patients who meet the inclusion criteria of the currently completed trials. Conclusions: The incremental cost per QALY for cardiac resynchronization is similar to that of other commonly used interventions but is sensitive to changes in several key variables. Resynchronization therapy should not be considered in patients with comorbid illness that shortens life expectancy.	Univ Washington, Harborview Prehosp Emergency Care Res & Training, Harborview Med Ctr, Seattle, WA 98104 USA; Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON, Canada; Univ Alberta, Edmonton, AB, Canada; Case Western Reserve Univ, Cleveland, OH 44106 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Ottawa; Ottawa Hospital Research Institute; University of Alberta; Case Western Reserve University	Nichol, G (corresponding author), Univ Washington, Harborview Prehosp Emergency Care Res & Training, Harborview Med Ctr, 325 9th Ave,Box 359747, Seattle, WA 98104 USA.	nichol@u.washington.edu	Nichol, Graham/Z-4996-2019	Kaul, Padma/0000-0003-2239-3944				Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Abraham WT, 2000, J CARD FAIL, V6, P369, DOI 10.1054/jcaf.2000.20841; Abrams KR, 2000, METHODS METAANALYSIS; *ALB EV BAS PRACT, 2003, SYST REV BIV PAC HEA; Auricchio A, 2002, J AM COLL CARDIOL, V39, P2026, DOI 10.1016/S0735-1097(02)01895-8; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; Bigger JT, 1997, NEW ENGL J MED, V337, P1569, DOI 10.1056/NEJM199711273372201; Bridges John F P, 2003, Appl Health Econ Health Policy, V2, P213; Briggs A, 1998, HEALTH ECON, V7, P723, DOI 10.1002/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.3.CO;2-F; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHRISTENSEN R, 1989, DATA DISTRIBUTIONS S; Connolly SJ, 2000, EUR HEART J, V21, P2071, DOI 10.1053/euhj.2000.2476; CRITCHFIELD GC, 1986, MED DECIS MAKING, V6, P85, DOI 10.1177/0272989X8600600205; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Eichhorn E, 2001, NEW ENGL J MED, V344, P1659; Ezekowitz JA, 2003, ANN INTERN MED, V138, P445, DOI 10.7326/0003-4819-138-6-200303180-00007; *FDA, 2002, P010012 FDA; FEENY D, 1995, PHARMACOECONOMICS, V7, P490, DOI 10.2165/00019053-199507060-00004; FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P585, DOI 10.1016/0895-4356(89)90155-8; Furlong W, 1990, WORKING PAPER SERIES, V90-9; Garrigue S, 2002, HEART, V87, P529, DOI 10.1136/heart.87.6.529; Gold MR, 1996, COST EFFECTIVENESS H; Gold MR, 1996, COST EFFECTIVENESS H, P425; Hirth RA, 2000, MED DECIS MAKING, V20, P332, DOI 10.1177/0272989X0002000310; Kaul P, 2003, J AM COLL CARDIOL, V41, p535A; Leclercq C, 2002, EUR HEART J, V23, P1780, DOI 10.1053/euhj.2002.3232; Llewellyn-Thomas H. A., 2000, ADAPTATION CHANGING, P109; LlewellynThomas HA, 1996, MED CARE, V34, pDS109; Lloyd-Williams F, 2003, J CLIN EPIDEMIOL, V56, P1157, DOI 10.1016/S0895-4356(03)00205-1; Lothgren M, 2000, HEALTH ECON, V9, P623, DOI 10.1002/1099-1050(200010)9:7<623::AID-HEC539>3.0.CO;2-V; MASON J, 1993, BRIT MED J, V306, P570, DOI 10.1136/bmj.306.6877.570; Masoudi FA, 2003, AM HEART J, V146, P250, DOI 10.1016/S0002-8703(03)00189-3; Massie BM, 1998, LANCET, V352, P29; McAlister FA, 2004, ANN INTERN MED, V141, P381, DOI 10.7326/0003-4819-141-5-200409070-00101; *N AM SOC PAC EL, CPT COD GUID; *NAT HEART LUNG BL, 2002, NHLBI FACT BOOK; Nichol G, 2003, CIRCULATION, V108, P697, DOI 10.1161/01.CIR.0000084545.65645.28; Owens DK, 1997, ANN INTERN MED, V126, P1, DOI 10.7326/0003-4819-126-1-199701010-00001; Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; PORTER M, 1984, SOC SCI MED, V19, P1197, DOI 10.1016/0277-9536(84)90370-8; Rose EA, 2001, NEW ENGL J MED, V345, P1435, DOI 10.1056/NEJMoa012175; Shamim W, 1999, INT J CARDIOL, V70, P171, DOI 10.1016/S0167-5273(99)00077-7; Sox HC, 1988, MED DECISION MAKING; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; TORRANCE GW, 1995, PHARMACOECONOMICS, V7, P503, DOI 10.2165/00019053-199507060-00005; Uretsky BF, 2000, CIRCULATION, V102, P611, DOI 10.1161/01.CIR.102.6.611; *US DEP HHS, 2001, US DEC LIF TABL 1998; US Department of Labor. Bureau of Labor Statistics, CONS PRIC IND; VANHOUT BA, 1994, HEALTH ECON, V3, P309, DOI 10.1002/hec.4730030505; VANNEUMANN J, 1994, THEORY GAMES EC BEHA; Wilkoff BL, 2002, JAMA-J AM MED ASSOC, V288, P3115; WINER BJ, 1971, LATIN SQUARES RELATE, P685; Xiao HB, 1996, INT J CARDIOL, V53, P163, DOI 10.1016/0167-5273(95)02502-2; Young JB, 2003, JAMA-J AM MED ASSOC, V289, P2685, DOI 10.1001/jama.289.20.2685	59	83	83	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	2004	141	5					343	351		10.7326/0003-4819-141-5-200409070-00102	http://dx.doi.org/10.7326/0003-4819-141-5-200409070-00102			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CW	15353425				2022-12-28	WOS:000223733800002
J	Warburton, MS; Jackson, MA; Norton, R; Bhabra, M				Warburton, MS; Jackson, MA; Norton, R; Bhabra, M			Lesson of the week - Rare causes of haemoptysis in suspected pulmonary embolism	BMJ-BRITISH MEDICAL JOURNAL			English	Review									New Cross Hosp, Dept Gen Med, Wolverhampton WV6 7OQ, England; Walsgrave Gen Hosp, Coventry, W Midlands, England	New Cross Hospital	Warburton, MS (corresponding author), New Cross Hosp, Dept Gen Med, Wolverhampton WV6 7OQ, England.	matthew_karen@sayang.freeserve.co.uk						BICKERSTAFF LK, 1982, SURGERY, V92, P1103; Campbell IA, 2003, THORAX, V58, P470	2	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 4	2004	329	7465					557	558		10.1136/bmj.329.7465.557	http://dx.doi.org/10.1136/bmj.329.7465.557			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853DE	15345631	Green Published			2022-12-28	WOS:000223805800026
J	Acton, A				Acton, A			ABC of burns - When we leave hospital: a patient's perspective of burn injury	BRITISH MEDICAL JOURNAL			English	Review									Phoenix Soc Burn Survivors, E Grand Rapids, MI 49506 USA		Acton, A (corresponding author), Phoenix Soc Burn Survivors, E Grand Rapids, MI 49506 USA.							Cash T. F., 1997, BODY IMAGE WORKBOOK; QUAYLE BK, 2001, BURN SUPPORT NEW SUM, P2	2	3	3	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 28	2004	329	7464					504	506		10.1136/bmj.329.7464.504	http://dx.doi.org/10.1136/bmj.329.7464.504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KS	15331482	Green Published			2022-12-28	WOS:000223684600027
J	Morris, CG; McCoy, W; Lavery, GG				Morris, CG; McCoy, W; Lavery, GG			Spinal immobilisation for unconscious patients with multiple injuries	BRITISH MEDICAL JOURNAL			English	Review							INTENSIVE-CARE UNITS; CERVICAL-SPINE; TRAUMA PATIENTS; PRESSURE SORES; RISK-FACTORS; CORD-INJURY; EMERGENCY-DEPARTMENT; DYNAMIC FLUOROSCOPY; HEAD-INJURY; POLYTRAUMA		Royal Victoria Hosp, Reg Intens Care Unit, Belfast BT12 6BA, Antrim, North Ireland		Morris, CG (corresponding author), Royal Victoria Hosp, Reg Intens Care Unit, Belfast BT12 6BA, Antrim, North Ireland.	cmorris@doctors.org.uk						Ajani AE, 1998, ANAESTH INTENS CARE, V26, P487, DOI 10.1177/0310057X9802600502; American College of Surgeons Committee on Trauma, 1997, ADV TRAUM LIF SUPP D; BACHULIS BL, 1987, AM J SURG, V153, P473, DOI 10.1016/0002-9610(87)90796-3; BAUER TM, 1990, J HOSP INFECT, V15, P301, DOI 10.1016/0195-6701(90)90087-5; BEIRNE JC, 1995, INT J ORAL MAX SURG, V24, P26, DOI 10.1016/S0901-5027(05)80852-5; Berne JD, 1999, J TRAUMA, V47, P896, DOI 10.1097/00005373-199911000-00014; Blackmore CC, 1999, RADIOLOGY, V211, P759, DOI 10.1148/radiology.211.3.r99jn22759; BLAHD WH, 1984, J EMERGENCY MED, V2, P243; Bolinger B, 2004, J TRAUMA, V56, P132, DOI 10.1097/01.TA.0000044629.69247.0A; Brohi K, 2000, J TRAUMA, V49, P76, DOI 10.1097/00005373-200007000-00011; Brooks RA, 2001, J TRAUMA, V50, P862; Chendrasekhar A, 1998, AM SURGEON, V64, P604; Chiu WC, 2001, J TRAUMA, V50, P457, DOI 10.1097/00005373-200103000-00009; Cooke MW, 1998, J ACCID EMERG MED, V15, P108; Cox M W., 2001, Curr Surg, V58, P96, DOI 10.1016/S0149-7944(00)00441-4; Curry K, 1992, J Neurosci Nurs, V24, P185; DAVIS JW, 1995, J TRAUMA, V39, P435; Davis JW, 2001, J TRAUMA, V50, P1044, DOI 10.1097/00005373-200106000-00011; Demetriades D, 2000, J TRAUMA, V48, P724, DOI 10.1097/00005373-200004000-00022; Eastern Association for the Surgery of Trauma, 2000, DET CERV SPIN STAB T; Ersoy G, 1995, Eur J Emerg Med, V2, P191, DOI 10.1097/00063110-199512000-00004; Farling PA, 2002, ANAESTHESIA, V57, P421; Grossman MD, 1999, J TRAUMA, V47, P684, DOI 10.1097/00005373-199910000-00012; Gupta KJ, 1997, BRIT MED J, V314, P1652, DOI 10.1136/bmj.314.7095.1652; Harris MB, 2000, SPINE, V25, P2884, DOI 10.1097/00007632-200011150-00008; Hauswald M, 2000, Air Med J, V19, P126, DOI 10.1016/S1067-991X(00)90001-4; Holly LT, 2002, J NEUROSURG, V96, P285, DOI 10.3171/spi.2002.96.3.0285; HUEBNER J, 1989, INTENS CARE MED, V15, P179, DOI 10.1007/BF01058570; Iida H, 1999, J TRAUMA, V46, P450, DOI 10.1097/00005373-199903000-00018; Kato H, 1998, ANN PLAS SURG, V40, P39, DOI 10.1097/00000637-199801000-00008; LIEBERMAN IH, 1994, J BONE JOINT SURG BR, V76B, P877, DOI 10.1302/0301-620X.76B6.7983110; LINARES HA, 1987, ORTHOPEDICS, V10, P571; MACDONALD RL, 1990, J TRAUMA, V30, P392, DOI 10.1097/00005373-199030040-00004; MARCIANO FF, 1997, NEUROSURGERY, V41, P740; MAWSON AR, 1993, ARCH PHYS MED REHAB, V74, P745, DOI 10.1016/0003-9993(93)90037-B; MAWSON AR, 1988, AM J PHYS MED REHAB, V67, P123, DOI 10.1097/00002060-198806000-00007; McKinley WO, 1999, ARCH PHYS MED REHAB, V80, P1402, DOI 10.1016/S0003-9993(99)90251-4; Mirvis S E, 1995, J Intensive Care Med, V10, P15; Mirvis SE, 2001, EMERG RADIOL, V8, P3, DOI 10.1007/PL00011865; Morris CG, 2004, ANAESTHESIA, V59, P755, DOI 10.1111/j.1365-2044.2004.03743.x; Morris CG, 2004, BRIT J RADIOL, V77, P216, DOI 10.1259/bjr/50404042; Morris CGT, 2004, ANAESTHESIA, V59, P464, DOI 10.1111/j.1365-2044.2004.03666.x; Morris CGT, 2003, ANAESTHESIA, V58, P1051, DOI 10.1046/j.1365-2044.2003.03519.x; NAWOCZENSKI DA, 1987, SPINAL CORD INJURY C, P99; *NIH, 1998, REH PERS TRAUM BRAIN, V16, P1; Nunez DB, 1996, RADIOGRAPHICS, V16, P1307, DOI 10.1148/radiographics.16.6.8946537; OSullivan KL, 1997, J TRAUMA, V42, P276, DOI 10.1097/00005373-199702000-00016; Porter KM, 2003, RESUSCITATION, V58, P117, DOI 10.1016/S0300-9572(03)00078-9; REID DC, 1987, J TRAUMA, V27, P980, DOI 10.1097/00005373-198709000-00005; Robert KQ, 2000, SOUTHERN MED J, V93, P974; Sees DW, 1998, J TRAUMA, V45, P768, DOI 10.1097/00005373-199810000-00026; Velmahos GC, 1996, J TRAUMA, V40, P768, DOI 10.1097/00005373-199605000-00015	52	42	42	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 28	2004	329	7464					495	499		10.1136/bmj.329.7464.495	http://dx.doi.org/10.1136/bmj.329.7464.495			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KS	15331475	Green Published, Green Submitted			2022-12-28	WOS:000223684600017
J	Colhoun, HM; Betteridge, DJ; Durrington, PN; Hitman, GA; Neil, HAW; Livingstone, SJ; Thomason, MJ; Mackness, MI; Charlton-Menys, V; Fuller, JH				Colhoun, HM; Betteridge, DJ; Durrington, PN; Hitman, GA; Neil, HAW; Livingstone, SJ; Thomason, MJ; Mackness, MI; Charlton-Menys, V; Fuller, JH		CARDS Investigators	Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial	LANCET			English	Article							CORONARY-HEART-DISEASE; RISK-FACTORS; MYOCARDIAL-INFARCTION; STROKE; CHOLESTEROL; MORTALITY; SURVIVAL; MELLITUS; AVERAGE; EVENTS	Background Type 2 diabetes is associated with a substantially increased risk of cardiovascular disease, but the role of lipid-lowering therapy with statins for the primary prevention of cardiovascular disease in diabetes is inadequately defined. We aimed to assess the effectiveness of atorvastatin 10 mg daily for primary prevention of major cardiovascular events in patients with type 2 diabetes without high concentrations of LDL-cholesterol. Methods 2838 patients aged 40-75 years in 132 centres in the UK and Ireland were randomised to placebo (n=1410) or atorvastatin 10 mg daily (n=1428). Study entrants had no documented previous history of cardiovascular disease, an LDL-cholesterol concentration of 4.14 mmol/L or lower, a fasting triglyceride amount of 6.78 mmol/L or less, and at least one of the following: retinopathy, albuminuria, current smoking, or hypertension. The primary endpoint was time to first occurrence of the following: acute coronary heart disease events, coronary revascularisation, or stroke. Analysis was by intention to treat. Findings The trial was terminated 2 years earlier than expected because the prespecified early stopping rule for efficacy had been met. Median duration of follow-up was 3.9 years (IQR 3.0-4.7). 127 patients allocated placebo (2.46 per 100 person-years at risk) and 83 allocated atorvastatin (1.54 per 100 person-years at risk) had at least one major cardiovascular event (rate reduction 37% [95% CI-52 to-17], p=0.001). Treatment would be expected to prevent at least 37 major vascular events per 1000 such people treated for 4 years. Assessed separately, acute coronary heart disease events were reduced by 36% (-55 to -9), coronary revascularisations by 31% (-59 to 16), and rate of stroke by 48% (-69 to -11). Atorvastatin reduced the death rate by 27% (-48 to 1, p=0.059). No excess of adverse events was noted in the atorvastatin group. Interpretation Atorvastatin 10 mg daily is safe and efficacious in reducing the risk of first cardiovascular disease events, including stroke, in patients with type 2 diabetes without high LDL-cholesterol. No justification is available for having a particular threshold level of LDL-cholesterol as the sole arbiter of which patients with type 2 diabetes should receive statins. The debate about whether all people with this disorder warrant statin treatment should now focus on whether any patients are at sufficiently low risk for this treatment to be withheld.	Royal Free & Univ Coll, EURODIAB, Dept Epidemiol & Publ Hlth, Sch Med, London, England; UCL, Middlesex Hosp, London, England; Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England; Barts & London Queen Marys Sch Med & Dent, Ctr Diabet & Metab Med, London, England; Univ Oxford, Ctr Diabet Endocrinol & Metab, Oxford, England	University of London; University College London; UCL Medical School; University of London; University College London; University of Manchester; University of London; Queen Mary University London; University of Oxford	Colhoun, HM (corresponding author), Univ Coll Dublin, Conway Inst, Dublin 4, Ireland.	helen.colhoun@ucd.ie	Adiels, Martin/C-9278-2011; Syed, Akheel A/G-3138-2011	Syed, Akheel A/0000-0001-8696-7121; Thomason, Margaret/0000-0003-3590-0140; Colhoun, Helen/0000-0002-8345-3288				[Anonymous], 1995, Am J Cardiol, V75, P1130; Chun BY, 1997, DIABETES CARE, V20, P704, DOI 10.2337/diacare.20.5.704; Colhoun HM, 2002, DIABETIC MED, V19, P201, DOI 10.1046/j.1464-5491.2002.00643.x; Collins R, 2004, LANCET, V363, P757; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins R, 2003, LANCET, V361, P2005; De Backer G, 2003, EUR J CARDIOV PREV R, V10, pS1, DOI 10.1097/01.hjr.0000087913.96265.e2; de Jong G, 2003, J CLIN EPIDEMIOL, V56, P262, DOI 10.1016/S0895-4356(02)00572-3; Evans JMM, 2002, BRIT MED J, V324, P939, DOI 10.1136/bmj.324.7343.939; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Goldberg RB, 1998, CIRCULATION, V98, P2513, DOI 10.1161/01.CIR.98.23.2513; Haffner Steven M, 2004, Diabetes Care, V27 Suppl 1, pS68; Ho JE, 2003, STROKE, V34, P2812, DOI 10.1161/01.STR.0000102901.41780.5C; Kothari V, 2002, STROKE, V33, P1776, DOI 10.1161/01.STR.0000020091.07144.C7; Leiter LA, 2004, DIABETES, V53, pA285; MACKNESS MI, 1992, LIPOPROTEIN ANAL PRA; McCarron P, 2001, PUBLIC HEALTH, V115, P12, DOI 10.1038/sj.ph.1900724; NAUCK M, 2000, HDB LIPOPROTEIN TEST, P221; OBORNE CA, 2003, INT J PHARM PRACTICE, V11, pR73; PETO R, 1978, BIOMEDICINE, V28, P24; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Rodgers A, 1998, LANCET, V352, P1801; Saydah SH, 2004, JAMA-J AM MED ASSOC, V291, P335, DOI 10.1001/jama.291.3.335; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Smith SC, 2004, CIRCULATION, V109, P3112, DOI 10.1161/01.CIR.0000133427.35111.67; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stevens RJ, 2001, CLIN SCI, V101, P671, DOI 10.1042/CS20000335; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Turner RC, 1998, BMJ-BRIT MED J, V316, P823, DOI 10.1136/bmj.316.7134.823; WANNAMETHEE G, 1995, BRIT HEART J, V74, P324; Zhang X, 2003, INT J EPIDEMIOL, V32, P563, DOI 10.1093/ije/dyg106	31	2664	2877	2	207	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	2004	364	9435					685	696		10.1016/S0140-6736(04)16895-5	http://dx.doi.org/10.1016/S0140-6736(04)16895-5			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847WO	15325833				2022-12-28	WOS:000223428900030
J	May, RM				May, RM			Raising Europe's game	NATURE			English	Editorial Material									Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	May, RM (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.							Blair T, 1998, SCIENCE, V281, P1141, DOI 10.1126/science.281.5380.1141; King DA, 2004, NATURE, V430, P311, DOI 10.1038/430311a; May RM, 1997, SCIENCE, V275, P793, DOI 10.1126/science.275.5301.793; May RM, 1998, SCIENCE, V281, P49, DOI 10.1126/science.281.5373.49; *OECD, 2001, OECD BAS SCI TECHN S; *ROYAL SOC, 2004, FUT FUND EUR SCI BAS; *ROYAL SOC, PLAC FUND RES EUR RE; STIGLITZ J, 1995, SUPPORTING R D PROMO	8	7	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					831	832		10.1038/430831a	http://dx.doi.org/10.1038/430831a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318194				2022-12-28	WOS:000223369800017
J	Karhadkar, SS; Bova, GS; Abdallah, N; Dhara, S; Gardner, D; Maitra, A; Isaacs, JT; Berman, DM; Beachy, PA				Karhadkar, SS; Bova, GS; Abdallah, N; Dhara, S; Gardner, D; Maitra, A; Isaacs, JT; Berman, DM; Beachy, PA			Hedgehog signalling in prostate regeneration, neoplasia and metastasis	NATURE			English	Article							INTERMEDIATE FILAMENT PROTEIN; SONIC-HEDGEHOG; STEM-CELLS; SUPPRESSOR GENE; CANCER; GROWTH; INHIBITION; RAT; DIFFERENTIATION; PROLIFERATION	Metastatic cancers adopt certain properties of normal cells in developing or regenerating organs, such as the ability to proliferate and alter tissue organization. We find here that activity of the Hedgehog (Hh) signalling pathway, which has essential roles in developmental patterning(1-6), is required for regeneration of prostate epithelium, and that continuous pathway activation transforms prostate progenitor cells and renders them tumorigenic. Elevated pathway activity furthermore distinguishes metastatic from localized prostate cancer, and pathway manipulation can modulate invasiveness and metastasis. Pathway activity is triggered in response to endogenous expression of Hh ligands, and is dependent upon the expression of Smoothened, an essential Hh response component(1,2,7) that is not expressed in benign prostate epithelial cells. Monitoring and manipulating Hh pathway activity may thus offer significant improvements in diagnosis and treatment of prostate cancers with metastatic potential.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; ARS, USDA, Poisonous Plant Res Lab, Logan, UT 84341 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; United States Department of Agriculture (USDA)	Berman, DM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.	dberman@jhmi.edu; pbeachy@jhmi.edu	Karhadkar, Sunil/Y-9235-2019; berman, david/HIR-4177-2022	Karhadkar, Sunil/0000-0001-7943-0203; Bova, George/0000-0003-1639-3104; berman, david/0000-0001-5985-3698				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; ALBINI A, 1987, CANCER RES, V47, P3239; Bandyopadhyay S, 2003, CANCER RES, V63, P1731; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Berman DM, 2004, DEV BIOL, V267, P387, DOI 10.1016/j.ydbio.2003.11.018; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Freestone SH, 2003, DEV BIOL, V264, P352, DOI 10.1016/j.ydbio.2003.08.018; Garraway LA, 2003, PROSTATE, V55, P206, DOI 10.1002/pros.10244; Guang RJ, 2000, CANCER RES, V60, P749; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; KACHINSKY AM, 1994, DEV BIOL, V165, P216, DOI 10.1006/dbio.1994.1248; Lamm MLG, 2002, DEV BIOL, V249, P349, DOI 10.1006/dbio.2002.0774; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Meeker AK, 1996, ENDOCRINOLOGY, V137, P5743, DOI 10.1210/en.137.12.5743; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Park HL, 2000, DEVELOPMENT, V127, P1593; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Zulewski H, 2001, DIABETES, V50, P521, DOI 10.2337/diabetes.50.3.521	32	853	950	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	2004	431	7009					707	712		10.1038/nature02962	http://dx.doi.org/10.1038/nature02962			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	859WS	15361885				2022-12-28	WOS:000224299300045
J	Wilkinson, P; Pattenden, S; Armstrong, B; Fletcher, A; Kovats, RS; Mangtani, P; McMichael, AJ				Wilkinson, P; Pattenden, S; Armstrong, B; Fletcher, A; Kovats, RS; Mangtani, P; McMichael, AJ			Vulnerability to winter mortality in elderly people in Britain: population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SEASONAL-VARIATION; TEMPERATURE; DEPRIVATION; ENGLAND; RISK	Objective To examine the determinants of vulnerability to winter mortality in elderly British people. Design Population based cohort study (119389 person years of follow up). Setting 106 general practices from the Medical Research Council trial of assessment and management of older people in Britain. Participants People aged greater than or equal to75 years. Main outcome measures Mortality (10123 deaths) determined by follow up through the Office for National Statistics. Results Month to month variation accounted for 17% of annual all cause mortality, but only 7.8% after adjustment for temperature. The overall winter:non-winter rate ratio was 1.31 (95% confidence interval 1.26 to 1.36). There was little evidence that this ratio varied by geographical region, age, or any of the personal, socioeconomic, or clinical factors examined, with two exceptions: after adjustment for all major covariates the winter:non-winter ratio in women compared with men was 1.11 (1.00 to 1.23), and those with a self reported history of respiratory illness had a winter:non-winter ratio of 1.20 (1.08 to 1.34) times that of people without a history of respiratory illness. There was no evidence that socioeconomic deprivation or self reported financial worries were predictive of winter death. Conclusion Except for female sex and pre-existing respiratory illness, there was little evidence for vulnerability to winter death associated with factors thought to lead to vulnerability. The lack of socioeconomic gradient suggests that policies aimed at relief of fuel poverty may need to be supplemented by additional measures to tackle the burden of excess winter deaths in elderly people.	Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Wilkinson, P (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	paul.wilkinson@lshtm.ac.uk		Mangtani, Punam/0000-0001-7074-2999; Wilkinson, Paul/0000-0001-7456-259X; Kovats, Sari/0000-0002-4823-8099; armstrong, benedict/0000-0003-4407-0409				Armstong B, 2000, EPIDEMIOLOGY, V11, pS113; Aylin P, 2001, INT J EPIDEMIOL, V30, P1100, DOI 10.1093/ije/30.5.1100; Bokenes L, 2000, Int J Circumpolar Health, V59, P216; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; Carstairs V, 1995, J EPIDEMIOL COMMUN H, V49, pS3, DOI 10.1136/jech.49.Suppl_2.S3; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; Curwen M., 1990, HLTH TRENDS, V22, P169; Fletcher AE, 2002, BMC HEALTH SERV RES, V2, DOI 10.1186/1472-6963-2-21; Goodwin J, 2000, Int J Circumpolar Health, V59, P195; Huber P. H., 1981, ROBUST STAT; Keatinge WR, 1997, LANCET, V349, P1341, DOI 10.1016/S0140-6736(96)12338-2; KEATINGE WR, 1989, INT J BIOMETEOROL, V33, P71, DOI 10.1007/BF01686280; Laake K, 1996, AGE AGEING, V25, P343, DOI 10.1093/ageing/25.5.343; Lawlor DA, 2000, J PUBLIC HEALTH MED, V22, P176, DOI 10.1093/pubmed/22.2.176; MCKEE CM, 1989, EUR J EPIDEMIOL, V5, P178, DOI 10.1007/BF00156826; NEILD PJ, 1994, CLIN SCI, V86, P43, DOI 10.1042/cs0860043; O'Neill M, 2003, EPIDEMIOLOGY, V14, pS101, DOI 10.1097/00001648-200309001-00244; Pattenden S, 2003, J EPIDEMIOL COMMUN H, V57, P628, DOI 10.1136/jech.57.8.628; Schwartz J B, 1996, PDA J Pharm Sci Technol, V50, P197; Shah S, 1999, J EPIDEMIOL COMMUN H, V53, P499, DOI 10.1136/jech.53.8.499; Sheth T, 1999, J AM COLL CARDIOL, V33, P1916, DOI 10.1016/S0735-1097(99)00137-0; Smolander J, 2002, INT J SPORTS MED, V23, P86, DOI 10.1055/s-2002-20137; Stout RW, 1996, AGE AGEING, V25, P256, DOI 10.1093/ageing/25.3.256; van Rossum CTM, 2001, INT J EPIDEMIOL, V30, P1109, DOI 10.1093/ije/30.5.1109; Wilkinson P, 2001, COLD COMFORT SOCIAL; WOODHOUSE PR, 1993, J HYPERTENS, V11, P1267	26	176	180	1	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 18	2004	329	7467					647	651		10.1136/bmj.38167.589907.55	http://dx.doi.org/10.1136/bmj.38167.589907.55			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	856JU	15315961	Bronze, Green Published, Green Submitted, Green Accepted			2022-12-28	WOS:000224042300016
J	Blight, SK; Larue, RC; Mahapatra, A; Longstaff, DG; Chang, E; Zhao, G; Kang, PT; Church-Church, KB; Chan, MK; Krzycki, JA				Blight, SK; Larue, RC; Mahapatra, A; Longstaff, DG; Chang, E; Zhao, G; Kang, PT; Church-Church, KB; Chan, MK; Krzycki, JA			Direct charging of tRNA(CUA) with pyrrolysine in vitro and in vivo	NATURE			English	Article							TRANSFER-RNA-SYNTHETASES; AMINOACYL-TRANSFER-RNAS; ESCHERICHIA-COLI; METHANOSARCINA-BARKERI; GENETIC-CODE; CORRINOID PROTEIN; METHYLTRANSFERASE; ACID; MONOMETHYLAMINE; SELENOCYSTEINE	Pyrrolysine is the 22nd amino acid(1-3). An unresolved question has been how this atypical genetically encoded residue is inserted into proteins, because all previously described naturally occurring aminoacyl-tRNA synthetases are specific for one of the 20 universally distributed amino acids. Here we establish that synthetic L-pyrrolysine is attached as a free molecule to tRNA(CUA) by PylS, an archaeal class II aminoacyl-tRNA synthetase. PylS activates pyrrolysine with ATP and ligates pyrrolysine to tRNA(CUA) in vitro in reactions specific for pyrrolysine. The addition of pyrrolysine to Escherichia coli cells expressing pylT (encoding tRNA(CUA)) and pylS results in the translation of UAG in vivo as a sense codon. This is the first example from nature of direct aminoacylation of a tRNA with a non-canonical amino acid and shows that the genetic code of E. coli can be expanded to include UAG-directed pyrrolysine incorporation into proteins.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Ohio State Univ, Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, CCIC Mass Spectrometry & Proteom Facil, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Krzycki, JA (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12th Ave, Columbus, OH 43210 USA.	krzycki.1@osu.edu	Green, Kari B/H-3541-2011	Larue, Ross/0000-0002-0170-7345				Atkins JF, 2002, SCIENCE, V296, P1409, DOI 10.1126/science.1073339; Burke SA, 1997, J BIOL CHEM, V272, P16570, DOI 10.1074/jbc.272.26.16570; Burke SA, 1998, J BACTERIOL, V180, P3432, DOI 10.1128/JB.180.13.3432-3440.1998; Chin JW, 2003, SCIENCE, V301, P964, DOI 10.1126/science.1084772; COLE FX, 1970, BIOCHEMISTRY-US, V9, P480, DOI 10.1021/bi00805a005; Commans S, 1999, FEMS MICROBIOL REV, V23, P335, DOI 10.1111/j.1574-6976.1999.tb00403.x; Doring V, 2001, SCIENCE, V292, P501, DOI 10.1126/science.1057718; Francklyn C, 2002, RNA, V8, P1363, DOI 10.1017/S1355838202021180; Hao B, 2002, SCIENCE, V296, P1462, DOI 10.1126/science.1069556; HAO B, IN PRESS CHEM BIOL; HO YS, 1987, P NATL ACAD SCI USA, V84, P2185, DOI 10.1073/pnas.84.8.2185; Ibba M, 2004, GENE DEV, V18, P731, DOI 10.1101/gad.1187404; James CM, 2001, J BIOL CHEM, V276, P34252, DOI 10.1074/jbc.M102929200; Jester BC, 2003, P NATL ACAD SCI USA, V100, P14351, DOI 10.1073/pnas.2036253100; Kiick KL, 2001, FEBS LETT, V502, P25, DOI 10.1016/S0014-5793(01)02657-6; LaRiviere FJ, 2001, SCIENCE, V294, P165, DOI 10.1126/science.1064242; Paul L, 1996, J BACTERIOL, V178, P6599, DOI 10.1128/jb.178.22.6599-6607.1996; Paul L, 2000, J BACTERIOL, V182, P2520, DOI 10.1128/JB.182.9.2520-2529.2000; Polycarpo C, 2003, MOL CELL, V12, P287, DOI 10.1016/S1097-2765(03)00280-6; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; Smith MW, 1999, MICROBIOL-SGM, V145, P2891, DOI 10.1099/00221287-145-10-2891; Sowers K. R., 1995, P459; Srinivasan G, 2002, SCIENCE, V296, P1459, DOI 10.1126/science.1069588; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0	27	181	196	2	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	2004	431	7006					333	335		10.1038/nature02895	http://dx.doi.org/10.1038/nature02895			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	853XJ	15329732				2022-12-28	WOS:000223864000047
J	Schlienger, RG; Kraenzlin, ME; Jick, SS; Meier, CR				Schlienger, RG; Kraenzlin, ME; Jick, SS; Meier, CR			Use of beta-blockers and risk of fractures	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRACTICE RESEARCH DATABASE; OSTEOBLAST-LIKE CELLS; BONE-MINERAL DENSITY; THIAZIDE-DIURETICS; HIP FRACTURE; ADRENERGIC RECEPTORS; CONTROLLED-TRIAL; NERVOUS-SYSTEM; HYDROCHLOROTHIAZIDE; RESORPTION	Context Animal studies suggest that the beta-blocker propranolol increases bone formation, but data on whether use of beta-blockers (with or without concomitant use of thiazide diuretics) is associated with reduced fracture risk in humans are limited. Objective To determine whether use of beta-blockers alone or in combination with thiazides is associated with a decreased risk of fracture in adults. Design, Setting, and Participants Case-control analysis using the UK General Practice Research Database (GPRD). The study included 30601 case patients aged 30 to 79 years with an incident fracture diagnosis between 1993 and 1999 and 120819 controls, matched to cases on age, sex, calendar time, and general practice attended. Main Outcome Measures Odds ratios (ORs) of having a fracture in association with use of beta-blockers or a combination of beta-blockers with thiazides. Results The most frequent fractures were of the hand/lower arm (n=12837 [42.0%]) and of the foot (n=4627 [15.1%]). Compared with patients who did not use either beta-blockers or thiazide diuretics, the OR for current use of beta-blockers only (greater than or equal to3 prescriptions) was 0.77 (95% confidence interval [CI], 0.72-0.83); for current use of thiazides only (greater than or equal to3 prescriptions), 0.80 (95% CI, 0.74-0.86); and for combined current use of beta-blockers and thiazides, 0.71 (95% CI, 0.64-0.79). Data were adjusted for smoking; body mass index; number of practice visits; and use of calcium channel blockers, angiotensin-converting enzyme inhibitors, antipsychotics, antidepressants, statins, antiepileptics, benzodiazepines, corticosteroids, and estrogens. Conclusions Our data suggest that current use of beta-blockers is associated with a reduced risk of fractures, taken alone as well as in combination with thiazide diuretics. Many elderly patients with hypertension who are at risk of developing osteoporosis may potentially benefit from combined therapy with beta-blockers and thiazides.	Univ Basel Hosp, Div Clin Pharmacol & Toxicol, Basel Pharmacoepidemiol Unit, CH-4031 Basel, Switzerland; Univ Basel Hosp, Div Endocrinol Diabet & Clin Nutr, CH-4031 Basel, Switzerland; Univ Basel, Dept Pharmaceut Sci, Inst Clin Pharm, Basel, Switzerland; Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, Lexington, MA USA	University of Basel; University of Basel; University of Basel; Boston University	Meier, CR (corresponding author), Univ Basel Hosp, Div Clin Pharmacol & Toxicol, Basel Pharmacoepidemiol Unit, Hebelstr 2, CH-4031 Basel, Switzerland.	Meierch@uhbs.ch		Jick, Susan/0000-0002-2215-1067				Arai M, 2003, BBA-MOL CELL RES, V1640, P137, DOI 10.1016/S0167-4889(03)00042-9; Arnett TR, 1996, BONE, V18, P277, DOI 10.1016/8756-3282(95)00486-6; Aubin R, 1996, KIDNEY INT, V50, P1476, DOI 10.1038/ki.1996.461; Barry ELR, 1997, AM J PHYSIOL-CELL PH, V272, pC109, DOI 10.1152/ajpcell.1997.272.1.C109; Bauer DC, 2004, ARCH INTERN MED, V164, P146, DOI 10.1001/archinte.164.2.146; Cherruau M, 1999, BONE, V25, P545, DOI 10.1016/S8756-3282(99)00211-2; Cherruau M, 2003, J CELL PHYSIOL, V194, P341, DOI 10.1002/jcp.10209; Cock TA, 2003, LANCET, V362, P1572, DOI 10.1016/S0140-6736(03)14747-2; Cumming RG, 2003, CNS DRUGS, V17, P825, DOI 10.2165/00023210-200317110-00004; Ensrud KE, 2003, ARCH INTERN MED, V163, P949, DOI 10.1001/archinte.163.8.949; Feskanich D, 1997, OSTEOPOROSIS INT, V7, P79, DOI 10.1007/BF01623465; HALL TJ, 1994, CALCIFIED TISSUE INT, V55, P266, DOI 10.1007/BF00310404; Herings RMC, 1996, J CLIN EPIDEMIOL, V49, P115, DOI 10.1016/0895-4356(95)00552-8; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H, 1997, EPIDEMIOLOGY, V8, P446, DOI 10.1097/00001648-199707000-00017; Jick SS, 2003, PHARMACOTHERAPY, V23, P686, DOI 10.1592/phco.23.5.686.32205; LaCroix AZ, 2000, ANN INTERN MED, V133, P516, DOI 10.7326/0003-4819-133-7-200010030-00010; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; Meier CR, 2000, JAMA-J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205; Meier CR, 2000, ARCH INTERN MED, V160, P349, DOI 10.1001/archinte.160.3.349; MINKOWITZ B, 1991, J ORTHOPAED RES, V9, P869, DOI 10.1002/jor.1100090613; MOORE RE, 1993, BONE MINER, V23, P301, DOI 10.1016/S0169-6009(08)80105-5; Moser M, 1998, JAMA-J AM MED ASSOC, V279, P1813, DOI 10.1001/jama.279.22.1813; Pasco JA, 2004, J BONE MINER RES, V19, P19, DOI 10.1359/JBMR.0301214; Perez-Castrillon JL, 2003, AM J HYPERTENS, V16, P453, DOI 10.1016/S0895-7061(03)00845-8; RAY WA, 1989, LANCET, V1, P687; Reid IR, 2000, AM J MED, V109, P362, DOI 10.1016/S0002-9343(00)00510-6; Rejnmark L, 2003, EUR J CLIN INVEST, V33, P41, DOI 10.1046/j.1365-2362.2003.01103.x; Rodriguez LAG, 1998, BRIT J CLIN PHARMACO, V45, P419; Schoofs MWCJ, 2003, ANN INTERN MED, V139, P476, DOI 10.7326/0003-4819-139-6-200309160-00010; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Togari A, 1997, NEUROSCI LETT, V233, P125, DOI 10.1016/S0304-3940(97)00649-6; Togari A, 2002, MICROSC RES TECHNIQ, V58, P77, DOI 10.1002/jemt.10121; van Staa TP, 2000, RHEUMATOLOGY, V39, P1383, DOI 10.1093/rheumatology/39.12.1383; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; ZAWADA ET, 1987, MINER ELECTROL METAB, V13, P72	36	259	274	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2004	292	11					1326	1332		10.1001/jama.292.11.1326	http://dx.doi.org/10.1001/jama.292.11.1326			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	853YL	15367554	Bronze			2022-12-28	WOS:000223866800024
J	Cantillon, P; Irish, B; Sales, D				Cantillon, P; Irish, B; Sales, D			Using computers for assessment in medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CASE SIMULATIONS		NUI Galway, Dept Gen Practice, Galway, Ireland; Royal Coll Gen Practitioners, Examinat Dept, London SW7 1PU, England	Ollscoil na Gaillimhe-University of Galway	Cantillon, P (corresponding author), NUI Galway, Dept Gen Practice, Galway, Ireland.	peter.cantillon@migalway.ie						Appel J, 2002, AM J MED, V113, P172, DOI 10.1016/S0002-9343(02)01211-1; BOCIJ P, 1999, INT J ED TECHNOLOGY, V1, P1; Bull J., 2003, BLUEPRINT COMPUTER A; Dillon GF, 2002, ACAD MED, V77, pS94, DOI 10.1097/00001888-200210001-00029; Foubister SP, 1997, J COMPUT ASSIST LEAR, V13, P99, DOI 10.1046/j.1365-2729.1997.00012.x; Guagnano MT, 2002, ACAD MED, V77, P87, DOI 10.1097/00001888-200201000-00020; Hegarty M.K., 2002, CURR ANAESTH CRIT CA, V13, P194; Kreiter CD, 1999, ACAD MED, V74, P1125, DOI 10.1097/00001888-199910000-00016; NORMAN GR, 1987, MED EDUC, V21, P297, DOI 10.1111/j.1365-2923.1987.tb00367.x; Ogilvie RW, 1999, MED EDUC, V33, P828, DOI 10.1046/j.1365-2923.1999.00517.x; RUSSELL M, 1997, ED POLICY ANAL ARCH, V5; Schuwirth LWT, 2003, MED EDUC, V37, P65, DOI 10.1046/j.1365-2923.37.s1.8.x; SEALE J, 2002, USING CAA SUPPORT ST; SMART C, COMPUTER ASSISTED AS; SWETS JA, 1965, SCIENCE, V150, P572, DOI 10.1126/science.150.3696.572; Thelwall M, 2000, COMPUT EDUC, V34, P37, DOI 10.1016/S0360-1315(99)00037-8; WARD WC, 1982, APPL PSYCH MEAS, V6, P1, DOI 10.1177/014662168200600101; WEI H, 1999, MED COMPUTING TODAY; WHITTINGTON D, 1909, COMPUTER ASSISTED AS, P21; Wolfson PJ, 2001, ACAD MED, V76, P835, DOI 10.1097/00001888-200108000-00018	20	45	46	3	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 11	2004	329	7466					606	609		10.1136/bmj.329.7466.606	http://dx.doi.org/10.1136/bmj.329.7466.606			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	854SK	15361445	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000223923400019
J	Wylie, K				Wylie, K			ABC of sexual health - Gender related disorders	BRITISH MEDICAL JOURNAL			English	Review									Porterbrook Clin, Sheffield, S Yorkshire, England		Wylie, K (corresponding author), Porterbrook Clin, Sheffield, S Yorkshire, England.		Wylie, Kevan/C-5751-2011	Wylie, Kevan/0000-0003-3805-105X				BLANCARD R, 1990, CLIN MANAGEMENT GEND; BLANCHARD R, 2000, PSYCH ROUNDS, V4, P2; Department for Constitutional Affairs, 2004, GOV POL TRANSS PEOPL; Futterweit W, 1998, ARCH SEX BEHAV, V27, P209, DOI 10.1023/A:1018638715498; *H BENJ INT GEND D, STAND CAR GEND ID DI; Jaffrey Z, 1997, INVISIBLES TALE EUNU; Kruijver FPM, 2000, J CLIN ENDOCR METAB, V85, P2034, DOI 10.1210/jc.85.5.2034; Nanda S., 1999, NEITHER MAN WOMAN HI; ZHOU JN, 1995, NATURE, V378, P68, DOI 10.1038/378068a0	9	13	14	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 11	2004	329	7466					615	617		10.1136/bmj.329.7466.615	http://dx.doi.org/10.1136/bmj.329.7466.615			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	854SK	15361448	Green Published			2022-12-28	WOS:000223923400022
J	Kolbe, JJ; Glor, RE; Schettino, LRG; Lara, AC; Larson, A; Losos, JB				Kolbe, JJ; Glor, RE; Schettino, LRG; Lara, AC; Larson, A; Losos, JB			Genetic variation increases during biological invasion by a Cuban lizard	NATURE			English	Article							POPULATION BIOLOGY; UNITED-STATES; ANOLIS-SAGREI; EVOLUTION; PHENETICS; FLORIDA	A genetic paradox(1,2) exists in invasion biology: how do introduced populations, whose genetic variation has probably been depleted by population bottlenecks, persist and adapt to new conditions? Lessons from conservation genetics show that reduced genetic variation due to genetic drift and founder effects limits the ability of a population to adapt, and small population size increases the risk of extinction(1,3,4). Nonetheless, many introduced species experiencing these same conditions during initial introductions persist, expand their ranges, evolve rapidly and become invasive. To address this issue, we studied the brown anole, a worldwide invasive lizard. Genetic analyses indicate that at least eight introductions have occurred in Florida from across this lizard's native range, blending genetic variation from different geographic source populations and producing populations that contain substantially more, not less, genetic variation than native populations. Moreover, recently introduced brown anole populations around the world originate from Florida, and some have maintained these elevated levels of genetic variation. Here we show that one key to invasion success may be the occurrence of multiple introductions that transform among-population variation in native ranges to within-population variation in introduced areas. Furthermore, these genetically variable populations may be particularly potent sources for introductions elsewhere. The growing problem of invasive species introductions brings considerable economic and biological costs(5,6). If these costs are to be mitigated, a greater understanding of the causes, progression and consequences of biological invasions is needed(7).	Washington Univ, Dept Biol, St Louis, MO 63130 USA; CITMA, Inst Ecol & Sistemat, Havana 10800, Cuba	Washington University (WUSTL)	Kolbe, JJ (corresponding author), Washington Univ, Dept Biol, Campus Box 1137, St Louis, MO 63130 USA.	kolbe@biology.wustl.edu	Glor, Richard/N-4656-2013	Glor, Richard/0000-0002-3359-1631				Allendorf FW, 2003, CONSERV BIOL, V17, P24, DOI 10.1046/j.1523-1739.2003.02365.x; Campbell TS, 2003, BIOL INVASIONS, V5, P193, DOI 10.1023/A:1026172314139; Campbell Todd S., 1996, Herpetological Review, V27, P155; Campbell TS, 2000, ANAL EFFECTS EXOTIC; EHRLICH PR, 1989, BIOL INVASIONS GLOBA, P3125; Ellstrand NC, 2000, P NATL ACAD SCI USA, V97, P7043, DOI 10.1073/pnas.97.13.7043; Facon B, 2003, MOL ECOL, V12, P3027, DOI 10.1046/j.1365-294X.2003.01972.x; Frankham R, 1998, NATURE, V392, P441, DOI 10.1038/33022; Frankham R., 2010, INTRO CONSERVATION G, V2, DOI [10.1017/CBO9780511809002, 10.1017/CBO9780511808999]; Gerber GP, 2000, OECOLOGIA, V124, P599, DOI 10.1007/s004420000414; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Huey RB, 2000, SCIENCE, V287, P308, DOI 10.1126/science.287.5451.308; Kolar CS, 2002, SCIENCE, V298, P1233, DOI 10.1126/science.1075753; Lee CE, 2002, TRENDS ECOL EVOL, V17, P386, DOI 10.1016/S0169-5347(02)02554-5; LEE JC, 1992, COPEIA, P942, DOI 10.2307/1446624; LEE JC, 1985, COPEIA, P182, DOI 10.2307/1444808; LOSOS JB, 1993, OECOLOGIA, V95, P525, DOI 10.1007/BF00317437; Macey JR, 1997, J MOL EVOL, V44, P660, DOI 10.1007/PL00006190; Mack RN, 2000, ECOL APPL, V10, P689, DOI 10.1890/1051-0761(2000)010[0689:BICEGC]2.0.CO;2; Mooney HA, 2001, P NATL ACAD SCI USA, V98, P5446, DOI 10.1073/pnas.091093398; NOVAK SJ, 1993, HEREDITY, V71, P167, DOI 10.1038/hdy.1993.121; Nylander J.A.A., 2002, MRMODELTEST V1 0B; Pimentel D, 2000, BIOSCIENCE, V50, P53, DOI 10.1641/0006-3568(2000)050[0053:EAECON]2.3.CO;2; Queller DC, 2000, NATURE, V405, P519, DOI 10.1038/35014705; Roderick GK, 2003, NAT REV GENET, V4, P889, DOI 10.1038/nrg1201; Sakai AK, 2001, ANNU REV ECOL SYST, V32, P305, DOI 10.1146/annurev.ecolsys.32.081501.114037; Tsutsui ND, 2000, P NATL ACAD SCI USA, V97, P5948, DOI 10.1073/pnas.100110397; Wilcove DS, 1998, BIOSCIENCE, V48, P607, DOI 10.2307/1313420; WILLIAMS EE, 1969, Q REV BIOL, V44, P345, DOI 10.1086/406245; Williamson M., 1996, BIOL INVASIONS	30	774	817	7	356	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	2004	431	7005					177	181		10.1038/nature02807	http://dx.doi.org/10.1038/nature02807			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356629				2022-12-28	WOS:000223746000042
J	Nowak-Gottl, U; Kosch, A				Nowak-Gottl, U; Kosch, A			Factor VIII, D-dimer, and thromboembolism in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Childrens Hosp, Dept Pediat Hematol & Oncol, Munster, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munster	Nowak-Gottl, U (corresponding author), Univ Childrens Hosp, Dept Pediat Hematol & Oncol, Munster, Germany.							ANDREW M, 1995, THROMB HAEMOSTASIS, V74, P415; Cushman M, 2003, BLOOD, V101, P1243, DOI 10.1182/blood-2002-05-1416	2	8	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2004	351	11					1051	1053		10.1056/NEJMp048150	http://dx.doi.org/10.1056/NEJMp048150			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CX	15356301				2022-12-28	WOS:000223733900003
J	Poulton, SW; Fralick, PW; Canfield, DE				Poulton, SW; Fralick, PW; Canfield, DE			The transition to a sulphidic ocean similar to 1.84 billion years ago	NATURE			English	Article							GUNFLINT FORMATION; PYRITE FORMATION; IRON; EVOLUTION; ANOXIA; MODEL; CHEMISTRY; SULFATE; ONTARIO; ISOTOPE	The Proterozoic aeon (2.5 to 0.54 billion years (Gyr) ago) marks the time between the largely anoxic world of the Archean (>2.5Gyr ago)(1) and the dominantly oxic world of the Phanerozoic (<0.54 Gyr ago). The course of ocean chemistry through the Proterozoic has traditionally been explained by progressive oxygenation of the deep ocean in response to an increase in atmospheric oxygen around 2.3 Gyr ago. This postulated rise in the oxygen content of the ocean is in turn thought to have led to the oxidation of dissolved iron, Fe(II), thus ending the deposition of banded iron formations (BIF) around 1.8 Gyr ago(1,2). An alternative interpretation suggests that the increasing atmospheric oxygen levels enhanced sulphide weathering on land and the flux of sulphate to the oceans. This increased rates of sulphate reduction, resulting in Fe(II) removal in the form of pyrite as the oceans became sulphidic(3). Here we investigate sediments from the similar to 1.8-Gyr-old Animikie group, Canada, which were deposited during the final stages of the main global period of BIF deposition. This allows us to evaluate the two competing hypotheses for the termination of BIF deposition. We use iron-sulphur-carbon (Fe-S-C) systematics to demonstrate continued ocean anoxia after the final global deposition of BIF and show that a transition to sulphidic bottom waters was ultimately responsible for the termination of BIF deposition. Sulphidic conditions may have persisted until a second major rise in oxygen between 0.8 to 0.58 Gyr ago(4,5), possibly reducing global rates of primary production and arresting the pace of algal evolution(6).	Univ So Denmark, Inst Biol, Danish Ctr Earth Syst Sci, DK-5230 Odense M, Denmark; Lakehead Univ, Dept Geol, Thunder Bay, ON P7B 5E1, Canada	University of Southern Denmark; Lakehead University	Poulton, SW (corresponding author), Univ So Denmark, Inst Biol, Danish Ctr Earth Syst Sci, Campusvej 55, DK-5230 Odense M, Denmark.	s.poulton@biology.sdu.dk	Canfield, Don/C-1735-2012	Canfield, Don/0000-0001-7602-8366; Poulton, Simon/0000-0001-7621-189X				Anbar AD, 2002, SCIENCE, V297, P1137, DOI 10.1126/science.1069651; Anderson TF, 2004, AM J SCI, V304, P203, DOI 10.2475/ajs.304.3.203; Arnold GL, 2004, SCIENCE, V304, P87, DOI 10.1126/science.1091785; BERNER RA, 1984, GEOLOGY, V12, P365, DOI 10.1130/0091-7613(1984)12<365:CMFDFF>2.0.CO;2; Brocks JJ, 2004, GEOCHIM COSMOCHIM AC, V68, pA796; Canfield DE, 1999, AM J SCI, V299, P697, DOI 10.2475/ajs.299.7-9.697; Canfield DE, 1998, NATURE, V396, P450, DOI 10.1038/24839; Canfield DE, 1996, NATURE, V382, P127, DOI 10.1038/382127a0; CARRIGAN WJ, 1991, PRECAMBRIAN RES, V52, P347, DOI 10.1016/0301-9268(91)90088-R; CLOUD P, 1972, AM J SCI, V272, P537, DOI 10.2475/ajs.272.6.537; DERRY LA, 1992, GEOCHIM COSMOCHIM AC, V56, P1317, DOI 10.1016/0016-7037(92)90064-P; DERRY LA, 1990, GEOCHIM COSMOCHIM AC, V54, P2965, DOI 10.1016/0016-7037(90)90114-Z; DREVER JI, 1974, GEOL SOC AM BULL, V85, P1099, DOI 10.1130/0016-7606(1974)85<1099:GMFTOO>2.0.CO;2; Fralick P, 2002, CAN J EARTH SCI, V39, P1085, DOI 10.1139/E02-028; Habicht KS, 2002, SCIENCE, V298, P2372, DOI 10.1126/science.1078265; Holland HD., 1984, CHEM EVOLUTION ATMOS; KISSIN SA, 2003, LAKE SUPERIOR I P, V49, P43; Lyons TW, 1997, GEOCHIM COSMOCHIM AC, V61, P3367, DOI 10.1016/S0016-7037(97)00174-9; OJAKANGAS RW, 1983, GEOL SOC AM MEM, V160, P49; Passier HF, 1999, NATURE, V397, P146, DOI 10.1038/16441; Poulton SW, 2002, AM J SCI, V302, P774, DOI 10.2475/ajs.302.9.774; POULTON SW, UNPUB CHEM GEOL; Pufahl PK, 2004, SEDIMENTOLOGY, V51, P791, DOI 10.1111/j.1365-3091.2004.00651.x; RAISWELL R, 1985, AM J SCI, V285, P710, DOI 10.2475/ajs.285.8.710; Raiswell R, 1998, AM J SCI, V298, P219, DOI 10.2475/ajs.298.3.219; Raiswell R, 2001, J SEDIMENT RES, V71, P286, DOI 10.1306/070300710286; Schidlowski M., 1983, P149; Shen Y, 2003, NATURE, V423, P632, DOI 10.1038/nature01651; Shen YN, 2002, AM J SCI, V302, P81, DOI 10.2475/ajs.302.2.81; STRAUSS H, 1993, PRECAMBRIAN RES, V63, P225, DOI 10.1016/0301-9268(93)90035-Z	30	336	355	5	135	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	2004	431	7005					173	177		10.1038/nature02912	http://dx.doi.org/10.1038/nature02912			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HI	15356628				2022-12-28	WOS:000223746000041
J	Herzlinger, RE; Parsa-Parsi, R				Herzlinger, RE; Parsa-Parsi, R			Consumer-driven health care - Lessons from Switzerland	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-STATE; SURGERY MORTALITY; QUALITY; FAILURE	Switzerland's consumer-driven health care system achieves universal insurance and high quality of care at significantly lower costs than the employer-based US system and without the constrained resources that can characterize government-controlled systems. Unlike other systems in which the choice and most of the funding for health insurance is provided by third parties, such as employers and governments, in the Swiss system, individuals are required to purchase their own health insurance. The positive results achieved by the Swiss system may be attributed to its consumer control, price transparency of the insurance plans, risk adjustment of insurers, and solidarity. However, the constraints the Swiss system places on hospitals and physicians and the paucity of provider quality information may unduly limit its impact. The Swiss health care system holds important lessons, including evidence about its feasibility and equity, for the United States, which is now embarking on its own consumer-driven health care system.	Harvard Univ, Sch Business, Boston, MA 02163 USA; Harvard Med Int, Boston, MA USA	Harvard University; Harvard University; Harvard Medical School	Herzlinger, RE (corresponding author), Harvard Univ, Sch Business, Mellon Hall,Soldiers Field Rd,A3-3, Boston, MA 02163 USA.	rherzlinger@hbs.edu						Anderson GF, 2003, HEALTH AFFAIR, V22, P89, DOI 10.1377/hlthaff.22.3.89; Beck K, 2003, HEALTH POLICY, V65, P63, DOI 10.1016/S0168-8510(02)00117-3; BENKO L, 2002, MODERN HEALTHCARE, V32, P30; Bentley J M, 1998, Jt Comm J Qual Improv, V24, P40; Birkmeyer JD, 2002, HEALTH AFFAIR, V21, P234, DOI 10.1377/hlthaff.21.5.234; *BUND GES, 2002, STAT OBL KRANK 2002, P94; *BUND SOZ, 2003, SCHWEIZ SOZ 2003, P145; *BUND SOZ, 2002, STAT KRANK 2001, P62; *BUND SOZ, 2000, STAT WAHLB FRANCH KR; *BUND SOZ, 2001, STAT KRANK 2000, P88; *BUND SOZ, 2002, PRAM 2003 VERZ ZUG K, P8; *BUND STAT, 2001, RECHTL WIRTSCH STAT, P5; *BUND STAT, 2000, GES GES SCHWEIZ 1997, P49; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; COLOMBO F, 2001, LABOR MARKET SOCIAL, V53, P36; *COM BANK, COM BANK AUT AFF IND; Coulter A, 2001, HEALTH AFFAIR, V20, P244, DOI 10.1377/hlthaff.20.3.244; Cunningham R, 2002, HEALTH AFFAIR, V21, P24, DOI 10.1377/hlthaff.21.1.24; *DEP HLTH HUM SERV, 2003, HLTH US 2002; DOMENIGHETTI G, 2001, VERSORGUNGSSICHERHEI; DZIUBAN SW, 1994, ANN THORAC SURG, V58, P1871, DOI 10.1016/0003-4975(94)91730-2; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; FANG S, 2000, MANAGEMENT RES NEWS, V26, P116; FREUDENHEIM M, 2001, NY TIMES        0313, pA1; GABEL JR, 2003, HLTH AFF MILLWOOD S, pW395; GERDTHAM UG, 1992, DEV HLTH EC, V1, P287; Goldman DP, 2002, P NATL ACAD SCI USA, V99, P10929, DOI 10.1073/pnas.162086599; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HERZLINGER RE, 2003, 302033 HARV BUS SCH; HERZLINGER RE, 2004, CONSUMER DRIVEN HLTH, P797; HERZLINGER RE, 2004, CONSUMER DRIVEN HLTH, P74; HUTH P, 1999, KOSTENDRUCK BEWIRKT, V1; IGLEHART JK, 2002, NEW ENGL J MED, V342, P2007; Keeler EB, 1999, J HEALTH ECON, V18, P69, DOI 10.1016/S0167-6296(98)00036-8; *KOST GES, 2002, DET ERG 2000; LYALL S, 2000, NY TIMES        0210, pA1; MARCOTTE BJ, 2004, CONSUMER DRIVEN HLTH, P213; Marmot M, 1999, HEALTH AFFAIR, V18, P42, DOI 10.1377/hlthaff.18.3.42; Martin RM, 2003, BMJ-BRIT MED J, V326, P188, DOI 10.1136/bmj.326.7382.188; McLaughlin CG, 1999, MED CARE RES REV, V56, P24, DOI 10.1177/107755899773743855; MOFFIT RE, 2001, HERITAGE LECT, P15; Mukamel DB, 1998, MED CARE, V36, P945, DOI 10.1097/00005650-199807000-00002; Naylor CD, 1999, HEALTH AFFAIR, V18, P9, DOI 10.1377/hlthaff.18.3.9; *ORG EC COOP DEV, 2002, OECD HLTH DAT 2002; PETERSEN ED, 1998, CARDIAC SURG, V324, P993; Quill BE, 2001, PUBLIC HEALTH REP, V116, P505; ROMANO M, 2000, MOD HEALTHCARE, V30, P16; Sage WM, 2003, HEALTH AFFAIR, V22, P31, DOI 10.1377/hlthaff.22.2.31; *SCHWEIZ VISANA VE, 2002, LEIST AUSG 2002; Shaw Diana V, 2003, J Health Care Finance, V29, P28; *SHERL CO, 2003, PULSE, pR5; SILOWCARROLL S, 2002, E HLTH OPTIONS BUSIN, P13; *SOZ UNGL GES SCHW, 2002, SPEZ GES BEFR 1997, P108; *US BUR CENS, 2001, STAT ABSTR US 2001; *US BUR CENS, 2003, STAT ABSTR US 2003, P104; *US BUR CENS, 2002, STAT ABSTR US 2002; *US C, PERF POT CONS DRIV H; Whellan DJ, 2001, ARCH INTERN MED, V161, P2223, DOI 10.1001/archinte.161.18.2223; *WHO, 2000, WORLD HLTH REP 2000, P176; Wong MD, 2002, NEW ENGL J MED, V347, P1585, DOI 10.1056/NEJMsa012979; Zweifel P, 2000, J HEALTH POLIT POLIC, V25, P937, DOI 10.1215/03616878-25-5-937; 2002, WARDS AUTOMOTIVE YB, P202; 2002, MANAGED HEALTHCA JAN, P52; SCHWEIZER BEOBACHTER; 2002, MANAGED CARE, V7, P2; 2000, MEPS EMPLOYER SPONSO; BUNDESAMT STAT 2002; 2002, MEDTRONICS HLTH INSU; 2004, INSIDE CONSUMER DIRE, V2, P1	69	74	75	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2004	292	10					1213	1220		10.1001/jama.292.10.1213	http://dx.doi.org/10.1001/jama.292.10.1213			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	851ZA	15353534				2022-12-28	WOS:000223723800021
J	Leung, GM; Rainer, TH; Lau, FL; Wong, IOL; Tong, A; Wong, TW; Kong, JHB; Hedley, AJ; Lam, TH				Leung, GM; Rainer, TH; Lau, FL; Wong, IOL; Tong, A; Wong, TW; Kong, JHB; Hedley, AJ; Lam, TH		Hosp Authority SARS Collaborative	A clinical prediction rule for diagnosing severe acute respiratory syndrome in the emergency department	ANNALS OF INTERNAL MEDICINE			English	Article							HONG-KONG; SARS CORONAVIRUS; LABORATORY TESTS; OUTBREAK; VALIDATION; PNEUMONIA; MORTALITY; INFECTION; DISEASE; MODELS	Background: Accurate, objective models of triage for patients with suspected severe acute respiratory syndrome (SARS) could assess risks and improve decisions about isolation and inpatient treatment. Objective: To develop and validate a clinical prediction rule for identifying patients with SARS in an emergency department setting. Design: Retrospective analysis using a 2-step coefficient-based multivariable logistic regression scoring method with internal validation by bootstrapping. Setting: 2 hospitals in Hong Kong Participants: 1274 consecutive patients from 1 hospital and 1375 consecutive patients from another hospital. Measurements: Points were assigned on the basis of history, physical examination, and simple investigations obtained at presentation. The outcome measure was a final diagnosis of SARS, as confirmed by World Health Organization laboratory criteria. Results: Predictors for SARS on the basis of history (step 1) included previous contact with a patient with SARS and the presence of fever, myalgia, and malaise. Age 65 years and older and younger than 18 years and the presence of sputum, abdominal pain, sore throat, and rhinorrhea were inversely related to having SARS. In step 2, haziness or pneumonic consolidation on chest radiographs and low lymphocyte and platelet counts, in addition to a positive contact history and fever were associated with a higher probability of SARS. A high neutrophil count, the extremes of age, and sputum production were associated with a lower probability of SARS. In the derivation sample, the observed incidence of SARS was 4.4% for those assigned to the low-risk group (in steps 1 or 2); in the high-risk group, incidence of SARS was 21.0% for quartile 1, 39.5% for quartile 2, 61.2% for quartile 3, and 79.7% for quartile 4. This prediction rule achieved an optimism-corrected sensitivity of 0.90, a specificity of 0.62, and an area under the receiver-operating characteristic curve of 0.85. Limitations: The prediction rule may not apply to isolated cases occurring during an interepidemic period. Generalizability of the findings should be confirmed in other SARS-affected countries and should be prospectively validated if SARS returns. Conclusions: our findings suggest that a simple model that uses clinical data at the time of presentation to an emergency department during an acute outbreak predicted the incidence of SARS and provided good diagnostic utility.	Chinese Univ Hong Kong, Prince Wales Hosp, Accid & Emergency Med Acad Unit, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, United Christian Hosp, Pamela Youde Nethersole E Hosp, Shatin, Hong Kong, Peoples R China; Hong Kong Hosp Author, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Pamela Youde Nethersole Eastern Hospital; United Christian Hospital	Rainer, TH (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Accid & Emergency Med Acad Unit, Shatin, Hong Kong, Peoples R China.	b875722@mailserv.cuhk.edu.hk	Leung, Gabriel Matthew/C-4336-2009; Rainer, Timothy/I-2591-2013; Wong, Oi Ling/C-4538-2009; Hedley, Anthony/C-4305-2009; Hedley, Anthony J/A-9113-2013; Wong, Tze Wai/K-5344-2013; Lam, Tai Hing/C-4317-2009	Rainer, Timothy/0000-0003-3355-3237; Lam, Tai Hing/0000-0002-2033-9971; Leung, Gabriel/0000-0002-2503-6283				Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; Efron B, 1998, INTRO BOOTSTRAP; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Fouchier RAM, 2004, CAN MED ASSOC J, V170, P63; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hon KLE, 2003, LANCET, V361, P1701, DOI 10.1016/S0140-6736(03)13364-8; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Lee DS, 2003, JAMA-J AM MED ASSOC, V290, P2581, DOI 10.1001/jama.290.19.2581; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; LEUNG CM, IN PRESS EMERG INFEC; Leung GM, 2003, J EPIDEMIOL COMMUN H, V57, P857, DOI 10.1136/jech.57.11.857; LEUNG GM, IN PRESS SARS 1 PLAG; Ng EKO, 2003, CLIN CHEM, V49, P1976, DOI 10.1373/clinchem.2003.024125; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Poon LLM, 2003, J CLIN VIROL, V28, P233, DOI 10.1016/j.jcv.2003.08.004; Rainer TH, 2004, ANN INTERN MED, V140, P614, DOI 10.7326/0003-4819-140-8-200404200-00008; Rainer TH, 2003, BRIT MED J, V326, P1354, DOI 10.1136/bmj.326.7403.1354; Steyerberg EW, 2001, MED DECIS MAKING, V21, P45, DOI 10.1177/0272989X0102100106; Steyerberg EW, 2003, J CLIN EPIDEMIOL, V56, P441, DOI 10.1016/S0895-4356(03)00047-7; Sullivan LM, 2004, STAT MED, V23, P1631, DOI 10.1002/sim.1742; Tang P, 2004, CAN MED ASSOC J, V170, P47; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; WHO, 2003, US LAB METH SARS DIA; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Wong KT, 2003, RADIOLOGY, V228, P395, DOI 10.1148/radiol.2283030541; World Health Organization, 2003, CAS DEF SURV SEV AC	29	33	33	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	2004	141	5					333	342		10.7326/0003-4819-141-5-200409070-00106	http://dx.doi.org/10.7326/0003-4819-141-5-200409070-00106			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CW	15326019	Green Accepted, Green Submitted			2022-12-28	WOS:000223733800001
J	Kerr, DJ				Kerr, DJ			Two errors	LANCET			English	Editorial Material									Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England	Radcliffe Infirmary	Kerr, DJ (corresponding author), Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England.	david.kerr@clinical-pharmacology.oxford.ac.uk							0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	2004	364	9437					907	907		10.1016/S0140-6736(04)16988-2	http://dx.doi.org/10.1016/S0140-6736(04)16988-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351200				2022-12-28	WOS:000223685200039
J	Chang, CP; Neilson, JR; Bayle, JH; Gestwicki, JE; Kuo, A; Stankunas, K; Graef, IA; Crabtree, GR				Chang, CP; Neilson, JR; Bayle, JH; Gestwicki, JE; Kuo, A; Stankunas, K; Graef, IA; Crabtree, GR			A field of myocardial-endocardial NFAT signaling underlies heart valve morphogenesis	CELL			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR; GROWTH-FACTOR; EMBRYONIC LETHALITY; CARDIAC DEVELOPMENT; CUSHION FORMATION; DNA-BINDING; CALCINEURIN; VEGF; IDENTIFICATION	The delicate leaflets that make up vertebrate heart valves are essential for our moment-to-moment existence. Abnormalities of valve formation are the most common serious human congenital defect. Despite their importance, relatively little is known about valve development. We show that the initiation of heart valve morphogenesis in mice requires calcineurin/NFAT to repress VEGF expression in the myocardium underlying the site of prospective valve formation. This repression of VEGF at E9 is essential for endocardial cells to transform into mesenchymal cells. Later, at Ell, a second wave of calcineurin/NFAT signaling is required in the endocardium, adjacent to the earlier myocardial site of NFAT action, to direct valvular elongation and refinement. Thus, NFAT signaling functions sequentially from myocardium to endocardium within a valvular morphogenetic field to initiate and perpetuate embryonic valve formation. This mechanism also operates in zebrafish, indicating a conserved role for calcineurin/NFAT signaling in vertebrate heart valve morphogenesis.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Div Cardiovasc, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University	Crabtree, GR (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.	crabtree@stanford.edu		Neilson, Joel R./0000-0002-3408-608X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL072092] Funding Source: NIH RePORTER; NHLBI NIH HHS [R21 HL72092-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiyama H, 2004, P NATL ACAD SCI USA, V101, P6502, DOI 10.1073/pnas.0401711101; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Brickner ME, 2000, NEW ENGL J MED, V342, P256, DOI 10.1056/NEJM200001273420407; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CARPENTER SJ, 1980, ANAT REC, V197, P221, DOI 10.1002/ar.1091970211; Chang CP, 2003, GENESIS, V36, P7, DOI 10.1002/gene.10186; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Dor Y, 2001, DEVELOPMENT, V128, P1531; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; DVORAK HF, 1979, J IMMUNOL, V122, P166; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; Erickson SL, 1997, DEVELOPMENT, V124, P4999; Fedak PWM, 2002, CIRCULATION, V106, P900, DOI 10.1161/01.CIR.0000027905.26586.E8; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Gitler AD, 2003, NAT GENET, V33, P75, DOI 10.1038/ng1059; Graef IA, 2003, CELL, V113, P657, DOI 10.1016/S0092-8674(03)00390-8; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Haigh JJ, 2000, DEVELOPMENT, V127, P1445; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; Hurlstone AFL, 2003, NATURE, V425, P633, DOI 10.1038/nature02028; Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kuo CJ, 2001, P NATL ACAD SCI USA, V98, P4605, DOI 10.1073/pnas.081615298; Lakkis MM, 1998, DEVELOPMENT, V125, P4359; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Miquerol L, 2000, DEVELOPMENT, V127, P3941; Miquerol L, 1999, DEV BIOL, V212, P307, DOI 10.1006/dbio.1999.9355; MJAATVEDT CH, 1989, DEV BIOL, V136, P118, DOI 10.1016/0012-1606(89)90135-8; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Moorman AFM, 1998, CIRC RES, V82, P629, DOI 10.1161/01.RES.82.6.629; Nakajima Y, 2000, ANAT RECORD, V258, P119, DOI 10.1002/(SICI)1097-0185(20000201)258:2<119::AID-AR1>3.0.CO;2-U; Neilson JR, 2004, IMMUNITY, V20, P255, DOI 10.1016/S1074-7613(04)00052-4; Olson EN, 2003, GENE DEV, V17, P1937, DOI 10.1101/gad.1110103; PARR MB, 1986, BIOL REPROD, V34, P393, DOI 10.1095/biolreprod34.2.393; Ramsdell AF, 1998, ACTA ANAT, V162, P1; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Reynolds LP, 2001, BIOL REPROD, V64, P1033, DOI 10.1095/biolreprod64.4.1033; RUNYAN RB, 1983, DEV BIOL, V95, P108, DOI 10.1016/0012-1606(83)90010-6; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; STURM K, 1993, METHOD ENZYMOL, V225, P164; Timmerman LA, 2004, GENE DEV, V18, P99, DOI 10.1101/gad.276304; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WESTERFIELD M, 1995, ZEBRAFISH BOOK; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0	56	257	263	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2004	118	5					649	663		10.1016/j.cell.2004.08.010	http://dx.doi.org/10.1016/j.cell.2004.08.010			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	852BN	15339668	Bronze			2022-12-28	WOS:000223730300014
J	Macfarlane, A; Martin, G				Macfarlane, A; Martin, G			Beyond the ivory tower - A world of glass	SCIENCE			English	Editorial Material									Univ Cambridge, Dept Social Anthropol, Cambridge CB2 3RF, England	University of Cambridge	Macfarlane, A (corresponding author), Univ Cambridge, Dept Social Anthropol, Cambridge CB2 3RF, England.	am12@cam.ac.uk							0	16	17	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1407	1408		10.1126/science.1093597	http://dx.doi.org/10.1126/science.1093597			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353785				2022-12-28	WOS:000223761900028
J	Matroule, JY; Lam, H; Burnette, DT; Jacobs-Wagner, C				Matroule, JY; Lam, H; Burnette, DT; Jacobs-Wagner, C			Cytokinesis monitoring during development: Rapid pole-to-pole shuttling of a signaling protein by localized kinase and phosphatase in Caulobacter	CELL			English	Article							ASYMMETRIC CELL-DIVISION; RESPONSE REGULATOR; ESCHERICHIA-COLI; DYNAMIC LOCALIZATION; CYCLE REGULATION; CRESCENTUS; DIFFERENTIATION; TRANSDUCTION; DOMAIN; ENVZ	For successful generation of different cell types by asymmetric cell division, cell differentiation should be initiated only after completion of division. Here, we describe a control mechanism by which Caulobacter couples the initiation of a developmental program to the completion of cytokinesis. Genetic evidence indicates that localization of the signaling protein DivK at the flagellated pole prevents premature initiation of development. Photobleaching and FRET experiments show that polar localization of DivK is dynamic with rapid pole-to-pole shuttling of diffusible DivK generated by the localized activities of PleC phosphatase and DivJ kinase at opposite poles. This shuttling is interrupted upon completion of cytokinesis by the segregation of PleC and DivJ to different daughter cells, resulting in disruption of DivK localization at the flagellated pole and subsequent initiation of development in the flagellated progeny. Thus, dynamic polar localization of a diffusible protein provides a control mechanism that monitors cytokinesis to regulate development.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University	Jacobs-Wagner, C (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, POB 208103, New Haven, CT 06520 USA.	christine.jacobs-wagner@yale.edu		Jacobs-Wagner, Christine/0000-0003-0980-5334	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065835] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM065835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOL CHEM, V264, P14090; Aldridge P, 1999, MOL MICROBIOL, V32, P379, DOI 10.1046/j.1365-2958.1999.01358.x; Alley MRK, 2001, MOL MICROBIOL, V40, P1335, DOI 10.1046/j.1365-2958.2001.02476.x; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Doe CQ, 2001, CURR OPIN CELL BIOL, V13, P68, DOI 10.1016/S0955-0674(00)00176-9; Elowitz MB, 1999, J BACTERIOL, V181, P197, DOI 10.1128/JB.181.1.197-203.1999; ELY B, 1991, METHOD ENZYMOL, V204, P372; EVINGER M, 1977, J BACTERIOL, V132, P294, DOI 10.1128/JB.132.1.294-301.1977; HECHT GB, 1995, EMBO J, V14, P3915, DOI 10.1002/j.1460-2075.1995.tb00063.x; Hsing WH, 1998, J BACTERIOL, V180, P4538, DOI 10.1128/JB.180.17.4538-4546.1998; Hsing WH, 1997, J BACTERIOL, V179, P3729, DOI 10.1128/jb.179.11.3729-3735.1997; HUGUENEL ED, 1982, DIFFERENTIATION, V21, P71, DOI 10.1111/j.1432-0436.1982.tb01199.x; Hung DY, 2002, P NATL ACAD SCI USA, V99, P13160, DOI 10.1073/pnas.202495099; Jacobs C, 2001, P NATL ACAD SCI USA, V98, P4095, DOI 10.1073/pnas.051609998; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Lam H, 2003, DEV CELL, V5, P149, DOI 10.1016/S1534-5807(03)00191-6; Laub MT, 2002, P NATL ACAD SCI USA, V99, P4632, DOI 10.1073/pnas.062065699; Losick R, 1999, GENE DEV, V13, P377, DOI 10.1101/gad.13.4.377; Lu BW, 2000, ANNU REV NEUROSCI, V23, P531, DOI 10.1146/annurev.neuro.23.1.531; Ohta N, 1996, TRENDS MICROBIOL, V4, P326, DOI 10.1016/0966-842X(96)10050-0; Ohta N, 2000, PROKARYOTIC DEVELOPMENT, P341; Ohta N, 2003, J BACTERIOL, V185, P4424, DOI 10.1128/JB.185.15.4424-4431.2003; OSLEY MA, 1977, P NATL ACAD SCI USA, V74, P124, DOI 10.1073/pnas.74.1.124; OSLEY MA, 1977, CELL, V12, P393, DOI 10.1016/0092-8674(77)90115-5; Paul R, 2004, GENE DEV, V18, P715, DOI 10.1101/gad.289504; Roberts RC, 1996, J BACTERIOL, V178, P1829, DOI 10.1128/jb.178.7.1829-1841.1996; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SOMMER JM, 1989, J BACTERIOL, V171, P392, DOI 10.1128/jb.171.1.392-401.1989; SOMMER JM, 1991, GENETICS, V129, P623; SPRATT BG, 1986, GENE, V41, P337, DOI 10.1016/0378-1119(86)90117-4; TERRANA B, 1976, J BACTERIOL, V128, P456, DOI 10.1128/JB.128.1.456-462.1976; Tomomori C., 2003, HISTIDINE KINASES SI, P11, DOI [10.1016/B978-012372484-7/50003-5, DOI 10.1016/B978-012372484-7/50003-5]; Viollier PH, 2002, EMBO J, V21, P4420, DOI 10.1093/emboj/cdf454; WANG SP, 1993, P NATL ACAD SCI USA, V90, P630, DOI 10.1073/pnas.90.2.630; Wang Y, 2001, MOL MICROBIOL, V40, P347, DOI 10.1046/j.1365-2958.2001.02395.x; Wheeler RT, 1999, MOL CELL, V4, P683, DOI 10.1016/S1097-2765(00)80379-2; Wu JG, 1998, P NATL ACAD SCI USA, V95, P1443, DOI 10.1073/pnas.95.4.1443; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Youvan D. C., 1997, BIOTECHNOLOGY, V3, P1; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	40	109	110	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	2004	118	5					579	590		10.1016/j.cell.2004.08.019	http://dx.doi.org/10.1016/j.cell.2004.08.019			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	852BN	15339663	Bronze			2022-12-28	WOS:000223730300009
J	Bourc'his, D; Bestor, TH				Bourc'his, D; Bestor, TH			Meiotic catastrophe and retrotransposon reactivation in male germ cells lacking Dnmt3L	NATURE			English	Article							CYTOSINE METHYLATION; GENE FAMILY; EXPRESSION; IMPRINTS; MICE	Mammalian genomes employ heritable cytosine methylation in the long-term silencing of retrotransposons and genes subject to genomic imprinting and X chromosome inactivation. Little is known of the mechanisms that direct cytosine methylation to specific sequences. Here we show that DNA methyltransferase 3-like (Dnmt3L (ref. 1)) is expressed in testes during a brief perinatal period in the non-dividing precursors of spermatogonial stem cells at a stage where retrotransposons undergo de novo methylation. Deletion of the Dnmt3L gene prevented the de novo methylation of both long-terminal-repeat (LTR) and non-LTR retrotransposons, which were transcribed at high levels in spermatogonia and spermatocytes. Loss of Dnmt3L from early germ cells also caused meiotic failure in spermatocytes, which do not express Dnmt3L. Whereas dispersed repeated sequences were demethylated in mutant germ cells, tandem repeats in pericentric regions were methylated normally. This result indicates that the Dnmt3L protein might have a function in the de novo methylation of dispersed repeated sequences in a premeiotic genome scanning process that occurs in male germ cells at about the time of birth.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Columbia University	Bestor, TH (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 701 W 168th St, New York, NY 10032 USA.	thb12@columbia.edu		Bourc'his, Deborah/0000-0001-9499-7291				Aapola U, 2000, GENOMICS, V65, P293, DOI 10.1006/geno.2000.6168; Bestor TH, 2003, TRENDS GENET, V19, P185, DOI 10.1016/S0168-9525(03)00049-0; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; CAMBARERI EB, 1989, SCIENCE, V244, P1571, DOI 10.1126/science.2544994; Chedin F, 2002, P NATL ACAD SCI USA, V99, P16916, DOI 10.1073/pnas.262443999; Davis TL, 1999, GENOMICS, V58, P18, DOI 10.1006/geno.1999.5813; DOBSON MJ, 1994, J CELL SCI, V107, P2749; ENDERS GC, 1994, DEV BIOL, V163, P331, DOI 10.1006/dbio.1994.1152; Hata K, 2002, DEVELOPMENT, V129, P1983; Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; La Salle S, 2004, DEV BIOL, V268, P403, DOI 10.1016/j.ydbio.2003.12.031; Lin SP, 2003, NAT GENET, V35, P97, DOI 10.1038/ng1233; Maloisel L, 1998, GENE DEV, V12, P1381, DOI 10.1101/gad.12.9.1381; Odorisio T, 1998, NAT GENET, V18, P257, DOI 10.1038/ng0398-257; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Peters AHFM, 1997, CHROMOSOME RES, V5, P66, DOI 10.1023/A:1018445520117; Petes TD, 2001, NAT REV GENET, V2, P360, DOI 10.1038/35072078; PIETRAS DF, 1983, NUCLEIC ACIDS RES, V11, P6965, DOI 10.1093/nar/11.20.6965; PONZETTOZIMMERMAN C, 1984, NUCLEIC ACIDS RES, V12, P2807, DOI 10.1093/nar/12.6.2807; SANFORD J, 1984, NUCLEIC ACIDS RES, V12, P2822; Ueda T, 2000, GENES CELLS, V5, P649, DOI 10.1046/j.1365-2443.2000.00351.x; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	25	820	842	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2004	431	7004					96	99		10.1038/nature02886	http://dx.doi.org/10.1038/nature02886			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15318244				2022-12-28	WOS:000223641500049
J	Auvin, S; Vallee, L				Auvin, S; Vallee, L			Neuronal lipofuscinosis	LANCET			English	Editorial Material									Hop Roger Salengro, Serv Neurol Pediat, F-59037 Lille, France	Universite de Lille - ISITE; CHU Lille	Auvin, S (corresponding author), Hop Roger Salengro, Serv Neurol Pediat, F-59037 Lille, France.	s-auvin@chru-lille.fr	Auvin, Stéphane/AAB-7824-2021	Auvin, Stéphane/0000-0003-3874-9749					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	2004	364	9436					786	786		10.1016/S0140-6736(04)16938-9	http://dx.doi.org/10.1016/S0140-6736(04)16938-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337405				2022-12-28	WOS:000223569600030
J	Moscona, A				Moscona, A			Oseltamivir-resistant influenza?	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; A VIRUSES; ORAL OSELTAMIVIR; NEURAMINIDASE; INHIBITORS; ZANAMIVIR; PREVENTION; H5N1; RIMANTADINE; EFFICACY		CUNY Mt Sinai Sch Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Moscona, A (corresponding author), CUNY Mt Sinai Sch Med, New York, NY 10029 USA.	Anne.moscona@mssm.edu						BRADSHER K, 2004, NY TIMES        0821; *CDCP, 2004, UPD INFL A H5N1 SARS; *CSIRO, 2004, CSIRO BAS DRUG EFF B; Hayden FG, 2000, ANTIVIR THER, V5, P205; Hayden FG, 2000, NEW ENGL J MED, V343, P1282, DOI 10.1056/NEJM200011023431801; Hayden FG, 1999, JAMA-J AM MED ASSOC, V282, P1240, DOI 10.1001/jama.282.13.1240; HAYDEN FG, 1992, CURR TOP MICROBIOL, V176, P119; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; Herlocher ML, 2002, ANTIVIR RES, V54, P99, DOI 10.1016/S0166-3542(01)00214-5; Leneva IA, 2001, ANTIMICROB AGENTS CH, V45, P1216, DOI 10.1128/AAC.45.4.1216-1224.2001; Leneva IA, 2000, ANTIVIR RES, V48, P101, DOI 10.1016/S0166-3542(00)00123-6; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746; McKimm-Breschkin J, 2003, ANTIMICROB AGENTS CH, V47, P2264, DOI 10.1128/AAC.47.7.2264-2272.2003; McKimm-Breschkin JL, 1998, J VIROL, V72, P2456, DOI 10.1128/JVI.72.3.2456-2462.1998; McKimm-Breschkin JL, 2000, ANTIVIR RES, V47, P1, DOI 10.1016/S0166-3542(00)00103-0; MEINDL P, 1974, VIROLOGY, V58, P457, DOI 10.1016/0042-6822(74)90080-4; Monto AS, 1999, JAMA-J AM MED ASSOC, V282, P31, DOI 10.1001/jama.282.1.31; Tumpey TM, 2002, P NATL ACAD SCI USA, V99, P13849, DOI 10.1073/pnas.212519699; Varghese JN, 1998, STRUCT FOLD DES, V6, P735, DOI 10.1016/S0969-2126(98)00075-6; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; Welliver R, 2001, JAMA-J AM MED ASSOC, V285, P748, DOI 10.1001/jama.285.6.748; Whitley RJ, 2001, PEDIATR INFECT DIS J, V20, P127, DOI 10.1097/00006454-200102000-00002; Ziegler T, 1999, J INFECT DIS, V180, P935, DOI 10.1086/314994	23	27	28	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	2004	364	9436					733	734		10.1016/S0140-6736(04)16947-X	http://dx.doi.org/10.1016/S0140-6736(04)16947-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337382				2022-12-28	WOS:000223569600003
J	Portenoy, RK				Portenoy, RK			Appropriate use of opioids for persistent non-cancer pain	LANCET			English	Editorial Material									Beth Israel Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA	Harvard University; Beth Israel Deaconess Medical Center	Portenoy, RK (corresponding author), Beth Israel Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA.	Rportenoy@chpnet.org						American Academy of Pain Medicine and American Pain Society, US OP TREATM CHRON P; [Anonymous], 2000, ACH BAL NAT OP CONTR; Chou R, 2003, J PAIN SYMPTOM MANAG, V26, P1026, DOI 10.1016/j.jpainsymman.2003.03.003; Portenoy RK, 1997, COMPREHENSIVE TXB SU, P563; Rosenblum A, 2003, JAMA-J AM MED ASSOC, V289, P2370, DOI 10.1001/jama.289.18.2370; *ROYAL COLL AN ROY, 2004, REC APPR US OP PERS; Zacny J, 2003, DRUG ALCOHOL DEPEN, V69, P215, DOI 10.1016/S0376-8716(03)00003-6; ZENZ M, 1992, J PAIN SYMPTOM MANAG, V7, P69, DOI 10.1016/0885-3924(92)90116-Y	8	26	27	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	2004	364	9436					739	740		10.1016/S0140-6736(04)16951-1	http://dx.doi.org/10.1016/S0140-6736(04)16951-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849VO	15337386				2022-12-28	WOS:000223569600007
J	Schulz, R; Belle, SH; Czaja, SJ; McGinnis, KA; Stevens, A; Zhang, S				Schulz, R; Belle, SH; Czaja, SJ; McGinnis, KA; Stevens, A; Zhang, S			Long-term care placement of dementia patients and caregiver health and well-being	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NURSING-HOME PLACEMENT; ALZHEIMERS-DISEASE; FAMILY CAREGIVERS; OLDER-PEOPLE; INSTITUTIONALIZATION; BURDEN; REACH; PREDICTORS; PROJECT; TIME	Context Placing a relative with dementia into a long-term care facility is common among caregivers. Placement transition and factors that affect caregiver health and well-being after placement of the patient are not well described. Objective To assess the impact of placing a relative with dementia in a long-term care facility on caregivers' health and well-being. Design, Setting, and Participants Prospective study from 1996 to 2000 of the placement transition in a sample of 1222 caregiver-patient dyads recruited from 6 US sites. A total of 180 patients were placed in a long-term care facility during the 18-month follow-up period. Data collected before and after placement were analyzed to identify factors associated with placement, the nature of contact between caregivers and their institutionalized relatives after placement, and the relation of both of these factors to health outcomes among dementia caregivers. Main Outcome Measures Caregiver depression (symptoms on the Center for Epidemiological Studies-Depression [CES-D] scale; range, 0-60) and anxiety (State Trait Inventory; range, 10-40) and use of prescription medications for depression and anxiety. Results Caregivers who institutionalized their relative reported depressive symptoms and anxiety to be as high as they were while in-home caregivers. Overall CES-D scores for depression did not change from before to after placement (median [IQR], 15.0 [8-24.5] and 15.0 [7.7-28]; P=.64). Overall anxiety scores on the State Trait Inventory also did not change significantly (median [IQR], 22.0 (19-27] before vs 21.1 [18-27] after; P=.21). These effects were most pronounced among caregivers who were married to the patient (P=.02 for depression), visited more frequently (P=.01 for depression and P<.001 for anxiety), and were less satisfied with the help they received from others (P=.003 for depression and P<.001 for anxiety). The use of antidepressants did not change significantly before (21.1%) to after (17.9%) placement (P=.16). The use of anxiolytics before to after placement increased from 14.6% to 19% (P=.02), and nearly half of caregivers (48.3%) were at risk for clinical depression following placement of their relative. Conclusions The transition to institutional care is particularly difficult for spouses, almost half of whom visit the patient daily and continue to provide help with physical care during their visits. Clinical interventions that better prepare the caregiver for a placement transition and treat their depression and anxiety following placement may be of great benefit to these individuals.	Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA 15260 USA; Univ Miami, Dept Psychiat & Behav Sci, Miami, FL 33152 USA; Univ Miami, Ctr Aging, Miami, FL 33152 USA; Univ Alabama Birmingham, Div Gerontol & Geriatr Med, Birmingham, AL USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Miami; University of Miami; University of Alabama System; University of Alabama Birmingham	Schulz, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Psychiat, 121 Univ Pl,6th Floor, Pittsburgh, PA 15260 USA.	schulz@pitt.edu			NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P60MD000207] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL065112] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH052247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [U01NR004261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG013305] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL65112] Funding Source: Medline; NIA NIH HHS [UO1-AG13305] Funding Source: Medline; NIMHD NIH HHS [P60 MD000207] Funding Source: Medline; NIMH NIH HHS [P30 MH52247] Funding Source: Medline; NINR NIH HHS [U01-NR04261] Funding Source: Medline	NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		BOWKER AH, 1948, J AM STAT ASSOC, V43, P572, DOI 10.2307/2280710; COLLINS C, 1994, NURS RES, V43, P221; COX DR, 1972, J R STAT SOC B, V34, P187; Dellasega C, 1991, J Community Health Nurs, V8, P197, DOI 10.1207/s15327655jchn0804_2; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gitlin LN, 2003, PSYCHOL AGING, V18, P361, DOI 10.1037/0882-7974.18.3.361; GRAFSTROM M, 1995, ALZ DIS ASSOC DIS, V9, P78, DOI 10.1097/00002093-199509020-00004; Hebert R, 2001, J GERONTOL A-BIOL, V56, pM693, DOI 10.1093/gerona/56.11.M693; Heyman A, 1997, NEUROLOGY, V48, P1304, DOI 10.1212/WNL.48.5.1304; Kaplan L, 1999, FAM PROCESS, V38, P85, DOI 10.1111/j.1545-5300.1999.00085.x; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Keefe J, 2000, FAM RELAT, V49, P235, DOI 10.1111/j.1741-3729.2000.00235.x; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Levesque L., 2000, AM OURNAL ALZHEIMERS, V15, P229; Magaziner J, 2000, GERONTOLOGIST, V40, P663, DOI 10.1093/geront/40.6.663; McDowell I, 2002, GERONTOLOGIST, V42, P643; MONTGOMERY RJV, 1994, J GERONTOL, V49, pS62, DOI 10.1093/geronj/49.2.S62; Pot AM, 2001, INT J GERIATR PSYCH, V16, P273, DOI 10.1002/gps.331; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROTHENHAEUSLER HB, 1997, Z GERONTOPSYCHOL PSY, V10, P61; Schulz R, 2001, JAMA-J AM MED ASSOC, V285, P3123, DOI 10.1001/jama.285.24.3123; Schulz R, 2003, NEW ENGL J MED, V349, P1936, DOI 10.1056/NEJMsa035373; Schulz R, 1997, ANN BEHAV MED, V19, P110, DOI 10.1007/BF02883327; Schulz R, 2002, GERONTOLOGIST, V42, P589, DOI 10.1093/geront/42.5.589; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Smith GE, 2000, J AM GERIATR SOC, V48, P519, DOI 10.1111/j.1532-5415.2000.tb04998.x; Spielberger C. D., 1973, MANUAL STATE TRAIT I; Stevens A, 2004, J AGING HEALTH, V16, P375, DOI 10.1177/0898264304264206; STEVENS AB, IN PRESS AGING MENT; Tarlow BJ, 2004, RES AGING, V26, P429, DOI 10.1177/0164027504264493; TERI L, 1992, PSYCHOL AGING, V7, P622, DOI 10.1037/0882-7974.7.4.622; Tornatore JB, 2002, GERONTOLOGIST, V42, P497, DOI 10.1093/geront/42.4.497; Whitlatch CJ, 2001, GERONTOLOGIST, V41, P462, DOI 10.1093/geront/41.4.462; Wisniewski SR, 2003, PSYCHOL AGING, V18, P375, DOI 10.1037/0882-7974.18.3.375; Yaffe K, 2002, JAMA-J AM MED ASSOC, V287, P2090, DOI 10.1001/jama.287.16.2090; Yamamoto-Mitani N, 2002, J GERONTOL B-PSYCHOL, V57, pS234, DOI 10.1093/geronb/57.4.S234; ZARIT SH, 1992, GERONTOLOGIST, V32, P665, DOI 10.1093/geront/32.5.665	37	228	234	1	34	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2004	292	8					961	967		10.1001/jama.292.8.961	http://dx.doi.org/10.1001/jama.292.8.961			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	847WR	15328328				2022-12-28	WOS:000223429200021
J	Wilson, APR; Gibbons, C; Reeves, BC; Hodgson, B; Liu, M; Plummer, D; Krukowski, ZH; Bruce, J; Wilson, J; Pearson, A				Wilson, APR; Gibbons, C; Reeves, BC; Hodgson, B; Liu, M; Plummer, D; Krukowski, ZH; Bruce, J; Wilson, J; Pearson, A			Surgical wound infection as a performance indicator: agreement of common definitions of wound infection in 4773 patients	BRITISH MEDICAL JOURNAL			English	Article							SCORING METHOD; VALIDATION; ASEPSIS	Objective To assess the level of agreement between common definitions of wound infection that might be used as performance indicators. Design Prospective observational study. Setting London teaching hospital group receiving emergency cases as well as tertiary referrals. Participants 4773 surgical patients staying in hospital at least two nights. Main outcome measures Numbers of wound infections based on purulent discharge alone, on the Centers for Disease Control (CDC) definition of wound infection, on the nosocomial infection national surveillance scheme (NINSS) version of the CDC definition, and on the ASEPSIS scoring method. Results 5804 surgical wounds were assessed during 5028 separate hospital admissions. The mean percentage of wounds classified as infected differed substantially with different definitions: 19.2% with the CDC definition (95% confidence interval 18.1% to 20.4%), 14.6% (13.6% to 15.6%) with the NINSS version, 12.3% (11.4% to 13.2%) with pus alone, and 6.8% (6.1% to 7.5%) with an ASEPSIS score >20. The agreement between definitions with respect to individual wounds was poor. Wounds with pus were automatically defined as infected with the CDC, NINSS, and pus alone definitions, but only 39% (283/714) of these had ASEPSIS scores >20. Conclusions Small changes made to the CDC definition or even in its interpretation, as with the NINSS version, caused major variation in estimated percentage of wound infection. Substantial numbers of wounds were differently classified across the grades of infection. A single definition used consistently can show changes in percentage wound infection over time at a single centre, but differences in interpretation prevent comparison between different centres.	UCL Hosp, Dept Clin Microbiol, London WC1E 6DB, England; London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England; UCL Hosp, Dept Phys Med, London, England; Sch Med, Dept Surg, Aberdeen, Scotland; Sch Med, Dept Publ Hlth, Aberdeen, Scotland; HPA Cent Publ Hlth Lab, Nosomial Infect Surveillance Unit, London, England; Hlth VFM Audit, Natl Audit Off, London, England	University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of Aberdeen; University of Aberdeen	Wilson, APR (corresponding author), UCL Hosp, Dept Clin Microbiol, London WC1E 6DB, England.	peter.wilson@uclh.nhs.uk	Bruce, Julie/G-7588-2014	Bruce, Julie/0000-0002-8462-7999; Wilson, Andrew Peter Richard/0000-0003-1109-5650				ARMITAGE P, 2001, STAT METHODS MED RES, P703; Beaujean D, 2002, EUR J CLIN MICROBIOL, V21, P444, DOI 10.1007/s10096-002-0745-x; Bruce J, 2001, Health Technol Assess, V5, P1; BYRNE DJ, 1989, BIOMED PHARMACOTHER, V43, P669, DOI 10.1016/0753-3322(89)90085-1; Colson M, 2003, INT J QUAL HEALTH C, V15, P445, DOI 10.1093/intqhc/mzg070; CRUSE PJE, 1980, SURG CLIN N AM, V60, P27; *DEP HLTH, 2001, NHS PLAN TECHN SUPPL, P57; DONALDSON I, 2003, PLCMO20034 DEP HLTH; DONALDSON L, 2003, PLCMO20034 DEP HLTH; Gaynes R, 2001, EMERG INFECT DIS, V7, P295, DOI 10.3201/eid0702.010230; GILEGEA MJ, 1987, INFECT CONT HOSP EP, V8, P277, DOI 10.1017/S0195941700066236; HORAN TC, 1992, INFECT CONT HOSP EP, V13, P606; Lilford R, 2004, LANCET, V363, P1147, DOI 10.1016/S0140-6736(04)15901-1; MEAD PB, 1986, ARCH SURG-CHICAGO, V121, P458; Plowman R., 1999, SOCIOECONOMIC BURDEN; Smith BH, 1997, PAIN, V71, P141, DOI 10.1016/S0304-3959(97)03347-2; Wilson APR, 1998, J HOSP INFECT, V39, P119, DOI 10.1016/S0195-6701(98)90325-5; WILSON APR, 1986, LANCET, V1, P1208; WILSON APR, 1986, LANCET, V1, P311; Wilson JA, 2002, J HOSP INFECT, V52, P114, DOI 10.1053/jhin.2002.1272	20	133	141	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 25	2004	329	7468					720	723		10.1136/bmj.38232.646227.DE	http://dx.doi.org/10.1136/bmj.38232.646227.DE			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	858RV	15367425	Green Published, Green Accepted, Bronze, Green Submitted			2022-12-28	WOS:000224210300020
J	Coleman, FC; Figueira, WF; Ueland, JS; Crowder, LB				Coleman, FC; Figueira, WF; Ueland, JS; Crowder, LB			The impact of United States recreational fisheries on marine fish populations	SCIENCE			English	Article							SOUTH-AFRICA; CAPE COAST; MANAGEMENT; ECOSYSTEMS; NORTHWESTERN; MORTALITY; GROUPERS; SPARIDAE; FLORIDA; WATERS	We evaluated the commercial and recreational fishery landings over the past 22 years, first at the national level, then for populations of concern (those that are overfished or experiencing overfishing), and finally by region. Recreational landings in 2002 account for 4% of total marine fish landed in the United States. With large industrial fisheries excluded (e.g., menhaden and Pollock), the recreational component rises to 10%. Among populations of concern, recreational landings in 2002 account for 23% of the total nationwide, rising to 38% in the South Atlantic and 64% in the Gulf of Mexico. Moreover, it affects many of the most-valued overfished species-including red drum, bocaccio, and red snapper-alI of which are taken primarily in the recreational fishery.	Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA; Duke Univ, Nicholas Sch Environm & Earth Sci, Beaufort, NC 28516 USA; Florida State Univ, Dept Geog, Tallahassee, FL 32306 USA	State University System of Florida; Florida State University; Duke University; State University System of Florida; Florida State University	Coleman, FC (corresponding author), Florida State Univ, Dept Biol Sci, B-157, Tallahassee, FL 32306 USA.	coleman@bio.fsu.edu	Figueira, Will/A-5163-2009	Figueira, Will/0000-0001-9472-8710				BENNETT BA, 1993, S AFR J MARINE SCI, V13, P1; Botsford LW, 1997, SCIENCE, V277, P509, DOI 10.1126/science.277.5325.509; BUXTON CD, 1991, S AFR J MARINE SCI, V10, P285; Clapp D. F., 1989, N AM J FISH MANAGE, V9, P81, DOI DOI 10.1577/1548-8675(1989)009<0081:HMOSBC>2.3.CO;2; COLLINS MR, 1999, AM J FISH MANAGE, V19, P828; Friedlander AM, 2002, MAR ECOL PROG SER, V230, P253, DOI 10.3354/meps230253; Gitschlag Gregg R., 1994, North American Journal of Fisheries Management, V14, P131, DOI 10.1577/1548-8675(1994)014<0131:FEOSRO>2.3.CO;2; GUCCIONE DV, 1999, 98FEG02 FISH GRANT P; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Jouvenel JY, 2001, AQUAT CONSERV, V11, P1, DOI 10.1002/aqc.424; MALCHOFF MH, 1995, NA36FD0102 NOAANMFS; McGovern JC, 2002, N AM J FISH MANAGE, V22, P1151, DOI 10.1577/1548-8675(2002)022<1151:TASDIL>2.0.CO;2; Muoneke Maurice I., 1994, Reviews in Fisheries Science, V2, P123; Myers RA, 2003, NATURE, V423, P280, DOI 10.1038/nature01610; *NAT RES COUNC, 2002, SUST MAR FISH; National Research Council, 2002, EFF TRAWL DREDG SEAF; *NMFS, 1996, NMFSFSPO19 NOAA; PANKHURST NW, 1992, AUST J MAR FRESH RES, V43, P345, DOI 10.1071/MF9920345; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; PAULY D, 1995, TRENDS ECOL EVOL, V10, P430, DOI 10.1016/S0169-5347(00)89171-5; PAULY D, 2002, PERFECT OCEAN; QUINN SP, 1989, N AM J FISH MANAGE, V9, P86, DOI DOI 10.1577/1548-8675(1989)009<0086:RR0VRL>2.3.C0;2; Schroeder DM, 2002, CAL COOP OCEAN FISH, V43, P182; Sluka RD, 1998, FISH B-NOAA, V96, P388; Sutinen JG, 2003, MAR POLICY, V27, P471, DOI 10.1016/S0308-597X(03)00079-4; Taylor RG, 2001, N AM J FISH MANAGE, V21, P70, DOI 10.1577/1548-8675(2001)021<0070:CARMRO>2.0.CO;2; Thrush SF, 2002, ANNU REV ECOL SYST, V33, P449, DOI 10.1146/annurev.ecolsys.33.010802.150515; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494; Westera M, 2003, J EXP MAR BIOL ECOL, V294, P145, DOI 10.1016/S0022-0981(03)00268-5; Wilson RR, 1996, B MAR SCI, V58, P234; Young GC, 1999, MAR FRESHWATER RES, V50, P633, DOI 10.1071/MF98139	31	468	478	2	154	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	2004	305	5692					1958	1960		10.1126/science.1100397	http://dx.doi.org/10.1126/science.1100397			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	857RM	15331771				2022-12-28	WOS:000224136000047
J	Stanfield, RL; Dooley, H; Flajnik, MF; Wilson, IA				Stanfield, RL; Dooley, H; Flajnik, MF; Wilson, IA			Crystal structure of a shark single-domain antibody V region in complex with lysozyme	SCIENCE			English	Article							ANTIGEN RECEPTOR; SOMATIC DIVERSIFICATION; VARIABLE DOMAIN; LOOP STRUCTURES; LIGHT-CHAINS; IMMUNOGLOBULINS; VERTEBRATE; EVOLUTION; FRAGMENT; REARRANGEMENT	Cartilaginous fish are the phylogenetically oldest living organisms known to possess components of the vertebrate adaptive immune system. Key to their immune response are heavy-chain, homodimeric immunoglobulins called new antigen receptors (IgNARs), in which the variable (V) domains recognize antigens with only a single immunoglobulin domain, akin to camelid heavy-chain V domains. The 1.45 angstrom resolution crystal structure of the type I IgNAR V domain in complex with hen egg-white lysozyme (HEL) reveals a minimal antigen-binding domain that contains only two of the three conventional complementarity-determining regions but still binds HEL with nanomolar affinity by means of a binding interface comparable in size to conventional antibodies.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Maryland, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; Natl Aquarium, Baltimore, MD 21202 USA	Scripps Research Institute; Scripps Research Institute; University System of Maryland; University of Maryland Baltimore	Wilson, IA (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wilson@scripps.edu	Stanfield, Robyn/AAH-3190-2019; Dooley, Helen/N-9872-2018	Dooley, Helen/0000-0002-2570-574X; Flajnik, Martin Francis/0000-0002-2792-5084; stanfield, robyn/0000-0001-9521-9184	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038273, R01GM038273] Funding Source: NIH RePORTER; NCRR NIH HHS [RR06603] Funding Source: Medline; NIGMS NIH HHS [GM38273] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; DAVIES J, 1994, FEBS LETT, V339, P285, DOI 10.1016/0014-5793(94)80432-X; Decanniere K, 1999, STRUCTURE, V7, P361, DOI 10.1016/S0969-2126(99)80049-5; Decanniere K, 2001, J MOL BIOL, V313, P473, DOI 10.1006/jmbi.2001.5075; Decanniere K, 2000, J MOL BIOL, V300, P83, DOI 10.1006/jmbi.2000.3839; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; Desmyter A, 2002, J BIOL CHEM, V277, P23645, DOI 10.1074/jbc.M202327200; Desmyter A, 2001, J BIOL CHEM, V276, P26285, DOI 10.1074/jbc.M102107200; Diaz M, 2002, IMMUNOGENETICS, V54, P501, DOI 10.1007/s00251-002-0479-z; Diaz M, 1998, IMMUNOL REV, V162, P13, DOI 10.1111/j.1600-065X.1998.tb01425.x; Dooley H, 2003, MOL IMMUNOL, V40, P25, DOI 10.1016/S0161-5890(03)00084-1; Dumoulin M, 2003, NATURE, V424, P783, DOI 10.1038/nature01870; FLAJNIK MJ, UNPUB; GREENBERG AS, 1995, NATURE, V374, P168, DOI 10.1038/374168a0; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; HINDS KR, 1986, NATURE, V320, P546, DOI 10.1038/320546a0; KOKUBU F, 1988, EMBO J, V7, P3413, DOI 10.1002/j.1460-2075.1988.tb03215.x; Lee SS, 2000, J EXP MED, V191, P1637, DOI 10.1084/jem.191.10.1637; Loris R, 2003, J BIOL CHEM, V278, P28252, DOI 10.1074/jbc.M302336200; MUYLDERMANS S, 1994, PROTEIN ENG, V7, P1129, DOI 10.1093/protein/7.9.1129; Nuttall SD, 2002, FEBS LETT, V516, P80, DOI 10.1016/S0014-5793(02)02506-1; Nuttall SD, 2001, MOL IMMUNOL, V38, P313, DOI 10.1016/S0161-5890(01)00057-8; Pancer Z, 2004, NATURE, V430, P174, DOI 10.1038/nature02740; Richards MH, 2000, MOL BIOL EVOL, V17, P146, DOI 10.1093/oxfordjournals.molbev.a026227; Roux KH, 1998, P NATL ACAD SCI USA, V95, P11804, DOI 10.1073/pnas.95.20.11804; Spinelli S, 1996, NAT STRUCT BIOL, V3, P752, DOI 10.1038/nsb0996-752; Spinelli S, 2000, BIOCHEMISTRY-US, V39, P1217, DOI 10.1021/bi991830w; Spinelli S, 2001, J MOL BIOL, V311, P123, DOI 10.1006/jmbi.2001.4856; Streltsov VA, 2004, P NATL ACAD SCI USA, V101, P12444, DOI 10.1073/pnas.0403509101; Vranken W, 2002, BIOCHEMISTRY-US, V41, P8570, DOI 10.1021/bi012169a	30	201	239	3	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	2004	305	5691					1770	1773		10.1126/science.1101148	http://dx.doi.org/10.1126/science.1101148			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	856IS	15319492				2022-12-28	WOS:000224039500040
J	Weinstein, AR; Sesso, HD; Lee, IM; Cook, NR; Manson, JE; Buring, JE; Gaziano, JM				Weinstein, AR; Sesso, HD; Lee, IM; Cook, NR; Manson, JE; Buring, JE; Gaziano, JM			Relationship of physical activity vs body mass index with type 2 diabetes in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTOR; LIFE-STYLE; MELLITUS; EXERCISE; PREVENTION; OBESITY; DISEASE; WEIGHT; HEALTH; DIET	Context Physical inactivity and body mass index (BMI) are established independent risk factors in the development of type 2 diabetes; however, their comparative importance and joint relationship with diabetes are unclear. Objective To examine the relative contributions and joint association of physical activity and BMI with diabetes. Design, Setting, and Participants Prospective cohort study of 37878 women free of cardiovascular disease, cancer, and diabetes with 6.9 years of mean follow-up. Weight, height, and recreational activities were reported at study entry. Normal weight was defined as a BMI of less than 25; overweight, 25 to less than 30; and obese, 30 or higher. Active was defined as expending more than 1000 kcal on recreational activities per week. Main Outcome Measure Incident type 2 diabetes, defined as anew self-reported diagnosis of diabetes. Results During the follow-up, 1361 cases of incident diabetes occurred. Individually, BMI and physical Activity were significant predictors of incident diabetes. Compared with normal-weight individuals, the multivariate-adjusted hazard ratio (HR) was 3.22 (95% confidence interval [CI], 2.69-3.87) for overweight individuals and 9.09 (95% CI, 7.62-10.8) for obese individuals. For overall activity (kilocalories expended per week), compared with the least active first quartile, the multivariate-adjusted HRs were 0.91 (95% CI, 0.79-1.06) for the second quartile, 0.86 (95% CI, 0.74-1.01) for the third, and 0.82 (95% CI, 0.70-0.97) for the fourth (P for trend=.01). In the combined analyses, overweight and obese participants, whether active or inactive, had significantly elevated risks, compared with normal-weight active individuals. The multivariate-adjusted HRS were 1.15 (95% CI, 0.83-1.59) for normal-weight inactive, 3.68 (95% CI, 2.63-5.15) for overweight active, 4.16 (95% CI, 3.05-5.66) for overweight inactive, 11.5 (95% CI, 8.34-15.9) for obese active, and 11.8 (95% CI, 8.75-16.0) for obese inactive participants. Conclusions Although BMI and physical inactivity are independent predictors of incident diabetes, the magnitude of the association with BMI was greater than with physical activity in combined analyses. These findings underscore the critical importance of adiposity as a determinant of diabetes.	Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston VA Healthcare Syst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Boston Healthcare System	Weinstein, AR (corresponding author), Womens Hlth Ctr Hlth Care Associates, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,Atrium Suite, Boston, MA 02115 USA.	aweinste@bidmc.harvard.edu	Lee, I-Min/ABD-5409-2021		NCI NIH HHS [CA-4799] Funding Source: Medline; NHLBI NIH HHS [HL-65727, HL-43851] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043851, R03HL065727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blumenthal JA, 2000, ARCH INTERN MED, V160, P1947, DOI 10.1001/archinte.160.13.1947; Boden G, 2001, ENDOCRIN METAB CLIN, V30, P801, DOI 10.1016/S0889-8529(05)70216-4; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P30; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; Folsom AR, 2000, AM J PUBLIC HEALTH, V90, P134, DOI 10.2105/AJPH.90.1.134; Gavin JR, 1997, DIABETES CARE, V20, P1183; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; Hu FB, 1999, JAMA-J AM MED ASSOC, V282, P1433, DOI 10.1001/jama.282.15.1433; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Lee IM, 1996, RES Q EXERCISE SPORT, V67, P206, DOI 10.1080/02701367.1996.10607944; Lee IM, 2001, JAMA-J AM MED ASSOC, V285, P1447, DOI 10.1001/jama.285.11.1447; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; PAOLISSO G, 1995, DIABETOLOGIA, V38, P1213, DOI 10.1007/BF00422371; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Rexrode KM, 2000, J WOMEN HEALTH GEN-B, V9, P19, DOI 10.1089/152460900318911; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; Willet W., 1998, NUTR EPIDEMIOLOGY, P74, DOI DOI 10.1093/ACPROF:OSO/9780195122978.001.0001; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991; World Health Organization Expert Committee on Physical Status, 1995, US INT ANTHR REP WHO	27	245	255	2	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2004	292	10					1188	1194		10.1001/jama.292.10.1188	http://dx.doi.org/10.1001/jama.292.10.1188			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851ZA	15353531	Bronze			2022-12-28	WOS:000223723800018
J	Doherty, RB				Doherty, RB			Assessing the new medicare prescription drug law	ANNALS OF INTERNAL MEDICINE			English	Article								The Medicare Modernization Act (MMA) is the product of a political compromise to attract moderate Republicans and enough Democrats without losing Republican conservatives. The compromise offered more private health plans to beneficiaries while maintaining and improving traditional Medicare's benefits. This compromise did not settle the debate over the legislation, which is a major issue in the 2004 elections. Voters poorly understand the law because of its complexity. In this paper, I explain how the policy decisions made by the U.S. Congress have contributed to the law's complexity and controversy. I examine the new private health plan options that will be offered to beneficiaries, improvements made to traditional Medicare, and the impact of introducing income-based determinations into Medicare. I also discuss the impact of the drug benefit on beneficiaries in different income and assets categories and Congress's decision to prohibit the federal government from directly negotiating prices with drug manufacturers. I conclude by assessing the major claims made by critics and proponents. Both might be more circumspect in their assessments of the law's impact, since it is impossible to predict how a law of such complexity, with so many human variables, will work out in the end. The MMA is a worthwhile but imperfect effort to extend drug coverage to seniors who are most in need. It deserves neither condemnation nor indiscriminate praise but instead a commitment to help it succeed.	Amer Coll Physicians, Customer Serv, Philadelphia, PA 19106 USA	American College of Physicians	Doherty, RB (corresponding author), Amer Coll Physicians, Customer Serv, 190 N Independence Mall W, Philadelphia, PA 19106 USA.							*AARP, MED CHANG COULD AFF; Altman DE, 2004, NEW ENGL J MED, V350, P9, DOI 10.1056/NEJMp038224; BALL RM, 1997, MED PREPARING CHALLE; BUSH GW, 2003, REMARKS PRESIDENT SI; Holtz-Eakin D, 2004, COMMUNICATION   0123; *KAIS FAM FDN, 2004, MARCH APR 2004 KAIS; KENNEDY EM, 2003, DINGELL ANNOUNCE THE; 2003, ANG SEN CONTR EUPH W; 2004, PRESCR DRUG COV MED	9	25	25	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	2004	141	5					391	395		10.7326/0003-4819-141-5-200409070-00100	http://dx.doi.org/10.7326/0003-4819-141-5-200409070-00100			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CW	15353431				2022-12-28	WOS:000223733800008
J	Pickhardt, PJ; Nugent, PA; Mysliwiec, PA; Choi, JR; Schindler, WR				Pickhardt, PJ; Nugent, PA; Mysliwiec, PA; Choi, JR; Schindler, WR			Location of adenomas missed by optical colonoscopy	ANNALS OF INTERNAL MEDICINE			English	Article							VIRTUAL COLONOSCOPY; COLORECTAL NEOPLASIA; POLYPS; POLYPECTOMY; COLONOGRAPHY; SURVEILLANCE; CANCER; COLON; RATES	Background: Previous estimates of the adenoma miss rate with optical colonoscopy (OC) are hindered by the use of OC as its own reference standard. Objective: To evaluate the frequency and characteristics of colorectal neoplasms that are missed prospectively on OC by using virtual colonoscopy (VC) as a separate reference standard. Design: Prospective, multicenter screening trial. Setting: 3 medical centers. Participants: 1233 asymptomatic adults who underwent same-day VC and OC. Measurements: Colorectal neoplasms (adenomatous polyps) missed at OC before VC results were unblinded. Results: Fourteen (93.3%) of 15 nonrectal neoplasms were located on a fold; 10 (71.4%) of these were located on the backside of a fold. Five (83.3%) of 6 rectal lesions were located within 10 cm of the anal verge. Limitations: Estimation of the OC miss rate depended on polyp detection on both VC and second-look OC and therefore underestimates the true OC miss rate, particularly for smaller polyps. Conclusions: Most clinically significant adenomas missed prospectively on OC are located behind a fold or near the anal verge. The 12% OC miss rate for large adenomas (greater than or equal to10 mm) when state-of-the-art 3-dimensional VC is used as a separate reference standard is increased from the previous 0% to 6% estimates derived by using OC as its own reference standard.	Univ Wisconsin, Sch Med, Dept Radiol, Clin Sci Ctr E3311, Madison, WI 53792 USA; Uniformed Serv Univ Hlth Sci, Natl Naval Med Ctr, Bethesda, MD 20814 USA; NCI, Bethesda, MD 20892 USA; Walter Reed Army Med Ctr, Washington, DC 20307 USA; Naval Med Ctr San Diego, San Diego, CA USA	University of Wisconsin System; University of Wisconsin Madison; Uniformed Services University of the Health Sciences - USA; Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Navy; Naval Medical Center San Diego	Pickhardt, PJ (corresponding author), Univ Wisconsin, Sch Med, Dept Radiol, Clin Sci Ctr E3311, 600 Highland Ave, Madison, WI 53792 USA.	ppickhardt@mail.radiology.wisc.edu						Bond JH, 2003, ENDOSCOPY, V35, P27, DOI 10.1055/s-2003-36410; Bond JH, 2001, ENDOSCOPY, V33, P454, DOI 10.1055/s-2001-14266; Cotton PB, 2004, JAMA-J AM MED ASSOC, V291, P1713, DOI 10.1001/jama.291.14.1713; Gopalswamy N, 1997, GASTROINTEST ENDOSC, V46, P497, DOI 10.1016/S0016-5107(97)70003-8; GROBO JL, 1982, AM J JASTROENTEROL, V77, P865; HIXSON LJ, 1991, GASTROINTEST ENDOSC, V37, P125, DOI 10.1016/S0016-5107(91)70668-8; KRONBORG O, 1981, SCAND J GASTROENTERO, V16, P879, DOI 10.3109/00365528109181817; NEUGUT AI, 1995, GASTROENTEROLOGY, V108, P402, DOI 10.1016/0016-5085(95)90066-7; Pickhardt PJ, 2004, NEW ENGL J MED, V350, P1149; Pickhardt PJ, 2003, AM J ROENTGENOL, V181, P799, DOI 10.2214/ajr.181.3.1810799; Pickhardt PJ, 2003, NEW ENGL J MED, V349, P2191, DOI 10.1056/NEJMoa031618; Pineau BC, 2003, GASTROENTEROLOGY, V125, P304, DOI 10.1016/S0016-5085(03)00885-0; Rex DK, 2003, AM J GASTROENTEROL, V98, P1504, DOI 10.1016/S0002-9270(03)00244-2; Rex DK, 1997, GASTROENTEROLOGY, V112, P24, DOI 10.1016/S0016-5085(97)70214-2; SAKAI Y, 2000, GASTROENTEROLOGIC EN, V2, P1253; Tada M, 1997, DIS COLON RECTUM, V40, P618, DOI 10.1007/BF02055390; Villavicencio R T, 2000, Semin Gastrointest Dis, V11, P185; WAYE JD, 1982, ENDOSCOPY, V14, P79, DOI 10.1055/s-2007-1021585; Winawer SJ, 2000, NEW ENGL J MED, V342, P1766, DOI 10.1056/NEJM200006153422401	19	337	346	1	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	2004	141	5					352	359		10.7326/0003-4819-141-5-200409070-00009	http://dx.doi.org/10.7326/0003-4819-141-5-200409070-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	852CW	15353426				2022-12-28	WOS:000223733800003
J	Astrup, A; Larsen, TM; Harper, A				Astrup, A; Larsen, TM; Harper, A			Atkins and other low-carbohydrate diets: hoax or an effective tool for weight loss?	LANCET			English	Review							LOW-FAT DIET; CARDIOVASCULAR RISK-FACTORS; RANDOMIZED-TRIAL; KETOGENIC DIET; OBESITY; PROTEIN; ADOLESCENTS; LIPIDS	Context The Atkins diet books have sold more than 45 million copies over 40 years, and in the obesity epidemic this diet and accompanying Atkins food products are popular. The diet claims to be effective at producing weight loss despite ad-libitum consumption of fatty meat, butter, and other high-fat dairy products, restricting only the intake of carbohydrates to under 30 g a day. Low-carbohydrate diets have been regarded as fad diets, but recent research questions this view. Starting point A systematic review of low-carbohydrate diets found that the weight loss achieved is associated with the duration of the diet and restriction of energy intake, but not with restriction of carbohydrates. Two groups have reported longer-term randomised studies that compared instruction in the low-carbohydrate diet with a low-fat calorie-reduced diet in obese patients (N Engl J Med 2003; 348: 2082-90; Ann Intern Med 2004; 140: 778-85). Both trials showed better weight loss on the low-carbohydrate diet after 6 months, but no difference after 12 months. Where next? The apparent paradox that ad-libitum intake of high-fat foods produces weight loss might be due to severe restriction of carbohydrate depleting glycogen stores, leading to excretion of bound water, the ketogenic nature of the diet being appetite suppressing, the high protein-content being highly satiating and reducing spontaneous food intake, or limited food choices leading to decreased energy intake. Long-term studies are needed to measure changes in nutritional status and body composition during the low-carbohydrate diet, and to assess fasting and postprandial cardiovascular risk factors and adverse effects. Without that information, low-carbohydrate diets cannot be recommended.	RVA Univ, Ctr Adv Food Res, Dept Human Nutr, DK-1958 Frederiksberg C, Denmark		Astrup, A (corresponding author), RVA Univ, Ctr Adv Food Res, Dept Human Nutr, DK-1958 Frederiksberg C, Denmark.	ast@kvi.dk	Biguzzi, Felipe A/E-4724-2015; Meinert Larsen, Thomas/D-4818-2015; Astrup, Arne/B-1407-2015	Meinert Larsen, Thomas/0000-0001-7621-3131; Astrup, Arne/0000-0001-8968-8996				*ATK NUTR INC, 2004, INTRO ATK HOM; ATKINS RC, 1998, DR ATKINS NEW DIET R; BANTING W, 1869, COMMUNICATION; Best TH, 2000, NEUROLOGY, V54, P2328, DOI 10.1212/WNL.54.12.2328; Bravata DM, 2003, JAMA-J AM MED ASSOC, V289, P1837, DOI 10.1001/jama.289.14.1837; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; Daniels SR, 2003, J PEDIATR-US, V142, P225, DOI 10.1067/mpd.2003.114; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Freedman MR, 2001, OBES RES, V9, p1S, DOI 10.1038/oby.2001.113; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Krauss RM, 2000, CIRCULATION, V102, P2284; Kwiterovich PO, 2003, JAMA-J AM MED ASSOC, V290, P912, DOI 10.1001/jama.290.7.912; Mikkelsen PB, 2000, AM J CLIN NUTR, V72, P1135; Porrini M, 1997, PHYSIOL BEHAV, V62, P563, DOI 10.1016/S0031-9384(97)00162-5; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; SEARS B, 1995, ZONE; Sharman MJ, 2004, J NUTR, V134, P880, DOI 10.1093/jn/134.4.880; Singh RB, 2002, LANCET, V360, P1455, DOI 10.1016/S0140-6736(02)11472-3; Skov AR, 1999, INT J OBESITY, V23, P528, DOI 10.1038/sj.ijo.0800867; Sondike SB, 2003, J PEDIATR-US, V142, P253, DOI 10.1067/mpd.2003.4; Stern L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007; Westman EC, 2002, AM J MED, V113, P30, DOI 10.1016/S0002-9343(02)01129-4; Willi SM, 1998, PEDIATRICS, V101, P61, DOI 10.1542/peds.101.1.61; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006	24	270	275	6	145	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2004	364	9437					897	899		10.1016/S0140-6736(04)16986-9	http://dx.doi.org/10.1016/S0140-6736(04)16986-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KY	15351198				2022-12-28	WOS:000223685200037
J	Christiano, AM				Christiano, AM			Epithelial stem cells: Stepping out of their niche	CELL			English	Editorial Material							HAIR FOLLICLE; SKIN	In this issue of Cell, Blanpain et al. (2004) have shown that two subpopulations of cells exist within the hair follicle stem cell niche. Despite being partially differentiated, clonal populations of suprabasal bulge region cells can regenerate skin and hair follicles as well as a new stem cell niche. The findings suggest that early lineage commitments of epithelial cells in the hair follicle may be reversible.	Columbia Univ Coll Phys & Surg, Dept Dermatol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Columbia University; Columbia University	Christiano, AM (corresponding author), Columbia Univ Coll Phys & Surg, Dept Dermatol, 630 W 168th St, New York, NY 10032 USA.							AKIYAMA M, 1995, J INVEST DERMATOL, V105, P844, DOI 10.1111/1523-1747.ep12326649; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; NARISAWA Y, 1994, J INVEST DERMATOL, V102, P506, DOI 10.1111/1523-1747.ep12373164; Nishimura EK, 2002, NATURE, V416, P854, DOI 10.1038/416854a; Panteleyev AA, 2001, J CELL SCI, V114, P3419; Sieber-Blum Maya, 2004, Birth Defects Res C Embryo Today, V72, P162, DOI 10.1002/bdrc.20008; STOHR P, 1903, ANAT HEFTE, V23, P1; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436	10	39	44	1	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	2004	118	5					530	532		10.1016/j.cell.2004.08.024	http://dx.doi.org/10.1016/j.cell.2004.08.024			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	852BN	15339656	Bronze			2022-12-28	WOS:000223730300002
J	Ericson, LM; Fan, H; Peng, HQ; Davis, VA; Zhou, W; Sulpizio, J; Wang, YH; Booker, R; Vavro, J; Guthy, C; Parra-Vasquez, ANG; Kim, MJ; Ramesh, S; Saini, RK; Kittrell, C; Lavin, G; Schmidt, H; Adams, WW; Billups, WE; Pasquali, M; Hwang, WF; Hauge, RH; Fischer, JE; Smalley, RE				Ericson, LM; Fan, H; Peng, HQ; Davis, VA; Zhou, W; Sulpizio, J; Wang, YH; Booker, R; Vavro, J; Guthy, C; Parra-Vasquez, ANG; Kim, MJ; Ramesh, S; Saini, RK; Kittrell, C; Lavin, G; Schmidt, H; Adams, WW; Billups, WE; Pasquali, M; Hwang, WF; Hauge, RH; Fischer, JE; Smalley, RE			Macroscopic, neat, single-walled carbon nanotube fibers	SCIENCE			English	Article							PREFERRED ORIENTATION; ROPES	Well-aligned macroscopic fibers composed solely of single-walled carbon nanotubes (SWNTs) were produced by conventional spinning. Fuming sulfuric acid charges SWNTs and promotes their ordering into an aligned phase of individual mobile SWNTs surrounded by acid anions. This ordered dispersion was extruded via solution spinning into continuous lengths of macroscopic neat SWNT fibers. Such fibers possess interesting structural composition and physical properties.	Rice Univ, Ctr Nanoscale Sci & Technol, Houston, TX 77005 USA; Rice Univ, Carbon Nanotechnol Lab, Houston, TX 77005 USA; Rice Univ, Dept Chem Engn, Houston, TX 77005 USA; Rice Univ, Dept Chem, Houston, TX 77005 USA; Univ Penn, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA; Carbon Consultat, Swarthmore, PA 19081 USA	Rice University; Rice University; Rice University; Rice University; University of Pennsylvania	Hwang, WF (corresponding author), Rice Univ, Ctr Nanoscale Sci & Technol, Houston, TX 77005 USA.	whwang@rice.edu; smalley@rice.edu	Parra-Vasquez, Nicholas/E-9001-2013; Pasquali, Matteo/A-2489-2008; Adams, Wade/A-7305-2010; Hauge, Robert H/A-7008-2011; Wang, YuHuang/B-4738-2009; Zhou, Wei/C-6504-2008	Pasquali, Matteo/0000-0001-5951-395X; Hauge, Robert H/0000-0002-3656-0152; Wang, YuHuang/0000-0002-5664-1849; Zhou, Wei/0000-0002-5461-3617; Davis, Virginia/0000-0003-3126-3893				Allan DR, 2002, J CHEM SOC DALTON, P1867, DOI 10.1039/b109395a; Andrews R, 1999, APPL PHYS LETT, V75, P1329, DOI 10.1063/1.124683; Besteman K, 2003, NANO LETT, V3, P727, DOI 10.1021/nl034139u; Bronikowski MJ, 2001, J VAC SCI TECHNOL A, V19, P1800, DOI 10.1116/1.1380721; Che JW, 2000, NANOTECHNOLOGY, V11, P65, DOI 10.1088/0957-4484/11/2/305; Chiang IW, 2001, J PHYS CHEM B, V105, P1157, DOI 10.1021/jp003453z; Dalton AB, 2003, NATURE, V423, P703, DOI 10.1038/423703a; Davis VA, 2004, MACROMOLECULES, V37, P154, DOI 10.1021/ma0352328; Duesberg GS, 2000, PHYS REV LETT, V85, P5436, DOI 10.1103/PhysRevLett.85.5436; ERICSON LM, 2003, THESIS RICE U HOUSTO; Fischer JE, 2003, J APPL PHYS, V93, P2157, DOI 10.1063/1.1536733; Fischer JE, 1997, PHYS REV B, V55, pR4921, DOI 10.1103/PhysRevB.55.R4921; Gommans HH, 2000, J APPL PHYS, V88, P2509, DOI 10.1063/1.1287128; Hone J, 1999, PHYS REV B, V59, pR2514, DOI 10.1103/PhysRevB.59.R2514; Jiang KL, 2002, NATURE, V419, P801, DOI 10.1038/419801a; Krishnan A, 1998, PHYS REV B, V58, P14013, DOI 10.1103/PhysRevB.58.14013; Kumar S, 2002, MACROMOLECULES, V35, P9039, DOI 10.1021/ma0205055; Li YL, 2004, SCIENCE, V304, P276, DOI 10.1126/science.1094982; McEuen PL, 2002, IEEE T NANOTECHNOL, V1, P78, DOI 10.1109/TNANO.2002.1005429; Nikolaev P, 1999, CHEM PHYS LETT, V313, P91, DOI 10.1016/S0009-2614(99)01029-5; Ramesh S, 2004, J PHYS CHEM B, V108, P8794, DOI 10.1021/jp036971t; Seidel R, 2004, NANO LETT, V4, P831, DOI 10.1021/nl049776e; SMALLEY RE, 2003, Patent No. 20030170166US; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Tsabba Y, 2002, J POLYM SCI POL PHYS, V40, P1087, DOI 10.1002/polb.10168; Vigolo B, 2000, SCIENCE, V290, P1331, DOI 10.1126/science.290.5495.1331; Vigolo B, 2002, APPL PHYS LETT, V81, P1210, DOI 10.1063/1.1497706; Walters DA, 1999, APPL PHYS LETT, V74, P3803, DOI 10.1063/1.124185; Wei BQ, 2002, NANO LETT, V2, P1105, DOI [10.1021/nl025719e, 10.1021/n1025719e]; Yu MF, 2000, PHYS REV LETT, V84, P5552, DOI 10.1103/PhysRevLett.84.5552; Zhou W, 2004, J APPL PHYS, V95, P649, DOI 10.1063/1.1627457; Zhu HW, 2002, SCIENCE, V296, P884, DOI 10.1126/science.1066996	33	700	744	14	433	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1447	1450		10.1126/science.1101398	http://dx.doi.org/10.1126/science.1101398			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353797				2022-12-28	WOS:000223761900043
J	Gardner, A; West, SA				Gardner, A; West, SA			Spite among siblings	SCIENCE			English	Editorial Material							POLYEMBRYONIC WASP; COMPETITION		Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Gardner, A (corresponding author), Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JT, Midlothian, Scotland.	andy.gardner@ed.ac.uk	West, Stuart A/M-3608-2014; Gardner, Andy/K-5353-2013	West, Stuart A/0000-0003-2152-3153; Gardner, Andy/0000-0002-1304-3734				Donnell DM, 2004, P NATL ACAD SCI USA, V101, P10095, DOI 10.1073/pnas.0403625101; Frank, 1998, FDN SOCIAL EVOLUTION; Gardner A, 2004, J EVOLUTION BIOL, V17, P1195, DOI 10.1111/j.1420-9101.2004.00775.x; Giron D, 2004, NATURE, V430, P676, DOI 10.1038/nature02721; GIRON D, 2004, P R SOC B S     0617, DOI DOI 10.1098/RSB1.2004.0205; Grafen A., 1985, Oxford Surveys in Evolutionary Biology, V2, P28; Griffin AS, 2004, NATURE, V430, P1024, DOI 10.1038/nature02744; HAMILTON WD, 1963, AM NAT, V97, P354, DOI 10.1086/497114; HAMILTON WD, 1970, NATURE, V228, P1218, DOI 10.1038/2281218a0	9	23	24	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1413	1414		10.1126/science.1103635	http://dx.doi.org/10.1126/science.1103635			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353789				2022-12-28	WOS:000223761900032
J	Tsao, H; Atkins, MB; Sober, AJ				Tsao, H; Atkins, MB; Sober, AJ			Medical progress - Management of cutaneous melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SENTINEL LYMPH-NODE; COOPERATIVE-ONCOLOGY-GROUP; HIGH-DOSE INTERFERON-ALPHA-2B; HIGH-RISK MELANOMA; PROSPECTIVE RANDOMIZED-TRIAL; METASTATIC MELANOMA; MALIGNANT-MELANOMA; PROGNOSTIC-FACTORS; ADJUVANT THERAPY; PHASE-III		Massachusetts Gen Hosp, Dept Dermatol, Melanoma Ctr, Boston, MA 02114 USA; Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Biol Therapy Program, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Cutaneous Oncol Program, Boston, MA 02215 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Tsao, H (corresponding author), Massachusetts Gen Hosp, Dept Dermatol, Melanoma Ctr, BArtlett 622,48 Blossom St, Boston, MA 02114 USA.							Agarwala Sanjiv S., 1996, Current Opinion in Oncology, V8, P167, DOI 10.1097/00001622-199603000-00015; Agarwala SS, 2002, J CLIN ONCOL, V20, P125, DOI 10.1200/JCO.20.1.125; ALBERT LS, 1990, J AM ACAD DERMATOL, V22, P69, DOI 10.1016/0190-9622(90)70010-F; Allen IE, 1998, CANC THER, V1, P168; Anderson C M, 1995, Oncology (Williston Park), V9, P1149; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Atkins MB, 2002, CLIN CANCER RES, V8, P3075; ATKINS MB, 2000, PRINCIPLES PRACTICE, P50; ATKINS MB, 2003, P AN M AM SOC CLIN, V22, P708; Atkins MB, 2003, CUTANEOUS MELANOMA, P589; Balch CM, 2000, ANN SURG ONCOL, V7, P87, DOI 10.1007/s10434-000-0087-9; Balch CM, 2001, ANN SURG ONCOL, V8, P101, DOI 10.1007/s10434-001-0101-x; Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; Berd D, 1997, J CLIN ONCOL, V15, P2359, DOI 10.1200/JCO.1997.15.6.2359; Bergen M, 2003, EXPERT OPIN BIOL TH, V3, P377, DOI 10.1517/eobt.3.2.377.21150; BERWICK M, 2003, CUTANEOUS MELANOMA, V15; Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; Bleicher RJ, 2003, J CLIN ONCOL, V21, P1326, DOI 10.1200/JCO.2003.06.123; BLISS JM, 1995, INT J CANCER, V62, P367, DOI 10.1002/ijc.2910620402; Bystryn JC, 2001, CLIN CANCER RES, V7, P1882; Carlson GW, 2003, ANN SURG ONCOL, V10, P575, DOI 10.1245/ASO.2003.03.054; Carlson GW, 2003, ANN SURG ONCOL, V10, P408, DOI 10.1245/ASO.2003.03.055; Carson KF, 1996, AM J SURG PATHOL, V20, P834, DOI 10.1097/00000478-199607000-00006; Cascinelli N, 1998, SEMIN SURG ONCOL, V14, P272, DOI 10.1002/(SICI)1098-2388(199806)14:4<272::AID-SSU2>3.0.CO;2-#; Cascinelli N, 1998, LANCET, V351, P793, DOI 10.1016/S0140-6736(97)08260-3; Cascinelli N, 2001, LANCET, V358, P866, DOI 10.1016/S0140-6736(01)06068-8; CLARK WH, 1978, ARCH DERMATOL, V114, P732, DOI 10.1001/archderm.114.5.732; Cochran AJ, 2001, MODERN PATHOL, V14, P604, DOI 10.1038/modpathol.3880358; Cohn-Cedermark G, 2000, CANCER-AM CANCER SOC, V89, P1495, DOI 10.1002/1097-0142(20001001)89:7<1495::AID-CNCR12>3.0.CO;2-D; Cole BF, 1996, J CLIN ONCOL, V14, P2666, DOI 10.1200/JCO.1996.14.10.2666; Crosby T, 2000, COCHRANE DB SYST REV, V2; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dubois RW, 2001, ARCH DERMATOL, V137, P1217; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Eggermont AMM, 2001, EUR J CANCER, V37, P2147, DOI 10.1016/S0959-8049(01)00272-6; Elwood JM, 1997, INT J CANCER, V73, P198, DOI 10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R; Epstein DS, 1999, JAMA-J AM MED ASSOC, V281, P640, DOI 10.1001/jama.281.7.640; Essner R, 2002, ANN SURG ONCOL, V9, P754, DOI 10.1245/ASO.2001.06.024; Eton O, 2002, J CLIN ONCOL, V20, P2045, DOI 10.1200/JCO.2002.07.044; FLAHERTY KT, PHASE I II TRIAL BAY; Gershenwald JE, 1999, J CLIN ONCOL, V17, P976, DOI 10.1200/JCO.1999.17.3.976; Goggins WB, 2003, CANCER, V97, P639, DOI 10.1002/cncr.11116; GOLLOB J, 2001, PROG P AM SOC CLIN O, V20, pA357; Gollob JA, 2003, J CLIN ONCOL, V21, P2564, DOI 10.1200/JCO.2003.12.119; GREENE MH, 1985, ANN INTERN MED, V102, P458, DOI 10.7326/0003-4819-102-4-458; Grob JJ, 1998, LANCET, V351, P1905, DOI 10.1016/S0140-6736(97)12445-X; HALL WH, 1992, JAMA-J AM MED ASSOC, V268, P1314, DOI 10.1001/jama.1992.03490100112037; Hancock BW, 2004, J CLIN ONCOL, V22, P53, DOI 10.1200/JCO.2004.03.185; Heaton KM, 1998, ANN SURG ONCOL, V5, P322, DOI 10.1007/BF02303495; Hillner BE, 1997, J CLIN ONCOL, V15, P2351, DOI 10.1200/JCO.1997.15.6.2351; Hsueh EC, 1998, J CLIN ONCOL, V16, P2913, DOI 10.1200/JCO.1998.16.9.2913; Hwu WJ, 2003, J CLIN ONCOL, V21, P3351, DOI 10.1200/JCO.2003.02.061; Jansen L, 2000, BRIT J SURG, V87, P484, DOI 10.1046/j.1365-2168.2000.01362.x; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; KANG S, 1992, CANCER, V70, P1911, DOI 10.1002/1097-0142(19921001)70:7<1911::AID-CNCR2820700718>3.0.CO;2-Q; Katris P, 1996, AUST NZ J SURG, V66, P101, DOI 10.1111/j.1445-2197.1996.tb01122.x; KAWAKAMI Y, 1995, J IMMUNOL, V154, P3961; Keilholz U, 2002, J IMMUNOTHER, V25, P97, DOI 10.1097/00002371-200203000-00001; Keilholz U, 1997, J CLIN ONCOL, V15, P2579, DOI 10.1200/JCO.1997.15.7.2579; Keilholz U, 1998, J CLIN ONCOL, V16, P2921, DOI 10.1200/JCO.1998.16.9.2921; KEILHOLZ U, 2003, P AN M AM SOC CLIN, V22, P708; Khayat D, 2003, CANCER-AM CANCER SOC, V97, P1941, DOI 10.1002/cncr.11272; Kilbridge KL, 2001, J CLIN ONCOL, V19, P812, DOI 10.1200/JCO.2001.19.3.812; Kirkwood JM, 2000, J CLIN ONCOL, V18, P2444, DOI 10.1200/JCO.2000.18.12.2444; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; Kirkwood JM, 2001, J CLIN ONCOL, V19, P2370, DOI 10.1200/JCO.2001.19.9.2370; Kirkwood JM, 2004, CLIN CANCER RES, V10, P1670, DOI 10.1158/1078-0432.CCR-1103-3; Kirkwood JM, 2002, J CLIN ONCOL, V20, P3703, DOI 10.1200/JCO.2002.03.052; KIRKWOOD JM, 2003, P AN M AM SOC CLIN, V22, P709; Koh HK, 1996, J AM ACAD DERMATOL, V34, P971, DOI 10.1016/S0190-9622(96)90274-1; KRAEMER KH, 1986, NEW ENGL J MED, V315, P1615; Lens MB, 2002, ARCH SURG-CHICAGO, V137, P1101, DOI 10.1001/archsurg.137.10.1101; Lens MB, 2002, J CLIN ONCOL, V20, P1818, DOI 10.1200/JCO.2002.07.070; LIVINGSTON PO, 1994, J CLIN ONCOL, V12, P1036, DOI 10.1200/JCO.1994.12.5.1036; LYNCH HT, 1978, J MED GENET, V15, P352, DOI 10.1136/jmg.15.5.352; Manola J, 2000, J CLIN ONCOL, V18, P3782, DOI 10.1200/JCO.2000.18.22.3782; Margolin K, 1997, CLIN CANCER RES, V3, P565; McMasters KM, 2001, ANN SURG ONCOL, V8, P192, DOI 10.1007/s10434-001-0192-4; Melas D, 2000, ENVIRON SCI POLLUT R, V7, P97, DOI 10.1065/espr2000.02.016; Middleton MR, 2000, J CLIN ONCOL, V18, P158, DOI 10.1200/JCO.2000.18.1.158; Middleton MR, 2000, J CLIN ONCOL, V18, P2351; MILLWARD MJ, RANDOMIZED MULTINATI; Mitchell MS, 1998, SEMIN ONCOL, V25, P623; MITCHELL MS, 2003, PROG P AM SOC CLIN O, V22, P7096; MORTON DL, 1993, J CLIN ONCOL, V11, P1751, DOI 10.1200/JCO.1993.11.9.1751; MORTON DL, 2003, CUTANEOUS MELANOMA, P547; Musselman DL, 2001, NEW ENGL J MED, V344, P961, DOI 10.1056/NEJM200103293441303; National Cancer Institute, SEER CANC STAT REV 1; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; PARMIANI G, 2002, PROG P AM SOC CLIN O, V21, pA13; Pehamberger H, 1998, J CLIN ONCOL, V16, P1425, DOI 10.1200/JCO.1998.16.4.1425; Perrott RE, 2003, J AM ACAD DERMATOL, V49, P567, DOI 10.1067/S0190-9622(03)02136-4; RAMPEN FHJ, 1991, J AM ACAD DERMATOL, V25, P776, DOI 10.1016/S0190-9622(08)80968-1; REINTGEN DS, 2003, CUTANEOUS MELANOMA, P353; Rosenberg SA, 1999, J CLIN ONCOL, V17, P968, DOI 10.1200/JCO.1999.17.3.968; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; ROSS MI, 2003, CUTANEOUS MELANOMA, P209; Santinami M, 2001, Surg Oncol Clin N Am, V10, P935; Shivers SC, 1998, JAMA-J AM MED ASSOC, V280, P1410, DOI 10.1001/jama.280.16.1410; SIM FH, 1986, MAYO CLIN PROC, V61, P697, DOI 10.1016/S0025-6196(12)62768-2; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Soiffer R, 2003, J CLIN ONCOL, V21, P3343, DOI 10.1200/JCO.2003.07.005; Sosman JA, 2002, J CLIN ONCOL, V20, P2067, DOI 10.1200/JCO.2002.08.072; SUMMERS Y, 1999, P AN M AM SOC CLIN, V18, pA531; Terhune MH, 1998, ARCH DERMATOL, V134, P569, DOI 10.1001/archderm.134.5.569; Thomas JM, 2004, NEW ENGL J MED, V350, P757, DOI 10.1056/NEJMoa030681; Thompson JF, 2003, CUTANEOUS MELANOMA, P329; Tsao H, 2004, ARCH DERMATOL, V140, P67, DOI 10.1001/archderm.140.1.67; Tsao H, 2002, ARCH DERMATOL, V138, P799, DOI 10.1001/archderm.138.6.799; Tsao H, 2003, ARCH DERMATOL, V139, P282, DOI 10.1001/archderm.139.3.282; Tsao HS, 1998, CLIN DERMATOL, V16, P67, DOI 10.1016/S0738-081X(97)00191-0; Tsao HS, 2003, CUTANEOUS MELANOMA, P121; VERONESI U, 1977, NEW ENGL J MED, V297, P627, DOI 10.1056/NEJM197709222971202; VERONESI U, 1988, NEW ENGL J MED, V318, P1159, DOI 10.1056/NEJM198805053181804; VERONESI U, 1991, NEW ENGL J MED, V325, P292; Vuylsteke RJCLM, 2003, J CLIN ONCOL, V21, P1057, DOI 10.1200/JCO.2003.07.170; WEBER JS, 2003, P AN M AM SOC CLIN, V22, P710; Wrightson WR, 2003, ANN SURG ONCOL, V10, P676, DOI 10.1245/ASO.2003.10.001; Yu LL, 1999, CANCER, V86, P617, DOI 10.1002/(SICI)1097-0142(19990815)86:4<617::AID-CNCR10>3.0.CO;2-S	119	622	650	1	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2004	351	10					998	1012		10.1056/NEJMra041245	http://dx.doi.org/10.1056/NEJMra041245			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	850UB	15342808				2022-12-28	WOS:000223637400010
J	Carucci, D				Carucci, D			Know thine enemy	NATURE			English	Article							PLASMODIUM-FALCIPARUM; LIFE-CYCLE; PROTEINS; INVASION; SEQUENCE; GENOME		Fdn Natl Inst Hlth, Bethesda, MD USA	National Institutes of Health (NIH) - USA	Carucci, D (corresponding author), Fdn Natl Inst Hlth, Bethesda, MD USA.							BORDECH Z, 2003, PLOS BIOL, V1, pE5; Cowman AF, 2002, SCIENCE, V298, P126, DOI 10.1126/science.1078169; Doolan DL, 2003, J EXP BIOL, V206, P3789, DOI 10.1242/jeb.00615; Doolan DL, 2003, P NATL ACAD SCI USA, V100, P9952, DOI 10.1073/pnas.1633254100; Duraisingh MT, 2003, EMBO J, V22, P1047, DOI 10.1093/emboj/cdg096; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Volkman SK, 2002, SCIENCE, V298, P216, DOI 10.1126/science.1075642	10	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					944	945		10.1038/430944a	http://dx.doi.org/10.1038/430944a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318241	Bronze			2022-12-28	WOS:000223369800064
J	Hoffman, S				Hoffman, S			Save the children	NATURE			English	Article							CIRCUMSPOROZOITE PROTEIN VACCINE; PLASMODIUM; MALARIA; GENOMICS; EFFICACY		Sanaria, Rockville, MD USA	Sanaria Inc.	Hoffman, S (corresponding author), Sanaria, Rockville, MD USA.							Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4; Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409; Hoffman SL, 2002, NATURE, V415, P702, DOI 10.1038/415702a; Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534; Long CA, 2002, SCIENCE, V297, P345, DOI 10.1126/science.1074484; Luke TC, 2003, J EXP BIOL, V206, P3803, DOI 10.1242/jeb.00644; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202	8	11	16	0	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					940	941		10.1038/430940a	http://dx.doi.org/10.1038/430940a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318239				2022-12-28	WOS:000223369800062
J	Ridley, R; Toure, Y				Ridley, R; Toure, Y			Winning the drugs war	NATURE			English	Article							DISCOVERY		UNICEF UNDP World Bank WHO Special Programme Res, New York, NY 10017 USA	UNICEF	Ridley, R (corresponding author), UNICEF UNDP World Bank WHO Special Programme Res, New York, NY 10017 USA.							Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; Alloueche A, 2004, LANCET, V363, P1843, DOI 10.1016/S0140-6736(04)16350-2; [Anonymous], 2004, SCAL HOM BAS MAN MAL; [Anonymous], 2003, AFR MAL REP 2003; Fidock DA, 2004, NAT REV DRUG DISCOV, V3, P509, DOI 10.1038/nrd1416; Lang T, 2003, LANCET INFECT DIS, V3, P162, DOI 10.1016/S1473-3099(03)00547-4; *MMV, 2004, MED MAL VENT ANN REP; Nwaka S, 2003, NAT REV DRUG DISCOV, V2, P919, DOI 10.1038/nrd1230; Ridley RG, 2002, NATURE, V415, P686, DOI 10.1038/415686a; Vennerstrom JL, 2004, NATURE, V430, P900, DOI 10.1038/nature02779	10	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					942	943		10.1038/430942a	http://dx.doi.org/10.1038/430942a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318240				2022-12-28	WOS:000223369800063
J	Sackett, DL				Sackett, DL			Editorial independence at the BMJ - ... and the author apologises unreservedly	BRITISH MEDICAL JOURNAL			English	Letter									Trout Res & Educ Ctr Irish Lake, Markdale, ON N0C 1H0, Canada		Sackett, DL (corresponding author), Trout Res & Educ Ctr Irish Lake, RR 1, Markdale, ON N0C 1H0, Canada.	sackett@bmts.com							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 11	2004	329	7466					624	625		10.1136/bmj.329.7466.624-d	http://dx.doi.org/10.1136/bmj.329.7466.624-d			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	854SK	15361455	Green Published			2022-12-28	WOS:000223923400037
J	Khademi, S; O'Connell, J; Remis, J; Robles-Colmenares, Y; Miericke, LJW; Stroud, RM				Khademi, S; O'Connell, J; Remis, J; Robles-Colmenares, Y; Miericke, LJW; Stroud, RM			Mechanism of ammonia transport by Amt/MEP/Rh: Structure of AmtB at 1.3.5 angstrom	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PROTEIN; ESCHERICHIA-COLI; PHYLOGENETIC CHARACTERIZATION; CORYNEBACTERIUM-GLUTAMICUM; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; GREEN-ALGA; FAMILY; GLNK; NH4+	The first structure of an ammonia channel from the Amt/MEP/Rh protein superfamily, determined to 1.35 angstrom resolution, shows it to be a channel that spans the membrane 11 times. Two structurally similar halves span the membrane with opposite polarity. Structures with and without ammonia or methyl ammonia show a vestibule that recruits NH4+/NH3, a binding site for NH4+, and a 20 angstrom-long hydrophobic channel that lowers the NH4+ pK(a) to below 6 and conducts NH3. Favorable interactions for NH3 are seen within the channel and use conserved histidines. Reconstitution of AmtB into vesicles shows that AmtB conducts uncharged NH3.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Stroud, RM (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, S412C Genentech Hall,600 16th St, San Francisco, CA 94143 USA.	stroud@msg.ucsf.edu	Stroud, Rhonda/GQZ-0151-2022	Stroud, Rhonda/0000-0001-5242-8015	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024485, R37GM024485] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24485] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atkinson MR, 1998, MOL MICROBIOL, V29, P431, DOI 10.1046/j.1365-2958.1998.00932.x; Blakey D, 2002, BIOCHEM J, V364, P527, DOI 10.1042/BJ20011761; BROACH J, 1976, J BACTERIOL, V128, P86, DOI 10.1128/JB.128.1.86-98.1976; Coutts G, 2002, EMBO J, V21, P536, DOI 10.1093/emboj/21.4.536; DEREWENDA ZS, 1995, J MOL BIOL, V252, P248, DOI 10.1006/jmbi.1995.0492; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; HACKETTE SL, 1970, J BIOL CHEM, V245, P4241; Javelle A, 2004, J BIOL CHEM, V279, P8530, DOI 10.1074/jbc.M312399200; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; KHADEMI S, UNPUB; KNEPPER MA, 1989, PHYSIOL REV, V69, P179, DOI 10.1152/physrev.1989.69.1.179; Ludewig U, 2002, J BIOL CHEM, V277, P13548, DOI 10.1074/jbc.M200739200; LUDEWIG U, IN PRESS J PHYSL LON; MARINI AM, 1994, EMBO J, V13, P3456, DOI 10.1002/j.1460-2075.1994.tb06651.x; Marini AM, 1997, TRENDS BIOCHEM SCI, V22, P460, DOI 10.1016/S0968-0004(97)01132-8; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; Meier-Wagner J, 2001, MICROBIOL-UK, V147, P135, DOI 10.1099/00221287-147-1-135; Morais-Cabral JH, 2001, NATURE, V414, P37, DOI 10.1038/35102000; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PRIVER NA, 1993, BIOCHEMISTRY-US, V32, P2459, DOI 10.1021/bi00061a002; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Saier MH, 1999, BBA-REV BIOMEMBRANES, V1422, P1, DOI 10.1016/S0304-4157(98)00023-9; Siewe RM, 1996, J BIOL CHEM, V271, P5398, DOI 10.1074/jbc.271.10.5398; Sohlenkamp C, 2002, PLANT PHYSIOL, V130, P1788, DOI 10.1104/pp.008599; Soupene E, 2004, P NATL ACAD SCI USA, V101, P7787, DOI 10.1073/pnas.0401809101; Soupene E, 1998, P NATL ACAD SCI USA, V95, P7030, DOI 10.1073/pnas.95.12.7030; Soupene E, 2002, P NATL ACAD SCI USA, V99, P7769, DOI 10.1073/pnas.112225599; Soupene E, 2002, J BACTERIOL, V184, P3396, DOI 10.1128/JB.184.12.3396-3400.2002; Soupene E, 2002, P NATL ACAD SCI USA, V99, P3926, DOI 10.1073/pnas.062043799; Tate R, 1998, MOL PLANT MICROBE IN, V11, P188, DOI 10.1094/MPMI.1998.11.3.188; Thomas GH, 2000, MOL MICROBIOL, V37, P331, DOI 10.1046/j.1365-2958.2000.01994.x; WANG MY, 1993, PLANT PHYSIOL, V103, P1259, DOI 10.1104/pp.103.4.1463; Westhoff CM, 2004, J BIOL CHEM, V279, P17443, DOI 10.1074/jbc.M311853200; Westhoff CM, 2002, J BIOL CHEM, V277, P12499, DOI 10.1074/jbc.C200060200	36	516	528	5	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2004	305	5690					1587	1594		10.1126/science.1101952	http://dx.doi.org/10.1126/science.1101952			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361618				2022-12-28	WOS:000223891200035
J	Li, SR; Zhou, DY; Lu, MM; Morrisey, EE				Li, SR; Zhou, DY; Lu, MM; Morrisey, EE			Advanced cardiac morphogenesis does not require heart tube fusion	SCIENCE			English	Article							VENTRAL MORPHOGENESIS; TRANSCRIPTION FACTOR; ZEBRAFISH; CELLS; ASYMMETRY; ENDODERM; GATA4; MESP1; GENES; MICE	The bilateral cardiac mesoderm migrates from the lateral region of the embryo to the ventral midline, where it fuses to form the primitive heart tube. It is generally accepted that migration and fusion are essential for subsequent stages of cardiac morphogenesis. We present evidence that, in Foxp4 mutant embryonic mice, each bilateral heart-forming region is capable of developing into a highly differentiated four-chambered mammalian heart in the absence of midline fusion. These data demonstrate that left-right chamber specification, cardiac looping, septation, cardiac myocyte differentiation, and endocardial cushion formation are preprogrammed in the precardiac mesoderm and do not require midline positional identity or heart tube fusion.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Morrisey, EE (corresponding author), Univ Penn, Dept Med, Philadelphia, PA 19104 USA.	emorrise@mail.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071589] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL71589] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander J, 1999, DEV BIOL, V215, P343, DOI 10.1006/dbio.1999.9441; Bisgrove BW, 2000, DEVELOPMENT, V127, P3567; Bisgrove BW, 2001, AM J MED GENET, V101, P315, DOI 10.1002/ajmg.1180; Brand T, 2003, DEV BIOL, V258, P1, DOI 10.1016/S0012-1606(03)00112-X; Cai CL, 2003, DEV CELL, V5, P877, DOI 10.1016/S1534-5807(03)00363-0; Gitler AD, 2004, DEV CELL, V7, P107, DOI 10.1016/j.devcel.2004.06.002; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Li S., UNPUB; Lin CR, 1999, NATURE, V401, P279, DOI 10.1038/45803; Lu MM, 2002, MECH DEVELOP, V119, pS197, DOI 10.1016/S0925-4773(03)00116-3; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Reiter JF, 1999, GENE DEV, V13, P2983, DOI 10.1101/gad.13.22.2983; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Saga Y, 1999, DEVELOPMENT, V126, P3437; Saga Y, 1998, MECH DEVELOP, V75, P53, DOI 10.1016/S0925-4773(98)00077-X; Sedmera D, 2000, ANAT RECORD, V258, P319, DOI 10.1002/(SICI)1097-0185(20000401)258:4<319::AID-AR1>3.0.CO;2-O; Shu WG, 2001, J BIOL CHEM, V276, P27488, DOI 10.1074/jbc.M100636200; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Thomas T, 1998, DEV BIOL, V196, P228, DOI 10.1006/dbio.1998.8849; Van Der Zwaag B, 2002, DEV DYNAM, V225, P336, DOI 10.1002/dvdy.10159; Yelon D, 1999, SEMIN CELL DEV BIOL, V10, P93, DOI 10.1006/scdb.1998.0278	23	73	76	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2004	305	5690					1619	1622		10.1126/science.1098674	http://dx.doi.org/10.1126/science.1098674			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361625				2022-12-28	WOS:000223891200043
J	Van Oost, K; Govers, G; Quine, TA; Heckrath, G				Van Oost, K; Govers, G; Quine, TA; Heckrath, G			Comment on "Managing soil carbon" (I)	SCIENCE			English	Editorial Material							EROSION		Katholieke Univ Leuven, Phys & Reg Geog Res Grp, B-3000 Louvain, Belgium; Univ Exeter, Dept Geog, Exeter EX4 4RJ, Devon, England; Danish Inst Agr Sci, Dept Agroecol, DK-8830 Tjele, Denmark	KU Leuven; University of Exeter; Aarhus University	Van Oost, K (corresponding author), Katholieke Univ Leuven, Phys & Reg Geog Res Grp, Redingenstr 16B, B-3000 Louvain, Belgium.	k.vanoost@exeter.ac.uk	Quine, Timothy A/B-2984-2010; Govers, Gerard/A-8298-2008; Van Oost, Kristof/B-6941-2008	Govers, Gerard/0000-0001-9884-4778; 				Govers G, 1999, SOIL TILL RES, V51, P167; Lai R., 2005, SOIL TILL RES, V81, P137; LAI R, 2004, SCIENCE, V305; Lal R, 1999, J SOIL WATER CONSERV, V54, P374; Lal R, 2004, SCIENCE, V304, P393, DOI 10.1126/science.1093079; Lal R, 2003, ENVIRON INT, V29, P437, DOI 10.1016/S0160-4120(02)00192-7; Smith P, 1998, GLOB CHANGE BIOL, V4, P679, DOI 10.1046/j.1365-2486.1998.00185.x; Smith P, 2004, EUR J AGRON, V20, P229, DOI 10.1016/j.eja.2003.08.002; Stallard RF, 1998, GLOBAL BIOGEOCHEM CY, V12, P231, DOI 10.1029/98GB00741	9	51	52	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	2004	305	5690					1567	1567						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15361608				2022-12-28	WOS:000223891200021
J	Sontheimer, EJ; Carthew, RW				Sontheimer, EJ; Carthew, RW			Argonaute journeys into the heart of RISC	SCIENCE			English	Editorial Material							SIRNAS; RNAI		Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Sontheimer, EJ (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	erik@northwestern.edu; r-carthew@northwestern.edu		Sontheimer, Erik/0000-0002-0881-0310	NIGMS NIH HHS [R01 GM068743, R01 GM077581] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068743, R01GM077581] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Grewal SIS, 2004, CURR OPIN CELL BIOL, V16, P230, DOI 10.1016/j.ceb.2004.04.002; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hannon, 2003, RNAI GUIDE GENE SILE; Joshua-Tor L, 2004, STRUCTURE, V12, P1120, DOI 10.1016/j.str.2004.06.008; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514	10	41	50	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	2004	305	5689					1409	1410		10.1126/science.1103076	http://dx.doi.org/10.1126/science.1103076			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852NK	15353786				2022-12-28	WOS:000223761900029
J	Nakagawara, M; Hanai, H; Kajimura, M				Nakagawara, M; Hanai, H; Kajimura, M			Detection of liver abscesses by T-1-weighted magnetic resonance imaging	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Seirei Hamamatsu Gen Hosp, Hamamatsu, Shizuoka 4308558, Japan; Hamamatsu Univ Sch Med, Hamamatsu, Shizuoka 4313192, Japan	Hamamatsu University School of Medicine	Nakagawara, M (corresponding author), Seirei Hamamatsu Gen Hosp, Hamamatsu, Shizuoka 4308558, Japan.								0	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	2004	351	10					1013	1013		10.1056/NEJMicm990183	http://dx.doi.org/10.1056/NEJMicm990183			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	850UB	15342809				2022-12-28	WOS:000223637400011
J	Stott, L; Cannariato, K; Thunell, R; Haug, GH; Koutavas, A; Lund, S				Stott, L; Cannariato, K; Thunell, R; Haug, GH; Koutavas, A; Lund, S			Decline of surface temperature and salinity in the western tropical Pacific Ocean in the Holocene epoch	NATURE			English	Article							EL-NINO; EQUATORIAL PACIFIC; SEA-LEVEL; CLIMATE; VARIABILITY; BALANCE	In the present-day climate, surface water salinities are low in the western tropical Pacific Ocean and increase towards the eastern part of the basin(1). The salinity of surface waters in the tropical Pacific Ocean is thought to be controlled by a combination of atmospheric convection, precipitation, evaporation and ocean dynamics(2), and on interannual timescales significant variability is associated with the El Nino/Southern Oscillation cycles. However, little is known about the variability of the coupled ocean atmosphere system on timescales of centuries to millennia. Here we combine oxygen isotope and Mg/Ca data from foraminifers retrieved from three sediment cores in the western tropical Pacific Ocean to reconstruct Holocene sea surface temperatures and salinities in the region. We find a decrease in sea surface temperatures of similar to0.5 degreesC over the past 10,000 yr, whereas sea surface salinities decreased by similar to1.5 practical salinity units. Our data imply either that the Pacific basin as a whole has become progressively less salty or that the present salinity gradient along the Equator has developed relatively recently.	Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA; Univ S Carolina, Dept Geol Sci, Columbia, SC 29205 USA; Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany; MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA	University of Southern California; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences; Massachusetts Institute of Technology (MIT)	Stott, L (corresponding author), Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA.	stott@usc.edu						Aggarwal PK, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019911; Clement AC, 1999, PALEOCEANOGRAPHY, V14, P441, DOI 10.1029/1999PA900013; Cronin MF, 1998, J GEOPHYS RES-OCEANS, V103, P27567, DOI 10.1029/98JC02605; deMenocal P, 2000, SCIENCE, V288, P2198, DOI 10.1126/science.288.5474.2198; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; Fairbanks RG, 1997, CORAL REEFS, V16, pS93, DOI 10.1007/s003380050245; Gagan MK, 1998, SCIENCE, V279, P1014, DOI 10.1126/science.279.5353.1014; Haug GH, 2001, SCIENCE, V293, P1304, DOI 10.1126/science.1059725; Lea DW, 2000, SCIENCE, V289, P1719, DOI 10.1126/science.289.5485.1719; Levitus S., 1994, WORLD OCEAN ATLAS 19, V3; Liu ZY, 2000, GEOPHYS RES LETT, V27, P2265, DOI 10.1029/2000GL011452; McPhaden MJ, 1999, SCIENCE, V283, P950, DOI 10.1126/science.283.5404.950; Morimoto M, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013521; Nurnberg D, 1996, GEOCHIM COSMOCHIM AC, V60, P803, DOI 10.1016/0016-7037(95)00446-7; Oppo DW, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2001GC000260; PRELL WL, 1986, NATURE, V323, P526, DOI 10.1038/323526a0; Schmittner A, 2000, GEOPHYS RES LETT, V27, P1163, DOI 10.1029/1999GL011048; Sun DZ, 1998, GEOPHYS RES LETT, V25, P2659, DOI 10.1029/98GL01813; Waelbroeck C, 2002, QUATERNARY SCI REV, V21, P295, DOI 10.1016/S0277-3791(01)00101-9	19	349	387	5	125	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	2004	431	7004					56	59		10.1038/nature02903	http://dx.doi.org/10.1038/nature02903			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850VC	15343330	Green Published, Green Submitted			2022-12-28	WOS:000223641500039
J	Abe, F; Bennett, DP; Bond, IA; Eguchi, S; Furuta, Y; Hearnshaw, JB; Kamiya, K; Kilmartin, PM; Kurata, Y; Masuda, K; Matsubara, Y; Muraki, Y; Noda, S; Okajima, K; Rakich, A; Rattenbury, NJ; Sako, T; Sekiguchi, T; Sullivan, DJ; Sumi, T; Tristram, PJ; Yanagisawa, T; Yock, PCM; Gal-Yam, A; Lipkin, Y; Maoz, D; Ofek, EO; Udalski, A; Szewczyk, O; Zebrun, K; Soszynski, I; Szymanski, MK; Kubiak, M; Pietrzynski, G; Wyrzykowski, L				Abe, F; Bennett, DP; Bond, IA; Eguchi, S; Furuta, Y; Hearnshaw, JB; Kamiya, K; Kilmartin, PM; Kurata, Y; Masuda, K; Matsubara, Y; Muraki, Y; Noda, S; Okajima, K; Rakich, A; Rattenbury, NJ; Sako, T; Sekiguchi, T; Sullivan, DJ; Sumi, T; Tristram, PJ; Yanagisawa, T; Yock, PCM; Gal-Yam, A; Lipkin, Y; Maoz, D; Ofek, EO; Udalski, A; Szewczyk, O; Zebrun, K; Soszynski, I; Szymanski, MK; Kubiak, M; Pietrzynski, G; Wyrzykowski, L			Search for low-mass exoplanets by gravitational microlensing at high magnification	SCIENCE			English	Article							EXTRASOLAR PLANETS; LENSING EXPERIMENT; SYSTEMS; EVENTS; COMPANIONS; FREQUENCY; MOA	Observations of the gravitational microlensing event MOA 2003-BLG-32/OGLE 2003-BLG-219 are presented, for which the peak magnification was over 500, the highest yet reported. Continuous observations around the peak enabled a sensitive search for planets orbiting the Lens star. No planets were detected. Planets 1.3 times heavier than Earth were excluded from more than 50% of the projected annular region from approximately 2.3 to 3.6 astronomical units surrounding the tens star, Uranus-mass planets were excluded from 0.9 to 8.7 astronomical units, and planets 1.3 times heavier than Saturn were exclude from 0.2 to 60 astronomical units. These are the largest regions of sensitivity yet achieved in searches for extrasolar planets orbiting any star.	Univ Manchester, Dept Phys & Astron, Manchester, Lancs, England; Nagoya Univ, Solar Terr Environm Lab, Nagoya, Aichi 46401, Japan; Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA; Massey Univ Albany, Inst Informat & Math Sci, Auckland, New Zealand; Univ Canterbury, Dept Phys & Astron, Christchurch 1, New Zealand; Natl Astron Observ, Tokyo 181, Japan; Electro Opt Syst, Canberra, ACT, Australia; Univ Victoria, Sch Chem & Phys Sci, Wellington, New Zealand; Princeton Univ, Dept Astrophys Sci, Princeton, NJ 08544 USA; Univ Auckland, Dept Phys, Auckland, New Zealand; Natl Aerosp Lab, Tokyo, Japan; CALTECH, Dept Astron, Pasadena, CA 91025 USA; Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Phys & Astron, IL-69978 Tel Aviv, Israel; Univ Warsaw Observ, PL-00478 Warsaw, Poland; Univ Concepcion, Dept Fis, Concepcion, Chile	University of Manchester; Nagoya University; University of Notre Dame; Massey University; University of Canterbury; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); Victoria University Wellington; Princeton University; University of Auckland; Japan Aerospace Exploration Agency (JAXA); California Institute of Technology; Tel Aviv University; University of Warsaw; Warsaw University Observatory; Universidad de Concepcion	Rattenbury, NJ (corresponding author), Univ Manchester, Dept Phys & Astron, Manchester, Lancs, England.	njr@jb.man.ac.uk	Szymański, Michał Krzysztof/X-5627-2019; Rattenbury, Nicholas James/ABB-2102-2021; Szymański, Michał K/H-6951-2018	Szymański, Michał Krzysztof/0000-0002-0548-8995; Rattenbury, Nicholas James/0000-0001-5069-319X; Szymański, Michał K/0000-0002-0548-8995; Yock, Philip/0000-0001-9716-7752; Soszynski, Igor/0000-0002-7777-0842; Pietrzynski, Grzegorz/0000-0002-9443-4138; Udalski, Andrzej/0000-0001-5207-5619; Wyrzykowski, Lukasz/0000-0002-9658-6151				Alard C, 1998, ASTROPHYS J, V503, P325, DOI 10.1086/305984; Alcock C, 2001, NATURE, V414, P617, DOI 10.1038/414617a; Bennett DP, 2002, ASTROPHYS J, V574, P985, DOI 10.1086/340977; Bennett DP, 1996, ASTROPHYS J, V472, P660, DOI 10.1086/178096; Bond IA, 2004, ASTROPHYS J, V606, pL155, DOI 10.1086/420928; Bond IA, 2001, MON NOT R ASTRON SOC, V327, P868, DOI 10.1046/j.1365-8711.2001.04776.x; Bond IA, 2002, MON NOT R ASTRON SOC, V331, pL19, DOI 10.1046/j.1365-8711.2002.05374.x; Bond IA, 2002, MON NOT R ASTRON SOC, V333, P71, DOI 10.1046/j.1365-8711.2002.05380.x; Borucki WJ, 1996, ASTROPHYS SPACE SCI, V241, P111; Boss AP, 2002, ICARUS, V156, P291, DOI 10.1006/icar.2002.6816; Gaudi BS, 2002, ASTROPHYS J, V566, P463, DOI 10.1086/337987; GOULD A, 1992, ASTROPHYS J, V396, P104, DOI 10.1086/171700; Griest K, 1998, ASTROPHYS J, V500, P37, DOI 10.1086/305729; Holtzman JA, 1998, ASTRON J, V115, P1946, DOI 10.1086/300336; Ida S, 2004, ASTROPHYS J, V604, P388, DOI 10.1086/381724; Irion R, 2004, SCIENCE, V303, P30, DOI 10.1126/science.303.5654.30; Kokubo E, 2002, ASTROPHYS J, V581, P666, DOI 10.1086/344105; LIEBES S, 1964, PHYS REV B, V133, pB835, DOI 10.1103/PhysRev.133.B835; Lissauer JJ, 1999, NATURE, V402, pC11, DOI 10.1038/35011503; MAO S, 1991, ASTROPHYS J, V374, pL37, DOI 10.1086/186066; Rattenbury NJ, 2002, MON NOT R ASTRON SOC, V335, P159, DOI 10.1046/j.1365-8711.2002.05607.x; Rhie SH, 2000, ASTROPHYS J, V533, P378, DOI 10.1086/308634; SCHECHTER PL, 1993, PUBL ASTRON SOC PAC, V105, P1342, DOI 10.1086/133316; Thommes EW, 1999, NATURE, V402, P635, DOI 10.1038/45185; Udalski A, 2002, ACTA ASTRONOM, V52, P217; Zoccali M, 2000, ASTROPHYS J, V530, P418, DOI 10.1086/308359	27	35	36	3	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	2004	305	5688					1264	1266		10.1126/science.1100714	http://dx.doi.org/10.1126/science.1100714			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850PJ	15333833				2022-12-28	WOS:000223624600033
J	Judson, HF				Judson, HF			First among equals - Francis Crick	NEW ENGLAND JOURNAL OF MEDICINE			English	Biographical-Item																			0	0	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2004	351	9					858	858		10.1056/NEJMp048233	http://dx.doi.org/10.1056/NEJMp048233			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849BM	15329422				2022-12-28	WOS:000223512500006
J	Archbold, RA; Robinson, NM; Schilling, R				Archbold, RA; Robinson, NM; Schilling, R			Radial artery access for coronary angiography and percutaneous coronary intervention	BRITISH MEDICAL JOURNAL			English	Review							ACUTE MYOCARDIAL-INFARCTION; CARDIAC-CATHETERIZATION; TRANSRADIAL APPROACH; VASCULAR COMPLICATIONS; CONSECUTIVE PATIENTS; SYSTEMATIC USE; ANGIOPLASTY; EXPERIENCE; DEVICE; VS.		London Chest Hosp, Dept Cardiol, London E2 9JX, England; St Bartholomews Hosp, Dept Cardiol, London, England	University of London; Queen Mary University London; University of London; Queen Mary University London	Archbold, RA (corresponding author), London Chest Hosp, Dept Cardiol, London E2 9JX, England.	Andrew.Archbold@bartsandthelondon.nhs.uk		Archbold, Richard/0000-0002-9847-070X				Almany SL, 1999, RADIAL ARTERY ACCESS; Amin FR, 2000, INT J CARDIOL, V76, P235, DOI 10.1016/S0167-5273(00)00386-7; Banning AP, 2003, HEART, V89, P665, DOI 10.1136/heart.89.6.665; Benit E, 1996, CATHETER CARDIO DIAG, V38, P352, DOI 10.1002/(SICI)1097-0304(199608)38:4<352::AID-CCD5>3.0.CO;2-6; Black A. J., 1999, European Heart Journal, V20, P268; *BRIT CARD INT SOC, BCIS 2002 PCI AUD DA; Caputo RP, 2001, CATHETER CARDIO INTE, V54, P188, DOI 10.1002/ccd.1264; Choussat R, 2000, EUR HEART J, V21, P662, DOI 10.1053/euhj.1999.1945; Cooper CJ, 1999, AM HEART J, V138, P430, DOI 10.1016/S0002-8703(99)70143-2; Dahm JB, 2002, CATHETER CARDIO INTE, V57, P172, DOI 10.1002/ccd.10321; Dangas G, 2001, J AM COLL CARDIOL, V38, P638, DOI 10.1016/S0735-1097(01)01449-8; Duffin D C, 2001, J Invasive Cardiol, V13, P354; Eggebrecht H, 2002, CATHETER CARDIO INTE, V57, P486, DOI 10.1002/ccd.10254; ElShiekh RA, 1997, CATHETER CARDIO DIAG, V40, P166, DOI 10.1002/(SICI)1097-0304(199702)40:2<166::AID-CCD10>3.0.CO;2-P; Hamon M, 2002, CATHETER CARDIO INTE, V55, P340, DOI 10.1002/ccd.10105; Hildick-Smith DJR, 1998, INT J CARDIOL, V64, P231, DOI 10.1016/S0167-5273(98)00074-6; KIEMENEIJ F, 1995, AM HEART J, V129, P1, DOI 10.1016/0002-8703(95)90034-9; Kiemeneij F, 1997, J AM COLL CARDIOL, V29, P323, DOI 10.1016/S0735-1097(96)00486-X; Kiemeneij F, 1997, J AM COLL CARDIOL, V29, P1269, DOI 10.1016/S0735-1097(97)00064-8; KIMENEIJ F, 1995, J INVASIVE CARDIOL, V7, pA5; Louvard Y, 2002, CATHETER CARDIO INTE, V55, P206, DOI 10.1002/ccd.10120; Louvard Y, 2001, CATHETER CARDIO INTE, V52, P181, DOI 10.1002/1522-726X(200102)52:2<181::AID-CCD1044>3.0.CO;2-G; Mann T, 1998, J AM COLL CARDIOL, V32, P572, DOI 10.1016/S0735-1097(98)00288-5; Mann T, 2000, CATHETER CARDIO INTE, V49, P150, DOI 10.1002/(SICI)1522-726X(200002)49:2<150::AID-CCD7>3.0.CO;2-F; MANN T, 1996, J INVAS CARDIOL SD, V8, P40; MASSETTI M, 2003, TRANSRADIAL APPROACH, P255; Mathias D W, 2000, J Invasive Cardiol, V12, P547; Morice MC, 2000, CATHETER CARDIO INTE, V51, P417, DOI 10.1002/1522-726X(200012)51:4<417::AID-CCD9>3.0.CO;2-Y; Mulukutla SR, 2002, CATHETER CARDIO INTE, V57, P167, DOI 10.1002/ccd.10300; Nagai S, 1999, AM J CARDIOL, V83, P180, DOI 10.1016/S0002-9149(98)00821-2; Philippe F, 2004, CATHETER CARDIO INTE, V61, P67, DOI 10.1002/ccd.10675; Schneider JE, 1997, J INVASIVE CARDIOL, V9, P569; Shibata Y, 1998, CATHETER CARDIO DIAG, V43, P344, DOI 10.1002/(SICI)1097-0304(199803)43:3<344::AID-CCD24>3.0.CO;2-K; Slagboom T, 2001, CATHETER CARDIO INTE, V53, P204, DOI 10.1002/ccd.1149; Spaulding C, 1996, CATHETER CARDIO DIAG, V39, P365, DOI 10.1002/(SICI)1097-0304(199612)39:4<365::AID-CCD8>3.0.CO;2-B; Stella PR, 1997, CATHETER CARDIO DIAG, V40, P156, DOI 10.1002/(SICI)1097-0304(199702)40:2<156::AID-CCD7>3.0.CO;2-A; Talwar S, 2003, HEART, V89, pA18; Terashima M, 2001, CATHETER CARDIO INTE, V53, P410, DOI 10.1002/ccd.1192; Yokoyama N, 2000, CATHETER CARDIO INTE, V49, P357, DOI 10.1002/(SICI)1522-726X(200004)49:4<357::AID-CCD1>3.0.CO;2-Z; Yoo BS, 2003, CATHETER CARDIO INTE, V58, P301, DOI 10.1002/ccd.10400	40	67	77	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 21	2004	329	7463					443	446B		10.1136/bmj.329.7463.443	http://dx.doi.org/10.1136/bmj.329.7463.443			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	849EA	15321904	Green Published			2022-12-28	WOS:000223520300025
J	Klausner, R; Alonso, P				Klausner, R; Alonso, P			An attack on all fronts	NATURE			English	Article							PLACEBO-CONTROLLED TRIAL; GLOBAL FUND; MALARIA		Bill & Melinda Gates Fdn, Global Hlth Program, Seattle, WA 98102 USA; Ctr Invest Saude Manhica, Manhica, Mozambique; Univ Barcelona, IDIBAPS, Hosp Clin, Ctr Int Hlth, E-08007 Barcelona, Spain	Bill & Melinda Gates Foundation; Centro de Investigacao em Saude de Manhica; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Klausner, R (corresponding author), Bill & Melinda Gates Fdn, Global Hlth Program, Seattle, WA 98102 USA.		Alonso, Pedro L/AAZ-3645-2020	Alonso, Pedro L/0000-0003-3292-3443				Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; [Anonymous], 2003, AFR MAL REP 2003; Attaran A, 2004, LANCET, V363, P237, DOI 10.1016/S0140-6736(03)15330-5; BOYD MARK F., 1939, AMER JOUR TROP MED, V19, P1; Butler D, 2004, NATURE, V429, P588, DOI 10.1038/429588a; Lengeler C, 2004, COCHRANE DATABASE SY; Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2; Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8	8	13	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	2004	430	7002					930	931		10.1038/430930a	http://dx.doi.org/10.1038/430930a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15318232	Bronze			2022-12-28	WOS:000223369800055
J	Stramer, SL; Glynn, SA; Kleinman, SH; Strong, DM; Caglioti, S; Wright, DJ; Dodd, RY; Busch, MP				Stramer, SL; Glynn, SA; Kleinman, SH; Strong, DM; Caglioti, S; Wright, DJ; Dodd, RY; Busch, MP		Natl Heart Lung Blood Inst Nucleic	Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C; UNITED-STATES; COST-EFFECTIVENESS; RNA; RISK; NAT; TRANSMISSION; TRANSFUSION; SAFETY	BACKGROUND Testing of blood donors for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) RNA by means of nucleic acid amplification was introduced in the United States as an investigational screening test in mid-1999 to identify donations made during the window period before seroconversion. METHODS We analyzed all antibody-nonreactive donations that were confirmed to be positive for HIV-1 and HCV RNA on nucleic acid - amplification testing of "minipools" ( pools of 16 to 24 donations) by the main blood-collection programs in the United States during the first three years of nucleic acid screening. RESULTS Among 37,164,054 units screened, 12 were confirmed to be positive for HIV-1 RNA or 1 in 3.1 million donations - only 2 of which were detected by HIV-1 p24 antigen testing. For HCV, of 39,721,404 units screened, 170 were confirmed to be positive for HCV RNA, or 1 in 230,000 donations ( or 1 in 270,000 on the basis of 139 donations confirmed to be positive for HCV RNA with the use of a more sensitive HCV-antibody test). The respective rates of positive HCV and HIV-1 nucleic acid - amplification tests were 3.3 and 4.1 times as high among first-time donors as among donors who gave blood repeatedly. Follow-up studies of 67 HCV RNA - positive donors demonstrated that seroconversion occurred a median of 35 days after the index donation, followed by a low rate of resolution of viremia; three cases of long-term immunologically silent HCV infection were documented. CONCLUSIONS Minipool nucleic acid - amplification testing has helped prevent the transmission of approximately 5 HIV-1 infections and 56 HCV infections annually and has reduced the residual risk of transfusion-transmitted HIV-1 and HCV to approximately 1 in 2 million blood units.	Amer Red Cross, Natl Testing & Reference Labs, Gaithersburg, MD 20877 USA; Amer Red Cross, Rockville, MD USA; WESTAT Corp, Rockville, MD 20850 USA; Univ British Columbia, Victoria, BC, Canada; Puget Sound Blood Ctr, Seattle, WA 98104 USA; Blood Syst Lab, Tempe, AZ USA; Blood Syst Res Inst, Blood Ctr Pacific, San Francisco, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	American Red Cross; American Red Cross; Westat; University of British Columbia; Puget Sound Blood Center; Vitalant; Vitalant Research Institute; University of California System; University of California San Francisco	Stramer, SL (corresponding author), Amer Red Cross, Natl Testing & Reference Labs, 9315 Gaither Rd, Gaithersburg, MD 20877 USA.	stramers@usa.redcross.org	Abrams, William R/A-5782-2008		NHLBI NIH HHS [N01-HB-97082, N01-HB-97081, N01-HB-97080, N01-HB-97078, N01-HB-47114, N01-HB-97079, N01-HB-97077] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097080, N01HB097077, N01HB097078, N01HB047114, N01HB097082, N01HB097079, N01HB097081] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alter Miriam J, 2003, MMWR Recomm Rep, V52, P1; Beld M, 1999, BLOOD, V94, P1183, DOI 10.1182/blood.V94.4.1183.416k15_1183_1191; Busch MP, 2000, TRANSFUSION, V40, P1157, DOI 10.1046/j.1537-2995.2000.40101157.x; Busch MP, 2003, JAMA-J AM MED ASSOC, V289, P959, DOI 10.1001/jama.289.8.959; Busch MP, 1998, INFUSIONSTHERAPIE, V25, P194; Busch MP, 2001, TRANSFUS CLIN BIOL, V8, P200, DOI 10.1016/S1246-7820(01)00125-2; Busch MP, 2001, BLOOD SAFETY IN THE NEW MILLENNIUM, P33; Chamberland ME, 2002, CLIN INFECT DIS, V34, P797, DOI 10.1086/338787; Delwart EL, 2004, VOX SANG, V86, P171, DOI 10.1111/j.0042-9007.2004.00416.x; Dodd RY, 2002, TRANSFUSION, V42, P975, DOI 10.1046/j.1537-2995.2002.00174.x; Dodd RY, 2003, NEW ENGL J MED, V349, P1205, DOI 10.1056/NEJMp038138; Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005; Galel SA, 2002, TRANSFUSION, V42, P1507, DOI 10.1046/j.1537-2995.2002.00236.x; Giachetti C, 2002, J CLIN MICROBIOL, V40, P2408, DOI 10.1128/JCM.40.7.2408-2419.2002; Grant PR, 2002, TRANSFUSION MED, V12, P229, DOI 10.1046/j.1365-3148.2002.00382.x; Jackson BR, 2003, TRANSFUSION, V43, P721, DOI 10.1046/j.1537-2995.2003.00392.x; Janssen RS, 1999, JAMA-J AM MED ASSOC, V281, P1893; LEHMANN EL, 1959, TESTING STATISTICAL, P140; MAPLE PAC, 1994, J MED VIROL, V44, P43, DOI 10.1002/jmv.1890440109; Marshall DA, 2004, VOX SANG, V86, P28, DOI 10.1111/j.0042-9007.2004.00379.x; McCullough J, 2000, TRANSFUSION, V40, P143; *NAT BLOOD DAT RES, 2003, 2002 NAT BLOOD COLL; Notari EP, 2001, TRANSFUSION, V41, P751, DOI 10.1046/j.1537-2995.2001.41060751.x; Orland JR, 2001, HEPATOLOGY, V33, P321, DOI 10.1053/jhep.2001.22112; Orton SL, 2004, TRANSFUSION, V44, P275, DOI 10.1111/j.1537-2995.2004.00623.x; Pealer LN, 2003, NEW ENGL J MED, V349, P1236, DOI 10.1056/NEJMoa030969; Peoples BG, 2000, TRANSFUSION, V40, P1280, DOI 10.1046/j.1537-2995.2000.40101280.x; PRATT JW, 1981, CONCEPTS NONPARAMETR, P41; Schmidt WN, 1997, J INFECT DIS, V176, P27, DOI 10.1086/514033; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Schreiber GB, 2002, TRANSFUSION, V42, P414, DOI 10.1046/j.1525-1438.2002.00084.x; Stramer SL, 2000, TRANSFUSION, V40, P1165, DOI 10.1046/j.1537-2995.2000.40101165.x; Stramer SL, 2001, TRANSFUSION, V41, P1079; Stramer SL, 1999, TRANSFUSION, V39, p2S; Tobler LH, 1997, CLIN CHEM, V43, P1487; Tobler LH, 2003, TRANSFUSION, V43, P1452, DOI 10.1046/j.1537-2995.2003.00521.x; 2004, MMWR MORB MORTAL WKL, V53, P281	37	368	402	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2004	351	8					760	768		10.1056/NEJMoa040085	http://dx.doi.org/10.1056/NEJMoa040085			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847CY	15317889				2022-12-28	WOS:000223367900008
J	Binder, EF; Brown, M; Sinacore, DR; Steger-May, K; Yarasheski, KE; Schechtman, KB				Binder, EF; Brown, M; Sinacore, DR; Steger-May, K; Yarasheski, KE; Schechtman, KB			Effects of extended outpatient rehabilitation after hip fracture - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GERIATRIC-PATIENTS; PHYSICAL FUNCTION; OLDER-ADULTS; RECOVERY; BALANCE; STRENGTH; EXERCISE; MASS; VALIDITY; FRAILTY	Context Hip fractures are common in the elderly, and despite standard rehabilitation, many patients fail to regain their prefracture ambulatory or functional status. Objective To determine whether extended outpatient rehabilitation that includes progressive resistance training improves physical function and reduces disability compared with low-intensity home exercise among physically frail elderly patients with hi p fracture. Design, Setting, and Patients Randomized controlled trial conducted between August 1998 and May 2003 among 90 community-dwelling women and men aged 65 years or older who had had surgical repair of a proximal femur fracture no more than 16 weeks prior and had completed standard physical therapy. Intervention Participants were randomly assigned to 6 months of either supervised physical therapy and exercise training (n=46) or home exercise (control condition; n=44). Main Outcome Measures Primary outcome measures were total scores on a modified Physical Performance Test (PPT), the Functional Status Questionnaire physical function subscale (FSQ), and activities of daily living scales. Secondary outcome measures were standardized measures of skeletal muscle strength, gait, balance, quality of life, and body composition. Participants were evaluated at baseline, 3 months, and 6 months. Results. Changes over time in the PPT and FSQ scores favored the physical therapy group (P=.003 and P=.01, respectively). Mean change (SD) in PPT score for physical therapy was +6.5 (5.5) points (95% confidence interval [CI], 4.6-8.3), and for the control condition was +2.5 (3.7) points (95% Cl, 1.4-3.6 points). Mean change (SD) in FSQ score for physical therapy was +5.2 (5.4) points (95% Cl, 3.5-6.9) and for the control condition was +2.9 (3.8) points (95% Cl, 1.7-4.0). Physical therapy also had significantly greater improvements than the control condition in measures of muscle strength, walking speed, balance, and perceived health but not bone mineral density or fat-free mass. Conclusion In community-dwelling frail elderly patients with hip fracture, 6 months of extended outpatient rehabilitation that includes progressive resistance training can improve physical function and quality of life and reduce disability compared with low-intensity home exercise.	Washington Univ, Sch Med, Dept Internal Med, Div Geriatr & Nutr Sci, St Louis, MO 63108 USA; Washington Univ, Sch Med, Program Phys Therapy, St Louis, MO 63108 USA; Washington Univ, Sch Med, Div Biostat, St Louis, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Binder, EF (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Geriatr & Nutr Sci, 4488 Forest Pk Blvd,Suite 201, St Louis, MO 63108 USA.	ebinder@im.wustl.edu	PT, David R. Sinacore/AAS-3377-2020; Yarasheski, Kevin/AAC-7450-2021; Yarasheski, Kevin E/A-3025-2008	PT, David R. Sinacore/0000-0002-7242-3585; Yarasheski, Kevin/0000-0001-5436-2451; 	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG013629] Funding Source: NIH RePORTER; NCRR NIH HHS [5-M01 RR00036] Funding Source: Medline; NIA NIH HHS [P60 AG013629] Funding Source: Medline; NIDDK NIH HHS [P30 DK56341] Funding Source: Medline; PHS HHS [R01 G15795] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALOIA JF, 1992, OSTEOPOROSIS INT, V2, P88, DOI 10.1007/BF01623842; BERG KO, 1992, ARCH PHYS MED REHAB, V73, P1073; Binder EF, 2002, J AM GERIATR SOC, V50, P1921, DOI 10.1046/j.1532-5415.2002.50601.x; BINDER EF, 2000, CLIN EXERC PHYSL, V2, P84; BOHANNON RW, 1984, PHYS THER, V64, P1067, DOI 10.1093/ptj/64.7.1067; BONAR SK, 1990, J AM GERIATR SOC, V38, P1139, DOI 10.1111/j.1532-5415.1990.tb01378.x; Brown M, 2000, J GERONTOL A-BIOL, V55, pM350, DOI 10.1093/gerona/55.6.M350; Buchner DM, 1997, J GERONTOL A-BIOL, V52, pM218, DOI 10.1093/gerona/52A.4.M218; Cameron ID, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000106; Colon-Emeric CS, 2000, AM J MED, V109, P324, DOI 10.1016/S0002-9343(00)00504-0; *CTR MED MED SERV, CARR MAN 3, pCH2; CUMMINGS SR, 1988, J AM GERIATR SOC, V36, P801, DOI 10.1111/j.1532-5415.1988.tb04263.x; Dirschl DR, 1997, BONE, V21, P79, DOI 10.1016/S8756-3282(97)00082-3; Duboeuf F, 1991, Osteoporos Int, V1, P242; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FILLENBAUM GG, 1981, J GERONTOL, V36, P428, DOI 10.1093/geronj/36.4.428; Fox KM, 2000, OSTEOPOROSIS INT, V11, P31, DOI 10.1007/s001980050003; GLOTH FM, 1995, J AM GERIATR SOC, V43, P822, DOI 10.1111/j.1532-5415.1995.tb07059.x; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hauer K, 2002, AGE AGEING, V31, P49, DOI 10.1093/ageing/31.1.49; Hoenig H, 1996, ARCH PHYS MED REHAB, V77, P58, DOI 10.1016/S0003-9993(96)90221-X; JETTE AM, 1987, PHYS THER, V67, P1854, DOI 10.1093/ptj/67.12.1854; JETTE AM, 1987, ARCH PHYS MED REHAB, V68, P735; JOHANSON NA, 1992, J BONE JOINT SURG AM, V74A, P587, DOI 10.2106/00004623-199274040-00015; JOHNELL O, 1985, ACTA ORTHOP SCAND, V56, P302, DOI 10.3109/17453678508993019; JUDGE JO, 1994, J AM GERIATR SOC, V42, P937, DOI 10.1111/j.1532-5415.1994.tb06584.x; Karlsson M, 1996, BONE, V18, P19, DOI 10.1016/8756-3282(95)00422-X; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; King AC, 1998, AM J PREV MED, V15, P316, DOI 10.1016/S0749-3797(98)00085-3; KOVAL KJ, 1995, CLIN ORTHOP RELAT R, P150; Koval KJ, 1996, J ORTHOP TRAUMA, V10, P531, DOI 10.1097/00005131-199611000-00004; Magaziner J, 2000, J GERONTOL A-BIOL, V55, pM498, DOI 10.1093/gerona/55.9.M498; MAROTTOLI RA, 1992, J AM GERIATR SOC, V40, P861, DOI 10.1111/j.1532-5415.1992.tb01980.x; *MI MED SERV, MED B FIN LOC MED RE; MOSSEY JM, 1989, AM J PUBLIC HEALTH, V79, P279, DOI 10.2105/AJPH.79.3.279; REUBEN DB, 1992, J GERONTOL, V47, pM106, DOI 10.1093/geronj/47.4.M106; REUBEN DB, 1990, J AM GERIATR SOC, V38, P1105, DOI 10.1111/j.1532-5415.1990.tb01373.x; Schafer JL., 1997, ANAL INCOMPLETE MULT, DOI 10.1201/9781439821862; SCHRODER HM, 1993, CLIN ORTHOP RELAT R, P166; Sherrington C, 2003, AUST J PHYSIOTHER, V49, P15, DOI 10.1016/S0004-9514(14)60184-7; Tinetti ME, 1999, ARCH PHYS MED REHAB, V80, P916, DOI 10.1016/S0003-9993(99)90083-7; Visser M, 2000, J GERONTOL A-BIOL, V55, pM434, DOI 10.1093/gerona/55.8.M434; Ware JE., 1993, HLTH SURVEY MANUAL I; WEISMAN Y, 1986, J AM GERIATR SOC, V34, P515, DOI 10.1111/j.1532-5415.1986.tb04243.x; Wolinsky FD, 1997, AM J PUBLIC HEALTH, V87, P398, DOI 10.2105/AJPH.87.3.398; WOLINSKY FD, 1994, AM J PUBLIC HEALTH, V84, P1316, DOI 10.2105/AJPH.84.8.1316; ZUCKERMAN JD, 1992, CLIN ORTHOP RELAT R, P213	48	254	264	1	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2004	292	7					837	846		10.1001/jama.292.7.837	http://dx.doi.org/10.1001/jama.292.7.837			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847FO	15315998	Bronze			2022-12-28	WOS:000223378300024
J	Gartner, ZJ; Tse, BN; Grubina, R; Doyon, JB; Snyder, TM; Liu, DR				Gartner, ZJ; Tse, BN; Grubina, R; Doyon, JB; Snyder, TM; Liu, DR			DNA-templated organic synthesis and selection of a library of macrocycles	SCIENCE			English	Article							CARBONIC-ANHYDRASE	The translation of nucleic acid libraries into corresponding synthetic compounds would enable selection and amplification principles to be applied to man-made molecules. We used multistep DNA-templated organic synthesis to translate libraries of DNA sequences, each containing three "codons," into libraries of sequence-programmed synthetic small-molecule macrocycles. The resulting DNA-macrocycle conjugates were subjected to in vitro selections for protein affinity. The identity of a single macrocycle possessing known target protein affinity was inferred through the sequence of the amplified DNA template surviving the selection. This work represents the translation, selection, and amplification of libraries of nucleic acids encoding synthetic small molecules rather than biological macromolecules.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Liu, DR (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.	drliu@fas.harvard.edu	Liu, David R./HCH-3132-2022	gartner, zev/0000-0001-7803-1219; Snyder, Thomas/0000-0001-7256-7821	NIGMS NIH HHS [R01GM065865, R01 GM065865-02, R01 GM065865-04, R01 GM065865-01A2, R01 GM065865-03, R01 GM065865] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Calderone CT, 2002, ANGEW CHEM INT EDIT, V41, P4104, DOI 10.1002/1521-3773(20021104)41:21<4104::AID-ANIE4104>3.0.CO;2-O; Doyon JB, 2003, J AM CHEM SOC, V125, P12372, DOI 10.1021/ja036065u; Gartner ZJ, 2003, ANGEW CHEM INT EDIT, V42, P1370, DOI 10.1002/anie.200390351; Gartner ZJ, 2002, ANGEW CHEM INT EDIT, V41, P1796, DOI 10.1002/1521-3773(20020517)41:10<1796::AID-ANIE1796>3.0.CO;2-Z; Gartner ZJ, 2002, J AM CHEM SOC, V124, P10304, DOI 10.1021/ja027307d; Gartner ZJ, 2001, J AM CHEM SOC, V123, P6961, DOI 10.1021/ja015873n; Halpin DR, 2004, PLOS BIOL, V2, P1022, DOI 10.1371/journal.pbio.0020174; JAIN A, 1994, J MED CHEM, V37, P2100, DOI 10.1021/jm00039a023; Joyce GF, 2004, ANNU REV BIOCHEM, V73, P791, DOI 10.1146/annurev.biochem.73.011303.073717; Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099; Li C., 1997, ORGANIC REACTIONS AQ; Lin HN, 2002, ANGEW CHEM INT EDIT, V41, P4403; MARYANOFF BE, 1989, CHEM REV, V89, P863, DOI 10.1021/cr00094a007; Taylor SV, 2001, ANGEW CHEM INT EDIT, V40, P3310, DOI 10.1002/1521-3773(20010917)40:18<3310::AID-ANIE3310>3.0.CO;2-P; Tripp BC, 2001, J BIOL CHEM, V276, P48615, DOI 10.1074/jbc.R100045200; Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611; WOODWARD RB, 1981, J AM CHEM SOC, V103, P3210, DOI 10.1021/ja00401a049	17	367	407	4	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	2004	305	5690					1601	1605		10.1126/science.1102629	http://dx.doi.org/10.1126/science.1102629			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	854GV	15319493	Green Accepted			2022-12-28	WOS:000223891200038
